<SEC-DOCUMENT>0001493152-17-002678.txt : 20170321
<SEC-HEADER>0001493152-17-002678.hdr.sgml : 20170321
<ACCEPTANCE-DATETIME>20170321141413
ACCESSION NUMBER:		0001493152-17-002678
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170321
DATE AS OF CHANGE:		20170321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		17703830

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Mark One)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[X]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the fiscal year ended December 31, 2016</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    the transition period from &nbsp;____ to _____</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
file number: 000-19871 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or Other Jurisdiction of</I><BR>
    <I>Incorporation or Organization)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer </I><BR>
    <I>Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5
Hamada Street</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yokneam
2069204 Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address
including zip code of registrant&rsquo;s Principal Executive Offices)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(908)
938-5561</B><BR>
(Registrant&rsquo;s Telephone Number, Including Area Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Securities
registered under Section 12(b) of the Act:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, Par value $0.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASDAQ
    Capital Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered under Section 12(g) of the Act: None</B><BR>
<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
[&nbsp;&nbsp;] No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [&nbsp;&nbsp;] No
[X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months/(or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not
contained herein, and will not be contained, to the best of the registrant&rsquo;s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 24%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer&nbsp;&nbsp;[&nbsp;&nbsp;] </FONT></TD>
    <TD STYLE="width: 38%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer&nbsp;&nbsp;[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
filer&nbsp;&nbsp; &nbsp;[&nbsp;&nbsp;]&nbsp;&nbsp;(Do not check if smaller reporting company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company&nbsp;&nbsp;[X]</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [&nbsp;&nbsp;] No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant&rsquo;s most recently completed second fiscal quarter: $43,048,260 at June 30, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock outstanding as of March 16, 2017: 27,251,333 shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">INFORMATION
CONCERNING FORWARD-LOOKING STATEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
report contains forward-looking statements. Forward-looking statements are projections in respect of future events or our future
financial performance. In some cases, you can identify forward-looking statements by terminology such as &ldquo;may&rdquo;, &ldquo;should&rdquo;,
&ldquo;intends&rdquo;, &ldquo;expects&rdquo;, &ldquo;will&rdquo;, &ldquo;plans&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;,
&ldquo;estimates&rdquo;, &ldquo;predicts&rdquo;, &ldquo;potential&rdquo;, or &ldquo;continue&rdquo; or the negative of these terms
or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and
other factors, including the risks listed under the section entitled &ldquo;Risk Factors&rdquo; commencing on page 12 of this
report, which may cause our or our industry&rsquo;s actual results, levels of activity or performance to be materially different
from any future results, levels of activity or performance expressed or implied by these forward-looking statements.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.6in; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Page
    </B>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
    I</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    1B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved
    Staff Comments</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
    Safety Disclosures</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
    II</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected
    Financial Data</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2<FONT STYLE="color: Black">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    7A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    and Qualitative Disclosures about Market Risk</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements and Supplementary Data</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
    and Procedures</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    9B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Information</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
    III</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
    Executive Officers and Corporate Governance</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Compensation</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">38</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">42</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Relationships and Related Transactions, and Director Independence</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">43</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Accountant Fees and Services</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">45</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
    IV</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Item
    15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    and Financial Statement Schedules</FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="color: Black">46</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>NOTE
REGARDING REFERENCES TO OUR COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this Form 10-K, the words &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Microbot&rdquo;
refer to Microbot Medical Inc., including our directly and indirectly wholly-owned subsidiaries and, unless the context otherwise
requires, the historical business, financial statements and operations of Microbot are of Microbot Medical Ltd., an Israeli corporation
(&ldquo;Microbot Israel&rdquo;) which became a wholly-owned subsidiary of the Company on November 28, 2016. &ldquo;StemCells&rdquo;
or &ldquo;StemCells, Inc.&rdquo; refers to the Company prior to its merger transaction with Microbot Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>Item
1.</B> <B><U>Description of Business.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics
assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its
micro-robotic technologies with the goal of improving surgical outcomes for patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus
and Normal Pressure Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially
for use in colonoscopy procedures. Microbot&rsquo;s product candidates are being designed to bring greater functionality to conventional
medical devices and to reduce the known risks associated with such devices. Microbot is currently aiming to complete pre-clinical
studies required for regulatory submission for both product candidates within the next 24 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
currently holds an intellectual property portfolio that comprises nine patent families, which include nine patents granted
in the United States, twelve patents granted outside the United States, and fifteen patent applications pending
worldwide. We have an exclusive license to key components of our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate
of Incorporation was restated on February 14, 1992 to change the name of the Company to CytoTherapeutics, Inc. On May 24, 2000,
the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc. On November
28, 2016, C&amp;RD Israel Ltd. (&ldquo;Merger Sub&rdquo;), a wholly-owned subsidiary of the Company, completed its merger with
and into Microbot Medical Ltd. (&ldquo;Microbot Israel&rdquo;), with Microbot Israel surviving as a wholly-owned subsidiary of
the Company (the &ldquo;Merger&rdquo;). On November 28, 2016, in connection with the Merger, the Company changed its name from
&ldquo;StemCells, Inc.&rdquo; to Microbot Medical Inc., and each outstanding share of Microbot Israel capital stock was converted
into the right to receive shares of our common stock. In addition, all outstanding options to purchase the ordinary shares of
Microbot Israel were assumed by the Company and converted into options to purchase shares of the Common Stock. On November 29,
2016, the stock of the Company began trading on the Nasdaq Capital Market under the symbol &ldquo;MBOT&rdquo;. Prior to the Merger,
the Company was a biopharmaceutical company that operated in one segment, the research, development, and commercialization of
stem cell therapeutics and related technologies. Substantially all of the material assets relating to the stem cell business were
sold on November 29, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Industry
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shunt
Systems</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hydrocephalus
is a medical condition in which there is an abnormal accumulation of cerebrospinal fluid, or CSF, in the brain that can cause
increased intracranial pressure. It is estimated that one in every 500 babies are born with hydrocephalus, and over 1,000,000
people in the United States currently live with hydrocephalus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symptoms
of hydrocephalus vary with age, disease progression and individual tolerance to the condition, but they can include convulsion,
tunnel vision, mental disability or dementia-like symptoms and even death. Normal Pressure Hypocephalus (&ldquo;NPH&rdquo;) is
a type of hydrocephalus that usually occurs in older adults. NPH is generally treated as distinct from other types of hydrocephalus
because it develops slowly over time. In NPH, the drainage of CSF is blocked gradually and the excess fluid builds up slowly.
This slow accumulation means that the fluid pressure may not be as high as in other types of hydrocephalus. It is estimated that
more than 700,000 Americans have NPH, but less than 20% receive an appropriate diagnosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hydrocephalus
is most often treated by the surgical insertion of a shunt system. The shunt system diverts the flow of CSF from the brain&rsquo;s
ventricles (or the lumbar subarachnoid space) to another part of the body where the fluid can be more readily absorbed. Hydrocephalus
shunt designs have changed little since their introduction in the 1950s. A shunt system typically consists of three parts: the
distal tubing or shunt (a flexible and sturdy plastic tube), the ventricular catheter (the proximal catheter), and a valve. The
end of the shunt system with the proximal catheter is placed in the ventricles (within the CSF) and the distal catheter is placed
in the site of the body where the CSF can be drained. A valve is located along the shunt to maintain and regulate the rate of
CSF flow. Current systems can be created from separate components or bought as complete units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
treatment of hydrocephalus with existing shunt systems often includes complications as well. For example, approximately 50% of
shunts used in the pediatric population fail within two years of placement and repeated neurosurgical operations are often required.
Ventricular catheter blockage, or occlusions, is by far the most frequent event that results in shunt failure. Shunt occlusion
occurs when there is a partial or complete blockage of the shunt that causes it to function intermittently or not at all. Such
a shunt blockage can be caused by the accumulation of blood cells, tissue, or bacteria in any part of the shunt system. In the
event of shunt occlusion, CSF begins to accumulate in the brain or lumbar region again and the symptoms of untreated hydrocephalus
can reappear until a shunt replacement surgery is performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
several companies are active in the field of hydrocephalus treatment and the manufacturing of shunt systems and shunt components,
Microbot believes that the majority of those companies are focusing on the development of valves. The development of a &ldquo;smart
shunt&rdquo; &ndash; a shunt that could provide data to the physician on patient conditions and shunt function with sensor based
controls, or correct the high failure rate of existing shunt systems &ndash; is for the most part at an academic and conceptual
level only. Reports of smart shunt technologies are typically focused on a subset of components with remaining factors left unspecified,
such as hardware, control algorithms or power management. Microbot does not believe that a smart shunt that can prevent functional
failures has been developed to date. Because of the limited innovation in this area, Microbot believes an opportunity exists to
provide patients suffering from hydrocephalus or NPH with a more effective instrument for treating their condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Endoscopic
Equipment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endoscopes
are medical devices used to look inside a body cavity or organ with minimally invasive surgery. The North American flexible endoscopes
market was valued at $1.27 billion in 2013, and is expected to reach $1.91 billion by 2018, at a CAGR of 8.5% during the period
2013 to 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colonoscopy
is a procedure that allows a physician to examine the colon using an endoscope. It is a commonly performed procedure for the diagnosis
and treatment of a range of conditions, including for the screening and surveillance of colorectal neoplasia, or colorectal cancer.
Annually, between 15 and 20 million endoscopy procedures are conducted in the United States with reusable endoscope devices to
screen various sections of a patient&rsquo;s gastrointestinal, or GI, tract. However, according to data from the American Cancer
Society, it is estimated that over 50,000 Americans will die from colorectal cancer and approximately 95,000 new cases of colon
cancer will be diagnosed in 2016. It is the third leading cause of cancer deaths in spite of being highly preventable with early
identification and removal of colorectal adenomas, or polyps. Colonoscopy with removal of colorectal polyps has been shown to
be the most effective way of preventing colorectal cancer. And colonoscopy is generally considered the gold standard for the detection
and treatment of adenomas. However, using current colonoscopic technology, approximately 30% of polyps are missed. In addition,
the technique remains underutilized &ndash; less than 50% of eligible Americans, based on guidelines established by organizations
including the American Cancer Society, United States Preventive Services Task Force, and U.S. Multi-Society Task Force on Colorectal
Cancer, have undergone screening, with more than 45% of colon cancers being diagnosed at a time when the cancer has become incurable.
This reluctance can be linked to patients&rsquo; general discomfort associated with the colonoscopy screening procedure, due to
the use of mechanical force to insert the endoscope into the colon. The procedure is widely perceived to be uncomfortable, and
it also can sometimes damage or perforate the bowel wall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colonoscopy
techniques that improve the Adenoma Detection Rate, or ADR, and reduce patient discomfort could optimize the potential of colonoscopy
for the prevention of colorectal cancer. Microbot believes that it has the potential to develop a robotic endoscope product that
addresses this issue of patient discomfort, which it believes will improve patients&rsquo; willingness to get this important screening
test &ndash; with the additional benefit of providing a new tool to health care practitioners for use in the identification and
treatment of colorectal polyps.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot&rsquo;s
Product Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Self-Cleaning
Shunt (SCS)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Self-Cleaning Shunt, or SCS, device is designed to act as the ventricular catheter portion of a CSF shunt system that is used
to relieve hydrocephalus and NPH. It is designed to work as an alternative to any ventricular catheter options currently on the
market and to connect to all existing shunt system valves currently on the market; therefore, the successful commercialization
of the SCS is not dependent on any single shunt system. Initially, Microbot expects the SCS device to be an aftermarket purchase
that would be deployed to modify existing products by the end user. Microbot believes that the use of its SCS device will be able
to reduce, and potentially eliminate, shunt occlusions, and by doing so Microbot believes its SCS has the potential to become
the gold-standard ventricular shunt in the treatment of Hydrocephalus and NPH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SCS device embeds an internal robotic cleaning mechanism in the lumen, or inside space, of the ventricular catheter which prevents
cell accumulation and tissue ingrowth into the catheter. The SCS device consists of a silicone tube with a perforated titanium
tip, which connects to a standard shunt valve at its distal end. The internal cleaning mechanism is embedded in the lumen of the
titanium tip. Once activated, the cleaning mechanism keeps tissue from entering the catheter perforations while maintaining the
CSF flow in the ventricular catheter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
internal cleaning mechanism of the SCS device is activated by means of an induced magnetic field, which is currently designed
to be externally generated by the patient through a user-friendly headset that transmits the magnetic field at a pre-determined
frequency and operating sequence protocol. The magnetic field that is created by the headset is then captured by a flexible coil
and circuit board that is placed just under the patient&rsquo;s scalp in the location where the valve is located. The circuit
board assembly converts the magnetic field into the power necessary to activate the cleaning mechanism within the proximal part
of the ventricular catheter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has completed the development of an SCS prototype and is currently completing the safety testing, general proof of concept testing
and performance testing for the device, which Microbot began in mid-2013. Microbot had a pre-submission meeting with the FDA in
mid-2014. On January 27, 2017, Microbot entered into a research agreement with The Washington University in St. Louis to develop
the protocol for and to execute the necessary animal study to determine the effectiveness of the Microbot&rsquo;s SCS prototype.
The initial research is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018.
Upon the completion of animal studies, Microbot may conduct clinical trials if they are requested by the FDA or if Microbot decides
that the data from such trials would improve the marketability of the product candidate. Microbot believes that the study results
of its first generation SCS device should be submitted to the FDA by late 2018. The proposed indication for use of the SCS device
would be for the treatment of hydrocephalus as a component of a shunt system when draining or shunting of CSF is indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
Carolyn Harris, PhD at Wayne State University (WSU) in Detroit, will run an in vitro study of our SCS device. The main objective
of this study is to test and finalize the design of Microbot&rsquo;s SCS, using Dr. Harris&rsquo; bio-reactor system that mimics
human brain tissue three-dimensionally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
may also conduct clinical trials for the SCS in other countries where such trials are necessary for Microbot to sell its SCS device
in such country&rsquo;s market, although it has no current plans to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TipCAT</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TipCAT is a semi-disposable, flexible, self-propelled endoscope. A mechanism comprising a series of interconnected balloons at
the device&rsquo;s tip provides the TipCAT with its forward locomotion capability. The device has the capability to self-propel
within natural tubular lumens such as the colon, blood vessels, and the urinary tract. The TipCAT is designed to be fully-equipped
with a contemporary endoscope, including a high-quality camera, steering capability while maintaining a standard working channel
for treatments. The TipCAT thus offers functionality and visualization features equivalent to modern endoscopes, along with unique
advantages associated with its physiologically adapted self-propelling mechanism, flexibility, and design.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TipCAT consists of two parts:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    disposable self-propulsion module, which is a series of interconnected, sequentially inflatable balloons constructed on an
    inner tube (i.e., the working channel); and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    re-usable module isolated from contact with the tissue/body fluids, containing a camera, LED lighting and a steering system.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the self-propulsion module, the air to inflate the balloons is supplied from a single channel. The sequential inflating and deflating
of the balloons creates an inchworm-like forward motion. Therefore, unlike standard endoscopes, the TipCAT does not need to be
mechanically forced into the patient&rsquo;s lumen using external pressure; rather, it will gently advance itself through the
organ&rsquo;s anatomy. As a result, the TipCAT is designed to be able to reach every part of the lumen under examination regardless
of the topography, be less operator dependent, and greatly reduce the likelihood of damage to lumen structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Microbot believes that use of the TipCAT will improve ADR by straightening the intestinal topography, smoothing colon topography
and improving tissue visualization. In addition, by incorporating the TipCAT in therapeutic procedures, Microbot believes that
the inflated balloons will provide the additional benefits of assisting the physician in centralizing endoscope optics and allowing
for the colonoscope to be secured in each treatment position throughout the procedure, resulting in more efficient and effective
procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TipCAT is also designed such that only disposable parts are in direct contact with the lumen tissue, which should eliminate the
risk of cross contamination between patients and the need for post-use reprocessing. Reducing dependence on reprocessing procedures
is important from a regulatory perspective because safety issues related to the reprocessing of reusable medical devices are a
growing concern for regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
TipCAT prototype was shown to self-propel and self-navigate in curved plastic pipes and curved ex-vivo colon. In addition, in
its first feasibility study, the prototype device was tested in a live animal experiment and successfully self-propelled through
segments of the animal&rsquo;s colon, with no post-procedural damage. All tests were conducted at AMIT (Alfred Mann Institute
of Technology at the Technion), prior to the licensing of TipCAT by Microbot. Microbot is currently reviewing the design and general
proof of concept of the TipCAT and working closely with experts in the field to define the optimal design. Microbot expects animal
studies for this device to begin in late 2017. Upon the completion of animal studies, Microbot may conduct clinical trials if
they are requested by the FDA or if Microbot decides that the data from such trials would improve the marketability of the product
candidate. Regulatory approval or clearance for marketing the TipCAT colonoscope in the United States is targeted to occur soon
after the applicable animal or clinical trials are completed, depending on when the applicable premarket submission is finalized
and filed with FDA, and Microbot&rsquo;s ability to raise money and conduct the necessary trials for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
also plans to further develop the TipCAT for application for other diagnostic and therapeutic endoscopic procedures outside of
colonoscopy, such as Chronic Total Occlusion, or CTO, urethroscopy and catheterization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
may conduct clinical trials for the TipCAT in other countries where such trials are necessary for Microbot to sell its TipCAT
device in such country&rsquo;s market, although it has no current plans to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
goal is to generate sales of its products, once they have received regulatory approval, by establishing SCS and TipCAT devices
as the standard-of-care in the eyes of doctors, surgeons, patients and medical facilities, as well as getting the support of payors
and insurance companies. Microbot believes that it can achieve this objective by working with hospitals to demonstrate the key
benefits of its products. Microbot&rsquo;s strategy includes the following key elements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.15in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Continue
    to refine existing product candidates and develop additional micro-robotic solutions</B>. As Microbot prepares to bring its
    initial product candidates through pre-clinical and clinical trials, if necessary, and eventually to market, it continues
    to focus on improving its product candidates to respond to clinical data and patient and physician feedback. Microbot also
    expects to continue to innovate in the micro-robotics field by continuing to find ways of using its technology to solve unmet
    needs, with the overarching goal of providing a safer, more effective and more efficient surgical environment for patients
    and physicians.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Establish
    and leverage relationships with key institutions and leading clinicians</B>. Microbot intends to develop relationships with
    a relatively small number of hospitals and clinics through its clinical stage. Microbot&rsquo;s objective will be to maintain
    clinical focus with such hospitals and clinics so as to establish the SCS and TipCAT as the standard of care in such institutions
    for their respective procedures. Microbot also expects to identify key clinicians in the hydrocephalus and colonoscopy specialties
    with the expectation that such clinical focus will accelerate the adoption of its candidate products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Continuously
    invest in research and development</B>. Microbot&rsquo;s most significant expense has historically been research and development,
    and Microbot expects that this will continue in the foreseeable future, including expenses it expects to incur to improve
    on its prototype products in order to respond to clinical data, to develop additional applications using its technologies
    and to develop future product candidates.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explore
    partnerships for the introduction of Microbot&rsquo;s products</B>. Microbot intends to focus its marketing and sales efforts
    initially on pursuing collaborations with global medical device companies that have established sales and distribution networks.
    Microbot will seek to enter collaborations and partnerships with strategic players that offer synergies with Microbot&rsquo;s
    product candidates and expertise.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Seek
    additional IP and technologies to complement and strengthen Microbot&rsquo;s current IP portfolio</B>. Microbot intends to
    continue exploring new technologies, IP and know-how to add to its current portfolio and to allow Microbot to enter new spaces
    and strengthen its overall product portfolio.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SCS
Opportunities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SCS is designed to prevent shunt occlusions in hydrocephalus and NPH patients who have undergone or are undergoing the surgical
insertion of a shunt system. For purposes of its marketing strategy, Microbot has split the market for shunt systems into two
sub-markets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
    shunt placement; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shunt
    replacement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
SCS device is universal (meaning that it is designed to be attachable to any valve on the market); therefore, Microbot&rsquo;s
initial go-to-market strategy is the development of strategic partnerships with leading global medical device companies with ready
sales and distribution channels. Outside of a strategic partnership, it is most likely that Microbot&rsquo;s SCS product will
be initially used in shunt replacement surgeries to replace occluded ventricular catheters. Accordingly, Microbot intends to establish
key hospital and clinic relationships that will allow it to diffuse the technology among experts and other stakeholders. Microbot
is also planning to apply for the SCS device to be covered under the current reimbursement codes in the United States for use
in hydrocephalus and NPH shunt procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TipCAT
Opportunities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
expects that its initial go-to-market strategy for the TipCAT will be to establish key hospital and clinic relationships in the
field of colonoscopy that will allow Microbot to introduce and then diffuse the technology among colonoscopy experts and other
stakeholders. Generally, Microbot expects the hospitals and clinics selected for the TipCAT clinical trials to also start using
the product commercially, which will help to promote and support market uptake of the TipCAT product. Because Microbot expects
the use of the TipCAT to increase the number of colonoscopy procedures that can be performed at any such facility, Microbot will
seek to promote the technology among the doctors and experts involved in the distribution and buying groups within such selected
partner hospitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>SCS
Competitive Landscape</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
academic research groups, such as at the New Jersey Institute of Technology, are currently researching sensing and obstruction-resistant
catheter designs, and the Smart Sensors and Integrated Microsystems (SSIM) Program at Wayne State University has publicized that
it is engaging in smart shunt development activity. However, based on its knowledge of the patented technologies, Microbot believes
that these technologies are still early in the research and development cycle. The SCS also faces non-direct competition from
Aqueduct Neurosciences, Inc., which is developing a non-shunt, electro-mechanical technology platform to control the draining
of cerebrospinal fluid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
does not expect its SCS device to directly compete against shunt systems currently available in the market. The SCS device is
designed to replace a component of existing shunt systems and is expected to be an aftermarket purchase that would be used to
modify existing products by the end user. However, there can be no assurance that Microbot&rsquo;s product candidate will be accepted
by the shunt market as an alternative component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TipCAT
Competitive Landscape</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for endoscopy products is highly competitive with several players operating both at a global and regional level. The leading
players in the colonoscopy space are Pentax, Fuji and Olympus, which dominate the U.S. market for reusable colonoscopes. However,
Microbot believes that the most relevant competitors to TipCAT are smaller companies such as GI View and SMART Medical Systems,
which produce disposable, self-propelled colonoscopes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GI
View produces a colonoscope with 360&deg; omni-directional visualization and offers self-propelled intubation created using balloons
and low pressure CO<SUB>2</SUB> gas. In addition, the GI View product is single use and disposable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SMART
Medical Systems&rsquo; product, which, according to publicly available information is being commercialized by Pentax, is introduced
by a physician through a standard colonoscope&rsquo;s tool channel and uses its balloon technology to anchor the bowel, which
enables the colonoscope to be maneuvered beyond challenging lumen sections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
believes the TipCAT can successfully compete against its relevant competitors in that it offers all of the following attributes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to have varied dimensions during insertion and any subsequent point of a procedure, so as to accommodate the particular
    diameters of the organ at any moment, allows for the straightening of an organ&rsquo;s topography and improved visualization;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disposability,
    which protects against cross-contamination;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    working channel for therapeutic interventions (and additional visualization capabilities);</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lower
    cost; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    self-propelling mechanism, allowing for passage through challenging anatomical structures while eliminating tissue trauma.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of Microbot&rsquo;s competitors currently have significantly greater resources than Microbot does; have established relationships
with healthcare professionals, customers and third-party payors; and have long-term contracts with group purchasing organizations
in the United States. In addition, many of Microbot&rsquo;s competitors have established distributor networks, greater resources
for product development, sales and marketing, additional lines of products and the ability to offer financial incentives such
as rebates, bundled products or discounts on other product lines that Microbot cannot provide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
products could also be rendered obsolete or uneconomical by technological advances developed in the future by existing or new
competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
is currently developing its first two product candidates, the SCS and TipCAT based on technological platforms licensed from The
Technion Research and Development Foundation Ltd., or TRDF, as further discussed below, and Microbot plans to develop other micro-robotic
solutions through internal research and development, to strengthen its intellectual property position, and continue exploring
strategic collaborations and accretive acquisition opportunities. Microbot currently holds an intellectual property portfolio
that includes 9 patent families, which include 9 patents granted in the US, 12 patents granted outside the US, and 15 patent
applications pending worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
relies or intends to rely on intellectual property licensed or developed, including patents, trade secrets, trademarks, technical
innovations, laws of unfair competition and various licensing agreements, to provide its future growth, to build its competitive
position and to protect its intellectual property. As Microbot continues to expand its intellectual property portfolio, it is
critical for Microbot to continue to invest in filing patent applications to protect its technology, inventions, and improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
requires its employees and consultants to execute confidentiality agreements in connection with their employment or consulting
relationships with Microbot. Microbot also requires its employees and consultants who work on its product candidates to agree
to disclose and assign to Microbot all inventions conceived during the term of their service, while using Microbot property, or
which relate to Microbot&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
applications in the United States and in foreign countries are maintained in secrecy for a period of time after filing, which
results in a delay between the actual discoveries and the filing of related patent applications and the time when discoveries
are published in scientific and patent literature. Patents issued and patent applications filed relating to medical devices are
numerous, and there can be no assurance that current and potential competitors and other third parties have not filed or in the
future will not file applications for, or have not received or in the future will not receive, patents or obtain additional proprietary
rights relating to product candidates, products, devices or processes used or proposed to be used by Microbot. Microbot believes
that the technologies it employs in its products and systems do not infringe the valid claims of any third party patents. There
can be no assurance, however, that third parties will not seek to assert that Microbot devices and systems infringe their patents
or seek to expand their patent claims to cover aspects of Microbot&rsquo;s products and systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry in general has been characterized by substantial litigation regarding patents and other intellectual property
rights. Any such claims, regardless of their merit, could be time-consuming and expensive to respond to and could divert Microbot&rsquo;s
technical and management personnel. Microbot may be involved in litigation to defend against claims of infringement by other patent
holders, to enforce patents issued to Microbot, or to protect Microbot&rsquo;s trade secrets. If any relevant claims of third-party
patents are upheld as valid and enforceable in any litigation or administrative proceeding, Microbot could be prevented from practicing
the subject matter claimed in such patents, or would be required to obtain licenses from the patent owners of each such patent,
or to redesign Microbot&rsquo;s products, devices or processes to avoid infringement. There can be no assurance that such licenses
would be available or, if available, would be available on terms acceptable to Microbot or Microbot would be successful in any
attempt to redesign products or processes to avoid infringement. Accordingly, an adverse determination in a judicial or administrative
proceeding or failure to obtain necessary licenses could prevent Microbot from manufacturing and selling its products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
U.S. patents which cover Microbot&rsquo;s product candidates will expire between 2026 and 2032, excluding any patent term extensions
that might be available following the grant of marketing authorization. Issued patents outside of the United States directed to
Microbot&rsquo;s product candidates will expire between 2026 and 2032.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>License
Agreement with the Technion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2012, Microbot entered into a license agreement with TRDF, the technology transfer subsidiary of The Technion Institute of
Technology, pursuant to which it obtained an exclusive, worldwide, royalty-bearing, sub-licensable license to certain patents
and inventions relating to the SCS and TipCAT technology platforms invented by Professor Moshe Shoham, a director of and advisor
to the Company, and in certain circumstances other TRDF-related persons. Pursuant to the terms of the license agreement, in order
to maintain the license with respect to each platform, Microbot must use commercially reasonable efforts to develop products covered
by the license, including meeting certain agreed upon development milestones. The milestones for SCS include commencing initial
studies in humans by December 2018 and commencing a full clinical trial, if necessary, by December 2019. The milestones for TipCAT
include commencing initial studies in humans, if needed, by December 2018 and commencing a full clinical trial, if necessary,
by December 2020. Failure to meet any development milestone will give TRDF the right to terminate the license with respect to
the technology underlying the missed milestone. Although Microbot expects to meet the milestone requirements, TRDF has demonstrated
flexibility with respect to amending the terms of the license to extend the milestone dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
partial consideration for the grant of the licenses under the agreement, Microbot issued a number of shares to TRDF equal to 3%
of its issued and outstanding shares at such time on a fully diluted basis. Such shares were initially subject to antidilution
protections but are no longer subject to adjustment. In addition, as partial consideration for the licenses granted, Microbot
agreed to pay TRDF royalties of between 1.5% and 3.0% of net sales of products covered by the licenses, subject to certain reductions,
and certain percentages of amounts received by Microbot in the event of sublicensing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of termination of the license by Microbot without cause or by TRDF for cause, TRDF has the right to receive a non-exclusive
license from Microbot with respect to improvements to the licensed technologies made by Microbot. In such cases, TRDF would pay
a royalty of 10% of the income received by TRDF in connection its sublicensing of such patent right and related intellectual property.
If the license from TRDF were to be terminated with respect with either of the technology platforms underlying the SCS or the
TipCAT, Microbot would no longer be able to continue its development of the related product candidate. However, Microbot believes
that its current intellectual property portfolio, and its ongoing efforts to expand into other micro-robotic surgical technologies,
will give it the flexibility to shift its resources towards developing and commercializing related products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
research and development programs are generally pursued by engineers and scientists employed by Microbot in its offices in Israel
on a full-time basis or as consultants, or through partnerships with industry leaders in manufacturing and design and researchers
in academia. Microbot is also working with subcontractors in developing specific components of its technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of Microbot&rsquo;s research and development efforts are to continue to introduce incremental enhancements
to the capabilities of its candidate products and to advance the development of proposed products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has received funds from the Israeli Innovation Authority (formerly known as the Office of the Chief Scientist in Israel), for
research and development activities. Microbot received a grant from the Israeli Innovation Authority in 2012, which grant reimbursed
Microbot for 50% of its research and development expenses, up to $764,466. This first grant from the Israeli Innovation Authority
ended in 2014. After the expiration of the first grant, Microbot received approval for an additional grant from the Israeli Innovation
Authority which reimbursed Microbot for 50% of its research and development expenses for the period from May 1, 2014 through September
30, 2015, up to $924,166. After the expiration of the second grant, Microbot received an approval for a third grant from the Israeli
Innovation Authority which reimbursed Microbot for 50% of its research and development expenses for the period from May 1, 2016
through April 30, 2017, up to $1,026,050. Microbot expects to continue to access government funding in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended December 31, 2016, Microbot incurred research and development expenses of approximately $901,000 compared
to research and development expenses of $823,000 for the fiscal year ended December 31, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has already made plans to develop a second version of its SCS device that will have an embedded controller and battery. This alternative
design will allow the cleaning mechanism to be automatically activated, without the need for the patient&rsquo;s involvement in
the activation process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2017, Microbot entered into a research agreement with The Washington University in St. Louis to develop the protocol
for and to execute the necessary animal study to determine the effectiveness of the Microbot&rsquo;s SCS prototype. The initial
research is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018. Upon the
completion of animal studies, Microbot may conduct clinical trials if they are requested by the FDA or if Microbot decides that
the data from such trials would improve the marketability of the product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
does not have any manufacturing facilities or manufacturing personnel. Microbot currently relies, and expects to continue to rely,
on third parties for the manufacturing of its product candidates for preclinical and clinical testing, as well as for commercial
manufacturing if its product candidates receive marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has not yet established a sales, marketing or product distribution infrastructure for its product candidates, which are still
in development stages. Microbot plans to access the U.S. markets for hydrocephalus, NPH, and colonoscopy with its initial device
offerings through strategic partnerships but may develop its own focused, specialized sales force or distribution channels once
it has several commercialized products in its portfolio. Microbot has not yet developed a commercial strategy outside of the United
States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
medical technology products and operations are subject to extensive regulation in the United States and other countries. Most
notably, if Microbot seeks to sell its products in the United States, its products will be subject to the Federal Food, Drug,
and Cosmetic Act (FDCA) as implemented and enforced by the U.S. Food and Drug Administration (FDA). The FDA regulates the development,
bench and clinical testing, manufacturing, labeling, storage, record-keeping, promotion, marketing, sales, distribution and post-market
support and reporting of medical devices in the United States to ensure that medical products distributed domestically are safe
and effective for their intended uses. Regulatory policy affecting its products can change at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of medical devices in the United States, in addition to being regulated by the FDA, are also regulated by the Federal
Trade Commission and by state regulatory and enforcement authorities. Recently, promotional activities for FDA-regulated products
of other companies have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection
statutes. In addition, under the federal Lanham Act and similar state laws, competitors and others can initiate litigation relating
to advertising claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
countries where Microbot wishes to sell its products may require similar or more onerous approvals to manufacture or market its
products. Government agencies in those countries also enforce laws and regulations that govern the development, testing, manufacturing,
labeling, advertising, marketing and distribution, and market surveillance of medical device products. These regulatory requirements
can change rapidly with relatively short notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
regulations Microbot encounters in the United States and in other jurisdictions are the regulations that are common to all businesses,
such as employment legislation, implied warranty laws, and environmental, health and safety standards, to the extent applicable.
In the future, Microbot will also encounter industry-specific government regulations that would govern its products, if and when
they are developed for commercial use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>U.S.
Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA governs the following activities that Microbot performs, will perform, upon the clearance or approval of its product candidates,
or that are performed on its behalf, to ensure that medical products distributed domestically or exported internationally are
safe and effective for their intended uses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    design, and development;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    safety, testing, labeling and storage;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">record
    keeping procedures; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    marketing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous FDA regulatory requirements governing the approval or clearance and subsequent commercial marketing of Microbot&rsquo;s
products. These include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely submission of product listing and establishment registration information, along with associated establishment user
    fees;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    compliance with the Quality System Regulation, or QSR, which require specification developers and manufacturers, including
    third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures
    during all aspects of the manufacturing process;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
    regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clearance
    or approval of product modifications that could significantly affect the safety or effectiveness of the device or that would
    constitute a major change in intended use;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    Device Reporting regulations (MDR), which require that manufacturers keep detailed records of investigations or complaints
    against their devices and to report to the FDA if their device may have caused or contributed to a death or serious injury
    or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    use of the Corrective and Preventive Actions process to identify and correct or prevent significant systemic failures of products
    or processes or in trends which suggest same;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-approval
    restrictions or conditions, including post-approval study commitments;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness
    data for the device; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">notices
    of correction or removal and recall regulations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, before Microbot can commercially distribute medical devices in the United States, Microbot must obtain,
depending on the classification of the device, either prior 510(k) clearance, 510(k) de-novo clearance or premarket approval (PMA),
from the FDA. The FDA classifies medical devices into one of three classes based on the degree of risk associated with each medical
device and the extent of regulatory controls needed to ensure the device&rsquo;s safety and effectiveness:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    I devices, which are low risk and subject to only general controls (e.g., registration and listing, medical device labeling
    compliance, MDRs, Quality System Regulations, and prohibitions against adulteration and misbranding) and, in some cases, to
    the 510(k) premarket clearance requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    II devices, which are moderate risk and generally require 510(k) or 510(k) de-novo premarket clearance before they may be
    commercially marketed in the United States as well as general controls and potentially special controls like performance standards
    or specific labeling requirements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    III devices, which are devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable
    devices, or devices deemed not substantially equivalent to a predicate device. Class III devices generally require the submission
    and approval of a PMA supported by clinical trial data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
expect the medical products in its pipeline currently to be classified as Class II. Class II devices are those for which general
controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information
to establish special controls. Special controls can include performance standards, post-market surveillance, patient histories
and FDA guidance documents. Premarket review and clearance by the FDA for these devices is generally accomplished through the
510(k) or 510(k) de-novo premarket notification process. As part of the 510(k) or 510(k) de-novo notification process, FDA may
require the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
    of comprehensive product description and indications for use;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    review of predicate devices and development of data supporting the new product&rsquo;s substantial equivalence to one or more
    predicate devices; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    appropriate and required, certain types of clinical trials (IDE submission and approval may be required for conducting a clinical
    trial in the US).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve use of the medical device on human subjects under the supervision of qualified investigators in accordance with
current Good Clinical Practices (GCPs), including the requirement that all research subjects provide informed consent for their
participation in the clinical study. A written protocol with predefined end points, an appropriate sample size and pre-determined
patient inclusion and exclusion criteria, is required before initiating and conducting a clinical trial. All clinical investigations
of devices to determine safety and effectiveness must be conducted in accordance with the FDA&rsquo;s Investigational device Exemption,
or IDE, regulations that among other things, govern investigational device labeling, prohibit promotion of the investigational
device, and specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the
device presents a &ldquo;significant risk,&rdquo; as defined by the FDA, the agency requires the device sponsor to submit an IDE
application, which must become effective prior to commencing human clinical trials. The IDE will automatically become effective
30 days after receipt by the FDA, unless the FDA denies the application or notifies the company that the investigation is on hold
and may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE that requires modification,
the FDA may permit a clinical trial to proceed under a conditional approval. In addition, the study must be approved by, and conducted
under the oversight of, an Institutional Review Board (IRB) for each clinical site. If the device presents a non-significant risk
to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate
approval from the FDA, but it must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that
the investigators obtain informed consent, and labeling and record-keeping requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
    successful completion of all required testing, a detailed 510(k) premarket notification or 510(k) de-novo is submitted to
    the FDA requesting clearance to market the product. The notification includes all relevant data from pertinent preclinical
    and clinical trials, together with detailed information relating to the product&rsquo;s manufacturing controls and proposed
    labeling, and other relevant documentation.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    510(k) clearance letter from the FDA will authorize commercial marketing of the device for one or more specific indications
    for use.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    510(k) clearance, Microbot will be required to comply with a number of post-clearance requirements, including, but not limited
    to, Medical Device Reporting and complaint handling, and, if applicable, reporting of corrective actions. Also, quality control
    and manufacturing procedures must continue to conform to QSRs. The FDA periodically inspects manufacturing facilities to assess
    compliance with QSRs, which impose extensive procedural, substantive, and record keeping requirements on medical device manufacturers.
    In addition, changes to the manufacturing process are strictly regulated, and, depending on the change, validation activities
    may need to be performed. Accordingly, manufacturers must continue to expend time, money and effort in the area of production
    and quality control to maintain compliance with QSRs and other types of regulatory controls.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) clearance from FDA, any modification that could significantly affect its safety or effectiveness, or
that would constitute a major change in its intended use or technological characteristics, requires a new 510(k) clearance or
could require a PMA. The FDA requires each manufacturer to make the determination of whether a modification requires a new 510(k)
notification or PMA in the first instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer&rsquo;s
decision not to seek a new 510(k) clearance or PMA for a particular change, the FDA may retroactively require the manufacturer
to seek 510(k) clearance or PMA. The FDA can also require the manufacturer to cease U.S. marketing and/or recall the modified
device until additional 510(k) clearance or PMA approval is obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and the Federal Trade Commission, or FTC, will also regulate the advertising claims of Microbot&rsquo;s products to ensure
that the claims Microbot makes are consistent with its regulatory clearances, that there is scientific data to substantiate the
claims and that product advertising is neither false nor misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain 510(k) clearance, Microbot must submit a notification to the FDA demonstrating that its proposed device is substantially
equivalent to a predicate device (i.e., a device that was in commercial distribution before May 28, 1976, a device that has been
reclassified from Class III to Class I or Class II, or a 510(k)-cleared device). The FDA&rsquo;s 510(k) clearance process generally
takes from three to 12 months from the date the application is submitted but also can take significantly longer. If the FDA determines
that the device or its intended use is not substantially equivalent to a predicate device, the device is automatically placed
into Class III, requiring the submission of a PMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that the FDA will grant Microbot 510(k) clearance for its pipeline medical device products, and failure to obtain
the necessary clearances for its products would adversely affect Microbot&rsquo;s ability to grow its business. Delays in receipt
or failure to receive the necessary clearances, or the failure to comply with existing or future regulatory requirements, could
reduce its business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices
that cannot be cleared through the 510(k) process due to lack of a predicate device but would be considered low or moderate risk
may be eligible for the 510(k) de-novo process. In 1997, the Food and Drug Administration Modernization Act, or FDAMA added the
de novo classification pathway now codified in section 513(f)(2) of the FD&amp;C Act. This law established an alternate pathway
to classify new devices into Class I or II that had automatically been placed in Class III after receiving a Not Substantially
Equivalent, or NSE, determination in response to a 510(k) submission. Through this regulatory process, a sponsor who receives
an NSE determination may, within 30 days of receipt, request FDA to make a risk-based classification of the device through what
is called a &ldquo;de novo request.&rdquo; In 2012, section 513(f)(2) of the FD&amp;C Act was amended by section 607 of the Food
and Drug Administration Safety and Innovation Act (FDASIA), in order to provide a second option for de novo classification. Under
this second pathway, a sponsor who determines that there is no legally marketed device upon which to base a determination of substantial
equivalence can submit a de novo request to FDA without first submitting a 510(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Microbot receives a Not Substantially Equivalent determination for either of its device candidates in response
to a 510(k) submission, the Microbot device may still be eligible for the 510(k) de-novo classification process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices
that cannot be cleared through the 510(k) or 510(k) de-novo classification process require the submission of a PMA. The PMA process
is much more time consuming and demanding than the 510(k) notification process. A PMA must be supported by extensive data, including
but not limited to data obtained from preclinical and/or clinical studies and data relating to manufacturing and labeling, to
demonstrate to the FDA&rsquo;s satisfaction the safety and effectiveness of the device. After a PMA application is submitted,
the FDA&rsquo;s in-depth review of the information generally takes between one and three years and may take significantly longer.
If the FDA does not grant 510(k) clearance to its products, there is no guarantee that Microbot will submit a PMA or that if Microbot
does, that the FDA would grant a PMA approval of Microbot&rsquo;s products, either of which would adversely affect Microbot&rsquo;s
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the United States, Microbot will be subject to a variety of foreign regulations governing clinical
trials, marketing authorization and commercial sales and distribution of its products in foreign countries. The approval process
varies from country to country, and the time may be longer or shorter than that required for FDA approval or clearance. The requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
sales of medical devices are subject to foreign governmental regulations which vary substantially from country to country. Whether
or not Microbot obtains FDA approval or clearance for its products, Microbot will be required to make new regulatory submissions
to the comparable regulatory authorities of foreign countries before Microbot can commence clinical trials or marketing of the
product in such countries. The time required to obtain certification or approval by a foreign country may be longer or shorter
than that required for FDA clearance or approval, and the requirements may differ. Below are summaries of the regulatory systems
for medical devices in Europe and Israel, where Microbot currently anticipates marketing its products. However, its products may
also be marketed in other countries that have different systems or minimal requirements for medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Europe</B>.
The primary regulatory body in Europe is the European Union, or E.U., which consists of 28 member states and has a coordinated
system for the authorization of medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
E.U. has adopted legislation, in the form of directives to be implemented in each member state, concerning the regulation of medical
devices within the European Union. The directives include, among others, the Medical Device Directive, or MDD, that establishes
certain requirements with which medical devices must comply before they can be commercialized in the European Economic Area, or
EEA (which comprises the member states of the E.U. plus Norway, Liechtenstein and Iceland). Under the MDD, medical devices are
classified into four Classes, I, IIa, IIb, and III, with Class I being the lowest risk and Class III being the highest risk. However,
the E.U. authorities, including the European Commission, do not have direct regulatory over medical device manufacturers under
the MDD. Rather, the MDD directs E.U. Member States to implement laws and regulations consistent with the provisions set forth
in the directive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the MDD, to demonstrate compliance of a medical device with the essential requirements, manufacturers must undergo a conformity
assessment procedure, which varies according to the type of medical device and its classification. An accredited body known as
a &ldquo;Notified Body&rdquo;, which is an entity designated by an E.U. Member State (or competent authority) to perform conformity
assessments, will typically audit and examine the manufacturer&rsquo;s quality system for the production, quality, design and
final inspection of the medical devices and review a Technical File containing technical documents regarding the device, including
but limited to, detailed device description, manufacturing information, preclinical and clinical tests, risk analysis, compliance
with essential requirements, etc., before issuing a certification demonstrating compliance with the essential requirements. Medical
devices that comply with the essential requirements are entitled to bear the Conformit&eacute; Europ&eacute;ene, or CE Mark. Medical
devices properly bearing the CE Mark may be commercially distributed throughout the EEA. Under the MDD, notified bodies are also
charged with performing periodic inspections to verify that a manufacturer&rsquo;s quality system, particularly the production
and quality controls, is adequately executed and maintained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the MDD requires all medical device manufacturers to inform the competent authorities of their respective Member States
of the address(es) of any business facilities and descriptions of any certified medical device products. The MDD also requires
manufacturers to file vigilance reports in the event a device malfunction, deterioration in performance, or inadequate instructions
or labeling results in, or could lead to, death or serious harm to a patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2012, the European Commission published proposals for the revision of the EU regulatory framework for medical devices.
The proposal would replace the MDD with a new regulation, the Medical Devices Regulation, or MDR. Unlike the MDD that must be
implemented into national laws, the Medical Devices Regulation would be directly applicable in all EEA member states and so is
intended to eliminate current national differences in regulation of medical devices. E.U. lawmakers published a revised draft
of the proposed MDR in June 2016, which continues to be discussed within the Council of the European Union and the European Parliament.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final
formal adoption is expected both by the European Council and the European Parliament during the second quarter of 2017. If finally
adopted, the MDR is expected to become applicable three years thereafter. The adoption of the MDR may, however, be materially
delayed due to disagreements about specific portions of the regulation, as well as the implementation process. In its current
form it would, among other things, impose additional reporting requirements on manufacturers of high risk medical devices, impose
an obligation on manufacturers to appoint a &ldquo;qualified person&rdquo; responsible for regulatory compliance, and provide
for more strict clinical evidence requirements. These new rules and procedures will likely result in increased regulatory oversight
of all medical devices marketed in the E.U., and this may, in turn, increase the costs, time and requirements that need to be
met in order to place a medical devices on the EEA market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
intends to apply for the CE Mark for each of its medical device products. There is no guarantee that Microbot will be granted
a CE Mark for all or any of its pipeline products and failure to obtain the CE Mark would adversely affect its ability to grow
its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Israel</B>.
Israel&rsquo;s Medical Devices Law generally requires the registration of all medical products with the Ministry of Health, or
MOH, Registrar as a precondition for production and distribution in Israel. Special exemptions may apply under limited circumstances
and for purposes such as the provision of essential medical treatment, research and development of the medical device, and personal
use, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
of medical devices requires the submission of an application to the Ministry of Health Medical Institutions and Devices Licensing
Department, or AMAR. An application for the registration of a medical device includes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and address of the manufacturer, and of the importer as applicable;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of the intended use of the medical device and of its medical indications;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical
    details of the medical device and of its components, and in the event that the device or the components are not new, information
    should be provided on the date or renovation;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    attesting to the safety of the device, issued by a competent authority of one of the following countries: Australia, Canada,
    European Community (EC), Member States (MSs), Israel, Japan, or the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
    on any risk which may be associated with the use of the device (including precautionary measures to be taken);</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instructions
    for use of the device in Hebrew; the MOH may allow the instructions to be in English for certain devices;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
    of the standards to which the device complies;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of the technical and maintenance services, including periodic checks and inspections; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Declaration,
    as appropriate: of the local manufacturer/importer, and of the foreign manufacturer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the application includes a certificate issued by a competent authority of one of the following &ldquo;recognized&rdquo; countries:
Australia, Canada, European Community (CE) Member States (MSs), Japan, or the United States, the registration process is generally
expedited, but could still take 6-9 months for approval. If such certificate is not available, the registration process will take
significantly longer and a license is rarely issued. Furthermore, the MOH will determine what type of testing is needed. In general,
in the case of Israeli manufactured devices that are not registered or authorized in any &ldquo;recognized&rdquo; country, the
application requires presentation of a risk analysis, a clinical evaluation, a summary of the clinical trials, and expert opinions
regarding the device&rsquo;s safety and effectiveness. Additional requirements may apply during the registration period, including
follow-up reviews, to improve the quality and safety of the devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to regulations issued by Israel&rsquo;s Minister of Health in June 2013, a decision on a request to register a medical device
must be delivered by AMAR within 120 days from the date of the request, although this rarely occurs. The current rules for the
registration of medical devices do not provide for an expedited approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted by the MOH, a license (marketing authorization) for a medical device is valid for five years from the date of registration
of the device, except for implants with a life-supporting function, for which the validity is for only two years from the date
of registration. Furthermore, the holder of the license, the Israeli Registration Holder, or IRH, must do the following to maintain
its license:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reside
    and maintain a place of business in Israel and serve as the regulatory representative.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Respond
    to questions from AMAR concerning the registered products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    adverse events to AMAR.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renew
    the registration on time to keep the market approval active.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comply
    with post-marketing requirements, including reporting of adverse and unexpected events occurring in Israel or in other countries
    where the device is in use.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Getting
a device listed on Israel&rsquo;s four major Sick Funds (health insurance entities) is also necessary in order for Israeli hospitals
and health care providers to order such products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
intends to apply for a license from the MOH for each of its medical devices. There is no guarantee that Microbot will be granted
licenses for its pipeline products and failure to obtain such licenses would adversely affect its ability to grow its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
Chief Executive Officer, President and Chairman, Harel Gadot, is based in Microbot&rsquo;s U.S. office located in Hingham, Massachusetts.
Additionally, Microbot currently has six full-time employees and one part time employee based in its office located in Yokneam,
Israel. These employees oversee day-to-day operations of the Company supporting management and leading engineering, manufacturing,
intellectual property and administration functions of the Company. As required, Microbot also engages consultants to provide services
to the Company, including regulatory, legal and corporate services. Microbot has no unionized employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
currently plans to hire an additional 4-6 full-time employees within the next 12 months subject to the availability of funds,
whose principal responsibilities will be the support of its operational, research and development, and clinical development activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>Item
1A. <U>Risk Factors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. Our business, operating results,
financial performance, and share price may be materially adversely affected by a number of factors, including but not limited
to the following risk factors, any one of which could cause actual results to vary materially from anticipated results or from
those expressed in any forward-looking statements made by us in this Annual Report on Form 10-K or in other reports, press releases
or other statements issued from time to time. Additional factors that may cause such a difference are set forth elsewhere in this
Annual Report on Form 10-K. Forward-looking statements speak only as of the date of this report. We do not undertake any obligation
to publicly update any forward-looking statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Microbot&rsquo;s Financial Position and Need for Additional Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
has had no revenue and has incurred significant operating losses since inception and is expected to continue to incur significant
operating losses for the foreseeable future. The Company may never become profitable or, if achieved, be able to sustain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has incurred significant operating losses since its inception and expects to incur significant losses for the foreseeable future
as Microbot continues its preclinical and clinical development programs for its existing product candidates, SCS and TipCAT; its
research and development of any other future product candidates; and all other work necessary to obtain regulatory clearances
or approvals for its product candidates in the United States and other markets. In the future, Microbot intends to continue conducting
micro-robotics research and development; performing necessary animal and clinical testing; working towards medical device regulatory
compliance; and, if SCS, TipCAT or other future product candidates are approved or cleared for commercial distribution, engaging
in appropriate sales and marketing activities that, together with anticipated general and administrative expenses, will likely
result in Microbot incurring further significant losses for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
is a development-stage medical device company and currently generates no revenue from product sales, and may never be able to
commercialize SCS, TipCAT or other future product candidates. Microbot does not currently have the required approvals or clearances
to market or test in humans SCS, TipCAT or any other future product candidates and Microbot may never receive them. Microbot does
not anticipate generating significant revenues until it can successfully develop, commercialize and sell products derived from
its product pipeline, of which Microbot can give no assurance. Even if Microbot or any of its future development partners succeed
in commercializing any of its product candidates, Microbot may never generate revenues significant enough to achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with its product development pipeline and strategy, Microbot cannot accurately
predict when it will achieve profitability, if ever. Failure to become and remain profitable would depress the value of the Company
and could impair its ability to raise capital, which may force the Company to curtail or discontinue its research and development
programs and/or day-to-day operations. Furthermore, there can be no assurance that profitability, if achieved, can be sustained
on an ongoing basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot&rsquo;s
business depends on the success of the SCS and the TipCAT, both of which are still in pre-clinical development. If Microbot is
unable to obtain regulatory approval for or to successfully commercialize these products, its business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the primary focus of Microbot&rsquo;s product development has been on SCS, for the treatment of hydrocephalus and normal
pressure hydrocephalus, or NPH, and TipCAT, a self-propelling, semi-disposable endoscope being developed initially for use in
colonoscopy procedures. Successful continued development and ultimate regulatory approval or clearance of both SCS and TipCAT
are critical to the future success of Microbot&rsquo;s business. Microbot has invested, and will continue to invest, a significant
portion of its time and financial resources in the development, pre-clinical and clinical testing of and obtaining regulatory
authorization for SCS and TipCAT. Microbot will need to raise sufficient funds to successfully complete its development of these
products. The future regulatory and commercial success of SCS and TipCAT is subject to a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
    may not have sufficient financial and other resources to complete the necessary clinical trials for SCS and TipCAT;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    clinical trials are required for FDA clearance or approval of SCS or TipCAT, Microbot may not be able to obtain adequate evidence
    from such clinical trials of safety and effectiveness in order to receive the applicable clearance or approval from the FDA;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
    does not know the degree to which SCS or TipCAT will be accepted and adopted by physicians, patients and payors, even if approved
    or cleared by FDA for commercial marketing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Microbot is unable to successfully navigate these risks and achieve commercial success for its products, its business will be
significantly harmed and Microbot may never become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
has a limited operating history, which may make it difficult to evaluate the prospects for the Company&rsquo;s future viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has a limited operating history upon which an evaluation of its business plan or performance and prospects can be made. The business
and prospects of Microbot must be considered in the light of the potential problems, delays, uncertainties and complications that
may be encountered in connection with a newly established business. The risks include, but are not limited to, the possibility
that Microbot will not be able to develop functional and scalable products, or that although functional and scalable, its products
will not be economical to market; that its competitors hold proprietary rights that may preclude Microbot from marketing such
products; that its competitors market a superior or equivalent product; that Microbot is not able to upgrade and enhance its technologies
and products to accommodate new features and expanded service offerings; or the failure to receive necessary regulatory clearances
or approvals for its products. To successfully introduce and market its products at a profit, Microbot must establish brand name
recognition and competitive advantages for its products. There are no assurances that Microbot can successfully address these
challenges. If it is unsuccessful, Microbot and its business, financial condition and operating results could be materially and
adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
operations to date have been limited to organizing the company, entering into licensing arrangements to initially obtain rights
to its technologies, developing and securing its technologies, raising capital, developing regulatory and reimbursement strategies
for its product candidates and preparing for pre-clinical and clinical trials of the SCS and TipCAT. Microbot has not yet demonstrated
its ability to successfully complete development of any product candidate, obtain marketing clearance or approval, manufacture
a commercial-scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary
for successful product commercialization. Consequently, any predictions made about Microbot&rsquo;s future success or viability
may not be as accurate as they could be if Microbot had a longer operating history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
will need substantial additional funding. If Microbot is unable to raise capital when needed, it could be forced to delay, reduce
or eliminate its product development programs or commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Microbot has funded its operations primarily through private placement offerings of debt and equity securities, grants and
loans. Microbot does not know when, or if, it will generate any revenue, but does not expect to generate significant revenue unless
and until it obtains regulatory clearance or approval of and commercializes one of its current or future product candidates. It
is anticipated that the Company will continue to incur losses for the foreseeable future, and that losses will increase as it
continues the development of, and seeks regulatory review of, its product candidates, and begins to commercialize any approved
or cleared products following a successful regulatory review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
expects the research and development expenses of the Company to increase substantially in future periods as it conducts pre-clinical
studies in large animals and potentially clinical trials for its product candidates, and especially if it initiates additional
research programs for future product candidates. In addition, if the Company obtains marketing clearance or approval for any of
its product candidates, it expects to incur significant commercialization expenses related to product manufacturing, marketing
and sales. Furthermore, Microbot expects to incur additional costs associated with operating as a public company in the United
States. Accordingly, the Company will need to obtain substantial additional funding in connection with its continuing operations.
If the Company is unable to raise capital when needed or on attractive terms, it could be forced to delay, reduce or eliminate
its research and development programs or any future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
believes that the net cash of the Company will be sufficient to fund the Company for at least 12 months and fund operations necessary
to continue development activities of the SCS and TipCAT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may need to raise additional funds through equity offerings or otherwise in order to meet expected future liquidity needs,
including the introduction of the SCS device into the hydrocephalus and NPH market, and introducing the TipCAT as a next-generation
colonoscope. The Company&rsquo;s future capital requirements, generally, will depend on many factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and outcomes of the product candidates&rsquo; regulatory reviews, subsequent approvals or clearances, or other regulatory
    actions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, design, duration and any potential delays of the clinical trials that could be conducted at the FDA&rsquo;s request
    using Microbot&rsquo;s product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of acquiring, licensing or investing in businesses, product candidates and technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to maintain, expand and defend the scope of Microbot&rsquo;s intellectual property portfolio;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to secure or establish sales, marketing and commercial manufacturing capabilities or arrangements with third parties
    regarding same;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company&rsquo;s need and ability to hire additional management and scientific and medical personnel; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs to operate as a public company in the United States, including the need to implement additional financial and reporting
    systems and other internal systems and infrastructure for the Company&rsquo;s business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital may cause dilution to the Company&rsquo;s investors, restrict its operations or require it to relinquish rights
to its technologies or product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as the Company can generate substantial product revenues, it expects to finance its cash needs through a combination
of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. The Company does not have any
committed external source of funds. To the extent that the Company raises additional capital through the sale of equity or convertible
debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation
or other preferences that adversely affect the rights of holder of the Company&rsquo;s common stock. Debt financing, if available,
may involve agreements that include covenants limiting or restricting the Company&rsquo;s ability to take specific actions, such
as incurring additional debt, making capital expenditures, declaring dividends or other distributions, selling or licensing intellectual
property rights, and other operating restrictions that could adversely affect the Company&rsquo;s ability to conduct its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Company raises additional funds through licensing, collaboration or similar arrangements, it may have to relinquish valuable
rights to its technologies, future revenue streams, research and development programs or product candidates or to grant licenses
on terms that may not be favorable to the Company. If the Company is unable to raise additional funds through equity or debt financings
or other arrangements when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization
efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to the Development and Commercialization of Microbot&rsquo;s Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot&rsquo;s
business depends heavily on the success of its lead product candidates, the SCS and the TipCAT. If Microbot is unable to commercialize
the SCS or the TipCAT or experiences significant delays in doing so, Microbot&rsquo;s business will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2017 Microbot entered into a research agreement with The Washington University to develop the protocol for and to
execute the necessary animal study to determine the effectiveness of the Microbot&rsquo;s SCS prototype. The initial research
is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018. Upon the completion
of animal studies, Microbot may conduct clinical trials if they are requested by the FDA or if Microbot decides that the data
from such trials would improve the marketability of the product candidate. The TipCAT is expected to enter animal studies in 2018.
Upon the completion of animal studies, Microbot may conduct clinical trials if they are requested by the FDA or if Microbot decides
that the data from such trials would improve the marketability of the product candidate. After all necessary clinical and performance
data supporting the safety and effectiveness of each product candidate are collected, Microbot must still obtain FDA clearance
or approval to market the device and those regulatory processes can take several months to several years to be completed. Therefore,
Microbot&rsquo;s ability to generate product revenues will not occur for at least the next few years, if at all, and will depend
heavily on the successful commercialization of SCS and TipCAT in their respective intended markets. The success of each of these
product candidates will depend on a number of factors, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Company&rsquo;s ability to obtain additional capital;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    completion of animal studies and, if necessary, human clinical trials and the collection of sufficient data to demonstrate
    that the device is safe and effective for its intended use;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals or clearances from FDA and other applicable regulatory authorities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing arrangements with one or more third parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protections;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protecting
    Microbot&rsquo;s rights in its intellectual property portfolio;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    sales, marketing and distribution capabilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">generating
    commercial sales of SCS and TipCAT, as applicable, if and when approved, whether alone or in collaboration with other entities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of SCS and TipCAT, as applicable, if and when commercially launched, by the medical community, patients and third-party payors;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    competing with existing shunt and endoscope products on the market and any new competing products that may enter the market;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    quality and an acceptable safety profile of SCS and TipCAT, as applicable, following clearance or approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Microbot does not achieve one or more of these factors in a timely manner or at all, it could experience significant delays or
an inability to successfully commercialize SCS and/or TipCAT, which would materially harm its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot&rsquo;s
product candidates are subject to an uncertain and potentially lengthy domestic regulatory review process. If Microbot does not
obtain and maintain the necessary regulatory authorizations from the Food and Drug Administration, Microbot will not be able to
sell its product candidates in the United States.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
product candidates and operations are subject to extensive regulation in the United States by the FDA under the agency&rsquo;s
medical device authorities. The FDA regulates the development, bench and clinical testing, manufacturing, labeling, storage, record-keeping,
promotion, marketing sales, distribution and post-market support and reporting of medical devices in the United States to ensure
that medical products distributed domestically are safe and effective for their intended uses. Microbot expects its product candidates
to be classified as Class II. In order to market Class II products for use in the United States, Microbot must first obtain clearance
from the FDA pursuant to Section 510(k) of the Federal Food, Drug, and Cosmetic Act. Clearance under Section 510(k) requires a
demonstration that a new device is substantially equivalent to another device with 510(k) clearance or grandfathered status or
to a device that was reclassified from Class III to Class II or Class I.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that the device or its intended use is not substantially equivalent to a predicate device, the device is automatically
placed into Class III, requiring the submission of a premarket approval application (PMA). There is no guarantee that the FDA
will agree with Microbot&rsquo;s determination that a 510(k) notification is the appropriate regulatory pathway for its products,
or that FDA will grant Microbot 510(k) clearance for its pipeline medical device products even if that pathway is accepted. Failure
to obtain the necessary clearances for its products would adversely affect Microbot&rsquo;s ability to grow its business. Delays
in receipt or failure to receive the necessary clearances, or the failure to comply with existing or future regulatory requirements,
could reduce our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices
that cannot be cleared through the 510(k) process due to lack of a predicate device but would be considered low or moderate risk
(in other words, they do not rise to the level of requiring the approval of a PMA) may be eligible for the 510(k) de novo classification
process. If FDA determines that either of Microbot&rsquo;s product candidates is not eligible for a traditional 510(k), the Microbot
device may still be eligible for the 510(k) de novo process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if one or both of Microbot&rsquo;s product candidates receives 510(k) clearance from FDA, under either the traditional pathway
or the de novo 510(k) pathway, any subsequent modification that could significantly affect the device&rsquo;s safety or effectiveness,
or that would cause them to be marketed for additional indications for use, may require a new 510(k) clearance or a PMA for the
modified products before Microbot will be permitted to market them in the United States. The FDA can require a manufacturer to
cease U.S. marketing and/or recall the modified device until it is satisfied that the appropriate 510(k) clearance or PMA approval
is obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may not act favorably or quickly in its review of Microbot&rsquo;s 510(k), de novo 510(k), or PMA submissions, as applicable,
or Microbot may encounter significant difficulties and costs in its efforts to obtain FDA clearance or approval, any of which
could delay or preclude its sale of its product candidates in the United States. Furthermore, the FDA may request additional data
or require Microbot to conduct further testing, or compile more data, including clinical data and clinical studies, in support
of its 510(k) submission or potentially a de novo 510(k).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
the regulatory policies affecting Microbot&rsquo;s proposed product candidates can change at any time. The changes and their potential
impact on Microbot&rsquo;s business cannot be accurately predicted. For example, in 2011, the FDA announced a Plan of Action to
modernize and improve the FDA&rsquo;s premarket review of medical devices, and has implemented, and continues to implement, reforms
intended to streamline the premarket review process. In addition, as part of the Food and Drug Administration Safety and Innovation
Act of 2012, Congress enacted several reforms through the Medical Device Regulatory Improvements and additional miscellaneous
provisions which will further affect both pre- and post-approval medical device regulation. Changes in the FDA 510(k) process
could make clearance more difficult to obtain, increase delay, add uncertainty and have other significant adverse effects on Microbot&rsquo;s
ability to obtain and maintain clearance for its product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also, instead of accepting any kind of 510(k) submission, classify a product as high-risk and require Microbot to submit
a PMA for the initial clearance, which is typically a much more complex, lengthy and burdensome application than a 510(k) submission.
To support a PMA, the FDA would likely require that Microbot conduct one or more clinical studies to demonstrate that the device
is safe and effective. In some cases such studies may be requested for a 510(k) or de novo 510(k) as well. Microbot may not be
able to meet the requirements to obtain 510(k) clearance or PMA approval, in which case the FDA may not grant any necessary clearances
or approvals. In addition, the FDA may place significant limitations upon the intended use of its product candidates as a condition
to a 510(k) clearance or PMA approval. Product applications can also be denied or withdrawn due to failure to comply with regulatory
requirements or the occurrence of unforeseen problems following clearance or approval. Any delays or failure to obtain FDA clearance
or approval of new products Microbot develops, any limitations imposed by the FDA on new product use or the costs of obtaining
FDA clearance or approvals could have a material adverse effect on Microbot&rsquo;s business, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with the regulations or obtain the approvals described above could have a material adverse effect on Microbot&rsquo;s
business, financial condition and results of operations. There can be no assurance that clinical trials will meet desired endpoints,
produce meaningful or useful data and be free of unexpected adverse effects, and such uncertainty could preclude or delay market
clearance or authorizations resulting in significant financial costs and reduced revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>At
this time, Microbot does not know whether the FDA will require it to submit clinical data in support of its future marketing applications
for either product candidate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
anticipates that each of its existing product candidates, SCS and TipCAT, will be classified by the FDA as Class II and thus be
eligible for marketing pursuant to a cleared 510(k) notification. However, there is no guarantee that the FDA will agree with
the Company&rsquo;s determination or that the FDA would accept the predicate devices that Microbot intends to submit in its 510(k)
notifications in order to establish that its new device product is substantially equivalent to one or more predicate devices.
The FDA also may request additional data in response to a 510(k) notification, or require Microbot to conduct further testing
or compile more data in support of its 510(k) submission or de novo 510(k), as appropriate. Such additional data could include
clinical data that must be derived from human clinical studies that are designed appropriately to address the potential questions
from the FDA regarding a proposed product&rsquo;s safety or effectiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness
of a medical device, a company must, among other things, apply for and obtain Institutional Review Board, or IRB, approval of
the proposed investigation. In addition, if the clinical study involves a &ldquo;significant risk&rdquo; (as defined by the FDA)
to human health, the sponsor of the investigation must also submit and obtain FDA approval of an Investigational Device Exemption,
or IDE, application. Microbot may not be able to obtain FDA and/or IRB approval to undertake clinical trials in the United States
for any new devices Microbot intends to market in the United States in the future. Any type of clinical study in humans requires
the investment of substantial expense, professional resources and time. Moreover, the timing of the commencement, continuation
and completion of any future clinical trial may be subject to significant delays attributable to various causes, including scheduling
conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling patients who meet
trial eligibility criteria, failure of patients to complete the clinical trial, delay in or failure to obtain IRB approval to
conduct a clinical trial at a prospective site, and shortages of supply in the investigational device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
addition of one or more mandatory clinical trials to the development timeline for one or both Microbot product candidates would
significantly increase the costs associated with developing and commercializing the product and delay the timing of U.S. regulatory
authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unsuccessful
animal studies, clinical trials or procedures relating to product candidates under development could have a material adverse effect
on Microbot&rsquo;s prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory approval process for new products and new indications for existing products requires extensive data and procedures,
including the development of regulatory and quality standards and, potentially, certain clinical studies. Unfavorable or inconsistent
data from current or future clinical trials or other studies conducted by Microbot or third parties, including the studies now
being performed by The Washington University or perceptions regarding such data, could adversely affect Microbot&rsquo;s ability
to obtain necessary device clearance or approval and the market&rsquo;s view of Microbot&rsquo;s future prospects. Failure to
successfully complete these studies in a timely and cost-effective manner could have a material adverse effect on Microbot&rsquo;s
prospects. Because animal trials, clinical trials and other types of scientific studies are inherently uncertain, there can be
no assurance that these trials or studies will be completed in a timely or cost-effective manner or result in a commercially viable
product. Clinical trials or studies may experience significant setbacks even if earlier preclinical or animal studies have shown
promising results. Furthermore, preliminary results from clinical trials may be contradicted by subsequent clinical analysis.
Results from clinical trials may also not be supported by actual long-term studies or clinical experience. If preliminary clinical
results are later contradicted, or if initial results cannot be supported by actual long-term studies or clinical experience,
Microbot&rsquo;s business could be adversely affected. Clinical trials also may be suspended or terminated by us, the FDA or other
regulatory authorities at any time if it is believed that the trial participants face unacceptable health risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
has no prior experience in conducting clinical trials and will depend upon the ability of third parties, including contract research
organizations, collaborative academic groups, future clinical trial sites and investigators, to conduct or to assist the Company
in conducting clinical trials for its product candidates, if such trials become necessary.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a development-stage, pre-clinical company, Microbot has no prior experience in designing, initiating, conducting and monitoring
human clinical trials, if data from such trials become necessary in order to obtain regulatory clearance or approval of our product
candidates. Should the FDA or another regulatory agency in a foreign market request clinical data to support the safety and effectiveness
of Microbot&rsquo;s product candidates, Microbot will depend upon its ability and/or the ability of future collaborators, contract
research organizations, clinical trial sites and investigators to successfully design, initiate, conduct and monitor such clinical
trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
by Microbot or by any of these future collaborating parties to timely and effectively initiate, conduct and monitor a future clinical
trial could significantly delay or materially impair Microbot&rsquo;s ability to complete those clinical trials and/or obtain
regulatory clearance or approval of its product candidates and, consequently, could delay or materially impair its ability to
generate revenues from the commercialization of those products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the commercial opportunity for SCS and TipCAT is smaller than Microbot anticipates, Microbot&rsquo;s future revenue from SCS and
TipCAT will be adversely affected and Microbot&rsquo;s business will suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the size of the commercial opportunities in any of Microbot&rsquo;s target markets is smaller than it anticipates, Microbot may
not be able to achieve profitability and growth. Microbot is developing SCS as a device for the treatment of hydrocephalus and
NPH and is developing TipCAT as an endoscopic tool, with colonoscopy as the most immediate application of the TipCAT technology.
Microbot expects its future revenues to be primarily derived from the sales of the SCS and TipCAT, neither of which has undergone
an FDA pre-market review process necessary to commercialize the product candidate in the United States. It is difficult to predict
the penetration, future growth rate or size of the market for Microbot&rsquo;s product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of the SCS and TipCAT will require broad acceptance of the devices by the doctors and other medical professionals
who specialize in the procedures targeted by each device, a limited number of whom may be able to influence device selection and
purchasing decisions. If Microbot&rsquo;s technologies are not broadly accepted and perceived as having significant advantages
over existing medical devices, then it will not meet its business objectives. Such perceptions are likely to be based on a determination
by medical facilities and physicians that Microbot&rsquo;s product candidates are safe and effective, are cost-effective in comparison
to existing devices, and represent acceptable methods of treatment. Microbot cannot assure that it will be able to establish the
relationships and arrangements with medical facilities and physicians necessary to support the market uptake of its product candidates.
In addition, its competitors may develop new technologies for the same markets Microbot is targeting that are more attractive
to medical facilities and physicians. If doctors and other medical professionals do not consider Microbot product candidates to
be suitable for application in the procedures we are targeting and an improvement over the use of existing or competing products,
Microbot&rsquo;s business goals will not be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Customers
will be unlikely to buy the SCS or the TipCAT unless Microbot can demonstrate that they can be produced for sale to consumers
at attractive prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, Microbot has focused primarily on research and development of the first generation versions of the SCS and the TipCAT. Consequently,
Microbot has no experience in manufacturing its product candidates, and intends to manufacture its product candidates through
third-party manufacturers. Microbot can offer no assurance that either it or its manufacturing partners will develop efficient,
automated, low-cost manufacturing capabilities and processes to meet the quality, price, engineering, design and production standards
or production volumes required to successfully mass produce its commercial products. Even if its manufacturing partners are successful
in developing such manufacturing capability and quality processes, including the assurance of GMP-compliant device manufacturing,
there can be no assurance that Microbot can timely meet its product commercialization schedule or the production and delivery
requirements of potential customers. A failure to develop such manufacturing processes and capabilities could have a material
adverse effect on Microbot&rsquo;s business and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed price of Microbot&rsquo;s product candidates, once approved for sale, will be dependent on material and other manufacturing
costs. Microbot cannot offer any assurances that its manufacturing partner will be able manufacture its product candidates at
a competitive price or that achieving cost reductions will not cause a reduction in the performance, reliability and longevity
of its product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
has relied on, and intends to continue to rely on, third-party manufacturers to produce its product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
currently relies, and expects to rely for the foreseeable future, on third-party manufacturers to produce and supply its product
candidates, and it expects to rely on third parties to manufacture the commercialized products as well, should they receive the
necessary regulatory clearance or approval. Reliance on third-party manufacturers entails risks to which Microbot would not be
subject if Microbot manufactured its product candidates or future commercial products itself, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    on supply availability resulting from capacity, internal operational problems or scheduling constraints of third parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    regulatory non-compliance or other violations by the third-party manufacturer that could result in quality assurance issues
    or government enforcement action that has a negative effect on Microbot&rsquo;s product candidates and distribution strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible breach of manufacturing agreements by third parties because of various factors beyond Microbot&rsquo;s control; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possible termination or non-renewal of manufacturing agreements by third parties for various reasons beyond Microbot&rsquo;s
    control, at a time that is costly or inconvenient to Microbot.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Microbot is not able to maintain its key manufacturing relationships, Microbot may fail to find replacement manufacturers or develop
its own manufacturing capabilities, which could delay or impair Microbot&rsquo;s ability to obtain regulatory clearance or approval
for its product candidates and could substantially increase its costs or deplete profit margins, if any. If Microbot does find
replacement manufacturers, Microbot may not be able to enter into agreements with them on terms and conditions favorable to it
and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign
regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot&rsquo;s product candidates are not considered to be a safe and effective alternative to existing technologies, Microbot
will not be commercially successful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SCS and TipCAT rely on new technologies, and Microbot&rsquo;s success will depend on acceptance of these technologies by the medical
community as safe, clinically effective, cost effective and a preferred device as compared to products of its competitors. Microbot
does not have long-term data regarding efficacy, safety and clinical outcomes associated with the use of SCS or TipCAT. Any data
that is generated in the future may not be positive or may not support the product candidates&rsquo; regulatory dossiers, which
would negatively affect market acceptance and the rate at which its product candidates are adopted. Equally important will be
physicians&rsquo; perceptions of the safety of Microbot&rsquo;s product candidates because Microbot&rsquo;s technologies are relatively
new. If, over the long term, Microbot&rsquo;s product candidates do not meet surgeons&rsquo; expectations as to safety, efficacy
and ease of use, they may not become widely adopted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
acceptance of Microbot&rsquo;s product candidates will also be affected by other factors, including Microbot&rsquo;s ability to
convince key opinion leaders to provide recommendations regarding its product candidates; convince distributors that its technologies
are attractive alternatives to existing and competing technologies; supply and service sufficient quantities of products directly
or through marketing alliances; and price products competitively in light of the current macroeconomic environment, which is becoming
increasingly price sensitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
may be subject to penalties and may be precluded from marketing its product candidates if Microbot fails to comply with extensive
governmental regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
believes that its medical device product candidates will be categorized as Class II devices, which typically require a 510(k)
or 510(k) de-novo premarket submission to the FDA. However, the FDA has not made any determination about whether Microbot&rsquo;s
medical product candidates are Class II medical devices and may disagree with that classification. If the FDA determines that
Microbot&rsquo;s product candidates should be reclassified as Class III medical devices, Microbot could be precluded from marketing
the devices for clinical use within the United States for months, years or longer, depending on the specifics of the change in
classification. Reclassification of any of Microbot&rsquo;s product candidates as Class III medical devices could significantly
increase Microbot&rsquo;s regulatory costs, including the timing and expense associated with required clinical trials and other
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and non-U.S. regulatory authorities require that Microbot product candidates be manufactured according to rigorous standards.
These regulatory requirements significantly increase Microbot&rsquo;s production costs, which may prevent Microbot from offering
products within the price range and in quantities necessary to meet market demands. If Microbot or one of its third-party manufacturers
changes an approved manufacturing process, the FDA may need to review the process before it may be used. Failure to comply with
applicable pre-market and post-market regulatory requirements could subject Microbot to enforcement actions, including warning
letters, fines, injunctions and civil penalties, recall or seizure of its products, operating restrictions, partial suspension
or total shutdown of its production, and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot is not able to both obtain and maintain adequate levels of third-party reimbursement for procedures involving its product
candidates after they are approved for marketing and launched commercially, it would have a material adverse effect on Microbot&rsquo;s
business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers and related facilities are generally reimbursed for their services through payment systems managed by various governmental
agencies worldwide, private insurance companies, and managed care organizations. The manner and level of reimbursement in any
given case may depend on the site of care, the procedure(s) performed, the final patient diagnosis, the device(s) utilized, available
budget, or a combination of these factors, and coverage and payment levels are determined at each payor&rsquo;s discretion. The
coverage policies and reimbursement levels of these third-party payors may impact the decisions of healthcare providers and facilities
regarding which medical products they purchase and the prices they are willing to pay for those products. Microbot cannot assure
you that its sales will not be impeded and its business harmed if third-party payors fail to provide reimbursement for Microbot
products that healthcare providers view as adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, Microbot expects that its product candidates, once approved, will be purchased primarily by medical institutions,
which then bill various third-party payors, such as the Centers for Medicare &amp; Medicaid Services, or CMS, which administers
the Medicare program through Medicare Administrative Contractors, and other government health care programs and private insurance
plans, for the healthcare products and services provided to their patients. The process involved in applying for coverage and
incremental reimbursement from CMS is lengthy and expensive. Moreover, many private payors look to CMS in setting their reimbursement
policies and amounts. If CMS or other agencies limit coverage for procedures utilizing Microbot&rsquo;s products or decrease or
limit reimbursement payments for doctors and hospitals utilizing Microbot&rsquo;s products, this may affect coverage and reimbursement
determinations by many private payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a procedure involving a medical device is not reimbursed separately by a government or private insurer, then a medical institution
would have to absorb the cost of Microbot&rsquo;s products as part of the cost of the procedure in which the products are used.
At this time, Microbot does not know the extent to which medical institutions would consider insurers&rsquo; payment levels adequate
to cover the cost of its products. Failure by hospitals and surgeons to receive an amount that they consider to be adequate reimbursement
for procedures in which Microbot products are used could deter them from purchasing Microbot products and limit sales growth for
those products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has no control over payor decision-making with respect to coverage and payment levels for its medical device product candidates,
once they are approved. Additionally, Microbot expects many payors to continue to explore cost-containment strategies (e.g., comparative
and cost-effectiveness analyses, so-called &rdquo;pay-for-performance&rdquo; programs implemented by various public government
health care programs and private third-party payors, and expansion of payment bundling initiatives, and other such methods that
shift medical cost risk to providers) that may potentially impact coverage and/or payment levels for Microbot&rsquo;s current
product candidates or products Microbot develops in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Microbot&rsquo;s product offerings are used across diverse healthcare settings, they will be affected to varying degrees by the
different payment systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
outcome studies for the SCS may not provide sufficient data to make Microbot&rsquo;s product candidates the standard of care.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
business plan relies on the broad adoption by surgeons of the SCS for primary shunt placement procedures to prevent shunt occlusions.
Although Microbot believes the occurrence of shunt occlusion complications is well known among physicians practicing in the relevant
medical fields, SCS may be adopted for replacement shunt surgeries only. Neurosurgeons may adopt SCS for primary shunt placement
procedures only upon additional clinical studies with longer follow up periods, if at all. It may also be necessary to provide
outcome studies on the preventative capabilities of the SCS in order to convince the medical community of its safety and efficacy.
Clinical studies may not show an advantage in SCS based procedures in a timely manner, or at all, and outcome studies have not
been designed at this time, and may be too large and too costly for Microbot to conduct. Both situations could prevent broad adoption
of the SCS and materially impact Microbot&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
products may in the future be subject to mandatory product recalls that could harm its reputation, business and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event
of material deficiencies or defects in design or manufacture that could pose a risk of injury to patients. In the case of the
FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device
would cause serious injury or death, although in most cases this mandatory recall authority is not used because manufacturers
typically initiate a voluntary recall when a device violation is discovered. In addition, foreign governmental bodies have the
authority to require the recall of Microbot products in the event of material deficiencies or defects in design or manufacture.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated
or voluntary recall by Microbot or one of its distributors could occur as a result of component failures, manufacturing errors,
design or labeling defects or other deficiencies and issues. Recalls of any Microbot products would divert managerial and financial
resources and have an adverse effect on Microbot&rsquo;s financial condition and results of operations, and any future recall
announcements could harm Microbot&rsquo;s reputation with customers and negatively affect its sales. In addition, the FDA could
take enforcement action, including any of the following sanctions for failing to timely report a recall to the FDA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">detention
    or seizure of Microbot products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions or partial suspension or total shutdown of production;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    or delaying requests for 510(k) clearance or premarket approval of new products or modified products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing
    510(k) clearances or other types of regulatory authorizations -that have already been granted;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
    to grant export approval for Microbot products; or</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot&rsquo;s future commercialized products cause or contribute to a death or a serious injury, Microbot will be subject to
Medical Device Reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
FDA regulations, Microbot will be required to report to the FDA any incident in which a marketed medical device product may have
caused or contributed to a death or serious injury or in which a medical device malfunctioned and, if the malfunction were to
recur, would likely cause or contribute to death or serious injury. In addition, all manufacturers placing medical devices in
European Union markets are legally bound to report any serious or potentially serious incidents involving devices they produce
or sell to the relevant authority in whose jurisdiction the incident occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
anticipates that in the future it is likely that we may experience events that would require reporting to the FDA pursuant to
the Medical Device Reporting (MDR) regulations. Any adverse event involving a Microbot product could result in future voluntary
corrective actions, such as product actions or customer notifications, or agency actions, such as inspection, mandatory recall
or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending Microbot in a lawsuit,
will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation
and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
could be exposed to significant liability claims if Microbot is unable to obtain insurance at acceptable costs and adequate levels
or otherwise protect itself against potential product liability claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, manufacture, marketing and sale of medical devices entail the inherent risk of liability claims or product recalls. Product
liability insurance is expensive and may not be available on acceptable terms, if at all. A successful product liability claim
or product recall could inhibit or prevent the successful commercialization of Microbot&rsquo;s products, cause a significant
financial burden on Microbot, or both, which in any case could have a material adverse effect on Microbot&rsquo;s business and
financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
results of Microbot&rsquo;s research and development efforts are uncertain and there can be no assurance of the commercial success
of Microbot&rsquo;s product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
believe that its success will depend in part on its ability to expand its product offerings and continue to improve its existing
product candidates in response to changing technologies, customer demands and competitive pressures. As such, Microbot expects
to continue dedicating significant resources in research and development. The product candidates and services being developed
by Microbot may not be technologically successful. In addition, the length of Microbot&rsquo;s product candidates and service
development cycle may be greater than Microbot originally expected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot fail to retain certain of its key personnel and attract and retain additional qualified personnel, Microbot might not
be able to pursue its growth strategy effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
is dependent on its senior management, in particular Harel Gadot, Microbot&rsquo;s Chairman, President and Chief Executive Officer.
Although Microbot believes that its relationship with members of its senior management is positive, there can be no assurance
that the services of any of these individuals will continue to be available to Microbot in the future. Microbot&rsquo;s future
success will depend in part on its ability to retain its management and scientific teams, to identify, hire and retain additional
qualified personnel with expertise in research and development and sales and marketing, and to effectively provide for the succession
of senior management, when necessary. Competition for qualified personnel in the medical device industry is intense and finding
and retaining qualified personnel with experience in the industry is very difficult. Microbot believes that there are only a limited
number of individuals with the requisite skills to serve in key positions at Microbot, particularly in Israel, and it competes
for key personnel with other medical equipment and technology companies, as well as research institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
does not carry, and does not intend to carry, any key man life insurance policies on any of its existing executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to International Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot fails to obtain regulatory clearances in other countries for its product candidates under development, Microbot will
not be able to commercialize these product candidates in those countries.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for Microbot to market its product candidates in countries other than the United States, it must comply with the safety
and quality regulations in such countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, these regulations, including the requirements for approvals, clearance or grant of Conformit&eacute; Europ&eacute;enne,
or CE, Certificates of Conformity and the time required for regulatory review, vary from country to country. Failure to obtain
regulatory approval, clearance or CE Certificates of Conformity (or equivalent) in any foreign country in which Microbot plans
to market its product candidates may harm its ability to generate revenue and harm its business. Approval and CE marking procedures
vary among countries and can involve additional product testing and additional administrative review periods. The time required
to obtain approval or CE Certificate of Conformity in other countries might differ from that required to obtain FDA clearance.
The regulatory approval or CE marking process in other countries may include all of the risks detailed above regarding FDA clearance
in the United States. Regulatory approval or the CE marking of a product candidate in one country does not ensure regulatory approval
in another, but a failure or delay in obtaining regulatory approval or a CE Certificate of Conformity in one country may negatively
impact the regulatory process in others. Failure to obtain regulatory approval or a CE Certificate of Conformity in other countries
or any delay or setback in obtaining such approval could have the same adverse effects described above regarding FDA clearance
in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
cannot be certain that it will be successful in complying with the requirements of the CE Certificate of Conformity and receiving
a CE Mark for its product candidates or in continuing to meet the requirements of the Medical Devices Directive in the European
Economic Area (EEA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel&rsquo;s
Medical Devices Law generally requires the registration of all medical products with the Ministry of Health, or MOH, Registrar
through the submission of an application to the Ministry of Health Medical Institutions and Devices Licensing Department, or AMAR.
If the application includes a certificate issued by a competent authority of a &ldquo;recognized&rdquo; country, which includes
Australia, Canada, the European Community Member States, Japan or the United States, the registration process is expedited, but
is generally still expected to take 6 to 9 months for approval. If certification from a recognized country is not available, the
registration process takes significantly longer and a license is rarely issued under such circumstances, as the MOH may require
the presentation of significant additional clinical data. Once granted, a license (marketing authorization) for a medical device
is valid for five years from the date of registration of the device, except for implants with a life-supporting function, for
which the validity is for only two years from the date of registration. Furthermore, the holder of the license must meet several
additional requirements to maintain the license. Microbot cannot be certain that it will be successful in applying for a license
from the MOH for its product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
operations in international markets involve inherent risks that Microbot may not be able to control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
business plan includes the marketing and sale of its proposed product candidates internationally, and specifically in Europe and
Israel. Accordingly, Microbot&rsquo;s results could be materially and adversely affected by a variety of factors relating to international
business operations that it may or may not be able to control, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    macroeconomic conditions affecting geographies where Microbot intends to do business;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency exchange rates;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    or social unrest or economic instability in a specific country or region;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
    costs of doing business in certain foreign countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">infringement
    claims on foreign patents, copyrights or trademark rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing operations across disparate geographic areas;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    associated with enforcing agreements and intellectual property rights through foreign legal systems;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade
    protection measures and other regulatory requirements, which affect Microbot&rsquo;s ability to import or export its product
    candidates from or to various countries;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    tax consequences;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in legal and regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">military
    conflict, terrorist activities, natural disasters and medical epidemics; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
    ability to recruit and retain channel partners in foreign jurisdictions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot&rsquo;s
financial results may be affected by fluctuations in exchange rates and Microbot&rsquo;s current currency hedging strategy may
not be sufficient to counter such fluctuations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
financial statements are denominated in U.S. dollars and the financial results of the Company are denominated in U.S. dollars,
while a significant portion of Microbot&rsquo;s business is conducted, and a substantial portion of its operating expenses are
payable, in currencies other than the U.S. dollar. Exchange rate fluctuations may have an adverse impact on Microbot&rsquo;s future
revenues or expenses as presented in the financial statements. Microbot may in the future use financial instruments, such as forward
foreign currency contracts, in its management of foreign currency exposure. These contracts would primarily require Microbot to
purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates. Microbot may be exposed to a credit
loss in the event of non-performance by the counterparties of these contracts. In addition, these financial instruments may not
adequately manage Microbot&rsquo;s foreign currency exposure. Microbot&rsquo;s results of operations could be adversely affected
if Microbot is unable to successfully manage currency fluctuations in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Microbot&rsquo;s Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot&rsquo;s
right to develop and commercialize its existing product candidates are subject to the terms and condition of a license granted
to Microbot by Technion Research and Development Foundation Ltd. and termination of the license with respect to one or both of
the technology platforms underlying the product candidates would result in Microbot ceasing its development efforts for the applicable
product candidate(s).</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
entered into a license agreement with Technion Research and Development Foundation Ltd., or TRDF, in 2012 pursuant to which Microbot
obtained an exclusive, worldwide, royalty-bearing, sub-licensable license to certain patents and inventions relating to the SCS
and TipCAT technology platforms. Pursuant to the terms of the license agreement, in order to maintain the license with respect
to each platform, Microbot must use commercially reasonable efforts to develop products covered by the license, including meeting
certain agreed upon development milestones. TRDF has the option to terminate a license granted with respect a particular technology
in the event Microbot fails to meet a development milestone associated with such technology. Therefore, the failure to meet development
milestones may lead to a complete termination of the applicable license agreement and result in Microbot ceasing its development
efforts for the applicable product candidate. The milestones for SCS include commencing initial studies in humans by December
2018 and commencing a clinical trial, if necessary, by December 2019. The milestones for TipCAT include commencing initial studies
in humans by December 2018 and commencing a full clinical trial, if necessary, by December 2020. Failure to meet any development
milestone will give TRDF the right to terminate the license with respect to the technology underlying the missed milestone. Although
Microbot expects to meet the milestone requirements, TRDF has demonstrated flexibility with respect to amending the terms of the
license to extend the milestone dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the license agreement, Microbot is also subject to various other obligations, including obligations with respect to payment upon
the achievement of certain milestones and royalties on product sales. TRDF may terminate the license agreement under certain circumstances,
including material breaches by Microbot or under certain bankruptcy or insolvency events. In the case of termination of the license
by Microbot without cause or by TRDF for cause, TRDF has the right to receive a non-exclusive license from Microbot with respect
to improvements to the licensed technologies made by Microbot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
TRDF were to terminate the license agreement or if Microbot was to otherwise lose the ability to exploit the licensed patents,
Microbot&rsquo;s competitive advantage could be reduced or terminated, and Microbot will likely not be able to find a source to
replace the licensed technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
if there is any future dispute between Microbot and TRDF regarding the respective parties&rsquo; rights under the license agreement,
Microbot&rsquo;s ability to develop and commercialize the SCS and TipCAT may be materially harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
may not meet its product candidates&rsquo; development and commercialization objectives in a timely manner or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has established internal goals, based upon expectations with respect to its technologies, which Microbot has used to assess its
progress toward developing its product candidates. These goals relate to technology and design improvements as well as to dates
for achieving specific development results. If the product candidates exhibit technical defects or are unable to meet cost or
performance goals, Microbot&rsquo;s commercialization schedule could be delayed and potential purchasers of its initial commercialized
products may decline to purchase such products or may opt to pursue alternative products, which would materially harm its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation and infringement claims could cause Microbot to incur significant expenses or prevent Microbot from selling
certain of its product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
medical device industry is characterized by extensive intellectual property litigation. From time to time, Microbot might be the
subject of claims by third parties of potential infringement or misappropriation. Regardless of outcome, such claims are expensive
to defend and divert the time and effort of Microbot&rsquo;s management and operating personnel from other business issues. A
successful claim or claims of patent or other intellectual property infringement against Microbot could result in its payment
of significant monetary damages and/or royalty payments or negatively impact its ability to sell current or future products in
the affected category and could have a material adverse effect on its business, cash flows, financial condition or results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
Microbot or TRDF are unable to protect the patents or other proprietary rights relating to Microbot&rsquo;s product candidates,
or if Microbot infringes on the patents or other proprietary rights of others, Microbot&rsquo;s competitiveness and business prospects
may be materially damaged.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
success depends on its ability to protect its intellectual property (including its licensed intellectual property) and its proprietary
technologies. Microbot&rsquo;s commercial success depends in part on its ability to obtain and maintain patent protection and
trade secret protection for its product candidates, proprietary technologies, and their uses, as well as its ability to operate
without infringing upon the proprietary rights of others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
currently holds, through licenses or otherwise, an intellectual property portfolio that includes U.S. and international patents
and pending patents, and other patents under development. Microbot intends to continue to seek legal protection, primarily through
patents, including the TRDF licensed patents, for its proprietary technology. Seeking patent protection is a lengthy and costly
process, and there can be no assurance that patents will be issued from any pending applications, or that any claims allowed from
existing or pending patents will be sufficiently broad or strong to protect its proprietary technology. There is also no guarantee
that any patents Microbot holds, through licenses or otherwise, will not be challenged, invalidated or circumvented, or that the
patent rights granted will provide competitive advantages to Microbot. Microbot&rsquo;s competitors have developed and may continue
to develop and obtain patents for technologies that are similar or superior to Microbot&rsquo;s technologies. In addition, the
laws of foreign jurisdictions in which Microbot develops, manufactures or sells its product candidates may not protect Microbot&rsquo;s
intellectual property rights to the same extent as do the laws of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
outcomes in current or future legal disputes regarding patent and other intellectual property rights could result in the loss
of Microbot&rsquo;s intellectual property rights, subject Microbot to significant liabilities to third parties, require Microbot
to seek licenses from third parties on terms that may not be reasonable or favorable to Microbot, prevent Microbot from manufacturing,
importing or selling its product candidates, or compel Microbot to redesign its product candidates to avoid infringing third parties&rsquo;
intellectual property. As a result, Microbot may be required to incur substantial costs to prosecute, enforce or defend its intellectual
property rights if they are challenged. Any of these circumstances could have a material adverse effect on Microbot&rsquo;s business,
financial condition and resources or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has the first right, but not the obligation, to control the prosecution, maintenance or enforcement of the licensed patents from
TRDF. However, there may be situations in which Microbot will not have control over the prosecution, maintenance or enforcement
of the patents that Microbot licenses, or may not have sufficient ability to consult and input into the patent prosecution and
maintenance process with respect to such patents. If Microbot does not control the patent prosecution and maintenance process
with respect to the TRDF licensed patents, TRDF may elect to do so but may fail to take the steps that are necessary or desirable
in order to obtain, maintain and enforce the licensed patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
ability to develop intellectual property depends in large part on hiring, retaining and motivating highly qualified design and
engineering staff and consultants with the knowledge and technical competence to advance its technology and productivity goals.
To protect Microbot&rsquo;s trade secrets and proprietary information, Microbot has entered into confidentiality agreements with
its employees, as well as with consultants and other parties. If these agreements prove inadequate or are breached, Microbot&rsquo;s
remedies may not be sufficient to cover its losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dependence
on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights
may result in Microbot&rsquo;s payment of significant monetary damages or impact offerings in its product portfolios.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
long-term success largely depends on its ability to market technologically competitive product candidates. If Microbot fails to
obtain or maintain adequate intellectual property protection, it may not be able to prevent third parties from using its proprietary
technologies or may lose access to technologies critical to our product candidates. Also, Microbot currently pending or future
patent applications may not result in issued patents, and issued patents are subject to claims concerning priority, scope and
other issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Microbot has not filed applications for all of our patents internationally and it may not be able to prevent third parties from
using its proprietary technologies or may lose access to technologies critical to its product candidates in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Microbot
has facilities located in Israel, and therefore, political conditions in Israel may affect Microbot&rsquo;s operations and results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
has facilities located in Israel. In addition, three of its seven directors are residents of Israel. Accordingly, political, economic
and military conditions in Israel will directly or indirectly affect Microbot&rsquo;s operations and results. Since the establishment
of the State of Israel, a number of armed conflicts have taken place between Israel and its Arab neighbors. An ongoing state of
hostility, varying in degree and intensity has led to security and economic problems for Israel. For a number of years there have
been continuing hostilities between Israel and the Palestinians. This includes hostilities with the Islamic movement Hamas in
the Gaza Strip, which have adversely affected the peace process and at times resulted in armed conflicts. Such hostilities have
negatively influenced Israel&rsquo;s economy as well as impaired Israel&rsquo;s relationships with several other countries. Israel
also faces threats from Hezbollah militants in Lebanon, from ISIS and rebel forces in Syria, from the government of Iran and other
potential threats from additional countries in the region. Moreover, some of Israel&rsquo;s neighboring countries have recently
undergone or are undergoing significant political changes. These political, economic and military conditions in Israel could have
a material adverse effect on Microbot&rsquo;s business, financial condition, results of operations and future growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Political
relations could limit Microbot&rsquo;s ability to sell or buy internationally.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
could be adversely affected by the interruption or reduction of trade between Israel and its trading partners. Some countries,
companies and organizations continue to participate in a boycott of Israeli firms and others doing business with Israel, with
Israeli companies or with Israeli-owned companies operating in other countries. Foreign government defense export policies towards
Israel could also make it more difficult for us to obtain the export authorizations necessary for Microbot&rsquo;s activities.
Also, over the past several years there have been calls in Europe and elsewhere to reduce trade with Israel. There can be no assurance
that restrictive laws, policies or practices directed towards Israel or Israeli businesses will not have an adverse impact on
Microbot&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Israel&rsquo;s
economy may become unstable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, Israel&rsquo;s economy may experience inflation or deflation, low foreign exchange reserves, fluctuations in world
commodity prices, military conflicts and civil unrest. For these and other reasons, the government of Israel has intervened in
the economy employing fiscal and monetary policies, import duties, foreign currency restrictions, controls of wages, prices and
foreign currency exchange rates and regulations regarding the lending limits of Israeli banks to companies considered to be in
an affiliated group. The Israeli government has periodically changed its policies in these areas. Reoccurrence of previous destabilizing
factors could make it more difficult for Microbot to operate its business and could adversely affect its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exchange
rate fluctuations between the U.S. dollar and the NIS currencies may negatively affect Microbot&rsquo;s operating costs.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of Microbot&rsquo;s expenses are paid in New Israeli Shekels, or NIS, but its financial statements are denominated
in U.S. dollars. As a result, Microbot is exposed to the risks that the NIS may appreciate relative to the U.S. dollar, or the
NIS instead devalues relative to the U.S. dollar, and the inflation rate in Israel may exceed such rate of devaluation of the
NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the U.S. dollar cost of Microbot&rsquo;s
operations in Israel would increase and Microbot&rsquo;s U.S. dollar-denominated results of operations would be adversely affected.
Microbot cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against
the U.S. dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
primary expenses paid in NIS that are not linked to the U.S. dollar are employee expenses in Israel and lease payments on its
Israeli facility. If Microbot is unsuccessful in hedging against its position in NIS, a change in the value of the NIS compared
to the U.S. dollar could increase Microbot&rsquo;s research and development expenses, labor costs and general and administrative
expenses, and as a result, have a negative impact on Microbot&rsquo;s profits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Funding
and other benefits provided by Israeli government programs may be terminated or reduced in the future and the terms of such funding
may have a significant impact on future corporate decisions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
participates in programs under the auspices of the Israeli Innovation Authority, for which it receives funding for the development
of its technologies and product candidates. If Microbot fails to comply with the conditions applicable to this program, it may
be required to pay additional penalties or make refunds and may be denied future benefits. From time to time, the government of
Israel has discussed reducing or eliminating the benefits available under this program, and therefore these benefits may not be
available in the future at their current levels or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
research and development efforts from inception until now have been financed in part through such Israeli Innovation Authority
royalty bearing grants in an aggregate amount of approximately $901,000 through December 31, 2016. With respect to such grants
Microbot is committed to pay royalties at a rate of between 3% to 3.5% on sales proceeds up to the total amount of grants received,
linked to the dollar, plus interest at an annual rate of USD LIBOR. In addition, as a recipient of Israeli Innovation Authority
grants, Microbot must comply with the requirements of the Israeli Encouragement of Industrial Research and Development Law, 1984,
or the R&amp;D Law, and related regulations. Under the terms of the grants and the R&amp;D Law, Microbot is restricted from transferring
any technologies, know-how, manufacturing or manufacturing rights developed using Israeli Innovation Authority grants outside
of Israel without the prior approval of Israeli Innovation Authority. Therefore, if aspects of its technologies are deemed to
have been developed with Israeli Innovation Authority funding, the discretionary approval of an Israeli Innovation Authority committee
would be required for any transfer to third parties outside of Israel of the technologies, know-how, manufacturing or manufacturing
rights related to such aspects. Furthermore, the Israeli Innovation Authority may impose certain conditions on any arrangement
under which it permits Microbot to transfer technology or development outside of Israel or may not grant such approvals at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved, the transfer of Israeli Innovation Authority -supported technology or know-how outside of Israel may involve the payment
of significant fees, which will depend on the value of the transferred technology or know-how, the total amount Israeli Innovation
Authority funding received by Microbot, the number of years since the funding and other factors. These restrictions and requirements
for payment may impair Microbot&rsquo;s ability to sell its technology assets outside of Israel or to outsource or transfer development
or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the amount of consideration
available to Microbot&rsquo;s shareholders in a transaction involving the transfer of technology or know-how developed with Israeli
Innovation Authority funding outside of Israel (such as through a merger or other similar transaction) may be reduced by any amounts
that Microbot is required to pay to the Israeli Innovation Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
of Microbot&rsquo;s employees and officers are obligated to perform military reserve duty in Israel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
Israeli adult male citizens and permanent residents are obligated to perform annual military reserve duty up to a specified age.
They also may be called to active duty at any time under emergency circumstances, which could have a disruptive impact on Microbot&rsquo;s
workforce.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
may be difficult to enforce a non-Israeli judgment against Microbot or its officers and directors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
operating subsidiary of the Company is incorporated in Israel. Some of Microbot&rsquo;s executive officers and directors are not
residents of the United States, and a substantial portion of Microbot&rsquo;s assets and the assets of its executive officers
and directors are located outside the United States. Therefore, a judgment obtained against Microbot, or any of these persons,
including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the
United States and may not necessarily be enforced by an Israeli court. It also may be difficult to affect service of process on
these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws
in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel
is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim,
it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content
of applicable U.S. law often involves the testimony of expert witnesses, which can be a time consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters
described above. As a result of the difficulty associated with enforcing a judgment against Microbot in Israel, it may be impossible
to collect any damages awarded by either a U.S. or foreign court.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Microbot&rsquo;s Securities and Governance Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
executive officers and directors, through their ownership of common stock, can substantially influence the outcome of matters
requiring shareholder approval and may prevent you and other stockholders from influencing significant corporate decisions, which
could result in conflicts of interest that could cause the Company&rsquo;s stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers and directors collectively beneficially own shares of Common Stock equal to approximately 41% of our outstanding
shares of Common Stock. As a result, such individuals will have the ability, acting together, to substantially influence the election
of our directors and the outcome of corporate actions requiring shareholder approval, such as: (i) a merger or a sale of our Company,
(ii) a sale of all or substantially all of our assets, and (iii) amendments to our articles of incorporation and bylaws. This
concentration of voting power and control could have a significant effect in delaying, deferring or preventing an action that
might otherwise be beneficial to our other shareholders and be disadvantageous to our shareholders with interests different from
those individuals. These individuals also have significant control over our business, policies and affairs as officers and/or
directors of our Company. These stockholders may exert influence in delaying or preventing a change in control of the Company,
even if such change in control would benefit the other stockholders of the Company. Lastly, the significant concentration of stock
ownership may adversely affect the market value of the Company&rsquo;s common stock due to investors&rsquo; perception that conflicts
of interest may exist or arise. Therefore, you should not invest in reliance on your ability to have any control over the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not expect to pay cash dividends on our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying cash dividends on
our Common Stock in the future. Investors seeking cash dividends should not invest in our Common Stock for that purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions in the Company&rsquo;s charter and bylaws under Delaware law may prevent or frustrate attempts by stockholders to change
the board of directors or current management and could make a third-party acquisition of the Company difficult.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in the Company&rsquo;s certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management.
These provisions include a classified board of directors. In addition, because the Company is incorporated in Delaware, it is
governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of outstanding voting
stock from merging or combining with the Company. Although the Company believes these provisions collectively will provide for
an opportunity to receive higher bids by requiring potential acquirors to negotiate with the Company&rsquo;s board of directors,
they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate
or prevent any attempts by the Company&rsquo;s stockholders to replace or remove then current management by making it more difficult
for stockholders to replace members of the board of directors, which is responsible for appointing members of management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price for our Common Stock may be volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our Common Stock may be volatile and subject to wide fluctuations in response to factors including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial or operational estimates or projections;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    in markets generally;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of companies similar to ours;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of new products, acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intellectual property position; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic or political conditions in the United States, Israel or elsewhere.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the securities market has from time to time experienced significant price and volume fluctuations that are not related
to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market
price of shares of our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
issuance of shares upon exercise of outstanding warrants could cause immediate and substantial dilution to existing stockholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of shares upon exercise of warrants could result in substantial dilution to the interests of other stockholders since
the holders of such warrants may ultimately convert and sell the full amount issuable on conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to the Merger</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
our determination to purchase Microbot Israel was based in part on certain financial and other projections about future results,
and projections are subject to inherent risks and uncertainties, the Merger consideration may be greater than the fair market
value of Microbot Israel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Israel provided financial and other projections to us in connection with the determination to purchase Microbot Israel and the
consideration to be paid for Microbot Israel, and we relied in part on Microbot Israel&rsquo;s projections for purposes of valuing
Microbot Israel and agreeing on the purchase price. The valuation was not necessarily indicative of the actual value of Microbot
Israel. Accordingly, if actual financial results in the future are lower than the projections we relied upon, the consideration
may be greater than the fair market value of Microbot Israel, as acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
can give no assurance that the financial and other projections we relied upon are accurate and will be met in the future because
the projections reflect numerous estimates and assumptions with respect to industry performance, general business, economic, regulatory,
market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond Microbot
Israel&rsquo;s and our control. As a result, actual results may differ materially from these projections. It is expected that
there will be differences between actual and projected results because the projections covered multiple years and such information
by its nature becomes less reliable with each successive year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the benefits of the acquisition of Microbot Israel do not meet the expectations of the marketplace, or financial or industry analysts,
the market price of our common stock may decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may decline as a result of the Merger if the Microbot Israel subsidiary does not perform as expected
or we do not otherwise achieve the perceived benefits of the Merger as rapidly as, or to the extent anticipated by the marketplace
or financial or industry analysts. Accordingly, investors may experience a loss as a result of a decreasing stock price and we
may not be able to raise future capital, if necessary, in the equity markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
weakness in internal control over financial reporting or disclosure controls and procedures could result in a loss of investor
confidence in our financial reports and lead to a stock price decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to evaluate our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act of 2002 and
report the results in our annual report on Form 10-K. We are also required to maintain effective disclosure controls and procedures.
After the acquisition of Microbot Israel, our internal controls and our disclosure controls and procedures will need to expand
to encompass activities related to those assets. If material weakness arise as a result and they are not remedied, we will be
unable to assert that our internal controls are effective. Any failure to have effective internal control over financial reporting
or disclosure controls and procedures covering the combined business post-Merger could cause investors to lose confidence in the
accuracy and completeness of our financial reports, limit our ability to raise financing or lead to regulatory sanctions, any
of which could result in a material adverse effect on our business or decline in the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>Item
1B. <U>Unresolved Staff Comments</U></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>Item
2. <U>Description of Property.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot&rsquo;s
principal executive office is located at 25 Recreation Drive, Unit 108, Hingham, MA 02043. Microbot also has facilities in premises
of approximately 1,840 square feet at 5 Hamada Street, 2<SUP>nd</SUP> Floor, Yokneam, Israel. Microbot plans to relocate to a
larger facility in Israel within the next 8-18 months, which will provide the space and infrastructure necessary to accommodate
its development work based on its current operating plan. Microbot does not own any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>Item
3. <U>Legal Proceedings.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time
to time that may harm business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently a party in any legal proceeding or governmental regulatory proceeding nor are we currently aware of any pending
or potential legal proceeding or governmental regulatory proceeding proposed to be initiated against us that would have a material
adverse effect on us or our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>Item
4. <U>Mine Safety Disclosures</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_008"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_009"></A>Item 5. <U>Market for Registrant&rsquo;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our common
stock is listed on the NASDAQ Capital Market under the symbol &ldquo;MBOT&rdquo; since November 29, 2016. Prior to that, our
common stock was traded under the symbol &ldquo;STEM.&rdquo; The following table sets forth for the periods indicated, the
high and low closing prices of our common stock on the NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">High</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended December 31, 2016:</B></FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 63%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1<SUP>st </SUP>Quarter</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">46.33</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">27.10</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2<SUP>nd </SUP>Quarter</FONT>(1)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.24</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.26</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3<SUP>rd </SUP>Quarter</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23.40</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.24</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4<SUP>th </SUP>Quarter</FONT>(2)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.69</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.85</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">High</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended December 31, 2015:</B></FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 63%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1<SUP>st </SUP>Quarter</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149.04</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">105.30</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2<SUP>nd </SUP>Quarter</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">109.09</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54.43</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3<SUP>rd </SUP>Quarter</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63.72</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41.04</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4<SUP>th </SUP>Quarter</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">59.40</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42.12</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) The Company effected a 1-for-12 reverse stock split on May
6, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) The Company effected a 1-for-9 reverse stock split on November
28, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 16, 2017 there were approximately
245 holders of record of our common stock, and the closing sales price of our common stock as reported on the NASDAQ Capital
Market was $6.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dividend Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have never paid
cash dividends on our common stock and we do not anticipate paying cash dividends on common stock in the foreseeable future. The
payment of dividends on our common stock will depend on earnings, financial condition, debt covenants in place, and other business
and economic factors affecting us at such time as our Board of Directors may consider relevant. If we do not pay dividends, our
common stock may be less valuable because a return on a stockholders&rsquo; investment will only occur if our stock price appreciates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Equity Compensation Plan Information Table</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
provides information about shares of our common stock that may be issued upon the exercise of options under all of our existing
compensation plans as of December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of securities to be issued upon exercise of outstanding options, warrants and rights</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted-average exercise price of outstanding options, warrants and rights</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of securities remaining available for future issuance</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Plan Category</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity compensation plans approved by
    security holders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left; padding-left: 10pt">2013 Equity Incentive Plan</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">791</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right">1,120.50</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity compensation plans not approved by security holders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Microbot Israel Employee Stock Option Plan(2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,447,223</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock Options(3)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,167,693</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,615,707</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not intend to grant any additional securities under this Plan.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such options were originally issued by Microbot Israel under its Employee Stock Option Plan, and represented the right to purchase an aggregate of 500,000 of Microbot Israel&rsquo;s ordinary shares. As of the effective time of the Merger, such options were retroactively adjusted to reflect the Merger and now represent the right to purchase shares of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such options were originally issued by Microbot Israel to MEDX Ventures Group LLC, of which Mr. Gadot is the Chief Executive Officer, Company Group Chairman and majority equity owner, and represented the right to purchase an aggregate of 403,592 of Microbot Israel&rsquo;s ordinary shares. As of the effective time of the Merger, such options were retroactively adjusted to reflect the Merger and now represent the right to purchase shares of our common stock.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with
the Merger, the Company issued an aggregate of 26,644,979 shares of Common Stock to the existing shareholders of Microbot Israel
and assumed options to purchase an aggregate of 2,614,916 shares of common stock to the existing optionholders of Microbot Israel.
Additionally, the Company issued an aggregate of 7,802,639 restricted shares of its Common Stock or rights to receive Common Stock,
to certain advisors. Such sales were exempt from registration under Section 4(a)(2) and Regulation D under the Securities Act of
1933, as amended, and the rules promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 27, 2016,
the Company exchanged approximately 9,735,925 shares or rights to acquire shares of its common stock, for approximately 9,736 shares
of a newly designated class of Series A Convertible Preferred Stock, par value $0.01 per share. The issuance of the 9,736 shares
of Preferred Stock was exempt from registration under Section 4(a)(2) and/or 3(a)(9) under the Securities Act of 1933, as amended,
and the rules promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_010"></A>Item 6. Selected Financial Data.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">This item is not required for a smaller
reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_011"></A>Item 7. <U>Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Certain information
contained in this MD&amp;A includes &ldquo;forward-looking statements.&rdquo; Statements which are not historical reflect our current
expectations and projections about our future results, performance, liquidity, financial condition and results of operations, prospects
and opportunities and are based upon information currently available to us and our management and their interpretation of what
is believed to be significant factors affecting our existing and proposed business, including many assumptions regarding future
events. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could
differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result
of various risks, uncertainties and other factors, including those risks described in detail in the section of this Annual Report
on Form 10-K entitled &ldquo;Risk Factors&rdquo; as well as elsewhere in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Forward-looking statements,
which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the
words &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;scheduled,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo;
or &ldquo;project&rdquo; or the negative of these words or other variations on these words or comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In light of these
risks and uncertainties, and especially given the nature of our existing and proposed business, there can be no assurance that
the forward-looking statements contained in this section and elsewhere in this Annual Report on Form 10-K will in fact occur. Potential
investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities
laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information,
future events, changed circumstances or any other reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot is a pre-clinical
medical device company specializing in the research, design and development of next generation micro-robotics assisted medical
technologies targeting the minimally invasive surgery space. Microbot is primarily focused on leveraging its micro-robotic technologies
with the goal of improving surgical outcomes for patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot is currently
developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure
Hydrocephalus, or NPH; and TipCAT, a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy
procedures. Microbot&rsquo;s product candidates are being designed to bring greater functionality to conventional medical devices
and to reduce the known risks associated with such devices. Microbot is currently aiming to complete pre-clinical studies required
for regulatory submission for both product candidates within the next 24 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has no products
approved for commercial sale and has not generated any revenues from product sales since its inception in 2010. From inception
to December 31, 2016, Microbot has raised cash proceeds of approximately $6,300,000 to fund operations, primarily from
government grants, loans, and private placement offerings of debt and equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has never
been profitable and has incurred significant operating losses in each year since inception. Net losses for the years ended December
31, 2016 and 2015 were approximately $9,663,000 and $921,000, respectively. Substantially all of Microbot&rsquo;s operating losses
resulted from expenses incurred in connection with its research and development programs and from general and administrative costs
associated with its operations. As of December 31, 2016, Microbot had a net working capital of approximately $2,532,000, consisting
primarily of cash and cash equivalents. Microbot expects to continue to incur significant expenses and increasing operating losses
for at least the next several years as it continues the clinical development of, and seeks regulatory approval for its product
candidates. Accordingly, Microbot will continue to require substantial additional capital to continue its clinical development
and potential commercialization activities, however, at this time it believes that its net cash will be sufficient to fund its
operations for at least 12 months and fund operations necessary to continue development activities of the SCS and TipCAT.
The amount and timing of Microbot&rsquo;s future funding requirements will depend on many factors, including the timing and results
of its clinical development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Estimated completion
dates and costs for Microbot&rsquo;s clinical development and research programs can vary significantly for each current and future
product candidate and are difficult to predict. As a result, Microbot cannot estimate with any degree of certainty the costs it
will incur in connection with development of its product candidates at this point in time. Microbot anticipates it will make determinations
as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an
ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials,
its ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing
assessments as to each current or future product candidate&rsquo;s commercial potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Financial Operations
Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Research and
Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Research and development
expenses consist primarily of salaries and related expenses and overhead for Microbot&rsquo;s research, development and engineering
personnel, prototype materials and research studies, obtaining and maintaining Microbot&rsquo;s patent portfolio. Microbot expenses
its research and development costs as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>General and
Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">General and administrative
expenses consist primarily of the costs associated with management costs , professional fees for accounting, auditing, consulting
and legal services, and allocated overhead expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot expects that
its general and administrative expenses may increase in the future as it expands its operating activities, maintains and expands
its patent portfolio and incurs additional costs associated with the Merger, the preparation of becoming a public company and maintaining
compliance with exchange listing and SEC requirements. Microbot expects these potential increases will likely include management
costs, legal fees, accounting fees, directors&rsquo; and officers&rsquo; liability insurance premiums and expenses associated with
investor relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has incurred
net losses and has not recorded any income tax benefits for the losses. It is still in its development stage and has not yet generated
revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Critical Accounting Policies and Significant
Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot&rsquo;s management&rsquo;s
discussion and analysis of its financial condition and results of operations are based on its financial statements, which have
been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements
requires Microbot to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the
disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, Microbot evaluates
its estimates and judgments, including those related to accrued research and development expenses. Microbot bases its estimates
on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">While Microbot&rsquo;s
significant accounting policies are described in more detail in the notes to its financial statements, Microbot believes the following
accounting policies are the most critical for fully understanding and evaluating its financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Foreign Currency
Translation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot&rsquo;s functional
currency is the U.S. dollars, and its reporting currency is the U.S. dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Government Grant
and Input Tax Credit Recoveries</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot from time
to time has received, and may in the future continue to receive, grants from the Israeli Innovation Authority to cover eligible
company expenditures. These are presented as other income in the statement of operations and comprehensive loss as the grant funds
are used for or applied towards a number of Microbot&rsquo;s operating expenses, such as salaries and benefits, research and development
and professional and consulting fees. The recoveries are recognized in the corresponding period when such expenses are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot recognizes
research and development expenses as incurred, typically estimated based on an evaluation of the progress to completion of specific
tasks using data such as clinical site activations, manufacturing steps completed, or information provided by vendors on their
actual costs incurred. Microbot determines the estimates by reviewing contracts, vendor agreements and purchase orders, and through
discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials
or services and the agreed-upon fee to be paid for such services. These estimates are made as of each balance sheet date based
on facts and circumstances known to Microbot at that time. If the actual timing of the performance of services or the level of
effort varies from the estimate, Microbot will adjust the estimate accordingly. Nonrefundable advance payments for goods and services,
including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research
and development activities, are capitalized as prepaid expenses and recognized as expense in the period that the related goods
are consumed or services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot may pay fees
to third-parties for manufacturing and other services that are based on contractual milestones that may result in uneven payment
flows. There may be instances in which payments made to vendors will exceed the level of services provided and result in a prepayment
of the research and development expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Comparison of
Years Ended December 31, 2016 and 2015</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
sets forth the key components of Microbot&rsquo;s results of operations for the years ended December 31, 2016 and 2015 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years Ended <BR>
December 31,</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase/</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development
    expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">901</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">823</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">78</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,734</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,642</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Research and Development
Expenses</I>. Microbot&rsquo;s research and development expenses were approximately $948,000 for the year ended December 31, 2016,
compared to approximately $823,000 for the same period in 2015. The increase in research and development expenses of approximately
$78,000 in 2016 was primarily due to an increase in the cost of materials. Microbot expects its research and development expenses
to increase over time as Microbot advances its development programs and begins pre-clinical and clinical trials for SCS and TipCAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>General and Administrative
Expenses</I>. General and administrative expenses were approximately $8,734,000 for the year ended December 31, 2016, compared
to approximately $92,000 for the same period in 2015. The substantial increase in general and administrative expenses of approximately
$8,642,000 in 2016 was primarily due to share based compensation of $676,000, and shares for services issued to consultants relating
to our merger with Microbot Medical Ltd., an Israeli company, in November 2016 of approximately $7,258,000, as well as legal and
professional services paid mainly due to the merger activities. Microbot believes its general and administrative expenses may increase
over time as it advances its programs, increases its headcount and operating activities and incurs expenses associated with being
a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Financing Expenses</I>.
Financing expenses were approximately $28,000 for the year ended December 31, 2016, compared to income of approximately $6,000
for the same period in 2015. The net increase in financial expenses was primarily due to revaluation and interest of Microbot&rsquo;s
convertible loans and changes in fair value of derivative warrants and currency exchange differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Liquidity and Capital
Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has incurred
losses since inception and negative cash flows from operating activities for the years ended December 31, 2016 and 2015. As of
December 31, 2016, Microbot had a net working capital of approximately $2,495,000, consisting primarily of cash and cash equivalents.
Microbot anticipates that it will continue to incur net losses for the foreseeable future as it continues research and development
efforts of its product candidates, hires additional staff, including clinical, scientific, operational, financial and management
personnel, and incurs additional costs associated with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has funded
its operations through the issuance of capital stock, grants from the Israeli Innovation Authority, and convertible debt. As of
December 31, 2016, Microbot raised total cash proceeds of approximately $6,300,000, had a shareholders&rsquo; deficit
of approximately $9,663,000 and incurred a total cumulative loss of approximately $13,035,000 from inception (November 2010) to
December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As a result of the
sale of certain of the assets of StemCells, on November 29, 2016, Microbot raised approximately $2.8 million in cash, after taking
into account the payment of $495,000 to certain StemCells employees but excluding $400,000 held in escrow to satisfy any indemnification
claims of the buyer of the assets. Additionally, subsequent to December 31, 2016, we sold an aggregate of 700,000 shares of our
common stock for net proceeds, after deducting placement agent fees and expenses, of approximately $3.25 million. As a result of
such cash, Microbot believes that its net cash will be sufficient to fund its operations for at least 12 months and fund operations
necessary to continue development activities of the SCS and TipCAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot plans to
continue to fund its research and development and other operating expenses, other development activities relating to additional
product candidates, and the associated losses from operations, through future issuances of debt and/or equity securities and possibly
additional grants from the Israeli Innovation Authority. The capital raises from issuances of convertible debt and equity securities
could result in additional dilution to Microbot&rsquo;s shareholders. In addition, to the extent Microbot determines to incur additional
indebtedness, Microbot&rsquo;s incurrence of additional debt could result in debt service obligations and operating and financing
covenants that would restrict its operations. Microbot can provide no assurance that financing will be available in the amounts
it needs or on terms acceptable to it, if at all. If Microbot is not able to secure adequate additional working capital when it
becomes needed, it may be required to make reductions in spending, extend payment terms with suppliers, liquidate assets where
possible and/or suspend or curtail planned research programs. Any of these actions could materially harm Microbot&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
provides a summary of the net cash flow activity for each of the periods set forth below (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    ended</FONT><FONT STYLE="font-size: 10pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cash
    used in operating activities</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"></TD>
    <TD STYLE="width: 8%; text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(786</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 8%; text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(765</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(25</FONT></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,083</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">413</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,272</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double">$<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(354</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Comparison of the Years Ended December
31, 2016 and 2015</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Cash used in operating
activities for the year ended December 31, 2016 was approximately $786,000, calculated by adjusting net loss from operations by
approximately $9,663,000 to eliminate non-cash and expense items not involving cash flows such as depreciation and accumulated
interest on convertible loans, as well as other changes in assets and liabilities resulting in non-cash adjustments in the income
statement. Cash used in operating activities for the year ended December 31, 2015 was approximately $765, similarly adjusted by
approximately $921,000. Net cash provided by financing activities of approximately $3,083,000 for the year ended December 31, 2016
consisted of proceeds from the sale of convertible promissory notes to existing shareholders of Microbot and net proceeds from
assets and liabilities acquired as a result of the merger which was accounted for as a reverse capitalization, compared to approximately
$2,002,000 in the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Off Balance Sheet
Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot has no off-balance
sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in
financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">In the table below, we set forth our legally
binding and enforceable contractual cash obligations at December 31, 2016 (in thousands).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payments due by period</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less than 1 year</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">1-3 years</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">3-5 years</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">More than 5 years</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long-term debt obligations</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,029</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,029</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital lease obligations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">90</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating lease obligations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase obligations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other long-term liabilities reflected on the Registrant&rsquo;s balance sheet under GAAP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_012"></A>Item 7A. <U>Quantitative and Qualitative
Disclosures About Market Risk.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Interest Rate Risk</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot&rsquo;s cash
and cash equivalents as of December 31, 2016 consisted of readily available checking and money market funds. Microbot&rsquo;s primary
exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates.
However, because of the short-term nature of the instruments in Microbot&rsquo;s portfolio, a sudden change in market interest
rates would not be expected to have a material impact on Microbot&rsquo;s financial condition and/or results of operations. Microbot
does not believe that its cash or cash equivalents have significant risk of default or illiquidity. While Microbot believes its
cash and cash equivalents do not contain excessive risk, Microbot cannot provide absolute assurance that in the future its investments
will not be subject to adverse changes in market value. In addition, Microbot maintains significant amounts of cash and cash equivalents
at one or more financial institutions that are in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Foreign Exchange Risks</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our financial statements
are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business
is conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Exchange rate fluctuations
may have an adverse impact on our future revenues, if any, or expenses as presented in the financial statements. We may in the
future use financial instruments, such as forward foreign currency contracts, in its management of foreign currency exposure. These
contracts would primarily require us to purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates.
We may be exposed to a credit loss in the event of non-performance by the counterparties of these contracts. In addition, these
financial instruments may not adequately manage our foreign currency exposure. Our results of operations could be adversely affected
if we are unable to successfully manage currency fluctuations in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Effects of Inflation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Inflation generally
affects Microbot by increasing its clinical trial costs. Microbot does not believe that inflation and changing prices had a significant
impact on its results of operations for any periods presented herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_013"></A>Item 8. <U>Financial Statements and Supplementary
Data.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The consolidated financial
statements and supplementary data required by this item are included in this Annual Report on From 10-K immediately following Part
IV and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Item 9. <U><A NAME="a_014"></A>Changes in and Disagreements
with Accountants on Accounting and Financial Disclosure.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Item 9A. <U><A NAME="a_015"></A>Controls and Procedures.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><U>Disclosure Controls
and Procedures</U>. We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange
Act). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Chief Executive
Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2016. Based on that review and
evaluation, the Chief Executive Officer and Chief Financial Officer, along with the management of the Company, have determined
that as of December 31, 2016, the disclosure controls and procedures were effective to provide reasonable assurance that information
required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the SEC&rsquo;s rules and forms and were effective to provide reasonable assurance
that such information is accumulated and communicated to our management, including our principal executive officer and principal
financial officer, as appropriate to allow timely decisions regarding required disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><U>Management&rsquo;s
Annual Report on Internal Control Over Financial Reporting.</U> Our management is responsible for establishing and maintaining
effective internal control over financial reporting (as defined in Rule 13a &ndash; 15(f) of the Exchange Act). There are inherent
limitations to the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding
of controls. Accordingly, even effective internal controls can provide only reasonable assurance with respect to financial statement
preparation. Further, because of changes in conditions, the effectiveness of internal control may vary over time. We have assessed
the effectiveness of our internal controls over financial reporting (as defined in Rule 13a -15(f) of the Exchange Act) as of December
31, 2016, and have concluded that, as of December 31, 2016, our internal control over financial reporting was effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This annual report
does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting.
Management&rsquo;s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the
Securities and Exchange Commission that permit us to provide only management&rsquo;s report in this annual report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><U>Changes in Internal
Control Over Financial Reporting.</U> There were no changes in our internal control over financial reporting, identified in connection
with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are
reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_016"></A>Item 9B. <U>Other Information.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><A NAME="a_017"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_018"></A>Item 10. Directors, Executive Officers,
and Corporate Governance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We currently have
seven directors serving on our Board of Directors (our &ldquo;Board&rdquo;). The Board currently consists of Harel Gadot, Yoav
Waizer, Moshe Shoham, Yoseph Bornstein, Solomon Mayer, Scott Burell and Martin Madden. All of such directors were either directors
of Microbot Israel prior to the Merger or were appointed to the Board as of or subsequent to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Messrs. Gadot, Waizer
and Madden are Class I directors whose terms expire at the Company&rsquo;s 2019 annual meeting of stockholders. Messrs. Mayer and
Burell are Class II directors whose terms expire at the Company&rsquo;s 2017 annual meeting of stockholders. Messrs. Bornstein
and Shoham are Class III directors whose terms expire at the Company&rsquo;s 2018 annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Management and Director Changes of the
Company prior to or upon the Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 18, 2016,
Dr. Ian Massey was appointed as the Company&rsquo;s President and Chief Executive Officer. Dr. Massey was also elected to the Company&rsquo;s
Board of Directors. Dr. Massey succeeded Martin McGlynn, who resigned as Chief Executive Officer and as a director of the Company
effective January 17, 2016. On August 15, 2016, Mr. Massey resigned from his position as Chief Executive Officer, President and
as a director of the Company. On August 15, 2016, Gregory Schiffman resigned from his position as the Chief Financial Officer of
the Company. On August 15, 2016, Kenneth Stratton commenced serving as interim President. On August 15, 2016, R. Scott Greer, Alan
Trounson and Irving Weissman resigned from their positions as members of the Board, as well as members of the respective Board
committees on which they serve. On November 28, 2016, effective immediately prior to the effective time of the Merger, each of
Eric Bjerkholt, Ricardo Levy and John Schwartz resigned from the Board and any respective committees of the Board of Directors
on which they served. In addition, on November 28, 2016, Kenneth Stratton resigned from his position as the interim President,
General Counsel and Secretary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
lists the names, ages and positions of the individuals who serve as executive officers and directors of the Company, as of March
16, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Age</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Harel Gadot</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">44</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 61%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">President, Chief Executive Officer and Chairman of the Board of Directors</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoav Waizer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moshe Shoham</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">65</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoseph Bornstein</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">58</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Solomon Mayer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">63</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Scott Burell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Martin Madden</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Harel Gadot</I>,
became President, Chief Executive Officer and Chairman of the Company&rsquo;s Board of Directors following the consummation of
the Merger. Mr. Gadot is a co-founder of Microbot Israel and has served as Microbot Israel&rsquo;s Chief Executive Officer since
Microbot Israel was founded in November 2010. He has been the Chairman of Microbot Israel&rsquo;s board of directors since July
2014. He also serves as the Chairman of XACT Robotics Ltd. since August 2013 and MEDX Xelerator LP since July 2016. From December
2007 to April 2010 Mr. Gadot was a Worldwide Group Marketing Director at Ethicon Inc., a Johnson and Johnson Company, where he
was responsible for the global strategic marketing of the company. Mr. Gadot also held management positions, as well as leading
regional strategic position for Europe, Middle-East and Africa, as well as In Israel, while at Johnson and Johnson. Mr. Gadot served
as director for ConTIPI Ltd. from August 2010 until November 2013 when ConTIPI Ltd. was acquired by Kimberly-Clark Corporation.
Mr. Gadot holds a B.Sc.in Business from Siena College, Loudonville NY, and an M.B.A. from the University of Manchester, UK. The
Company believes that Mr. Gadot is qualified to serve as Chairman of the Board and as President and Chief Executive Officer of
the Company due to his extensive experience in strategic marketing in the medical device industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Yoav Waizer</I>,
became a director of the Company following the Merger and has served as a member of the Board of Directors of Microbot Israel since
May 2015. Mr. Waizer is a Partner and Chief Executive Officer of Medica Venture Partners, a healthcare dedicated venture investing
out of Israel in innovative capital-starved early stage and special situation companies, since November 2005. Prior to his Tenure
at Medica, Mr. Waizer served as CFO &amp; COO at Cedar Fund, a venture capital fund focuses on investing in Israel-related high-tech
companies in the telecom, networking, Internet-infrastructure and enterprise software areas and prior to that Mr. Waizer was the
CFO of Star Ventures Israel, the Israeli fund of Star Ventures, a $1 billion venture capital fund investing in all stages of development
within the Telecom, Enterprise S/W, Wireless and Life Sciences sectors. Mr. Waizer is currently a director of InterCure Ltd., a
company focused on investing in medical technology companies that is traded on the Tel Aviv Stock exchange. Mr. Waizer holds Master
of Business Administration in Information Systems and B.Sc. in Accounting and Statistics, both from the Tel-Aviv University. The
Company believes that Mr. Waizer is qualified to serve as a member of the Company&rsquo;s board due to his extensive investment
experience and extensive knowledge of the life sciences industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Moshe Shoham, D.Sc.</I>,
became a director of the Company following the Merger. Dr. Shoham is a co-founder of Microbot Israel and has served as Chairman
of Microbot Israel&rsquo;s Scientific Advisor Board and as a Director since Microbot Israel was founded in November 2010. Prof.
Shoham has been the head of the robotics laboratory at the Technion-Israel Institute of Technology, Department of Mechanical Engineering
since October 1990 and has been a professor in the Department of Mechanical Engineering at the Technion-Israel Institute of Technology
since October 1989. Prior to that, Dr. Shoham was the director of the robotic laboratory in the Department of Mechanical Engineering
at Columbia University from September 1986 to September 1989. Dr. Shoham has served as a foreign member of the National Academy
of Engineering in the United States since October 2014. In addition, Dr. Shoham founded Mazor Surgical Technologies Ltd., a publically
traded medical device company in the field of surgical robotics, and has been its Chief Technology Officer since January 2003.
Dr. Shoham earned a B.Sc. in 1978, a M.Sc. in 1982 and a D.Sc. in 1986 from the Technion-Israel Institute of Technology. The Company
believes that Dr. Shoham is qualified to serve as Chairman of the Company&rsquo;s Scientific Advisory Board and as a member of
the Board due to his extensive knowledge of the Company&rsquo;s technologies and the surgical robotics industry, and his extensive
business and academic experience in the field of surgical robotics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Yoseph Bornstein</I>,
became a director of the Company following the Merger . Mr. Bornstein is a co-founder of Microbot Israel and has been a member
of the Board of Directors since Microbot Israel was founded in November 2010. Mr. Bornstein founded Shizim Ltd., a life science
holding group in October 2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies
Ltd., a provider of clinical research services and educational programs in Israel since January 2002. He is the Chairman of Biotis
Ltd., a service company for the bio-pharmaceutical industry, since June 2000. In addition, he is the Chairman of Dolphin Medical
Ltd., a service company for the medical device industry, since April 2012 and the Chairman of ASIS Enterprises B.B.G. Ltd., a business
August 2007. In October 1992, Mr. Bornstein founded Pharmateam Ltd., an Israeli company that specialized in representing international
pharmaceutical companies which was sold in 2000. Mr. Bornstein is also a founder of a number of other privately held life-science
companies. Mr. Bornstein served as the Biotechnology Committee Chairman of the Unites States-Israel Science &amp; Technology Commission
(the &ldquo;USISTF&rdquo;) from September 2002 to February 2005 as well as a consultant for USISTF from September 2002 to February
2005. He is also the founder of ILSI-Israel Life Science Industry Organization and ITTN-Israel Tech Transfer Organization. The
Company believes that Mr. Bornstein is qualified to serve as a member of the Board due to his extensive experience in, and knowledge
of, the life sciences industry and international business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Solomon Mayer</I>,
became a director of the Company following the Merger. Mr. Mayer has served as a member of the Board of Directors of Microbot Israel
since June 2014, as the designated director of Alpha Capital. Mr. Mayer has served as the President and Chief Executive Officer
of Mooney Aviation Company since June 1999. He also serves as President of Chailife Line, an organization devoted to help restore
normalcy to family life and better enable them to withstand the crises and challenges of serious pediatric illness. In addition,
Mr. Mayer serves as a Director of the Laniado Hospital, International Medical Search Co. of New York, Blastgard International,
Inc. and Ironwood Gold Corp. The Company believes that Mr. Mayer is qualified to serve as a member of the Board due to his investment
experience and extensive management experience as an executive and director of a variety of companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Scott R. Burell</I>,
became a director of the Company following the Merger. He is the Chief Financial Officer, Secretary and Treasurer of CombiMatrix
Corporation (NASDAQ: CBMX), a family health-focused clinical molecular diagnostic laboratory specializing in pre-implantation
genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders, since November 2006. He successfully
led the split-off of CombiMatrix in 2007 from its former parent, has led several successful public and private debt and equity
financing transactions as well as CombiMatrix&rsquo;s reorganization in 2010. Prior to this, Mr. Burell had served as CombiMatrix&rsquo;s
Vice President of Finance since November 2001 and as its Controller from February 2001 to November 2001. From May 1999 to first
joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc., a publicly traded technology and
information infrastructure company located in Seattle. Prior to this, Mr. Burell spent 9 years with Arthur Andersen&rsquo;s Audit
and Business Advisory practice in Seattle. During his tenure in public accounting, Mr. Burell worked with many clients, both public
and private, in the high-tech and healthcare markets, and was involved in numerous public offerings, spin-offs, mergers and acquisitions.
Mr. Burell is also a Board member and Audit Committee Chairman of AgEagle Aerial Systems, Inc., a private agricultural drone
company based in Kansas. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant
(currently inactive). He holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University.
The Company believes Mr. Burell&rsquo;s qualifications to serve on the Board include his experience as an executive of a public
life sciences company and knowledge of financial accounting in the medical technology field.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Martin Madden</I>,
became a director of the Company since February 6, 2017. Mr. Madden has held various positions at Johnson &amp; Johnson and its
affiliates from 1986 to January 2017, most recently as Vice President, Research &amp; Development of DePuy Synthes, a Johnson &amp;
Johnson Company, from February 2016 to January 2017. Prior to that, from July 2015 to February 2016, Mr. Madden was the Vice President,
New Product Development of Johnson &amp; Johnson Medical Devices. From January 2012 to July 2015, Mr. Madden was the Vice President,
Research &amp; Development of Johnson &amp; Johnson&rsquo;s Global Surgery Group. Mr. Madden holds a MBA from Columbia University,
a M.S. from Carnegie Mellon University in Mechanical Engineering, and a B.S. from the University of Dayton in Mechanical Engineering.
The Company believes that Mr. Madden is qualified to serve as a member of the Board due to his extensive experience in research
and development, portfolio planning, technology assessment and assimilation, and project management and budgeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Executive Officers </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Following are the
name, age and other information for our named executive officers, as of March 16, 2017. All company officers have been appointed
to serve until their successors are elected and qualified or until their earlier resignation or removal. Information regarding
Harel Gadot, our Chairman, President and Chief Executive Officer, is set forth above under &ldquo;&ndash;Board of Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Age</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Position</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">David Ben Naim</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">48</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 62%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yehezkel (Hezi) Himelfarb</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">59</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">General Manager and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">David Ben Naim, became
the Company&rsquo;s Chief Financial Officer following the consummation of the Merger. Mr. Ben Naim is the general manager of DBN
Finance Services Ltd., a company which provides outsourcing financial services to public and private companies, since 2014. Through
DBN Finance Services, Mr. Ben Naim has acted as the outsourced CFO for Emerald Medical Applications Corp. (OTC:MRLA), a digital
health startup company engaged in the development, sale and service of imaging solutions, and Tempramed Inc., a private medical
device company. Prior to that, Mr. Ben Naim served as Chief Financial Officer for several companies in the biomedical and technology
industries. From July 2012 to September 2014, Mr. Ben Naim served as Chief Financial Officer for Insuline Medical Ltd. (TASE: INSL),
an Israel-based company focused on improving performance of insulin treatment methods. From 2008 until 2011, Mr. Ben Naim served
as Chief Financial Officer of Crow Technologies 1977 Ltd. (OTC:CRWTF), a company that designs, develops, manufactures and sells
a broad range of security and alarm systems. From 2007 to 2008, Mr. Ben Naim served as Chief Financial Officer of Ilex Medical
Ltd. (TASE:ILX), a leading company in the medical diagnostics field. From 2003 to 2007, Mr. Ben Naim was the Corporate Controller
of Tadiran Telecom Ltd. He started his career in 1998 at Deloitte &amp; Touche where he left in 2003 as an Audit Senior Manager.
Mr. Ben Naim holds a B.A. in social sciences from Open University, Israel, a CPA license from Ramat Gan College, Israel, and an
M.B.A. from Ono Academic College, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Yehezkel (Hezi) Himelfarb,
became the Company&rsquo;s Chief Operating Officer and General Manager of the Company&rsquo;s Israeli operations on December 5,
2016. Mr. Himelfarb was the Chief Executive Officer from 2008 through November 2016 and a member of the board of directors from
2008 through August 2016 of IceCure Medical Ltd., a Tel Aviv Stock Exchange listed company that develops advanced cryotherapy systems
(cryoablation) intended for the growing physician-office market. Prior to that, from 1999 to 2008, Mr. Himelfarb was the President,
Chief Executive Officer and a member of the board of directors of Remon Medical Technologies, Inc., a venture backed US/Israeli
company that developed and commercialized smart, miniature implants which enabled physicians to assess and treat a variety of medical
conditions, where he, among other things, led its acquisition by Boston Scientific. From 1996 to 1999, he was the Vice President
and Chief Operating Officer of Medtronic-InStent (Israel), which was part of Medtronic&rsquo;s vascular division. From 1982 to
1996, Mr. Himelfarb had various positions at Scitex Corporation Ltd., which was an Israeli-based company specializing in specialty
equipment production. Mr. Himelfarb holds a B.Sc. in Electronic Engineering and an M.B.A. in Marketing and Engineering Management,
both from Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Committees of the Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Presently, the Board
has three standing committees &mdash; the Audit Committee, the Compensation and Stock Option Committee (the &ldquo;Compensation
Committee&rdquo;), and the Corporate Governance and Nominating Committee (the &ldquo;Corporate Governance Committee&rdquo;). All
members of the Audit Committee, the Compensation Committee, and the Corporate Governance Committee are, and are required by the
charters of the respective committees to be, independent as determined under Nasdaq Listing rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Audit Committee </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Audit Committee
is composed of Messrs. Burell, Waizer and Bornstein. Each of the members of the Audit Committee is independent, and the Board has
determined that Mr. Burell is an &ldquo;audit committee financial expert,&rdquo; as defined in SEC rules. The Audit Committee acts
pursuant to a written charter which is available through our website at www.microbotmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The primary function
of the Audit Committee is to assist the Board of Directors in fulfilling its oversight responsibilities. The Audit Committee does
this primarily by reviewing the Company&rsquo;s financial reports and other financial information as well as the Company&rsquo;s
systems of internal controls regarding finance, accounting, legal compliance, and ethics that management and the Board of Directors
have established. The Audit Committee also assesses the Company&rsquo;s auditing, accounting and financial processes more generally.
The Audit Committee recommends to the Board of Directors the appointment of a firm of independent auditors to audit the financial
statements of the Company and meets with such personnel of the Company to review the scope and the results of the annual audit,
the amount of audit fees, the company&rsquo;s internal accounting controls, the Company&rsquo;s financial statements contained
in this proxy statement, and other related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Compensation Committee </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Compensation Committee
is composed of Messrs. Burell and Bornstein. Each of the members of the Compensation Committee is independent. The Compensation
Committee acts pursuant to a written charter which is available through our website at www.microbotmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Compensation Committee
acts pursuant to a written charter. The Compensation Committee makes recommendations to the Board of Directors and management concerning
salaries in general, determines executive compensation and approves incentive compensation for employees and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Nominating and Governance Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Corporate Governance
Committee is composed of Messrs. Shoham, Waizer and Burell. Each of the members of the Corporate Governance Committee is
independent. The Corporate Governance Committee acts pursuant to a written charter which is available through our website at www.microbotmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Corporate Governance
Committee oversees nominations to the Board and considers the experience, ability and character of potential nominees to serve
as directors, as well as particular skills or knowledge that may be desirable in light of the Company&rsquo;s position at any time.
From time to time, the Corporate Governance Committee may engage the services of a paid search firm to help the Corporate Governance
Committee identify potential nominees to the Board. The Corporate Governance Committee and Board seek to nominate and appoint candidates
to the Board who have significant business experience, technical expertise or personal attributes, or a combination of these, sufficient
to suggest, in the Board&rsquo;s judgment, that the candidate would have the ability to help direct the affairs of the company
and enhance the Board as a whole. The Corporate Governance Committee may identify potential candidates through any reliable means
available, including recommendations of past or current members of the Board from their knowledge of the industry and of the Company.
The Corporate Governance Committee also considers past service on the Board or on the board of directors of other publicly traded
or technology focused companies. The Corporate Governance Committee has not adopted a formulaic approach to evaluating potential
nominees to the Board; it does not have a formal policy concerning diversity, for example. Rather, the Corporate Governance Committee
weighs and considers the experience, expertise, intellect, and judgment of potential nominees irrespective of their race, gender,
age, religion, or other personal characteristics. The Corporate Governance Committee may look for nominees that can bring new skill
sets or diverse business perspectives. Potential candidates recommended by security holders will be considered as provided in the
company&rsquo;s &ldquo;Policy Regarding Shareholder Candidates for Nomination as a Director,&rdquo; which sets forth the procedures
and conditions for such recommendations. This policy is available through our website at www.microbotmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">There were no material
changes to the procedures by which securityholders may recommend nominees to the Board, since the Company last provided the disclosure
in this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Director Oversight and Qualifications
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">While management is
responsible for the day-to-day management of the risks the company faces, the Board, as a whole and through its committees, has
responsibility for the oversight of risk management. An important part of risk management is not only understanding the risks facing
the company and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate
for the company. In support of this oversight function, the Board receives regular reports from our Chief Executive Officer and
members of senior management on operational, financial, legal, and regulatory issues and risks. The Audit Committee additionally
is charged under its charter with oversight of financial risk, including the company&rsquo;s internal controls, and it receives
regular reports from management, the company&rsquo;s internal auditors and the company&rsquo;s independent auditors. The chairman
of the Board and independent members of the Board work together to provide strong, independent oversight of the company&rsquo;s
management and affairs through its standing committees and, when necessary, special meetings of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Code of Business Conduct and Ethics </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We have adopted a
Code of Ethics and Conduct that applies to all of our directors, officers, employees, and consultants. A copy of our code of ethics
is posted on our website at www.microbotmedical.com. We intend to disclose any substantive amendment or waivers to this code on
our website. There were no substantive amendments or waivers to this code in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Section 16(a) Beneficial Ownership Reporting
Compliance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Section 16(a) of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), requires our executive officers, directors, and persons
who own more than 10% of a registered class of our equity securities, to file with the SEC reports of ownership of our securities
and changes in reported ownership. Executive officers, directors and greater than 10% beneficial owners are required by SEC rules
to furnish us with copies of all Section 16(a) reports they file. Based solely on a review of the copies of such forms furnished
to us, or written representations from the reporting persons that no Form 5 was required, we believe that, during the fiscal year
ended December 31, 2016, all Section 16(a) filing requirements applicable to our officers, directors and greater than 10% beneficial
owners have been met, with the following exceptions: Gregory T. Schiffman filed two late Form 4&rsquo;s and one late Form 4 amendment;
Ian J. Massey filed one late Form 4; George Koshy filed one late Form 4; and David Ben Naim filed one late Form 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_019"></A>Item 11. Executive Compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
sets forth information regarding each element of compensation that was paid or awarded to the named executive officers of the Company
for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 8pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name and &nbsp;Principal &nbsp;Position</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bonus ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock Awards ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option Awards ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Equity Incentive Plan Compensation ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other &nbsp;Compensation ($)</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total ($)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Harel Gadot(1)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">91,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">91,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">184,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">186,000(2)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">370,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hezi Himelfarb(3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Operating</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer &amp; General</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">David Ben Naim(4)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="32" STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive Officers of StemCells in 2016 (Through Merger)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Martin McGlynn</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">952,396</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">570,000(5)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,522,396</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former Chief</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">570,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,908,360</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,362</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,522,722</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">570,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219,450</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,334</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">832,784</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ian Massey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">359,325</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;(6)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">216,667(7)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">575,992(8)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former President &amp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">291,569</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">94,615</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">765,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,690</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,161,874</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gregory Schiffman</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">413,437</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;(9)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">187,500(10)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">600,937(8)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former Chief</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">487,920</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,114</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,146,034</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">157,500</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">458,500</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28,110</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,094,110</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kenneth Stratton</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">478,476</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">189,667(11)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">668,143</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former interim</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">320,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">102,400</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">364,800</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">33,510</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">820,710</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">President, General Counsel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">320,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89,600</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,580</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">442,180</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">George Koshy</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">616,123(12)</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">616,123</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former Chief</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Gadot&rsquo;s compensation prior to the Merger on November 28, 2016 was paid pursuant to a consulting agreement with MEDX Ventures Group LLC, of which Mr. Gadot is the Chief Executive Officer, Company Group Chairman and majority equity owner.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts
                                         shown do not reflect cash compensation actually received by the named executive officer.
                                         Instead, the amounts shown are the non-cash aggregate grant date fair values of stock
                                         option awards made during the periods presented as determined pursuant to ASC Topic 718
                                         and excludes the effect of forfeiture assumptions. The assumptions used to calculate
                                         the fair value of stock option awards are set forth under Note 10 to the Consolidated
                                         Financial Statements included herein.</P>


</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Himelfarb commenced employment in December 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Ben Naim commenced employment in December 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of his separation agreement with the Company, among other things, Mr. McGlynn received a one-time lump sum payment of $570,000.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with an amendment to Dr.
Massey&rsquo;s then-existing employment agreement, on January 14, 2016, StemCells awarded him restricted stock units to receive
up to 1,250,000 shares of common stock, with vesting of these units tied to the timely and successful conduct and completion of
its Phase II clinical study in spinal cord injury. An additional award of restricted stock units to receive up to 378,460 shares
of common stock, with the same vesting, was made on March 15, 2016.</P>



<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of his separation agreement with the Company, among other things, Mr. Massey received a one-time lump sum payment of $216,667.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(8)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Does not include value of restricted stock units
    granted in 2016.</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 15, 2016, StemCells awarded Mr.
Schiffman restricted stock units to receive up to 720,000 shares of common stock, with vesting of these units tied to the timely
and successful conduct and completion of its Phase II clinical study in spinal cord injury.</P>



<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of his separation agreement with the Company, among other things, Mr. Schiffman received a one-time lump sum payment of $187,500 plus COBRA premiums for a period of twelve months following termination.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>


    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the terms of his separation agreement with the Company, among other things, Mr. Stratton received a one-time lump sum payment of $141,667 plus COBRA premiums for a period of twelve months following termination. In addition, Mr. Stratton was awarded a $48,000 transaction success fee in connection with the completion of the Merger as an incentive for his management of the business during the negotiations and the pre-closing period.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes annual base compensation and retention
    payments to Mr. Koshy in 2016.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the outstanding
equity awards held by each of the named executive officers as of the end of the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option
    Awards</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    Awards</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Name</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of</FONT><FONT STYLE="font-size: 8pt"><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Securities</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Underlying</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Unexercised</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable</FONT></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of</FONT><FONT STYLE="font-size: 8pt"><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Securities</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Underlying</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Unexercised</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Unexercisable</FONT></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option
    Exercise Price</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Option</FONT><FONT STYLE="font-size: 8pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Expiration Date</FONT></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of Shares or Units of Stock That Have Not Vested</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Market
    value of Shares of Units of Stock That Have Not Vested</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Harel Gadot
    (1)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.28</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">9/01/2024</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Hezi Himelfarb</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">David Ben Naim</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="32" STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Former
    Executive Officers of StemCells</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Martin McGlynn</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Ian Massey</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Greg Schiffman</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Kenneth Stratton</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">139(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,829.60(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2/28/2017</FONT><FONT STYLE="font-size: 8pt"></FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">George Koshy</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">80(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,386.80(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8/23/2017</FONT><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">52(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,890.00(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">5/15/2019</FONT><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">23(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,101.60(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6/01/2020</FONT><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&ndash;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such options were granted to MEDX Ventures Group LLC, which is controlled by Mr. Gadot, under Microbot Israel&rsquo;s Employee Stock Option Plan, and represented the right to receive 403,592 ordinary shares of Microbot Israel at an exercise price of $0.8 per share. As of the Merger, the options represent the right to receive 1,167,693 shares of the common stock of the Company, at an exercise price of $0.28 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted to reflect the Company&rsquo;s 1:9 reverse stock split.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    options expired on approximately February 28, 2017, pursuant to the terms of the option grant, as a result of Mr.
    Koshy ceasing to be employed by the Company as of approximately November 28, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Harel Gadot Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company entered
into an employment agreement (the &ldquo;Gadot Agreement&rdquo;) with Harel Gadot on November 28, 2016, to serve as the Company&rsquo;s
Chairman of the Board of Directors and Chief Executive Officer, on an indefinite basis subject to the termination provisions described
in the Agreement. Pursuant to the terms of the Gadot Agreement, Mr. Gadot shall receive an annual base salary of $360,000. The
salary will be reviewed on an annual basis by the Compensation Committee of the Company to determine potential increases taking
into account such performance metrics and criteria as established by the Executive and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Gadot shall also
be entitled to receive a target annual cash bonus of up to a maximum amount of 40% of base salary. On March 9, 2017, the Company
adopted a 2017 bonus plan (the &ldquo;Bonus Plan&rdquo;). The Bonus Plan provides for the payment of Messrs. Gadot&rsquo;s bonus
based on certain milestones of the Company being satisfied, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having closed a financing of at least $3 million in the first quarter of 2017, at which time 20% of the bonus would be payable. Such milestone was satisfied in January 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having closed a financing of at least $10 million by the end of the third quarter of 2017, at which time 20% of the bonus would be payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having entered into research agreements with Wayne State University (the &ldquo;Wayne Agreement&rdquo;) and The Washington University in St. Louis (the &ldquo;Washington Agreement&rdquo;) by the end of the first quarter of 2017, at which time 20% of the bonus would be payable. Such milestone was satisfied in January 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having initiated studies pursuant to both the Wayne Agreement and the Washington Agreement, by the end of April 2017, at which time 15% of the bonus would be payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having completed the initial study from at least one of the Wayne Agreement and the Washington Agreement, by the end of 2017, at which time 15% of the bonus would be payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company meeting its 2017 budget, as approved by the Board of Directors of the Company by March 31, 2017, at which time 10% of the bonus would be payable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Gadot shall be
further entitled to a monthly automobile allowance and tax gross up on such allowance of $1,150, and shall be granted options to
purchase shares of common stock of the Company representing 5% of the issued and outstanding shares of the Company, based on vesting
and other terms to be determined by the Compensation Committee of the Board of Directors subsequent to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event Mr. Gadot&rsquo;s
employment is terminated as a result of death, Mr. Gadot&rsquo;s estate would be entitled to receive any earned annual salary,
bonus, reimbursement of business expenses and accrued vacation, if any, that is unpaid up to the date of Mr. Gadot&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event Mr. Gadot&rsquo;s
employment is terminated as a result of disability, Mr. Gadot would be entitled to receive any earned annual salary, bonus, reimbursement
of business expenses and accrued vacation, if any, incurred up to the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event Mr. Gadot&rsquo;s
employment is terminated by the Company for cause, Mr. Gadot would be entitled to receive any compensation then due and payable
incurred up to the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event Mr. Gadot&rsquo;s
employment is terminated by the Company without cause, he would be entitled to receive (i) any earned annual salary; (ii) 12 months&rsquo;
pay and full benefits, (iii) a pro rata bonus equal to the maximum target bonus for that calendar year; (iv) the dollar value of
unused and accrued vacation days; and (v) applicable premiums (inclusive of premiums for Mr. Gadot&rsquo;s dependents) pursuant
to the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended, for twelve (12) months from the date of termination
for any benefits plan sponsored by the Company. In addition, 100% of any unvested portion of his stock options shall immediately
vest and become exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The agreement contains
customary non-competition and non-solicitation provisions pursuant to which Mr. Gadot agrees not to compete and solicit with the
Company. Mr. Gadot also agreed to customary terms regarding confidentiality and ownership of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Hezi Himelfarb Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We entered into an
employment agreement (the &ldquo;Himelfarb Agreement&rdquo;) with Mr. Himelfarb on December 5, 2016, to serve as our Chief Operating
Office and General Manager, on an indefinite basis subject to the termination provisions described in the Himelfarb Agreement.
Pursuant to the terms of the Himelfarb Agreement, Mr. Himelfarb shall receive a base salary of 64,000 New Israeli Shekel (NIS)
per month or NIS 768,000 per year, or the equivalent of approximately $211,624 per annum based on an exchange rate of $.28
for NIS 1.0. The salary will be reviewed on an annual basis by the Company&rsquo;s Board of Directors to determine potential
salary increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Himelfarb shall
be entitled to grants or payments subject to the adoption by the Company at its discretion of a bonus plan or policy. On March
9, 2017, the Company adopted the Bonus Plan. The Bonus Plan provides for the payment of Messrs. Himelfarb&rsquo;s bonus of
up to 25% of his base salary based on certain milestones of the Company being satisfied, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having closed a financing of at least $3 million in the first quarter of 2017, at which time 20% of the bonus would be payable. Such milestone was satisfied in January 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having closed a financing of at least $10 million by the end of the third quarter of 2017, at which time 20% of the bonus would be payable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having entered into research agreements with Wayne State University (the &ldquo;Wayne Agreement&rdquo;) and The Washington University in St. Louis (the &ldquo;Washington Agreement&rdquo;) by the end of the first quarter of 2017, at which time 20% of the bonus would be payable. Such milestone was satisfied in January 2017.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having initiated studies pursuant to both the Wayne Agreement and the Washington Agreement, by the end of April 2017, at which time 15% of the bonus would be payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company having completed the initial study from at least one of the Wayne Agreement and the Washington Agreement, by the end of 2017, at which time 15% of the bonus would be payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company meeting its 2017 budget, as approved by the Board of Directors of the Company by March 31, 2017, at which time 10% of the bonus would be payable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Himelfarb shall
also entitled participate in the Company&rsquo;s motor vehicle program and receive a motor vehicle from the Company&rsquo;s vehicle
pool, which shall be leased or rented by the Company for use by Mr. Himelfarb. The Company shall pay an amount equal to 8.33% of
Mr. Himelfarb&rsquo;s salary, which shall be allocated to a fund for severance pay to Mr. Himelfarb, and an additional amount equal
to 6.25% of Mr. Himelfarb&rsquo;s salary (6.5% as of January 1, 2017), which shall be allocated to a pension plan, in addition
to disability insurance contributions and as otherwise may be required by applicable Israeli law from time to time. The Company
shall also contribute to an educational fund an amount equal to 7.5% of each monthly payment of Mr. Himelfarb&rsquo;s full salary.
Mr. Himelfarb is also entitled to options to purchase 1,087,627 shares of the Company&rsquo;s common stock, which represents 3%
of the Company&rsquo;s issued and outstanding shares of common stock as of the closing of the Company&rsquo;s merger transaction
with the Subsidiary on November 28, 2016. Such options have not yet been granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Himelfarb Agreement
contains customary non-competition provisions pursuant to which Mr. Himelfarb agrees not to compete with the Company. Mr. Himelfarb
also agreed to customary terms regarding confidentiality and ownership of intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>David Ben Naim Services Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We entered into a
services agreement (the &ldquo;Services Agreement&rdquo;) with DBN Finance Services effective October 31, 2016, to provide outsourced
CFO services. Pursuant to the terms of the Services Agreement, DBN Finance Services will provide its services exclusively through
Mr. David Ben Naim, who will serve as the principal financial and accounting officer of Microbot Israel and the Company. Mr. Ben
Naim&rsquo;s engagement will continue on an indefinite basis subject to the termination provisions described in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Pursuant to the Agreement,
the Company shall pay the Service Provider a fixed fee of NIS15,000, or the equivalent of approximately $4,133 per month based
on an exchange rate of $.28 for NIS1.0, plus VAT per month, and the Company shall reimburse DBN Finance Services for reasonable
and customary out of pocket expenses incurred by it or Mr. Ben Naim connection with the performance of the duties under the Services
Agreement. In addition, the Company shall maintain for the benefit of Mr. Ben Naim, a Directors and Officers insurance policy,
according to the Company&rsquo;s policy for other directors and officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Both the Company and
DBN Finance Services shall have the right to terminate the Agreement for any reason or without reason at any time by furnishing
the other party with a 30-day notice of termination. The Company shall further be entitled to terminate the Services Agreement
for &ldquo;cause&rdquo; without notice, in which case neither DBN Finance Services nor Mr. Ben Naim shall be entitled to any compensation
due to such early termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">DBN Finance Services
and Mr. Ben Naim agreed to customary provisions regarding confidentiality and intellectual property ownership. The Services Agreement
also contains customary non-competition and non-solicitation provisions pursuant to which DBN Finance Services and Mr. Ben Naim
agree not to compete and solicit with the Company during the term of the Agreement and for a period of twelve (12) months following
the termination of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Indemnification Agreements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In connection with
the Merger, the Company entered into indemnification agreements with each of its outgoing directors and executive officers, Eric
Bjerkholt, R. Scott Greer, Ricardo Levy, Ph.D., Ian Massey, D.Phil., John Schwartz, Ph.D., Alan Trounson, Ph.D. and Irving Weissman,
M.D., as well as with its newly appointed directors. Pursuant to the indemnification agreements, the Company has agreed to indemnify
and hold harmless these current and former directors and officers to the fullest extent permitted by the Delaware General Corporation
Law. The agreements generally cover expenses that a director or officer incurs or amounts that a director or officer becomes obligated
to pay because of any proceeding to which he is made or threatened to be made a party or participant by reason of his service as
a current or former director, officer, employee or agent of the Company, provided that he acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of the Company. The agreements also provide for the advancement
of expenses to the directors and officers subject to specified conditions. There are certain exceptions to the Company&rsquo;s
obligation to indemnify the directors and officers, and, with certain exceptions, with respect to proceedings that he initiates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Limits on Liability and Indemnification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We provide directors
and officers insurance for our current directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our certificate of
incorporation eliminate the personal liability of our directors to the fullest extent permitted by law. The certificate of incorporation
further provide that the Company will indemnify its officers and directors to the fullest extent permitted by law. We believe that
this indemnification covers at least negligence on the part of the indemnified parties. Insofar as indemnification for liabilities
under the Securities Act may be permitted to our directors, officers, and controlling persons under the foregoing provisions or
otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Securities Act of 1933 and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Director Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company adopted
a compensation package for the non-management members of its Board, pursuant to which each such Board member would receive for
his services $12,000 per annum, $750 per duly called Board meeting and $250 per unanimous written consent. Furthermore, each member
of the Audit Committee of the Board receives an additional $10,000 per annum, and other committee members receive an additional
$5,000 per annum. All such Board members, provided they do not otherwise beneficially own (or represent holders who beneficially
own) over 2.5% of the Company&rsquo;s outstanding shares of common stock, are also eligible to receive stock options and other
equity incentive grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
summarizes cash-based and equity compensation information for our outside directors, including annual Board and committee retainer
fees and meeting attendance fees, for the year ended December 31, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fees
    earned or paid in cash</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    Awards</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option
    Awards</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Equity
    Incentive Plan Compensation</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonqualified
    Deferred Compensation Earnings</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
    Other Compensation</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoav Waizer</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moshe Shoham</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">330,834</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24,000(2)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right">354,834</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoseph Bornstein</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Solomon Mayer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Scott Burell</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Martin Madden</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts
                                         shown do not reflect cash compensation actually received by the director. Instead, the
                                         amounts shown are the non-cash aggregate grant date fair values of stock option awards
                                         made during the period presented as determined pursuant to ASC Topic 718 and excludes
                                         the effect of forfeiture assumptions. The assumptions used to calculate the fair value
                                         of stock option awards are set forth under Note 10 to the Consolidated Financial Statements
                                         included herein.</P>


</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents consulting fees paid to Professor Shoham.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Mr. Gadot received
compensation for his services to the Company as set forth under the summary compensation table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_020"></A>Item 12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table
shows the number of shares of our common stock beneficially owned, as of March 16, 2017, by (i) each of our directors, (ii) each
of our named executive officers, (iii) all of our current directors and executive officers as a group, and (iv) all those known
by us to be to a beneficial owner of more than 5% of the company&rsquo;s common stock. In general, &ldquo;beneficial ownership&rdquo;
refers to shares that an individual or entity has the power to vote or dispose of, and any rights to acquire common stock that
are currently exercisable or will become exercisable within 60 days of March 16, 2017. We calculated percentage ownership in accordance
with the rules of the SEC. The percentage of common stock beneficially owned is based on 27,251,333 shares outstanding
as of March 16, 2017. In addition, shares issuable pursuant to options or other convertible securities that may be acquired within
60 days of March 16, 2017 are deemed to be issued and outstanding and have been treated as outstanding in calculating and determining
the beneficial ownership and percentage ownership of those persons possessing those securities, but not for any other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This table is based
on information supplied by each prospective director, officer and principal stockholder of the Company. Except as indicated in
footnotes to this table, the Company believes that the stockholders named in this table have sole voting and investment power
with respect to all shares of Common Stock shown to be beneficially owned by them, based on information provided by such stockholders.
Unless otherwise indicated, the address for each director, executive officer and 5% or greater stockholders of the Company
listed is: c/o Microbot Medical Inc., 5 Hamada Street Yokneam 2069204, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial Owner</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of Shares Beneficially Owned</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percentage of Common Stock Beneficially Owned</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors and Executive Officers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 62%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Harel Gadot(1)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,820,664</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.44</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoav Waizer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Moshe Shoham(2)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,550,231</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.12</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Yoseph Bornstein(3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,305,409</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.47</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Solomon Mayer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Scott Burell</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Martin Madden</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">David Ben Naim</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yehezkel (Hezi) Himelfarb</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All current directors and executive
    officers as a group (9 persons)(4)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,676,304</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42.85</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Five Percent Stockholders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">LSA - Life Science Accelerator Ltd.(3)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,305,409</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.47</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Technion Research and Development Foundation
    </FONT>Ltd.(5)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,555,339</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.05</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">MEDX Ventures Group LLC(6)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,820,664</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.44</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leon Lewkowicz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,149,438</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.56</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Saber Holding GmbH</FONT>(7)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,307,003</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.80</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">GreenBlock Capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,950,660</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.16</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lane Ventures</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,950,660</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.16</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,167,960 shares of the Company&rsquo;s common stock issuable upon the exercise of options granted to MEDX Ventures Group. All of such shares and options are held by MEDX Ventures Group LLC, which is beneficially owned by Mr. Gadot. See Note 5 below. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 708,141 shares of the Company&rsquo;s common stock issuable upon the exercise of options. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on representations and other information made or provided to Microbot by Mr. Bornstein, Mr. Bornstein is the CEO and Director
    of LSA and of Shizim, and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA.
    Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these
    entities and has an address of 16 Iris Street, Rosh-Ha&rsquo;Ayin Israel 4858022.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes shares of the Company&rsquo;s common stock issuable upon the exercise of options as set forth in footnotes (1) and (2). </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The address of Technion Research and Development
    Foundation is Technion City, Malat Bldg., 5th Floor, Haifa, Israel 3200003.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 1,167,960 shares of the Company&rsquo;s common stock issuable upon the exercise of options granted to MEDX Ventures Group. Mr. Gadot is the Chief Executive Officer, Company Group Chairman and majority equity owner of MEDX Venture Group and thus may be deemed to share voting and investment power over the shares beneficially owned by this entity. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to a Schedule 13D/A-1 filed on January
    9, 2017, Mrs. Sandra Berkson owns 100% of the equity of Saber Holding GmbH. Mr. Avram Berkson and Mrs. Sandra Berkson have
    shared power with Saber to vote or direct the vote, and to dispose or direct the disposition, of such shares. Saber&rsquo;s
    address is Krummbaumgasse 10/20, 1020 Wein, Austria.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_021"></A>Item 13. Certain Relationships and Related Transactions, and
Director Independence.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Related parties can
include any of our directors or executive officers, certain of our stockholders and their immediate family members. Each year,
we prepare and require our directors and executive officers to complete Director and Officer Questionnaires identifying any transactions
with us in which the officer or director or their family members have an interest. This helps us identify potential conflicts of
interest. A conflict of interest occurs when an individual&rsquo;s private interest interferes, or appears to interfere, in any
way with the interests of the company as a whole. Our code of ethics requires all directors, officers and employees who may have
a potential or apparent conflict of interest to immediately notify our general counsel, who serves as our compliance officer. In
addition, the Corporate Governance Committee is responsible for considering and reporting to the Board any questions of possible
conflicts of interest of Board members. Our code of ethics further requires pre-clearance before any employee, officer or director
engages in any personal or business activity that may raise concerns about conflict, potential conflict or apparent conflict of
interest. Copies of our code of ethics and the Corporate Governance Committee charter are posted on the corporate governance section
of our website at www.microbotmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2011, Microbot
Israel entered into a consulting agreement with MEDX Ventures Group LLC, of which Mr. Gadot is the Chief Executive Officer, Company
Group Chairman and majority equity owner (the &ldquo;Gadot Consulting Agreement&rdquo;), pursuant to which Mr. Gadot served as
Microbot Israel&rsquo;s Chief Executive Officer. Under the terms of the Gadot Consulting Agreement, MEDX Ventures Group received
a monthly fee of $17,000, which amount was to increase to $25,000 per month upon the consummation of a merger or other similar
transaction. Under the Gadot Consulting Agreement, MEDX Ventures Group and Mr. Gadot was subject to customary non-competition,
non-solicitation, confidentiality and intellectual property ownership provisions. In addition, MEDX Ventures Group was entitled
to receive reimbursement for all direct expenses in connection with the performance of services under the Gadot Consulting Agreement.
Either Microbot or MEDX Ventures Group was entitled to terminate the Gadot Consulting Agreement upon 60 days&rsquo; written notice.
MEDX Ventures Group LLC is a stockholder of Microbot. As a result of the Merger, the Gadot Consulting Agreement was terminated
in November 2016 and was replaced with an employment agreement between the Company and Mr. Gadot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In 2015, Microbot
Israel issued convertible promissory notes, at an interest rate of 10%, in the aggregate principal amount of $411,500 (the &ldquo;2015
Notes&rdquo;) to certain investors and Microbot Israel shareholders. The 2015 Notes matured on July 8, 2016. The principal and
accrued but unpaid interest on the 2015 Notes converted into 452,650 shares of Series A Preferred Stock of Microbot Israel and
warrants to purchase 409,750 shares of Series A Preferred Stock of Microbot Israel. The table below sets forth the 2015 Notes with
aggregate principal in excess of $120,000 that were purchased by Microbot&rsquo;s directors, executive officers and holders of
more than 5% of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of 2015 Bridge Note Holder</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding Principal </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Purchased in 2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 79%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Saber Holding GmbH</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leon Lewkowicz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">140,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In 2016, Microbot
Israel issued convertible promissory notes, at an annual interest rate of 10%, in the aggregate principal amount of $750,000 (the
&ldquo;2016 Notes&rdquo;) to certain investors and Microbot Israel shareholders. The principal and accrued but unpaid interest
on the 2016 Notes converted, at a 20% discount, into common stock upon the consummation of the Merger. The table below sets forth
the 2016 Notes with aggregate principal in excess of $120,000 that were purchased by Microbot Israel&rsquo;s directors, executive
officers and holders of more than 5% of its capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of 2016 Bridge Note Holder</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding Principal </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Purchased in 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 79%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Alpha Capital Anstalt</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">400,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Saber Holding GmbH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leon Lewkowicz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,000</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Microbot Israel entered
into a license agreement with Technion Research and Development Foundation Ltd., or TRDF, in 2012 pursuant to which Microbot Israel
obtained an exclusive, worldwide, royalty-bearing, sub-licensable license to certain patents and inventions relating to the SCS
and TipCAT technology platforms. TRDF is a founding member of Microbot and current beneficially owns approximately 14.5% of Microbot&rsquo;s
ordinary shares on an as converted basis. See &ldquo;Description of Business &ndash; Intellectual Property&rdquo; for a description
of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 15, 2016,
Microbot Israel and Alpha Capital Anstalt (&ldquo;Alpha Capital&rdquo;), an existing shareholder of Microbot Israel, entered into
an agreement pursuant to which, among other things, Alpha Capital agreed to fund a proposed $4 million private placement, which
obligation would be reduced dollar-for-dollar by any third party investors investing in such private placement. This agreement
was superseded by the Letter Agreement referred to below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company entered
into a letter agreement (the &ldquo;Letter Agreement&rdquo;) with Alpha Capital, dated November 18, 2016 but effective November
28, 2016 pursuant to which Alpha Capital committed to make a cash investment into the Company, no later than December 31, 2016,
in an amount equal to the difference between $4 million and the amount of cash released to the Company, by December 31, 2016, out
of escrow pursuant to the Company&rsquo;s asset sale transaction with BOCO Silicon Valley, Inc., a California corporation. The
Company waived Alpha Capital&rsquo;s commitments under the Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On August 15, 2016,
concurrently with the execution of the Merger Agreement, the Company issued a 5.0% secured note (the &ldquo;Secured Note&rdquo;)
to Alpha Capital, in the principal amount of $2 million, payable upon the earlier of (i) 30 days following the consummation of
the Merger and (ii) December 31, 2016. In addition, on August 15, 2016, the Company and Alpha Capital entered into a Security Agreement
to secure the Company&rsquo;s obligations under the Secured Note (the &ldquo;Security Agreement&rdquo;). The Company&rsquo;s obligations
under the Secured Note were secured by a first priority security interest in all of the Company&rsquo;s intellectual property and
certain other general assets. As of November 28, 2016, the Company entered into a Securities Exchange Agreement (the &ldquo;Exchange
Agreement&rdquo;) with Alpha Capital, providing for the issuance to Alpha Capital of a convertible promissory note by the Company
(the &ldquo;Convertible Note&rdquo;) in a principal amount of $2,028,767, which is equal to the principal and accrued interest
under the Secured Note, in exchange for (a) the full satisfaction, termination and cancellation of the Secured Note and (b) the
release and termination of the Security Agreement and the first priority security interest granted thereunder. The Convertible
Note is convertible into the Company&rsquo;s common stock any time after November 28, 2017 until the maturity date of November
28, 2019, based on a conversion price of $0.64, subject to adjustments as provided in the Convertible Note and the other terms
and the conditions specified in the Convertible Note. Pursuant to the terms of the Note, the Company is obligated to pay interest
on the outstanding principal amount owed under the Note at a fixed rate per annum of 6.0%, payable at maturity or earlier conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 16, 2016,
the Company entered into a Securities Exchange Agreement with Alpha Capital, pursuant to which Alpha exchanged approximately 9,735,925
shares or rights to acquire shares of the common stock of the Company held by it, for approximately 9,736 shares of a newly designated
class of Series A Convertible Preferred Stock, par value $0.01 per share. The common stock and common stock underlying the rights
include all of the shares of common stock issued or issuable to Alpha Capital pursuant to the Merger. The closing of the exchange
was effective as of December 27, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Director Independence </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">NASDAQ&rsquo;s listing
standards and the Company&rsquo;s Corporate Governance Guidelines require that the Company&rsquo;s Board of Directors consist of
a majority of independent directors, as determined under the applicable NASDAQ listing rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The independent members
of our Board are Messrs. Waizer, Shoham, Bornstein, Mayer, Burell and Madden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_022"></A>Item 14. Principal Accountant Fees and Services.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Audit and Tax Fees </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Board, upon the
recommendation of the Audit Committee, has selected the independent accounting firm of Brightman Almagor Zohar &amp; Co., a Member
of Deloitte Touche Tohmatsu Limited, to audit the accounts of the Company for the year ending December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Audit Committee
considered the tax compliance services provided by Brightman Almagor Zohar &amp; Co., concluded that provision of such services
is compatible with maintaining the independence of the independent accountants, and approved the provision by Brightman Almagor
Zohar &amp; Co. of tax compliance services with respect to the year ending December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Audit Committee
received the following information concerning the fees of the independent accountants for the years ended December 31, 2016 and
2015, has considered whether the provision of these services is compatible with independence of the independent accountants, and
concluded that it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year Ended</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">12/31/16</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">12/31/15</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit Fees (1)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,000</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Audit-Related Fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All Other Fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees represents fees for the integrated audit of our annual consolidated financial statements and reviews of the interim consolidated
    financial statements, and review of audit-related SEC filings; also includes fees related to issuing comfort letter(s). </FONT>Also
    includes tax filing fees.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Audit and tax fees include administrative overhead
charges and reimbursement for out-of-pocket expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Pre-Approval Policies and Procedures
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Audit Committee
has adopted policies and procedures for pre-approving all services (audit and non-audit) performed by our independent auditors.
In accordance with such policies and procedures, the Audit Committee is required to pre-approve all audit and non-audit services
to be performed by the independent auditors in order to assure that the provision of such services is in accordance with the rules
and regulations of the SEC and does not impair the auditors&rsquo; independence. Under the policy, pre-approval is generally provided
up to one year and any pre-approval is detailed as to the particular service or category of services and is subject to a specific
budget. In addition, the Audit Committee may pre-approve additional services on a case-by-case basis. During 2015 and through November
28, 2016, Microbot Israel did not have a standing audit committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B><A NAME="a_023"></A>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B><A NAME="a_024"></A>Item 15. Exhibits and Financial Statement
Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) The following documents are filed as part
of this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) Financial Statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The financial statements
are filed as part of this Annual Report on Form 10-K commencing on page F-1 and are hereby incorporated by reference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) Financial Statement Schedules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The financial statement
schedules are omitted as they are either not applicable or the information required is presented in the financial statements and
notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(3) Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The documents set
forth below are filed herewith or incorporated by reference to the location indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.7in; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 0.1in; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title or Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">2.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify">Agreement and plan of
    merger and Reorganization, dated as of August 15, 2016, by and among StemCells, Inc., C&amp;RD Israel Ltd. and Microbot Medical
    Ltd.(1)</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restated
    Certificate of Incorporation of the Registrant(2)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Amendment to the Restated Certificate of Incorporation of the Registrant(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated By-Laws of the Registrant(4)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate
    of Designations of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock(5)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">4.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify">Form of Series A Warrant(6)</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">4.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify">Form of Series B Warrant(6)</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    Agreement between the Company and Alpha Capital Anstalt(3) </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Exchange Agreement between the Company and Alpha Capital Anstalt(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Promissory Note in favor of Alpha Capital Anstalt(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement, by and between the Company and each of its directors and officers(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement with Harel Gadot(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
    Agreement with DBN Finance Services Ltd.(3)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement with Yehezkel Himelfarb(7) </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Exchange Agreement with Alpha Capital Anstalt(5) </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated as of January 5, 2017(8) </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Agreement, dated as of January 4, 2017(8)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, dated as of November 11, 2016, by and among StemCells, Inc., Stem Cell Sciences Holdings Limited, Stemcells California, Inc., and Boco Silicon Valley, Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escrow Agreement, as of November 11, 2016, by and among BOCO Silicon Valley, Inc., StemCells, Inc., Continental Stock Transfer &amp; Trust Company, Kenneth B. Stratton and Alpha Capital Anstalt</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Research Agreement, dated as of January 27, 2017, with The Washington University</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, as of June 20, 2012, by and between Technion Research and Development Foundation, and Microbot Medical Ltd.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2013 Equity Incentive Plan(9) </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    agreement, dated January&nbsp;10, 2016, between the Registrant and Martin McGlynn(10)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">10.17*&nbsp;</P></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Severance
                                    Buy-Out Agreement, Compromise and Release, by and between StemCells, Inc. and Ken Stratton,
                                    dated June 6, 2016(11)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance
    Buy-Out Agreement, Compromise and Release, by and between StemCells, Inc. and Gregory Schiffman, dated June 6, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance
    Buy-Out Agreement, Compromise and Release, by and between StemCells, Inc. and Ian Massey, dated June 6, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation
    and Consulting Agreement, by and between StemCells, Inc. and Ken Stratton, dated June 6, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation
    and Consulting Agreement, by and between StemCells, Inc. and Gregory Schiffman, dated June&nbsp;6, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation
    and Consulting Agreement, by and between StemCells, Inc. and Ian Massey, dated June 6, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trust
    Agreement, by and between the StemCells, Inc. and David A Bradlow, dated June 16, 2016(11)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Voting Agreement, dated as of August 15, 2016, by and&nbsp;among StemCells, Inc., and certain stockholders of Microbot
    Medical Ltd. (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00%
    Secured Note issued on August 15, 2016 by StemCells, Inc. (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset
    Purchase Agreement, dated as of July 13, 2016, by and between StemCells, Inc. and Miltenyi Biotec, Inc. (1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Settlement
    Agreement, dated as of July 29, 2016, by and among BMR-Pacific Research Center LP and StemCells, Inc. (1)</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="width: 0.1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries of the Registrant</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification Pursuant to Securities Exchange Act Rule 13(a)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Harel Gadot, Chief Executive Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification Pursuant to Securities Exchange Act Rule 13(a)-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (David Ben Naim, Chief Financial Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Harel Gadot, Chief Executive Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (David Ben Naim, Chief Financial Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Labels</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.Pre</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">Incorporated by reference
                                         to the Registrant&rsquo;s Current Report on Form 8-K filed on August 15, 2016.</P>


</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and filed on March 15, 2007.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K filed on November 29, 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
    by reference to the Registrant&rsquo;s Current report on Form 8-K filed on May 3, 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(5)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K filed on December 16, 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(6)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorporated by reference to the Registrant&rsquo;s
    Current Report on Form 8-K filed on March 11, 2016.</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(7)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I<FONT STYLE="font-size: 10pt">ncorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K filed on December 8, 2016.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(8)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">I<FONT STYLE="font-size: 10pt">ncorporated by reference to the Registrant&rsquo;s Current Report on Form 8-K filed on January 5, 2017.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s definitive proxy statement filed October 31, 2013.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(10)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorporated by reference to the Registrant&rsquo;s
    Quarterly Report on Form 10-Q for the Quarter ended March 31, 2016, filed on May 10, 2016.</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(11)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Incorporated by reference to the Registrant&rsquo;s
    Quarterly Report on Form 10-Q for the Quarter ended June 30, 2016, filed on August 15, 2016.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">* Indicates Management contract or compensatory
plan or arrangement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 53%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>President, Chief Executive Officer and Chairman</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 21, 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature </B>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Harel Gadot</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman, President and Chief Executive Officer </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harel Gadot</B> &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ David Ben Naim </I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David Ben Naim</B> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Moshe Shoham &nbsp;</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Moshe Shoham</B> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Yoav Waizer</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yoav Waizer</B> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Yoseph Bornstein</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Yoseph Bornstein</B> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Solomon Mayer</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Solomon Mayer</B> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Scott Burell</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scott Burell </B>&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Martin Madden</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Martin Madden</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MICROBOT MEDICAL INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS OF DECEMBER 31, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 90%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Page</U></B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2 &ndash; F-3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_002">Consolidated Balance Sheets as of December 31, 2016, and 2015</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_003">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2016 and 2015</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_004">Consolidated Statements of Shareholders&rsquo; Equity (Deficit) for the years ended December 31, 2016 and 2015</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_005">Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7 &ndash; F-8</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#f_006">Notes to the Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9 &ndash; F-24</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 48; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><IMG SRC="image_003.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B><A NAME="f_001"></A>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>TO THE BOARD OF DIRECTORS
AND STOCKHOLDERS OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>MICROBOT MEDICAL INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheet of Microbot Medical Inc. and its subsidiaries (the &ldquo;Company&rdquo;) as of December 31, 2016 and the related
consolidated statement of comprehensive loss, stockholders&rsquo; equity, and cash flows for the year in the period ended December
31, 2016. These financial statements are the responsibility of the Company&rsquo;s Board of Directors and management. Our responsibility
is to express an opinion on the financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits
included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control
over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our opinion, based on our audits, such consolidated
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2016 and
the results of its operations and cash flows for the year in the period ended December 31, 2016 in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Brightman Almagor Zohar &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Certified Public Accountants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Member of Deloitte Touche Tohmatsu Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tel Aviv, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>March 21, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="color: Red; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEPENDENT AUDITORS&rsquo; REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO THE SHAREHOLDERS OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MICROBOT MEDICAL LTD. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying financial
statements of Microbot Medical Ltd. (&ldquo;the Company&rdquo;), which comprise the balance sheets as of December 31, 2015 and
the related statement of comprehensive loss, statements of changes in shareholders&rsquo; deficit and statements of cash flows
for the year then ended and the related notes to the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management&rsquo;s Responsibility for the Financial
Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management is responsible for the preparation
and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States
of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair
presentation of financial statements that are free from material misstatement, whether due to fraud or error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Auditors&rsquo; Responsibility</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our responsibility is to express an opinion
on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free from material misstatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An audit involves performing procedures to
obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor&rsquo;s
judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
In making those risk assessments, the auditor considers internal control relevant to the Company&rsquo;s preparation and fair presentation
of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the Company&rsquo;s internal control. Accordingly, we express no such opinion.
An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting
estimates made by management, as well as evaluating the overall presentation of the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that the audit evidence we have
obtained is sufficient and appropriate to provide a basis for our audit opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Opinion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of the Company as of December 31, 2015 and the results
of operations, changes in shareholders&rsquo; equity and cash flows for the year then ended in accordance with generally accepted
accounting principles in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Without qualifying our opinion, we draw attention
to Note 1 to the financial statements regarding risk factors and the Company&rsquo;s business condition. As described in that note,
the Company is dependent on outside financing and on the continuing support of its investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Brightman Almagor Zohar &amp; Co. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Certified Public Accountants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Member of Deloitte Touche Tohmatsu Limited </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>July 27, 2016 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U><A NAME="f_002"></A>Consolidated Balance Sheets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 63%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,709</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other receivables</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">606</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,315</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">491</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fixed assets, net</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,368</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">529</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY (DEFICIT)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Trade payables</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">201</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">582</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">783</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">174</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long term liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible notes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">76</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">419</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative warrant liability</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">313</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">389</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">419</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Temporary equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock of $0.01 par value; issued and outstanding: 10,702,838 shares as of December 31, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders&rsquo; equity (deficit)*:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock of $0.01 par value (Microbot Medical Ltd.); Authorized: 11,610,843 shares as of December 31, 2015; issued and outstanding: 8,708,132 shares as of December 31, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock of $0.01 par value (Microbot Medical Inc.); Authorized: 1,000,000 shares as of December 31, 2016; issued and outstanding: 9,736 shares as of December 31, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock of $0.01 par value; Authorized: 220,000,000 and 58,054,213 shares as of December 31, 2016, and December 31, 2015, respectively; issued and outstanding: 15,848,136 and 13,182,660 shares as of December 31, 2016, and December 31, 2015, respectively</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">266</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">132</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,465</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,089</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated deficit</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(13,035</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,372</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,696</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(64</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,368</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">529</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31 2015 share data represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 14.2pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of these consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U><A NAME="f_003"></A>Consolidated Statements of Comprehensive
Loss</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years ended</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands, except <BR>
per share data)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 63%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses, net</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">901</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">823</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,734</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,635</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(915</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Financing income (expenses), net</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(28</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,663</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(921</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic and diluted net loss per share</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.04</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of these consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U><A NAME="f_004"></A>Consolidated Statements of Shareholder&rsquo;s
Equity (Deficit)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Dollars in Thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Temporary</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred A Shares &ndash; Microbot Medical Ltd. </B></P> <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Pre - merger)*</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Preferred A Shares &ndash; Microbot Medical Inc.</B></P> <P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Post - merger)*</B></P></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Additional paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt">Total <BR> shareholders&rsquo;<BR> equity</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">equity</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Numer</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">capital</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">deficit</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(deficit)</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; font: bold 8pt Times New Roman, Times, Serif">Balance, December 31, 2014</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 4%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; font: 8pt Times New Roman, Times, Serif; text-align: right">8,708,132</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">13,182,660</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">132</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">3,089</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">(2,451</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">857</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(921</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(921</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif">Balances, December 31, 2015</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">8,708,132</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">87</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">13,182,660</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">132</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">3,089</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(3,372</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(64</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Conversion of convertible notes and exercise of warrants issued upon conversion</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">4,746,237</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">48</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">1,803</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">1.851</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Effect of reverse recapitalization</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(13,454,369</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(135</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">15,301,675</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">153</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">454</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">472</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Common Stock classified as temporary equity</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">500</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(500</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(500</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Beneficial Conversion Feature recorded on convertible debt acquired in reverse recapitalization</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,029</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,029</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">Transaction costs incurred in reverse recapitalization</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">7,802,639</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">78</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">6,817</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">6,895</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">Cancellation of ordinary shares and issuance of preferred shares</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">9,736</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(9,736,000</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(97</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">97</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">Share based compensation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">676</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">676</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(9,663</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(9,663</TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances, December 31, 2016</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">500</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left; border-right: Black 1.5pt solid">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">9,736</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">**26,550,974</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">266</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">14,465</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">(13,035</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">1,696</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share data for periods prior to the reverse recapitalization represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 10,702,838 shares of common stock classified as temporary equity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of these consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U><A NAME="f_005"></A>Consolidated Statements of Cash Flows</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years ended</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">OPERATING ACTIVITIES</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,663</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(921</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest and revaluation of convertible notes, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">333</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share based transaction costs incurred in reverse recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,258</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in fair value of derivative warrant liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(262</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based compensation expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">676</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in assets and liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase in other receivables</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">538</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase in other payables and accrued liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">324</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in operating activities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(786</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(765</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">INVESTMENT ACTIVITIES</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of property and equipment</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(25</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash used in investing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(25</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FINANCING ACTIVITIES</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Acquisition of a subsidiary in connection with reverse recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">269</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transaction costs incurred in reverse recapitalization</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(347</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,002</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise of warrants issued upon conversion of notes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">409</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance of convertible notes</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">750</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">413</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,083</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">413</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,272</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(354</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents at the beginning of the year</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">791</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash and cash equivalents at the end of the year</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,709</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of these consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Consolidated Statements of Cash Flows</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Supplemental information for Cash Flow:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-decoration: underline; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Assets acquired (liabilities assumed):</U></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>As of </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>November 28, 2016</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(in thousands)</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 81%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current assets excluding cash and cash equivalents</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,618</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">811</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Derivative warrant liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">575</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible note</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,029</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reverse recapitalization effect on equity</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">472</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash acquired in connection with reverse recapitalization</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">269</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of these consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U><A NAME="f_006"></A>Notes to Consolidated Financial Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 1 GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>A. <FONT STYLE="font-size: 10pt">Description of business:</FONT></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot Medical Inc. (the &ldquo;Company&rdquo;) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to CytoTherapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (&ldquo;Microbot Israel&rdquo;), and C&amp;RD Israel Ltd. (&ldquo;Merger Sub&rdquo;), an Israeli corporation and wholly-owned subsidiary of the Company, whereby Merger Sub merged with and into Microbot Israel and Microbot Israel surviving as a wholly-owned subsidiary of the Company (the &ldquo;Merger&rdquo;). Pursuant to the terms of the Merger, at the effective time of the Merger, each outstanding ordinary share of Microbot Israel capital stock was converted into the right to receive approximately 2.9 shares of the Company&rsquo;s common stock, par value $0.01 per share, after giving effect to a one for nine reverse stock split (the &ldquo;Reverse Stock Split&rdquo;), for an aggregate of 26,550,974 shares of Company&rsquo;s common Stock issued to the former Microbot Israel shareholders. In addition, all outstanding options to purchase the ordinary shares of Microbot Israel were assumed by the Company and converted into options to purchase an aggregate of 2,614,916 shares of the Company&rsquo;s common Stock. Additionally, the Company issued an aggregate of 7,802,639 restricted shares of its common stock or rights to receive the Company&rsquo;s common stock, to certain advisers. On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company&rsquo;s common stock began trading on the Nasdaq Capital Market under the symbol &ldquo;MBOT&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the Merger Microbot Israel became a wholly owned subsidiary of the Company. The transaction between the Company and Microbot Israel was accounted for as a reverse recapitalization. As the shareholders of Microbot Israel received the largest ownership interest in the Company, Microbot Israel was determined to be the &ldquo;accounting acquirer&rdquo; in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Microbot Israel. Unless indicated otherwise, pre-acquisition share, options and warrants data included in these financial statements is retroactively adjusted to reflect the Reverse Stock Split and the Merger.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Merger, the Company was a biopharmaceutical company that conducts research, development, and commercialization of stem cell therapeutics and related technologies. Substantially the sale of all material assets relating to the stem cell business were completed on November 29, 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiaries are collectively referred to as the &ldquo;Company&rdquo;. &ldquo;StemCells&rdquo; or &ldquo;StemCells, Inc.&rdquo; refers to the Company prior to the Merger.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>B. <FONT STYLE="font-size: 10pt">Risk
    factors:</FONT></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    date the Company has not generated revenues from its operations. As of the date of issuance of these financial statements,
    the Company has a cash and cash equivalent balance of approximately $6.7 million, which the Company believes is sufficient
    to fund its operations for more than 12 months from the date of issuance of these financial statements and sufficient to fund
    its operations necessary to continue development activities of its current proposed products. The Company plans to continue
    to fund its current operations as well as other development activities relating to additional product candidates, through
    future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 1 GENERAL (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C. Use of estimates:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management&rsquo;s best judgment, actual results may differ from these estimates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies applied in the preparation of the financial statements are as follows:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.Basis of presentation:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&ldquo;US GAAP&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B. Financial statement in U.S. dollars:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The functional currency of the Company is the U.S. dollar (&ldquo;dollar&rdquo;) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, &ldquo;Foreign Currency Translation&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C. Cash and cash equivalents:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D. Fair value of financial instruments:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of cash and cash equivalents, other receivable and other accounts payable approximate their fair value due to the short-term maturity of these instruments.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 8.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.75in; text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 1 </B>- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 2</B> - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Level 3</B> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.5pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>E. Fixed assets:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets are presented at cost, net of investment grants received and less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>%</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research equipment and software</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-33</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 77%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leasehold improvements</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture and office equipment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F. Liabilities due to termination of employment agreements</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (&ldquo;Article 14&rdquo;) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company&rsquo;s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>G. Basic and diluted net loss per share</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights by the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 &ldquo;Earnings per Share&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>H. Research and development expenses, net:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
    Convertible notes:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 &ldquo;Debt with Conversion and Other Options&rdquo;, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the Notes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B><U>MICROBOT MEDICAL
INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Cont.).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, &ldquo;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>J. Share-based compensation:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 718-10, &ldquo;Share-Based Payment,&rdquo; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to service providers, employees and directors including stock options under the Company&rsquo;s stock plans based on estimated fair values. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&rsquo;s statement of operations.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company&rsquo;s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the &ldquo;simplified&rdquo; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>K. Reclassification:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Certain
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior <FONT STYLE="font-weight: normal; font-style: normal">year
    amounts have</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">been <FONT STYLE="font-weight: normal; font-style: normal">reclassified
    to conform</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the current <FONT STYLE="font-weight: normal; font-style: normal">year
    presentation</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>L. Transaction Costs:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M. Recent Accounting Standards:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2014, the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for us beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it is unable to determine the expected impact the new standard will have on its consolidated financial statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (Cont.).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2016, the FASB issued ASU 2016-01 &ldquo;Recognition and Measurement of Financial Assets and Financial Liabilities&rdquo;, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (&ldquo;ASU 2016-02&rdquo;), which amends, among other things, the existing guidance by requiring lessees to recognize lease assets (right-to-use) and liabilities (for reasonably certain lease payments) arising from operating leases on the balance sheet. For leases with a term of twelve months or less, ASU 2016-02 permits an entity to make an accounting policy election to recognize such leases as lease expense, generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (&ldquo;ASU 2016-09&rdquo;), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments &ndash; Credit Losses &ndash; Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The standard is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. The Company is evaluating the impact of the adoption on our consolidated balance sheet, results of operations, cash flows and disclosures.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 3 - CASH AND CASH EQUIVALENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,709</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">427</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deposits</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,709</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">437</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 4 - OTHER RECEIVABLES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deposit in escrow account (*)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">505</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Government institutions</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">86</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">606</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(*) Purchase Agreement with BOCO. </B>On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &ldquo;Sellers&rdquo;), entered into an Asset Purchase Agreement (the &ldquo;Asset Purchase Agreement&rdquo;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&ldquo;BOCO US&rdquo;). </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the Sellers sold to BOCO US certain stem and progenitor cell lines that have been researched, studied or manufactured by the Company since 2007 (the &ldquo;Cell Lines&rdquo;) and certain other tangible and intangible assets, including intellectual property and books and records, related to the foregoing (together with the Cell Lines, the &ldquo;Assets&rdquo;) in exchange for $4 million in cash (the &ldquo;Asset Consideration&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the Asset Consideration, $300,000 was provided to the Company prior to November 11, 2016 in exchange for the Sellers&rsquo; agreement not to solicit or reach any agreement with any third party pertaining to the sale of the Assets, and $400,000 will remain in a twelve-month escrow for the benefit of BOCO US to satisfy certain indemnification obligations of the Sellers which may arise and which, subject to any valid indemnification claims of BOCO US, will be released to the Company at the end of such 12-month period. In addition, sixteen former employees of the Company received, in the aggregate, $495,000, in accordance with their June 2016 agreements with the Company under which each accepted a more than 50% reduction in his or her severance award otherwise payable.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Asset Purchase Agreement contains certain covenants prohibiting the Sellers from, during the four-year period immediately following the completion of the Asset Sale, (a) engaging in or having certain financial interests in a business that is engaged in the research, development or commercialization of the Cell Lines, or (b) soliciting for employment employees of BOCO US.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 29, 2016, the Sellers completed the sale of the Assets.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The opening balance sheet as of the Merger date included a receivable balance with respect to sale of the Assets of $3.5 million, from which $2.8 million were collected prior to December 31, 2016. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 5 - FIXED ASSETS, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cost:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research equipment and software</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture and office equipment</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">63</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">117</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated Depreciation:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research equipment and software</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furniture and office equipment</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 6 - ACCRUED LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employees</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">102</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">121</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Government institution</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">456</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Israeli Innovation Authority</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">582</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">149</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 7 - CONVERTIBLE LOAN FROM SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 8, 2015, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. According to the loan agreement, Microbot Israel received an amount of $419,000. The loan bore interest of 10%, and was converted to both equity shares and preferred shares warrants of Microbot Israel on the nine-month anniversary of the loan. The Company concluded the conversion feature is not a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &ldquo;Debt with Conversion and Other Options&rdquo;. Accordingly, the proceeds were recorded in liabilities in their entirety at the date of issuance.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2016, the outstanding principal and accrued interest were converted into 1,315,023 Series A preferred shares, of Microbot Israel (the &ldquo;Series A Preferred Shares&rdquo;) and 1,188,275 warrants to purchase the Series A Preferred Shares, at an exercise price of $1.00 per share. The preferred shares warrants were exercised in full in September 2016 for total gross proceeds to Microbot Israel of $409,750.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2016, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. The loan bore interest at a fixed rate of 10% per annum beginning on the issuance date.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At maturity, all of the outstanding principal and accrued interest was converted into Microbot Israel&rsquo;s ordinary shares subject to the conversion or default events specified in the loan agreement, based on a conversion price that represents a 20% discount on Microbot Israel&rsquo;s valuation upon such default events. Furthermore, in the event of a reverse merger transaction or a qualified financing, each as defined in the convertible loan agreement with respect to such loans, all of the outstanding principal and accrued interest would be converted into the securities issued in the reverse merger or the qualified financing, as the case may be.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 28, 2016, upon the consummation of the Merger, the loan was converted into an aggregate of 2,242,939 shares of Company&rsquo;s common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded the value of the loan is predominantly based on a fixed monetary amount known at the date of issuance as represented by the 20% discount on the Company&rsquo;s valuation. Accordingly, the loan was classified as debt and is measured at its fair value, pursuant to the provisions of ASC 480-10, &ldquo;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the loan is measured based on observable inputs as the fixed monetary value of the variable amount of shares to be issued upon conversion (level 2 measurement). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 7 - CONVERTIBLE LOAN FROM SHAREHOLDERS
(Cont.).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secured Note to Alpha Capital Anstalt:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 15, 2016, concurrent with the execution of the Agreement and Plan of Merger (see Note 1A), StemCells Inc issued a 5.0% secured note (the &ldquo;Note&rdquo;) to Alpha Capital Anstalt (&ldquo;Alpha Capital&rdquo;), in the principal amount of $2 million, for value received, payable upon the earlier of (i) 30 days following the consummation of the Merger and (ii) December 31, 2016. Proceeds from the Note were used for the payment of costs and expenses in connection with the Merger and operational expenses leading to such Closing.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Note bears interest at 5% per annum, payable monthly in arrears on the first of the month, beginning on January 1, 2017 until the principal amount is paid in full. In addition, the Note is secured by a first priority security interest in all of the Company&rsquo;s intellectual property and certain other general assets pursuant to a Security Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities Exchange Agreement with Alpha Capital:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of the effective time of the Merger, the Company entered into a Securities Exchange Agreement (the &ldquo;Exchange
    Agreement&rdquo;) with Alpha Capital, providing for the issuance to Alpha Capital of a convertible promissory note by the
    Company (the &ldquo;Convertible Note&rdquo;) in a principal amount of $2,028,767, which is equal to the principal and accrued
    interest under the Note, in exchange for (a) the full satisfaction, termination and cancellation of the Note and (b) the
    release and termination of the Security Agreement and the first priority security interest granted thereunder.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Convertible Note is convertible into the Company&rsquo;s Common Stock any time after November 28, 2017 and until the maturity date of November 28, 2019, based on a conversion price of $0.64, subject to adjustments as provided in the Exchange Agreement. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Convertible Note, the Company is obligated to pay interest on the outstanding principal amount owed under the Convertible Note at a fixed rate per annum of 6.0%, payable at maturity or earlier upon conversion. The Exchange Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Convertible Note also contains certain customary events of default.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Exchange Agreement represented the consummation of the original intent of the Company and Alpha Capital, as of the date of execution of the Merger Agreement (August 2016), to enter into a $2 million convertible note sale transaction, upon the consummation of the Merger, the Company accounted for the convertible note in accordance with such economic substance, as if it had been issued for a cash consideration equal to the principal and accrued interest on the Note, as of the effective date of the Merger, in the amount of $2,029,000 (the &ldquo;Assumed Consideration&rdquo;), which is equal to the principal amount of the Convertible Note as determined in the Exchange Agreement. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded the conversion feature of the Convertible Note, based on the commitment date of November 28 2016 (the Exchange Agreement date), is a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &ldquo;Debt with Conversion and Other Options&rdquo;. Accordingly, $2,029,000 of the Assumed Consideration was recorded in equity with a corresponding discount on the Convertible Note, to be amortized over its term through maturity. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 8 - DERIVATIVE WARRANT LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of StemCell&rsquo;s obligations under the Merger Agreement, in August 2016, StemCells negotiated with certain institutional holders of its 2016 Series A and Series B Warrants, issued by prior to the Merger, to have such holders surrender their 2016 Series B Warrants in exchange for a reduced exercise price of $0.30 per share on their existing 2016 Series A Warrants and the elimination of the anti-dilution price protection in the 2016 Series A Warrants. As a result, the exercise price for all outstanding 2011 Series A Warrants and 2016 Series A and Series B Warrants was reset to $0.30 per share. Subsequent to the reset of the exercise price, an aggregate of 531,814 (from an outstanding aggregate of 578,081) 2011 Series A Warrants were exercised. For the exercise of these warrants, the Company issued 531,814 shares of its common stock prior to the Merger.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remaining outstanding warrants and terms as of the closing date of the Merger (November 28, 2016) and as of Dec 31 2016 is as follows: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance Date</FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding as of November 28, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise Price </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Per Share</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable as of December 31, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercisable </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Through</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A (2011)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">64,230</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: right"></TD>
    <TD STYLE="width: 9%; text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">151.20</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ndash;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A (2013)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,814</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">194.40</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,814</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">October 2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A (2013)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,718</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">183.60</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,718</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2023</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A (2015)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,139</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">91.80</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,139</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2020</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A (2016)(a)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,047</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">2.70</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,047</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2018</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series B (2016)(a)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,116</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: right">$<FONT STYLE="font-family: Times New Roman, Times, Serif">2.70</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,116</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">March 2022</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left">__________________</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As such anti-dilution price protection, does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at November 28, 2016 and December 31, 2016, was approximately $575,000 and $313,000, respectively.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As quoted prices in active markets for identical or similar warrants are not available, the Company uses directly observable inputs in the valuation of its derivative warrant liabilities (level 2 measurement). </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company uses the Black-Scholes valuation model to estimate fair value of these warrants. In using this model, the Company makes certain assumptions about risk-free interest rates, dividend yields, volatility, expected term of the warrants and other assumptions. Risk-free interest rates are derived from the yield on U.S. Treasury debt securities. Dividend yields are based on our historical dividend payments, which have been zero to date. Volatility is estimated from the historical volatility of our common stock as traded on NASDAQ. The expected term of the warrants is based on the time to expiration of the warrants from the date of measurement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of November 28, 2016 and December 31, 2016 (in thousands):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 8 - DERIVATIVE WARRANT LIABILITIES (Cont.).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Series A<BR>
        (2011)</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Series A (2013)</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Series A (2013)</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Series A (2015)</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series A</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">(2016)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series B</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">(2016)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balances at November 28, 2016</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">45</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">81</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">388</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">575</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancelled</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes in fair value</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(23</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(38</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(161</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(262</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balances at December 31, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">227</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">313</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In accordance with ASC-820-10-50-2(g),
the Company has performed a sensitivity analysis of the derivative warrant liabilities of the Company which are classified as level
3 financial instruments. The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables in
the Black-Scholes model that vary overtime, namely, the volatility and the risk free rate. A 5.0% decrease in volatility would
decrease the value of the warrants to $301,000; a 5.0% increase in volatility would increase the value of the warrants to $312,000.
A 5.0% decrease or increase in the risk free rate would not have materially changed the value of the warrants; the value of the
warrants is not strongly correlated with small changes in interest rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 9 - COMMITMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Microbot Israel obtained from the
Israeli Innovation Authority grants for participation in research and development for the years 2013 through 2016 in the total
amount of approximately $0.9 million, and, in return, Microbot Israel is obligated to pay royalties amounting to 3% of its future
sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar to the New Israeli Shekel and bears
interest of Libor per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The repayment of the grants is contingent
upon the successful completion of the Company&rsquo;s research and development programs and generating sales. The Company has no
obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial
risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Microbot Israel signed an agreement
with the Technion Research and Development Foundation (&ldquo;TRDF&rdquo;) in June 2012 by which TRDF transferred to Microbot Israel
a global, exclusive, royalty-bearing license. As partial consideration for the license, Microbot Israel shall pay TRDF royalties
on net sales (between 1.5%-3%) and on sublicense income as detailed in the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Lease Agreements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In June 2016, the Company entered
into an office lease agreement, with a term ending on September 30, 2017. According to the lease agreement, the monthly office
lease payment is approximately $3,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In December 2016, the Company entered
into certain lease agreements for automobiles, which will end on December 31, 2019. According to the lease agreements,
the monthly automobile lease payments are approximately $2,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Compensation liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company incurred compensation
commitments of approximately $0.4 million to a former executive that management estimates as remote as therefore is not reflected
in these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Ordinary shares confer upon the
holders voting rights and the right to receive cash and stock dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Each share of the Series A Convertible
Preferred Stock issued by the Company in December 2016, is convertible, at the option of the holder, into 1,000 shares of Common
Stock, and confer upon the holder dividend rights on an as converted basis. The shares of Series A Preferred Stock do not confer
upon the holder voting rights and do not confer upon the holder a preference upon a liquidation event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Share Capital
Developments:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The authorized capital stock consists
of 221,000,000 shares of capital stock, which consists of 220,000,000 shares of common stock, par value $0.01 (the &ldquo;Common
Stock&rdquo;), and 1,000,000 of undesignated preferred stock, par value $0.01 (the &ldquo;Preferred Stock&rdquo;). As of December
31, 2016, the Company had 26,550,974 shares of Common Stock issued and outstanding, and 9,736 shares of Series A Convertible Preferred
Stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On November 28, 2016, the Company
filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State of the State
of Delaware to (i) effect the Reverse Stock Split, (ii) change its name from &ldquo;StemCells , Inc.&rdquo; to &ldquo;Microbot
Medical Inc.&rdquo; and (iii) increase the number of authorized shares of the Common Stock from 200,000,000 to 220,000,000 shares
(the &ldquo;Certificate of Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As a result of the Reverse Stock
Split, the number of issued and outstanding shares of the Common Stock immediately prior to the Reverse Stock Split were reduced
into a smaller number of shares, such that every nine shares of the Common Stock held by a stockholder immediately prior to the
Reverse Stock Split were combined and reclassified into one share of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Immediately following the Reverse
Stock Split and the Merger, there were 36,254,240 shares of the Common Stock issued and outstanding, which included certain rights
to receive shares of Common Stock or equivalent securities but excludes shares underlying outstanding stock options and warrants
and the Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On December 27, 2016, the Company
exchanged 9,735,925 shares or rights to acquire shares of its Common Stock, for 9,736 shares of a newly designated class of Series
A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><B>Employee Stock Option Grant:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In September 2014, Microbot Israel&rsquo;s
board of directors approved a grant of 403,592 stock options (1,167,693 stock options as retroactively adjusted to reflect the
Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise price of
$0.8 ($0.28 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On May 2, 2016, Microbot Israel&rsquo;s
board of directors approved a grant of 500,000 stock options (1,447,223 as retroactively adjusted to reflect the Merger) to certain
of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel,
at an exercise price equal to the ordinary share&rsquo;s par value. The stock options were fully vested at the date of grant. As
a result, the Company recognized compensation expenses in the amount of $675,389 included in general and administrative expenses.
As the exercise price of the stock options is nominal, Microbot Israel estimated the fair value of the options as equal to the
Company&rsquo;s share price of $1.35 ($0.47 as retroactively adjusted to reflect the Merger) at the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 SHARE CAPITAL (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">A summary of the Company&rsquo;s
option activity related to options to employees and directors, and related information is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the year ended December 31, 2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of stock options</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average exercise price</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate intrinsic value</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding at beginning of period</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,447,223</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancelled</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding at end of period</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,614,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.13</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,611,049</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested and expected-to-vest at end of period</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,614,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.39</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,611,049</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than $0.01.</FONT></TD></TR>
</TABLE>
<P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the year ended December 31, 2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number of stock options</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average exercise price</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aggregate intrinsic value</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding at beginning of period</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancelled</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding at end of period</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested and expected-to-vest at end of period</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The aggregate intrinsic value in
the table above represents the total intrinsic value (the difference between the fair market value of the Company&rsquo;s and Microbot
Israel&rsquo;s common shares on December 31, 2016 and December 31, 2015 respectively and the exercise price, multiplied by the
number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock option
holders exercised their stock options on those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The stock options outstanding as
of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercise price</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock options outstanding as of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average remaining contractual life &ndash; years as of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock options exercisable as of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.28</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,447,223</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.5</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,447,223</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,614,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,614,916</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,167,693</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than $0.01.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 10 SHARE CAPITAL (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">Compensation expense
recorded by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended
December 31, 2016 and 2015 was $675,389 and $186,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">The fair value
of the stock options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average
assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years ended December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected volatility</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">77.3</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">70.0</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk-free interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.6</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dividend yield</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected life of up to (years)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.0</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Shares issued to service provider</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In connection with the Merger, the
Company issued an aggregate of 7,802,639 restricted shares of its common stock to certain advisors. The fair value of the award
of $9,987,000 was estimated based on the Company&rsquo;s common share price of $1.28 as of the date of grant. The portion of the
expense in excess of the cash and other current assets acquired in the Merger, in the amount of $7,262,000, was included in general
and administrative expenses in the Statement of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Securities Exchange Agreement
with Alpha Capital </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On December 16, 2016, the Company
entered into a Securities Exchange Agreement with Alpha Capital, pursuant to which Alpha Capital exchanged 9,736,000 shares of
common stock or rights to acquire shares of the common stock held by it, for 9,736 shares of a newly designated class of Series
A Convertible Preferred Stock, par value $0.01 per share (the &ldquo;Preferred Stock&rdquo;). The common stock and common stock
underlying the rights to acquire common stock include all of the shares of common stock issued or issuable to Alpha Capital pursuant
to the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The 9,735,925 shares of common stock
and the rights to acquire common stock were cancelled and the Company&rsquo;s issued and outstanding shares of Common Stock were
reduced to 26,518,315.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Repurchase of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company intends to enter
into a definitive agreement with up to three Israeli shareholders that were former shareholders of Microbot Medical Ltd., pursuant
to which the Company would repurchase, at a discount on the fair value of the share at the date of repurchase, up to $500,000
of the Company&rsquo;s common stock held by them, in the aggregate, if and to the extent such shareholders are unable to sell
enough of their shares to cover certain of their Israeli tax liabilities resulting from the Merger. Such repurchase(s), if any,
would occur only after the two year anniversary of the Merger. The transaction is subject to negotiating final terms and entering
into definitive agreements with such shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company evaluated whether
an embedded derivative that requires bifurcation exists within such shares that may be subject to repurchase. The Company concluded
the fair value of such derivative instrument would be nominal and in any case would represent an asset to the Company as (a) the
settlement requires acquiring the shares at a discount on the fair market value of the share at the time of re purchase and in
no circumstances the acquisition price will be higher than approximately one dollar per share (representing 25% discount on the
fair market value of the share at the merger closing date) and (b)it is assumed that the selling shareholders would use such right
as last resort as such repurchase at a discount on the fair market value of such shares results in a loss to be incurred
by the selling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In accordance with ASC 480-10-S99-3A
(formerly EITF D-98), the Company classified the maximum amount it may be required to pay in the event the repurchase right is
exercised ($500,000) as temporary equity.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The basic and diluted net loss
per share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as
follows (in thousands, except share and per share data):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 11 BASIC AND DILUTED NET LOSS PER SHARE
(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year Ended December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss attributable to shareholders of the company</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,663</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">921</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss attributable to shareholders of preferred shares</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(<FONT STYLE="font-family: Times New Roman, Times, Serif">3,954</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(<FONT STYLE="font-family: Times New Roman, Times, Serif">360</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss used in the calculation of basic net loss per share</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,709</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">561</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss per share</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.40</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.04</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted average number of common shares</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,293,296</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13,182,660</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As the inclusion of common share
equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic
net loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The weighted average number of common
shares outstanding has been retroactively restated for the equivalent number of common shares received by the accounting acquirer
as a result of the reverse recapitalization and reverse stock split as if these common shares had been outstanding as of the beginning
of the earliest period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 12 RESEARCH AND DEVELOPMENT EXPENSES,
NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payroll and related expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">491</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">464</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Materials</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">155</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">75</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">37</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Office and maintenance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rent</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">253</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">365</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">76</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less grants received from Israeli Innovation Authority</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(213</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(201</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">901</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">823</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 13 GENERAL AND ADMINISTRATIVE EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years ended December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payroll and related expenses</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">45</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">528</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common shares issued for services</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,258</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Travel</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">180</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">15</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share-based compensation</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">676</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,734</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">92</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 14 - FINANCE EXPENSES, NET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years ended December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bank fees and interest</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of derivative warrant liability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(262</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exchange rate differences</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(44</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revaluation and interest on convertible loans</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">333</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 15 - TRANSACTIONS AND BALANCES WITH
INTERESTED AND RELATED PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><B>A. Transactions:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year ended</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payroll and related expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors fees and insurance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subcontracted work and consulting</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">253</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">122</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">253</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">122</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><B>B. Balances:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of</FONT><BR> <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other accounts payable</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD>
    <TD STYLE="width: 11%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">$</TD>
    <TD STYLE="width: 11%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 16 - TAXES ON INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to income
taxes under the Israeli and U.S. tax laws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>Corporate tax rates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to Israeli
corporate tax rate of 26.5% in the years 2015 and 2014, 25% in the year 2016, 24% in 2017 and 23% from 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to a blended
U.S. tax rate (Federal as well as state corporate tax) of 35%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>MICROBOT MEDICAL INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Notes to Consolidated Financial Statements
</U>(Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 16 - TAXES ON INCOME (Cont.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2016, the Company generated net operating losses in Israel of approximately $5,556, which may be carried forward and offset against taxable income in the future for an indefinite period.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2016, the Company generated net operating losses in the U.S. of approximately $475,496. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the &ldquo;change in ownership&rdquo; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify; text-indent: -30.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31,</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(in thousands)</FONT></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss carry-forward</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">481,052</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">471,980</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total deferred tax assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">481,052</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">471,980</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation allowance</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(481,052</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(471,980</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net deferred tax assets</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>NOTE 17 - SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purchase Agreement</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the &ldquo;Purchaser&rdquo;) for the purchase and sale of an aggregate of 700,000 shares of the Company&rsquo;s common stock in a registered direct offering for $5.00 per share or gross proceeds of $3.5 million. The Company paid the placement agent a fee of $210,000 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Contract Research Agreement</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 27, 2017, the Company entered into a Contract Research Agreement (the &ldquo;Research Agreement&rdquo;) with The Washington University (&ldquo;Washington U.&rdquo;), pursuant to which the parties will collaborate to determine the effectiveness of the Company&rsquo;s self-cleaning shunt. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The initial research to be performed by Washington U. is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of the initial study, to be paid by the Company, is expected to be approximately $130,000, with the cost of any further studies to be determined. Pursuant to the Research Agreement, all rights, title and interest in the data, information and results obtained or arrived at by Washington U. in the performance of its services under the Research Agreement, as well as any patentable inventions obtained or arrived at in the performance of such services, will be jointly owned by the Company and Washington U., and each will have full right to practice and grant licenses in joint inventions. Additionally, Washington U. granted to the Company: (a) a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable license to use and practice patentable inventions (other than joint inventions and improvements to Washington U.&rsquo;s animal models) obtained or arrived at by Washington U. in the provision of its services under the Research Agreement (&ldquo;University Inventions&rdquo;) with respect to the self-cleaning shunt; and (b) an exclusive option to obtain an exclusive worldwide license in University Inventions, on terms to be negotiated between the parties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>ex10-11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTION
COPY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSET
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DATED
AS OF NOVEMBER 11, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BY
AND AMONG</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS,
INC.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEM
CELL SCIENCES HOLDINGS LIMITED,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS
CALIFORNIA, INC.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCO
SILICON VALLEY, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    I PURCHASE PRICE AND CLOSING</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 83%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
    and Purchase of the Purchased Assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery
    of the Purchased Assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded
    Assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumption
    of Liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
    Liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    Price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    1.7. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    II REPRESENTATIONS AND WARRANTIES OF THE SELLER</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
    Standing and Corporate Power</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchased
    Assets</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
    Noncontravention; Voting Requirements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals and Consents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
    SEC Documents; Undisclosed Liabilities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.7. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
    With Laws; Permits</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.8. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.9. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.10. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
    Products IP Contracts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.11. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    Property</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.12. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.13. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers
    and Other Advisors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.14. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    Party Transactions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    2.15. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency;
    Fair Consideration; No Fraudulent Conveyance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    III REPRESENTATIONS AND WARRANTIES OF BOCO US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization,
    Standing and Corporate Power</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority;
    Noncontravention</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental
    Approvals and Consents</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    3.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Capability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    IV PRE-CLOSING COVENANTS AND AGREEMENTS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct
    of the Business Prior to Closing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercially
    Reasonable Efforts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Shopping</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    4.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
    Merger; Stockholder Approval</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>

</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    V POST-CLOSING COVENANTS AND AGREEMENTS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 83%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    Announcements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
    to Information</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    and Expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
    Assurances</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
    Products IP Contracts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.7. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
    Non-Competition and Non-Solicitation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.8. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    of Names</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    5.9. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Tax Matters</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    VI CONDITIONS TO CLOSING</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    to BOCO US&rsquo;s Obligation to Close</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    to the Sellers&rsquo; Obligation to Close</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    6.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions
    to Obligations of Each Party to Close</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    VII TERMINATION</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Circumstances
    for Termination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    7.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of Termination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    VIII INDEMNIFICATION</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Survival
    of Representations and Warranties; Indemnification</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    Procedures</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations
    on Indemnification</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnity
    Escrow</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    Treatment of Indemnity Payments</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    8.6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    Remedies</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
    IX MISCELLANEOUS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.1. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.2. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.3. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire
    Agreement; No Third Party Beneficiaries</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.4. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing
    Law</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.5. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arbitration</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.6. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific
    Performance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.7. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.8. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.9. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.10. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.11. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    Other Warranties</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    9.12. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English
    Language</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
</TABLE>


<FONT STYLE="font: 10pt Times New Roman, Times, Serif">
&nbsp;</FONT>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR CLEAR="ALL">
<FONT STYLE="font-size: 10pt"><B>List of Exhibits and Schedules</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Escrow Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    B</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of UCC-3 Termination Statement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    C</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Bill of Sale</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    D-1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Assignment of Patents and Patent Applications</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    D-2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Assignment of Trademarks</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    D-3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Assignment of Domain Names</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    E</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Assignment and Assumption Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    F</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Receipt</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    G</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter
    of Intent</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    1.1(l)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
    Products Inventory</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratories</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    2.11(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Updated
    IP Docket</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
    9.9(l)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
    Products IP Contracts</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSET
PURCHASE AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
ASSET PURCHASE AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;), dated as of November 11, 2016 (the &ldquo;<U>Execution Date</U>&rdquo;),
is among STEMCELLS, INC., a Delaware corporation (&ldquo;<U>STEMCELLS Parent</U>&rdquo;), STEM CELL SCIENCES HOLDINGS LIMITED,
a private limited company registered in Scotland that is a wholly-owned subsidiary of STEMCELLS Parent (&ldquo;<U>STEMCELLS Holdings</U>&rdquo;),
STEMCELLS CALIFORNIA, INC., a California corporation that is a wholly-owned subsidiary of Holdings (&ldquo;<U>STEMCELLS Subsidiary</U>&rdquo;),
and BOCO Silicon Valley, Inc., a California corporation (&ldquo;<U>BOCO US</U>&rdquo;). STEMCELLS Parent, STEMCELLS Holdings and
STEMCELLS Subsidiary are referred to herein collectively as the &ldquo;<U>Sellers</U>&rdquo; and each is individually referred
to as a &ldquo;<U>Seller</U>.&rdquo; The Sellers, on the one hand, and BOCO US, on the other hand, are referred to herein collectively
as the &ldquo;<U>Parties</U>&rdquo; or &ldquo;<U>parties</U>&rdquo; hereto; and each is individually referred to as a &ldquo;<U>Party</U>&rdquo;
or &ldquo;<U>party</U>&rdquo; hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Boards of Directors of the Sellers and the Board of Directors of BOCO US have approved the acquisition of the Purchased Assets
by BOCO US on the terms and subject to the conditions set forth in this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
BOCO US desires to purchase from the Sellers, and the Sellers desires to sell to BOCO US, the Purchased Assets, upon the terms
and subject to the conditions hereinafter set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the representations, warranties, covenants and agreements contained in this Agreement, and intending
to be legally bound hereby, the Sellers, BOCO US hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
I</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASE
PRICE AND CLOSING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.1. Sale and Purchase of the Purchased Assets</B>. Subject to the terms and conditions set forth in this Agreement, at the time
set forth in Section 1.7, the Sellers shall sell, transfer and assign (or cause to be sold, transferred, assigned and delivered)
to BOCO US, and BOCO US shall purchase and acquire, free and clear of any Liens, all right, title and interest in and to the Purchased
Assets. Delivery of the Purchased Assets shall be made in accordance with Section 1.2. For purposes of this Agreement, the &ldquo;<U>Purchased
Assets</U>&rdquo; shall mean all of the Sellers&rsquo; rights, titles to, or interests as of the Closing in the following assets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the Key Products, including all formulations thereof and all proprietary rights of the Sellers embodied in or associated with
the Key Products which is not otherwise set forth in this Section 1.1;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
all Intellectual Property Rights embodied or disclosed in or otherwise related to the Key Products, or the research, production,
manufacture, or development of any Key Product, including the Intellectual Property Rights described in Section 2.11(c) of the
Sellers Disclosure Schedule (the &ldquo;<U>Key Products IP Rights</U>&rdquo;), together with all of the Sellers&rsquo; rights
to sue and obtain damages and equitable relief for past, present and future infringement, misappropriation or violation of any
of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
all written disclosures of all inventions made by all of the Sellers&rsquo; present or former officers, directors, employees,
consultants or other third parties who developed or co-developed any Key Products or any Intellectual Property Rights embodied
or disclosed therein (the &ldquo;<U>Identified Employees</U>&rdquo;) and the right to enforce any and all written assignments
by each Identified Employee of any and all such inventions, work product, results and deliverables that relate solely to the Key
Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
all rights to the use of the names (i) &ldquo;StemCells, Inc.,&rdquo; (ii) &ldquo;HuCNS-SC,&rdquo; and (iii) &ldquo;hLEC,&rdquo;
and any service marks, trademarks, trade names, d/b/a names, fictitious names, identifying symbols, logos, emblems, signs or insignia
containing or comprising the foregoing (the &ldquo;<U>Seller Marks</U>&rdquo;), and any name or mark confusingly similar thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
all rights to the website: <U>http://www.stemcellsinc.com/</U>, including the domain name and all other intellectual property
rights or proprietary rights included therein (the &ldquo;<U>Seller Website</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
all notebooks, records and other media embodying the Key Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
all filings and supporting documents and other correspondence submitted to and received from any Regulatory Authority relating
to the Key Products, and all data contained therein or incorporated therein by reference, including any Investigational New Drug
application (IND), Clinical Trial Application (CTA), investigator&rsquo;s brochures, pharmacology/toxicology data and reports,
correspondence to and from a Regulatory Authority, written summaries of any oral discussions with a Regulatory Authority, including
minutes from teleconferences and meetings with a Regulatory Authority, registrations and licenses, adverse event files, complaint
files and manufacturing and testing records, all qualification and validation documents, and all documentation pertaining to any
Regulatory Authority inspections (the &ldquo;<U>Purchased Assets Regulatory Documentation</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
all data, information, publications, studies and other materials of the Sellers embodying or relating to (i) the clinical and
non-clinical (including <I>in vitro</I> and animal) testing of the Key Products performed by or on behalf of the Sellers, and
(ii) clinical field experience with the Key Products that is necessary or useful for making regulatory filings for, or marketing
of, the Key Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all authorizations, registrations, filings, permits, licenses, franchises, orders, approvals, concessions, consents and other
regulatory approvals issued by any Regulatory Authority to the Sellers which are required (i) for clinical testing of any Key
Products, or (ii) for the handling, possession, importation, marketing, promotion, pricing or sale of any Key Products and all
applications for any of the aforementioned items;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
all environmental, health and safety records and permits issued to the Sellers for the Key Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
all manufacturing product records relating to any Key Products, including all of the reports, files, data and other documents
and information produced by or for the Sellers in connection with the manufacture of any Key Products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
all inventory of finished Key Products and all materials, samples, assays, reagents, chemicals generated or used by the Sellers
(or Persons working on their behalf) in the research, development, manufacture or use of any Key Product, including the inventory
set forth in Section 1.1(l) of the Sellers Disclosure Schedule (collectively, the &ldquo;<U>Purchased Cell Banks</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
all rights, benefits and interests under the Edinburgh License Agreement, as amended;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
all rights, benefits and interests under any Key Products IP Contracts, as amended, which may be assigned to BOCO US or to one
of its Affiliates; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
all claims, causes of action, defenses and rights of offset or counterclaim (at any time or in any matter existing or arising,
whether choate or inchoate, known or unknown, contingent or noncontingent), with respect to any Key Products, Key Products IP
Contracts or Key Products IP Rights, including (i) claims under warranties or guarantees or indemnities, to the extent related
to the Purchased Assets or the Assumed Liabilities, and (ii) claims against any of the Identified Employees for any misuse of
the Confidential Information included in the Purchased Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent any of the Purchased Assets consist of records, files, notebooks or other information, and such information is included
in media that also contains information relating to any of the Excluded Assets, then the Purchased Assets shall include the original
of such media, and the Sellers shall be entitled to retain a copy of the information relating to the Excluded Assets, or to receive
a copy from BOCO US if all of the copies are delivered to BOCO US, in each case subject to compliance with Section 5.2, Section
5.3 and Section 5.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.2. Delivery of the Purchased Assets</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
At the Closing, the Sellers shall deliver or make available the Purchased Assets, other than the Seller Website, within the Sellers&rsquo;
possession and control, to BOCO US through (i) delivery of two WD My Book Duo 12TB hard drives (P/N WDBLWE0120JCH) (the &ldquo;<U>Hard
Drives</U>&rdquo;), (ii) access to the boxes of documents identified on Section 1.2(a) of the Sellers Disclosure Schedule (the
&ldquo;<U>Identified Boxes</U>&rdquo;) being stored pursuant to an agreement by and between STEMCELLS Parent and DataSafe (the
&ldquo;<U>DataSafe Agreement</U>&rdquo;), (iii) access to the Sellers&rsquo; SharePoint drive hosted by Microsoft Corporation
(which shall remain fully active and accessible by BOCO US until the later of: (x) 90 days after Closing and (2) 180 days after
Execution Date, at the sole expense of STREMCELLS Parent) and (iv) access to the Purchased Cell Banks which are in the custody
of the laboratories identified on Section 1.2 of the Sellers Disclosure Schedule, which shall remain in the custody of the laboratories
identified on Section 1.2 of the Sellers Disclosure Schedule pursuant to the terms of the Sellers&rsquo; existing agreements with
Miltenyi Biotech and Fisher Bioservices or a newly executed agreement with BOCO US, as applicable. Within 90 days following the
Closing Date, the Sellers shall transfer all of their rights, title and interest in the Seller Website to BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Sellers undertake that, for the period of 90 days immediately following the Closing Date, upon BOCO US&rsquo;s reasonable
request, the Sellers will use commercially reasonable efforts to provide to BOCO US, and to procure that the employees and agents
of and professional advisers to the Sellers will provide to BOCO US, whatever information and assistance is reasonably necessary
to effectuate the transfer of record or legal ownership of the Purchased Assets to BOCO US. The Sellers shall pay any costs and
expenses reasonably incurred by the Sellers and their respective employees, agents and/or professional advisers in the provision
of this information and assistance (excluding, for the avoidance of doubt, any costs or expenses incurred in the provision of
services, including mailing, shipment and cell storage, provided by third parties).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.3. Excluded Assets</B>. Other than the Purchased Assets, none of the Sellers shall sell, transfer, assign or deliver to BOCO
US any of their rights, titles to or interests in any of their other assets (the &ldquo;<U>Excluded Assets</U>&rdquo;), which
are not part of the sale and purchase contemplated hereunder, are excluded from the Purchased Assets, and shall remain the property
of the Sellers after the Closing. The following assets of the Sellers are examples of Excluded Assets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all cash, cash equivalents and short term investments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
all personnel records and other records that the Sellers are required by applicable Laws to retain in their possession;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
all financial records;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
all corporate records;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
all third-party contracts other than any Key Products IP Contracts and the Edinburgh License Agreements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
all legal records;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
all claims for refund of Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
any employees; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all rights of the Sellers under this Agreement or any other agreement, instrument, certificate or document required to be delivered
to the Sellers at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.4. Assumption of Liabilities</B>. Effective as of the Closing, the Sellers shall not have any liability or obligation with respect
to, and BOCO US shall assume and thereafter pay, perform and discharge when due, without recourse to the Sellers, only the Liabilities
that become due payable with respect to the Purchased Assets solely as a result of actions or omissions of BOCO US or its Affiliates
after the Closing (collectively, the &ldquo;<U>Assumed Liabilities</U>&rdquo;). BOCO US shall take, and cause its Affiliates to
take, all reasonable steps to mitigate any Assumed Liabilities upon and after becoming aware of any event that that could reasonably
be expected to give rise to such Assumed Liabilities. For the avoidance of doubt, Assumed Liabilities shall not include any Liabilities
of any kind existing prior to the Closing Date, or which become Liabilities after the Closing, solely to the extent resulting
from actions taken by any of the Sellers prior to the Closing, including any Liabilities relating to any course of conduct, breach,
violation or other action of any of the Sellers which occurred prior to the Closing, <U>provided</U> that such action was not
required by this Agreement or taken at the request or direction of BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.5. Retained Liabilities</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Notwithstanding anything to the contrary contained in this Agreement, other than the Assumed Liabilities, BOCO US and its Affiliates
shall not have any liability or obligation with respect to, shall not assume or agree to pay, perform or discharge, and shall
not be deemed by virtue of the execution and delivery of this Agreement or any document delivered at the Closing pursuant to this
Agreement, or as a result of the consummation of the Transactions, to have assumed, or to have agreed to pay, perform or discharge,
any liability or obligation of the Sellers, whether primary or secondary, direct or indirect, known or unknown, asserted or unasserted,
due or to become due, accrued, absolute, contingent or otherwise, and whether arising prior to the Closing Date (such Liabilities
not assumed by BOCO US and its Affiliates, are collectively referred to as the &ldquo;<U>Retained Liabilities</U>&rdquo;). The
&ldquo;Retained Liabilities&rdquo; shall include, to the extent that they are not Assumed Liabilities, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
all Liabilities of the Sellers, or any member of any consolidated, affiliated, combined or unitary group of which Seller or any
of its Subsidiaries is or has been a member, for Taxes (including any Liability for Taxes relating to any of the Purchased Assets,
or the ownership, control, lease or license of any of the Purchased Assets);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all Liabilities of the Sellers arising pursuant to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
all Liabilities and obligations of the Sellers arising under the Sellers&rsquo; employee benefit plans or relating to payroll,
vacation, sick leave, workers&rsquo; compensation and unemployment benefits of any kind;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
all Liabilities of the Sellers in connection with any claims, actions, suits, audits, inquiries, proceedings by any Governmental
Authority or third party (including any stockholders of the Sellers, whether brought directly, derivatively or otherwise, but
not including any Liabilities arising solely from the ownership, control, license or use of the Purchased Assets by or on behalf
of BOCO US or any of its Affiliates following the Closing), including any claims, actions, suits, audits, inquiries, proceedings
arising as a result of or relating to the entry into the Agreement or the consummation of the Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
all Liabilities of the Sellers relating to, arising out of or incurred in connection with any of the Excluded Assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
all Liabilities of the Sellers arising under any environmental Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
all Liabilities of the Sellers arising as a result of violations of any Laws by Sellers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
all Liabilities of the Sellers for Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
all Liabilities arising out of or resulting from any breach by the Sellers under any Key Products IP Contracts prior to the date
on which any such Key Products IP Contract is transferred by the Sellers to BOCO US in accordance with the terms of this Agreement;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
all Liabilities arising out of or related to any broker&rsquo;s, finder&rsquo;s, advisory or other similar fee or commission,
or the reimbursement of expenses, in connection with the Transactions based upon arrangements made by or on behalf of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Sellers shall pay, discharge and perform all of the Retained Liabilities when due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.6. Purchase Price</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On the terms and subject to the conditions set forth in this Agreement, as consideration for the sale, transfer, assignment and
delivery of the Purchased Assets to BOCO US, BOCO US shall purchase and acquire all rights, titles and interests in and to the
Purchased Assets for an aggregate purchase price equal to USD4,000,000 if the Closing occurs on or before December 1, 2016 and
an aggregate purchase price equal to USD3,900,000 if the Closing occurs after December 1, 2016 (the &ldquo;<U>Purchase Price</U>&rdquo;).
The Parties hereby acknowledge and agree that USD300,000 of the Purchase Price (the &ldquo;<U>Letter Agreement Deposit Amount</U>&rdquo;)
was paid prior to the Execution Date by Bright Oceans Corporation (HK) Limited, on behalf of BOCO US, to the Sellers pursuant
to that certain letter agreement attached as <B>Exhibit G</B> to this Agreement, which USD300,000 shall be treated in all respects
as if such amount had been funded by BOCO US as a portion of the Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On the date hereof, BOCO US, STEMCELLS Parent and Continental Stock Transfer &amp; Trust Company, a New York corporation (the
&ldquo;<U>Escrow Agent</U>&rdquo;), are executing and delivering an Escrow Agreement in the form attached hereto as <B>Exhibit
A</B> (the &ldquo;<U>Escrow Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
On November 14, 2016, BOCO US will fund USD3,700,000 (the &ldquo;<U>Escrow Deposit</U>&rdquo;) to the Escrow Agent in cash by
wire transfer of immediately available funds to the account designated in writing by the Escrow Agent pursuant to the Escrow Agreement
(the &ldquo;<U>Escrow Account</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Of the Purchase Price, the amount of USD100,000 shall be in consideration for the assignment of the Edinburgh License Agreement
to BOCO US. 12.82% of the remaining Purchase Price shall be in consideration for the assignment of patents and patent applications
included within the Purchased Assets, other than the patents and patent applications licensed under the Edinburgh License Agreement,
to BOCO US. 25.64% of the remaining Purchase Price shall be in consideration for the assignment of the Trade Secrets included
within the Purchased Assets to BOCO US. 61.28% of the remaining Purchase Price shall be in consideration for the sale and transfer
of Purchased Cell Banks to BOCO US. 0.26% of the remaining Purchase Price shall be in consideration for the transfer of books
and records included within the Purchased Assets, including Purchased Assets Regulatory Documentation, to BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
1.7. Closing</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The closing (the &ldquo;<U>Closing</U>&rdquo;) of the purchase and sale of the Purchased Assets shall take place at 10:00 a.m.
(Los Angeles time) on the date that is three Business Days after the day on which all of the conditions to closing set forth in
ARTICLE VI are satisfied or waived (other than conditions that are intended to be satisfied at the Closing), or at such other
date, time or place as the Parties may agree (the &ldquo;<U>Closing Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
At the Closing, the Sellers and BOCO US shall execute and deliver the following documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
a duly authorized UCC-3 in the form attached hereto as <B>Exhibit B</B> from Alpha Capital Anstalt evidencing the release of its
lien on the Purchased Assets, effective as of the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
a duly executed bill of sale in the form attached hereto as <B>Exhibit C </B>for all other Purchased Assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
duly executed assignments in the forms attached hereto as <B>Exhibit D-1, Exhibit D-2 and Exhibit D-3</B>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
a duly executed assignment and assumption agreement in sale in the form attached hereto as <B>Exhibit E</B>, effecting the assignment
to and assumption by BOCO US of the Purchased Assets and the Assumed Liabilities; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
a receipt for an amount equal to the Purchase Price <U>minus</U> the Letter Agreement Deposit Amount <U>minus</U> the Holdback
Amount (as defined in Section 8.3(a)) (such amount, the &ldquo;<U>Closing Purchase Price</U>,&rdquo; which, for the avoidance
of doubt, shall equal USD3,300,000, if the Closing occurs on or before December 1, 2016, and USD3,200,000, if the Closing occurs
after December 1, 2016) in the form attached hereto as <B>Exhibit F</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
At least three Business Days prior to the Closing (after all of the conditions to the Closing set forth in ARTICLE VI are satisfied
or waived (other than conditions that are intended to be satisfied at the Closing)) in accordance with ARTICLE VI, BOCO US and
STEMCELLS Parent shall sign and deliver joint written instructions to the Escrow Agent substantially in the form attached as Schedule
2 to the Escrow Agreement notifying the Escrow Agent of the Closing Date and directing the Escrow Agent to release funds in accordance
with the provisions of Section 1.7(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
At the Closing, except as provided by Section 1.7(e), the Escrow Agent shall release from the Escrow Account in accordance with
the terms of the Escrow Agreement (i) to STEMCELLS Parent, an amount equal to 85% of the Closing Purchase Price from the Escrow
Account and (ii) to the individuals whose consulting agreements are described in Section 2.14 of the Sellers Disclosure Schedule
(the &ldquo;<U>Consultants</U>&rdquo;), an aggregate amount equal to 15% of the Closing Purchase Price, in accordance with the
terms of such consulting agreements. USD400,000 of the Purchase Price will remain in the Escrow Account pursuant to the terms
of Section 8.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
If the Closing has not occurred by December 1, 2016, then USD100,000 of the Escrow Deposit will be returned by the Escrow Agent
to BOCO US. At the Closing, the remainder of the Escrow Deposit will be divided 85%/15%, as provided in Section 1.7(d), with USD400,000
remaining as the holdback pursuant to the terms of Section 8.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Closing shall take place at the offices of Dentons US, LLP, 1530 Page Mill Road, Suite 200, Palo Alto, CA 94304-1125, USA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
II</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPRESENTATIONS
AND WARRANTIES OF THE SELLER</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth in the disclosure schedule delivered by the Sellers to BOCO US (the &ldquo;<U>Sellers Disclosure Schedule</U>&rdquo;)
prior to the execution of this Agreement, the Sellers represent and warrant to BOCO US that as of the Closing Date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.1. Organization, Standing and Corporate Power.</B> Each of the Sellers is duly organized, validly existing and in good corporate
standing (or equivalent status) under the Laws of the state of its incorporation or organization and has all requisite corporate
power and authority to own, lease and operate its properties and assets and to carry on its business as it is now being conducted.
Each of the Sellers is duly licensed or qualified to do business and is in good standing (or equivalent status) as a foreign corporation
or other entity in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties
and assets owned, leased or operated by it requires such license or qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.2. Purchased Assets</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Sellers have good, valid and marketable title to all of the Purchased Assets free and clear of any Liens. Except as set forth
in Section 2.2(a) of the Sellers Disclosure Schedule the Purchased Assets include all of the assets, rights and properties (including
Intellectual Property Rights) of the Sellers that are currently held for use by the Sellers for the manufacture, study, commercialization
or development of the Key Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as set forth in Section 2.2(b) of the Sellers Disclosure Schedule, all of the Purchased Cell Banks has been maintained
in accordance with normal industry practice and in accordance with all applicable Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth in Section 2.2(c) of the Sellers Disclosure Schedule, to the Knowledge of the Sellers, the Hard Drives and/or
the Identified Boxes contain accurate copies of the Purchased Assets that have previously been reduced to a tangible format (written,
electronic or otherwise) still within the Sellers&rsquo; possession or control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.3. Authority; Noncontravention; Voting Requirements</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Sellers have all requisite corporate power and authority to execute and deliver this Agreement and to perform their obligations
hereunder and to consummate the Transactions. The execution, delivery and performance by the Sellers of this Agreement and the
consummation by them of the Transactions, have been duly and validly authorized by all necessary corporate action on the part
of the Sellers and no other corporate action on the part of the Sellers is necessary to authorize the execution, delivery and
performance by the Sellers of this Agreement or the consummation by them of the Transactions. This Agreement has been duly and
validly executed and delivered by the Sellers and, assuming due authorization, execution and delivery by the other parties hereto,
constitutes legal, valid and binding obligations of the Sellers, enforceable against the Sellers in accordance with its terms,
except that such enforceability may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and
other similar Laws affecting creditors&rsquo; rights generally and by general principles of equity (the &ldquo;<U>Bankruptcy and
Equity Exception</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The STEMCELLS Parent Board of Directors, at a meeting duly called and held at which all of the members of the STEMCELLS Parent
Board of Directors were present in person or by telephone in compliance with the applicable provisions of the Delaware General
Corporation Law (the &ldquo;<U>DGCL</U>&rdquo;), has duly and unanimously adopted resolutions (i) adopting and approving this
Agreement and approving the Transactions, and (ii) declaring that this Agreement and the Transactions are advisable and in the
best interests of the Sellers and its stockholders, and none of the aforesaid actions by the STEMCELLS Parent Board of Directors
has been amended, rescinded or modified as of the Closing Date. No further corporate action is required by the STEMCELLS Parent
Board of Directors in order for the Sellers to approve this Agreement or the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None of the execution and delivery of this Agreement by the Sellers, the consummation by the Sellers of the Transactions or compliance
by the Sellers with any of the terms or provisions hereof will (i) conflict with, or result in a violation or breach of, any provision
of any certificate of incorporation, certificate of formation, bylaws, operating agreement or comparable organizational document
(each an &ldquo;<U>Organizational Document</U>&rdquo;) of the Sellers, (ii) violate any Laws applicable to the Purchased Assets,
(iii) conflict with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both)
a default (or give rise to a right of termination, cancellation or acceleration of any obligations or loss of any material benefit)
under, require a consent or waiver under, require the payment of a penalty under, any terms, conditions or provisions of any loan
or credit agreement, debenture, note, bond, mortgage, indenture, deed of trust or Contract to which the Sellers is a party or
by which any of the Purchased Assets may be bound, or (iv) result in the creation or imposition of any Lien on any Purchased Asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The DGCL does not require that this Agreement or the Transactions be approved by holders of any class or series of capital stock
of the STEMCELLS Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.4. Governmental Approvals and Consents</B>. Except for filings required under, and compliance with other applicable requirements
of, the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and the Securities Act of 1933, as
amended (the &ldquo;<U>Securities Act</U>&rdquo;), the rules and regulations promulgated under the Exchange Act and the Securities
Act, the rules and regulations of the Nasdaq Stock Market (&ldquo;<U>Nasdaq</U>&rdquo;), no consents or approvals of, or filings,
declarations or registrations with, any Governmental Authority are necessary (a) for the execution and delivery of this Agreement
by the Sellers or the consummation by the Sellers of the Transactions, (b) to avoid the breach of the Key Products IP Contracts
or the creation of a Lien on any of the Purchased Assets, or (c) to enable BOCO US to own the Purchased Assets following the Closing
Date, except in each case as would not reasonably be expected to have, individually or in the aggregate, a Seller Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.5. Seller SEC Documents; Undisclosed Liabilities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Since December 31, 2015, the Sellers have timely filed or furnished, as applicable, all reports, forms, schedules, statements,
prospectuses, registration statements and other document required to be filed or furnished by the Sellers under the Securities
Act or the Exchange Act, as the case may be (such documents, collectively, and in each case including all exhibits and schedules
thereto and documents incorporated by reference therein, the &ldquo;<U>Seller SEC Documents</U>&rdquo;). Each Seller SEC Document,
as of its filing date or, if amended or supplemented prior to the date of this Agreement, as of the date of its last such amendment
or supplement, complied as to form, and each such Seller SEC Document filed subsequent to the date hereof will comply as to form,
in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and
regulations promulgated thereunder, applicable to such Seller SEC Documents. Each Seller SEC Document, as of its filing date or,
if amended or supplemented prior to the date of this Agreement, as of the date of its last such amendment or supplement, did not,
and each such Seller SEC Document filed subsequent to the date hereof will not, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in
light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
None of the Sellers has any liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise) other
than liabilities or obligations that (i) have been discharged or paid in full prior to the date of this Agreement in the ordinary
course of business, or (ii) are accrued or reserved against in the most recent financial statements included in the Sellers SEC
Documents filed prior to the date hereof or are reflected in the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.6. Legal Proceedings</B>. To the extent relating to the Purchased Assets, (a) there is no legal or administrative proceeding,
claim, suit or action pending or, to the Knowledge of the Sellers, threatened, against or affecting, the Sellers, any of their
respective assets or rights, any of the Identified Employees in their respective capacities as such before (or, in the case of
threatened actions, suits, investigations or proceedings, would be before) any arbitrator or Governmental Authority, nor (b) is
there any injunction, order, judgment, ruling or decree (&ldquo;<U>Order</U>&rdquo;) of any arbitrator or Governmental Authority
imposed upon or outstanding against the Sellers, or any of their respective assets or rights, or, to the Knowledge of the Sellers,
investigation by any Governmental Authority involving the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.7. Compliance With Laws; Permits</B>. Each of the Sellers has been and is currently in compliance in all material respects with
all laws, injunctions, judgments, decrees, rulings, statutes, ordinances, codes, rules, regulations, decrees and orders of Governmental
Authorities, including the Occupational Safety and Health Act of 1970 (29 U.S.C. &sect; 651 et seq.) and rules and regulations
of the U.S. Securities Exchange Commission and Nasdaq (collectively, &ldquo;<U>Laws</U>&rdquo;) applicable to the Purchased Assets
or the Identified Employees, including Laws relating to occupational safety and health, manufacturing practice, labeling, handling
and use of compounds and products and employee exposure monitoring and control. None of the Sellers has received any written notice
or other written communication alleging or relating to a possible violation by the Sellers of any Laws applicable to the Purchased
Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.8. Taxes</B>. There are no federal, state, county, local or foreign taxes due and payable by the Sellers which have not been
timely paid, which is reasonably likely to result in the creation of any Lien upon any of the Purchased Assets. There are no accrued
and unpaid federal, state, country, local or foreign taxes of the Sellers which are due, whether or not assessed or disputed,
which is reasonably likely to result in the creation of any Lien upon any of the Purchased Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.9. Personnel Matters</B>. There are no claims or legal proceedings pending or, to the Knowledge of the Sellers, threatened,
by or between the Sellers and any of the Identified Employees which: (i) questions the validity of any assignment by any of the
Identified Employees of any Key Products IP Rights, (ii) demands payment for any assignment by any of the Identified Employees
of any Key Products IP Rights or (iii) which is reasonably likely to result in the creation of any Lien upon any of the Purchased
Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.10. Key Products IP Contracts</B>. The Sellers have heretofore made available to BOCO US true, correct and complete copies of
the Key Products IP Contracts. Except as set forth in Section 2.10 of the Sellers Disclosure Schedule: (a) each of the Key Products
IP Contract constitutes the valid and legally binding obligation of the Sellers, enforceable in accordance with its terms (subject
to the Bankruptcy and Equity Exception) and (b) to the Knowledge of Sellers, is in full force and effect. The Sellers are not
(and with the giving of notice or lapse of time would not be) in material breach of, or default under, any Key Products IP Contract
and, to the Knowledge of the Sellers, no other party thereto is in material breach of, or default under, in any respect, any Key
Products IP Contracts. To Sellers&rsquo; Knowledge, there exist no Contracts which could reasonably be expected to impose material
obligations on or bind BOCO US or any of its Affiliates in any material way upon or following consummation of the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.11. Intellectual Property</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Sellers exclusively own, have a valid license or otherwise have the valid right to use or access, all Key Products IP Rights
free and clear of all Liens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Except as set forth in Section 2.11(b) of the Sellers Disclosure Schedule, to the Knowledge of the Sellers, all of the Trade Secrets
included in the Key Product IP Rights that have been reduced to a tangible form by the Sellers are, if still within Seller&rsquo;s
possession and control, included in either the Hard Drives or the Identified Boxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Section 2.11(c) of the Sellers Disclosure Schedule sets forth a true, correct and complete list of (i) each patent, patent application,
trademark registration, trademark application, copyright registration and domain name registration in which the Sellers have or
purports to have an ownership interest of any nature relating to the Key Products (whether exclusively, jointly with another Person,
or otherwise) (collectively, &ldquo;<U>Key Products Registered IP</U>&rdquo;), (ii) the jurisdiction in which such item of the
Key Products Registered IP has been registered or filed and the applicable registration or serial number, (iii) any other Person
that has an ownership interest in such item of the Key Products Registered IP and the nature of such ownership interest. Except
as set forth in Section 2.11(c) of the Sellers Disclosure Schedule, each of the material Key Products Registered IP is subsisting,
and, to the Sellers&rsquo; Knowledge, valid and enforceable, and has not been adjudged invalid or unenforceable in whole or part.
Except as set forth in Section 2.11(c) of the Sellers Disclosure Schedule, no Key Products IP Right is subject to any outstanding
decree, order, injunction, judgment or ruling restricting the use of such Intellectual Property Right or that is reasonably likely
to impair the validity or enforceability of such Intellectual Property Right. Except as set forth in Section 2.11(c) of the Sellers
Disclosure Schedule, to the Knowledge of the Sellers, no Person has asserted by way of declaratory action, invalidation action,
nullity action, revocation action, opposition, reexamination or similar action that the Key Products IP Rights are invalid and/or
unenforceable, except in connection with any legal proceeding that has been disclosed to BOCO US and which legal proceeding is
no longer pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as set forth in Section 2.11(d) of the Sellers Disclosure Schedule, there are no pending or, to the Knowledge of the Sellers,
threatened claims (i) that, with respect to the Purchased Assets, the Sellers have infringed, misappropriated or otherwise violated,
or is infringing, misappropriating or otherwise violating (including with respect to the manufacture, use, distribution, marketing,
or sale by the Sellers of any Key Products), any Intellectual Property Rights of any Person, (ii) based upon or challenging or
seeking to deny or restrict the use by or ownership of the Sellers of any of the Key Products IP Rights, or (iii) alleging that
any Key Products IP Right is being licensed or sublicensed in conflict with the terms of any license or other Contract. No Person
has asserted by way of allegation, &ldquo;cease and desist&rdquo; demands, unsolicited offers of license or otherwise or, to the
Sellers&rsquo; Knowledge, has the right to assert any claim regarding the use of, or challenging or questioning the Sellers&rsquo;
right or title in, any of the Key Products IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
To the Knowledge of the Sellers, no Person or Persons is or are infringing, misappropriating or otherwise violating any Key Products
IP Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Sellers have taken reasonable security measures, including measures against unauthorized disclosure, to protect the secrecy,
confidentiality, and value of its Trade Secrets and other Confidential Information related to the Key Products. With respect to
the Key Products, to Sellers&rsquo; Knowledge, none of the Identified Employees (i) is obligated (or was obligated at any time
while employed by the Sellers) under any Contract to assign any invention made, conceived, or reduced to practice during the period
of such Identified Employee&rsquo;s employment by the Sellers to any Person other than the Sellers, (ii) has assigned to any Person
other than the Sellers any inventions made, conceived, or reduced to practice during the period of such Identified Employee&rsquo;s
employment by the Seller or (iii) has retained any tangible form of the Trade Secrets or other Confidential Information related
to the Key Products. To the Knowledge of the Sellers, neither the execution nor delivery of this Agreement will conflict with
or result in a breach of the terms, conditions or provisions of, or constitute a default under, any Contract, covenant or instrument
under which any of its Identified Employees are now obligated. The Sellers do not believe that they are utilizing, or that it
will be necessary to utilize, in connection with the Key Products, any inventions of any of the Identified Employees made prior
to their employment by the Sellers that have not been licensed to or acquired by the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Except as set forth in Section 2.11(g) of the Sellers Disclosure Schedule, the execution and delivery of this Agreement by the
Sellers do not, and the consummation by the Sellers of the Transactions and compliance by the Sellers with the provisions of this
Agreement will not, (i) alter, impair, diminish or result in the loss of any rights or interests of the Sellers in respect of
any material Key Products IP Rights or under any Key Products IP Contract, (ii) grant or require the Sellers or BOCO US or its
Affiliates to grant to any Person any rights in respect of any material Key Products IP Rights, or (iii) subject the Sellers or
BOCO US or its Affiliates to any increase in or acceleration of royalties or other payments in respect of any Key Products IP
Rights or under any Key Products IP Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.12. Regulatory Matters</B>. With respect to the Key Products:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To the extent relating to the Purchased Assets, the Sellers are in compliance in all material respects with all applicable statutes,
rules and regulations of the FDA, and, to the extent applicable, other Regulatory Authorities, with respect to the clinical testing,
manufacture, labeling, storing, testing, or distribution of their compounds and products, including current &ldquo;Good Manufacturing
Practice,&rdquo; or cGMP regulations, &ldquo;Good Clinical Practice&rdquo; or GCP regulations to the extent the clinical data
from any of their clinical studies is used to support regulatory approval of the Sellers&rsquo; products, &ldquo;Good Laboratory
Practice&rdquo; (as such terms are defined in applicable Laws) or GLP regulations to the extent the non-clinical data from Seller
non-clinical studies is used to support regulatory approval of any products of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent relating to the Purchased Assets, the Sellers are in compliance in all material respects with all applicable registration
and listing requirements set forth at 21 U.S.C. &sect; 360 and all similar applicable laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None of the Sellers, nor, to the Knowledge of the Sellers, any Person who is providing or has provided services to the Sellers
(including Third Party Suppliers), is in receipt of notice of, or is subject to, any adverse inspection, finding of non-compliance,
compelled or voluntary recall, investigation, penalty for corrective or remedial action or other compliance or enforcement action,
by the FDA or any other applicable Regulatory Authority, relating to the Purchased Assets. There are no pending or, to the Knowledge
of the Sellers, threatened actions, proceedings or complaints by the FDA or any other applicable Regulatory Authority against
the Sellers, or any Person providing services to the Sellers (including Third Party Suppliers), relating to the Purchased Assets.
The Sellers have not received an FDA 483 or similar inspection report or warning letter relating to the Purchased Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Except as set forth in Section 2.12(d) of the Sellers Disclosure Schedule, the Purchased Cell Banks, including, to the Sellers&rsquo;
Knowledge, all key materials, reagents, active pharmaceutical ingredients, compounds and products used in the manufacture of the
Purchased Cell Banks supplied by third-party suppliers (&ldquo;<U>Third Party Suppliers</U>&rdquo;), have been manufactured, handled,
stored and distributed in accordance with applicable Laws, including current &ldquo;Good Manufacturing Practice,&rdquo; or cGMP
regulations, except as has not had, or would not reasonably be expected to have, individually or in the aggregate, a Seller Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
None of the Sellers has received any notification from the FDA or any other applicable Regulatory Authority indicating that any
of the Key Products are misbranded or adulterated as defined in 21 U.S.C. &sect; 321, et seq., as amended, and the rules and regulations
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Neither the Sellers nor, to the Sellers&rsquo; Knowledge, any of the Identified Employees, has made an untrue statement of a material
fact or fraudulent statement to the FDA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed
to the FDA or any other Regulatory Authority, or committed an act, made a statement or failed to make a statement, in each case
relating to the Purchased Assets, that, at the time such disclosure was made, would reasonably be expected to provide a basis
for any investigation by, and, to the Knowledge of the Sellers, no such investigation has been instituted or threatened by, (i)
the FDA pursuant to its &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&rdquo; set forth in
56 Fed. Reg. 46191 (September 10, 1991), (ii) Department of Health and Human Services Officer of Inspector General or Department
of Justice pursuant to the Federal Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7(b)) or the Federal False Claims Act (31 U.S.C.
&sect; 3729 et seq.), or (iii) any equivalent statute of any jurisdiction in the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Sellers have not used in any capacity the services of any Persons debarred under any jurisdiction&rsquo;s debarment provisions
including subsections 306(a) or 306(b) of the Generic Drug Enforcement Act of 1992, disqualified as a testing facility under CFR
Part 58, subpart K, or disqualified as a clinical investigator under 21 CFR 312.70, in connection with any of the services relating
to the Purchased Assets performed by the Sellers or its contractors. To the Sellers&rsquo; Knowledge, there are no pending or
threatened actions, suits, claims, investigations or legal or administrative proceedings relating to the debarment or disqualification
of any Person performing any services relating to the Purchased Assets for the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Sellers have complied in all material respects with all applicable Laws, guidelines and regulations relating to the collection
and/or use of the human cell lines, tissue, human clinical isolates or similar human-derived materials and the Sellers have obtained
any approvals, consents, and/or authorization required by applicable Laws (including the Health Insurance Portability and Accountability
Act and regulations promulgated thereunder) for the collection, use, and/or transfer of such human cell lines, tissue, human clinical
isolates or similar human-derived materials. Such human cell lines, tissue, human clinical isolates or similar human-derived materials
may be used without any obligations to the individuals or entities who contributed the materials, including any obligations of
compensation to such individuals or entities who contributed the materials for any purposes, including any obligations of compensation
to such individuals or entities who contributed the materials or any other third party for the intellectual property associated
with, or commercial use of, such materials for any purposes, other than payment obligations which do not exceed $50,000 in the
aggregate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.13. Brokers and Other Advisors</B>. No agent, broker, investment banker, financial advisor or other Person is entitled to any
broker&rsquo;s, finder&rsquo;s, advisory or other similar fee or commission, or the reimbursement of expenses, in connection with
the Transactions based upon arrangements made by or on behalf of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.14. Related Party Transactions</B>. Except as set forth in Section 2.14 of the Sellers Disclosure Schedule, as of the date hereof,
no, director, officer or other Affiliate of the Sellers or any of such Person&rsquo;s Affiliates, or any entity in which any such
Person has a direct or indirect material interest, (a) has any right, title, or interest in any Key Products IP Rights, or (b)
is party to or bound by any Key Products IP Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
2.15. Solvency; Fair Consideration; No Fraudulent Conveyance.</B> Upon the consummation of the Transactions, the Sellers will
be Solvent. The Sellers are not entering into this Agreement and consummating the Transactions with the intent to defraud, delay
or hinder the Sellers&rsquo; creditors and the consummation of the Transactions will not have any such effect. The Transactions
do not constitute a fraudulent conveyance, or otherwise give rise to any right of any creditor of the Sellers whatsoever to any
of the Purchased Assets after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
III</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">REPRESENTATIONS AND WARRANTIES OF BOCO US</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCO
US represents and warrants to the Sellers that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.1. Organization, Standing and Corporate Power</B>. BOCO US is duly organized and validly existing under the Laws of the state
of its incorporation and has all requisite corporate power and authority to own, lease and operate its properties and assets and
to carry on its business as it is now being conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.2. Authority; Noncontravention</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
BOCO US has all requisite corporate or other power and authority to execute and deliver this Agreement, and to perform its obligations
hereunder and to consummate the Transactions. The execution, delivery and performance by BOCO US of this Agreement, and the consummation
by BOCO US of the Transactions, have been duly authorized by all necessary corporate or other action on the part of BOCO US, and
no other corporate or other action on the part of BOCO US is necessary to authorize the execution, delivery and performance by
BOCO US of this Agreement or the consummation by it of the Transactions. This Agreement has been duly executed and delivered by
BOCO US and, assuming due authorization, execution and delivery hereof by the Sellers, constitutes a legal, valid and binding
obligation of BOCO US, enforceable against BOCO US in accordance with its terms, subject to the Bankruptcy and Equity Exception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
None of the execution and delivery of this Agreement by BOCO US, the consummation by BOCO US of the Transactions or compliance
by BOCO US with any of the terms or provisions hereof will (i) conflict with, or result in a violation or breach of, any provision
of any Organizational Document of BOCO US, (ii) violate any Laws applicable to BOCO US or its properties or assets or (iii) conflict
with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both) a default (or
give rise to a right of termination, cancellation or acceleration of any obligations or loss of any material benefit) under, require
a consent or waiver under, require the payment of a penalty under, any terms, conditions or provisions of any loan or credit agreement,
debenture, note, bond, mortgage, indenture, deed of trust or Contract to which BOCO US is a party and by which any of its properties
or assets are subject, except, in each case of clauses (ii) and (iii), as would not reasonably be expected to have, individually
or in the aggregate, a material and adverse effect on the ability of BOCO US to consummate the Transactions (a &ldquo;<U>BOCO
US Material Adverse Effect</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.3. Governmental Approvals and Consents</B>. No consents or approvals of, or filings, declarations or registrations with, any
Governmental Authority are necessary (a) for the execution and delivery of this Agreement by BOCO US or the consummation by BOCO
US of the Transactions, or (b) to enable BOCO US to own the Purchased Assets following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.4. Legal Proceedings</B>. There is no legal or administrative proceeding, claim, suit or action pending or, threatened before
any arbitrator or Governmental Authority, that would be expected to prevent, delay, make illegal or otherwise interfere with the
ability of BOCO US to consummate the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
3.5. Financial Capability</B>. BOCO US has ready access to sufficient funds to pay the Purchase Price on the terms and conditions
contemplated by this Agreement and to perform and consummate the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
IV</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRE-CLOSING
COVENANTS AND AGREEMENTS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.1. Conduct of the Business Prior to Closing</B>. Except as contemplated in this Agreement, as required by applicable Law or
with the written consent of BOCO US, from the Execution Date until the Closing or the earlier termination of this Agreement pursuant
to its terms, the Sellers shall use commercially reasonable efforts to maintain the Purchased Assets in the same condition as
they are on the Execution Date. Without limiting the generality of the foregoing, as contemplated in this Agreement, as required
by applicable Law or with the written consent of BOCO US, from the Execution Date until the Closing or the earlier termination
of this Agreement pursuant to its terms, the Sellers shall not:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
divest, sell, transfer, lease, license, abandon, allow to lapse, mortgage, pledge or otherwise dispose of, or encumber, or agree
to divest, sell, transfer, lease, license, abandon, allow to lapse, mortgage, pledge or otherwise dispose of, or encumber, any
of the Purchased Assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
amend, modify or terminate any Key Products IP Contract, except in connection with the assignment of any right, benefit or interest
thereunder to BOCO US pursuant to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
abandon, let lapse or cancel any Key Products IP Rights; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
alter in any way any of the files on the Hard Drives without the prior written authorization from BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.2. Commercially Reasonable Efforts</B>. From the Execution Date until the Closing, each of the Sellers and BOCO US shall use
commercially reasonable efforts to cause to be fulfilled and satisfied all of the conditions to Closing set forth in ARTICLE VI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.3. No Shopping</B>. Subject to BOCO US&rsquo;s funding the Escrow Deposit in accordance with Section 1.6(c), until the earlier
of (a) the Closing and (b) the termination of this Agreement pursuant to its terms, no Seller shall, nor shall any Seller authorize
or permit any of its representatives to, (i) initiate, solicit or knowingly encourage the submission of any proposal concerning
the sale of all or any part of Purchased Assets (a &ldquo;<U>Competing Transaction</U>&rdquo;) or (ii) hold any discussions or
enter into any agreements with, or provide any information or respond to, any third party concerning a proposed Competing Transaction
or cooperate in any way with, agree to, assist or participate in, solicit, consider, entertain, facilitate or encourage any effort
or attempt by any third party to do or seek any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.4. Microbot Merger; Stockholder Approval</B>. Following the Execution Date and until all obligations of STEMCLLS Parent to complete
the Microbot Merger are terminated, STEMCELLS Parent shall continue to take all commercially reasonable action necessary in accordance
with the DGCL and its certificate of incorporation and bylaws to consummate the Microbot Merger. In the event that, prior to any
consummation of the Microbot Merger, all agreements under which STEMCELLS Parent and Microbot have agreed to consummate the Microbot
Merger have been terminated in accordance with their respective terms and all applicable Laws, and no party thereto has in good
faith contested any such termination, STEMCELLS Parent shall thereafter take all commerically reasonable action necessary in accordance
with the DGCL and its certificate of incorporation and bylaws to seek the affirmative votes or consents of its stockholders to
approve and adopt the Transactions (the &ldquo;<U>Transactions Stockholder Approval</U>&rdquo;). All actions taken pursuant to
this Section 4.4 shall be taken at the sole cost and expense of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
4.5. Access to Information Prior to the Closing</B>. If the Closing does not occur on or before December 1, 2016, the Sellers
shall, during the period from December 1, 2016 through the Closing Date: (a) give BOCO US and its authorized representatives reasonable
access during regular business hours to the Hard Drives and the Identified Boxes as BOCO US may reasonably request for the sole
purpose of cataloging what is included in the Hard Drives and the Identified Boxes; and (b) use their commercially reasonable
efforts to enable BOCO US to have access to the Hard Drives and the Identified Boxes and provide BOCO US with answers to inquiries
regarding the Purchased Assets for the purpose referenced above; <U>provided</U> that the total time spent by the Sellers or BOCO
US in connection with the foregoing shall not exceed 30 hours in the aggregate. In connection with BOCO US&rsquo;s access to the
Purchased Assets as set forth in this Section 4.5, BOCO US shall be accompanied at all times by a representative of the Sellers
(who may be a former employee or consultant designated by the Sellers) unless the Sellers otherwise agree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
V</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">POST-CLOSING COVENANTS AND AGREEMENTS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.1. Public Announcements</B>. Notwithstanding anything to the contrary, both BOCO US and the Sellers may issue a press release
or other public announcement of the Transactions after the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.2. Access to Information</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Sellers shall preserve until the 12-month anniversary of the Closing Date all books, Contracts and records possessed by the
Sellers which are not included in the Purchased Assets which may reasonably be expected to contain information relating to any
of the Purchased Assets; provided that if the Sellers decide to dispose of any books, Contracts and records possessed by the Sellers
which are not included in the Purchased Assets which may reasonably be expected to contain information of scientific importance
directly relating to any of the Purchased Assets prior to the 6 year anniversary of the Closing, the Sellers shall first notify
BOCO US at least 30 days prior to any such disposition and BOCO US shall have the right, at its own expense, to retrieve all originals
and all copies of such information before it is disposed of by the Sellers. If BOCO US exercises its right to retrieve any books,
Contracts and records pursuant to this Section 5.2(a), the Sellers shall use their commercially reasonable efforts to cooperate
with BOCO US to assist BOCO US with the retrieval of any such books, Contracts and records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
For the 12-month period beginning on the Closing Date, the Sellers shall afford to BOCO US and its representatives reasonable
access during normal business hours to all of its properties, books, Contracts and records related to the Purchased Assets, and
the Sellers shall instruct their employees, counsel, financial advisors, auditors and other authorized representatives to cooperate
with BOCO US, in connection with any reasonable request for such access. BOCO US and its representatives shall have the right
to make copies of such books, Contracts and records as may be reasonably necessary to make full use of the Purchased Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event that a Seller becomes subject to any action, suit, investigation or proceeding related to the Purchased Assets or
is required to file or furnish any document with any Governmental Authority related to the Purchased Assets, or access to the
Purchased Assets by the Sellers is reasonably necessary for compliance with any applicable Law, BOCO US shall afford to the Sellers
and their representatives reasonable access during normal business hours to all of the properties, books, Contracts and records
included within the Purchased Assets which are still in the possession of BOCO US and its Affiliates, and BOCO US shall instruct
their employees, counsel, financial advisors, auditors and other authorized representatives to cooperate with the Sellers, in
connection with any reasonable request for such access. The Sellers and their representatives shall have the right, at the Sellers&rsquo;
sole expense, to make copies of such books, Contracts and records as may be reasonably necessary for the foregoing purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.3. Confidentiality</B>. The Sellers recognize that by reason of their ownership of the Purchased Assets, including the use and
ownership of the Key Products, the Sellers have acquired Confidential Information and Trade Secrets concerning the Key Products
and the other Purchased Assets, the use or disclosure of which could cause BOCO US or its Affiliates substantial loss and damages.
Accordingly, the Sellers covenant to BOCO US that the Sellers will not, except in performance of its obligations to BOCO US or
with the prior written consent of BOCO US, disclose, or cause any third party to disclose, any Confidential Information relating
to the Key Products or other Purchased Assets that they may learn or have learned by reason of their ownership of the Key Products
or other Purchased Assets, unless (a) it is available to the public prior to the Closing or becomes generally available to the
public other than as a result of disclosure by the Sellers or any of its Affiliates as a result of a breach of this Section 5.3,
(b) disclosure is required by applicable Law , (c) disclosure is necessary to defend or prosecute any indemnification claim or
any litigation or dispute, including in connection with any claim of any Seller against BOCO US, or (d) such information becomes
available to a Seller on a non-confidential basis from a source other than BOCO US or any of its Affiliates, without, to the Seller&rsquo;s
Knowledge, being subject to any contractual or other obligation of confidentiality to BOCO US or any of its Affiliates. Notwithstanding
the foregoing, the provisions of this Section 5.3 do not apply to: (i) the issue by the Parties of the announcements described
herein, (ii) any announcement required to be made by any Party by virtue of the regulations of the SEC or any analogous securities
regulatory authority of any Governmental Authority outside of the United States, by any Governmental Authority competent to require
the same, or by any applicable Law or applicable requirement of a stock exchange, <U>provided</U> that in any of the foregoing
instances, the other Party, to the extent lawful and practicable, is first given a reasonable opportunity to take the necessary
measures to prevent or otherwise limit the content of such announcement; (iii) any statement or disclosure made in good faith
by any Party after the Closing Date in connection with any civil, criminal, regulatory or arbitration proceedings in any jurisdiction
brought or threatened by or against it in relation to this Agreement or any other document(s) referred to in it, or (iv) any disclosure
made by a Party to its professional advisers, collaborators, lenders, and business associates provided that such disclosure is
made under obligations of confidentiality. Moreover, nothing in this Section 5.3 shall limit in any way the ability of any Party
to consult any professional adviser (including a tax adviser independent from all other entities involved in the transaction)
in relation to any matter arising out of this Agreement or any of the other documents referred to in it, including the tax treatment
and tax structure of the Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.4. Fees and Expenses</B>. Except as expressly set forth in this Agreement, all fees and expenses incurred in connection with
the Transactions shall be paid by the party incurring such expenses, whether or not the Transactions are consummated. For the
avoidance of doubt, except as expressly set forth in this Agreement, all fees and expenses incurred in connection with the Transactions
by the Sellers shall be borne by the Sellers and none shall be borne by, or be the responsibility of BOCO US or included in the
Assumed Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.5. Further Assurances</B>. In the event that at any time during the 90-day period immediately after the Closing Date any further
action is necessary to fully effect the Transactions, including the assignment of any Key Products IP Rights, each of the Parties
shall take, or cause to be taken, at BOCO US&rsquo;s sole expense, such further action (including (i) transferring to BOCO US
any asset or liability contemplated by this Agreement to be a Purchased Asset or an Assumed Liability, respectively, which was
not transferred to BOCO US at or before the Closing, and (ii) the execution and delivery of such further instruments and documents)
as the other Party may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.6. Key Products IP Contracts</B>. For the period of 90 days immediately following the Closing Date, upon BOCO US&rsquo;s written
request, the Sellers will use commercially reasonable efforts to assign to either BOCO US or to one of its designated Affiliates
each of the Key Products IP Contacts if not assigned at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.7. Seller Non-Competition and Non-Solicitation</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
During the four-year period immediately following the Closing Date, none of the Sellers nor any of their Affiliates will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
engage in, cause any third party to engage in, own, or have any financial interest in, a business that is engaged in, the research,
development or commercialization of any of the Key Products for any purpose anywhere in the United States and any other country
that the Sellers engaged in the research, development or commercialization of the Key Products in prior to the Closing, <U>provided
</U>that such ownership or financial interest shall not apply to any investment of up to 1% of any class of publicly traded securities
or up to 5% of the securities of a private company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
solicit or attempt to solicit any Person who is or has been a supplier, distributor, collaborator, contract research organization,
licensor, licensee or any other business relation of the Sellers within the past three years to (A) cease doing business with
BOCO US or its Affiliates, or (B) alter or limit its business relationship with BOCO US or its Affiliates; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
solicit, or cause any third party to solicit, for employment or employ any employee of BOCO US or its Affiliates, or request,
induce or advise any employee to leave the employment of BOCO US or any of its Affiliates, without the prior written consent of
BOCO US; <U>provided</U>, that a general offer of employment to the public shall not be deemed prohibited hereunder as long as
not specifically directed at employees of BOCO US or any of its Affiliates. For the avoidance of doubt, upon the closing of the
Microbot Merger, Microbot shall be considered an Affiliate of STEMCELLS Parent and will thereby be subject to the foregoing provisions
of this Section 5.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The nature and scope of the foregoing protection has been carefully considered by the parties hereto. The parties hereto agree
and acknowledge that the duration, scope and geographic areas applicable to such provisions are fair, reasonable and necessary
and that adequate compensation has been received by the Sellers for such obligations. If, however, for any reason any court of
competent jurisdiction determines in a final and non-appealable judgment that any such restrictions are not reasonable, such restrictions
shall be interpreted, modified or rewritten to include as much of the duration, scope and geographic area identified in this Section
5.7 as will render such restrictions valid and enforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
In the event of a breach or threatened breach of this Section 5.7, BOCO US shall be entitled, without the posting of a bond, to
an injunction restraining such breach. Nothing herein contained shall be construed as prohibiting any party from pursuing any
other remedy available to it for such breach or threatened breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.8. Change of Names</B>. Promptly upon the Closing, the Sellers shall take commercially reasonable efforts to discontinue their
use of any and all Seller Marks. Notwithstanding the foregoing, BOCO US hereby grants to the Sellers a limited, worldwide, non-transferable,
non-sublicensable, royalty-free, fully paid-up, non-exclusive license solely to use, reproduce and display the Seller Marks solely
on existing forms, stationery and other materials bearing the Seller Marks as of the Closing or to indicate, for informational
purposes, the transfer of the Purchased Assets and to make filings and other submissions required by Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
5.9. Certain Tax Matters</B>. Notwithstanding anything herein to the contrary, the Sellers shall be solely liable for, and shall
pay when due, any transfer, gains, documentary, sales, use, registration, stamp, value-added or other similar Taxes (&ldquo;<U>Transfer
Taxes</U>&rdquo;) payable by reason of the Transactions, and the Sellers shall file, at their expense, all necessary Tax Returns
and other documentation with respect to all Transfer Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
VI</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDITIONS
TO CLOSING</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.1. Conditions to BOCO US&rsquo;s Obligation to Close</B>. The obligations of BOCO US to consummate the Transactions shall be
subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived
by BOCO US in writing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The representations and warranties of Sellers in ARTICLE II shall be true and correct in all respects as of the Closing (or, to
the extent such representations and warranties speak as of a specific date or time, they shall be true in all respects as of such
date or time), except as otherwise contemplated by this Agreement and except for such inaccuracies under such representations
and warranties which, taken together in their entirety, would not, individually or in the aggregate, result in a Seller Material
Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
the Sellers shall have performed, in all material respects, all covenants and obligations in this Agreement required to be performed
by the Sellers as of the Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
there shall not have occurred any Seller Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.2. Conditions to the Sellers&rsquo; Obligation to Close</B>. The obligations of the Sellers to consummate the Transactions shall
be subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived
by the Sellers in writing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
the representations and warranties of BOCO US in ARTICLE III shall be true and correct in all respects as of the Closing Date
(or, to the extent such representations and warranties speak as of a specific date or time, they shall be true in all respects
as of such date or time) and except for such inaccuracies under such representations and warranties which, taken together in their
entirety, would not, individually or in the aggregate, impair or delay the ability of BOCO US to consummate the Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
BOCO US shall have performed its obligations in Section 1.6(c) and any other material covenants and obligations required in this
Agreement to be performed by BOCO US as of the Closing Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
there shall not have occurred any BOCO US Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
6.3. Conditions to Obligations of Each Party to Close</B>. The respective obligations of each Party to consummate the Transactions
shall be subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, which may be waived
by mutual consent of the Sellers and BOCO US, in writing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<B>No Legal Impediments to Closing</B>. There shall not be in effect any Order issued by any Governmental Authority preventing
the consummation of the Transactions, seeking any Losses as a result of the Transactions, or otherwise affecting the right or
ability of BOCO US to own, operate or control the Purchased Assets. There shall not be any applicable Law prohibiting the Sellers
from selling or BOCO US from owning, operating or controlling the Purchased Assets or that makes this Agreement or the consummation
of the Transactions illegal; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<B>Microbot Merger; Stockholder Approval</B>. The Microbot Merger will have been consummated or the Transactions Stockholder Approval
will have been obtained in accordance with Section 4.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
VII</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">TERMINATION</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.1. Circumstances for Termination</B>. At any time prior to the Closing, this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
shall terminate immediately upon BOCO US&rsquo;s failure to fund the Escrow Deposit in accordance with Section 1.6(c); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
may be terminated by written notice explaining the reason for such termination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
by the mutual written consent of BOCO US and the Sellers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
by either BOCO US or the Sellers, if (i) the non-terminating Party is in material breach of any material provision of this Agreement
and such breach shall not have been cured within 30 days of receipt by such Party of written notice from the terminating Party
of such breach and (ii) the terminating Party is not, on the date of termination, in material breach of any material provision
of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
by either the Sellers or BOCO US, if the Closing has not occurred on or prior to 120 days from the Execution Date (the &ldquo;<B>Drop-Dead
Date</B>&rdquo;) for any reason; <U>provided further</U>, <U>however</U>, that the rights to terminate this Agreement under this
Section 7.1(b)(iii) shall not be available to any Party whose breach of any covenants or agreements contained in this Agreement
has been the cause of, or resulted in, the failure of the Closing Date to occur on or before the Drop-Dead Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
by either Party at any time following 180 days from the Execution Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
7.2. Effect of Termination</B>. If this Agreement is terminated in accordance with Section 7.1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all obligations of the Parties hereunder shall immediately terminate, except for the obligations set forth in Section 5.4, this
Section 7.2 and Section 9.5, <FONT STYLE="font-weight: normal"><U>provided</U>, <U>however</U>, that nothing herein shall relieve
any Party from Liability for any breach of this Agreement prior to such termination; and</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
to the extent that BOCO US has funded the Escrow Account with the Escrow Deposit pursuant to Section 1.6(c), the Escrow Agent
shall release the Escrow Deposit to BOCO US from the Escrow Account in accordance with the terms of the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
VIII</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEMNIFICATION</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.1. Survival of Representations and Warranties; Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The representations and warranties of the parties contained in this Agreement and any document delivered pursuant to this Agreement
shall survive the Closing until the date that is one year following the Closing Date (the &ldquo;<U>Survival Period</U>&rdquo;);
<U>provided</U>, <U>however</U>, that any claim with respect to fraud, criminal activity or willful misconduct on the part of
the Sellers will survive and can be made by a BOCO Indemnified Party at any time. Notwithstanding anything to the contrary in
this Section 8.1, the indemnification obligations pursuant to this ARTICLE VIII shall not terminate with respect to any indemnification
claim made by a BOCO Indemnified Party prior to the expiration of the applicable Survival Period until such claim is resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
From and after the Closing, and subject to the terms of this ARTICLE VIII, the Sellers hereby jointly and severally agree to indemnify,
defend and hold harmless BOCO US and its Affiliates and their respective directors, managers, officers, employees, equity holders,
members, partners, agents, attorneys, representatives, successors and assigns (collectively, the &ldquo;<U>BOCO Indemnified Parties</U>&rdquo;)
from and against, and pay to the applicable BOCO Indemnified Parties, the amount of any and all losses, liabilities, claims, obligations,
deficiencies, demands, judgments, damages (including consequential damages), interest, fines, penalties, claims, suits, actions,
causes of action, assessments, awards, costs and expenses (including costs of investigation and defense and reasonable attorneys&rsquo;
and other professionals&rsquo; fees), whether or not involving a third party claim (individually, a &ldquo;<U>Loss</U>&rdquo;
and, collectively, &ldquo;<U>Losses</U>&rdquo;) actually incurred by the BOCO Indemnified Parties and solely to the extent based
upon, attributable to or resulting from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
any inaccuracy in or breach of the representations or warranties made by the Sellers in Section 2.1, Section 2.2, Section 2.3
and Section 2.4 of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
any inaccuracy in or breach of the representations or warranties made by the Sellers in Section 2.11 of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any inaccuracy in or breach of the representations or warranties made by the Sellers in Section 2.5, Section 2.6, Section 2.7,
Section 2.8, Section 2.9, Section 2.12, Section 2.13, Section 2.14 and Section 2.15 this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
any breach or non-performance of any covenant or other agreement prior to the Closing on the part of the Sellers under this Agreement
or any document delivered pursuant to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
any breach or non-performance of any covenant or other agreement after the Closing on the part of the Sellers under this Agreement
or any document delivered pursuant to this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
any misuse after the Closing of any Trade Secrets or other Confidential Information solely to the extent related to the Key Products
by any of the Sellers or any of their Affiliates; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
any of the Excluded Assets or any of the Retained Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.2. Indemnification Procedures</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any claim for indemnification on account of a Loss which does not result from a Third Party Claim (a &ldquo;<U>Direct Claim</U>&rdquo;)
shall be asserted by the BOCO Indemnified Party giving the Sellers prompt written notice thereof. The failure to give such prompt
written notice, <U>provided</U> that such notice is delivered within the Survival Period, shall not, however, relieve the Sellers
of their indemnification obligations, except to the extent the Sellers can demonstrate actual material loss and prejudice as a
result of such failure. Such notice by the BOCO Indemnified Party shall describe the Direct Claim and include a reasonably detailed
description of the amount of the Loss (the &ldquo;<U>Claimed Amount</U>&rdquo;) actually incurred by the BOCO Indemnified Party
and matter or condition set forth in Section 8.1(b) allegedly giving rise to the Direct Claim. The Sellers shall have 60 days
after their receipt of such notice (the &ldquo;<U>Direct Claim Response Period</U>&rdquo;) to respond in writing to such Direct
Claim. During such Direct Claim Response Period, the BOCO Indemnified Party shall allow the Sellers and their professional advisors
to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount
paid in respect of the Direct Claim is attributable to such matter or circumstance, and the BOCO Indemnified Party shall assist
the Sellers&rsquo; investigation by giving such information and assistance (including access to the BOCO Indemnified Party&rsquo;s
premises and personnel and the right to examine and copy any accounts, documents or records) as the Sellers or any of their professional
advisors may reasonably request. If the Sellers dispute their obligation to pay the Claimed Amount, BOCO US and the Sellers shall
attempt in good faith to reach an agreement as to the disputed matter. If BOCO US and the Sellers shall have failed to resolve
such disputed matters within 90 days after expiration of the Direct Claim Response Period, then such outstanding dispute shall
be determined by arbitration conducted in accordance with Section 9.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event that any Legal Proceedings shall be instituted or that any claim or demand shall be asserted by any third party in
respect of which indemnification may be sought under Section 8.1(b) hereof (a &ldquo;<U>Third Party Claim</U>&rdquo;), the BOCO
Indemnified Party shall promptly cause written notice of the assertion of any Third Party Claim of which it has knowledge which
is covered by this indemnity to be forwarded to the Sellers. The failure of the BOCO Indemnified Party to give reasonably prompt
notice of any Third Party Claim, <U>provided</U> that such notice is delivered within the Survival Period, shall not release,
waive or otherwise affect the Sellers&rsquo; obligations with respect thereto except to the extent that the Sellers can demonstrate
actual material loss and prejudice as a result of such failure. Subject to the provisions of this Section 8.2, the Sellers shall
have the right, at their sole expense, to be represented by counsel of their choice and to defend against, negotiate, settle or
otherwise deal with any Third Party Claim which relates to any Losses indemnified against by them hereunder. If the Sellers elect
to defend against, negotiate, settle or otherwise deal with any Third Party Claim which relates to any Losses indemnified against
by them hereunder, they shall, within twenty days of the BOCO Indemnified Party&rsquo;s written notice of the assertion of such
Third Party Claim (or sooner, if the nature of the Third Party Claim so requires), notify the BOCO Indemnified Party of their
intent to do so; <U>provided</U> that the Sellers must conduct their defense of the Third Party Claim actively and diligently
thereafter in order to preserve their rights in this regard. If the Sellers elect not to defend against, negotiate, settle or
otherwise deal with any Third Party Claim which relates to any Losses indemnified against by them hereunder, fails to notify the
BOCO Indemnified Party of their election as herein provided or contests their obligation to indemnify the BOCO Indemnified Party
for such Losses under this Agreement, the BOCO Indemnified Party may (subject to the terms of this Section 8.2(b)) at its sole
expense defend against, negotiate, settle or otherwise deal with such Third Party Claim. If the Sellers shall assume the defense
of any Third Party Claim, the BOCO Indemnified Party may participate, at his, her or its own expense, in the defense of such Third
Party Claim; <U>provided</U>, <U>however</U>, that such BOCO Indemnified Party shall be entitled to participate in any such defense
with separate counsel if (i) so requested by the Sellers to participate or (ii) in the reasonable, good-faith opinion of counsel
to the BOCO Indemnified Party, a conflict with respect to such Third Party Claim exists between the BOCO Indemnified Party and
the Sellers that cannot be waived and would make such separate representation advisable. Each Party agrees to provide reasonable
access to each other Party to such documents and information as may reasonably by requested in connection with the defense, negotiation
or settlement of any such Third Party Claim. Notwithstanding anything in this Section 8.2 to the contrary, neither the Sellers
nor any BOCO Indemnified Party shall, without the written consent of the other Party, settle or compromise any Third Party Claim
or permit a default or consent to entry of any judgment unless (x) the claimant (or claimants) and such Party provide to such
other Party an unqualified release from all liability in respect of the Third Party Claim and such settlement or compromise, or
such default or entry of judgment, as applicable, does not oblige such other Party to take or forbear any action or waive any
right or (y) if such Third Party Claim is with respect to Taxes, such settlement or compromise, or such default or entry of judgment,
as applicable, could not reasonably be expected to have an adverse effect on the Sellers or BOCO US, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
After any final decision, judgment or award shall have been rendered by a Governmental Authority of competent jurisdiction and
the expiration of the time in which to appeal therefrom, or a settlement shall have been consummated, or the BOCO Indemnified
Party and the Sellers shall have arrived at a mutually binding agreement, in each case with respect to a Third Party Claim hereunder,
the BOCO Indemnified Party shall forward to the Sellers and the Escrow Agent notice of any sums due and owing by the Sellers pursuant
to this ARTICLE VIII with respect to such matter and the Sellers shall pay all of such remaining sums so due and owing to the
BOCO Indemnified Party in accordance with Section 8.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.3. Limitations on Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Notwithstanding anything to the contrary: (i) the Sellers&rsquo; maximum aggregate liability to the BOCO Indemnified Parties with
respect to all Losses and other payments arising out of or relating to the matters described in Section 8.1(b), including Section
8.1(b)(i) and Section 8.1(b)(vii), shall not exceed an amount equal to USD4,000,000 (the &ldquo;<U>Cap</U>&rdquo;); (ii) the Sellers&rsquo;
maximum aggregate liability to the BOCO Indemnified Parties with respect to all Losses and other payments arising out of or relating
to the matters described in Section 8.1(b)(ii), Section 8.1(b)(v) and Section 8.1(b)(vi) shall not exceed an amount equal to USD3,000,000,
(iii) the Sellers&rsquo; maximum aggregate liability to the BOCO Indemnified Parties with respect to all Losses and other payments
arising out of or relating to the matters described in Section 8.1(b)(iii) and Section 8.1(b)(iv) shall not exceed an amount equal
to USD400,000 (the &ldquo;<U>Holdback Amount</U>&rdquo;) and (iv) there shall be no Cap with respect to Losses arising from fraud,
criminal activity or willful misconduct on the part of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
There shall be disregarded for all purposes (including, for the avoidance of doubt, the application of the de minimis threshold
in Section 8.3(c) below) any Direct Claim or Third-Party Claim (each a &ldquo;<U>Claim</U>&rdquo;) in respect of which the amount
which a BOCO Indemnified Party would otherwise (but for the provisions of this Section 8.3(b)) be entitled to recover would be
less than USD10,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
None of the Sellers shall be obligated to indemnify any Person with respect to any Losses arising out or relating to matters described
in Section 8.1(b), until the aggregate amount of all Losses in respect of indemnification under Section 8.1(b) exceeds USD40,000
(the &ldquo;<U>Minimum</U>&rdquo;) in which event Seller shall be required to pay or be liable for all such Losses from the first
dollar.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purposes of determining the failure of any representations or warranties to be true and correct, the breach of any covenants
or agreements, and calculating Losses hereunder, any materiality or Seller Material Adverse Effect or BOCO US Material Adverse
Effect qualifications in the representations, warranties, covenants and agreements shall be disregarded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Notwithstanding anything contrary contained in this Agreement, (i) any Liability of the Sellers in respect of any Claim shall
terminate absolutely if the action or proceeding in respect of it shall not have been commenced by being both issued and served
on the Sellers, as the case may be, within the period of 6 months from the date on which the Sellers received notice from the
BOCO Indemnified Party of such Claim; (ii) none of the Sellers shall be liable in respect of any Claim based upon a Liability
that is contingent, only unless and until such contingent liability becomes an actual liability; and (iii) the Sellers shall cease
to have any Liability for any Claim, unless notice is given in accordance with Section 8.2 on or before the first anniversary
of Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Notwithstanding anything contrary contained in this Agreement, none of the Sellers shall have any liability in respect of any
Claim to the extent that BOCO US is insured against any loss or damage suffered by any Seller forming the basis of the Claim in
question under the terms of any insurance policy of BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Where the scope of any Seller&rsquo;s liability in relation to any particular matter the subject of a specific warranty has been
limited expressly pursuant to that or any other warranty or any other provision of this Agreement, the Sellers shall have no liability
in respect of any Claim relating to such matter other than under the terms of that specific warranty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
For the avoidance of doubt: (i) nothing herein shall limit BOCO US&rsquo;s obligation to mitigate its loss in respect of any Claim
to the extent reasonable and practicable; and (ii) no BOCO Indemnified Parties shall be entitled to recover damages in respect
of any Claim or otherwise obtain reimbursement or restitution more than once in respect of the same fact or subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.4. Indemnity Escrow</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any payment the Sellers are obligated to make to any BOCO Indemnified Parties pursuant to this ARTICLE VIII shall be paid, first,
to the extent there are sufficient funds in the Escrow Account, by release of funds to the BOCO Indemnified Parties from the Escrow
Account by the Escrow Agent in accordance with the provisions of the Escrow Agreement, within five Business Days after the date
notice of any sums due and owing is given to the Sellers (with a copy to the Escrow Agent pursuant to the Escrow Agreement), by
the applicable BOCO Indemnified Party and shall accordingly reduce the Escrow Account and, second, to the extent the Escrow Account
is insufficient to pay any remaining sums due, then Sellers shall be required to pay all such additional sums due and owing to
the BOCO Indemnified Parties by wire transfer of immediately available funds within five Business Days after the date of such
notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
On the expiration of the Survival Period, the Escrow Agent shall release the funds in the Escrow Account (to the extent not utilized
to pay for any indemnification claim), 85% of such funds to STEMCELLS Parent and 15% of such funds to the Consultants, in accordance
with the terms of the Escrow Agreement, except that the Escrow Agent shall retain an amount (up to the total amount then held
by the Escrow Agent) equal to the amount of claims for indemnification under this ARTICLE VIII asserted prior to such expiration
of the Survival Period but not yet resolved (&ldquo;<U>Unresolved Claims</U>&rdquo;). The Escrow Account retained for Unresolved
Claims shall be released by the Escrow Agent (to the extent not utilized to pay BOCO US for any such claims resolved in favor
of BOCO US) upon their resolution in accordance with this ARTICLE VIII and the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.5. Tax Treatment of Indemnity Payments</B>. Seller and BOCO US agree to treat any indemnity payment made pursuant to this this
ARTICLE VIII as an adjustment to the Purchase Price for all Tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
8.6. Exclusive Remedies</B>. Subject to Section 9.6, the parties acknowledge and agree that their sole and exclusive remedy with
respect to any and all claims (other than claims arising from fraud, criminal activity or willful misconduct) for any breach of
any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of
this Agreement shall be pursuant to the indemnification provisions set forth in this ARTICLE VIII. Notwithstanding the foregoing,
nothing contained in this Agreement shall limit a party&rsquo;s right to pursue equitable remedies, including, without limitation,
injunctive relief and specific performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ARTICLE
IX</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MISCELLANEOUS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.1. Assignment</B>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned or delegated,
in whole or in part, by operation of applicable Laws or otherwise, by any of the parties without the prior written consent of
the other parties; <U>provided</U>, that (a) BOCO US may assign any of its rights and obligations hereunder, in whole or in part,
to any of its Affiliates without obtaining the consent of the Sellers, and (b) each of the Sellers may assign any of its rights
and obligations hereunder, in whole or in part, without obtaining the consent of BOCO US, to any of their Affiliates and to any
third party by sale of stock or operation of Law in connection with a <I>bona fide</I> third party merger or sale of substantially
all of such Seller&rsquo;s assets to such third party. Subject to the preceding sentence, this Agreement shall be binding upon,
inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and permitted assigns. Any
purported assignment not permitted under this Section 9.1 shall be null and void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.2. Counterparts</B>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other
means of Electronic Transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.3. Entire Agreement; No Third Party Beneficiaries</B>. This Agreement, including the Sellers Disclosure Schedule, the exhibits
hereto, the documents and instruments relating to the Transactions referred to herein, and the Confidentiality Agreement constitute
the entire agreement, and supersede all prior agreements and understandings, both written and oral among the parties with respect
to the subject matter of this Agreement and the Confidentiality Agreement. Nothing in this Agreement, express or implied, is intended
to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under
or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.4. Governing Law. </B>This Agreement shall in all respects be governed by, and construed in accordance with, the Laws (excluding
conflict of laws rules and principles) of the State of New York applicable to agreements made and to be performed entirely within
such State, including all matters of construction, validity and performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.5. Arbitration</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Any controversy, claim or dispute arising out of or related to this Agreement or the interpretation, performance, or breach hereof,
including but not limited to alleged violations of state or federal statutory or common law rights or duties, all tort claims
and all claims for punitive damages (a &ldquo;<U>Dispute</U>&rdquo;), shall be resolved solely according to the procedures set
forth in this Section 9.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The parties shall attempt, whenever possible, to discuss and resolve any Disputes on an informal basis, in order to avoid the
expense and delay associated with arbitration. A party invoking these dispute resolution procedures shall deliver a notice to
the other parties (a &ldquo;<U>Dispute Notice</U>&rdquo;) of the claims it intends to bring and the relief sought, including sufficient
details regarding the factual, contractual or other legal bases for the party&rsquo;s claim as reasonably required to enable the
parties receiving the Dispute Notice to evaluate the claim and respond thereto. No arbitrator shall have authority to consider
or resolve any Dispute that is not first the subject of a Dispute Notice and subject to informal dispute resolution pursuant to
this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the parties are unable to resolve one or more Disputes informally, any party to the Dispute may initiate a confidential binding
arbitration proceeding for the final resolution of such remaining Disputes. A party shall initiate arbitration by delivering a
notice to the other parties (an &ldquo;<U>Arbitration Notice</U>&rdquo;) describing the Disputes to be arbitrated. Within 10 Business
Days of receiving an Arbitration Notice, the receiving party may deliver its own Arbitration Notice, specifying additional Disputes
to be submitted to arbitration. If more than one Dispute is to be arbitrated, the subject matters of the various Disputes need
not be related to each other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Any arbitration shall be submitted to the Hong Kong branch of the China International Economic and Trade Arbitration Commission
(&ldquo;<U>CIETAC</U>&rdquo;) for arbitration in accordance with the CIETAC&rsquo;s arbitration rules in effect at the time of
execution of this Agreement, which rules are incorporated herein by this reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The arbitration tribunal shall consist of three arbitrators (the &ldquo;<U>Arbitrators</U>&rdquo;): (a) one selected by BOCO US,
(b) one selected by the Sellers, and (c) one selected jointly by BOCO US and the Sellers, none of whom shall be a U.S. or Chinese
national. Each Arbitrator shall speak fluently both English and at least one of the Chinese languages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The arbitration tribunal shall issue a written opinion in English setting forth its award, factual determinations and the legal
basis for its decision. The arbitration proceedings will be conducted in English. BOCO US may, at its own option and expense,
have such opinion or such proceeding translated into Chinese.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The arbitration decision shall be binding and final upon the parties thereto, and judgment on any award rendered by the Arbitrators
may be entered in any court having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Each Party will bear its own costs associated with the resolution or arbitration of any Dispute. The costs to be paid to CIETAC
to conduct the arbitration will be shared 50% by the Sellers and 50% by BOCO US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.6. Specific Performance</B>. The parties agree that irreparable damage would occur in the event that any of the provisions of
Section 5.7 were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
BOCO US shall be entitled to an injunction or injunctions to prevent breaches of Section 5.7 and to enforce specifically the terms
and provisions thereof in any court having jurisdiction thereof, without bond or other security being required, this being in
addition to any other remedy to which BOCO US is entitled under applicable Laws or in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.7. Notices</B>. All notices, requests and other communications to any party hereunder shall be in writing and shall be deemed
given if delivered personally, or sent by nationally recognized overnight courier (providing proof of delivery) to the parties
at the following addresses:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to BOCO US, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCO
Silicon Valley, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43152
Nielson Court</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fremont,
CA 94539</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Shirley Zhou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy, which will not constitute notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dentons
US, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1530
Page Mill Road, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Palo
Alto, CA 94304-1125</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Peter Su</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan
Katz</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Sellers, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">StemCells,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39899
Balentine Drive, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newark,
CA 94560</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
President</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy, which will not constitute notice, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropes
&amp; Gray LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36F,
Park Place1601 Nanjing Road West</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai
200040, PRC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Arthur Mok, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69.1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
such other address or facsimile number as such party may hereafter specify by like notice to the other parties hereto. All such
notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received
prior to 5:00 p.m. (local time) on a Business Day in the place of receipt. Otherwise, any such notice, request or communication
shall be deemed to have been received on the next succeeding Business Day in the place of receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.8. Severability</B>. If any term or other provision of this Agreement is determined by a court of competent jurisdiction to
be invalid, illegal or incapable of being enforced by any rule of any applicable Laws or public policy, all other terms, provisions
and conditions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or
other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible to the fullest extent permitted by applicable
Laws in an acceptable manner to the end that the Transactions are fulfilled to the extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.9. Definitions</B>. As used in this Agreement, the following terms have the meanings ascribed thereto below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<U>Affiliate</U>&rdquo; shall mean, with respect to any Person, any other Person directly or indirectly controlling, controlled
by or under common control with such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<U>Business Day</U>&rdquo; shall mean a day except a Saturday, a Sunday or other day on which banks in Beijing, New York
or Tel Aviv are authorized or required by applicable Laws to be closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;<U>Confidential Information</U>&rdquo; shall mean all confidential or proprietary information, whether written or oral.
Notwithstanding the foregoing, Confidential Information shall not include information (i) which was publicly known prior to initial
disclosure of such information by a disclosing Person, (ii) that has become publicly known, in print or other tangible form, without
any act or omission of any Person other than the disclosing Person, (iii) received by a receiving party without restriction at
any time from a third party, other than the disclosing party, rightfully having possession of and the right to disclose such information,
(iv) shown to have been otherwise known by the receiving party prior to disclosure of such information by the disclosing party
to the receiving party, or (v) shown to have been independently developed by employees or agents of the receiving party without
access to or use of such information of the disclosing party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<U>Confidentiality Agreement</U>&rdquo; means that certain Mutual Confidential Disclosure Agreement, dated March 9, 2015,
as amended on September 25, 2016, by and between STEMCELLS Parent and Bright Oceans Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<U>Contracts</U>&rdquo; shall mean all written contracts, agreements, arrangements, leases, licenses, obligations, sales
and purchase orders, commitments, and other written arrangements or undertakings that are binding, or purport to be binding by
their terms, on the parties thereto, and any outstanding bids or proposals (which bids or proposals if accepted by the recipient
thereof would result in a binding contract).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;<U>Edinburgh Licence Agreement</U>&rdquo; shall mean that certain license agreement made between Stem Cells Sciences Limited
and the University of Edinburgh, dated January 31, 2006, as amended prior to the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;<U>FDA</U>&rdquo; shall mean the United States Food and Drug Administration or any successor federal agency thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;<U>GAAP</U>&rdquo; shall mean generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;<U>Governmental Authority</U>&rdquo; shall mean any government, court, regulatory or administrative agency, commission,
authority, department, court, or official, including any political subdivision thereof, any governmental self-regulatory agency
or any other governmental instrumentality, whether federal, state, local, domestic, foreign or multinational.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
&ldquo;<U>Indebtedness</U>&rdquo; shall mean all obligations and indebtedness of the Sellers (i) for borrowed money (other than
trade debt and other similar liabilities incurred in the ordinary course of business), (ii) evidenced by a note, bond, debenture
or similar instrument, (iii) created or arising under any capital lease, conditional sale, earn out or other arrangement for the
deferral of purchase price of any property, (iv) under letters of credit, banker&rsquo;s acceptances or similar credit transactions,
(v) for any other Person&rsquo;s obligation or indebtedness of the same type as any of the foregoing, whether as obligor, guarantor
or otherwise, (vi) for interest on any of the foregoing, and/or (vii) for any premiums, prepayment or termination fees, expenses
or breakage costs due upon prepayment of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
&ldquo;<U>Intellectual Property Rights</U>&rdquo; shall mean, collectively, all United States and non-United States (i) Trademarks,
(ii) copyrights, including computer software and Internet web sites, (iii) patents, inventions and discoveries, whether patentable
or not, (iv) Trade Secrets, (v) all other intellectual and industrial property not enumerated or described above, and (vi) all
registrations and applications therefor, and all reissues, reexaminations, provisionals, divisions, continuations, supplemental
protections, renewals, extensions, restorations and reversions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
&ldquo;<U>Key Products</U>&rdquo; shall mean all stem and progenitor cell lines that have been researched, studied or manufactured
by STEMCELLS Parent since January 1, 2007, consisting of: (i) HuCNS-SC neural stem cells, (ii) human liver engrafting cells or
&ldquo;hLEC&rdquo; cells (as described in expired U.S. Pat. Nos. 7,211,404 and 8,283,164 ), and (iii) oligo progenitor cells (as
described in U.S. Pat. Application No. 12/646,228).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
&ldquo;<U>Key Products IP Contracts</U>&rdquo; shall mean the contracts set forth in Section 9.9(m) of the Sellers Disclosure
Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
&ldquo;<U>Knowledge</U>&rdquo; of the Sellers (and words of similar import such as &ldquo;<U>to the Sellers&rsquo; Knowledge</U>&rdquo;)
shall mean the knowledge of Ken Stratton, President, General Counsel and Secretary of STEMCELLS Parent (&ldquo;<U>Stratton</U>&rdquo;),
after reasonable review and due inquiry of Ian Massey, former CEO of STEMCELLS Parent (&ldquo;<U>Massey</U>&rdquo;), Ann Tsukamoto,
former EVP of Research &amp; Development of STEMCELLS Parent (&ldquo;<U>Tsukamoto</U>&rdquo;), and Greg Schiffman, former CFO
of STEMCELLS Parent (&ldquo;<U>Schiffman</U>&rdquo; and together with Massey and Tsukamoto, the &ldquo;<U>Former Executives</U>&rdquo;),
with the understanding that solely with respect to Section 2.2, Section 2.11 and Section 2.12, &ldquo;Knowledge&rdquo; shall mean
the actual knowledge of Stratton, after inquiry of the Former Executives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
&ldquo;<U>Liability</U>&rdquo; shall mean, with respect to any Person, any liability or obligation of such Person of any kind,
character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated,
secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise
and whether or not the same is required to be accrued on the financial statements of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
&ldquo;<U>Lien</U>&rdquo; shall mean, with respect to any property or asset (including any security), any mortgage, lien, pledge,
charge, security interest, encumbrance or other adverse claim of any kind in respect of such property or asset, but shall not
include (i) non-monetary liens and other imperfections of title as do not materially detract from the value or impair the use
of the property subject thereto or make such property unmarketable, (ii) non-exclusive licenses of Intellectual Property Rights,
and (iii) exclusive licenses of Intellectual Property Rights outside the field of developing any of the Key Products as human
therapeutics. For purposes of this Agreement, a Person shall be deemed to own subject to a Lien any property or asset that it
has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other
title retention agreement relating to such property or asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
&ldquo;<U>Microbot</U>&rdquo; shall mean Microbot Medical Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
&ldquo;<U>Microbot Merger</U>&rdquo; shall mean the proposed change-of-control transaction between STEMCELLS Parent and Microbot,
as contemplated by the stockholder proxy materials filed by STEMCELLS Parent with the SEC on September 27, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
&ldquo;<U>Person</U>&rdquo; shall mean an individual, a corporation, a limited liability company, a partnership, an association,
a trust or any other entity, including a Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
&ldquo;<U>Regulatory Authority</U>&rdquo; shall mean any applicable Governmental Authority, domestic or foreign (including the
United Kingdom Medicines and Healthcare Products Regulatory Agency), involved in granting approvals for the testing, manufacturing,
marketing, reimbursement and/or pricing of a compound or product, and any successor Governmental Authority having substantially
the same function.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
&ldquo;<U>SEC</U>&rdquo; shall mean the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
&ldquo;<U>Seller Material Adverse Effect</U>&rdquo; shall mean (i) a material adverse effect on the Purchased Assets, taken as
a whole; <U>provided</U> that any effect resulting from any of the following shall not be considered when determining whether
a Seller Material Adverse Effect shall have occurred: (A) changes in the general market, capital markets, economic, legal, regulatory
or political conditions in the United States or any other region outside of the United States (including the commencement, continuation
or escalation of a war or material armed hostilities), (B) changes in GAAP, (C) changes or effects that generally affect the industries
in which the Sellers operated, so long as such changes or conditions in the industries in which the Sellers operates do not have
a materially disproportionate effect on the Purchased Assets, taken as a whole, compared with the assets of other companies operating
in such industries, (D) the announcement of this Agreement or the pendency or consummation of the Transactions, including the
impact that such execution and announcement and consummation have on the relationships, contractual or otherwise, of Sellers with
employees, customers, suppliers or partners and any litigation arising in connection with the transactions contemplated by this
Agreement, (E) compliance with the terms of, or the taking of any action required by, this Agreement by Sellers or any action
taken by Sellers at the request or direction of BOCO US, and (F) changes or effects that arise out of or are attributable to the
commencement, occurrence, continuation or intensification of any war, sabotage, armed hostilities or acts of terrorism; and (ii)
any event, change, development, effect, condition circumstance, matter, occurrence or state of facts that prevents or materially
delays, or would be reasonably expected to prevent or materially delay, consummation of the Transactions or the performance by
the Sellers of any of its material obligations under this Agreement. For the avoidance of any doubt, (i) the destruction of a
material portion of the Purchased Cell Banks or any other condition arising before the Closing Date which causes the Purchased
Cell Banks to be unusable or (ii) any Seller failing to be Solvent at all times up to and through the Closing of the Transactions
will be deemed to be a Seller Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
&ldquo;<U>Solvent</U>&rdquo; shall mean with respect to any Person that, as of any date of determination, (i) the amount of the
Fair Value and Present Fair Saleable Value of the assets of such Person exceeds as of such date its respective Stated Liabilities
and other Contingent Liabilities, (ii) such Person will not have, as of such date, an unreasonably small amount of capital for
the operation of the business in which such Person is engaged following such date (iii) such Person will have sufficient assets
and cash flow to pay its respective Stated Liabilities and other Contingent Liabilities as they mature or otherwise become due,
and (iv) such Person does not intend to, and does not believe that it will, incur debts beyond such Person&rsquo;s ability to
pay as such debts mature. For purposes of this definition (A) the term, &ldquo;Fair Value&rdquo; means the amount at which the
assets, in their entirety, of such Person would change hands between a willing buyer and a willing seller, within a commercially
reasonable period of time, each having reasonable knowledge of the relevant facts, with neither being under any compulsion to
act, (B) the term &ldquo;<U>Present Fair Saleable Value</U>&rdquo; means the amount that could be obtained by an independent willing
seller from an independent willing buyer if the assets of such Person are sold with reasonable promptness under normal selling
conditions in a current market, (C) the term &ldquo;<U>Stated Liabilities</U>&rdquo; means all known liabilities and recorded
liabilities (including Contingent Liabilities that would be recorded in accordance with GAAP consistently applied) of such Person,
and (D) the term &ldquo;<U>Contingent Liabilities</U>&rdquo; means the estimated amount of liability reasonably likely to result
from pending litigation, asserted claims and assessments, guaranties, uninsured risks and other contingent liabilities of such
Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
&ldquo;<U>Subsidiary</U>&rdquo; shall mean, with respect to any specified Person, any other Person of which (or in which) such
specified Person will, at the time, directly or indirectly through one or more subsidiaries, (a) own at least 50% of the outstanding
capital stock (or other shares of beneficial interest) having ordinary voting power to elect a majority of the board of directors
or other similar governing body (irrespective of whether at the time capital stock (or other shares of beneficial interest) of
any other class or classes of such Person shall or might have voting power upon the occurrence of any contingency), (b) hold at
least 50% of the interests in the capital or profits, (c) hold at least 50% of the beneficial interest (in the case of any such
Person that is a trust or estate), or (d) be a general partner (in the case of a partnership) or a managing member (in the case
of a limited liability company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
&ldquo;<U>Trademark</U>&rdquo; shall mean trademarks, service marks, trade dress, trade names, brand names, domain names and any
other indicia of origin or goodwill, together with all registrations and applications for registration thereof and all good will
associated therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
&ldquo;<U>Trade Secret</U>&rdquo; shall mean trade secrets, know-how, inventions (whether patented or patentable), technology,
data, data bases, preclinical and clinical study reports, protocols, data and analyses, and all other confidential or proprietary
information, including formulae, patterns, compilations, programs, devices, methods, techniques, processes, business methods,
drawings, prototypes, models, designs, customer lists, supplier lists, ideas, practices, test results, assays, techniques, specifications,
formulations, knowledge, skill, experience, materials and compositions of matter, including pharmaceutical, chemical and biological
materials, products, research tools, software programs, algorithms, computational combinatorial medicinal chemistry technologies,
scientific, technical, or test data, including pharmacological, biological, chemical, biochemical, toxicological and clinical
test data, analytical and quality control data, and stability data, safety data, studies, procedures, plans, diagrams, sketches,
documentation, and patent-related and other legal information or descriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
&ldquo;<U>Transactions</U>&rdquo; shall mean the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.10. Interpretation</B>. When a reference is made in this Agreement to an Article, a Section, Exhibit, Annex or Schedule, such
reference shall be to an Article of, a Section of, or an Exhibit, Annex or Schedule to, this Agreement unless otherwise indicated.
All Exhibits, Annexes and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement
as if set forth in full herein. The table of contents and headings contained in this Agreement are for reference purposes only
and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &ldquo;<U>include</U>,&rdquo;
&ldquo;<U>includes</U>&rdquo; or &ldquo;<U>including</U>&rdquo; are used in this Agreement, they shall be deemed to be followed
by the words &ldquo;<U>without limitation</U>,&rdquo; unless preceded by the word &ldquo;not.&rdquo; The words &ldquo;<U>hereof</U>,&rdquo;
&ldquo;<U>herein</U>&rdquo; and &ldquo;<U>hereunder</U>&rdquo; and words of similar import when used in this Agreement shall refer
to this Agreement as a whole and not to any particular provision of this Agreement. The word &ldquo;<U>extent</U>&rdquo; in the
phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and such phrase does not mean simply
&ldquo;if&rdquo;. All reference to &ldquo;dollars,&rdquo; &ldquo;USD&rdquo; or &ldquo;$&rdquo; shall be references to United States
dollars. All terms defined in this Agreement shall have the defined meanings when used in any document made or delivered pursuant
hereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as
the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. The parties hereto
have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent
or interpretation arises, this Agreement shall be construed as jointly drafted by the parties hereto and no presumption or burden
of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.11. No Other Warranties.</B> Except as specifically set forth in this Agreement, there are expressly excluded from this Agreement
to the fullest extent permitted by Law: (i) all warranties, conditions and other terms implied by Law; and (ii) any term that
may otherwise additionally be implied into this Agreement to give it business efficacy or as a result of extrinsic matters such
as custom, usage or course of dealing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
9.12. English Language</B>. This Agreement has been negotiated, drafted and entered into by the Parties in English. If this Agreement
is translated into another language, the English language text shall in any event prevail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have caused this Asset Purchase Agreement to be duly executed and delivered as of the date
first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS,
    INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCO
    SILICON VALLEY, INC.</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 44%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ken Stratton</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Xiangli Zhou</I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ken
    Stratton</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xiangli
    Zhou</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO/GM</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEM
    CELL SCIENCES HOLDINGS LIMITED</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ken Stratton</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ken
    Stratton</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS
    CALIFORNIA, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ken Stratton</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ken
    Stratton</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps; text-transform: uppercase">SIGNATURE
PAGE TO ASSET PURCHASE AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>3
<FILENAME>ex10-12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ESCROW
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>ESCROW AGREEMENT </B>(this &ldquo;<U>Escrow Agreement</U>&rdquo;) is made and entered into as of November 11, 2016, by and
among BOCO Silicon Valley, Inc., a California corporation (&ldquo;<U>Buyer</U>&rdquo;), STEMCELLS, INC., a Delaware corporation,
(&ldquo;<U>Seller</U>&rdquo;) under the Asset Purchase Agreement (as defined below), Continental Stock Transfer &amp; Trust Company,
a New York corporation, as escrow agent (the &ldquo;<U>Escrow Agent</U>&rdquo;), Kenneth B. Stratton in his capacity as representative
to the Consultants (as defined herein) (&ldquo;<U>Consultants&rsquo; Representative</U>&rdquo;), and Alpha Capital Anstalt (&ldquo;<U>Alpha
Capital</U>&rdquo;). Buyer and together with Seller, Consultants&rsquo; Representative and Alpha Capital are sometimes referred
to individually as &ldquo;<U>Party</U>&rdquo; and collectively as the &ldquo;<U>Parties</U>,&rdquo; <U>provided</U> that (a) Consultants&rsquo;
Representative is a Party solely with respect to Sections 3.2 and 4.3, Section 5, Section 6.3, Section 9 and Section 10 and (b)
Alpha Capital is a Party solely with respect to Section 3.2, Sections 5.3(a), 10.2(a), 10.4, 10.3, 10.4, 10.5, 10.7, 10.8, 10.9
and 10.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Buyer and Seller are parties to that certain Asset Purchase Agreement, dated as of November 11, 2016, by and among Buyer, Seller,
STEM CELL SCIENCES HOLDINGS LIMITED, a private limited company registered in Scotland that is a wholly-owned subsidiary of Seller
(&ldquo;<U>STEMCELLS Holdings</U>&rdquo;), and STEMCELLS CALIFORNIA, INC., a California corporation that is a wholly-owned subsidiary
of STEMCELL Holdings (as such agreement may be amended, restated or otherwise modified from time to time, the &ldquo;<U>Asset
Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Section 1.6(b) of the Asset Purchase Agreement requires Buyer and Seller to enter into this Escrow Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to the terms and conditions of Section 1.6(c) of the Asset Purchase Agreement, on November 10, 2016 (&ldquo;<U>Funding
Date</U>&rdquo;) Buyer has agreed to deliver to the Escrow Agent $3,700,000 (the &ldquo;<U>Escrow Deposit</U>,&rdquo; and together
with any and all interest and other amounts earned thereon from and after the date hereof and as reduced by any disbursements,
withdrawals or losses on investments, the &ldquo;<U>Escrow Funds</U>&rdquo;), which amount shall be held in a segregated account,
to serve as a source of payment of (a) the amounts to Seller pursuant to Section 1.7(d) and Section 8.4(b) of the Asset Purchase
Agreement, (b) the amounts to Buyer pursuant to Section 1.7(e) and Section 7.2(b) of the Asset Purchase Agreement, (c) the amounts
to the individuals whose consulting agreements are described in Section 2.14 of the Sellers Disclosure Schedule (as defined in
the Asset Purchase Agreement) and whose names are set forth in <U>Schedule 1</U> attached hereto (the &ldquo;<U>Consultants</U>&rdquo;),
pursuant to Section 1.7(d) and Section 8.4(b) of the Asset Purchase Agreement (the &ldquo;<U>Consultants&rsquo; Amounts</U>&rdquo;),
and (d) the amounts, if any, owed to Buyer by Seller pursuant to the payment and indemnification obligations set forth in Article
VIII of the Asset Purchase Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Seller and Alpha Capital are parties to that certain Partial Release of Security Interest, dated November 11, 2016, with respect
to that certain Security Agreement, dated as of August 15, 2016, by and between Seller and Alpha Capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE</B>, in consideration of the premises and mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, Buyer, Seller, Consultants&rsquo; Representative, the Escrow Agent
and Alpha Capital agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalized Terms</U>. Each capitalized
term which is used but not otherwise defined in this Escrow Agreement has the meaning assigned to such term in the Asset Purchase
Agreement; however, the Escrow Agent shall not be responsible for having knowledge of any term not defined within this Escrow
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Appointment of and Acceptance by Escrow
Agent</U>. Buyer and Seller hereby appoint and designate the Escrow Agent to acquire and maintain possession of the Escrow Funds
under the terms and conditions set forth herein and to act as escrow agent for the purposes set forth herein and under the terms
and conditions set forth herein, and the Escrow Agent hereby accepts such appointment and designation under the terms and conditions
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Receipt of Deposit; Establishment of
Escrow; Interest.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent shall hold in escrow, invest and disburse the Escrow Funds in accordance with the terms of this Escrow Agreement.
On the Funding Date, Buyer will deliver the Escrow Deposit to the Escrow Agent, and the Escrow Agent will acknowledge to Buyer
and Seller the Escrow Deposit upon receipt. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent shall establish a segregated account in which to hold the investments in which the Escrow Funds (or any portion thereof)
may, from time to time, be invested (the &ldquo;<U>Escrow Account</U>&rdquo;). The Escrow Agent shall also maintain and make available
to Buyer, Seller, Consultants&rsquo; Representative and Alpha Capital on a monthly basis, an account statement with respect to
the Escrow Account in form and substance as customarily provided by the Escrow Agent for escrow accounts for which it acts as
escrow agent. The Escrow Agent shall not dispose of the Escrow Funds except as expressly provided for in this Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment of the Escrow Funds</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the term of this Escrow Agreement, the Escrow Funds shall be invested in an interest-bearing demand deposit account at JPMorgan
Chase Bank, N.A. (&ldquo;<U>JPMorgan</U>&rdquo;). Interest-bearing demand deposit accounts have rates of interest or compensation
that may vary from time to time as determined by JPMorgan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party acknowledges that it was not offered any investment, tax or accounting advice or recommendation by the Escrow Agent with
regard to any investment and has made an independent assessment of the suitability and appropriateness of an interest-bearing
demand deposit account at JPMorgan. The Escrow Agent shall not have any liability for any loss sustained as a result of the deposit
of the Escrow Funds in an interest-bearing demand deposit account at JPMorgan; provided, that such losses shall not have resulted
from the gross negligence or willful misconduct of the Escrow Agent. The Escrow Agent shall have the right to withdraw funds from
the interest-bearing demand deposit account at JPMorgan in order to provide funds necessary to make required payments under this
Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
interest or other income earned under this Escrow Agreement shall be allocated to Seller and the Consultants and reported, by
Escrow Agent to the Internal Revenue Service (&ldquo;<U>IRS</U>&rdquo;), or any other taxing authority, on IRS Form 1099 or 1042S
(or other appropriate form) as income earned from the Escrow Deposit by Seller and the Consultants whether or not said income
has been distributed during such year. The Parties hereby represent to Escrow Agent that no other tax reporting of any kind is
required given the underlying transaction giving rise to this Escrow Agreement. Consultants&rsquo; Representative shall provide
to the Escrow Agent any tax documentation for Consultants&rsquo; Representative or any of the Consultants that may be reasonably
requested by the Escrow Agent prior to the Closing Date (and from time to time thereafter if the provided tax documentation expires
or becomes obsolete).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payments From the Escrow Funds</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>.
Except as otherwise specifically provided herein, the Escrow Agent shall release the Escrow Funds only pursuant to and in accordance
with: (a) joint written instructions signed by both Seller and Buyer, (b) a copy of a final and non-appealable award, judgment
or order issued by a court of competent jurisdiction adjudicating a dispute with respect to a disputed amount of an indemnification
claim, or (c) a copy of a final decision from an arbitrator in proceedings administered by the China International Economic and
Trade Arbitration Commission pursuant to Section 9.5 of the Asset Purchase Agreement. All disbursements made pursuant to this
<U>Section 5.1</U> shall be made in accordance with the provisions set forth in <U>Section 5.5</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
to Buyer for Indemnification Claims.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
time a BOCO Indemnified Party seeks recovery from the Escrow Funds on or prior to the Escrow Termination Date (as defined below)
for a claim under Article VIII of the Asset Purchase Agreement (an &ldquo;<U>Indemnification Claim</U>&rdquo;), such BOCO Indemnified
Party shall deliver a Claim Notice (as defined below) to Seller. &ldquo;<U>Claim Notice</U>&rdquo; shall mean a written claim
notice by a BOCO Indemnified Party to Seller making a claim for indemnification against Losses in respect of a claim for indemnification
pursuant to Section 8.2 of the Asset Purchase Agreement in compliance with Article VIII of the Asset Purchase Agreement, which
claim notice sets forth (i) a description, in reasonable detail, of the facts and circumstances by reason of which such claim
is being made, to the extent then known to the BOCO Indemnified Party, and (ii) the amount of the claim for which a BOCO Indemnified
Party is seeking indemnification (the &ldquo;<U>Claimed Amount</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
thirty (30) calendar days after receipt by Seller and the Escrow Agent of a Claim Notice (the &ldquo;<U>Response Period</U>&rdquo;),
Seller shall deliver to the BOCO Indemnified Party and to the Escrow Agent a written response (the &ldquo;<U>Response Notice</U>&rdquo;)
in which Seller shall instruct the Escrow Agent either (i) to release Escrow Funds in the full amount of the Claimed Amount to
the BOCO Indemnified Party from the Escrow Account, (ii) to release Escrow Funds equal to part, but not all, of the Claimed Amount
(the &ldquo;<U>Agreed Amount</U>&rdquo;) to BOCO Indemnified Party from the Escrow Account or (iii) to release no part of the
Escrow Funds from the Escrow Account to BOCO Indemnified Party in respect of the Claimed Amount. The Claimed Amount (or any part
thereof) that the Escrow Agent is instructed in the Response Notice not to release to BOCO Indemnified Party is herein referred
to as the &ldquo;Contested Amount.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Seller delivers a Response Notice instructing the Escrow Agent to release only the Agreed Amount to BOCO Indemnified Party, then
the Escrow Agent shall, promptly following the receipt of such Response Notice, and in any event within three (3) Business Days
of receipt and confirmation pursuant to Section 8 hereto, pay to BOCO Indemnified Party or its designee an amount equal to the
Agreed Amount from the Escrow Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Seller (i) fails to deliver a Response Notice, or otherwise fails to deliver instructions in a Response Notice with respect to
any Claimed Amount, within the Response Period, in which case all of the Claimed Amount shall constitute a Contested Amount, or
(ii) delivers a Response Notice stating that all or any portion of the Claimed Amount constitutes a Contested Amount, then the
BOCO Indemnified Party shall either (i) agree that the Contested Amount is not required to be paid from the Escrow Funds, in which
case such amount shall no longer be considered a Contested Amount for any purpose under this Agreement or (ii) initiate the dispute
resolution proceedings set forth in Section 9.5 of the Asset Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent shall only release and deliver any portion of a Contested Amount to BOCO Indemnified Party in accordance with (i)
joint written instructions signed by both Buyer and Seller or (ii) a final decision from an arbitrator in proceedings administered
by the China International Economic and Trade Arbitration Commission pursuant to Section 9.5 of the Asset Purchase Agreement which
identifies all or a portion of the Contested Amount as being owed to the BOCO Indemnified Party. The Escrow Agent shall be entitled
to conclusively rely on the opinion of counsel that the arbitration award is final and binding pursuant to Section 9.5 of the
Asset Purchase Agreement. Upon receipt of such joint written instruction or such final arbitration award, as the case may be,
the Escrow Agent shall pay to such BOCO Indemnified Party promptly, and in any event within three (3) Business Days of receipt
and confirmation pursuant to Section 5 hereto, an amount from the Escrow Funds equal to the lesser of (x) the amount required
to be paid to the BOCO Indemnified Party in accordance with the joint written instructions or final arbitration decision and (y)
the remaining amount of the Escrow Funds. In the event that Seller is the prevailing party in whole or in part in connection with
any such dispute, the portion of the Escrow Funds that was not released to any BOCO Indemnified Party pursuant to this <U>Section
5.2(e)</U> shall no longer be considered a Contested Amount for any purpose under this Agreement and shall remain in the Escrow
Account until released as provided pursuant to <U>Section 5.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
at Closing; Final Release.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
least three Business Days prior to the Closing Date, Buyer, Seller and Alpha Capital shall execute and provide to the Escrow Agent
duly executed joint written instructions in the form attached hereto as <U>Schedule 2</U> (the &ldquo;<U>Closing Release Instructions</U>&rdquo;).
Following the receipt of the Closing Release Instructions, the Escrow Agent shall, on the Closing Date, deliver to Seller and
the Consultants as a whole, as further specified in the Closing Payment Instructions, 85% and 15%, respectively, of the Closing
Purchase Price, which shall equal (i) $3,300,000 if the Closing Date is December 1, 2016 or prior thereto or (ii) $3,200,000 if
the Closing Date is after December 1, 2016. All disbursements made pursuant to this <U>Section 5.3(a)</U> shall be made in accordance
with the provisions set forth in <U>Section 5.5</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the first Business Day following the first anniversary of the Closing Date (the &ldquo;<U>Escrow Termination Date</U>&rdquo;),
the Escrow Agent shall deliver to Seller and the Consultants as a whole, 85% and 15%, respectively, of the amount of all of the
then remaining Escrow Funds in the Escrow Account less the aggregate amount of all Unresolved Claims (as defined below), with
the 15% of the amount of such Escrow Funds distributed by the Escrow Agent to the Consultants in accordance with <U>Schedule 3
</U>hereto (the &ldquo;<U>Consultants&rsquo; Distribution Allocation</U>&rdquo;). All disbursements made pursuant to this <U>Section
5.3(b)</U> shall be made in accordance with the provisions set forth in <U>Section 5.5</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
on or prior to 11:59 PM (New York time) on the day immediately preceding the Escrow Termination Date, a BOCO Indemnified Party
has delivered a Claim Notice that has not been resolved as of the Escrow Termination Date in accordance with Article VIII and
Section 9.5 of the Asset Purchase Agreement (each, an &ldquo;<U>Unresolved Claim</U>&rdquo;), then the Escrow Agent shall retain
in the Escrow Account an amount of Escrow Funds equal to the aggregate amount of the Claimed Amounts for all Unresolved Claims
for which the BOCO Indemnified Parties are seeking indemnification until such Unresolved Claims have been resolved in accordance
with Article VIII and Section 9.5 of the Asset Purchase Agreement. Following the resolution of each Unresolved Claim in accordance
with Article VIII and Section 9.5 of the Asset Purchase Agreement, the Escrow Agent shall be instructed to release and deliver
from the Escrow Account to Seller and the Consultants as a whole, 85% and 15%, respectively, of the amount of Escrow Funds equal
to the excess, if any, of (i) the amount then remaining in the Escrow Account over (ii) the aggregate amount of the Claimed Amounts
for all Unresolved Claims that remain outstanding following the resolution of such Unresolved Claim, with the 15% of the amount
of such Escrow Funds distributed to the Consultants by the Escrow Agent in accordance with the Consultants&rsquo; Distribution
Allocation. When all Unresolved Claims have been resolved in accordance with Article VIII and Section 9.5 of the Asset Purchase
Agreement, the Escrow Agent shall release and deliver from the Escrow Account to Seller and the Consultants as a whole, 85% and
15%, respectively, of the amount of all of the then remaining Escrow Funds which had been retained with respect to such Unresolved
Claims and not applied in payment thereof, with the 15% of the amount of such Escrow Funds distributed to the Consultants by the
Escrow Agent in accordance with the Consultants&rsquo; Distribution Allocation. All disbursements made pursuant to this Section
5.3(c) shall be made in accordance with the provisions set forth in <U>Section 5.5</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
to Buyer</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Closing has not occurred in accordance with the Asset Purchase Agreement on or before December 1, 2016 and Buyer has notified
the Escrow Agent and Seller of such event, then on the 10th day following such notice, the Escrow Agent shall deliver to Buyer
an amount equal to $100,000 from the Escrow Account pursuant to Section 1.7(d) of the Asset Purchase Agreement, unless Seller
shall have, in good faith, disputed in writing to the Escrow Agent and Buyer during the 10-day period after receipt of notice
from Buyer regarding the failure of the Closing to occur on or before December 1, 2016. If Seller does submit such a dispute in
writing prior to the end of such 10-day period, Buyer shall either (i) agree that such amount is not required to be paid to Buyer
pursuant to this Escrow Agreement or (B) initiate the dispute resolution proceedings set forth in Section 9.5 of the Asset Purchase
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Asset Purchase Agreement is terminated pursuant to Section 7.1 of the Asset Purchase Agreement and Buyer has notified the
Escrow Agent and Seller of such event, then on the 10th day following such notice, the Escrow Agent shall deliver to Buyer all
of the then remaining funds in the Escrow Account pursuant to Section 7.2(b) of the Asset Purchase Agreement, unless Seller shall
have, in good faith, disputed in writing to the Escrow Agent and Buyer during the 10-day period after receipt of notice from Buyer
regarding the termination of the Asset Purchase Agreement. If Seller does submit such a dispute in writing prior to the end of
such 10-day period, Buyer shall either (A) agree that such remaining funds are not required to be paid to Buyer pursuant to this
Escrow Agreement or (B) initiate the dispute resolution proceedings set forth in Section 9.5 of the Asset Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
to be Made in Immediately Available Funds.</U> Any payments required to be made to Buyer or its designee pursuant to this <U>Section
5</U> shall be made by wire transfer of immediately available funds to an account designated by Buyer in writing to the Escrow
Agent. Any payments required to be made to Seller or its designee pursuant to this <U>Section 5</U> shall be made by wire transfer
of immediately available funds to an account designated by Seller in writing to the Escrow Agent. Any payments required to be
made to a Consultant or his or her respective designee pursuant to this <U>Section 5</U> shall be made, at the discretion of Consultants&rsquo;
Representative, (i) by wire transfer of immediately available funds to an account designated by Consultants&rsquo; Representative
in writing to the Escrow Agent or (ii) by check payable to the name, and mailed by the Escrow Agent via a nationally recognized
overnight courier service to the address, in each case designated by Consultants&rsquo; Representative in writing to the Escrow
Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liability and Duties of the Escrow
Agent.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent&rsquo;s responsibilities, duties and obligations under this Escrow Agreement shall be determined solely by the express
provisions of this Escrow Agreement which shall be deemed purely ministerial in nature, and no other duties shall be implied,
and the Escrow Agent shall not pay the Escrow Funds, or any portion thereof, except in accordance with the terms of this Escrow
Agreement. The Escrow Agent shall be under no obligation to refer to any documents other than this Escrow Agreement and the instructions
and requests delivered to the Escrow Agent hereunder. The Escrow Agent shall not be obligated to recognize, and shall not have
any liability or responsibility arising under, any agreement to which the Escrow Agent is not a party, even though reference thereto
may be made herein. The Escrow Agent shall neither be responsible for, nor chargeable with, knowledge of, nor have any requirements
to comply with, the terms and conditions of any other agreement, instrument or document, other than this Escrow Agreement, between
or among Buyer and Seller in connection herewith, if any, including, without limitation, the Asset Purchase Agreement, nor shall
the Escrow Agent be required to determine if any person has complied with any such agreements, nor shall any additional obligations
of the Escrow Agent be inferred from the terms of such agreements, even though reference thereto may be made in this Escrow Agreement.
In the event of any conflict between the terms and provisions of this Escrow Agreement relating to the rights or obligations of
the Escrow Agent, those of the Asset Purchase Agreement, any schedule or exhibit attached to the Asset Purchase Agreement or any
other agreement among Buyer and Seller, the terms and conditions of this Escrow Agreement shall prevail. The Escrow Agent shall
have no duty to solicit any payments which may be due it or the Escrow Account, nor shall the Escrow Agent have any duty or obligation
to make any formulaic calculations of any kind hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent, including its officers, directors, employees and agents, shall not be liable to anyone whomsoever by reason of any
error of judgment or for any act done or step taken or omitted by the Escrow Agent, or for any mistake of fact or law or anything
which the Escrow Agent may do or refrain from doing in connection herewith, in good faith, unless caused by or arising out of
the Escrow Agent&rsquo;s (or any of its directors, officers, agents or employees) gross negligence, fraud or willful misconduct.
The Escrow Agent may consult with counsel of its own choice and shall have full and complete authorization and protection for
any action taken or suffered by the Escrow Agent hereunder in accordance with the opinion of such counsel. Buyer and Seller shall
jointly and severally indemnify and hold the Escrow Agent and its affiliates and their respective successors, assigns, directors,
agents and employees (collectively, the &ldquo;<U>Indemnitees</U>&rdquo;) from and against any and all actual and direct losses,
damages, claims, liabilities, penalties, judgments, settlements, litigation, investigations, costs or expenses (including, without
limitation, the reasonable fees and expenses of outside counsel) (collectively &ldquo;<U>Damages</U>&rdquo;) to the extent arising
out of (a) the Escrow Agent&rsquo;s (i) performance of this Escrow Agreement in compliance with the terms hereof, (ii) tax reporting
or withholding in respect of all amounts held in the Escrow Account, or (iii) enforcement of any rights or remedies under or in
connection with this Escrow Agreement, in each case of clause (i), (ii) or (iii), except to the extent that such Damages are finally
adjudicated by a court of competent jurisdiction to have been primarily caused by the gross negligence, fraud or willful misconduct
of any Indemnitee, or (b) the Escrow Agent&rsquo;s following any joint written instructions or other joint written directions
from Buyer and Seller, except to the extent that its following any such instruction or direction is expressly forbidden by the
terms hereof. Such indemnification shall survive the Escrow Agent&rsquo;s resignation or removal, or the termination of this Escrow
Agreement. For the avoidance of doubt, Consultants&rsquo; Representative, shall not have any obligation under this Escrow Agreement
to indemnify the Escrow Agent or any other Indemnitee for any Damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Escrow Agreement is a personal one, the Escrow Agent&rsquo;s duties hereunder being only to Buyer, Seller, Consultants&rsquo;
Representative and the Consultants, and their respective successors and permitted assigns, and to no other person whomsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent may rely or act upon joint written instructions bearing a signature or signatures properly believed by the Escrow
Agent to be genuine of Buyer and Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
case any property held by the Escrow Agent shall be attached, garnished or levied upon under a court order, or the delivery thereof
shall be stayed or enjoined by a court order, or any writ, order, judgment or decree shall be made or entered by any court, or
any order, judgment or decree shall be made or entered by any court affecting the property deposited under this Escrow Agreement
or any part thereof, the Escrow Agent is hereby expressly authorized, in its sole discretion, to obey and comply with all writs,
orders, judgments or decrees so entered or issued, whether with or without jurisdiction, and in case the Escrow Agent obeys or
complies with any such writ, order, judgment or decree, the Escrow Agent shall not be liable to Buyer or Seller or to any other
person by reason of such compliance in connection with such litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent reserves the right to resign at any time by giving written notice of resignation to Buyer and Seller specifying the
effective date thereof. Within thirty (30) days after receiving such notice, Buyer and Seller jointly shall appoint a successor
escrow agent to which the Escrow Agent shall distribute the property then held under this Escrow Agreement, <U>less</U> the Escrow
Agent&rsquo;s fees, costs and expenses, whereupon the Escrow Agent shall upon such distribution to a successor escrow agent, be
discharged of and from any and all further obligations arising in connection with this Escrow Agreement, except for such liability
and expenses which results from the Escrow Agent&rsquo;s fraud, gross negligence or willful misconduct. If a successor escrow
agent has not been appointed or has not accepted such appointment by the end of such thirty-day period, the Escrow Agent may apply
to a court of competent jurisdiction for the appointment of a successor escrow agent, and the costs, expenses and reasonable attorneys&rsquo;
fees which are incurred in connection with such proceeding shall be paid one-half by Buyer and one-half by Seller. Until a successor
escrow agent has accepted such appointment and the Escrow Agent has transferred the Escrow Funds to such successor escrow agent,
the Escrow Agent shall continue to retain and safeguard the Escrow Funds until receipt of a joint written instruction signed by
both Buyer and Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of any disagreement between Buyer and Seller resulting in adverse claims or demands being made in connection with the
Escrow Funds or in the event that the Escrow Agent is in doubt as to what action it should take hereunder, the Escrow Agent shall
be permitted to refrain from taking any action and its sole obligation shall be to keep safely all property held in escrow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent does not have any interest in the Escrow Funds but is serving as escrow holder only and has only possession thereof.
If any payments of income from the Escrow Funds shall be subject to withholding regulations then in force with respect to United
States taxes, Buyer and Seller agree to provide the Escrow Agent with appropriate forms for or with respect to such withholding.
This <U>Section 6.8</U>, <U>Section 6.1</U> and <U>Section 7</U> shall survive notwithstanding any termination of this Escrow
Agreement or the Escrow Agent&rsquo;s resignation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seller,
Buyer and Consultants&rsquo; Representative have provided the Escrow Agent with their respective fully executed IRS Form W-8,
or W-9, and/or other required documentation requested by the Escrow Agent prior to the date hereof. The Parties each represent
that its correct TIN assigned by the IRS, or any other taxing authority, is set forth in the delivered forms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation of the Escrow Agent</U>.
The Escrow Agent shall be entitled to fees in accordance with the fee schedule attached hereto as <U>Schedule 4</U>. Buyer and
Seller agree the &ldquo;Base Fee&rsquo; (as defined in Schedule 4) shall be paid by that one-half of Buyer and one-half by Seller.
Buyer and Seller agree the &ldquo;Variable Fee&rsquo; (as defined in Schedule 4) shall be paid solely by Seller. Buyer and Seller
shall also pay or reimburse the Escrow Agent upon request for all expenses, disbursements and advances, including, without limitation
reasonable attorney&rsquo;s fees and expenses, incurred or made by it following the date of this Escrow Agreement in connection
with the performance, modification and termination of this Escrow Agreement, which Buyer and Seller agree shall be paid one-half
by Buyer and one-half by Seller, except for any such expenses incurred solely in connection with the disbursement of the Consultants&rsquo;
Amounts, which shall be paid entirely by Seller. For the avoidance of doubt, Consultants&rsquo; Representative shall not have
any obligation under this Escrow Agreement to pay or reimburse the Escrow Agent any fee, expense, disbursement, advancement or
other amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Funds Transfer Agreement</U>. Any
instructions setting forth, claiming, containing, objecting to, or in any way related to the transfer or distribution of funds,
including but not limited to any such funds transfer instructions that may otherwise be set forth in a written instruction permitted
pursuant to <U>Section 5</U> of this Escrow Agreement, may, unless such requirement is waived by the Escrow Agent, be given to
the Escrow Agent only by PDF attached to an email, nationally recognized courier service, facsimile and no instruction for or
related to the transfer or distribution of the Escrow Funds, or any portion thereof, shall, unless such requirement is waived
by the Escrow Agent, be deemed delivered and effective unless the Escrow Agent actually shall have received such instruction by
facsimile at the number provided to the Parties by the Escrow Agent in accordance with <U>Section 9</U>. In the event funds transfer
instructions are given (other than in writing at the time of the execution of this Escrow Agreement) by PDF attached to an email,
nationally recognized courier service or facsimile, the Escrow Agent is authorized to seek confirmation of such instructions by
telephone call-back to the person or persons designated on <U>Schedule 5</U> hereto, and the Escrow Agent may rely upon the confirmations
of anyone purporting to be the person or persons so designated. Each funds transfer instruction shall be executed by an authorized
signatory; a list of such authorized signatories is set forth on <U>Schedule 5</U>. The undersigned is authorized to certify that
the signatories on <U>Schedule 5</U> are authorized signatories. The persons and telephone numbers for call-backs may be changed
only in writing actually received and acknowledged by the Escrow Agent. The Parties hereto acknowledge that such security procedure
is commercially reasonable. It is understood that the Escrow Agent and the beneficiary&rsquo;s bank in any funds transfer may
rely solely upon any account numbers or similar identifying number provided by any party hereto to identify (a) the beneficiary,
(b) the beneficiary&rsquo;s bank or (c) an intermediary bank. The Escrow Agent may apply funds for any payment order it executes
using any such identifying number, even where its use may result in a person other than the beneficiary being paid, or the transfer
of funds to a bank other than the beneficiary&rsquo;s bank, or an intermediary bank, so designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>. Except for communications
from Buyer, Seller or Consultants&rsquo; Representative setting forth, claiming, containing, objecting to, or in any way related
to the transfer or distribution of funds, including but not limited to funds transfer instructions (all of which shall be specifically
governed by <U>Section 8</U> of this Escrow Agreement), all notices, demands or other communications to be given or delivered
under or by reason of the provisions of this Escrow Agreement will be in writing and will be deemed to have been given upon delivery,
when delivered personally, mailed by certified or registered mail, return receipt requested and postage prepaid, or sent via a
nationally recognized overnight courier, or sent via facsimile, to the recipient with telephonic confirmation by the sending party.
Such notices, demands and other communications will be sent to the address indicated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Buyer:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOCO
    SILICON VALLEY, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43152
    Nielson Court</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fremont,
    CA 94539</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:Shirley
    Zhou</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy (which shall not constitute notice) to:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dentons
    US LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1221
    Avenue of the Americas</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10020-1089</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:Peter
    Su, Esq.,</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ilan
    Katz, Esq.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Seller:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">STEMCELLS,
    INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39899
    Balentine Drive, Suite 200</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newark,
    CA 94560</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:Kenneth
    Stratton</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:ken.stratton@stemcellsinc.com</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel.:(650)
    670-2282</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy (which shall not constitute notice) to:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropes
    &amp; Gray LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36F,
    Park Place</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1601
    Nanjing Road West</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shanghai
    200040, PRC</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Arthur Mok, Esq.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in">&nbsp;</TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to the Escrow Agent:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continental
    Stock Transfer &amp; Trust Company</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17
    Battery Place, 8<SUP>th</SUP> Floor</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10004</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:&nbsp;Accounting
    Department, Escrow Administration</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address: scarter@continentalstock.com</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.6in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 2in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Consultants&rsquo; Representative:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Kenneth B. Stratton</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">774
    Knoll Dr.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
    Carlos, CA 94070</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email;&nbsp;&nbsp;Ken_Stratton@sbcglobal.net</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel.:&nbsp;&nbsp;&nbsp;(650)
    670-2282</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
party may change the address to which notices are to be delivered by giving the other Parties notice in the manner provided in
this <U>Section 9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Section
10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Instructions
by Buyer, Seller and Consultants&rsquo; Representative</U>. Any instructions or notice delivered by Buyer, Seller and/or Consultants&rsquo;
Representative pursuant to this Escrow Agreement shall only be valid if signed by a person listed on <U>Schedule 5</U> under the
heading of Buyer, Seller or Consultants&rsquo; Representative, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement; Assignment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Escrow Agreement and, in regards to the Parties to this Escrow Agreement other than the Escrow Agent, the agreements and documents
referred to herein, contain the entire agreement and understanding among the Parties with respect to the subject matter hereof
and supersede all prior agreements and understandings, whether written or oral, relating to such subject matter in any way. In
regards to the Escrow Agent, this Escrow Agreement contains the entire agreement and understanding among the Parties with respect
to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise expressly set forth in this Escrow Agreement, this Escrow Agreement may not be assigned by any party (whether by
operation of law or otherwise) without the prior written consent of Buyer, Seller, Consultants&rsquo; Representative and the Escrow
Agent (which consent shall not be unreasonably withheld or delayed); <U>provided</U>, <U>however</U>, that Buyer or Seller may
assign any of its rights under this Escrow Agreement to one or more of its Affiliates or to any third party by sale of stock or
operation of law in connection with a <I>bona fide</I> third party merger or sale of substantially all of such Party&rsquo;s assets
to such third party, <U>provided</U> that any such assignment shall not relieve such Party of any of its obligations hereunder;
and <U>provided</U>, further, that the documentation of any successor or permitted assignee required in accordance with the Patriot
Act (defined below) must be provided to the Escrow Agent prior to any such assignment becoming effective. Any attempted assignment
of this Escrow Agreement not in accordance with the terms of this <U>Section 10.2</U> shall be void. Any banking association or
corporation into which the Escrow Agent (or substantially all of its escrow business) may be merged, converted or with which the
Escrow Agent may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Escrow
Agent shall be a party, or any banking association or corporation to which all or substantially all of the escrow business of
the Escrow Agent shall be sold or otherwise transferred, shall succeed to all the Escrow Agent&rsquo;s rights, obligations and
immunities hereunder without the execution or filing of any paper or any further act on the part of any of the Parties, anything
herein to the contrary notwithstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Escrow Agreement, and all claims or causes of action (whether in contract or tort) that may be based upon, arise
out of or relate to this Escrow Agreement, or the negotiation, execution or performance of this Escrow Agreement (including any
claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with
this Escrow Agreement or as an inducement to enter into this Escrow Agreement), shall be governed by the internal laws of the
State of New York as applicable to agreements made and to be performed entirely within the State of New York, without regard to
conflict of law principles or rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as otherwise expressly set forth in this Escrow Agreement, all fees and expenses incurred in connection
with this Escrow Agreement, including, without limitation, the fees and disbursements of counsel, financial advisors and accountants,
shall be paid by the Party incurring such fees or expenses; <U>provided</U>, <U>however</U>, that the Escrow Agent may impose,
charge or pass-through any fees or charges for accounts incurred by it in the performance of its duties under this Escrow Agreement,
including those levied by any governmental authority, which Buyer and Seller agree shall be paid one-half by Buyer and one-half
by Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction;
Interpretation</U>. The term &ldquo;this Escrow Agreement&rdquo; means this Escrow Agreement together with all schedules, exhibits
and annexes hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms
hereof. The headings contained in this Escrow Agreement are inserted for convenience only and shall not affect in any way the
meaning or interpretation of this Escrow Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this
Escrow Agreement for purposes of construing the provisions hereof, and all provisions of this Escrow Agreement shall be construed
according to their fair meaning and not strictly for or against any party hereto. Unless otherwise indicated to the contrary herein
by the context or use thereof: (i) the words, &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo; &ldquo;hereof&rdquo; and words of similar
import refer to this Escrow Agreement as a whole, including, without limitation, the schedules, exhibits and annexes, and not
to any particular section, subsection, paragraph, subparagraph or clause contained in this Escrow Agreement; (ii) masculine gender
shall also include the feminine and neutral genders, and vice versa; and (iii) words importing the singular shall also include
the plural, and vice versa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Parties
in Interest</U>. This Escrow Agreement shall be binding upon and inure solely to the benefit of the Parties and their respective
successors and permitted assigns and nothing in this Escrow Agreement, express or implied, is intend to or shall confer upon any
other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any provision of this Escrow Agreement for any reason shall be held to be illegal, invalid or unenforceable, such illegality
shall not affect any other provision of this Escrow Agreement, this Escrow Agreement shall be amended so as to enforce the illegal,
invalid or unenforceable provision to the maximum extent permitted by applicable Law, and the Parties shall cooperate in good
faith to further modify this Escrow Agreement so as to preserve to the maximum extent possible the intended benefits to be received
by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts;
Facsimile Signatures</U>. This Escrow Agreement may be executed in one or more counterparts, each of which shall be deemed to
be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature
page to this Escrow Agreement by facsimile or scanned pages shall be effective as delivery of a manually executed counterpart
to this Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of Jury Trial</U>. Each party hereto hereby waives, to the fullest extent permitted by law, any right to trial by jury of any
claim, demand, action, or cause of action (a) arising under this Escrow Agreement or (b) in any way connected with or related
or incidental to the dealings of the Parties in respect of this Escrow Agreement or any of the transactions related hereto, in
each case, whether now existing or hereafter arising, and whether in contract, tort, equity, or otherwise. Each party hereto hereby
further agrees and consents that any such claim, demand, action, or cause of action shall be decided by court trial without a
jury and that the Parties hereto may file a copy of this Escrow Agreement with any court as written evidence of the consent of
the Parties to the waiver of their right to trial by jury. To the extent that in any jurisdiction either party may now or hereafter
be entitled to claim for itself or its assets, immunity from suit, execution attachment (before or after judgment), or other legal
process, such party shall not claim, and it hereby irrevocably waives, such immunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction
and Venue</U>. Each of the Parties (a) submits to the exclusive jurisdiction of any state or federal court sitting in New York,
in any action or proceeding (whether in contract or tort) arising out of or relating to this Escrow Agreement, or the negotiation,
execution or performance of this Escrow Agreement (including any claim or cause of action based upon, arising out of or related
to any representation or warranty made in or in connection with this Escrow Agreement or as an inducement to enter into this Escrow
Agreement), (b) agrees that all such claims in respect of such action or proceeding shall be heard and determined in any such
court and (c) agrees not to bring any such action or proceeding in any other court. Each of the Parties waives any defense of
inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that
might be required of any other Parties with respect thereto. Each of the Parties agrees that service of summons and complaint
or any other process that might be served in any action or proceeding may be made on such party by sending or delivering a copy
of the process to the party to be served at the address of the party and in the manner provided for the giving of notices in <U>Section
9</U>. Nothing in this <U>Section 10.10</U>, however, shall affect the right of any party hereto to serve legal process in any
other manner permitted by Law. Each party hereto agrees that a final, non-appealable judgment in any action or proceeding so brought
shall be conclusive and may be enforced by suit on the judgment or in any other manner provided by Law. Buyer and Seller agree
to pursue any redress or recourse in connection with any dispute that is solely and exclusively among themselves (and/or any third
party) without making the Escrow Agent a party to the same. To the extent that in any jurisdiction any of the Parties may now
or hereafter be entitled to claim for itself or its assets, immunity from suit, execution attachment (before or after judgment),
or other legal process, such party shall not claim, and it hereby irrevocably waives, such immunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Escrow Agreement may not be amended or modified, except by a written instrument executed by Buyer, Seller, Consultants&rsquo;
Representative (solely with respect to provisions that may affect the rights or obligations of the Consultants hereunder), and
the Escrow Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Escrow Agreement shall remain in effect unless and until (a) the Escrow Funds and any interest or other amounts earned thereon
are distributed in full or (b) it is terminated in a written instrument executed by Buyer, Seller and Consultants&rsquo; Representative,
in which event, termination shall take effect no later than ten (10) Business Days after notice to the Escrow Agent of such termination.
Termination of this Escrow Agreement shall not impair the obligations of Buyer and Seller set forth in <U>Section 6.1</U>, <U>Section
6.2</U>, <U>Section 6.8</U> and <U>Section 7</U> of this Escrow Agreement accruing prior to such termination, which obligations
shall survive such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limited
Liability</U>. IN NO EVENT SHALL THE ESCROW AGENT, BE LIABLE, DIRECTLY OR INDIRECTLY, FOR ANY SPECIAL, INCIDENTAL, PUNITIVE, INDIRECT
OR CONSEQUENTIAL LOSSES OR DAMAGES OF ANY KIND WHATSOEVER (INCLUDING BUT NOT LIMITED TO LOST PROFITS), EVEN IF THE ESCROW AGENT,
HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES AND REGARDLESS OF THE FORM OF ACTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Force
Majeure</U>. Notwithstanding any other provision of this Escrow Agreement, the Escrow Agent shall not be obligated to perform
any obligation hereunder and shall not incur any liability for the nonperformance of any obligation hereunder to the extent that
the Escrow Agent is delayed in performing, or unable to perform, such obligation because of acts of God, war, terrorism, fire,
floods, strikes, electrical outages, equipment or transmission failures, or other causes reasonably beyond its control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Patriot
Act Disclosure</U>. Section 326 of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept
and Obstruct Terrorism Act of 2001 (&ldquo;<U>USA PATRIOT Act</U>&rdquo;) requires Escrow Agent to implement reasonable procedures
to verify the identity of any person that opens a new account with it. Accordingly, each of Buyer and Seller acknowledges that
Section 326 of the USA PATRIOT Act and Escrow Agent&rsquo;s identity verification procedures require Escrow Agent to obtain information
which may be used to confirm such party&rsquo;s identity including without limitation name, address and organizational documents
(&ldquo;identifying information&rdquo;). Each of Buyer and Seller agrees to provide Escrow Agent with and consent to Escrow Agent
obtaining from third parties any such identifying information required as a condition of opening an account with or using any
service provided by the Escrow Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consultants&rsquo;
Representative</U>. Consultants&rsquo; Representative may from time to time designate a successor to act as Consultants&rsquo;
Representative by delivering a written notice to the Escrow Agent, which successor shall be one of the Consultants and subject
to the written approval of Buyer, Seller and the Escrow Agreement, which approval shall not be unreasonably withheld or delayed.
Consultants&rsquo; Representative may resign at any time, <U>provided</U> that he or she designates a successor in accordance
with the preceding sentence. In the event that Consultant&rsquo;s Representative becomes incapacitated and has not designated
a successor in accordance with the first sentence of this Section 10.16, Ian Massey shall be designated as Consultants&rsquo;
Representative. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * *</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties have executed this Escrow Agreement on the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCO
    SILICON VALLEY, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Xiangli Zhou</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Xiangli Zhou</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;CEO/GM</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ken Stratton</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Ken Stratton</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINENTAL
    STOCK TRANSFER &amp; TRUST COMPANY</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><I>/s/</I>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>kenneth
    b. stratton</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    his capacity as representative to the Consultants</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Kenneth Stratton</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Alpha
    Capital Anstalt</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>solely
    with respect to Section 5.3(a)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    </I></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Closing
Release Instructions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
11, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continental
Stock Transfer &amp; Trust Company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17
Battery Place, 8<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Accounting Department, Escrow Administration</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
Address: scarter@continentalstock.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Release Instructions / Escrow Account no.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir/Madam:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
refer to the Escrow Agreement, made and entered into as of November 11, 2016, by and among BOCO Silicon Valley, Inc., StemCells,
Inc. (&ldquo;<U>Seller</U>&rdquo;), Continental Stock Transfer &amp; Trust Company, Kenneth B. Stratton in his capacity as representative
to the Consultants, and Alpha Capital Anstalt. Capitalized terms used but not defined in this letter shall have the meaning as
used in the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 5.3(a) of the Escrow Agreement, we hereby request you to release the Escrow Funds from the Escrow Account
on date of the Closing Date (the &ldquo;<U>Closing Date</U>&rdquo;) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    Seller:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.45in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount
    to Seller: </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    the bank account identified by the following information:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.45in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.45in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
    name</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank
    address</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    bank reference number as necessary</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correspondent
    banking details (if any)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account
    number</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
    name</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">viii.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary
    address</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Consultants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total
Amount to the Consultants: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Escrow Agent shall mail via a nationally recognized overnight courier service to each Consultant a check in the dollar amount
and to the address, in each case, set forth opposite the name of each such Consultant in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%; border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Consultant</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If the Closing Date is<BR>

    December 1, 2016 or<BR>
 prior thereto</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>If the Closing Date is<BR>

    after December 1, 2016</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 23%; border-bottom: Black 1.5pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the undersigned have executed these Closing Release Instructions on the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOCO
    SILICON VALLEY, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STEMCELLS,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Alpha
    Capital Anstalt</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
4</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
base fee shall be $400 per month (the &ldquo;<U>Base Fee</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
time a distribution is made to a Consultant, the Escrow Agent shall charge an administration fee of $50.00 per payment (the &ldquo;<U>Variable
Fee</U>&rdquo;). For example if an aggregate amount of $495,000 is paid at the Closing to 16 Consultants, a Variable Fee of $800
will be paid to the Escrow Agent for such payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
5</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
Number(s) for Call-backs and<BR>
Person(s) Designated to Give and Confirm Funds Transfer and Other Instructions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="6" STYLE="text-decoration: underline; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Buyer:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
    Number</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shirley
    Zhou</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="6" STYLE="text-decoration: underline; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Seller:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Stratton</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(650)
    670-2282</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">George
    Koshy</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="6" STYLE="text-decoration: underline; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Consultants&rsquo; Representative:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth
    Stratton</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(650)
    670-2282</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Ian
    Massey</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
funds transfer instructions must include the signature of the person(s) authorizing said funds transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>4
<FILENAME>ex10-13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTRACT
RESEARCH AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Contract Research Agreement is entered into as of this __ day of _________, 2017 (the &ldquo;Effective Date&rdquo;), by and between
The Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853
and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (&ldquo;University&rdquo;)
and Microbot Medical Ltd., a company formed under the laws of Israel, with offices at 5 Hamada Street, Yokneam, Israel (the &ldquo;Company&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
in the course of their research at University, Drs. James P. (Pat) McAllister II and David D. Limbrick, Jr (hereinafter &ldquo;the
Principal Investigators&rdquo;) have developed a method for making Models (as defined below); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company wishes to have the Principal Investigators and other members of their research teams at University perform certain
services, from time to time, for the Company using the Model (as further defined below, the &ldquo;Services&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
University is willing to perform the Services under the supervision of the Principal Investigators, in accordance with the Workplan
(as defined below), all in accordance with the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> the parties hereto, intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
used in this Agreement with an initial capital letter, the terms defined in this Section 1, whether used in the singular or the
plural, shall have the meanings specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Company
Device&rdquo;</B> shall mean the Company&rsquo;s proprietary device described in Exhibit A hereto, and any improvements, modifications
and derivatives thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Company
Device Results&rdquo;</B> shall mean Service Results resulting from experiments using shunts containing the Company Device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Joint
Inventions&rdquo;</B> shall mean any and all patentable inventions, other than Model Improvements, obtained or arrived at in the
performance of the Services for which (a) one or more inventor(s) is a member of the University Team and (b) one or more inventor(s)
is an employee or consultant of Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Model&rdquo;
</B>shall mean any animal model in which hydrocephalus has been induced experimentally by the University Team. Most likely these
will include pigs, sheep or ferrets at any age.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Model
Improvements&rdquo;</B> shall mean any and all improvements or modifications of the Model generated by members of the University
Team in the performance of the Services, but specifically excluding any improvements or modifications attributable to the Company
Device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Services&rdquo;
</B>shall mean the services to be performed by the University Team in accordance with the Workplan during the time period set
forth in the Workplan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Services
Results&rdquo;</B> shall mean any and all data, information and results obtained or arrived at by members of the University Team
in the performance of the Services, other than University Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.8.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&ldquo;University
Inventions&rdquo;</B> shall mean any and all patentable inventions, other than Model Improvements and Joint Inventions, obtained
or arrived at by members of the University Team in the performance of the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;University
Team&rdquo;</B> shall mean the Principal Investigators and other members of their research team working under the Principal Investigators&rsquo;
direction in the performance of the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Workplan&rdquo;
</B>means the written workplan attached hereto as Exhibit B, as may be amended, expanded or supplemented, from time to time, in
accordance with Section 2.1 by the mutual written agreement of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Services.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Workplans.
</B>From time to time during the term of this Agreement, the parties may decide to amend, expand or supplement the Workplan for
the performance of Services under this Agreement via written amendment. To the extent the terms in a Workplan shall at any time
conflict with the terms of this Agreement, the terms of this Agreement shall control, unless specifically stated otherwise in
the Workplan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
and Use of Company Device.</B> Company shall deliver units of the Company Device to the Principal Investigators in the amounts
and in accordance with the procedures set forth in the Workplan. University shall use the units of the Company Device solely for
the purpose of performing the Services under the Workplan. University shall not reverse engineer the Company Device nor undertake
any additional analyses of the Company Device, including, without limitation, any attempt to determine the composition, design,
structure or properties of the Company Device (except as specifically set forth in the Workplan), without the advance express
written permission of Company. Units of the Company Device shall not be used in humans. University shall not sell or transfer
units of the Company Device to any person other than members of the University Team without Company&rsquo;s prior written consent.
University shall comply with all applicable laws and regulations in the use of the units of the Company Device. Company&rsquo;s
transfer of the units Company Device to University shall not constitute a sale thereof or a grant, option or license under any
patent or other rights owned or controlled by Company. Upon completion of the Services, University shall return to Company all
units of the Company Device in its possession or control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
of Services. </B>University shall cause the University Team to perform the Services in accordance with the Workplan and state-of-the-art
scientific standards and laboratory practices. The Services will be directed and supervised by the Principal Investigators, who
shall have primary responsibility for the performance of the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees.
</B>In consideration for the performance of the Services, the Company shall pay University the amounts set forth in the Workplan
in accordance with the time schedule set forth in the Workplan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports.
</B>The Principal Investigators shall provide the Company written reports setting forth the Services Results, including raw data
and analyses, in accordance with the schedule set forth in the Workplan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Service
Results and Joint Inventions</U>. All rights, title and interest in and to the Service Results (other than the Model and Model
Improvements) and Joint Inventions will be jointly owned by the parties. Subject to Sections 5.4 and 6, Company and University
each shall have the full right to practice and to grant licenses under its interest in Joint Inventions (including with respect
to patent rights covering Joint Inventions) without any obligation to seek the consent of the other or to account for any profits
made as a result of any such license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Model
and all Model Improvements.</U> All rights, title and interest in and to the Model and all Model Improvements shall be owned solely
and exclusively by University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>University
Inventions.</U> University grants to Company: (a) a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable,
license (with the right to sublicense through multiple tiers of sublicenses in conjunction with the license of Company intellectual
property or sale of Company products) to use and practice University Inventions (including under any and all patent rights claiming
University Inventions) to develop, have developed, make, use, have made, market, sell, have sold and import the Company Device
or products for the prevention of occlusion and/or reduction of debris or tissue accumulation in shunts and/or shunts incorporating
such prevention devices that rely upon, make use of or are based on the Company Device; and (b) an exclusive option (the &ldquo;Option&rdquo;)
to obtain an exclusive, worldwide license, with the right to grant sublicenses, to make, use, sell, have made, have sold, offer
to sell, and import under University&rsquo;s rights in University Inventions on terms to be negotiated in good faith between the
parties. Company may exercise the Option by sending written notice to University at any time within ninety (90) days following
the receipt of a written disclosure from University describing in detail such University Invention (the &ldquo;Option Period&rdquo;).
If, at the end of the Option Period, Company has not exercised the Option, or in the event the Parties fail to reach a mutually
acceptable licensing arrangement within six (6) months after the Option Period, University shall be entitled to negotiate with
a third party for a license to University&rsquo;s rights in University Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential
Information. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Unless
agreed otherwise by the Company in writing, University shall not, during the term of this Agreement and for five (5) years thereafter,
disclose Company Confidential Information (as defined below) other than to members of the University Team or use Company Confidential
Information other than for the purpose of performing the Services. University shall ensure that all members of the University
Team are legally bound by obligations that impose confidentiality and non-use obligations comparable to those set forth in this
Section 6. University shall treat the Company Confidential Information with the same degree of confidentiality as it keeps its
own confidential information, but in all events no less than a reasonable degree of confidentiality. University shall safeguard
any and all copies of the Company Confidential Information against unauthorized disclosure, shall not tamper with, bypass or alter
its security features or attempt to do so, and shall take all reasonable steps to ensure that the provisions of this Agreement
are not violated by any person under University&rsquo;s control or in University&rsquo;s service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>For
purposes of this Agreement, &ldquo;Company Confidential Information&rdquo; means proprietary or confidential information relating
to the Company&rsquo;s scientific, technical, trade or business information relating to the subject matter of this Agreement (including,
without limitation, the technical attributes of Company Device which are not known to the public (&ldquo;Company Device Information&rdquo;))
disclosed by or on behalf of the Company to members of the University Team in connection with the Services. Both Parties agree
that in order for written information to be Confidential Information, it must be delivered in written form clearly marked as &ldquo;Confidential.&rdquo;
All information, other than Company Device Information, disclosed in oral or some other non-written form must be declared at the
time of delivery to be confidential and must be confirmed and summarized in writing and clearly marked as &ldquo;Confidential&rdquo;
within thirty (30) days of disclosure to be Company Confidential Information, <I>provided , however, </I>information that unintentionally
or inadvertently lacks such a legend, or that is disclosed orally or visually which is not subsequently documented, but, by its
nature, is reasonably understood to be Company Confidential Information shall be treated as such by University. Notwithstanding
the foregoing, information disclosed by Company to the University Team as set forth above shall not be deemed Company Confidential
Information to the extent such information: (i) was known to any member of the University Team at the time it was disclosed, as
evidenced by written records at the time of disclosure; (ii) is at the time of disclosure or later becomes publicly known under
circumstances involving no breach of this Agreement; (iii) is lawfully and in good faith made available to a member of the University
Team by a third party who is not subject to obligations of confidentiality to the Company with respect to such information; (iv)
is independently developed by a member of the University Team without the use of or reference to Company Confidential Information,
as demonstrated by documentary evidence; or (v) is required to be disclosed pursuant to a legal order or mandate. University agrees
to keep confidential all Company Device Results until such results are published in accordance with Section 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnity.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the rest of this agreement, Company shall indemnify, defend and hold harmless University, University personnel and representatives,
from and against any liability, cost, expense, damage, deficiency, loss or obligation or any kind or nature (including, without
limitation, reasonable attorney&rsquo;s fees and other costs and expenses of litigation) resulting from a claim, suit or proceeding
brought by a third party against University to the extent resulting from the use or commercialization of the Services Results
or University Inventions by Company or a Company&rsquo;s sublicensee (a &ldquo;Claim&rdquo;), except (in each case) to the extent
caused by the negligence or willful misconduct of University or anyone on its behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
University receives notice of any Claim, University shall, as promptly as is reasonably possible, give the Company notice of such
Claim; provided, however, that failure to give such notice promptly shall only relieve the Company of any indemnification obligation
it may have hereunder to the extent such failure diminishes the ability of the Company to respond to or to defend University against
such Claim. University and the Company shall consult and cooperate with each other regarding the response to and the defense of
any such Claim and the Company shall be entitled to assume sole control of the defense and/or represent the interests of University
in respect of such Claim, that shall include the right to select and direct legal counsel and other consultants to appear in proceedings
on behalf of University and propose, accept or reject offers of settlement, all at its sole cost provided that Company shall not
settle a claim which admits fault on behalf of University without University&rsquo;s prior written consent. Nothing herein shall
prevent University from retaining its own counsel and participating in its own defense at its own cost and expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
and Termination. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1.
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The term of this Agreement shall commence on the date first written above and,
unless terminated earlier in accordance with this Section 8, shall continue for a period of two (2) years, unless extended by
the mutual written agreement of the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2.
</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event that either party commits a material breach of its obligations under
this Agreement and fails to cure that breach within thirty (30) days after receiving written notice thereof, the other party may
terminate this Agreement immediately upon written notice to the party in breach</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.3.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
either Principal Investigator ceases to supervise the Services, the Company or University may terminate this Agreement upon written
notice to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.4.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination, the parties sole obligations to the other shall be to return all Company Confidential Information and pay any monies
due and owing up to the time of termination for work actually performed and all costs reasonably and properly incurred by the
parties as of the date that termination is effective, including all non-cancelable obligations reasonably and properly entered
into for the purposes of the Services, which may include any non-cancelable University Team salaries, fellowships or post-doctoral
stipends, and other non-cancelable executory obligations reasonably and properly incurred by the parties in furtherance of Services,
subject to the parties taking reasonable steps to mitigate and minimize such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.5.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
parties&rsquo; respective rights, obligations and duties under Sections 4, 5, 6, 7, 8, 9, 10, 11, and 12 , as well as any rights,
obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any
expiration or termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Publications.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
acknowledges that the Principal Investigators and University Team have the right and academic duty to publish the Service Results,
and agrees that the University Team will be permitted to present at symposia or professional meetings and to publish in books,
journals, and other media of their choosing, any and all Service Results, University Inventions, Models, and Model Improvements;
provided however, that University shall not disclose Company Confidential Information without the prior written consent of Company.
The University Team will at all times have the first opportunity to publish or present the Service Results, Models, and Model
Improvements subject to Section 9.2; provided however that Company shall be entitled to disclose Services Results and regulatory
and/or patent filings prior to any such publication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
University chooses to publish Service Results on its own (i.e. not publish jointly with Company), Company will be furnished a
copy of any proposed publication or a summary of a presentation containing Service Results in advance of submission in the case
of publication and rendering in the case of presentation. Company will have thirty (30) days after receipt to review the copy
or summary for specific matter which is Company Confidential Information and provide University with a written request for removal
or revision. If such a request is received within the thirty days, the Parties will have an additional thirty (30) days (a total
of sixty (60) days) to agree upon removal or revisions to protect the Company Confidential Information. Upon completion of this
publication process or, if applicable, confidentiality is specifically waived under Section 6, University may proceed with publication,
provided that University may not publish or otherwise disclose Company Confidential Information without Company&rsquo;s express
prior written approval. Company shall not encumber publication by University other than to remove Company Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
papers and presentations reporting Service Results will contain a dignified statement in a form that is customary and appropriate
in scholarly journals or presentations for acknowledging that financial support for such research was provided by Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Company
will not have an opportunity to change, alter or redact the contents of any student thesis, dissertation, or presentation thereof,
provided that no such thesis, dissertation or presentation may contain Company Confidential Information without Company&rsquo;s
prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer
and Limitation.</B> NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, EVERYTHING PROVIDED BY EITHER PARTY UNDER THIS AGREEMENT
IS UNDERSTOOD TO BE EXPERIMENTAL IN NATURE, MAY HAVE HAZARDOUS PROPERTIES, AND IS PROVIDED WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED
OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT
OF ANY THIRD-PARTY PATENT, TRADEMARK, COPYRIGHT OR ANY OTHER THIRD-PARTY RIGHT. NEITHER PARTY MAKES ANY WARRANTIES REGARDING THE
QUALITY, ACCURACY, COMMERCIAL VIABILITY OR ANY OTHER ASPECT OF ITS PERFORMANCE PURSUANT TO THIS AGREEMENT OR REGARDING THE PERFORMANCE,
VALIDITY, SAFETY, EFFICACY OR COMMERCIAL VIABILITY OF ANYTHING PROVIDED BY IT UNDER THIS AGREEMENT. IN NO EVENT SHALL UNIVERSITY
OR COMPANY BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT,
WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF THE PARTY IS ADVISED OF THE POSSIBLITY OF SUCH DAMAGES. EXCEPT FOR THEIR
RESPECTIVE INDEMNITY OBLIGATIONS AND BREACH OF CONFIDENTIALITY OBLIGATIONS, EACH OF UNIVERSITY&rsquo;S AND COMPANY&rsquo;S AGGREGATE
LIABILITY TO THE OTHER UNDER THIS AGREEMENT SHALL NOT EXCEED THE PAYMENTS MADE OR PAYMENTS DUE UNDER THIS AGREEMENT, RESPECTIVELY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.
</B>The parties shall obtain and maintain an adequate self-insurance or insurance program to protect against potential liabilities
and risk, including coverage for the indemnity obligations herein; provided that Company&rsquo;s obligations under this Section
11 shall come into effect only if and when the Company commences clinical trials (a) based on Services Results or (b) with a product
developed under the license granted to Company pursuant to Section 5.3. Prior to the first clinical study in humans of a product
developed under the license granted to Company pursuant to Section 5.3, Company shall obtain and maintain product liability insurance
in the amount of $5,000,000 per occurrence and $10,000,000 in the aggregate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.1.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire
Agreement.</B> This Agreement is the sole agreement with respect to the subject matter hereof and except as expressly set forth
herein, supersedes all other agreements and understandings between the parties with respect to same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.
</B>Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be
delivered personally, or may be sent by facsimile or certified mail, return receipt requested, to the following addresses, unless
the parties are subsequently notified of any change of address in accordance with this Section 9.2:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Hezi Himelfarb, COO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
Hamada Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yokneam</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to University:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
Research Office of Contracts</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Megan White</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
Brookings Dr., Campus Box 1054</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St.
Louis, MO 63130</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copy
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
P. McAllister</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Department
of Neurosurgery</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BJC
Institute of Health</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">425
S. Euclid, Campus Box 8057</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St.
Louis, MO 63110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice shall be deemed to have been received as follows: (i) by personal delivery, upon receipt; (ii) by facsimile, one business
day after transmission or dispatch; (iii) by airmail, seven (7) business days after delivery to the postal authorities by the
party serving notice. If notice is sent by facsimile, a confirming copy of the same shall be sent by mail to the same address.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law and Jurisdiction. </B>This Agreement will be governed by, and construed in accordance with, the substantive laws of the State
of New York, without giving effect to any choice or conflict of law provision, and sole jurisdiction is granted to the competent
court in the City of New York, NY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment;
Waiver. </B>This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of any party
at any time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce
the same. No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by conduct,
or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such
condition or of the breach of such term or any other term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Agency or Partnership. </B> Nothing contained in this Agreement shall give any party the right to bind another, or be deemed to
constitute either parties as agents for each other or as partners with each other or any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force
Majeure. </B>Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party, including
without limitation fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable
efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch
whenever such causes are removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.
</B> If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is
deemed unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Names
and Marks.</B> Neither Party may use the trademarks or name of the other Party or its employees for any commercial, advertisement,
or promotional purposes without the prior written consent of the other.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment.
</B>This Agreement may not be assigned by either party without the consent of the other, which consent shall not be unreasonably
withheld, except that each party may, without such consent, assign this Agreement and the rights, obligations and interests of
such party to any of its affiliates, to any purchaser of all or substantially all of its assets to which the subject matter of
this Agreement relates, or to any successor corporation resulting from any merger or consolidation of such party with or into
such corporation; provided, in each case, that the assignee agrees in writing to be bound by the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF, </B>the parties have caused this Agreement to be executed by their duly authorized representatives as of the
date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
    Medical Ltd.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
    Washington University </B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 34%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 34%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 16%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><I>/s/<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Melanie
    Roewe</FONT></I></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Harel Gadot</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Melanie
    Roewe, J.D.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Assistant Vice Chancellor<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
the undersigned, hereby confirm that I have read the Agreement, that its content is acceptable to me and that I will act in accordance
with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 42%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    James P. McAllister II</I>&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;January
    24, 2017</FONT></TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>James
    P. McAllister II, PhD</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 42%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David D. Limbrick</I>&nbsp;</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    26, 2017</FONT></TD>
    <TD STYLE="width: 10%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    D. Limbrick, Jr, MD, PhD</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Device</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>See
following pages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SCS
Product Description </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Head
Set Configuration</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approvals:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 19%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 19%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Author</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or
    Samocha</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Project
    Leader</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    1, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reviewed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yossi
    Porat</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S/W
    Engineer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    1, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approved
    By</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simon
    Sharon</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    1, 2016</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>The
Product</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Microbot SCS device is designed to serve as the ventricular catheter portion of a Cerebrospinal Fluid shunt system. The Microbot
ventricular catheter can connect to valves that are currently on the market. The advantage of the Microbot SCS device is its ability
to maintain CSF flow through the ventricular catheter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
further described below, the Microbot SCS device incorporates an internal cleaning mechanism embedded in the lumen of the ventricular
catheter. The internal part is comprised of a central shaft with small protrusions (resembling a stalk of wheat), which prevents
cell ingrowth into the catheter perforations using minute vibrational movements. The vibrational action is externally operated
by the patient wearing of a specially designed headset for approximately 5 minute per day. When activated, the headset applies
a small magnetic field, which causes the internal part to vibrate and thereby mechanically keeps tissue from entering the catheter
perforations while maintaining the CSF flow in the ventricular catheter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Microbot SCS ventricular catheter consists of a silicone tube with a perforated titanium tip, which connects to a standard shunt
valve at its distal end. The internal cleaning mechanism is embedded in the lumen of the titanium tip.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
internal cleaning mechanism vibrates by means of an induced magnetic field that is externally generated by a user friendly headset
that transmits a magnetic field with a pre-determined frequency and operating sequence protocol. The magnetic field that is created
by the headset externally, is captured by the intermediate flat flexible coil and PCB that are placed just under the patient&rsquo;s
scalp (in the same location where the valve is currently located). The actuated PCB assembly converts this power to an altering
current which flows through the wires to an internal coil located in the distal end of the catheter&rsquo;s titanium tube. The
internal coil produces an electromagnetic field which induces small vibrational movement of the internal cleaning mechanism within
the proximal part of the ventricular catheter. The vibrational movement maintains CSF flow in the ventricular catheter by preventing
surrounding tissue from entering the catheter perforations, without interfering with the cerebrospinal fluid (CSF) drainage. The
vibrational movements of the internal part drive out the infiltrating tissue from the catheter perforations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Global
view</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Microbot SCS device is composed of the following main components:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 14.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implanted
    Ventricular Catheter with vibrating internal part</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implanted
    Intermediate Flexible Coil and PCB Assembly</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
    Head Set Activation Unit</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Microbot SCS device is shown in Figure 1 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_005.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1 - Microbot SCS Device</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ventricular catheter is depicted in Figure 2 and contains:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Silicone tube
    with the following components embedded within the silicone: <FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.8in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small
    coil</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">wires</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titanium
    Tip with the vibrating internal part contained within its lumen.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
more detailed description of system&rsquo;s main components is provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Detailed
Component Description</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Silicone
Tube</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
silicone tube is constructed from the same material as standard silicone shunts and has similar inner and outer diameters as standard
ventricular catheters. The silicone tube is connected to the titanium tip at the proximal end and to a conventional, commercially
available CSF valve at the distal end. Compatibility with different valve systems will be demonstrated as part of the performance
data. The internal small coil is embedded inside the silicone tube at the proximal end. Electrical wires are embedded in the wall
thickness of the silicone tube (as shown in Figure 2 above) connecting the small coil and the intermediate flat flexible coil
assembly that are implanted under the scalp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Titanium
Tip</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
titanium tip is a perforated tube, similar to the standard silicone tips of ventricular catheters, only it is manufactured from
titanium instead of silicone. The titanium tip houses the vibrating internal cleaning mechanism and is designed to allow mobility
while protecting it during implantation of the ventricular catheter. The titanium tip is connected at the distal end to the silicone
tube. The tip may be made of other materials as well.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_007.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Internal
Part and Magnet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vibrating internal part (Figure 4) is located within the lumen of the titanium tip and maintains CSF flow by using vibrational
movements to prevent the tissue or other cells from entering and accumulating within the catheter perforations. The internal part
resembles a stalk of wheat with small arms or protrusions along a central shaft and has a small neodymium magnet at the end. The
internal part is also manufactured from titanium and the neodymium magnet will either be enclosed in a titanium housing or coated
with a biocompatible material (to be determined). The magnet is located in the internal small coil which is located in the silicone
tube, as shown in Figure 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_008.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5 shows the internal part within the titanium tip.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_009.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Internal
Actuator</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
6 shows the internal part inside the titanium tip, connected to the silicon tube.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_010.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
vibration of the internal part is achieved by an altering magnetic field which is generated by an electromagnet (internal small
coil up&rsquo;on actuating by the external headset). The magnetic field creates a moment on the magnet and causes it to rotate
around its axis. The minute magnet movement causes the internal part to vibrate slightly and mechanically drives out the tissue
or cells from the catheter perforations and thus prevents infiltration and lodging of the tissue in the catheter perforations.
The small coil is manufactured from gold/copper coated with biocompatible material and it is encapsulated inside the silicone
tube.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_011.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intermediate
Flexible Coil and PCB Assembly</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intermediate flat flexible coil and PCB assembly is implanted under the scalp near the implanted valve. This is a flexible printed
circuit board (PCB) that contains an intermediate coil made of thin gold\copper wires or other material. The entire flexible coil
assembly is encapsulated in silicone such that no internal component comes in contact with human tissue or fluids.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
electromagnetic power that is generated by the external head set unit is induced on the intermediate flexible coil and pcb assembly.
The PCB circuitry converts the power from the headset and generates the power that controls the vibrating internal part. The PCB
also sends and receives sensory data and from, and to, the headset. The flexible coil, PCB assembly and the silicone section that
leads to the PCB are connected to the silicone tube using a miniature connector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>External
Head Set Activation Unit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
external head set activation unit is the headset configuration schematically depicted in Figure 7. The headset is worm by the
patient once a day for a predetermined period of time. The head set contains an electromagnet that, when properly placed, is automatically
activated and transforms electromagnetic power on the intermediate flexible coil assembly to create vibration of the internal
part and initiates communication with the implant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="ex10-14_013.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7 - External Head Set Activation Unit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
head set is pre-adjusted for each patient such that when it is worn, the active area of the head set is positioned proximal to
the implanted flexible coil assembly and the electromagnetic energy is induced on the implanted coil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
head set contains a rechargeable battery. A charged battery will suffice for several days of operation. A microprocessor with
dedicated embedded software also resides in the headset. The vibration of the internal part is automatically initiated when the
patient places the external head set activation unit on his/her head. The head set activation unit contains a set of LED indicators
and auditory feedback, controlled by the embedded software which provides the patient and physician with treatment information.
The communication with the implant provides the means to receive sensory data from the implant regarding its state including malfunctions
it can experience. The headset has also the ability to upload SW updates to the implant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="ex10-14_002.jpg" ALT="" STYLE="height: 200; width: 373"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8 &ndash; Communication and power scheme</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following indications are provided by the headset:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    readiness, including battery state, charging indication, error indication (e.g. hardware failures).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment
    start - this indicates proper placement of the headset over the flexible coil.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    operation - &ldquo;treatment in progress&rdquo; indicates proper functioning of the vibrational movement of the internal part,
    while the headset is placed over the flexible coil.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    compliance &ndash; indicates user compliance with the treatment regimen.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following functions are enabled using the Headset via a USB port:</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charging
    the battery.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retrieving
    treatment history by the physician.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mode
of Operation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex10-14_012.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
activation by the user, the external head set activation unit generates an alternating magnetic field, which is induced on the
intermediate implanted flat flexible coil. The magnetic field is induced on the intermediate flexible coil assembly which generates
power for the PCB circuitry within the intermediate flexible coil assembly. The PCB circuitry generates an alternating current
that flows through the electromagnet (small coil) in the proximal ventricular catheter, generating an alternating magnetic field
which in turn generates the moment of the neodymium (Nd) magnet and vibrates the internal part. The vibrations maintain the perforations
in the proximal ventricular catheter clear of cell ingrowth and enable the CSF to flow freely, thus preventing the buildup of
tissue that causes occlusion. The communication between the headset and the implant is based on amplitude modulation..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Workplan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scope
of Work</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
VIVO TESTS OF THE MICROBOT MEDICAL SCS DEVICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington
University School of Medicine and the Saint Louis Children&rsquo;s Hospital Investigators:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
P. (Pat) McAllister, PhD; Professor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
D. Limbrick, Jr., MD, PhD: Professor and Chief of Pediatric Neurosurgery</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leandro
Castaneyra Ruiz, PhD: Visiting Researcher and Postdoctoral Fellow</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Microbot device seeks to prevent tissue obstructions from occluding cerebrospinal fluid (CSF) drainage catheters implanted into
the lateral ventricle. Therefore, the experiments will include implantation of these catheters into the lateral ventricle as part
of a CSF drainage system, or shunt. In animals that have developed hydrocephalus a ventricular catheter will be inserted into
the lateral ventricle and attached to a subcutaneous reservoir whose distal catheter will be subcutaneously placed into the peritoneal
cavity. This is the customary design for clinical shunts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
main objective of this study is to determine the effectiveness of the Microbot Medical SCS Device to prevent obstruction in cerebrospinal
fluid (CSF) catheters in a clinically relevant in vivo model of hydrocephalus. </B>To meet this objective one initial Specific
Aim will be addressed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aim
1: </B>Determine the effectiveness of a porcine model of hydrocephalus to test the Microbot Medical SCS Device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
short-term pilot study on 4-10 infant pigs is intended to solve any logistical issues and collect preliminary data before the
long-term efficacy testing begins in Aim 2. In particular, we will determine the extent of ventriculomegaly needed for implantation
of the SCS Device, the time needed prior to implantation, the time required for typical catheter obstruction to occur, the most
effective placement of the extracranial components subcutaneously and externally on the body of the pig, and how catheter obstruction
will be detected. This initial study will lead to a second Specific Aim that will be formulated once Aim 1 is complete; in other
words, once we have optimized the mechanics of catheter positioning (presumably in about 3 animals) we will begin testing different
device activation regimes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Experimental
Design</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the animal procedures will be reviewed and approved by the Washington University Animal Studies Committee in compliance with
federal regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aim
1: </B>Prior to testing the Microbot device, obstructive hydrocephalus will be induced in 4-10 infant pigs by intracisternal injection
of kaolin. These procedures have been conducted many times by the principal investigators (PIs) and have been shown to be reliable
and cost-effective methods for creating hydrocephalus in experimental animals. We will begin with the following age-based timeline,
with modifications applied as we learn more about the model and the mechanics of implanting the Microbot device:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-weeks
    of age: Kaolin induction of hydrocephalus</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-4
    weeks of age: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuroimaging
    &ndash; ultrasound, CT or MRI &ndash; to determine the size of the cerebral ventricles.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implantation
    of a non-activated Microbot device, which includes</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    1.5 cm ventricular catheter.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    drainage catheter 11-20 cm long implanted subcutaneously and inserted into the peritoneal cavity.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    10 cm silicone rod attached to a 2cm diameter coil both of which are implanted subcutaneously.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attachment
    externally to the body wall of a 3-4 cm receiver coil connected by wires to a 5x5 cm data collection box. A jacket will be
    customized to fit snugly around the animal and hold the equipment in pockets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4-10
    weeks of age: Practical testing of the data collection abilities of the Microbot device and the general effects of CSF drainage
    and obstruction on ventricular size and animal behavior. Most likely these tests will be conducted once a day or as needed
    to determine the feasibility of the animal model. The longer time points will be tested on animals that survived the 10 weeks
    period in order to identify any chronic complications that might affect Aim 2 experiments.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    the termination of the experiment each animal will undergo neuroimaging and intracranial pressure (ICP) measurements</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
animal will be monitored daily for neurological status and general health by Dr. McAllister and his trained personnel, as well
as the veterinary and animal care staff.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aim
2:</B> Following the pilot study to determine the optimal implantation parameters, the ability of the Microbot device to prevent
catheter obstruction will be tested in the groups described above. Initially each group will consist of 5-8 pigs; 5 animals will
be needed for routine statistical analyses so the higher number allows for complications that would remove an animal from the
study. The same estimated timeline and experimental design described in Aim 1 will be used with the exception that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    time following implantation for all experimental groups will be extended to at least 12 weeks.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    the Activated Group, the Microbot device will be turned on for the intervals that were determined in Aim 1. This frequency
    will also be determined initially by the in vitro experiments conducted in Dr. Harris&rsquo; lab at Wayne State University
    in Detroit.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    assessments of neurological outcome (balance, motor coordination, irritability, lethargy and other signs that change with
    increased ICP) will be performed on a regular (at least weekly) basis.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    assessments of catheter patency will be performed on a weekly basis.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ventricular
    catheters will be harvested at the end of the experiments and analyzed with routine histology for tissue obstruction.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
that future work may include autologous blood injections into the lateral ventricles to model post-hemorrhagic hydrocephalus and
test the efficacy of the Microbot device under these clinical conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
Timeline:</B> We will conduct these experiments as expeditiously as possible, but we anticipate that Aim 1 will be completed in
3-6 months and the comprehensive study will follow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Roles
and Responsibilities:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
McAllister</B>, as Principal Investigator, will oversee and supervise all aspects of this study. In addition, he will perform
all of the surgical procedures, monitor animals frequently, communicate frequently with the veterinary and support staff, supervise
the Research Associate/Postdoctoral Fellow, maintain protocols, and manage funding. He will participate in semi-weekly conference
calls with members of Microbot Medical. This effort will require 50% of his time for the 6-month study period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Limbrick</B>, as a pediatric neurosurgeon who specializes in the surgical management of hydrocephalus and current Chief of Pediatric
Neurosurgery at the Washington University School of Medicine and the St. Louis Children&rsquo;s Hospital, will be a clinical consultant
and co-investigator on this study. He will provide advice on all aspects of the study and occasionally participate in surgery.
This will constitute 5% effort but his salary and benefits will be cost shared by the Washington University School of Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Leandro Castaneyra Ruiz</B>, who is currently a postdoctoral fellow in the Limbrick/McAllister lab, will assist in all surgical
procedures and animal monitoring. In addition, he will perform all of the histology conducted on the ventricular catheters and
animal brains. This effort will require 75% of his time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUDGET
FOR AIM 1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>January
1 to June 30, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Personnel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
McAllister 50%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$24,384</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Castaneyra Ruiz 75%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$20,063</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Limbrick 5% cost-shared</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Personnel for 6 months</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$44,447</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Animals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase
    infant pigs @ $180 each x 10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,800</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administrative
    fee $25 x 10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
    - $205/2-3 pigs</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$750</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    diem - $15.50/d for 10-days postop single housing x 10 =&nbsp;&nbsp;$930;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-70
    days = $18.19/d double housing x 5 x 60d = $5,457</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,387</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposal
    fee = $85/pig x 10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">$850</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Veterinary
    consultation &amp; support</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Animals for 6 months </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$11,037</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surgery
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1<SUP>st
    </SUP>surgery (1 hr + 2 hr tech) = $550/pig x 10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$5,500</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2<SUP>nd
    </SUP>surgery (3 hr + tech) = $870/pig x 10</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$8,700</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Surgery for 6 months</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$14,200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuroimaging</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transport
    $250/2 pigs x 5 x 2 studies</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CT
    scans $180/h x 20 studies (2 per pig)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3,600</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Veterinary/animal
    care technical support&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$150/study x 20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultrasonography
    $50/study x 20</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Neuroimaging for 6 months</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$10,100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Histology
and Immunohistochemistry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reagents,
    fixatives, buffers</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$750</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stains
    and antibodies</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glass
    slides and coverslips</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$750</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.4in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital
    microscopy @ $20/h</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,000</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Histology and Immunohistochemistry for 6 months</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$5,500</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 56%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Direct Costs</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$85,284</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Indirect Costs @ 50%</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$42,642</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grand
    Total for 6 months</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$127,926</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUDGET
JUSTIFICATION for AIM 1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Personnel
</B>&ndash; described above in the Scope of Work, Roles and Responsibilities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Animals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Detailed
expenses are listed in the Budget Aim 1. A maximum of 10 animals has been requested but fewer pigs may be; every effort will be
made to use the minimal number of animals needed to satisfy the objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Surgery</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
surgeries will be needed on each animal: the first to induce hydrocephalus and the second to implant the Microbot device. Charges
are based on the current rate to use the operating room and the institutional (IACUC) requirement for a surgical assistant from
the Division of Comparative Medicine) to perform anesthesia and monitor each animal following surgery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuroimaging</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
assessments will be needed for each animal: the first just prior to implantation of the Microbot device to determine the extent
of ventriculomegaly and the second just prior to termination of the experiment to determine the effectiveness of the device. As
described under &ldquo;Animals&rdquo;, fewer studies may be conducted if the objectives have been met. Furthermore, if ultrasonography
can be shown to accurately determine the extent of ventriculomegaly then the CT scans will not be needed. However, if CT scans
are needed, then transportation and veterinary care expenses will be incurred as required by the IACUC protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Histology
and Immunohistochemistry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-mortem
analyses of the brain will include routine histology and targeted immunohistochemistry to determine (1) the effects of the Microbot
device on the brain as well as (2) the effectiveness of the Microbot device to maintain patency in the catheter. As described
previously, these costs will be reduced if fewer animals are needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indirect
Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
costs (often termed &ldquo;F&amp;A&rdquo;) are determined by the Washington University Joint Research Office for Contracts and
administered through the Office of Sponsored Research Services and Sponsored Projects Accounting. After extensive discussions
between Dr. McAllister and these offices, the rate of 50% of Direct Costs is non-negotiable. Therefore, $42,642 has been added
to the Direct Costs to provide a total budget of $127,926.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCOUNTING
AND PAYMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
will pay WU a total of $127,926 US (inclusive of all and any taxes. Such amount shall be paid on a fixed-price basis and CORPORATION
agrees that WU will retain residual funds, if any, upon completion of the Project. These payments shall be made as set out below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
fifteen (15) days of the Effective Date, CORPORATION will pay to WU the sum of $63,963US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
fifteen (15) days of after induction of Hydrocephalus in animal, CORPORATION will pay to WU the sum of $51,170.40US.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
will pay the remainder, $12,792.60US, within thirty (30) days of receipt of the Aim 1 Progress Report: Pilot Studies on the Porcine
Model of Hydrocephalus to Test the Microbot Medical SCS Device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Invoices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Invoices,
will be sent to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
Hamada Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yokneam,
20692</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Checks
shall reference WU Contract Number OTM10394 and will be made payable to Washington University in St. Louis and sent to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington
University</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsored
Projects Accounting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Campus
Box 1034</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">700
Rosedale Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">St.
Louis, MO 63112-1408</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FAX
314-935-4309</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
payments are made via wire transfer, CORPORATION agrees to be responsible for fees related to the wire transfer. The wire transfer
information is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>5
<FILENAME>ex10-14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
License Agreement is entered into as of the __ day of June, 2012 (the &ldquo;<B>Effective Date</B>&rdquo;), by and between Technion
Research and Development Foundation, a company formed under the laws of Israel, having a place of business at the Technion City,
Haifa 32000, Israel (&ldquo;<B>TRDF</B>&rdquo;) and Microbot Medical Ltd., a company formed under the laws of the State of Israel,
having a place of business at 147 Bar Yehuda Rd., Nesher, Israel (&ldquo;<B>Microbot</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
TRDF is the wholly-owned subsidiary of the Technion - Israel Institute of Technology (the &ldquo;<B>Technion</B>&rdquo;) and serves
as its commercial arm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Professor Moshe Shoham of the Technion (the &ldquo;<B>Inventor</B>&rdquo;) and members of his research team at the Technion have
developed certain technologies in the field of medical robotics;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
one of the inventions included in such technologies (i.e the invention disclosed in the Self Cleaning Shunt Patent Rights, as
defined below) is co-owned by TRDF and the Rambam Health Corporation, formerly the Fund for Medical Research, Development of Infrastructure
and Health Services - at Rambam Medical Center, (&ldquo;Rambam&rdquo;); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
pursuant to an agreement between TRDF and Rambam, TRDF has the sole authority to seek licensees for and grant licenses with respect
to such invention and the Self Cleaning Shunt Patent Rights; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Microbot wishes to obtain a license with respect to such technologies in order to develop, obtain regulatory approval for and
commercialize products based thereon;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
TRDF desires to have products based on such technology developed and commercialized to benefit the public;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
Microbot has represented to TRDF that Microbot shall commit itself to diligent efforts to develop and commercialize such products
in accordance with the terms of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
</B>THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever
used in this Agreement with an initial capital letter, the terms defined in this Article 1, whether used in the singular or the
plural, shall have the meanings specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to an entity, any person, organization or entity controlling, controlled by or under common control with,
such party. For purposes of this definition only, &ldquo;control&rdquo; of another person, organization or entity shall mean the
possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of
such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise. Without limiting
the foregoing, control shall be presumed to exist when a person, organization or entity (a) owns or directly controls fifty percent
(50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity or (b) possesses,
directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the
organization or other entity. The parties acknowledge that in the case of certain entities organized under the laws of certain
countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than
fifty percent (50%), and that in such cases such lower percentage shall be substituted in the preceding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Calendar
Quarter</B>&rdquo; means each of the periods of three (3) consecutive calendar months ending on March 31, June 30, September 30
and December 31, for so long as this Agreement is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Combination
Product</B>&rdquo; shall mean a combination of products sold for a single price and consisting of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;one
or more Licensed Product(s); and</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;one
or more product(s) that (i) can reasonably be deemed to be a separate product(s), independent of the Licensed Product(s) and (ii)
if sold as a separate product(s), independent of the Licensed Product(s) would not constitute a Licensed Product, (each such product
shall be referred to as an &ldquo;Other Product&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Development
Milestones</B>&rdquo; means the development milestones set forth in Exhibit A hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Development
Plan</B>&rdquo; means the plan for the development and commercialization of Licensed Products to be agreed to by the parties in
good faith prior to the first anniversary of the Effective Date, and to be attached hereto as Exhibit B, as such plan may be adjusted
from time to time pursuant to Section 4.2. The Development Plan will set forth Microbot&rsquo;s projected work plan for achieving
the Development Milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Improvement</B>&rdquo;
means any patentable invention conceived and/or reduced to practice in the laboratory of Shoham at the Technion for which Shoham
is an inventor and which is solely owned or otherwise controlled by TRDF (i.e. TRDF has the right to license), the practice of
which falls within the scope of any Valid Claim of the Licensed Technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Improvement
Patent Rights</B>&rdquo; shall mean any patents and patent applications that claim (solely to the extent that they claim) Improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Joint
Invention</B>&rdquo; means any patentable invention for which (a) Prof. Shoham is an inventor made (whether before or after the
Effective Date, but in any event not prior to December 9, 2010) in the performance of services for Microbot or in the performance
of duties as a member of the scientific advisory board of Microbot during periods in which Prof. Shoham is employed by the Technion
and (b) at least one employee, consultant, contractor and/or collaborator of Microbot who is not required under law, agreement
and/or under TRDF&rsquo;s Intellectual Property ByLaws, to assign his/her rights in such inventions to TRDF, is an inventor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Joint
Patent Rights</B>&rdquo; means any patents and patent applications claiming a Joint Invention, in each case solely with respect
to those claims claiming a Joint Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Licensed
Patent Rights</B>&rdquo; means the TRDF Patent Rights, the Shoham Patent Rights and the Joint Patent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Licensed
Product</B>&rdquo; means any product that (a) contains, utilizes, or incorporates, in whole or in part, Licensed Technology, (b)
is manufactured with the use of Licensed Technology, in whole or in part, (c) is otherwise covered, in whole or in part, by, or
falls within the scope of, any Valid Claim, or (d) any service that makes use of a product described in (a) (b), or (c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Licensed
Technology</B>&rdquo; means the Licensed Patent Rights, Shoham Inventions and Joint Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Net
Sales</B>&rdquo; means the gross amounts or other consideration received by or on behalf of Microbot and its Affiliates (in each
case, the &ldquo;Relevant Entity&rdquo;) on sales, leases or other transfers of Licensed Products, less the following to the extent
applicable on such sales, leases or other transfers and not previously deducted from the gross invoice price: (a) customary trade,
quantity or cash discounts to the extent actually allowed and taken; (b) amounts actually repaid or credited by reason of rejection
or return of any previously sold, leased or otherwise transferred Licensed Products; (c) customer freight charges that are paid
by or on behalf of the Relevant Entity; and (d) to the extent separately stated on purchase orders, invoices or other documents
of sale, any sales, value added or similar taxes, custom duties or other similar governmental charges levied directly on the production,
sale, transportation, delivery or use of a Licensed Product that are paid by or on behalf of the Relevant Entity, but not including
any tax levied with respect to income; provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.13.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>in
any transfers, or provision, of Licensed Products between a Relevant Entity and an Affiliate of such Relevant Entity not for the
purpose of resale by such Affiliate, Net Sales shall be equal to the fair market value of the Licensed Products so transferred
or provided, assuming an arm&rsquo;s length transaction made in the ordinary course of business, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.13.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>in
the event that a Relevant Entity receives non-cash consideration for any Licensed Products, or in the case of transactions not
at arm&rsquo;s length with a non-Affiliate of a Relevant Entity, Net Sales shall be calculated based on the fair market value
of such consideration or transaction, assuming an arm&rsquo;s length transaction made in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of Licensed Products by a Relevant Entity to its Affiliate for resale by such Affiliate shall not be deemed Net Sales. Instead,
Net Sales shall be determined based on the gross amount received by such Affiliate on resale of Licensed Products to an independent
third party purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that a Licensed Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product
shall be adjusted by multiplying Net Sales of such Combination Product in such country by the fraction A/(A+B), where A is the
average invoice price in such country of the Licensed Product included in such Combination Product when sold separately in such
country, and B is the average invoice price of the Other Products included in such Combination Product when sold separately in
such country. If, in a specific country, the Licensed Product and/or the Other Product(s) are not sold separately, a market price
for the Licensed Product and/or the Other Product(s) in the Combination Product, as applicable, shall be determined according
to separate sale prices in commensurate countries. If the Licensed Product in the Combination Product is not sold separately,
Net Sales of such Combination Product shall be adjusted by multiplying Net Sales of such Combination Product by the fraction (C-B)/C,
where C is the average invoice price of the Combination Product in such country, and B is the list price of the Other Products
included in such Combination Product when sold separately in such country. If, in a specific country, the Other Product(s) in
the Combination Product is not sold separately, a market price for the Licensed Product and the Other Product(s) in the Combination
Product shall be determined by Microbot in good faith. Microbot shall provide TRDF with a specific and separate written notification
stating that such good faith determination has been made by Microbot together with its written explanation for such determination,
together with the relevant quarterly royalty report. If TRDF disagrees with respect to the market price that should be attributed
to the Licensed Product and/or Other Product(s) in the Combination Product, as set forth in any royalty report provided under
Section 6, TRDF may notify Microbot in writing of such disagreement within ninety (90) days of receipt of the relevant notification
and report and the parties will resolve such disagreement in accordance with the procedure set forth in Exhibit C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Qualified
Financing</B>&rdquo; shall have the meaning prescribed in Section 11.2.4 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Self-Cleaning
Shunt Patent Rights</B>&rdquo; means (a) the patents and patent applications listed in Exhibit D (including the PCT application
and/or the US utility application claiming priority to such application and filed at the one year conversion date of such application(s));
(b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination,
substitution or extension of any patent application identified in (a); (c) any patents issuing on any patent application identified
in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part
application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled
to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents
or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application
identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, any other
patent term extensions and exclusivity periods and the like of any patents and patent applications identified in (a) through (e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Shoham
Invention</B>&rdquo; means any patentable invention for which Prof. Shoham is an inventor made (whether before or after the Effective
Date, but in any event not prior to December 9, 2010) in the performance of consulting or other services for Microbot under the
Shoham Agreement or any other agreement entered into between Microbot and Prof. Shoham pursuant to Section 2.7 or in the performance
of duties as a member of the scientific advisory board of Microbot during periods in which Prof. Shoham is employed by the Technion,
other than Joint Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Shoham
Patent Rights</B>&rdquo; means any patents and patent applications claiming a Shoham Invention, in each case solely with respect
to those claims claiming a Shoham Invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Sublicense</B>&rdquo;
means (a) any license or option to license granted by Microbot to a third party under any of the Licensed Technology, other than
licenses granted by Microbot to an Affiliate thereof or other contractor solely in order to enable such Affiliate or other contractor
to perform work on Microbot&rsquo;s behalf as described in Section 3.2 and (b) any further sublicense granted under Section 3.3.2.6
by a third party granted a Sublicense from Microbot described in clause (a) to another third party under such Licensed Technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Sublicense
Income</B>&rdquo; means any payments or other consideration that Microbot or any of its Affiliates receives in connection with
and as consideration for a Sublicense (including, but not limited to, upfront payments, milestones and royalties on sales), but
specifically excluding: (a) reimbursement for out-of-pocket expenses incurred by Microbot with respect to Licensed Patent Rights
(including amounts reimbursed under Section 7.2) for which Microbot has not previously been reimbursed; (b) amounts received from
a Sublicensee to cover reasonable, fully burdened, bona fide costs to be incurred by Microbot or its Affiliate in the performance
of research or development activities under a Sublicense agreement in connection with a Licensed Product or a product expected
to become a Licensed Product; (c) equity investments in Microbot made at arm&rsquo;s length to the extent such investments represent
fair market value taking into consideration reasonable premiums due to the strategic relationship (amount above such fair market
value will be deemed Sublicense Income); and (d) amounts received, during a period of no more than 12 months following first payment
on account of such amounts, from a Sublicensee that are ear-marked to cover reasonable, bona fide, fully-burdened costs to be
incurred by Microbot or its Affiliate in the performance of market education, marketing, clinical and/or other promotional activities
relating to the sale of Licensed Products, as set forth in budgets that are part of the Sublicense agreement. In the event that
Microbot or an Affiliate of Microbot receives non-cash consideration in connection with and as consideration for a Sublicense
or in the case of transactions not at arm&rsquo;s length, Sublicense Income shall be calculated based on the fair market value
of such consideration or transaction, at the time of the transaction, assuming an arm&rsquo;s length transaction made in the ordinary
course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Sublicensee</B>&rdquo;
means any person or entity granted a Sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>TipCat
Patent Rights</B>&rdquo; means (a) the patents and patent applications listed in Exhibit E (including the PCT application and/or
the US utility applications claiming priority to such application and filed at the one year conversion date of such applications);
(b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination,
substitution or extension of any patent application identified in (a); (c) any patents issuing on any patent application identified
in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part
application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled
to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents
or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application
identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, any other
patent term extensions and exclusivity periods and the like of any patents and patent applications identified in (a) through (e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>TRDF
Patent Rights</B>&rdquo; means the TipCat Patent Rights, and the Virob Patent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Valid
Claim</B>&rdquo; means: (a) a claim of an issued and unexpired patent within the Licensed Patent Rights that has not been (i)
held permanently revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, (ii) rendered unenforceable through disclaimer or otherwise, (iii)
abandoned or (iv) permanently lost through an interference or opposition proceeding without any right of appeal or review; or
(b) a pending claim of a pending patent application within the Licensed Patent Rights that (i) has been asserted and continues
to be prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refilling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Virob
Patent Rights</B>&rdquo; (a) the patents and patent applications listed in Exhibit F (including the PCT application and/or the
US utility application claiming priority to such applications and filed at the one year conversion date of such applications)
and Self-Cleaning Shunt Patent Rights; (b) any patent or patent application that claims priority to and is a divisional, continuation,
reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any patents issuing
on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions
thereof; (d) any claim of a continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions
or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described
in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs)
of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary
protection certificates, any other patent term extensions and exclusivity periods and the like of any patents and patent applications
identified in (a) through (e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right
and Title.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>TRDF
shall own all right, title and interest in and to the TRDF Patent Rights, Shoham Inventions and the Shoham Patent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>TRDF
and Microbot shall own jointly the entire right, title and interest in and to all Joint Inventions and Joint Patent Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>All
determinations of inventorship under this Agreement shall be made in accordance with United States patent law. In case of dispute
over inventorship, a mutually acceptable outside patent counsel shall make the determination of the inventor(s) by applying the
standards contained in United States patent law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Prof.
Shoham shall disclose to Microbot and TRDF in a confidential writing the development, making, conception or reduction to practice
of any Shoham Invention and Joint Invention, promptly after he becomes aware thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Microbot
shall disclose to TRDF in a confidential writing the development, making, conception or reduction to practice of any Shoham Invention
and Joint Invention promptly after it becomes aware thereof</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>TRDF
shall disclose to Microbot in a confidential writing the development, making, conception or reduction to practice of any Shoham
Invention and Joint Invention promptly after it becomes aware thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Prof.
Shoham shall enter into a agreement with Microbot, in the form attached hereto as Exhibit G (the &ldquo;Shoham Agreement&rdquo;).
Such Shoham Agreement shall be consistent with and subordinate to the provisions of this Section 2, and shall require the Inventor
to assign his rights in Shoham Inventions and Joint Inventions in a manner consistent with the provisions of this Section 2 and
shall allow Prof. Shoham to make the disclosures contemplated by Section 2. In the case of any discrepancy between Section 2 of
this Agreement and the Shoham Agreement, the terms of this Agreement shall prevail. So long as Professor Shoham remains a faculty
member of the Technion, any amendment to the Shoham Agreement and any new agreement between Professor Shoham and Microbot pursuant
to which Professor Shoham provides services and/or serves on the scientific advisory board of Microbot shall require the prior
written approval of TRDF. The aforesaid does not derogate from any rights TRDF may have with respect to any intellectual property
and/or inventions which may be conceived or developed by Professor Shoham that are neither Shoham Inventions nor Joint Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License
Grants</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License</B>.
Subject to the terms and conditions set forth in this Agreement, TRDF hereby grants to Microbot an exclusive, worldwide, royalty-bearing,
sub-licensable license under the Licensed Patent Rights (including under Rambam&rsquo;s interest in the Self Cleaning Patent Rights),
Shoham Inventions and Shoham Patent Rights and TRDF&rsquo;s interest in Joint Inventions and Joint Patent Rights for the sole
purpose of researching, developing, manufacturing, using, offering for sale and selling Licensed Products; provided, however,
that TRDF reserves the right, for itself and the Technion only, to practice the Licensed Technology and for Rambam to practice
the Self Cleaning Shunt Patent Rights, in each case solely for internal research, teaching and other educational purposes and
not for the purpose of commercial manufacture, distribution or provision of services for a fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliates
and Contractors</B>. Without derogating in any way from Microbot&rsquo;s right to grant Sublicenses to Affiliates under Section
3.3, the license granted to Microbot under Section 3.1 includes the right to have some or all of Microbot&rsquo;s rights under
Section 3.1 exercised or performed by one or more of Microbot&rsquo;s Affiliates and/or by contractors on Microbot&rsquo;s behalf
for Microbot&rsquo;s benefit without such right being deemed a Sublicense; provided, however, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>no
such Affiliate or contractor shall be entitled to grant a Sublicense to any third party; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>any
act or omission taken or made by an Affiliate or contractor of Microbot under the rights granted pursuant to this Section 3.2
will be deemed an act or omission by Microbot under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicenses</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicense
Grant</B>. Microbot shall be entitled to grant Sublicenses under the license granted pursuant to Sections 3.1 and 3.2 subject
to the terms of this Section 3.3. Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent
with the terms of this Agreement. Such Sublicenses shall be made only for consideration and in bona-fide arm&rsquo;s length transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicense
Agreements</B>. Sublicenses shall be granted only pursuant to written agreements, which shall be subject and subordinate to the
terms and conditions of this Agreement. Such Sublicense agreements shall contain, among other things, provisions to the following
effect:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>all
provisions necessary to ensure Microbot&rsquo;s ability to perform its obligations under this Agreement as they relate to such
Sublicense;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
provision comparable to Section 6.2 permitting an auditor appointed by Microbot to audit the Sublicensee&rsquo;s records;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
section substantially the same as Article 10 (Indemnification), which also shall state that the Indemnitees (as defined in Section
10.1) are intended third party beneficiaries of such Sublicense agreement for the purpose of enforcing such indemnification;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
provision stating that if the Sublicensee commences a legal action in which it challenges the validity of any of the TRDF Patent
Rights, then Microbot may terminate the Sublicense agreement specifically with respect to that entire specific family of TRDF
Patent Right which are being challenged, in whole or in part, by Sublicensee in such action (being either the entire family of
Virob Patent Rights (excluding the Self-Cleaning Shunt Patent Rights), Self-Cleaning Shunt Patent Rights, and/or TipCat Patent
Rights, as applicable), immediately upon written notice to Sublicensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
provision clarifying that, in the event of termination of the license set forth in Section 3.1 (in whole or in part (e.g., termination
in a particular country)), any existing Sublicense agreement shall terminate to the extent of such terminated license, subject
to TRDF&rsquo;s obligations under Section 11.3.1 to grant a direct license to the Sublicensee if the conditions set forth in Section
11.3.1 are met;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.2.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>unless
TRDF agrees otherwise pursuant to this Section 3.3.2.6, a provision prohibiting the Sublicensee from sublicensing its rights under
such Sublicense agreement. Microbot may, subject to TRDF&rsquo;s prior written consent that will not unreasonably be withheld,
include in the proposed Sublicense agreement a provision entitling the proposed Sublicensee to grant further Sublicenses, provided
however that sublicensees of such Sublicensee shall be prohibited from further sublicensing their rights under such sublicense
agreements without TRDF&rsquo;s prior written consent. If TRDF decides to reject Microbot&rsquo;s request to include such a provision,
TRDF shall provide Microbot with written notice of such rejection within twenty-one (21) days of receipt of Microbot&rsquo;s request,
which notice shall be accompanied by TRDF&rsquo;s written explanation for such rejection. If TRDF does not provide such notice
within such twenty-one (21) day period, TRDF shall be deemed to have agreed to Microbot&rsquo;s request and Microbot shall be
entitled to include provisions entitling the proposed Sublicensee to grant further Sublicenses. Any further Sublicenses will only
be made in accordance with the provisions of this Section 3.3; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
of Sublicense Agreement</B>. Microbot shall furnish TRDF with a copy of any such Sublicense agreement, and any amendments thereto,
(including any Sublicense agreement pursuant to which a Sublicensee grants a further Sublicense pursuant to Section 3.3.2.6) to
TRDF within sixty (60) days after execution thereof. Microbot may redact from such copies any technical information Microbot deems
confidential that does not affect the obligations of Microbot under this Agreement or TRDF&rsquo;s ability to monitor Microbot&rsquo;s
compliance with its obligations under this Agreement. TRDF shall keep any such copies of Sublicense agreements in its confidential
files, shall not disclose such agreements or the contents thereof to any third party (except auditors or legal advisors of TRDF
for the purpose set forth below), and shall use them solely for the purpose of monitoring Microbot&rsquo;s, its Affiliates&rsquo;
and Sublicensees&rsquo; compliance with their obligations and enforcing TRDF&rsquo;s rights under this Agreement. For clarity,
the full un-redacted versions of Sublicense agreements will be made available to the auditor appointed by TRDF in the case of
an audit performed in accordance with Section 6.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Enforcement
of Rights Under Sublicense Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Breach
by Sublicensee</B>. In the case of any act or omission by any Sublicensee that would have constituted a breach of this Agreement
by Microbot entitling TRDF to terminate this Agreement had it been the act or omission of Microbot hereunder, Microbot will notify
TRDF of such act or omission promptly after Microbot is informed thereof. Microbot and TRDF will discuss possible courses of action,
including, if necessary, terminating such Sublicense agreement in accordance with the terms thereof if the breach is not cured
within sixty (60) days. If such breach is not cured within such period and TRDF requests Microbot to terminate such Sublicense
agreement, Microbot will do so. Any Sublicense agreement between Microbot and a Sublicensee will include Microbot&rsquo;s right
to terminate the Sublicense agreement in case of such a breach by the Sublicensee. For clarity, if Microbot complies with the
terms of this Section 3.3.4.1, TRDF will not have the right to terminate this Agreement on account of such breach by such Sublicensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Challenge
of TRDF Patent Rights</B>. If a Sublicensee commences a legal action in which it challenges the validity of any of the TRDF Patent
Rights, Microbot will notify TRDF of such challenge promptly after Microbot is informed thereof. Microbot and TRDF will discuss
possible courses of action, including, if necessary, terminating the Sublicense agreement specifically with respect to that entire
specific family of TRDF Patent Rights which are being challenged, in whole or in part, by Sublicensee in such action (being either
the entire family of Virob Patent Rights (excluding the Self-Cleaning Shunt Patent Rights), Self-Cleaning Shunt Patent Rights
and/or TipCat Patent Rights, as applicable), If such challenge is not withdrawn within sixty days following such notice and TRDF
requests Microbot to terminate such Sublicense agreement with respect to the specific family of Patent Rights which are being
challenged, in whole or in part, Microbot will do so. For clarity, if Microbot complies with the terms of this Section 3,3.4.2,
TRDF will not have the right to terminate any part of this Agreement on account of challenge by such Sublicensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRDF
Consent</B>. Notwithstanding anything else to the contrary in this Agreement and without derogating from the provisions of Section
33.2 above, until achievement of Qualified Financing (as defined below) by Microbot, no Sublicense shall be granted under this
Agreement without the prior written consent of TRDF thereto. For clarity, a Sublicense agreement pursuant to which the Sublicensee
has an unconditional obligation to pay Microbot, within ninety days of the date of execution of such Sublicense Agreement amounts
that are sufficient to cause Microbot to achieve the Qualified Financing threshold shall be deemed to have been granted after
achievement of the Qualified Financing and Microbot will not be required to obtain TRDF&rsquo;s prior written consent with respect
thereto. For clarity, Microbot will not be required to obtain TRDF&rsquo;s prior written consent for the grant to a third party
of a right to negotiate for a Sublicense, if such grant does not provide such third party with the right to exercise such option
into an actual license/sublicense without such negotiation and mutual agreement to the terms of a license/sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Microbot&rsquo;s
Obligations under this Agreement</B>. Microbot shall remain fully liable for the performance of its and its Affiliate&rsquo;s
and subcontractor&rsquo;s obligations under this Agreement and no Sublicense shall relieve Microbot of any of its obligations
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Other Grant of Rights</B>. Other than as specifically set forth in Subsections 3.2 and 3.3 above and Section 8 below, Microbot
shall not be entitled to grant, directly or indirectly, to any person or entity any rights under the rights granted to Microbot
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Improvements</B>.
TRDF shall promptly provide Microbot with written notice of the filing of any patent application disclosing or claiming an Improvement
(each, an &ldquo;Improvement Notice&rdquo;) that is filed at any time prior to the third anniversary of the Effective Date. Microbot
will have ninety (90) days from the date of its receipt of an Improvement Notice to request in writing a license under any Improvement
Patent Rights relating to such Improvement. If Microbot notifies TRDF that it wishes such Improvement Patent Rights to be included
in this Agreement, this Agreement shall be amended to include such Improvement Patent Rights in the definition of Licensed Patent
Rights. The financial terms of this Agreement (e.g. royalty payments and payments on account of Sublicense Income) will apply
to the amended license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development
and Commercialization</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diligence</B>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Microbot
shall use commercially reasonable efforts, including funding consistent therewith, and/or shall cause its Affiliates or Sublicensees
to use commercially reasonable efforts, including funding consistent therewith, (a) to develop Licensed Products in accordance
with the Development Plan; (b) to introduce Licensed Products into the commercial market; and (c) to market Licensed Products
following such introduction into the market. In addition, Microbot, by itself or through its Affiliates or Sublicensees, shall
achieve each of the Development Milestones within the time periods specified in Exhibit A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Modification
of Development Plan</B>. Microbot may make, from time to time, such adjustments to the then applicable Development Plan as Microbot
believes, in its good faith judgment, are needed or desirable in order to ensure Microbot&rsquo;s ability to achieve the Development
Milestones. Notwithstanding the aforesaid, Microbot shall not be entitled to change the Development Milestones or the time frames
for achieving the Development Milestones without the prior written consent of TRDF thereto, except in accordance with the provisions
of Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Review
Meetings</B>. Until such time as Microbot has achieved all Development Milestones, at TRDF&rsquo;s request, not more than once
per calendar quarter, a Microbot senior officer, Prof. Shoham, and a TRDF representative shall conduct review meetings (which
may be in person, by video conference and/or by teleconference) (a) to review the progress being made under the Development Plan
and the progress being made in any other research and development activities conducted by Microbot or on its behalf and relating
to the Licensed Technology and (b) to review the progress and efforts being made towards accomplishing the Development Milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting</B>.
Within sixty (60) days after (a) the end of each six-month period prior to the achievement of all Development Milestones and (b)
the end of each calendar year after the achievement of all Development Milestones, Microbot shall furnish TRDF with a written
report summarizing its, its Affiliates&rsquo; and its Sublicensees&rsquo; efforts during the prior six-month or one-year period,
as applicable, to develop and commercialize Licensed Products, including without limitation: (a) research and development activities;
and (b) commercialization efforts and results. Each report shall contain a sufficient level of detail for TRDF to assess whether
Microbot is in compliance with its obligations under Section 4.1 and a discussion of intended efforts for the then forthcoming
year. Together with each report, Microbot shall provide TRDF with a copy of the then current Development Plan. In addition, prior
to the attainment of the Funding Threshold (as defined in Section 5.1.1.4) and of the Qualified Financing (as defined in Section
11.2.4), such report will set forth funding received by Microbot through the end of the period covered by such report that qualifies
for purposes of achievement of the Funding Threshold or of the Qualified Financing. The first report shall refer to the period
ending December 31, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Failure
to Meet Development Milestone</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
Microbot fails to meet the Development Milestone(s) within the timetable set forth therefore, TRDF will be entitled to terminate
the license granted under Section 3 with respect to the Virob Patent Rights (if the failure relates to a Virob Development Milestone)
or the TipCat Patent Rights (if the failure relates to a Tipcat Milestone), as applicable. For clarity, if TRDF exercises such
option to terminate the license with respect to the Virob Patent Rights or Tipcat Patent Rights, as applicable, this Agreement
shall not be terminated in its entirety; instead, such patent rights with respect to which Microbot failed to meet the Development
Milestone (i.e. Virob Patent Rights or Tipcat Patent Rights, as applicable) shall be removed from the definition of TRDF Patent
Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>TRDF&rsquo;s
rights under this Section 4.5 shall be TRDF&rsquo;s sole and exclusive remedy in respect of Microbot&rsquo;s failure to meet its
obligations with respect to Development Milestones, and Microbot shall have no further liability in respect of its failure to
meet its obligations with respect to Development Milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration
for Grant of License</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
Consideration</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definition</B>s.
For the purpose of this section, the following terms shall have the following definitions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Additional
Securities</B>&rdquo; means shares of capital, convertible securities, warrants, options or other rights to subscribe for, purchase
or acquire from Microbot any shares of Microbot, other than Excluded Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Excluded
Securities</B>&rdquo; means:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
shares or options granted to employees or consultants of Microbot pursuant to an incentive plan and any shares issuable upon exercise
of any such options constituting in the aggregate no more than twenty percent (20%) of Microbot&rsquo;s share capital on a fully
diluted basis immediately following the grant of the Initial License Shares; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
shares issued to shareholders of the Company, on a pro rata basis, in connection with a reorganization of Company&rsquo;s capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>&ldquo;<B>Fully Diluted Basis</B>&rdquo; means, as of a specified date, the number of ordinary shares of Microbot then outstanding
(assuming conversion of all outstanding shares other than ordinary shares into ordinary shares) plus the number of ordinary shares
of Microbot issuable upon exercise or conversion of then outstanding convertible securities, options, rights or warrants of Microbot
(which shall be determined without regard to whether such securities are then vested, exercisable or convertible), but excluding
Excluded Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>Funding
Threshold</B>&rdquo; means total funding of three (3) million U.S. Dollars ($3,000,000) from any source, including, without limitation,
equity investments, convertible loans, grants, sponsored research and revenues, obtained by Microbot since its formation, provided
that at least $2,500,000 of such amount must be in funding that (a) is not earmarked specifically for research involving a technology
platform that would not lead to Licensed Products and (b) does not provide the funder rights in intellectual property rights owned
or in-licensed by Microbot, other than reasonable, time-limited rights to negotiate a license agreement with respect to such intellectual
property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B>License
Shares</B>&rdquo; means the Initial License Shares (as defined in Section 5.1.2) and any additional shares that may be granted
to TRDF in accordance with Section 5,1.4, but excluding those shares held by TRDF constituting 28% of Microbot&rsquo;s issued
share capital, as reflected in the Cap Table.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial
Grant</B>. As partial consideration for the licenses granted hereunder, within thirty (30) days following the Effective Date,
Microbot shall issue to TRDF 135,000 Ordinary Shares of Microbot (representing three percent (3%) of the issued and outstanding
shares of Microbot, on a Fully Diluted Basis, immediately following such issuance) (collectively, the &ldquo;Initial License Shares&rdquo;)
and shall provide TRDF no later than such time a share certificate and an updated shareholder registrar, evidencing such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Warranties</B>. Microbot hereby represents and warrants to TRDF that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
capitalization table attached hereto as Exhibit H (the &ldquo;Cap Table&rdquo;) sets forth all of the outstanding capital of Microbot
on a Fully-Diluted Basis as of the Effective Date, including the shares issued to Technion on account of Professor Shoham&rsquo;s
involvement as a founder of Microbot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>other
than as set forth in the Cap Table and except for the preemptive rights and rights of first refusal under the Articles, as of
the Effective Date, there are no outstanding shares, convertible securities, outstanding warrants, options or other rights to
subscribe for, purchase or acquire from Microbot any shares of Microbot and there are no contracts or binding commitments providing
for the issuance of, or the granting of rights (including, without limitation, conversion rights, preemptive rights, anti-dilution
rights, and rights of first refusal) to acquire, any shares of Microbot or under which Microbot is, or may become, obligated to
issue any of its securities; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
License Shares shall, upon such issuance pursuant to the terms hereof, be duly authorized, validly issued, fully paid and nonassessable,
and will be free of all taxes, liens, charges, encumbrances, or other third-party rights, and restrictions on transfer, except
as set forth in Microbot&rsquo;s Articles of Association and applicable law, and will have the rights, preferences, privileges,
and restrictions set forth in the Articles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>as
of the Effective Date, the Articles of Association of Microbot are in the form attached hereto as Exhibit I.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Dilution</B>.
If, at any time, prior to the achievement of the Funding Threshold, Microbot issues Additional Securities that would cause the
License Shares to represent less than three percent (3%) of Microbot&rsquo;s outstanding shares on a Fully-Diluted Basis, Microbot
shall issue TRDF additional Ordinary Shares such that the License Shares shall represent three percent (3%) of the outstanding
shares of Microbot, on a Fully Diluted Basis, as calculated after giving effect to the anti-dilutive issuance. Any issuances of
such additional shares shall be in partial consideration for the licenses granted under the Agreement and TRDF shall not be required
to pay any further consideration for such shares. Such issuances shall continue until such time as Microbot has achieved the Funding
Threshold. For the avoidance of doubt, if any funding round achieves and supersedes the Funding Threshold, then TRDF shall be
entitled to anti-dilutive issuance as aforesaid with respect to such part of the funding that satisfies the Funding Threshold,
but will not be entitled to any anti-dilutive issuances with respect to amounts in excess of the Funding Threshold. In addition
and without derogating from the aforesaid or from any preemptive right to which TRDF may be entitled, for so long as the above
anti-dilution right is in effect, TRDF shall have the right to participate in any future round of investment and to purchase in
such round shares of Microbot, of the type issued in the framework of such round (and at the same price per share), in an amount
as shall be required to maintain TRDFs 3% ownership in License Shares, on a Fully Diluted Basis, or in any lesser amount as shall
be determined by TRDF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right
to Appoint an Observer</B>. Until achievement of the Funding Threshold, TRDF shall be entitled to designate one observer (&ldquo;Observer&rdquo;)
to attend all meetings of Microbot&rsquo;s Board of Directors, or any committees thereof, in a nonvoting observer capacity. Microbot
reserves the right to, and may exclude the Observer from any Board of Directors meeting or portion thereof if (a) the Board of
Directors determines, in its reasonable discretion, that attendance by the Observer could conflict with the Board of Director&rsquo;s
fiduciary obligations to Microbot or, (b) in the judgment of the Microbot&rsquo;s counsel, attendance by the Observer could adversely
affect the attorney-client privilege between Microbot and its counsel or (c) the Board of Directors determines, in its reasonable
discretion, that attendance by the Observer could place the Observer in a conflict of interest with Microbot. The Observer shall
be given copies of all notices, minutes, and consents of Microbot&rsquo;s Board of Directors meetings, and other materials that
are provided to the members of the Board of Directors of Microbot in connection with Board of Directors Meetings; provided that
Microbot may redact from any such material information that (a) in the judgment of the Microbot&rsquo;s counsel could adversely
effect the attorney-client privilege between Microbot and its counsel or (b) could place the Observer in a conflict of interest
with Microbot. The Observer shall sign a confidentiality agreement, in a form reasonably acceptable to Microbot, to cover information
distributed to Observer and information disclosed in Microbot&rsquo;s Board of Directors&rsquo; meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
Sales</B>. As partial consideration for the license granted hereunder, Microbot shall pay TRDF the following royalties, subject
to Sections 5.2.3 and 5.3:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>an
amount equal to three percent (3%) of Net Sales, if the Licensed Product sold is covered by a Valid Claim in the country in which
such Licensed Product is made and/or in the country in which such Licensed Product is sold; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>an
amount equal to one and a half percent (1.5%) of Net Sales, if the Licensed Product is not covered by a Valid Claim in the country
in which such Licensed Product is made and is not covered by a Valid Claim in the country in which such Licensed Product is sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicense
Income</B>. As partial consideration for the licenses granted hereunder, Microbot shall pay TRDF the following royalties on all
Sublicense Income, subject to Sections 5.2.3 and 5.3:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
the Sublicense is granted before the earlier of (a) first testing on human in a clinical trial and (b) the receipt of approval
in the case of a 510K route that does not require clinical studies, Microbot shall pay an amount equal to twenty percent (20%)
of all Sublicense Income with respect to such Sublicense;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
the Sublicense is granted (a) after first in human, but before regulatory approval in the case of a PMA or de novo 510K (i.e.
requiring clinical studies) route or (b) after regulatory approval in the case of a 510K route that does not require clinical
trials, Microbot shall pay an amount equal to fifteen percent (15%) of all Sublicense Income with respect to such Sublicense;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
the Sublicense is granted after regulatory approval in the case of a PMA or a de novo 510K (i.e. requiring clinical studies) route,
Microbot shall pay an amount equal to twelve percent (12%) of all Sublicense Income with respect to such Sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Notwithstanding
the foregoing, if (i) a Licensed Product is not covered by a Valid Claim within the TRDF Patent Rights or (ii) a Sublicense does
not include a sublicense under the TRDF Patent Rights, the royalty rates set forth in Sections 5.2.1 and 5.2.2 above will be reduced
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>if
(i) the Licensed Product is covered by a Valid Claim within the Shoham Patent Rights or (ii) the Sublicense includes a sublicense
under the Shoham Patent Rights, the royalty rate set forth in Sections 5.2.1 or 5.2.2, as applicable, will be reduced by thirty-three
percent (33%); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.2.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>if
(1) the Licensed Product is not covered by a Valid Claim within the Shoham Patent Rights or (ii) the Sublicense does not include
a sublicense under the Shoham Patent Rights, the royalty rate set forth in Sections 5.2.1 or 5.2.2, as applicable, will be reduced
by sixty-seven percent (67%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Royalties</B>. If, after arm&rsquo;s length negotiations, Microbot enters into a license agreement with an unaffiliated
third party for the license of intellectual property rights that Microbot reasonably believes (based on discussions with Microbot&rsquo;s
patent lawyer) are needed for the making, using or selling of a Licensed Product with respect to which royalties are due pursuant
to Section 5.2 or that may be subject to a Sublicense agreement with respect to which royalties are due pursuant to Section 5.2,
Microbot will be entitled to offset 50% of any amounts paid under such license agreement with respect to such Licensed Products
or Sublicense against royalty payments that are due under Section 5.2; provided that in no event shall any royalty payments to
TRDF be reduced by more than fifty percent (50%) of the amount otherwise due under Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports;
Payments; Records</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports
and Payments</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports</B>.
Within forty five (45) days after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in which
Net Sales are generated or Sublicense Income is received, Microbot shall deliver to TRDF a report containing the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
number of units of Licensed Products sold, leased or otherwise transferred by Microbot and its Affiliates for the applicable Calendar
Quarter, separately itemized according to the Licensed Product and type of License Technology to which such Licensed Product is
subject, country by country break down;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
gross amounts and other consideration received, billed or invoiced by Microbot and its Affiliates for Licensed Products sold,
leased or otherwise transferred or provided by Microbot and its Affiliates during the applicable Calendar Quarter;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
calculation of Net Sales for the applicable Calendar Quarter, separately itemized according to the Licensed Product and type of
License Technology to which such Licensed Product is subject, country by country and selling</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entity
break down, and including an itemized listing of applicable deductions and a calculation of the amount payable to TRDF thereon;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
detailed accounting of all Sublicense Income received during the applicable Calendar Quarter, including an explanation of the
basis for such Sublicense Income; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.1.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
total amount payable to TRDF in U.S. Dollars on Net Sales and Sublicense Income for the applicable Calendar Quarter, together
with the exchange rates used for conversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
such report shall be certified by a senior officer of Microbot on behalf of Microbot (or of the division that is responsible for
Licensed Products in the event Microbot or its assets are sold to a multi-national corporation) as true, correct and complete
in all material respects. If no amounts are due to TRDF for a particular Calendar Quarter, the report shall so state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment</B>.
Within forty five (45) days after the end of each Calendar Quarter, Microbot shall pay TRDF all amounts due with respect to Net
Sales and Sublicense Income for the applicable Calendar Quarter, against receipt of a valid VAT invoice/receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
Currency</B>. All payments due under this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S. Dollars
will be made at the conversion rate existing in the United States (as reported in the Wall Street Journal) on the last working
day of the applicable Calendar Quarter. Such payments will be without deduction of exchange, collection or other charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records</B>.
Microbot shall maintain, shall cause its Affiliates to maintain and shall ensure that Sublicensees agree to maintain, complete
and accurate records of Licensed Products that are made, used, sold, leased or otherwise transferred under this Agreement, any
amounts payable to TRDF in relation to such Licensed Products, and all Sublicense Income received by Microbot and its Affiliates,
which records shall include sufficient information to permit TRDF to confirm the accuracy of any reports or notifications delivered
to TRDF under Section 6.1. Microbot and/or its Affiliates and/or its Sublicensees, as applicable, shall retain such records relating
to a given Calendar Quarter for at least three (3) years after the conclusion of that Calendar Quarter, during which time TRDF
shall have the right, at its expense, to cause an independent, certified public accountant (or, in the event of a non-financial
audit, other appropriate auditor) to inspect such records of Microbot and its Affiliates during normal business hours for the
purposes of verifying the accuracy of any reports and payments delivered under this Agreement and Microbot&rsquo;s compliance
with the terms hereof; provided in each case, that such accountant or other auditor, as applicable, signs a confidentiality and
non-use agreement in a form acceptable to Microbot, in its reasonable discretion. Such accountant or other auditor, as applicable,
shall not disclose to TRDF any information other than information relating to the accuracy of reports and payments delivered under
this Agreement. The parties shall reconcile any underpayment or overpayment within thirty (30) days after the accountant delivers
the results of the audit. In the event that any audit performed under this Section 6.2 reveals an underpayment in excess of five
percent (5%) in any calendar year, the audited entity shall bear the full cost of such audit. TRDF may exercise its rights under
this Section 6.2 only once every year per audited entity and only with reasonable prior notice to the audited entity. With respect
to Sublicensees, TRDF may request such an audit be conducted for any Sublicensee, in which event, Microbot shall conduct such
audit, at TRDF&rsquo;s expense, no later than 30 days following such request, pursuant to the terms hereinabove, which shall apply
<I>mutatis mutandis</I> to such audit (including reimbursement of the expense of such audit by the Sublicensee if the audit reveals
an underpayment in excess of 5%), and shall provide TRDF with the results of any such audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late
Payments</B>. Any payments by Microbot that are not paid on or before the date such payments are due under this Agreement shall
bear interest at the rate of eight percent (8%) per annum. Interest shall accrue beginning on the first day following the due
date for payment and shall be compounded quarterly. Payment of such interest by Microbot shall not limit, in any way, TRDF&rsquo;s
right to exercise any other remedies TRDF may have as a consequence of the lateness of any payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
Method</B>. Each payment due to TRDF under this Agreement shall be paid by check or wire transfer of funds to TRDF&rsquo;s account
in accordance with written instructions provided by TRDF. If made by wire transfer, such payments shall be marked so as to refer
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VAT;
Withholding Taxes</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>All
amounts to be paid to TRDF pursuant to this Agreement are exclusive of value added tax. Microbot shall add value added tax, if
and to the extent required by law, to all such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
Microbot is required to withhold any amounts payable hereunder to TRDF due to the applicable laws of any country, and unless TRDF
provides Microbot an authorization from the relevant tax authorities not to do so, such amount will be deducted from the payment
to be made by Microbot and remitted to the appropriate taxing authority for the benefit of TRDF. Microbot will withhold only such
amounts as are required to be withheld by applicable law in the country from which payment is being made. Microbot shall submit
to TRDF originals of the remittance voucher and the official receipt evidencing the payment of the corresponding taxes with the
applicable royalty report. Microbot will cooperate with TRDF to provide such information and records as TRDF may require in connection
with any application by TRDF to the tax authorities in any country, including attempt to obtain an exemption or a credit for any
withholding tax paid in any country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent
Filing, Prosecution and Maintenance</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRDF
Patent Rights</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control</B>.
TRDF shall be responsible for the preparation, filing, prosecution, protection and maintenance of all TRDF Patent Rights. TRDF
shall: (a) use independent patent counsel reasonably acceptable to Microbot; (b) instruct such patent counsel to furnish Microbot
with copies of all material correspondence relating to the TRDF Patent Rights from the United States Patent and Trademark Office
(USPTO) and any other patent office, as well as copies of all material proposed responses to such correspondence in time for Microbot
to review and comment on each such response; (c) give Microbot an opportunity to review and comment on the text of each patent
application within the TRDF Patent Rights before filing; (d) supply Microbot with a copy of such application as filed, together
with notice of its filing date and serial number; and (e) at Microbot&rsquo;s request, keep Microbot advised of the status of
actual and prospective patent filings within the TRDF Patent Rights. At Microbot&rsquo;s request, TRDF shall give Microbot the
opportunity to provide comments on and make requests of TRDF concerning the preparation, filing, prosecution, protection and maintenance
of the TRDF Patent Rights, and shall consider such comments and requests in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses</B>.
Subject to Section 7.1.3, Microbot will pay for all out-of-pocket expenses incurred by TRDF following the Effective Date in the
preparation, filing, prosecution, protection and maintenance of the Patent Rights under Section 7.1.1, within thirty (30) days
after the date of each invoice from TRDF for such expenses. In addition, Microbot shall pay TRDF a total of $102,000 as reimbursement
for all documented, out-of-pocket expenses incurred by TRDF prior to the execution of this Agreement with respect to the preparation,
filing, prosecution, protection and maintenance of TRDF Patent Rights, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>$12,500
within six months following the Effective Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>$18,700
within twelve months following the Effective Date; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>$70,800
within twenty-four months following the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.1.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abandonment</B>.
If Microbot decides that it does not wish to pay for the preparation, filing, prosecution, protection or maintenance of any TRDF
Patent Rights in a particular country (&ldquo;<B>Abandoned Patent Rights</B>&rdquo;), Microbot shall provide TRDF with prompt
written notice of such election, specifying the country(ies) with respect to which it shall no longer pay for such Abandoned Patent
Rights. Upon receipt of such notice by TRDF, Microbot shall be released from its obligation to reimburse TRDF for the expenses
incurred thereafter as to such Abandoned Patent Rights; provided, however, that expenses authorized prior to the receipt by TRDF
of such notice shall be deemed incurred prior to the notice. In such event, any license granted by TRDF to Microbot hereunder
with respect to such Abandoned Patent Rights will terminate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shoham
Patent Rights and Joint Patent Rights</B>. Microbot shall be responsible, at its discretion and expense, for the preparation,
filing, prosecution, protection and maintenance of all Shoham Patent Rights and Joint Patent Rights. Microbot shall: (a) instruct
patent counsel to furnish TRDF with copies of all material correspondence relating to the Shoham Patent Rights or Joint Patent
Rights from the United States Patent and Trademark Office (USPTO) and any other patent office, as well as copies of all material
proposed responses to such correspondence in time for TRDF to review and comment on each such response; (b) give TRDF an opportunity
to review and comment on the text of each patent application within the Shoham Patent Rights or Joint Patent Rights before filing;
(c) supply TRDF with a copy of each such application as filed, together with notice of its filing date and serial number; and
(d) at TRDF&rsquo;s request, keep TRDF advised of the status of actual and prospective patent filings within the Shoham Patent
Rights or Joint Patent Rights. At TRDF&rsquo;s request, Microbot shall give TRDF the opportunity to provide comments on and make
requests of Microbot concerning the preparation, filing, prosecution, protection and maintenance of the Shoham Patent Rights and
Joint Patent Rights, and shall consider such comments and requests in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Microbot does not file, prosecute, protect or maintain any of the Shoham Patent Rights and/or Joint Patent Rights in a particular
country, TRDF may provide Microbot with written notice that it would like to do so at its own cost and expense. Such notice will
include the name the relevant country(ies). TRDF will be entitled to take over such filing, prosecution, protection or maintenance
of such Shoham Patent Rights and/or Joint Patent Rights in such country, unless Microbot provides TRDF within 90 days of receipt
of such written notice from TRDF with written notice that Microbot either (a) intends to take such action on its own behalf and
provided that Microbot takes substantial action to that effect within twelve (12) months of such notice from Microbot, or (b)
intends to protect such rights as trade secrets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Patent Rights</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice</B>.
In the event either party becomes aware of any possible or actual infringement of any of the Licensed Patent Rights (an &ldquo;<B>Infringement</B>&rdquo;),
that party shall promptly notify the other party in writing and provide it with details regarding such Infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Suit
by Microbot</B>. Microbot shall have the first right, but not the obligation, to take action in the prosecution, prevention, or
termination of any Infringement. Before Microbot commences an action with respect to any Infringement, Microbot shall consider
in good faith the views of TRDF and potential effects on the public interest in making its decision whether to sue. Should Microbot
elect to bring suit against an infringer, Microbot shall keep TRDF reasonably informed of the progress of the action and shall
give TRDF a reasonable opportunity in advance to consult with Microbot and offer its views about major decisions affecting the
litigation. Microbot shall give careful consideration to those views, but shall have the right to control the action; provided,
however, that if Microbot fails to defend in good faith the validity and/or enforceability of TRDF Patent Rights in the action,
or if Microbot&rsquo;s license to TRDF Patent Rights in the suit terminates, TRDF may elect to take control of the action pursuant
to Section 83. Should Microbot elect to bring suit against an infringer and TRDF is joined as party plaintiff in any such suit,
TRDF shall have the right to approve the counsel selected by Microbot to represent Microbot and TRDF, such approval not to be
unreasonably withheld. The expenses of such suit or suits that Microbot elects to bring, including any expenses of TRDF incurred
in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Microbot and Microbot
shall hold TRDF free, clear and harmless from and against any and all costs of such litigation, including attorney&rsquo;s fees.
Microbot shall not compromise or settle such litigation without the prior written consent of TRDF, which consent shall not be
unreasonably withheld or delayed. In the event Microbot exercises its right to sue pursuant to this Section 8.2, it shall first
reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and
character, including reasonable attorney&rsquo;s fees, necessarily incurred in the prosecution of any such suit. If, after such
reimbursement, any funds shall remain from said recovery, then TRDF shall receive an amount (a) equal to fifteen percent (15%)
of such remaining amounts if the Infringed patent rights are TRDF Patent Rights, (b) equal to ten percent (10%) of such remaining
amounts if the Infringed patent rights are Shoham Patent Rights and (c) equal to five percent (5%) of such amounts if the Infringed
patent rights are Joint Patent Rights. Microbot shall retain any amount remaining after such payment to TRDF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Suit
by TRDF</B>. If Microbot does not take action in the prosecution, prevention, or termination of any Infringement relating to Licensed
Patent Rights pursuant to Section 8.2 above, and has not commenced negotiations with the infringer for the discontinuance of said
Infringement, within ninety (90) days after receipt of notice to Microbot by TRDF of the existence of such Infringement, TRDF
may elect to do so. Should TRDF elect to bring suit against an infringer with respect to such an Infringement and Microbot is
joined as party plaintiff in any such suit, Microbot shall have the right to approve the counsel selected by TRDF to represent
TRDF and Microbot, such approval not to be unreasonably withheld. The expenses of such suit or suits that TRDF elects to bring,
including any expenses of Microbot incurred in conjunction with the prosecution of such suits or the settlement thereof, shall
be paid for entirely by TRDF and TRDF shall hold Microbot free, clear and harmless from and against any and all costs of such
litigation, including attorney&rsquo;s fees. TRDF shall not compromise or settle such litigation without the prior written consent
of Microbot, which consent shall not be unreasonably withheld or delayed. In the event TRDF exercises its right to sue pursuant
to this Section 8.3, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs
and expenses of every kind and character, including reasonable attorney&rsquo;s fees, necessarily incurred in the prosecution
of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Microbot shall receive an amount
(a) equal to fifteen percent (15%) of such remaining amounts if the Infringed patent rights are TRDF Patent Rights, (b) equal
to thirty five percent (35%) of such remaining amounts if the Infringed patent rights are Shoham Patent Rights, (c) and equal
to fifty percent (50%) of such amount if the Infringed patent rights are Joint Patent Rights. TRDF shall retain any amounts remaining
after such payment to Microbot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Own
Counsel</B>. Each party shall always have the right to be represented by counsel of its own selection and at its own expense in
any suit instituted under this Article 8 by the other party for Infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation</B>.
Each party agrees to cooperate fully in any action under this Article 8 that is controlled by the other party, provided that the
controlling party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection
with providing such assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Standing</B>.
If a party lacks standing and the other party has standing to bring any such suit, action or proceeding, then such other party
shall do so at the request of and at the expense of the party that lacks standing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warranties;
Limitation of Liability</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authority</B>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party hereby represents and warrants that it has the power and authority to execute and deliver this Agreement, and to perform
its obligations hereunder, and that the execution, delivery and performance by it of this Agreement and its compliance with the
terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms or provisions of or constitute
a default under: (i) any other right or obligation provided under any other agreement or obligation that it has with any third
party; (ii) the provisions of its charter documents; or (iii) any order, writ, injunction or decree of any court or governmental
authority entered against it or by which any of its property is bound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRDF
Representations and Warranties</B>. TRDF hereby represents, warrants and undertakes to Microbot as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>As
of the Effective Date, all persons listed as inventors on the TRDF Patent Rights, other than Dr. Zaaroor who is listed as one
of the inventors of the Self Cleaning Shunt Patent Rights, have assigned their rights in the inventions described in the TRDF
Patent Rights to TRDF and are required to do so by Technion policies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>TRDF
has not granted and undertakes not to grant during the term hereof any rights that are inconsistent with the rights granted to
Microbot under this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>It
has no actual knowledge, as of the date hereof, of any pending legal suit or proceeding against the Technion or TRDF by a third
party contesting the ownership or validity of the TRDF Patent Rights or claiming that the practice of the inventions claimed in
the TRDF Patent Rights will infringe the rights of a third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Microbot
Representations, Warranties and Covenants</B>. Microbot represents, warrants and covenants that it will comply, and will ensure
that its Affiliates comply, with all local, state, and international laws and regulations relating to the development, manufacture,
use, sale, importation and provision of Licensed Products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclaimer
of Other Warranties</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>NOTHING
CONTAINED HEREIN SHALL BE DEEMED TO BE A WARRANTY BY EITHER PARTY, OR RAMBAM, THAT IT CAN OR WILL BE ABLE TO OBTAIN PA&#9;TENTS
ON PATENT APPLICATIONS INCLUDED IN THE LICENSED PATENT RIGHTS, OR THAT ANY OF THE LICENSED PATENT RIGHTS WILL AFFORD ADEQUATE
OR COMMERCIALLY WORTHWHILE PROTECTION. SPECIFICALLY, AND WITHOUT LIMITING THE FOREGOING, TRDF MAKES NO WARRANTY OR REPRESENTATION
(A) REGARDING THE VALIDITY OR SCOPE OF THE LICENSED PATENT RIGHTS, OR (B) THAT THE EXPLOITATION OF THE LICENSED PATENT RIGHTS
OR ANY LICENSED PRODUCT WILL NOT INFRINGE ANY PATENTS OR OTHER INTELLECTUAL PROPERTY OF ANY THIRD PARTY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>NEITHER
PARTY, NOR RAMBAM, MAKES ANY WARRANTIES WHATSOEVER AS TO THE COMMERCIAL OR SCIENTIFIC VALUE OF THE LICENSED PATENT RIGHTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>EXCEPT
AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY, NOR RAMBAM, MAKES ANY WARRANTY OF ANY KIND, INCLUDING BUT NOT
LIMITED WITH RESPECT TO THE LICENSED PATENT RIGHTS, EXPRESS OR IMPLIED, AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, AND VALIDITY OF PATENT RIGHTS CLAIMS, WHETHER ISSUED OR PENDING, WITH RESPECT TO ANY
AND ALL OF THE FOREGOING.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation
of Liability</B>. Neither party, nor Rambam, will be liable to the other with respect to any subject matter of this Agreement
under any contract, negligence, strict liability or other legal or equitable theory for (a) any indirect, incidental, consequential
or punitive damages or lost profits or (b) cost of procurement of substitute goods, technology or services. In no event shall
TRDF&rsquo;s liability to Microbot exceed an amount equal to the consideration received by TRDF under this Agreement plus the
value of all Company equity issued to TRDF before or after the Effective Date (including amount received from the sale of such
equity).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnity</B>.
Microbot shall indemnify, defend and hold harmless TRDF, the Technion, Rambam and their respective directors, governing board
members, trustees, officers, faculty, professional staff, employees, students, and agents and their respective successors, heirs
and assigns (collectively, the &ldquo;Indemnitees&rdquo;) from and against any liability, damage, loss, cost, expense (including,
without limitation, reasonable attorney&rsquo;s fees and other costs and expenses of litigation), or obligation of any kind or
nature (collectively, &ldquo;Claims&rdquo;), incurred by or imposed upon the Indemnitees or any one of them in connection with
any third party claims, suits, actions, demands, judgments, or other proceedings to the extent resulting, directly or indirectly,
from the exercise of the license granted hereunder, or any use whatsoever of the Licensed Technology by Microbot, its Affiliates
and Sublicensees, including, without limitation, (i) the practice of the licenses granted hereunder by Microbot, its Affiliates,
Sublicensees, or its (or their) customers, (ii) the development, manufacture, testing, handling, storage, transportation, sale
or use or other disposition of any Licensed Product by Microbot, its Affiliates and Sublicensees; (iii) the exploitation or use
by Microbot, its Affiliates, or its Sublicensees of the Licensed Technology or any part thereof, (iv) any representation made
or warranty given by Microbot, its Affiliates or its Sublicensees with respect to Licensed Products or to Licensed Technology
and (v) any infringement claims relating to Licensed Products, except (in each case) to the extent caused by the gross negligence
or willful misconduct of the Indemnitee(s). The foregoing indemnification undertaking shall extend, without limitation, to product
liability claims and damages, and to claims, demands, liabilities, losses, costs and expenses attributed to death, personal injury
or property damage, or to penalties imposed on account of the violation of any law, regulations or governmental requirement, or
any other theory of liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedures</B>.
If any Indemnitee receives notice of any Claim, such Indemnitee shall, as promptly as is reasonably possible, give Microbot notice
of such Claim; provided, however, that failure to give such notice promptly shall only relieve Microbot of any indemnification
obligation it may have hereunder to the extent such failure prejudices the ability of Microbot to respond to or to defend the
Indemnitee against such Claim. TRDF and Microbot shall consult and cooperate with each other regarding the response to and the
defense of any such Claim and Microbot shall, upon its acknowledgment in writing of its obligation to indemnify the Indemnitee,
be entitled to and shall assume the defense or represent the interests of the Indemnitee in respect of such Claim, that shall
include the right to select and direct legal counsel and other consultants to appear in proceedings on behalf of the Indemnitee
and to propose, accept or reject offers of settlement, all at its sole cost; provided, however, that no such settlement shall
be made without the written consent of the Indemnitee, such consent not to be unreasonably withheld. Nothing herein shall prevent
the Indemnitee from retaining its own counsel and participating in its own defense at its own cost and expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</B>.
Beginning with the commencement of clinical trials on human patients using Licensed Product by or on behalf of Microbot, its Affiliate
or a Sublicensee, Microbot shall, at its sole cost and expense, procure and maintain insurance in an amount consistent with industry
standards and which provides adequate coverage to fulfill any potential obligation to the Indemnitees under this Article 10, taking
into consideration, among other things, the nature of the products commercialized. Such insurance shall be obtained from a reputable
insurance company. TRDF, the Technion and, with respect to products covered by the Self Cleaning Shunt Patent Rights only, Rambam
shall be added as additional insured parties under such insurance policy and the insurance shall include also the respective employees,
faculty, other researchers, officers, directors and governors of TRDF and the Technion, and, with respect to products covered
by the Self Cleaning Shunt Patent Rights only, of Rambam. The policy(ies) so issued shall include a &ldquo;cross-liability&rdquo;
provision pursuant to which the insurance is deemed to be separate insurance for each named insured (without right of subrogation
as against any of the insured under the policy, or any of their representatives, employees, officers, directors or anyone in their
name) and shall further provide that the insurer will be obliged to notify TRDF in writing at least thirty (30) days in advance
of the expiry or cancellation of the policy(ies). Microbot hereby undertakes to comply punctually with all obligations imposed
upon it under such policy(ies), including without limitation the obligation to pay in full and punctually all premiums and other
payments due under such policy(ies). Microbot shall submit to TRDF copies of the aforesaid insurance policy(ies) within 14 (fourteen)
days of the date of issue of each such policy and provide TRDF, upon request, with written evidence of such insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term
and Termination.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term</B>.
The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 11,
shall continue in full force and effect until the expiration of the last to expire Valid Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
Cause</B>. Microbot may terminate this Agreement at any time without cause upon sixty (60) days prior written notice to TRDF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
for Default</B>. In the event that either party commits a material breach of its obligations under this Agreement and fails to
cure that breach within sixty (60) days after receiving written notice thereof, the other party may terminate this Agreement immediately
upon written notice to the party in breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Partial
Termination for Patent Challenge</B>. If Microbot or an Affiliate of Microbot commences a legal action in which it challenges
the validity of any of the TRDF Patent Rights, then TRDF may terminate this Agreement specifically with respect to the entire
specific family of Patent Rights which are being challenged, in whole or in part, by Licensee in such action (being either the
entire family of Virob Patent Rights (excluding the Self Cleaning Shunt Patent Rights), Self-Cleaning Shunt Patent Rights, and/or
TipCat Patent Rights, as applicable), immediately upon written notice to Microbot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Failure
to Raise Capital</B>. TRDF may terminate this Agreement immediately upon written notice to Microbot if Microbot fails to raise,
from the time of its formation till the first anniversary of the Effective Date, funds in an aggregate amount of at least $700,000,
from any source (including, without limitation, equity investments, convertible loans, grants, sponsored research and revenues),
which are available for research, development and/or commercialization activities relating to the technology platforms disclosed
in the TipCat Patent Rights and/or the Virob Patent Rights (&ldquo;<B>Qualified Financing</B>&rdquo;). Microbot will provide written
notice to TRDF in the event of such failure no later than 14 days following the first anniversary of the Effective Date. In order
to exercise its rights under this Section 11.2.4, TRDF must provide such termination notice no later than forty-five (45) days
following the receipt of such notice from Microbot. For clarity, if TRDF does not provide such notice within such forty-five day
period, it will not be entitled to terminate this Agreement in accordance with the provisions of this Section 11.2.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.2.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bankruptcy</B>.
Subject to the following sentence, TRDF may terminate this Agreement upon written notice to Microbot if Microbot is adjudged bankrupt,
applies for judicial or extra-judicial settlement with its creditors, voluntarily files for bankruptcy, or in the event an involuntary
bankruptcy action is filed against Microbot and not dismissed within ninety (90) days, or if Microbot otherwise discontinues business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Termination</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
of Rights</B>. Upon termination of this Agreement by either party (a) the rights and licenses granted to Microbot under Article
3 shall terminate and (b) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense;
provided, however, that, for each Sublicensee, upon termination of a Sublicense agreement, if the Sublicensee is not then in breach
of the Sublicense agreement such that Microbot would have the right to terminate such Sublicense agreement, such Sublicensee shall
have the right to obtain a license directly from TRDF on the same terms and conditions as set forth herein, except that (x) the
scope of the license granted directly by TRDF to such Sublicensee shall be coextensive with the scope of the license granted by
Microbot to such Sublicensee and (y) if there is more than one Sublicensee, each Sublicensee that is granted a direct license
shall be responsible for only a pro rata share of the patent expense reimbursement due under this Agreement (based on the number
of direct licenses under the TRDF Patent Rights in effect on the date of reimbursement). Each Sublicensee shall be deemed a third
party beneficiary for purposes of this Section 11.3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accruing
Obligations</B>. Termination or expiration of this Agreement shall not relieve the parties of obligations accruing prior to such
termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant
Back License</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;License
to Improvements</B>. If Microbot terminates this Agreement without cause pursuant to Section 11.2.1 or TRDF terminates this Agreement
in accordance with any of the provisions of Section 11.2 (and except in the case of assignment pursuant to Section 11.3.4), Microbot
will, upon TRDF&rsquo;s first request, grant TRDF and shall cause its Affiliates to grant TRDF a non-exclusive, nontransferable,
royalty-bearing license, with the right to sublicense, under Microbot&rsquo;s rights in Microbot Improvement Patent Rights (as
defined below) solely to develop, make and have made, market, offer for sale, sell and import Licensed Products. If TRDF thereafter
grants a sublicense under any of such Microbot Improvement Patent Rights, TRDF shall pay Microbot an amount equal to 10% of all
Net Proceeds. The provisions of this Section 11.3.3 shall also apply with respect to partial termination of the license granted
under Section 3 above pursuant to the provisions of Section 4.5 or 11.2.3 above, but only with respect to the specific family
of TRDF Patent Rights with respect to which termination has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 11.3.3.1, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Net.
Proceeds&rdquo; means all consideration received by TRDF in connection with a TRDF License (as defined below), including without
limitation amounts received with respect to any Licensed Patent Rights included in such TRDF License, but specifically excluding:
(i) any research grants and (ii) reimbursement for out of pocket patent expenses incurred by TRDF with respect to the Valid Claims
licensed in such TRDF License which expenses have not been previously reimbursed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;Microbot
Improvement Patent Rights&rdquo; means any patents and patent applications owned or controlled by Microbot that claim an invention,
the practice of which would fall within the scope of a Valid Claim within the TRDF Patent Rights (or, in the case of a partial
termination of the license granted under Section 3 above pursuant to the provisions of Section 4.5 or 11.2.3 above, to that specific
family of TRDF Patent Rights with respect to which termination has occurred (i.e. the entire family of Virob Patent Rights (excluding
the Self Cleaning Shunt Patent Rights), Self-Cleaning Shunt Patent Rights, and/or TipCat Patent Rights, as applicable); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;TRDF
License&rdquo; means a license of or other grant of right (e.g. covenant not to sue) with respect to Microbot Improvement Patent
Rights granted alone or in conjunction with other Licensed Patent Rights (whether in a single transaction or multiple related
transactions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Intellectual Property</B>. If Microbot terminates this Agreement without cause pursuant to Section 11.2.1 or TRDF terminates this
Agreement in accordance with any of the provisions of Section 11.2 and TRDF wishes to obtain a license or other rights with respect
to intellectual property developed by Microbot with respect to Licensed Products that does not fall under the definition of Microbot
Improvement Patent Rights, including in connection with any information regarding regulatory filings or the right to cross reference
such regulatory filings made by Microbot, its Affiliates and/or Sublicensees with regard to the Licensed Products, TRDF may notify
Microbot of such desire, which notice shall identify the relevant intellectual property and the rights TRDF wishes to obtain.
Microbot agrees that if TRDF so notifies Microbot and Microbot is not prevented from granting such rights to TRDF by obligations
to one or more third parties, Microbot will enter into good faith negotiations with TRDF in an attempt to reach an agreement on
the terms under which Microbot shall grant rights in such intellectual property to TRDF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Failure to Raise $700,000</B>. Notwithstanding anything to the contrary in this Agreement, if TRDF terminates this Agreement pursuant
to the provisions of Section 11.2.4 above, Microbot will promptly, and in any event within 60 days from written notice to such
effect by TRDF, transfer and assign to TRDF Microbot&rsquo;s entire right, title, and interest in, to and under the Joint Inventions,
the Joint Patent Rights and the Improvement Patent Rights (the &ldquo;<B>Transferred Rights</B>&rdquo;) and shall execute all
documents and take all actions required to effect such assignment in full. In consideration for such a transfer, TRDF shall pay
Microbot an amount equal to 10% of all consideration received by TRDF in connection with a license or other grant of rights (e.g.
covenant not to sue) with respect to the Transferred Rights, whether granted alone or in conjunction with other Licensed Patent
Rights (whether in a single transaction or multiple related transactions), but specifically excluding (a) any research grants;
and (b) reimbursement for out of pocket patent expenses incurred by TRDF with respect to the Valid Claims transferred, which expenses
have not been previously reimbursed. Such amount to be paid by TRDF under this Section 11.2.4 will be capped at an amount equal
to the lower of (i) the total amount of funding received by Microbot in equity investments, convertible loans and shareholder
loans, that would have been counted as amounts transferred on account of a Qualified Financing, multiplied by two (2); or (ii)
US $1,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival</B>.
The parties&rsquo; respective rights, obligations and duties under Articles 2, 6 (except that the obligations with respect to
Section 6.1 will only survive until delivery of the report for the Calendar Quarter in which expiration or termination occurred),
10 and 11 and Sections 5.1, 9.5, 12.1, 12.2, 12.4 and 12.5, as well as any rights, obligations and duties which by their nature
extend beyond the expiration or termination of this Agreement, shall survive any expiration or termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Miscellaneous.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality</B>.
TRDF shall keep confidential, not disclose to any third party and not use for any purpose other than monitoring Microbot&rsquo;s
performance under this Agreement all reports, notices, documents and information (including information received in Review Meetings
pursuant to Section 4.3) provided to TRDF by Microbot under this Agreement; provided, however, that TRDF may include in its annual
reports totals derived from information received from Microbot (without attribution to Microbot) that show revenues generated
by the patents and patent applications licensed under this Agreement; and provided further that the nondisclosure and non-use
obligations shall not apply to any information that (a) is or becomes part of the public domain other than by breach by TRDF of
this Section 12.1, or (b) is required to be disclosed by TRDF pursuant to interrogatories, requests for information or documents,
subpoena, civil investigative demand issued by a court or governmental agency of competent jurisdiction or as otherwise required
by law (provided that, in such case, TRDF shall notify Microbot promptly upon receipt thereof and give Microbot sufficient advance
notice to permit it to seek a protective order or other similar order with respect to such information). To the extent that it
is reasonably necessary, TRDF may disclose information it is otherwise obligated under this Section 12.1 not to disclose to (i)
its employees and consultants on a need-to-know basis and on condition that such employees abide by the obligations set forth
in this Section 12.1 and (ii) in confidence, to lawyers, accountants and financial advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of Name</B>. Microbot shall not, and shall ensure that its Affiliates shall not and shall stipulate in Sublicense agreements that
Sublicensees shall not, use the name or insignia of the Technion or TRDF in any advertising, promotional or sales literature relating
to the subject matter of this Agreement, without the prior written approval of TRDF. Notwithstanding the foregoing, Microbot may
(a) make factual statement relating to the relationship of the parties and the fact that. Microbot is a licensee of the Licensed
Patent Rights and (b) make such disclosures as are required by applicable law or regulations, in each case without the prior written
approval of TRDF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Agreement</B>. This Agreement is the sole agreement with respect to the subject matter hereof and except as expressly set forth
herein, supersedes all other agreements and understandings between the parties with respect to the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>.
Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be delivered
personally, or may be sent by facsimile, overnight delivery or certified mail, return receipt requested, to the following addresses,
unless the parties are subsequently notified of any change of address in accordance with this Section 12.4:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 2in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    to Microbot:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">147
    Bar Yehuda Rd.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nesher</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn.:
    CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 148.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 2in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    &nbsp;to TRDF:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technion
    Research and Development </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foundation
    Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technology
    Transfer Office </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technion
    City, Senate Bldg.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technion
    City</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haifa
    32000</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn.:
    Manager</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice shall be deemed to have been received as follows: (a) by personal delivery, upon receipt; (b) by facsimile or overnight
delivery, one business day after transmission or dispatch; (c) by certified mail, as evidenced by the return receipt. If notice
is sent by facsimile, a confirming copy of the same shall be sent by mail to the same address.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispute
Resolution</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.5.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law and Jurisdiction</B>. This Agreement will be governed by, and construed in accordance with, the laws Israel, without giving
effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall
be determined by the law of the country in which the patent shall have been granted. The parties hereby agree that, subject to
Section 12.5.2, the competent court in Tel Aviv Israel shall have sole jurisdiction over any and all matters arising from this
Agreement, except that TRDF may bring suit against Microbot in any other jurisdiction outside Israel in which Microbot has assets
or a place of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.5.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disputes
Regarding Prof. Shoham Inventions</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
dispute between the parties regarding whether a particular invention, for which Prof. Shoham is an inventor, is a Shoham Invention
(a &ldquo;Dispute&rdquo;), shall first be submitted to mediation. A Dispute shall be submitted to mediation by written notice
from one party to the other party. In the mediation process, the parties will try to resolve their differences voluntarily with
the aid of an impartial mediator, who will attempt to facilitate negotiations. The mediator will be selected by agreement of the
parties. If the parties cannot agree on a mediator, the Israel Bar Association will designate a mediator at the request of a party.
The mediation will be conducted as specified by the mediator and agreed upon by the parties. The parties agree to discuss their
differences in good faith and to attempt, with the assistance of the mediator, to reach an amicable resolution of the dispute.
The mediation will be treated as a settlement discussion and therefore will be confidential. The mediator may not testify for
either party in any later proceeding relating to the dispute. No recording or transcript shall be made of the mediation proceedings.
Each party will bear its own costs in the mediation. The mediation will be for a period of up to thirty (30) days, unless extended
by the written agreement of the parties (the &ldquo;Mediation Period&rdquo;). The parties will share the fees and expenses of
the mediator equally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the parties are unable to resolve the Dispute during the Mediation Period, either party may notify the other in writing that it
wishes the Dispute to be resolved by binding arbitration. In such case, the Dispute shall be referred for the decision of a single
arbitrator who shall be appointed by agreement between the parties. If the parties do not reach agreement as to the arbitrator&rsquo;s
identity, the arbitrator shall be appointed by the President of the Israel Bar Association upon the application of either of the
parties. The arbitrator shall be released from the civil procedure and laws of evidence but shall be bound by the substantive
laws of Israel. The arbitrator&rsquo;s decision shall be final and bind the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding
Effect</B>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives,
successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headings</B>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
and subsection headings are inserted for convenience of reference only and do not form a part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</B>.
The parties may execute this Agreement in two or more counterparts, each of which shall be deemed an original.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment;
Waiver</B>. This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of either party
at any time or times to require performance of any provisions hereof shall in no manner affect the rights at a later time to enforce
the same. No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by conduct,
or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such
condition or of the breach of such term or any other term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Agency or Partnership</B>. Nothing contained in this Agreement shall give either party the right to bind the other, or be deemed
to constitute either party as agent for or partner of the other or any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment
and Successors</B>. This Agreement may not be assigned by either party without the consent of the other, which consent shall not
be unreasonably withheld, except that each party may, without such consent, assign this Agreement and the rights, obligations
and interests of such party to any of its Affiliates, or to any purchaser of all or substantially all of its assets, or of all
or substantially all of its assets to which the subject matter of this Agreement relates, or to any successor corporation resulting
from any merger or consolidation of such party with or into such corporation; provided (a) in each case, that the assignee agrees
in writing to be bound by the terms of this Agreement and (b) in the case of an assignment of only the assets to which the subject
matter of this Agreement relates (i.e. not the assignment of substantially all the assets of Microbot), if (i) in consideration
for such sale Microbot has received consideration of at least Ten Million US Dollars $10,000,000; and (ii) the entity to which
such assets are assigned had sales revenues of no less than US $100,000,000 in the calendar year preceding the date of assignment.
Notwithstanding, prior to the achievement of the Qualified Financing, Microbot may not assign this agreement in whole or in part
without TRDF&rsquo;s prior written approval. Any assignment purported or attempted to be made in violation of the terms of this
Section 12.11 shall be null and void and of no legal effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force
Majeure</B>. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party, including,
without limitation, fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable
efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch
whenever such causes are removed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interpretation</B>.
Each party hereto acknowledges and agrees that: (a) it and/or its counsel reviewed and negotiated the terms and provisions of
this Agreement and has contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved
against the drafting party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of
this Agreement shall be construed fairly as to both parties hereto and not in favor of or against either party, regardless of
which party was generally responsible for the preparation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</B>.
If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signatures
on following page</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties have caused this Agreement to be executed by their duly authorized representatives as of the
date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><B>Technion Research and Development</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>Microbot Medical Ltd.</B></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>Foundation Ltd.</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="width: 42%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    oded Shmueli</I></FONT></TD>
    <TD STYLE="width: 6%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="width: 42%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Prof. oded Shmueli</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Harel Gadot</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">Managing Director<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rambam
Declaration and Confirmation.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rambam
Health Corporation, formerly the Fund for Medical Research, Development of Infrastructure and Health Services - at Rambam Medical
Center, a non-profit association formed under the laws of the State of Israel, with offices at 8 Ha&rsquo;aliya St., Haifa, hereby
declares and confirms that it has read and agrees to the terms of this Agreement and authorizes TRDF to grant Microbot an exclusive
license under Rambam&rsquo;s interest in the Self-Cleaning Shunt Patent Rights in accordance with the terms of this Agreement
subject to the provisions of the Law of Patents - 5727- 1967.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rambam
acknowledges that TRDF will be responsible for making payments due to Rambam, if any, in respect of the rights and licenses granted
to Microbot hereunder with respect to the Self-Cleaning Shunt Patent Rights in accordance with arrangements between Rambam and
TRDF with respect to the Self-Cleaning Shunt Patent Rights. Rambam agrees that, in no event, shall Microbot have any obligation
to Rambam in respect of the licenses granted herein to Microbot, other than as specifically provided in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rambam
hereby, represents, warrant and covenants that: (a) Dr. Zaaroor has a assigned all of his rights in the inventions described in
the Self Cleaning Shunt Patent Rights to Rambam; and (b) Rambam has not granted and undertakes not to grant during the term of
this Agreement any rights under the Self Cleaning Shunt Patent Rights that are inconsistent with the rights granted to Microbot
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Fund for Medical Research, Development of Infrastructure and Health Services -at Rambam Medical Center:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 25%; text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<I>/s/</I></FONT></TD>
    <TD STYLE="width: 70%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF REGISTRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARY
    NAME</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATE
    OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
    Medical Ltd.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
31.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Harel Gadot, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Microbot Medical Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/S/
    <FONT STYLE="font-variant: small-caps"><B>HAREL GADOT</B></FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harel
    Gadot</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
31.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David Ben Naim, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Microbot Medical Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 21, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/S/
    <FONT STYLE="font-variant: small-caps"><B>DAVID BEN NAIM</B></FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    Ben Naim</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
32.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Microbot Medical Inc. (the &ldquo;Company&rdquo;) on Form 10-K for fiscal year ended December
31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, <B>Harel Gadot</B>,
President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906
of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations
of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    <FONT STYLE="font-variant: small-caps"><B>HAREL GADOT</B></FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harel
    Gadot</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
32.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Microbot Medical Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ended
December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, <B>David
Ben Naim</B>, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906
of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations
of the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ <FONT STYLE="font-variant: small-caps"><B>DAVID
    BEN NAIM</B></FONT></I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    Ben Naim</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    21, 2017</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ex10-14_005.jpg
<TEXT>
begin 644 ex10-14_005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L JH# 2(  A$! Q$!_\0
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M(O\ T%Z^6* /JK_AH/P3_=U/_P !A_\ %4?\-!^"?[NI_P#@,/\ XJOE6EH
M^J?^&@_!/]W4_P#P&'_Q5'_#0?@G^[J?_@,/_BJ^5:* /JK_ (:#\$_W=3_\
M!A_\51_PT'X)_NZG_P" P_\ BJ^5:* /JK_AH/P3_=U/_P !A_\ %4?\-!^"
M?[NI_P#@,/\ XJOE:B@#ZI_X:#\$_P!W4_\ P&'_ ,51_P -!^"?[NI_^ P_
M^*KY5HH ^JO^&@_!/]W4_P#P&'_Q5'_#0?@G^[J?_@,/_BJ^5:* /JK_ (:#
M\$_W=3_\!A_\51_PT'X)_NZG_P" P_\ BJ^5:* /JK_AH/P3_=U/_P !A_\
M%4?\-!^"?[NI_P#@,/\ XJOE6B@#ZJ_X:#\$_P!W4_\ P&'_ ,51_P -!^"?
M[NI_^ P_^*KY6HH ^J?^&@_!/]W4_P#P&'_Q5'_#0?@G^[J?_@,/_BJ^5:*
M/JK_ (:#\$_W=3_\!A_\51_PT'X)_NZG_P" P_\ BJ^5:* /JK_AH/P3_=U/
M_P !A_\ %4?\-!^"?[NI_P#@,/\ XJOE6B@#ZJ_X:#\$_P!W4_\ P&'_ ,51
M_P -!^"?[NI_^ P_^*KY5I: /JG_ (:#\$_W=3_\!A_\51_PT'X)_NZG_P"
MP_\ BJ^5:6@#ZI_X:#\$_P!W4_\ P&'_ ,51_P -!^"?[NI_^ P_^*KY5HH
M^JO^&@_!/]W4_P#P&'_Q5'_#0?@G^[J?_@,/_BJ^5:* /JK_ (:#\$_W=3_\
M!A_\51_PT'X)_NZG_P" P_\ BJ^5:* /JK_AH/P3_=U/_P !A_\ %4?\-!^"
M?[NI_P#@,/\ XJOE6B@#ZJ_X:#\$_P!W4_\ P&'_ ,51_P -!^"?[NI_^ P_
M^*KY6HH ^J?^&@_!/]W4_P#P&'_Q5'_#0?@G^[J?_@,/_BJ^5:* /JK_ (:#
M\$_W=3_\!A_\51_PT'X)_NZG_P" P_\ BJ^5:* /JK_AH/P3_=U/_P !A_\
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M_P"&@_!/]W4__ 8?_%4?\-!^"?[NI_\ @,/_ (JOE6B@#ZJ_X:#\$_W=3_\
M 8?_ !5'_#0?@G^[J?\ X##_ .*KY5I: /JG_AH/P3_=U/\ \!A_\51_PT'X
M)_NZG_X##_XJOE6B@#ZJ_P"&@_!/]W4__ 8?_%4?\-!^"?[NI_\ @,/_ (JO
ME6EH ^J?^&@_!/\ =U/_ ,!A_P#%4#]H+P4S !=3R3C_ (]A_P#%5\K4Z/\
MUJ?[PH ^^P<TM(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \G_:&
M_P"2;1?]A"+_ -!>OEBOJ?\ :&_Y)M%_V$(O_07KY8H *6DI: $HHHH ****
M %HHHH 2BBB@ HHHH **** "BBB@!:*** $HHHH **** "BBB@ I:2EH 2EI
M*6@!**** "BBB@ HHHH **** %HHHH 2BBB@ HHHH **** "EI*6@ I*6DH
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M#_9]\5ZBJR:E-::7&?X9&\R3\EX_6N\TW]G'P_ %.HZM?W3#J(@L2G]"?UH
M^::*^N[;X'^ K8#=I$DQ'>6YD.?R(%7A\(_ 8&/^$<MOQ=__ (J@#XVI:^P9
M_@SX!G&#H")[QSR+_)JP[_\ 9[\'70)M9=1LV[;)@X_)@?YT ?+-%>Y:Q^S=
MJ4(9]&UNWN .D=S&8S^8R/T%>9^(?A]XI\+[FU31[B.%>L\8\R/_ +Z7('XX
MH YFEHHH *='_K4_WA3:='_K4_WA0!]]BEI!2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'D_[0W_)-HO^PA%_Z"]?+%?:WCW3[/4M"AM[VWCGA^TJ
MVR09&0K5YW_PA_AO_H#6?_?NNNCA)58\R9Y^*S&&'GR2BV?-M+7TC_PA_AO_
M * UG_W[H_X0_P -_P#0&L_^_=:_V=/NCG_MFE_*_P #YMHKZ2_X0_PW_P!
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M=A\OJUM=EW/2M2\9:+IC%)+Q9)1_!%\Q_2N>N?B4S?\ 'EIK%<_>F;%9ND>
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M:NTKSWP+<B/6)X"?]=#D?53_ ($_E7H5>'BU:LSZ?+W?#Q%HHHKF.P***2@
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MNH"Q)FC-1[J-U 6),T9J/=1NH"Q)FC-1[J-U 6),T9J/=1NH"Q)FC-1[J-U
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M:#-EID"M'.EQ91W#M%YCHBK,K%!\P*'@*.&)SGK7_P"%Q^'_ /H'ZU_X!_\
MV5'_  N/P_\ ] _6O_ /_P"RH=.;5K,%5@MFOO1:\.^#]2T;6K:]GEM9=C7
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M$O\ \51_PA>@?\^+?^!$O_Q5 &_16#X)9F\$:(7=G;[''EG8L3\HZD\FMZ@
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M2A/^S=#_ .)HE=JT;)>HX**?-.[?HS:@@,DB@#-=II\/DVP%<3IUQK4;!_\
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M?V-IO:U0?0D5:W4;J7)'L/GGW*O]D6':)A])7']:L:?IUM!K&FR1^<&6]M\
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M@'K7GV=]#VVTHMLV7_L^X;=<LR1PQYB"'!:N?>X+R%LD\\9-7=2VBX,:D%4
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MICXK$U\;;+_@8JPV@W$(_P!%US48SZ2NLP_\>4G]:Q->@UJ"T >^M;E-P^_
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MS46ZC=7:<EB7-(3_ #%1[J"W\Q2>PTM3[-%+2"EKQCTPHHHH **** "BBB@
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MR.Q(/Z5WX#^(_0XL:O<10W&EW&HLTN:]8\RQ)N-&XU'FC- 6)-QI-QIF:3-
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MEW4;JBW4;J L2[J-U1;J-U 6)=U&ZHMU&Z@+$NZC=4>ZDW4!8EW4;JBW4;J
ML2[J-U1;J-U 6)=U&ZHMU&Z@+$NZC=46ZC=0%B7=3WG=XMC,2.@SVJONHW5,
MHJ2LT--K8C-J,Y\UZUM(U Z=.N\F2(G# ^E9NZEW5D\/3?0M5)(]2\M7C62/
ME&&0?:J=S%\IXJGX1U,7=@UE(?WL'*Y[K_\ 6K6N$KR:D'";BST(R4HW1@%<
M-2[:GFBPV::$R*0$)3--\OD<5;$0/>CR#ZT@L+ E:5NG2J]O%G'2M&&$C'2D
MRD6X8^E7XHQ@57@C)Q6A%'BH9HB2./VJTD8S21)FK2(*ELJP+&*E6/':G(HQ
M3\4BK#=H':FD"GFFXYH C8<52N(\@UHD<56F3(H0CR#QMH[6.H_;(U_<S'G'
M0-7*[J]PU;2X-2M7MKA28W&#CJ/<5Y%XDT4Z#JAM1+YJ%0Z-C''O7L83$*4>
M1[GF8FBXOF6QF;J-U1[J-U=QRV)-U&ZHMU&Z@+$NZC=46ZC=0%B7=1NJ+=1N
MH"Q+NHW5%NHW4!8EW4;JBW4NZ@+$FZC=46ZC=0%B7=1NJ+=1NH"Q+NHW5%NH
MW4!8EW4JM\P^HJ'=3E;YU^HI/8$M3[D%+2"EKR#L"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#R[X^<?#R+_ *_X_P#T%Z^9LU]+_'XX^'<7_7_%_P"@
MO7S'NKOPWP&-1:DN:,U%NHW5T$6)<T9J+=1NH"Q+FC-1;J-U 6)<T9J+=1NH
M"Q+FC-1;J-U 6)<T9J+=1NH"Q+FC-1;J-U 6)<T9J+=1NH"Q+FC-1;J-U 6)
M<T9J+=1NH"Q+FC-1;J-U 6)<T9J+=1NH"Q+FC-1;J-U 6)<T9J+=1NH"QI:3
MJ+Z;J4-RIX4X8>JGK7ILFV:-98R"CC<I]J\@S7HW@V^-]HK6[G,ELV/^ GI7
M#C:=TIHZ</+7E)[B/KQ51>.*UYXNO%9DB;7->=<ZF.45(!34'%2A:8A\'#8K
M6@&<5E(,,#6M:G.*DJ)H0#%7HAFJD*U>B4U#-$68Q5A:AC'2IU!S4E$J=*?C
MBFJ*?CB@8PTWO4A!IF.: %Q4<B<5,!05R* ,Z2/((Q7D_P 3,+K-JO\ TQY_
M.O89(^>E>&_$*[%QXNN4!.(56/![$#FNS INK<YL5_#.:S1FHLT;J]D\VQ+F
MC-1;J-U 6)<T9J+=1NH"Q+FC-1;J-U 6)<T9J+=1NH"Q+FC-1;J-U 6)<T9J
M+=1NH"Q+FC-1;J-U 6)<T9J+=1NH"Q+FE4_.OU%0[J<C?O%^HI/8$C[L%+2"
MEKR3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]H4D?#>(@X_XF$7
M_H+U\M>8_P#>-?4G[0W_ "3:+_L(1?\ H+U\L4U)K8+#_,?^\:/,?^\:92T^
M:7<5D.\Q_P"\:3S'_O&FT4<TNX60_P Q_P"\:/,?^\:911S2[A9#_,?^\:/,
M?^\:;11S2[A9#O,?^\:/,?\ O&F44<TNX60_S'_O&CS'_O&F44<TNX60_P Q
M_P"\:/,?^\:911S2[A9#O,?^\:7S'_O&F44<TNX60_S'_O&CS'_O&FT4<TNX
M60[S'_O&CS'_ +QIE%'-+N%D/\Q_[QH\Q_[QIE%'-+N%D/\ ,?\ O&CS'_O&
MF44<TNX60_S'_O&CS'_O&F4M'-+N%D.\Q_[QH\Q_[QIE+1S2[A9#O,?^\?SJ
M>UU&\LF9K:YDB9AABC8R*JT4G)O<9HG7M5/74)S_ ,#IAUC46ZWLQ_X%5&BI
MLAW9>&L:B.E[-_WU2_VUJ?\ S_3_ /?54**+(+LO_P!MZG_S_3_]]4]?$&KK
M]W4;@?\  ZS:*+(+LUAXFUL=-4N1_P #-.'BK7ATU:Z_[^&LBBBR#F?<V1XM
M\0#IJ]W_ -_#2_\ "7^(A_S&+S_OX:Q**+(.9]S<_P"$P\1?]!F\_P"_AH_X
M3'Q'_P!!F\_[^&L.BBR#F?<W/^$Q\1_]!F\_[^&D_P"$P\1?]!F\_P"_AK$H
MHL@YGW-S_A,?$?\ T&;S_OX:/^$Q\1_]!F\_[^&L.EHL@YGW-H^,/$1ZZS>?
M]_#67<7EQ=SO/<3/)*YRSL<DFH:2FM-@;;W'^8_]XTGF/_>--HJN:7<FR'^8
M_P#>-'F/_>-,I:.:7<+(=YC_ -XT>8_]XTRBCFEW"R'^8_\ >-'F/_>-,HHY
MI=PLA_F/_>-'F/\ WC3:*.:7<+(=YC_WC2>8_P#>--HHYI=PLA_F/_>-'F/_
M 'C3*6CFEW"R'>8_]XT>8_\ >-,HHYI=PLA_F/\ WC1YC_WC3*6CFEW"R'>8
M_P#>-.CD?S4^8_>%1TZ/_6I_O"CFEW"R/OL4M(*6I&%%%% !1110 4444 %%
M%% !1110 4444 %%%% 'D_[0W_)-HO\ L(1?^@O7RQ7U/^T-_P DVB_["$7_
M *"]?+% !2TE+0 E%%% !1110 M%%% "4444 %%%% !1110 4444 +1110 E
M%%% !1110 4444 %+24M "4M)2T )1110 4444 %%%% !1110 M%%% "4444
M %%%% !1110 4M)2T %)2TE !1110 4M)2T )1110 4444 +1110 E%%% !2
MTE+0 E%%% !2TE+0 4Z/_6I_O"FTZ/\ UJ?[PH ^^Q2T@I: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#R?]H;_ ))M%_V$(O\ T%Z^6*^I_P!H;_DF
MT7_80B_]!>OEB@ I:2EH 2BBB@ HHHH 6BBB@!**** "BBB@ HHHH **** %
MHHHH 2BBB@ HHHH **** "EI*6@!*6DI: $HHHH **** "BBB@ HHHH 6BBB
M@!**** "BBB@ HHHH *6DI: "DI:2@ HHHH *6DI: $HHHH **** %HHHH 2
MBBB@ I:2EH 2BBB@ I:2EH *='_K4_WA3:='_K4_WA0!]]BEI!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% ' _%_PMJOB_P %QZ;H\*2W0NTE*O($
M&T*P/)^HKPC_ (41X]_Z!UM_X%Q_XU]:T4 ?)7_"B/'O_0.MO_ N/_&C_A1'
MCW_H'6W_ (%Q_P"-?6M% 'R5_P *(\>_] ZV_P# N/\ QH_X41X]_P"@=;?^
M!<?^-?6M% 'R5_PHCQ[_ - ZV_\  N/_ !H_X41X]_Z!UM_X%Q_XU]:T4 ?)
M7_"B/'O_ $#K;_P+C_QH_P"%$>/?^@=;?^!<?^-?6M% 'R5_PHCQ[_T#K;_P
M+C_QH_X41X]_Z!UM_P"!<?\ C7UK10!\E?\ "B/'O_0.MO\ P+C_ ,:/^%$>
M/?\ H'6W_@7'_C7UK10!\E?\*(\>_P#0.MO_  +C_P :/^%$>/?^@=;?^!<?
M^-?6M% 'R5_PHCQ[_P! ZV_\"X_\:/\ A1'CW_H'6W_@7'_C7UK10!\E?\*(
M\>_] ZV_\"X_\:/^%$>/?^@=;?\ @7'_ (U]:T4 ?)7_  HCQ[_T#K;_ ,"X
M_P#&C_A1'CW_ *!UM_X%Q_XU]:T4 ?)7_"B/'O\ T#K;_P "X_\ &C_A1'CW
M_H'6W_@7'_C7UK10!\E?\*(\>_\ 0.MO_ N/_&C_ (41X]_Z!UM_X%Q_XU]:
MT4 ?)7_"B/'O_0.MO_ N/_&C_A1'CW_H'6W_ (%Q_P"-?6M% 'R5_P *(\>_
M] ZV_P# N/\ QH_X41X]_P"@=;?^!<?^-?6M% 'R5_PHCQ[_ - ZV_\  N/_
M !H_X41X]_Z!UM_X%Q_XU]:T4 ?)7_"B/'O_ $#K;_P+C_QH_P"%$>/?^@=;
M?^!<?^-?6M% 'R5_PHCQ[_T#K;_P+C_QH_X41X]_Z!UM_P"!<?\ C7UK10!\
ME?\ "B/'O_0.MO\ P+C_ ,:/^%$>/?\ H'6W_@7'_C7UK10!\E?\*(\>_P#0
M.MO_  +C_P :/^%$>/?^@=;?^!<?^-?6M% 'R5_PHCQ[_P! ZV_\"X_\:/\
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MH_X41X]_Z!UM_P"!<?\ C7UK10!\E?\ "B/'O_0.MO\ P+C_ ,:/^%$>/?\
MH'6W_@7'_C7UK10!\E?\*(\>_P#0.MO_  +C_P :/^%$>/?^@=;?^!<?^-?6
MM% 'R5_PHCQ[_P! ZV_\"X_\:/\ A1'CW_H'6W_@7'_C7UK10!\E?\*(\>_]
M ZV_\"X_\:/^%$>/?^@=;?\ @7'_ (U]:T4 ?)7_  HCQ[_T#K;_ ,"X_P#&
MG)\"?'BNI.GVV 0?^/M/\:^LZ* $%+110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10-14_006.jpg
<TEXT>
begin 644 ex10-14_006.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z : # 2(  A$! Q$!_\0
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M;\A_C7.4M'*@N=%_;]K_ ,\YOR'^-']OVO\ SSF_(?XUSM)1RH+G1_V_:_\
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MA?S_ ,,U+&+'; =JR=:DA?4-*LQF0_:3-(B<G$:DC/I\Q2M9;:YNO]:Y5#_
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MTC4!5 'H!5^.U [4R+4+:6".2WS-O4, H]?4]OYU(L5W<_?;RT_NQ\?F>O\
M*I&*\T%N=K'<_P#<7D__ %OQJO=7%U]CGF0""..-G]6X&?H*U;72DC "H!^%
M&N6HC\.:AZM;N@^I&!_.E<#.T#0UM=(LHROS+ BL3UR *Z"&R5!R,5/NCA4
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MREM8VUF#Y$05CU8\L?J3S79:/_R"H?\ @7_H1IM60(-8_P"05-_P'_T(5E>
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MWY9Q&F7<]%49)_ 5&[.N$5%617E\2ZBB,LGA^[\X< )+&R'_ (%D<?A^%5;
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M_P"*H\GQ'_T+4_\ X%P?_%5Z!11S,+'G_D^(_P#H6I__  +@_P#BJ/)\1?\
M0M3_ /@7!_\ %5Z!11S,+'GFFWRZGIEO>K&T0F0/L?&5]CCBNUT?_D%0_P#
MO_0C7G_AG_D6M/\ ^N0KT#1_^05#_P "_P#0C3EL)!K'_(*F_P" _P#H0K'\
M"2(/!MD"ZYW3=_\ IJ];&L?\@J;_ (#_ .A"N!?PSH$DC.^AZ:SL2S,UI&22
M>I/%)*Z'<])\V/\ YZ+^='FQ_P#/1?SKS7_A%O#W_0!TS_P#C_PI/^$7\/?]
M '3/_ ./_"CE"YZ7YL?_ #T7\Z/-C_YZ+^=>:?\ "+>'O^@#IG_@''_A2_\
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M,_\  ./_  HY0N>E^;'_ ,]%_.CS8_\ GHOYUYI_PBWA[_H Z9_X!Q_X4?\
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MMQV4?U(^E2Z8Z9D6X/F7,38+O_,#H/7Z$5FV]\()3',P7RP5))P ,_\ ZQ^
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M*\_Z%R[_ / B'_XJBS ZVO.K3_D*Z[_V$I/_ $%*V/\ A,KS_H7+O_P(A_\
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MC5'6UN$FC4"-AL8 8'^> ?\ @)KTTK(Q;U'3/=12PO=2(L!.&CBSQ]6Z],]
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MX4^J2L*Y!:6-K80^5:P1PIG)"#&3ZGU/N:L4E%,0M%)10 M%)10 O>BD[T4
M+1WI*.] "T4E% "]Z*3O10 M'>DH[T +1244 +WHI.]% "T=Z2CO0 M%)10
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-14_007.jpg
<TEXT>
begin 644 ex10-14_007.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #/ 4H# 2(  A$! Q$!_\0
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MB63S0[RHJB%D.,/\W?MC((%/F8K6.8_LOQ7_ - O2O\ P9/_ /&:/[+\5_\
M0+TK_P &3_\ QFNW@GBN8(YX)%DBD4,CJ<A@>A%24<S"QPG]E^*_^@7I7_@R
M?_XS1_9?BO\ Z!>E?^#)_P#XS79373PWEM;K:3RK-NW3(%V18&?FR<\]!@&K
M-',PL<)_9?BO_H%Z5_X,G_\ C-']E^*_^@7I7_@R?_XS7=T4<S"QPG]E^*_^
M@7I7_@R?_P",T?V7XK_Z!>E?^#)__C-=W11S,+'"?V7XK_Z!>E?^#)__ (S5
M?3+R2^LC+-"L,JRRPO&K[P&CD9#@X&1E<]!7H=>;Z+_QZ7/_ %_WG_I3)51;
M8-&A1115$A1110 4444 %%%% !1110 4M)2T )2TE% !2,RHA9F"J.22< 5B
MZOXGL=++1 ^?<C_EDAZ?4]OYUQ&I:S?ZPV+F7;#G(A3A1_C^-)R2*2N>EVMY
M;7L1EMIDE0'&Y#GFIZ\TT/49=)O!(F6B;B5/[P_Q%>DQ2)-$LL;!D<!E([@T
M)W$U8=1113$':BCM10 4444 %%%':@#K=+_Y!L'^[_6K=5-+_P"0;!_N_P!:
MMUDRS \9_P#(LR?]?-M_Z/CK?K \9_\ (LR?]?-M_P"CXZWZ .&\?7=M!K_@
MM9KB*,_VP&P[@<>5(,_3) _&H_%\J/XUTJQ-U($NM+OE>V$[!9"%3;\H.,\M
MSC/6N]HSSBI<;QMZ_BK M'?T_!W/'].U+24\'>#;);\H)[)P=]T1;F58E#*_
M=G!/RH".<]Q2:+J$.MOX(CO]8N)%N=&N/M:B^=/,=!'@MAAS][)Z\$'O7L&U
M>/E''(XZ4H  P!@5<G=M]_\ @_Y_@*UDD>+V&JR7^D^"5;59Y9I[6_B=1=MF
M0I&P3(!Y8'&#US5_P]X@MK[4/"B'6FD\SP_,MX1=M_KE$7WCGB0?-_M"O6::
ML:)]U%'7H*4M?Z]?\QGC7AZ2WN8_ ;3ZQ=N^IVMQ'?9U&3]\%3*@_-QAAVP>
MOJ:[KX;WGVSP>@-VUSY%W<P*[2^8P19G" L22?E"]>V*ZVBG?^OF*VW]=_Z^
M04444AA7D=C8:D1>7-AJQCW7]WFWN(5DBXN)!QC:PS_O$>U>N5YOHO\ QZ7/
M_7_>?^E,E5'<3*W]JZG9\:CH\CH.L]@_G+]2A ?\ &JW8ZSIVHNT=K=QO*H^
M:$G;(OU0X8?B*O55O=,L=20+>VD-P%Y7S$!*GU!Z@^XJQ%JBL?\ L:YM.=,U
M:YA Z0W7^DQ_^/'?^3@4HU#5;3B]TOST'_+:QD#_ (E&PP^B[J!&O15"TUK3
MKZ7R8;E1<=3!(#'*/JC88?E5^@ HHHH **** "BH;FZ@LX#-<RK%&.K,:X[5
M?&DLI:'3$\M.GGN/F/T';\:3:0TKG4:EK-CI4>ZYF 8_=C7EF^@_KTKB=5\4
MWVI%HX";6V/&%/SM]3_05B3/EFGN92S,<L[G)-%K*ESN\L-\IP<BH<FRE$C=
MXK9?G//91U-11&\O)5\A=D0/)]OZUJ)H\5Q<"9T);&,9XK>M-,Z#;Q4%&=;V
M3-CBNMT)WMT^RR9\L\H?0]Q4<5I' N7P/:H;K4$C3:F!CD'W%-.S$U<Z6BJF
MG7J:A9).I&>C =B.M6ZV(#M11VHH$%%%% !1VHH[4 =;I?\ R#8/]W^M6ZJ:
M9_R#8/\ =JW63+,#QG_R+,G_ %\VW_H^.M^L#QG_ ,BS)_U\VW_H^.M^@#SK
MQAH&F6VN^&"MI&S7NM'[2T@W&4-'(Q5CW7.,#IP*NZC+:>%]=TZSLM&MI=ME
M?75M*\Y5HMNUGC'RG:IW#UQC&*W];\.0ZY>Z9=37MW VG7'VF%8"F"^"OS;E
M)(P3TQ53Q+H$=]+_ &N)KPW5I97$$,$(4K)YJ@$$;2Q/RKT(J7=1=O/\M/Q&
ME>6OE^>OX&;HOC74KS4M"AU+28+:UURT,]I+#<F1E=4#E7!48R#D$$]*[:N/
M\&^'&@T7P_=:E)<O>Z?8K!%#.BK]G8JH?@ 9/&W)SQ]<GL*TFDG9>?YZ$1NU
M<****DH**** "BBB@ KS?1?^/2Y_Z_[S_P!*9*](KS?1?^/2Y_Z_[S_TIDJH
M[B9H44459(4444 07=C:7\7E7EM#<1YSME0, ?7FJ']C26W.G:C=6P'2*5O/
MC_)_F ]E9:UJ* ,O[7JUKQ=:>ET@_P"6EFX#?4QN1C\&8U+;ZS87,P@6?R[@
M]()U,4A^BL 3]15^L#7M=TFWA>UN8H[V0];?:''_  +/ _G1L,WB0H))  Y)
M/:N7U7QG;VY:+3U6YE''F'_5C_'\/SKB[J>ZO'(6XF@MMV?LJ2,8@/3#9Q^&
M*K37$5L=A^:3&0HJ'/L4HERZNKK49_.NYFE?MGHOT'05&R.(V\M07Q\H/K56
M&TO+YU9BT<8.>./T_P :Z2VT\MC(K,HP+;2)[IP]TQS_ '0>?_K?A71V6E*B
MA40*/0"M>UTT#DC JXTD%JO&"10!!;Z>L:[FP!4LMW%;KA,9]:S+W5@ <-6#
M<ZB\A.#0!K7NK=?FK#N+UY">:J23$G)-0/+[T =3X1U<6VI&TD;]U<<#/9^W
MY]/RKOZ\0,[(P93A@<@^AKU_1-175M'MKP8W.N' [,.#^M:0?0B2-#M11VHJ
MR0HHHH *.U%':@#KM-_Y!L'^[5JJNF_\@V#_ ':M5DRS+\1:;<:MH<UG:R1Q
MSL\;HTH)7*2*_..<?+BL*ZUCQ5:W+PM%HS%<<@R^F:[&N5UC_D*S?\!_]!%.
M*N)E+_A(/%/_ #PT?\Y:/^$A\4_\\-'_ #EI**OE0KB_\)!XI_YX:/\ G+1_
MPD/BG_GAH_YRTE%'*@N+_P )!XI_YX:/^<M'_"0>*?\ GAH_YRTE%'*@N+_P
MD/BG_GAH_P"<M'_"0>*?^>&C_G+244<J"XO_  D/BG_GAH_YRT?\)!XI_P">
M&C_G+244<J"XO_"0^*?^>&C_ )RU1TFUN+2Q,=T\33O/-,YB!"@R2,^!GGC=
MC\*NT4))!<****8@HHJ*YNH+.$S7$R11CJSG H EJCJ.K66E1;[J8*2/E0<L
MWT%<OJOC223=#I:%%Z>>XY/T!_K7+2.TDAFN9BSL>7D;)/XFI<^Q2B;>J>*[
M[4=T5O\ Z+;GC"GYV'N>WX5S[O% ,R-R><=S5@Q,T;",X8C@^AHLM#9B&N&\
MUOT/U]:S;N58BL96N]Q$150< YSFM.'2TEE65HP7'1B*UK32\!0$P!VQ6S%:
M1PKE\"D,SK33.G%::Q0VRY;&?2H+C48XE(3 K!O-5)) :@#8N]4" A3@5@7>
MILY(!K.FNGD/+54>7WH GEG9SDFJ[2$G Y-0O+[TR*]-K<).O)0Y% $MTLMM
M((YHVC<KN"L,'%4WF]ZEU&[^V2H_F&2X)VJ$.[(-;VB> K_4"D^I$VEN>=A_
MUC#Z=OQ_*FDV*YS$$5Q?7"P6L+S2MT5!DUZSX-T>]T;2&AOG4O(_F"-3GRP0
M.,UIZ9I%CH]OY-C;I$#]YARS?4]35ZM(QL2W<.U%':BJ)"BBB@ H[44=J .N
MTW_D&P?[M6JJZ;_R#8/]VK59,L*Y76/^0K-_P'_T$5U5<GJS$ZQ<KV&W_P!!
M%5'<3*=%%%62%%%% !1110 4444 %%%% !1110 4A8*I9B  .2>U9&K^)+'2
MB8V;SKC'$2'D?4]JX?4];O\ 6&*S/Y<':&,X7\?6DY)#2N=3J_C&VM=T-@HN
M9AP7_P"6:_CW_#\ZXV\O+O4Y_.NYFD;L#]U?H.U4I;B*W^7[S_W14]@+FYW-
M)&%3^' ZUFY-EI6*]Q<>1((8XRTC#(XX_P#KT^#29[QQ)<LP&>%'7_ZU;]MI
MY8@D5MVNF@#.,5(S+M=-)QQ6U;Z>J*"V *G9H+5>Q85EWFK8!P: -*6ZAMEP
MN,^M8M[J_7YJR;K46D)P:SI)B<DF@"W<7SR$\\51>7WJ)Y?>J[RT 3/+[U7>
M;WJ"2;WJ?3=+U#6[CR;&!GQ]YSPJ_4TP*TD_O6MHOA75-=976,P6IZSR#C\!
MU/\ +WKMM"\!6.G,L]^1>7(Z*P_=K^'?\?RKKP J@   < "K4.Y+D8>B>%--
MT-5>*/S;D=9Y!EOP]*W***LD****!!VHH[44 %%%% !1VHH[4 ==IO\ R#8/
M]VK55=-_Y!L'^[5JLF6%<KK'_(5F_P" _P#H(KJJY76/^0K-_P !_P#0151W
M$RC1115DA1110 4444 %%%% !145Q<0VL+33RI'&O5F.!7(:KXT9BT.EI@=#
M/(/_ $%?ZG\J3:0TKG4:AJMEI<6^[G5"?NH.6;Z#K7$:KXLO=0S%:;K6 ]U/
MSM^/;\*Q9&EN9FFGD>65NKN<DU7N3<*Z1V\1.X?> Z5#DV4D*[PP8,K@$GZD
MU:$/FH54D!A@$=JCL]#,C![DEV)SCM^)[UTUKIG3Y:@HPM/T)(RI(,C#H6[?
MA726NF=/EK1ALXX5R^!3+C48X5(3 H E6&&V7+XR.U5+O5%0$*<"L>\U8DD!
MJQI[MY#R: -&[U0N2 :RI;AG.2:@>7WJ!Y?>@"9Y?>J[R^]0O-[U7:4LP502
M3P .] $SS>]1PQW%[<+!:Q/-*W1$&372Z'X$O]3*SZ@6L[8\A2/WCCV';\?R
MKT;2M%L-&@\JR@5,_><\LWU-6HW)<CC-#^'9)6?6GR.HMXV_]"8?T_.N]MK6
M"S@2"VA2*)>B(N *EI:T22)O<2CM11VH$%%%% !1110 =J*.U% !1110 4=J
M*.U '7:;_P @V#_=JU573?\ D&P?[M6JR985RNL?\A6;_@/_ *"*ZJN5UC_D
M*S?\!_\ 0151W$RC1115DA1110 4444 !( R3@"N9U7QC:VNZ*Q NIAQN!^1
M?Q[_ (?G1X[CN6\.F2W=E$4JM* <;EY&#ZC)%<):E9X@ZCV(]#42DUH4E<LW
MM]>:I-YUY,SG.0O15^@[5G27B*=D(\QSP#V_^O6FMMYBE2,@C!JWI^BQ0X\N
M/!]3R:S+,W3[6[D9GG/#?=7'2MZUTTMC(K4M=- P2M7BT%JO8F@"O;Z<J ,V
M *FENH;9<+C/K6=>:M@$!L5@W.I/(3@T :U[J_7YJPKB^>0]>*J23$G).:KO
M+0!*\N>]0/+4+R^]5GF]Z )WF]ZK23>]6-/TW4-9N/)L;=Y3_$W15^IZ"O0M
M#\ 65CMGU$K>7 YV$?NU/T_B_'\JI1;$W8XK1O"^J:\5>*/R;8GF>08'X>M>
MD:'X1TW0U5T3S[KO/*,D'_9'\/\ /WK=50JA5  '  [4M:**1#=PI:2EIB$I
M:2EH 2CM11VH **** "BBB@ [44=J* "BBB@ H[44=J .NTW_D&P?[M6JJZ;
M_P @V#_=JU63+"N5UC_D*S?\!_\ 01755RNL?\A6;_@/_H(JH[B91HHHJR0H
MHHH **** (KFWCN[66WE7,<BE6'L:\;CBFT37)[.Y)V++L<D8X_A;Z<U[37$
M^.M&5_*U6-!QB*X]U/W6/T/'XU,U=%19)::;G!QFM588;9<OC/I6#HVJ2VME
M]AN>)81\C'^-.WY=/RJ*\U8DD!JR+->[U14!"D 5@7>J,Q(!K.GNVD)RU5&E
M]Z )Y;AG.2U5GE]Z@DG"GDGDXSCBH7F]Z )GEJL\WO4#S$G Y/I73:)X$U'5
M"LU]NLK8\X8?O&'L.WU--)L1S<:SW<ZPV\3RRL<!$&2:[?0_AVS[9]9DVCJ+
M>,\_\";^@_.NTTK1-/T:'R[*W5"?O.>7;ZGK6A6BCW)<B&UM;>R@6"VA2*)1
M@*@P!4U%%42%%%% !2TE+0 E+24M "4=J*.U !1110 4444 ':BCM10 4444
M %':BCM0!UVF_P#(-@_W:M55TW_D&P?[M6JR985RNL?\A6;_ (#_ .@BNJKE
M=8_Y"LW_  '_ -!%5'<3*-%%%62%%%% !1110 5'<01W5M);S*&BD4HRGN#4
ME% 'G&L0FVM6M7!%]IYRDAZS0GO^(_45AF<.H8'((S7H7BS1FU"Q%U;+F\M0
M64?\]%_B7_#WKRI)@K.@R%R2H/;VK*2LS1,N/+4#S5 \V.]26&GWVL7(@LH&
MD;N?X5^I[5(QR3VYM7CE("-D,!USZBK.B^&M5UYE:&+R[?\ BGDX7\/7\*[;
M0OA_:612XU)Q=7 Y\L?ZM?\ XK_/%=DJJBA54*H&  , 5HH=R7(P-#\'Z9HF
MV4)]HNA_RVD'(^@Z#^==!115DA1110(**** "BBB@ I:2EH 2EI*6@!*.U%'
M:@ HHHH **** #M11VHH **** "CM11VH Z[3?\ D&P?[M6JJZ;_ ,@V#_=J
MU63+"N5UC_D*3?\  ?\ T$5U5<9XDNH[?4959))'D*JJ1KEB2OZ?4\5<$V[(
M3V(J*S])FE^SFUNB3=6X"N2<[@?NMGOD=??-:%4F)IK<****!!1110 4444
M%><>,?"-PMU]OTN!Y5E;,D,:Y*MZ@#L?T->CT4FKC3L><Z'\/))=MQK+E%ZB
MWC;D_P"\>WX?G7?VEE;6%N(+6".&)>BH,5/10DD#=PHHHIB"BBB@ HHHH **
M** "BBB@ I:2EH 2EI*6@!*.U%':@ HHHH **** #M11VHH **** "CM11VH
M Z[3?^0;!_NU:JKIO_(-@_W:M5DRPK$O]'GNKZ2=&B ;&-Q.> /:MNBFG8#F
MO^$>NMV[=#G&,Y/^%+_8%W_?A_[Z/^%=)13YF*QS?]@7?]^'_OH_X4?V!=_W
MX?\ OH_X5TE<E:>/K6^EU2.UT?5)3I=R;:YVB'AAU(!DRPQSP,^U',[V"VER
MS_8%W_?A_P"^C_A1_8%W_?A_[Z/^%:6F:U#J-I+</;W%DD=P\ %VH0N5.-R\
MG*GL>]7C/$O65!QGEATHYF%CG_[ N_[\/_?1_P */[ N_P"_#_WT?\*Z#SX<
MX\U,\#[P[]*<LB.S*KJS(<, <D?6CF86.=_L"[_OP_\ ?1_PH_L"[_OP_P#?
M1_PIVH>,;33/$EAHUS8:BOVZ7R8;P0CR#)C.W.<YQWQCWX..BHYG:X6UL<W_
M &!=_P!^'_OH_P"%']@7?]^'_OH_X5M:A>FPMA*MI<73%U18K<*6)8XS\Q
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%HH&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-14_008.jpg
<TEXT>
begin 644 ex10-14_008.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #6 <4# 2(  A$! Q$!_\0
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M8]-OT^SV@M7=8+^S,6IVVGM%(R 2 [XRI =!U;&T[AD#I3V=F3>ZO_6QWO\
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M9%A1110 4444 %%%% !1110 4444 %%%% !1110!7OO^/"X_ZYM_*N8\%_\
M(5\1?]?,/_HE:Z>^_P"/"X_ZYM_*N'\/:_I.CZSKT>I7\%J\D\3()6V[AY2C
M(_&GT ] HK _X3?PQ_T'+'_OZ*/^$W\,?]!RQ_[^BD!OT5@?\)OX8_Z#EC_W
M]%'_  F_AC_H.6/_ ']% &_16!_PF_AC_H.6/_?T4?\ ";^&/^@Y8_\ ?T4
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M%']K>(/^A9_\GX_\*R+-^BL#^UO$'_0L_P#D_'_A1_:WB#_H6?\ R?C_ ,*
M-^BL#^UO$'_0L_\ D_'_ (4?VMX@_P"A9_\ )^/_  H WZ*P/[6\0?\ 0L_^
M3\?^%']K>(/^A9_\GX_\* -^BL#^UO$'_0L_^3\?^%']K>(/^A9_\GX_\* -
M^BL#^UO$'_0L_P#D_'_A1_:WB#_H6?\ R?C_ ,* -^BL#^UO$'_0L_\ D_'_
M (4?VMX@_P"A9_\ )^/_  H WZ*H:)J8UG1;741 T'GIN\IF!*'.,9'!Z44
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M%':@ K)\4?\ (JZK_P!>LG\JUJANK6"^M)K6YC$D$R%)$/1E/!% '?45@?\
M"&:'_P \+G_P-G_^+H_X0S0_^>%S_P"!L_\ \7619OT5@?\ "&:'_P \+G_P
M-G_^+H_X0S0_^>%S_P"!L_\ \70!OT5@?\(9H?\ SPN?_ V?_P"+H_X0S0_^
M>%S_ .!L_P#\70!OT5@?\(9H?_/"Y_\  V?_ .+H_P"$,T/_ )X7/_@;/_\
M%T ;]%8'_"&:'_SPN?\ P-G_ /BZ/^$,T/\ YX7/_@;/_P#%T ;]%8'_  AF
MA_\ /"Y_\#9__BZ/^$,T/_GA<_\ @;/_ /%T ;]%8'_"&:'_ ,\+G_P-G_\
MBZ/^$,T/_GA<_P#@;/\ _%T '@K_ )$[3?\ KF?_ $(T5KV%C;:98PV5G$(K
M:%=L: D[1^/-% !??\>%Q_US;^5<?787W_'A<?\ 7-OY5Q]7$3"BH5E82E'
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M#U^\/]KJ 9TE%16UU!>VT=S:S)-!(NY)(VRK#V-2T""BBB@ HHHH 6DI:2@
MHHHH *.]%'>@ HHHH *.U%':@ HHHH [BBBBLBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH KWW_ !X7'_7-OY5Q]=A??\>%Q_US;^5<?5Q$R.6/>O3)
M'ZCT_P ^U)%+N^5C\W;/&1_GK_ABI:BDBW<KUZD=.?7V/O\ SJA$M%5FEGC
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MS+>)R""R@X/:GU% YD0LR[26W8] >0/R-2T( J&>-Y-FP@$$9SZ9!_F!4U%
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MH(0HE;![;2OI@D_R9:.HR>BBB@0R8XB+8!VX;![X.:2 KY*A>0N4_+C^E2$
MC!Y!ID48C0*"2!ZT=1CZ***!!1110 M)2TE !1110 4444 %%%% !1110 44
M44 177_'I-_N-_*NE\)?\B9H7_8/M_\ T6M<U=?\>DW^XW\JZ7PE_P B9H7_
M &#[?_T6M3(I&Q2$ XR <'(S2T5 PINQ,8VC&<]*=10 A .,@'!R,TM%% "
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M''_A76_V!=?\](?^^C_A1_8%U_STA_[Z/^%%T&IR7_")^'/^A?TK_P  X_\
M"E_X1/PW_P!"_I7_ (!Q_P"%=9_8%U_STA_[Z/\ A1_8%U_STA_[Z/\ A1=!
MJ<U9Z%H^G3^?8Z58VLVTKYD%NB-@]L@=.*T*U?[ NO\ GI#_ -]'_"C^P+K_
M )Z0_P#?1_PHN@L95':M7^P+K_GI#_WT?\*/[ NO^>D/_?1_PHN@L95%:O\
M8%U_STA_[Z/^%']@77_/2'_OH_X4706.CHHHK,H**** "BBB@ HHHH ****
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MF>!=?3P3X,TJ]T(O-INL-<7L3S0LHA+.<_?PPPPX'Y4[PMX$U[3M0\)SWVB
M+8?;HYLR0N81(Y:)OO<@9[9(]*IVO_7870]D,\(W9E3Y#AOF'RGWI#<P#.9H
MQC.<L.,=:\/?P!XCN/ 6IV$VE7TFN^2;;>UU (+H&X$H=>02<%CER",D#.>.
MB\2^ 3+JGATZ3X=B:R@2[DO4!B'[R2$*I8,WS$L!R,],U+T5_P"MF_\ @>I2
M6MCT]IX456>5%5R I+ !B>F*R[/Q):7OB?4M CBG6[T^..65G5=C*XR-I!)[
M=P*\EU+P3XLN?!.CZ2NA.UW!HTMK+(;N,E)-X*I@OMP0H.X9/09%=KX3T36+
M/QUJVJ7]A)#;76G6<*2O+&Q:2-,."%8GJ>O0U5O>MZ_D3?3[OS_R+&H?$[1]
M+O\ 5K6[LM11-)DA2\N!'&8X_-^XW#[B/H,CTKL%N('8*LJ%BN_&X9V^N/2O
M.K'P.VI?$+Q5>Z_I$CZ5?/;/:[[D>7*8EP=Z(_/." PQ6;%X7\1CXD6NK#0W
MAT^#4[MV9+J-]\4D057^9]W)'*\ #&!U-2ME??\ K]2GN['IVH:QIVEZ?-?7
MMY#%;0IYCN6' Z?CSQ]:N(ZR1JZ$%6&01WKQ:+X8WO\ PIZ[L#H,*>)G9@-[
MQEV3[1Y@4.&*@;>V1S7L6GQB+3[>-;86H5 /( 4;/;Y>/RJOZ_ 3W^_\RS11
M12 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *DVE:=<W/VB>PM99^!YKPJS<=.2,\5;H
MHH **** "BBB@ HHHH **** "BBB@"&ZM+:]A\F[MXKB+(;9*@=<CH<&EM[6
MWLXO*MH(H(\YV1(%&?H*** ):*** "BBB@ HHHH **** "BBB@ HHHH ****
G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex10-14_009.jpg
<TEXT>
begin 644 ex10-14_009.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #O 78# 2(  A$! Q$!_\0
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M-'VVZ_Y^9O\ OX:.4+G845Q_VVZ_Y^9O^_AH^VW7_/S-_P!_#1RA<["BN/\
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MHHJR3,TC1?$>O6L]]#XBM+2'[7<0QPG3/,*K'*R#+>:,G"YZ"K__  AGB?\
MZ&VS_P#!1_\ ;JU? ?\ R+3_ /80O?\ TIDJQXIUR^\/:5/J5O8074%O'OD\
MRX,;9W   !&SUZ\5G=W+L87_  AGB?\ Z&VS_P#!1_\ ;J/^$,\3_P#0VV?_
M (*/_MU;-YXE;2/-?5UMH!#;373Q6\CS2-&FWYE&P<?,0<]#CMS5P>)M($HB
M>\6.3:25D1EVD)O*G(X;;\VWKCG%',%CFO\ A#/$_P#T-MG_ ."C_P"W4?\
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M?_KH/YT/8#KZ***R+"N,G.;B4CIO/\Z[.N+F&V>0>C'^=5$3&44459(4444
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ME&4F%/H6R1]%R*N6=E=B'RYYRX)R0HVC_P"O[^]:J6L<:Y8@#IS4H@)4!05
M_B;O^'_ZJFXRO!8HB\  "K21(1\B;O?H*<WE( 6&XCUY_2D,DC\\(OJW7\J+
M@94VF6SZ<UI*AD>RD66%5^0, =RC]"F?;-1W6L6=A;VTUF5"6[>8A3 4PL#N
M'X$?RJ#6+L6=W'=*TS+$OESE.3AB,$>A!QR.Q-<M=6#7=WN,TUO"2?+MQAF
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MEB*1D+<\@=>.N,UT%4;_ /X_M&_["<'_ *%0]AHT_P#A7-G_ -![Q!_X'?\
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M[?XTZ/2[.*19$APRG(.X]?SJY11=C"BBBD 4444 %%%% !1110 4'...M%%
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M/6DCAN];76%W699D8$$H3O&1D#G _&J[_"F595NHM7MGNX]7GU*/S[#?"1,
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4BBJ;;=V2E9604444AA1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex10-14_010.jpg
<TEXT>
begin 644 ex10-14_010.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ ;P# 2(  A$! Q$!_\0
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MFRLC%6&W!!P>HKFOMEU_S\S?]]FFHW$V=C17'?;+K_GYF_[[-'VRZ_Y^9O\
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M*7D=G.% [U4_X2B/_G[O?^_,W^%'*%ST*BO/?^$HC_Y^[W_OS-_A1_PE$?\
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MQWVRZ_Y^9O\ OLT?;+K_ )^9O^^S1RA<[&BN.^V77_/S-_WV:/MEU_S\S?\
M?9HY0N=C17'?;+K_ )^9O^^S1]LNO^?F;_OLT<H7.QHKCOMEU_S\S?\ ?9H^
MV77_ #\S?]]FCE"YV-%<=]LNO^?F;_OLT?;+K_GYF_[[-'*%SL:*X[[9=?\
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M>+G;.TGG;AE7SD8]NU(",W18[;:(N?[S#"_XFG)837)S<.7']WHOY?XUL06
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MI?8[_P#Z&+6/^_Z__$T?8[__ *&+6/\ O^O_ ,35VBBR"Y2^QW__ $,6L?\
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M4 4=8_Y!<W_ ?_0A7+5U.L?\@N;_ (#_ .A"N6JX[$LS]>_Y%W4_^O27_P!
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MP_Y\;;_OTO\ A1_9EA_SXVW_ 'Z7_"CF"QP7]O:/_P!!:Q_\"$_QH_M[1_\
MH+6/_@0G^-=[_9EA_P ^-M_WZ7_"C^S+#_GQMO\ OTO^%',%CCXI8YHEEBD6
M2-AE70Y!'J#76:/_ ,@N'_@7_H1KS_PN OAC3P  !"  *] T?_D%P_\  O\
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MFMHXM-FC1AF/>40@D?=.>_&3UKM?#R2CQCXIE>WN(XII;=HI)('19 (0#M)
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MG1_^07#_ ,"_]"-<M74Z/_R"X?\ @7_H1J9;#1>HHHJ"@HHHH HZQ_R"YO\
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M8[%_^P+7_GI-^8_PH_L"U_YZ3?F/\*DT/4H=7T>WOK>^M[V.49$]NA5&YP<
MDD8/&"<UHT-M"5C*_L"U_P">DWYC_"C^P+7_ )Z3?F/\*Y73/'\T>J>,/[<-
MM%IF@31QB6W@<N5;/+?,V<<=!5G5/B?H=EHNH7]LMS<RV4L4+P&W>-@TN/+)
MW 84@YS_ /6H3;M;K;\=AM6_KL=#_8%K_P ])OS'^%']@6O_ #TF_,?X56'C
M'1?[12P-Q(MPSK$5:)@%E9"ZQDD<.5!./ZD5F)\3_"TFF3:DMU=&RA3?)/\
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MP+7_ )Z3?F/\*/[ M?\ GI-^8_PKEO%_Q'@TFWVZ(\5Y=17-M%/NA=XE68C
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M[5TE%)JZL^UOEK_FP6CO_7]:'F$?PCFCTZSL_P"WXR+;2+C2]WV$_,)23O\
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1[A3_ +N?>NRHHHZ6#K<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10-14_011.jpg
<TEXT>
begin 644 ex10-14_011.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $D ?4# 2(  A$! Q$!_\0
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MIFC-']FK^8/[:G_(OO9Z7]MM/^?J'_OX*!>6K,JK<PEF. !(,DUYIFIM//\
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MZ?8',>._^0%%_P!?*_R:O/,UZ#X]_P"0#%_U\K_)J\YS7L8#^%\SY[-%^_\
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M?5'B_P!CU7_H ZQ_X R?X4?8]5_Z .L?^ ,G^%>T:IK>G:*EL^H7(B%U.MO
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M*7U]_P H?V8OYOP/"/M<'_/>+_OL4?:X/^>\7_?8KW?_ (1G0?\ H":;_P"
MD?\ A1_PC.@_] 33?_ 2/_"CZ^_Y0_LQ?S?@>$?:X/\ GO%_WV*/M<'_ #WB
M_P"^Q7N__",Z#_T!--_\!(_\*:WASP^BEFT73%4#))M8P /RH_M!_P H?V8O
MYOP/"OM<'_/>+_OL4?:X/^>\7_?8KW9?#?A]E#+HNF%2,@BUCY_2E_X1G0?^
M@)IO_@)'_A3^OO\ E#^S%_-^!X1]K@_Y[Q?]]BC[7!_SWB_[[%>[_P#",Z#_
M - 33?\ P$C_ ,*0^&M  ).B:8 /^G6/_"E_:#_E#^S%_-^!X3]K@_Y[Q?\
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M+&T9D=('CD\GS%\U4W ,6*!ON\\>N*Z'^T[#_G^MO^_J_P"-']IV'_/];?\
M?U?\:/\ ._Y?Y!_PW]?>>>R6VI3>*8$1]:.@27Y\L(UPN(S;-OW$?,$\S;C/
M?.*RA%KUQHK&4>(Q<PZ!*8@!=*3=+(?+SC&7P!P>O?->K_VG8?\ /];?]_5_
MQH_M.P_Y_K;_ +^K_C0.YP-Q-K-WK\\3R:Q;WBO%/IQAMY/(E3REW+(WW%&_
M?N#@'ICG%4;J&;5O!AE^S>(C?QBR^W03). )4F4R,BXRS8W$E,C 7VKTS^T[
M#_G^MO\ OZO^-']IV'_/];?]_5_QH_K\2;:6_K8X%SK4TTH4:I'J$>K*8_\
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MI5DWVD,)@8%(D#?>W#'.<#/KWI+KP_HM\D*7>DV,ZPQF*)9;=&"(1@J,C@'
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M>C=[UG["G_*C7V]7^9FO_P )-XE_Z&/4O^^U_P#B:/\ A)O$O_0QZE_WVO\
M\361N]Z-WO1["G_*@]O5_F9K_P#"3>)?^ACU+_OM?_B:/^$F\2_]#'J7_?:_
M_$UD;O>C=[T>PI_RH/;U?YF:_P#PDWB7_H8]2_[[7_XFC_A)O$O_ $,>I?\
M?:__ !-9&[WHW>]'L*?\J#V]7^9FO_PDWB7_ *&/4O\ OM?_ (FC_A)O$O\
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MZUU>H_#:72M"-]<7N^6-U,R1)D)'G#$=R1U[< U,JT(NS>I<,/4DKI'# Y.
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M@Y';(KF=*\=:D^AVEQ>Z?;R3RZ--JFZ.X*AO+*_)C9\N=W7GIWH;MO\ UO\
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MI'KLD4SS7#9MX6*C>,ALA<].,#/I3UV_K>PM+7_K:Y=_X55X'_Z%VV_[Z?\
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M_P")H^LP#V;/F/=1NKZ<_P"%!^#/[VI?^! _^)H_X4'X,_O:E_X$#_XFCZS
M/9L^8]U&ZOIS_A0?@S^]J7_@0/\ XFC_ (4'X,_O:E_X$#_XFCZS /9L^8]U
M&ZOIS_A0?@S^]J7_ ($#_P")H_X4'X,_O:E_X$#_ .)H^LP#V;/F/=73?#IC
M_P +'\/?]?T?\Z]V_P"%!^#/[VI?^! _^)J[I'P7\*Z)K%IJEHU_]HM91+'O
MG!7<.F1MJ98B#30U!W/1****XC4**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10-14_013.jpg
<TEXT>
begin 644 ex10-14_013.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G &0# 2(  A$! Q$!_\0
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MG=PS[.&\MPV*\"2Y1!B6-XAW+#*_F*WM UN71;S[9:I%*'0HP8\$9!X([\4
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex10-14_002.jpg
<TEXT>
begin 644 ex10-14_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 @0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHK^?C_@HA_P4_P!4\*2ZM\)OV>]3N%N$O#X8U3QGX=":GXC\3^*"&7_A#/ @
M5<J[HP5_% 9U7#+&<,[. ?LY\1OV@_@;\'TE7XF_%CX?^"?(3+6WB#Q1I-AJ
M(/4*-*:19SG^$B$]>0.WS]X;_P""C_["OBGQ#%X=T+]J#X976JWF;6T2[UC4
MM+TPN?77-;@A\.D\<,;D'@!B5R*_+']DG_@CY-\0(K#XX?MYWVN:[XHUQDUG
M2O@A9ZMKFGZ;H&[:ZGQOK>%\2>(-<:(OGP^TJP1.H4EV#HONO[2?_!#+]E7X
MIZ)J=[\%;?6/@#X_6VE_LB]TC5M9\0>!;R_1-ROKO@?79;I K<@-X;DLV(5L
M1DX! /VQLKVSU2TAO;&:WU#3[NV^T6EW:W*WUE=QMT*.I99!G!4KD$Y&=RD#
M4K^/G]D?]KK]HS_@EW\?9_V7_P!JM]3G^"_]LK::M:7=W_:6F> ],UIP=$^)
M/POUJ1&Q\.7VF*7PFR"2,$E?+E577^NW3M3T_6K&QU72[VVU#3]0M1=V5Y:S
M[["\L6"[95(WJ1M<<A3@Y#, "H -FBBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ KXG_;Y^*$WPL_9C^(%]92K;ZQXOL_\ A ='D7^*;Q 94G7OP/#J:TQ
MP=Y&>@%?;%?B7_P5W\8-/)\&?AG%-BW)\3>-=7!/_3--!T(=NC?VZI_W?84
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M7UU;+:ZGK#1S7WB.^'!'FZQK3RR28(&<;48@9'&#Y-J/[#G[7'P/#:I^R_\
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M);?1_#6D:=H]GY\[W3KIFC:8L,!>1B69UBA"NP +% 54*46LKPG$=12_\87
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M&>/=%MM;T'4^OVA5%[8:@8R4U72)67=H^MQ%F*31!7Z[@5+H?B_P/\6_C?\
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MTCH-T%\$>$5O/@'\"M'OQ]K\-&VT:]ED^*WC#2H<12:0OB7QJA\-SJS.1;Z
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M:)<W%U9Z7_HEIK.C?]!KOD5_0#_PZZ_8<_Z(=9?^%CXT_P#FCH_X==_L,_\
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MWJ1IU&I0?N?C7Q?HOP\\*^(O%_BG4H=.\/\ @W2-1\2:M-(("T>DZ=8F^O\
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M)\4++XJ0>&_$,/P^^(&K^ O"WQ1\&6EQHVD_$U]",46NZBWA2629-"O/#?B
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MWQJC?Q1H^,?,1XBC#K#DYV@^%,],,3S7F>H_M3?M ? V1K+]J[]FGQ3X<T^
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M^'R",G/ZU5@ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB3XEZUXV\N/*Y.D*[#<(B/ZQ^C!E^*CQ?Q=G<]I\)4Z<5;><IKEMI;24>Z_
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M3G/TFHHHKG.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?"2=>/-;;FA44HJWPM?/];\.<[RC"81X/';MMWVOKJ_OW\[G'WD,'VKR(/\
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ME2K'BVKA^&H<5-\6XG$5J6+4L3=XB/)7JSH^ZVOA_0?A)X5E'A#5[#PMX)\
M>'X([G0=3A,GAS1?#?AW388HD$CHKZ2;71M,< A7AC&[*AF=*^4OV+M>F\50
M>/\ ]J'XCZ#>>#?%?[1^NV>M^%+76Q&+;2/@GH8FTOX9Z$-755MUDN=+.J>+
M)A^Z=Y-?G!"HX8^<_%'X@_'?]HBW\*_LI>+_ -GOQ]\(M;^).KZ>/C%XLL]0
MDUOX4M\%-(E35_&C^$OB3H$!:+7/$X@TGPM+HGB<^$/%T=KKD\\%NT2B1OU!
M6QT/1=*BM%@L+;P_86*V$.FE(H;&VLM,5URRNH1S;V\<:QH!QL9_OAB\4:T,
MRQRQ2;IY1DJY4GJYU(4FJBLEKR1C*TI.4(QO'FDHMG/GN$Q? G"&:Y7C*F&Q
M'&?']5-U*7%%+B2C1X-X7K2=!JKPQ6JP<>,.+)T*TI-PKUN%^$:4HT*,JD4>
M<?$OP;X,^+^@)\./'OA30?%_A?7X)-0UG2/%NC6.M:=J%CI;@HT]JTA"O+=&
M,(T>Z9$!2)OF96^#/B;\*O%G[%?P\\5_%?\ 9R^+]WX=^'_@?1+C7I_V?_B=
M9:M\0/A;J,EO.C77A3P5KDTX^(_@#6O%$[P:#X1@T1_%7ABVNI(HD\%W]RPF
M/W'X6\':CH4,OB/P]J4^E7_B.X6]N]*NS'=>'DT^"#_B5V*VN!_88*.':*S+
MR1F0QJC945\D_&?Q _QL_:0^'OP!UW2V@\"?":VLOCS\9[M&:]\)W&L&_%I\
M%? VM:JRPO K^(+;5/B%+ @@EMWT/1&9DED?&F>T,)##3Q<HPI9G4<7"4)2L
MFI.FD[\J48Q;J04TG)<R<8J6B\(<WSNCF5/*,9F_UCPZI0J<6\8<)UJ3XBX5
MEPQPQ2I3J)<-\3TZE*'$W%<G0X0X<XIPD>%N*%4XIHM5N;!PY_T"^'E_KWB+
MP3X4UKQ?X='A3Q-K?AO2]4\0^%C=#4AH.J:GI:RZIHPU.-423[).[Q>8H0YC
MVL3G(DE4>(/%4%OE9-.\+8NKG:-N/$$A/EKG )$<#,^#@;MV,9).[JFNV.FZ
M%<ZW#+#<V_V7S+3R"K?:R00H0C((Y.,$X&[)S\M'A?1Y=*TB""Y ;4+D&[U2
MY!!WZC($+L!_$,Y QQ\O7YJ]B4FVV]]/P_S/S*K55>O]8C[J]ZR6J2DWHKW=
MDG9;O35L_/K_ (*1?M.>#_V;_P!FCQK;>(]$B\0^(_BSI$OPH^%OA[Q%X=U6
M_P# _B+QW\09=,\#:!;>/-6'AV[\,^'_  W9/XA/B;QG_P )-<6\+>"M"\3-
M'YBQB.OH?]E'X):5^S=^S;\%_@1I>KWWB>P^%WPV\-^%;CQ+K.J-K&IZ[J%K
MIJ?VQJD^I["T_P!LUJ6>>(H<I&ZC8Y7>?!_'/[<WP$L?&?CSX3^.M%\2VW@/
MP[J&F>"O%7Q0\2^$&UWX%-K^JZ1;ZWJ/A+6O&,D-QH6B:GHD.K:0U^_BTQ^'
MXQ<1P)*\WF>5]<W7BC3;_P (:=J/@;6-*U6P\1QV&G>&-1T:X&H:8WVE6']I
MZ9+I$DWG0P)YC Q,(U\I TFQ=C<=''83$WEALUBE=I1;7,^65G*2:O=M-)V:
MDXRM)\C1[.=\*\4<-X3*\1G_  S4R7*,\C&K"O.'-1DZD(3C%58*<'*%.K3G
M4P[JT\1"%6ES\*P56G*IT/A^[N==\0:[K'F3_P!C6F/#ND6Q*K'=M'*CZMJH
MX4\R;$3Y1E$;.&*BO1*X._U3PI\,/!UQJ_B'6-.\.>$_"&DO>ZOKNJW:6&G6
M&FQ(!)JFJN_EH@RAW-(2N\MRI("_G'^P?X@N/CA\<OVPOVK/!7Q%\6>(/V:O
MB%X^T[X<? ?0)_'&N^,_AKXHU#X3K+H'Q7^,_@"/7$G&AZ'XL^(#/X16'PA(
M/"3IX!DDB#%<#J/"/T!\:>"?"OQ5\%ZSX,\9Z-:Z_P"'/$^DZCHVL:=>6IDB
MO-/U:.2+4M.=9&BD@:2%FQMD5N%$;':*^*H?@;^T#^SD(KC]FWXC1?%+X::1
M;_9K;]G_ .-=X1>:%8.@6.P^'OQB:0^(]%6V:+Y=-\9Q>*0%"K%/&F#7V_J\
MUQ'-H>E:9*T6H7LZA;SS'F:VTN)]VJ.KR.A<JF BS+N#,IWK@5VWEB;SPZ"-
M638QEAC8\$'#!U82)D<(^Y5ZX!6L\3@L#BIO%)S4(\R5GI&$JMYP47S)\RL[
M*/Q7NKMM_2<.\:9SPQ@WECIX;/,FSR4:V(X4XKPZXDX7Q$Z5/V<:_(Y4YT<1
M&*E1I\4<,XGACBFE3O36(E3_ '<OB']D/X:>/?#UA\0_C)\;M'L_"_QI^-WB
MR+Q#XG\.VVIP:V?!?@G0+-M,^'/PVDUB#;'=Q>&- 5+V]C02(/%.M>(FB.V8
M5PG[0.GZ?^T?\?\ X;?LV"PM-8\"?#R#3?CM\;[9TB>.ZFT+4FE^"_A&\N"
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M>7K28(.U5NO:34UU7^7Y:HYSZRHHHKG.@**** "BBB@ HHHH **** "BBB@
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M@0P^'O%'B*W2*'PS!XFL?"WA-9/"&CZ!:30O- /+^UJ "BBB@ HHHH _ _\
M;6_92_:I\:_M;:[\8O@W\/\ P_XL\,:I\.?#'AJRN=6\6:3HY74M)F<ZLI@D
M+2QG'[L;P-S(2N =H^?S^RG_ ,%$BN3\#/ Y4C_H?M&/'T_X27^G7CK7],2;
M9$  C=03@'/'Y$>OT%*"H)4%(^P')''8<''!Z8R3UY-?S#Q=]%?PNXWXDS?B
MC.UQ2\ZSYOV\UB>6--+^6/LY6M_?DK*R6Q^SY'XZ\></9/DV2Y?5H1I9#%*@
MG&3;WWO-771145ZL_DX^+WA3]JO]GX^"KOXS?#3PEX3TGQQXPTGPQI5S9^(]
M'\2%=3<%DR- P?F4$CV'XUH^!O 'Q%_:V^)-Q\&/@O.=-\+Z4#_PM/XKCG3O
M"FF@$C0D /S>)#@[5')^G-?L!_P4=_9E\=_M2:1\ /A_X->VT^QL_B?J&K^,
M?%5U@VOA?PZO@_Q#$-3 )'F3O++%!$B_>F=44Y9*^P/@-\!?AK^SG\.M-^&G
MPYTP6&C:7&9[V_N0)M4UK47*+-K&MZGY:FZU>? \V9AE@,*BH,K^/Y3]#OAV
M?B?3J2I3H\$9#3I2E2J6E/BV=2$7*%1P=FJ<FXSE%M>Z[-W5OT#$_2)SE<!R
M3<7QOGTYJ=2*M"G3C.2C.5W)\S224;W;UM&"UD^ GP"^'7[./P]TGX;?#G2_
ML&C:9%FZO;@B;5=<U!@L<NKZUJJQ!KK6)3R\K?,> J(N"/>"P"9]3Z<\8Z9Q
MZ_EFAB@'.3T]N>N.A]/I[TOR,@Z@9_'/Z=A[=/S_ +NR_+\'EF#A@\'",<NC
M%\D+W44]&D^L7U;UOOKO_+M>OB<7B98K%2E*4I-N3;;DW>[>NCVLDDDDDE9(
MFHHHKT#(**** (9H8IXS%-$)HB!E6 8''3OG/N/\:_GH_P""F/\ P2)L?BOX
M8NOBS^S#/:>$_''PY\3M\6+'X;1V4ATAO%>A2R:YKFJ?"HD'_A ?$WB94VW'
MA="?!GB^6+0//CMU1-_]#M% '\Y7_!'C]IJ\B^(6O_ SQ7>6T%A\6/#.F_$S
MP':;38&P^)NBZ*O_  MOP4J#.YB%7Q0259MNX $,5;^C6OY/OVUOA]XK_9!_
M:H'BOP#JEK:W.@^)/^&@OV;_  Z-'R+_ %77=:(^*_@L'NI\.#7""0"5(RH/
MRC^G'X2?$WPU\9/AAX(^*?@Z\MM0\.^.O#>E>)-'O+8[E>+68@X8<Y 5G*G/
M)*L3D8KHQ"3DI+:7_ _I^:.<]0HHHKG.@**** "BBB@ HHHH **** "BBB@
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MH7BC1M)\3:+=08/V[2-:TQ=9TF4$$X,D,J,J@Y! 5QRP/6UB= 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXLTTRPT+Q[X$']@_"E4:3"*SKNCW%EPOB(DLIY']:E8@%%%% !1110 4444
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MT%SK/@O65!90#:^(H86=OF&SS,+G!'XG_P#!*_XE>/\ X4?'34/"'CCPK?\
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E&L;5UY=.AFGDLM.?7&"OJ,EO;[IRNULH\BN44 ?25%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex10-14_012.jpg
<TEXT>
begin 644 ex10-14_012.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (^ I8# 2(  A$! Q$!_\0
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M9NHVUO=75I'<PQS1Y8[9%##IZ&@#2HKA9=3T.U8K<:! 3&3'*(8%<K(-Y('
MXVH6^C+QS3Y=2T*.=8U\.*P+%?\ 4Q GDJ"!GNRD<XH [>BN.M[SP_,(M^BP
M)OV L88\*S*K;>N>C#G&/>JEOK7AR=4QH,;/(Q$:QPQG<=^U1R1@D$'GUZT
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M&ZLB%<[MW!!)_NUI5E6G_(S:E_U[V_\ .6@#4I:** "BBB@ I*6B@ I*6B@
MI*6B@!**6B@ HHHH 2BEHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRX_Z#%_^4/\ \;K1HH R(DN+76X;=[Z>XBDMY'*RA."K1@$;5']XUKUFS?\
M(R6G_7I/_P"AQ5I4 %%%% !24M% "44M% !5-_\ D+Q?]<'_ /0EJY51_P#D
M+Q?]<'_]"6@"U12T4 5)/^0M!_UPD_\ 0DJRPR.E5KBT::XCF2XEB9%9/DV\
M@D'G(/H*/LD__00N?^^8_P#XB@#E7\'WL2SW-K>L+R2YG?:)!$HCDE+[=Z)O
MS]P\[NA'0FI;KPUJTDL,\=^S3+N+/)<..2& ( &!P1P!C-=)]DG_ .@A<_\
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MO;_SEH U*6BB@ HHHH *2EHH *2EHH *2EHH 2BEHH **** $HI:* "BBB@
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M)_\ T.*M*@ HHHH ***2@!:*2B@!:I7$5S]MCGMTB<+&R$/(5ZD'L#Z5=HH
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M44 %%%)0 M%%)0 M%%)0 M%)10 M%%% !1244 +1110 4444 %%%% !1110
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MVLPVECOR< <?ZQNF/YY -^EI*6@ HHHH **** "BBB@ HHHH **** "BBB@
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MM/\ KTG_ /0XJTJS9O\ D9+3_KTG_P#0XJTJ "BBB@ HHI* %HI** %HHI*
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M -6BDI: "BBB@ HHI* %HHI* %HHI* %HI** %HHHH **2B@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7'_(0L_J__H-6ZJ7'_(0L
M_J__ *#0!;IK_<;Z4ZFO]QOI0!1T+_D7M-_Z]8O_ $ 5H5GZ%_R+VF_]>L7_
M * *T* "F2(70J&*DC&X=13Z* .5A;68M.G5I;N28Q7++*\*LRL),1X4 9^7
MG'>J46J^(/LS0BTG=MK;)7@8LW#_ # [5 QA1AE!.[OU/;XHP* .+BUOQ%]K
M0'3F:.60*P-O(HCX3*Y[_>?Y_N_+[TY=9\1P6T\\]A&1'&LA4QLH),9) )/
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M* *NF_\ (,MO^N8_E5NJFF_\@RV_ZYC^56J %HHHH RO$O\ R+.I_P#7L_\
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M **2EH *RK3_ )&;4O\ KWM_YRUJUE6G_(S:E_U[V_\ .6@#5HI*6@ HHHH
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M]>D__H<5:1KG9=* \0VJ_;;WFUF.?/.?OQ5>?189%Q-=7TBCD W3KS_P$@T
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M\S^T9B "'(_B]%_,B@#J],_Y!EM_US%6JP--\/V+:=;DF\R4'2^F'_L]6O\
MA';#UO/_  .G_P#BZ -:BLK_ (1VP];S_P #I_\ XNC_ (1VP];S_P #I_\
MXN@#4J&ZM8;RW:"=-\;=1DCIR"".0?>J'_".V'K>?^!T_P#\71_PCMAZWG_@
M=/\ _%T 21Z#I<4+Q+9ILDR7!).XG&23W/RCGVJI>Z#IEO93S1VH$@0\EF.3
M_>.3RW ^8\^]6/\ A';#UO/_  .G_P#BZK7VA64-E+*AN]R+N&Z\F89'J"V#
M^- %J?P]I5RL:S6:,(XUC4;B,*H8 <'IAF'T8CO2#P[I2N6%H QD,NX.V=Q)
M)[\ DGCIR>*U!TI: $I:** $I:** $I:** "LJT_Y&;4O^O>W_G+6K65:?\
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M2BLO[1KW_0,TW_P82?\ QFC[1KW_ $#--_\ !A)_\9H U:*R6NM=12QTW3<
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MR[0[X.(PJ'/4?,"3CUQVH WOM.K X-C8Y/;[:W_QJE^T:O\ \^%C_P"!K?\
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MA'5O^OA/_1,= "3?\C):?]>D_P#Z'%6E6;-_R,EI_P!>D_\ Z'%6E0 4444
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MM_MNRW;MN/LXSGT^_P!:6W:^NHHY8-7MI$D4.I%KU![_ 'Z )CJDG_0+O_\
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MX]*QWTZ?4_#VBQ0R>6JK$\C9;&WRB.Q!/)'>M^\_X\+C_KFW\JAT;_D!:?\
M]>T?_H(H YUK3Q5#;>1:W2LZ,8_-GVG<F2JL.^0I5CGJ1@=:FL;WQ/+?+#=V
M]O%$)@KR+&Q^0!SD9/?">N-U=3534S<KIET;( W0B8PCC[^#CKQUH YBXO\
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M ,"9/_BJT:* ,[^P['TN/_ F3_XJC^P['TN/_ F3_P"*K1HH SO[#L?2X_\
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M]+_A1_9Z?\][G_O^W^-']GI_SWN?^_[?XT 20VL%OGR(8X@>H10,_E5"Z/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0C#8****184444 %%%% &#XG3RDM+]>&@EV,?]E^/_0MM:UG*)K=6]15'Q.
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MN3+8V87$D*.IR&4$&GUB>#;QM0\&:-=-]^2SB+?7:,_K6W2*%HHHH *2EHH
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MEO,""/J#_,4 >F4M9&FZ_:WV(W(BF/\ "QX/T-:U '/^+]"&MZ*XB4?;+?\
M>V[=\CJOT(X_*L#X?ZWN)TZ5B%D!>('^%OXE_P ^AKOZ\GUF!_#_ (TF: ;5
M9UNX?Q/S#Z9!_.@#UFBHK>9+BWBGCY210ZGV(S4E "T4E% "T4E+0 5GV?\
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M=8B"W<.77[DJ':Z'V;_(K*NHP?&,;GLD>/\ QZNEH \ZU31+_1LR2DW-F/\
MEX1?F0?[:CI]1Q]*U-&\0S0*D=R3- 1P^<L!_45V. :YG4O#/E.UUI*JI/+V
MI.$?W7^Z?T/MUH Z.&:.>,21,&4]"*X?XBVF'TN^ Z2-;L?7<,C]5_6K.G:B
MUN[-%N4JVV6%Q@J?1AV/^>E/\97,.H>#Y;B,_-;S12%3U4[P/Y$T :7@^Y-Q
MX>A4G+0DQG\#D?H16]7(^!7_ -&O(2?NNK?F,?TKK: %HI** %HI*6@ K/L_
M^0KJ7^_'_P"@"M"L^S_Y"NI?[\?_ * * -"BBB@!LG^J?Z&DA_U$?^Z/Y4YA
MN4@]#6%>PZLC!;2\=4 P 40_S% &I?:=9ZG%%'>0+,D4J3H&_A=3E3^!JG=^
M&M+O;^:]FBF\Z>+R9@EQ(B2+@@;E5@"0"<$C(['I69Y?B+_G_;_OTG_Q-'E^
M(O\ G_;_ +])_P#$T6 M-X,T)UP;27JIR+J4'B(Q#G=G[A*^_?FI+GPCHMW$
ML<MM*0EO';HPN9 R)&P9,$-D,& (;K[U1\OQ%_S_ +?]^D_^)H\OQ%_S_M_W
MZ3_XF@"Z_A'1I+N*Z>&X,T?EX;[7+\QC8LA;YOF(+,<G).3FH5\#^'T>%DM9
MU,(4)B\F &W?MS\_)'F/U]:@\OQ%_P _[?\ ?I/_ (FCR_$7_/\ M_WZ3_XF
M@#5?P]IKZ);Z.89!96WE^2JS.&3RR"A#YW9!4<YJI%X+T&%0J6LV 8SS=RG[
MDIE7^+L[$_CZ<55\OQ%_S_M_WZ3_ .)H\OQ%_P _[?\ ?I/_ (FB^MP\C5M/
M#NEV-Y'=V\$B31F8JWGR'_6L'DR"V""P!P>G;%)/X;T>YU/^T9K&-[OS8YO-
M.<[XP0C?4!B/_P!59?E^(O\ G_;_ +])_P#$T>7XB_Y_V_[])_\ $T 79_"&
MB7(E$MK*?-,YDQ<RC=YP D'#=#@<=!CC%3'PSI365]:&"3R;YE>X'GR99E55
M!!W94@(O3'2LSR_$7_/^W_?I/_B:/+\1?\_[?]^D_P#B: --?#>EKH\VD^3*
M;*:1I9$:XD)+,^\G=NW<MSUJO<>#="NA*)K25A*9B_\ I4HSYI!DZ-WVCZ8X
MQ53R_$7_ #_M_P!^D_\ B:/+\1?\_P"W_?I/_B: +TWA+1;B:666VE9Y9'D<
M_:91EGC$3'[W= !_]>J__"">'OG_ -$FPR.A'VR; #;-V!OX),:'/7(S4/E^
M(O\ G_;_ +])_P#$T>7XB_Y_V_[])_\ $T 6+CP1H-U+/)/;3N9Q(L@^US '
MS H?@-QG:,X^M7_[!T\:N-4"2K=;%1BL[A'"YVETSM8C)P2":R/+\1?\_P"W
M_?I/_B:/+\1?\_[?]^D_^)H O77A+1KRYNYY[:1FNRK3*+B14+@ !PH; <;5
M^8 '@<T7'A+1;J$Q3VLC@K,K'[1("_FC$A8A@22 !D].V*H^7XB_Y_V_[])_
M\31Y?B+_ )_V_P"_2?\ Q- '3QHL<:QKG:H &3G@>YI6^Z:Y?R_$7_/^W_?I
M/_B:/+\1'@W[?]^D_P * *_@1KA])A:Z14G* NJ'(4^E7;/Q[X6OM3N--CUJ
MU2]MYG@>&9O+;>I((7=C=R.V:LZ%IKZ?#L:L_7?AOX2\1%WOM%MQ.W)G@'E2
M$^I*XS^.: .JX(R.E+6-X8\-V?A/0HM(L'GDMXF9@T[[G.3GJ !QTZ=!7+>)
M_'?B/POKDL<OA&6^TER%MKBUG!E;Y<ME!D]<^G% '67#E?$UD$&[?;3!_P#9
M *$'\^*U:X?X>>*]-\6"_NH'N#J2%/M<4T)3R <[4'; PW?).2:[BFQ(****
M0Q:*** $HHHH 6N6\:>!--\;6D<5])+%)$K+')'CC<1G(/7H*ZFB@#@?!?PJ
MTGP9>_;;>YGN+A00C. H4$8/'>N]HHIMW!*PM%%%( I*6DH "0!D]!7+^$HS
M?7NK>(6(9;^?R[?'3R(\JI_$[F_&I/&U]-#H@TZR8K?ZG(+2WQU7=]]O^ H&
M/X5MZ=90Z;IUO96Z!(8(UC11V &* +.*Y.2T6WU6]TB4E;34D9HR/X'[X_G^
M%=96)XGB*Z>E[&/WMI(LH/L.M7!ZV[F59>[S=M?\_P "WHEX][I,,DV!.N8Y
MAZ.IVM^HK1K$TIXTU:^CC;Y+E8[M!_O#:?U7/XUMU,MS2+N@HHJHU[O=H[2/
MSW4X9@<(I]V]?89-(9;HJ"&*</OGGW'&-B*%4?S)/X_A1+=Q1/Y>2\I&1&@R
MW_UA[GB@">BFQLSH&9"A/\)(R/RIU !1110 4444 %%%% &?J'_']I7_ %\M
M_P"B9*T*S]0_X_M*_P"OEO\ T3)6A0 44<T<T %07EREG9373JS)"A=@O4@#
M/%3\TA&001D'M0!Q_P#:7V[74NH(' 5%&&[X+'M]:Z>SN9+A&:2'RR#P,YS5
MD*%& ,#VI>: "BCFCF@#(UC0X]1_?POY%Z@PDP&0P_NL/XE_EVQ7!:KYP2XT
M^\1H)2NV1 >&'8J>XR.OYUZIS7->.;**?PU<W1C'VFV7S(9!U4Y&?P(ZB@#-
M\!R[Y[X>R9_,UV]>4^"?MKZ\GE;HRIQ,?X&4=?KGC'I7JO- "T4<T<T %%%%
M !6?9_\ (5U+_?C_ /0!6A6?9_\ (5U+_?C_ /0!0!H4444 %&*** $P*,"E
MHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*
M6B@!,"C I:* $P*,"EHH 3 HP*6B@!*6BJ>HW\>G6;3N"S9"H@ZNQX"CZFA:
M@,U/4TT^)<(TUQ(=L,"?>D;^@]3VJ'3M,=)SJ%^RR7\BX)'W(E_NI[>IZD_E
M2Z9ITL4LE]>N)+Z888C[L:]D7V]^YK3JF[:(FU]6-6*-)'D6-0[XW,!@MCID
M]ZY3QCX6UK79[2\T3Q/=:/<VJL B+NBER1]\9&>@ZY^E==25)1P7AJ?XDV6O
M6^G>([73+[36#;]2MFVLN%)&5XSD@#[HZ]:Z_5]9T[0; WVJ7<=K:AE0RR9P
M"3@=*O55U'2[#6+-K/4K."[MFY,4\8=<^N#W]Z %L-2L=4MA<:?>V]W">DD$
MH=?S%6J\WO/@OX?6\%[H5YJ6A70.=UE<-M]^#R/P(KT"]EEMK"XF@@:XFCB9
MHX5(!D8#(4$^IXH L45Y;;?&BUL)UM?%OA_5-"N"<;GB,D9]P<!OR!KT;2]4
MLM:TV#4=.N%N+2<%HY5! 89QWYZ@T 7**** "DHHH 6BBB@ JEJ]Q)::+?7,
M1 DAMY)$)&>0I(J[69XC8+X9U5F("BSE))Z ;#36Z$]CQ:75]4N;B&ZFU*Z>
M>+)C<R<IGKCTKU3P%J-WJ?ASS;R9II(YWC#MU(&,9]>M>.PR)+"DD;AT8 JR
MG((KUCX:?\BQ+_U]R?R6O2QD(JG=(X<-*3G9L[*H+V!;FSF@;HZ%3^534&O,
M.]JZL<;H\S)+HLK<.K36,GY;E_\ 0/UKLZXJ9?LKZ@!_RPU*WF7_ ($R@_S-
M=5J09].FC5RAD CW#JNXXS^M:5-[F-#X;=O^&(5+:JQ(9DL <#:<&?WSV3^?
MTZWT1(T5$4*BC 51@ 4(BQ1K&BA44!5 Z "JFKR/%I-RR,5;9MWC^$'@M^ .
M?PK,V$\V6_=E@<QVRDJTH^\Y'4+Z#W_+UJU#!%;ILB0*.I]2?4GN?>G11I#$
MD4:A40!54=@*=0 R::.WA>:5@L:#+,>PJHD<]\-]QNA@/W8 <,1_MG_V4?CG
MLS4OFN]-B?\ U37!+#U(1F4?F,_@*T:      8 [56DN_P!_Y$*>;*,;P#A4
M'^T?Z=:L.6",5&6QP/>J&B!3H]LX.7D3?*3U,A^]GWSF@#0HHHH **** ,_4
M/^/[2O\ KY;_ -$R5H5GZA_Q_:5_U\M_Z)DK0H **2B@!:*2B@!:*2B@!:*2
MB@ KSGQ;KTPU2[M/,/D0LJ>7G"M\H8Y'?D_I7HU>+>(I#/K&HLI.3=2 8;'0
M[>OX4 6?"LKW'B6S(X9IMW"E> ,]_I7L->3^ ;=F\21$\^5&[\$G'&._UKU>
M@!:*2B@!:*2EH *S[/\ Y"NI?[\?_H K0K/L_P#D*ZE_OQ_^@"@#0HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *R]6L+FYEL[FT:+SK60NL<V=CY4CJ.A&>#S6I133L)JYC?:M?Z?V78_7[:
MW_QNCS_$)_Y<M.'L;AS_ .R5LT4^;R"WF8RZM=VT\<>J620)(P1)XI?,3<>@
M;(!7/;M6Q63XH4'PSJ)[I S@^A7D'\P*U8SNC4^H%)[7!;V'4444AA1110!#
M<VMO>0-!=013PMPT<J!E/U!HM;2WL;6.UM((X+>)=L<42A54>@ Z5-10!YMK
M'A[XD:?K-YJ?A[Q-;7MO/*9!IU]'A4!Z(IYX'L5KI?!VJ^(]4L;C_A)=$CTN
M[AD$8$<N]91C.X=<#G'4UTE% !24M)0 M%%% !4-W;1WEG-;2C,<R-&X]01@
MU-10!XWJWPOE\-8OM(FO+W30Q:ZL(U7S4'=X>,$CJ4XSVYXKT3P9#I47AN!]
M&O/MEI,3()\\LQZY'8C&".V*WZY+5- OM'U&;7_"R)Y\IWWVELVV*]]64]$E
M_P!KH>C>M6ZDY+E;T(4(IW2U.NI#67H7B"P\0Z?]JLG8%&,<T$J[)8)!U1U/
M*L/_ -7%5=4UW=,=/TP>=>-\I8<K%[D^M3&+>P3FHJ[,F^83S:KLY\R\M85]
MR'4G^M===VRW=G-;LQ42(5W#J,]Q7-:3IRR7T,$4GF06$AEGEZ^;<$$8_P"
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M_OQ_^@"C[7J/_0,'_@0O^%064TL>IWGVJ)87FV.B!PW&-O\ ,&@#7HH!R**
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MO0+NDMPV8YT_YZPL?O(?S4\'WZ2H- HHHH ,8&!1110 4444 %%%% !1110
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MAA1110 4444 %%%% !7,:J[#Q9  >#;K_P"A/73URVK?\C=!_P!>R_\ H3T
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M_",Z%M;&T_8(<'Z?+0!T-%8'_"#>$?\ H5M$_P#!?%_\31_P@WA'_H5M$_\
M!?%_\30!OT5SW_"%>#LX_P"$9T+.=N/L$/7KC[M._P"$&\(_]"MHG_@OB_\
MB: -^BL#_A!O"/\ T*VB?^"^+_XFLO5/#6@Z3JWAVYTW1--LI_[3"^;;6B1M
M@PRY&5 .* .SHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_003.jpg
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ .<# 2(  A$! Q$!_\0
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MZ:!H^C[CX#^%)K<K!/J5O(1\KB<-@^X*\BO#/%OA>\\'^(I](O'60H \4RC
MEC.<,!VZ$$=B#R>M?8:_='TKP3]H2)%UC0)@!YDEO.K'U"LA'_H34"1C?!3Q
M++I'C-=)>0_8M4!0J3PLRJ2K?4@%??*^@KZ'U;5[#0],FU'4KE+:UA&7D?\
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MNAPO,IRKW+O/@^H#D@'Z"NOHH 0#%<WJ_@#PMKVI/J&J:1%<W;J%:5G<$@#
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06.-!A548 HJ6BJ22T&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_004.jpg
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ .<# 2(  A$! Q$!_\0
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MZ:!H^C[CX#^%)K<K!/J5O(1\KB<-@^X*\BO#/%OA>\\'^(I](O'60H \4RC
MEC.<,!VZ$$=B#R>M?8:_='TKP3]H2)%UC0)@!YDEO.K'U"LA'_H34"1C?!3Q
M++I'C-=)>0_8M4!0J3PLRJ2K?4@%??*^@KZ'U;5[#0],FU'4KE+:UA&7D?\
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MNAPO,IRKW+O/@^H#D@'Z"NOHH 0#%<WJ_@#PMKVI/J&J:1%<W;J%:5G<$@#
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06.-!A548 HJ6BJ22T&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>23
<FILENAME>mbot-20161231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:MBOT="http://microbotmedical.com/20161231">
    <link:schemaRef xlink:href="mbot-20161231.xsd" xlink:type="simple" />
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-03-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="eol_PE9562----168-K-0007_STD_0_20151231_0">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="eol_PE9562----168-K-0007_STD_0_20141231_0">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPreMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPostMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPostMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPostMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPostMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:PreferredASharesMicrobotMedicalLtdPostMergerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_TemporaryEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:TemporaryEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_TemporaryEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:TemporaryEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_TemporaryEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:TemporaryEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_TemporaryEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:TemporaryEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_TemporaryEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">MBOT:TemporaryEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-27</xbrli:startDate>
        <xbrli:endDate>2016-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember_custom_FormerMicrobotIsraelShareholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:FormerMicrobotIsraelShareholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-27</xbrli:startDate>
        <xbrli:endDate>2016-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_FurnitureAndOfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MBOT:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ResearchEquipmentAndSoftwareMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MBOT:ResearchEquipmentAndSoftwareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ResearchEquipmentAndSoftwareMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MBOT:ResearchEquipmentAndSoftwareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_PriorToNovemberElevenTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">MBOT:PriorToNovemberElevenTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_JuneTwoThousansdSixteenAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:JuneTwoThousansdSixteenAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_PriorToDecemberThirtyFirstTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">MBOT:PriorToDecemberThirtyFirstTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ResearchEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MBOT:ResearchEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ResearchEquipmentAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MBOT:ResearchEquipmentAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-07to2015-10-08_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-07</xbrli:startDate>
        <xbrli:endDate>2015-10-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-10-08_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-10-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-07-06to2016-07-07_custom_MicrobotIsraelMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-07-06</xbrli:startDate>
        <xbrli:endDate>2016-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-07-07_custom_MicrobotIsraelMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-05-11_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-15_custom_AlphaCapitalMember_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MBOT:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MBOT:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-31_custom_AlphaCapitalMember_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2016-08-31_custom_AlphaCapitalMember_custom_MergerAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:MergerAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2016-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2016-08-31_custom_TwoThousandSixteenSeriesAandBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">MBOT:TwoThousandSixteenSeriesAandBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2016-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_TwoThousandSixteenSeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">MBOT:TwoThousandSixteenSeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-27to2016-11-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-27</xbrli:startDate>
        <xbrli:endDate>2016-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_DecreaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:DecreaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_IncreaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:IncreaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesATwoThousandAndElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesATwoThousandAndElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesATwoThousandAndThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesATwoThousandAndThirteenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesATwoThousandAndFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesATwoThousandAndFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesATwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesATwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SeriesBTwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesBTwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_custom_SeriesBTwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesBTwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_SeriesBTwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesBTwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesATwoThousandAndElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesATwoThousandAndThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesATwoThousandAndThirteenOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndThirteenOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesATwoThousandAndFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesATwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesATwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SeriesBTwoThousandAndSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">MBOT:SeriesBTwoThousandAndSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_IsraeliInnovationAuthorityMember_custom_TwoThousandThirteenToSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">MBOT:IsraeliInnovationAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">MBOT:TwoThousandThirteenToSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:TheTechnicianResearchAndDevelopmentFoundationLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-06-01to2012-06-30_custom_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:TheTechnicianResearchAndDevelopmentFoundationLimitedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-06-01</xbrli:startDate>
        <xbrli:endDate>2012-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-06-01to2016-06-30_custom_OfficeLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:OfficeLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-06-01</xbrli:startDate>
        <xbrli:endDate>2016-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-01to2016-12-31_custom_CarLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:CarLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_FormerExecutiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:FormerExecutiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-26to2016-12-27_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-26</xbrli:startDate>
        <xbrli:endDate>2016-12-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-27_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-09-01to2014-09-30_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:BoardofDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-09-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-09-01to2014-09-30_us-gaap_ChiefExecutiveOfficerMember_custom_MEDXVentureGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MEDXVentureGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-09-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-05-01to2016-05-02_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:BoardofDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-05-01</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-05-01to2016-05-02_custom_EmployeesandDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:EmployeesandDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-05-01</xbrli:startDate>
        <xbrli:endDate>2016-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-05-02_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:BoardofDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-05-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_AdvisorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">MBOT:AdvisorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-15to2016-12-16_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-15</xbrli:startDate>
        <xbrli:endDate>2016-12-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-16_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-11-28_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-11-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:AlphaCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_InterestedandRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:InterestedandRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_InterestedandRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:InterestedandRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">MBOT:TwoThousandFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">MBOT:TwoThousandFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">MBOT:TwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">MBOT:TwoThousandSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">MBOT:TwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_USTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MBOT:USTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_IsraelTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_USTaxAuthorityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">MBOT:USTaxAuthorityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-04to2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:DefinitiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-04</xbrli:startDate>
        <xbrli:endDate>2017-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:DefinitiveSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-27_us-gaap_SubsequentEventMember_custom_ContractResearchAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:ContractResearchAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-28to2016-09-30_custom_MicrobotIsraelMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MBOT:MicrobotIsraelMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-28</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-11-26to2016-11-28_custom_LoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">MBOT:LoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-11-26</xbrli:startDate>
        <xbrli:endDate>2016-11-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ExercisePriceOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ExercisePriceTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">MBOT:ExercisePriceTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_DefinitiveAgreementMember_custom_ThreeIsraeliShareholdersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MBOT:DefinitiveAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MBOT:ThreeIsraeliShareholdersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_EscrowAccountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">MBOT:EscrowAccountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2016-01-01to2016-12-31">Microbot Medical Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2016-01-01to2016-12-31">0000883975</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2016-01-01to2016-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2016-01-01to2016-12-31">2016-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2016-01-01to2016-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2016-01-01to2016-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2016-01-01to2016-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2016-01-01to2016-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2016-01-01to2016-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2016-01-01to2016-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2016-01-01to2016-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityPublicFloat contextRef="AsOf2016-06-30" unitRef="USD" decimals="0">43048260</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2017-03-16" unitRef="Shares" decimals="INF">27251333</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">437000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE9562----168-K-0007_STD_0_20141231_0" unitRef="USD" decimals="-3">791000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">2709000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-11-28_custom_MicrobotIsraelMember" unitRef="USD" decimals="-3">6700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">491000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">3315000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">38000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">53000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">529000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">3368000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">25000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">201000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">174000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">783000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">419000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">76000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:CommonStockValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-0" decimals="-3">132000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-1" decimals="-3">266000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-2" decimals="-3">-3372000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-3" decimals="-3">-13035000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-4" decimals="-3">-64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="eol_PE9562----168-K-0007_STD_0_20141231_0" unitRef="USD" decimals="-3">857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-5" decimals="-3">1696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-0" decimals="-3">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-1" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-2" decimals="-3">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-3" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-4" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-5" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3089000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">14465000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">3089000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-3372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-13035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-2451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_custom_TemporaryEquityMember" unitRef="USD" decimals="-3">500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-6" decimals="-3">529000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-7" decimals="-3">3368000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommitmentsAndContingencies contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">313000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">419000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">389000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">500000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-8" decimals="-3">87000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-9" xsi:nil="true" />
    <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" xsi:nil="true" />
    <us-gaap:TemporaryEquitySharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">10702838</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" xsi:nil="true" />
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">10702838</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-07-07_custom_MicrobotIsraelMember_us-gaap_SeriesAPreferredStockMember" unitRef="USDPShares" decimals="INF">1.00</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-12-16_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">11610843</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">8708132</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">9736</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">8708132</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">9736</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-11-28_custom_MicrobotIsraelMember" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-05-02_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">58054213</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-11-28_us-gaap_MinimumMember" unitRef="Shares" decimals="INF">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-11-28_us-gaap_MaximumMember" unitRef="Shares" decimals="INF">220000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">13182660</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">15848136</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">13182660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">15848136</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-823000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">823000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-9663000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-921000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-6" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-7" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-8" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-9" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-9663000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">-921000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" decimals="INF">0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" decimals="INF">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-10" decimals="INF">8708132</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-11" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-12" decimals="INF">8708132</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2015-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-13" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-14" decimals="INF">9736</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-15" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">13182660</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-02-0" decimals="INF">26550974</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">13182660</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-16" decimals="INF">4746237</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-17" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">1851000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-18" decimals="-3">48000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-19" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="-3">1803000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <MBOT:EffectOfReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-20" decimals="INF">-13454369</MBOT:EffectOfReverseRecapitalizationShares>
    <MBOT:EffectOfReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-21" xsi:nil="true" />
    <MBOT:EffectOfReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">15301675</MBOT:EffectOfReverseRecapitalizationShares>
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">472000</MBOT:EffectOfReverseRecapitalization>
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-22" decimals="-3">-135000</MBOT:EffectOfReverseRecapitalization>
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-23" xsi:nil="true" />
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">153000</MBOT:EffectOfReverseRecapitalization>
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">454000</MBOT:EffectOfReverseRecapitalization>
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <MBOT:EffectOfReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">2029000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-24" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-25" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2029000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-26" xsi:nil="true" />
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-27" xsi:nil="true" />
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" decimals="-3">500000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <MBOT:TransactionCostsIncurredInReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-28" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-29" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalizationShares contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7802639</MBOT:TransactionCostsIncurredInReverseRecapitalizationShares>
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-347000</MBOT:TransactionCostsIncurredInReverseRecapitalization>
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-30" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-31" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">78000</MBOT:TransactionCostsIncurredInReverseRecapitalization>
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">6817000</MBOT:TransactionCostsIncurredInReverseRecapitalization>
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <MBOT:TransactionCostsIncurredInReverseRecapitalization contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="Shares" id="Foot-01-32" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="Shares" id="Foot-01-33" decimals="INF">9736</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-9736000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-34" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-35" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="-3">-97000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">97000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPreMergerMember" unitRef="USD" id="Foot-01-36" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_custom_PreferredASharesMicrobotMedicalLtdPostMergerMember" unitRef="USD" id="Foot-01-37" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_custom_TemporaryEquityMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">7262000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">-3618000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">811000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">2029000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">575000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <MBOT:ReverseRecapitalizationEffectOnEquity contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">472000</MBOT:ReverseRecapitalizationEffectOnEquity>
    <MBOT:CashAcquiredInConnectionWithReverseRecapitalization contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">269000</MBOT:CashAcquiredInConnectionWithReverseRecapitalization>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-333000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-7000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:RecapitalizationCosts contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">7258000</us-gaap:RecapitalizationCosts>
    <us-gaap:RecapitalizationCosts contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-262000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USD" decimals="-3">-31000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USD" decimals="-3">-9000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USD" decimals="-3">-23000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USD" decimals="-3">-38000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2016-01-01to2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USD" decimals="-3">-161000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-538000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-66000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">324000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">66000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-786000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-765000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <MBOT:AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">269000</MBOT:AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization>
    <MBOT:AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <MBOT:InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">2002000</MBOT:InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet>
    <MBOT:InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <MBOT:ExerciseOfWarrantsIssuedUponConversionOfNotes contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">409000</MBOT:ExerciseOfWarrantsIssuedUponConversionOfNotes>
    <MBOT:ExerciseOfWarrantsIssuedUponConversionOfNotes contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">750000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">413000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="From2015-10-07to2015-10-08_custom_MicrobotIsraelMember" unitRef="USD" decimals="0">419000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">3083000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">413000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">2272000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-354000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember" unitRef="Shares" decimals="INF">2900000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember_custom_FormerMicrobotIsraelShareholdersMember" unitRef="Shares" decimals="INF">26550974</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="From2016-01-01to2016-12-31_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1 contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember" unitRef="Shares" decimals="INF">2614916</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2016-01-01to2016-12-31">10,702,838</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember">one for nine reverse stock split </us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2016-11-27to2016-11-28">one-to-nine Reverse Stock Split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember" unitRef="Shares" decimals="INF">7802639</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2016-01-01to2016-12-31_custom_FurnitureAndOfficeEquipmentMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2016-01-01to2016-12-31_custom_ResearchEquipmentAndSoftwareMember_us-gaap_MaximumMember">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2016-01-01to2016-12-31_custom_ResearchEquipmentAndSoftwareMember_us-gaap_MinimumMember">P33Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2016-01-01to2016-12-31_us-gaap_LeaseholdImprovementsMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Cash contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">427000</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">2709000</us-gaap:Cash>
    <us-gaap:TimeDepositsAtCarryingValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">10000</us-gaap:TimeDepositsAtCarryingValue>
    <us-gaap:TimeDepositsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">4000000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="AsOf2016-12-31_custom_PriorToNovemberElevenTwoThousandSixteenMember" unitRef="USD" decimals="-3">300000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="AsOf2016-12-31_custom_JuneTwoThousansdSixteenAgreementsMember" unitRef="USD" decimals="-3">495000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="AsOf2016-12-31_custom_EscrowAccountMember" unitRef="USD" decimals="-3">400000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <MBOT:PercentageOfSeveranceAward contextRef="AsOf2016-12-31_custom_JuneTwoThousansdSixteenAgreementsMember" unitRef="Pure" decimals="INF">0.50</MBOT:PercentageOfSeveranceAward>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">3500000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="From2016-01-01to2016-12-31_custom_PriorToDecemberThirtyFirstTwoThousandSixteenMember" unitRef="USD" decimals="-3">2800000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:EscrowDeposit contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-03-0" xsi:nil="true" />
    <us-gaap:EscrowDeposit contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-03-1" decimals="-3">505000</us-gaap:EscrowDeposit>
    <us-gaap:GovernmentContractReceivable contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">14000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">15000</us-gaap:GovernmentContractReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">25000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">86000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">15000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">92000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="-3">63000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="-3">63000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-12-31_custom_ResearchEquipmentAndSoftwareMember" unitRef="USD" decimals="-3">54000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_custom_ResearchEquipmentAndSoftwareMember" unitRef="USD" decimals="-3">29000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">54000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">64000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="-3">36000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31_us-gaap_OfficeEquipmentMember" unitRef="USD" decimals="-3">42000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-12-31_custom_ResearchEquipmentAndSoftwareMember" unitRef="USD" decimals="-3">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-12-31_custom_ResearchEquipmentAndSoftwareMember" unitRef="USD" decimals="-3">18000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">121000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">102000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:RefundsDueUnderGovernmentContracts contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">18000</us-gaap:RefundsDueUnderGovernmentContracts>
    <us-gaap:RefundsDueUnderGovernmentContracts contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">24000</us-gaap:RefundsDueUnderGovernmentContracts>
    <us-gaap:OtherLiabilitiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">456000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2015-10-08_custom_MicrobotIsraelMember" unitRef="Pure" decimals="INF">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2016-08-15_custom_AlphaCapitalMember_us-gaap_SecuredDebtMember" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember" unitRef="Pure" decimals="INF">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2016-07-06to2016-07-07_custom_MicrobotIsraelMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1315023</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2016-11-26to2016-11-28_custom_LoanMember" unitRef="Shares" decimals="INF">2242939</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="From2016-07-06to2016-07-07_custom_MicrobotIsraelMember_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">1188275</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USDPShares" decimals="INF">151.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USDPShares" decimals="INF">194.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USDPShares" decimals="INF">183.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USDPShares" decimals="INF">91.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USDPShares" id="Foot-04-0" decimals="INF">2.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USDPShares" id="Foot-04-1" decimals="INF">2.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="AsOf2016-05-11_custom_MicrobotIsraelMember" unitRef="Pure" decimals="INF">0.10</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="AsOf2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember" unitRef="Pure" decimals="INF">0.060</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FairValueInputsDiscountRate contextRef="From2016-11-27to2016-11-28_custom_MicrobotIsraelMember" unitRef="Pure" decimals="INF">0.20</us-gaap:FairValueInputsDiscountRate>
    <us-gaap:FairValueInputsDiscountRate contextRef="From2016-01-01to2016-12-31_custom_MicrobotIsraelMember" unitRef="Pure" decimals="INF">0.20</us-gaap:FairValueInputsDiscountRate>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2016-08-15_custom_AlphaCapitalMember_us-gaap_SecuredDebtMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2016-08-31_custom_AlphaCapitalMember_custom_MergerAgreementMember" unitRef="USD" decimals="0">2000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebt contextRef="AsOf2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember" unitRef="USD" decimals="0">2028767</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2016-01-01to2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember">2019-11-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2016-12-31_custom_AlphaCapitalMember_custom_ConvertibleNoteMember" unitRef="USDPShares" decimals="INF">0.64</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2016-08-01to2016-08-31_custom_AlphaCapitalMember_custom_MergerAgreementMember" unitRef="USD" decimals="0">2029000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2016-08-01to2016-08-31_custom_AlphaCapitalMember_custom_MergerAgreementMember" unitRef="USD" decimals="0">2029000</us-gaap:AmortizationOfDebtDiscountPremium>
    <invest:InvestmentWarrantsExercisePrice contextRef="From2016-08-01to2016-08-31_custom_TwoThousandSixteenSeriesAandBWarrantsMember" unitRef="USDPShares" decimals="INF">0.30</invest:InvestmentWarrantsExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">531814</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <MBOT:WarrantCalculationDescription contextRef="From2016-01-01to2016-12-31">The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables in the Black-Scholes model that vary overtime, namely, the volatility and the risk free rate. </MBOT:WarrantCalculationDescription>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.05</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2016-01-01to2016-12-31_custom_DecreaseMember" unitRef="USD" decimals="-3">301000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="From2016-01-01to2016-12-31_custom_IncreaseMember" unitRef="USD" decimals="-3">312000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesATwoThousandAndElevenMember" unitRef="Shares" decimals="INF">64230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesATwoThousandAndThirteenMember" unitRef="Shares" decimals="INF">57814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="Shares" decimals="INF">2718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesATwoThousandAndFifteenMember" unitRef="Shares" decimals="INF">10139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesATwoThousandAndSixteenMember" unitRef="Shares" id="Foot-04-2" decimals="INF">10047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2016-11-28_custom_SeriesBTwoThousandAndSixteenMember" unitRef="Shares" id="Foot-04-3" decimals="INF">41116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="Shares" xsi:nil="true" />
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="Shares" decimals="INF">57814</MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber>
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="Shares" decimals="INF">2718</MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber>
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="Shares" decimals="INF">10139</MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber>
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="Shares" id="Foot-04-4" decimals="INF">10047</MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber>
    <MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber contextRef="AsOf2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="Shares" id="Foot-04-5" decimals="INF">41116</MBOT:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndElevenMember">2016-12-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenMember">2018-10-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember">2023-04-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndFifteenMember">2020-04-30</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndSixteenMember" id="Foot-04-6">2018-03-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2016-01-01to2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" id="Foot-04-7">2022-03-31</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesExercised contextRef="From2016-01-01to2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesCancelled contextRef="From2016-01-01to2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">575000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">313000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USD" decimals="-3">12000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USD" decimals="-3">9000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USD" decimals="-3">22000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USD" decimals="-3">43000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2016-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USD" decimals="-3">227000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesATwoThousandAndElevenMember" unitRef="USD" xsi:nil="true" />
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesATwoThousandAndThirteenMember" unitRef="USD" decimals="-3">43000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesATwoThousandAndThirteenOneMember" unitRef="USD" decimals="-3">18000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesATwoThousandAndFifteenMember" unitRef="USD" decimals="-3">45000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesATwoThousandAndSixteenMember" unitRef="USD" decimals="-3">81000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:DerivativeWarrantLiabilitiesBeginningBalance contextRef="AsOf2015-12-31_custom_SeriesBTwoThousandAndSixteenMember" unitRef="USD" decimals="-3">388000</MBOT:DerivativeWarrantLiabilitiesBeginningBalance>
    <MBOT:NetSalesRoyaltyPercentage contextRef="From2016-01-01to2016-12-31_custom_IsraeliInnovationAuthorityMember_custom_TwoThousandThirteenToSixteenMember" unitRef="Pure" decimals="INF">0.03</MBOT:NetSalesRoyaltyPercentage>
    <MBOT:NetSalesRoyaltyPercentage contextRef="From2012-06-01to2012-06-30_custom_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.015</MBOT:NetSalesRoyaltyPercentage>
    <MBOT:NetSalesRoyaltyPercentage contextRef="From2012-06-01to2012-06-30_custom_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.03</MBOT:NetSalesRoyaltyPercentage>
    <us-gaap:RevenueFromGrants contextRef="From2016-01-01to2016-12-31_custom_IsraeliInnovationAuthorityMember_custom_TwoThousandThirteenToSixteenMember" unitRef="USD" decimals="0">900000</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">213000</us-gaap:RevenueFromGrants>
    <us-gaap:RevenueFromGrants contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">201000</us-gaap:RevenueFromGrants>
    <us-gaap:PaymentsForLeaseCommissions contextRef="From2016-06-01to2016-06-30_custom_OfficeLeaseAgreementMember" unitRef="USD" decimals="0">3000</us-gaap:PaymentsForLeaseCommissions>
    <us-gaap:PaymentsForLeaseCommissions contextRef="From2016-12-01to2016-12-31_custom_CarLeaseAgreementMember" unitRef="USD" decimals="0">2500</us-gaap:PaymentsForLeaseCommissions>
    <us-gaap:OfficersCompensation contextRef="From2016-01-01to2016-12-31_custom_FormerExecutiveMember" unitRef="USD" decimals="0">400000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE9562----168-K-0007_STD_0_20141231_0" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">2614916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">1447223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2016-01-01to2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2015-01-01to2015-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USDPShares" decimals="INF">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE9562----168-K-0007_STD_0_20141231_0" unitRef="USDPShares" decimals="INF">.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" id="Foot-05-0" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-09-01to2014-09-30_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember" unitRef="USDPShares" decimals="INF">0.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-09-01to2014-09-30_us-gaap_ChiefExecutiveOfficerMember_custom_MEDXVentureGroupLLCMember" unitRef="USDPShares" decimals="INF">0.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-05-01to2016-05-02_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember" unitRef="USDPShares" decimals="INF">1.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-05-01to2016-05-02_custom_EmployeesandDirectorsMember" unitRef="USDPShares" decimals="INF">0.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">2614916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USDPShares" decimals="INF">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">0.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">15611049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">15611049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31">P7Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31">P8Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_custom_ExercisePriceOneMember">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_ExercisePriceOneMember">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-12-31_custom_ExercisePriceTwoMember">P9Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_custom_ExercisePriceTwoMember">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">45000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">491000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">464000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2016-01-01to2016-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:LaborAndRelatedExpense contextRef="From2015-01-01to2015-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfessionalFees contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">528000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">40000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">253000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">365000</us-gaap:ProfessionalFees>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">7258000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:TravelAndEntertainmentExpense contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">180000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">15000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">10000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">11000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">7000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">7000</us-gaap:Depreciation>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">47000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">26000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">675389</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-8734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-92000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">8734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">92000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfServicesDirectMaterials contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">155000</us-gaap:CostOfServicesDirectMaterials>
    <us-gaap:CostOfServicesDirectMaterials contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">11000</us-gaap:CostOfServicesDirectMaterials>
    <us-gaap:RoyaltyExpense contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">75000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">37000</us-gaap:RoyaltyExpense>
    <us-gaap:MaintenanceCosts contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">21000</us-gaap:MaintenanceCosts>
    <us-gaap:MaintenanceCosts contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">11000</us-gaap:MaintenanceCosts>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">36000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">29000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OtherExpenses contextRef="From2016-01-01to2016-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">76000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="From2015-01-01to2015-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">100000</us-gaap:OtherExpenses>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">5709000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">561000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-3954000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-360000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:CapitalUnitsAuthorized contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">221000000</us-gaap:CapitalUnitsAuthorized>
    <MBOT:RightsToAcquireSharesOfCommonStock contextRef="From2016-12-26to2016-12-27_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">9735925</MBOT:RightsToAcquireSharesOfCommonStock>
    <MBOT:RightsToAcquireSharesOfCommonStock contextRef="From2016-12-15to2016-12-16_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember" unitRef="Shares" decimals="INF">9736000</MBOT:RightsToAcquireSharesOfCommonStock>
    <MBOT:DesignatedPreferredStock contextRef="AsOf2016-12-27_us-gaap_SeriesAPreferredStockMember" unitRef="Shares" decimals="INF">9736</MBOT:DesignatedPreferredStock>
    <MBOT:DesignatedPreferredStock contextRef="AsOf2016-12-16_us-gaap_SeriesAPreferredStockMember_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember" unitRef="Shares" decimals="INF">9736</MBOT:DesignatedPreferredStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2014-09-01to2014-09-30_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember" unitRef="Shares" decimals="INF">403592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2014-09-01to2014-09-30_us-gaap_ChiefExecutiveOfficerMember_custom_MEDXVentureGroupLLCMember" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2016-05-01to2016-05-02_custom_BoardofDirectorsMember_custom_MicrobotIsraelMember" unitRef="Shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2016-05-01to2016-05-02_custom_EmployeesandDirectorsMember" unitRef="Shares" decimals="INF">1447223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2016-01-01to2016-12-31_custom_AdvisorsMember" unitRef="Shares" decimals="INF">7802639</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2016-01-01to2016-12-31_custom_AdvisorsMember" unitRef="USD" decimals="0">9987000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2016-12-31_us-gaap_RestrictedStockMember" unitRef="USDPShares" decimals="INF">1.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">14293296</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">13182660</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2016-01-01to2016-12-31" unitRef="Shares" decimals="INF">36254240</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2016-01-01to2016-12-31_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember" unitRef="Shares" decimals="INF">26518315</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2016-01-01to2016-12-31_custom_SecuritiesExchangeAgreementMember_custom_AlphaCapitalMember" unitRef="Shares" decimals="INF">9735925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">-1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">-1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">44000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">333000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">6000</us-gaap:InterestExpense>
    <us-gaap:NoninterestExpenseDirectorsFees contextRef="From2016-01-01to2016-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NoninterestExpenseDirectorsFees contextRef="From2015-01-01to2015-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="From2016-01-01to2016-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" decimals="-3">253000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="From2015-01-01to2015-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" decimals="-3">122000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="From2016-01-01to2016-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" decimals="-3">253000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="From2015-01-01to2015-12-31_custom_InterestedandRelatedPartiesMember" unitRef="USD" decimals="-3">122000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">9000</us-gaap:AccountsPayableOtherCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrentAndNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">9000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandFourteenMember" unitRef="Pure" decimals="INF">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandFifteenMember" unitRef="Pure" decimals="INF">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandSixteenMember" unitRef="Pure" decimals="INF">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandSeventeenMember" unitRef="Pure" decimals="INF">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_us-gaap_IsraelTaxAuthorityMember_custom_TwoThousandEighteenMember" unitRef="Pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-01-01to2016-12-31_custom_USTaxAuthorityMember" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-12-31_us-gaap_IsraelTaxAuthorityMember" unitRef="USD" decimals="0">5556</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2016-12-31_custom_USTaxAuthorityMember" unitRef="USD" decimals="0">475496</us-gaap:OperatingLossCarryforwards>
    <MBOT:OperatingLossCarryforwardsExpiration contextRef="From2016-01-01to2016-12-31_custom_USTaxAuthorityMember">2035</MBOT:OperatingLossCarryforwardsExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="0">471980</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">481052</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="0">471980</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">481052</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="0">471980</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">481052</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2017-01-04to2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember" unitRef="Shares" decimals="INF">700000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember" unitRef="USDPShares" decimals="INF">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2017-01-04to2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember" unitRef="USD" decimals="-3">3500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <MBOT:PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses contextRef="From2017-01-04to2017-01-05_us-gaap_SubsequentEventMember_custom_DefinitiveSecuritiesPurchaseAgreementMember" unitRef="USD" decimals="-3">210000</MBOT:PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses>
    <MBOT:CostOfInitialStudy contextRef="AsOf2017-01-27_us-gaap_SubsequentEventMember_custom_ContractResearchAgreementMember" unitRef="USD" decimals="-3">130000</MBOT:CostOfInitialStudy>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">313000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2016-11-28" unitRef="USD" decimals="-3">575000</us-gaap:DerivativeLiabilities>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">578081</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-12-31_custom_TwoThousandSixteenSeriesAWarrantsMember" unitRef="Shares" decimals="INF">531814</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:NatureOfOperations contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 GENERAL&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;A. Description of business:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Microbot Medical Inc. (the &amp;#8220;Company&amp;#8221;) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;It was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to CytoTherapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (&amp;#8220;Microbot Israel&amp;#8221;), and C&amp;#38;RD Israel Ltd. (&amp;#8220;Merger Sub&amp;#8221;), an Israeli corporation and wholly-owned subsidiary of the Company, whereby Merger Sub merged with and into Microbot Israel and Microbot Israel surviving as a wholly-owned subsidiary of the Company (the &amp;#8220;Merger&amp;#8221;). Pursuant to the terms of the Merger, at the effective time of the Merger, each outstanding ordinary share of Microbot Israel capital stock was converted into the right to receive approximately 2.9 shares of the Company&amp;#8217;s common stock, par value $0.01 per share, after giving effect to a one for nine reverse stock split (the &amp;#8220;Reverse Stock Split&amp;#8221;), for an aggregate of 26,550,974 shares of Company&amp;#8217;s common Stock issued to the former Microbot Israel shareholders. In addition, all outstanding options to purchase the ordinary shares of Microbot Israel were assumed by the Company and converted into options to purchase an aggregate of 2,614,916 shares of the Company&amp;#8217;s common Stock. Additionally, the Company issued an aggregate of 7,802,639 restricted shares of its common stock or rights to receive the Company&amp;#8217;s common stock, to certain advisers. On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company&amp;#8217;s common stock began trading on the Nasdaq Capital Market under the symbol &amp;#8220;MBOT&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;As a result of the Merger Microbot Israel became a wholly owned subsidiary of the Company. The transaction between the Company and Microbot Israel was accounted for as a reverse recapitalization. As the shareholders of Microbot Israel received the largest ownership interest in the Company, Microbot Israel was determined to be the &amp;#8220;accounting acquirer&amp;#8221; in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Microbot Israel. Unless indicated otherwise, pre-acquisition share, options and warrants data included in these financial statements is retroactively adjusted to reflect the Reverse Stock Split and the Merger.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Prior to the Merger, the Company was a biopharmaceutical company that conducts research, development, and commercialization of stem cell therapeutics and related technologies. Substantially the sale of all material assets relating to the stem cell business were completed on November 29, 2016.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company and its subsidiaries are collectively referred to as the &amp;#8220;Company&amp;#8221;. &amp;#8220;StemCells&amp;#8221; or &amp;#8220;StemCells, Inc.&amp;#8221; refers to the Company prior to the Merger.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;B. Risk factors:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;To date the Company has not generated revenues from its operations. As of the date of issuance of these financial statements, the Company has a cash and cash equivalent balance of approximately $6.7 million, which the Company believes is sufficient to fund its operations for more than 12 months from the date of issuance of these financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products. The Company plans to continue to fund its current operations as well as other development activities relating to additional product candidates, through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;C. Use of estimates:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management&amp;#8217;s best judgment, actual results may differ from these estimates.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The significant accounting policies applied in the preparation of the financial statements are as follows:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;A.Basis of presentation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;US GAAP&amp;#8221;).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;B. Financial statement in U.S. dollars:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The functional currency of the Company is the U.S. dollar (&amp;#8220;dollar&amp;#8221;) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, &amp;#8220;Foreign Currency Translation&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;C. Cash and cash equivalents:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;D. Fair value of financial instruments:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The carrying values of cash and cash equivalents, other receivable and other accounts payable approximate their fair value due to the short-term maturity of these instruments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 8.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 1 &lt;/b&gt;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt; - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt; - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;E. Fixed assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fixed assets are presented at cost, net of investment grants received and less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25-33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 77%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;F. Liabilities due to termination of employment agreements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (&amp;#8220;Article 14&amp;#8221;) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company&amp;#8217;s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;G. Basic and diluted net loss per share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Basic net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights by the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 &amp;#8220;Earnings per Share&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;H. Research and development expenses, net:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;I. Convertible notes:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 &amp;#8220;Debt with Conversion and Other Options&amp;#8221;, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the Notes.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, &amp;#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;J. Share-based compensation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company applies ASC 718-10, &amp;#8220;Share-Based Payment,&amp;#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to service providers, employees and directors including stock options under the Company&amp;#8217;s stock plans based on estimated fair values. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&amp;#8217;s statement of operations.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company&amp;#8217;s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the &amp;#8220;simplified&amp;#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;K. Reclassification:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;L. Transaction Costs:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;M. Recent Accounting Standards:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In May 2014, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for us beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it is unable to determine the expected impact the new standard will have on its consolidated financial statements.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In January 2016, the FASB issued ASU 2016-01 &amp;#8220;Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;), which amends, among other things, the existing guidance by requiring lessees to recognize lease assets (right-to-use) and liabilities (for reasonably certain lease payments) arising from operating leases on the balance sheet. For leases with a term of twelve months or less, ASU 2016-02 permits an entity to make an accounting policy election to recognize such leases as lease expense, generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (&amp;#8220;ASU 2016-09&amp;#8221;), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments &amp;#8211; Credit Losses &amp;#8211; Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The standard is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. The Company is evaluating the impact of the adoption on our consolidated balance sheet, results of operations, cash flows and disclosures.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 3 - CASH AND CASH EQUIVALENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;437&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 4 - OTHER RECEIVABLES &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Deposit in escrow account (*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;505&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Government institutions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Prepaid expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;606&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(*) Purchase Agreement with BOCO. &lt;/b&gt;On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &amp;#8220;Sellers&amp;#8221;), entered into an Asset Purchase Agreement (the &amp;#8220;Asset Purchase Agreement&amp;#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&amp;#8220;BOCO US&amp;#8221;). &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the Sellers sold to BOCO US certain stem and progenitor cell lines that have been researched, studied or manufactured by the Company since 2007 (the &amp;#8220;Cell Lines&amp;#8221;) and certain other tangible and intangible assets, including intellectual property and books and records, related to the foregoing (together with the Cell Lines, the &amp;#8220;Assets&amp;#8221;) in exchange for $4 million in cash (the &amp;#8220;Asset Consideration&amp;#8221;).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Of the Asset Consideration, $300,000 was provided to the Company prior to November 11, 2016 in exchange for the Sellers&amp;#8217; agreement not to solicit or reach any agreement with any third party pertaining to the sale of the Assets, and $400,000 will remain in a twelve-month escrow for the benefit of BOCO US to satisfy certain indemnification obligations of the Sellers which may arise and which, subject to any valid indemnification claims of BOCO US, will be released to the Company at the end of such 12-month period. In addition, sixteen former employees of the Company received, in the aggregate, $495,000, in accordance with their June 2016 agreements with the Company under which each accepted a more than 50% reduction in his or her severance award otherwise payable.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Asset Purchase Agreement contains certain covenants prohibiting the Sellers from, during the four-year period immediately following the completion of the Asset Sale, (a) engaging in or having certain financial interests in a business that is engaged in the research, development or commercialization of the Cell Lines, or (b) soliciting for employment employees of BOCO US.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On November 29, 2016, the Sellers completed the sale of the Assets.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The opening balance sheet as of the Merger date included a receivable balance with respect to sale of the Assets of $3.5 million, from which $2.8 million were collected prior to December 31, 2016. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 5 - FIXED ASSETS, NET&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;117&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Accumulated Depreciation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 - ACCRUED LIABILITIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;121&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Government institution&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Other current liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Israeli Innovation Authority&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;582&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;149&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7 - CONVERTIBLE LOAN FROM SHAREHOLDERS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On October 8, 2015, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. According to the loan agreement, Microbot Israel received an amount of $419,000. The loan bore interest of 10%, and was converted to both equity shares and preferred shares warrants of Microbot Israel on the nine-month anniversary of the loan. The Company concluded the conversion feature is not a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &amp;#8220;Debt with Conversion and Other Options&amp;#8221;. Accordingly, the proceeds were recorded in liabilities in their entirety at the date of issuance.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On July 7, 2016, the outstanding principal and accrued interest were converted into 1,315,023 Series A preferred shares, of Microbot Israel (the &amp;#8220;Series A Preferred Shares&amp;#8221;) and 1,188,275 warrants to purchase the Series A Preferred Shares, at an exercise price of $1.00 per share. The preferred shares warrants were exercised in full in September 2016 for total gross proceeds to Microbot Israel of $409,750.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On May 11, 2016, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. The loan bore interest at a fixed rate of 10% per annum beginning on the issuance date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;At maturity, all of the outstanding principal and accrued interest was converted into Microbot Israel&amp;#8217;s ordinary shares subject to the conversion or default events specified in the loan agreement, based on a conversion price that represents a 20% discount on Microbot Israel&amp;#8217;s valuation upon such default events. Furthermore, in the event of a reverse merger transaction or a qualified financing, each as defined in the convertible loan agreement with respect to such loans, all of the outstanding principal and accrued interest would be converted into the securities issued in the reverse merger or the qualified financing, as the case may be.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On November 28, 2016, upon the consummation of the Merger, the loan was converted into an aggregate of 2,242,939 shares of Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company concluded the value of the loan is predominantly based on a fixed monetary amount known at the date of issuance as represented by the 20% discount on the Company&amp;#8217;s valuation. Accordingly, the loan was classified as debt and is measured at its fair value, pursuant to the provisions of ASC 480-10, &amp;#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The fair value of the loan is measured based on observable inputs as the fixed monetary value of the variable amount of shares to be issued upon conversion (level 2 measurement). &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Secured Note to Alpha Capital Anstalt:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On August 15, 2016, concurrent with the execution of the Agreement and Plan of Merger (see Note 1A), StemCells Inc issued a 5.0% secured note (the &amp;#8220;Note&amp;#8221;) to Alpha Capital Anstalt (&amp;#8220;Alpha Capital&amp;#8221;), in the principal amount of $2 million, for value received, payable upon the earlier of (i) 30 days following the consummation of the Merger and (ii) December 31, 2016. Proceeds from the Note were used for the payment of costs and expenses in connection with the Merger and operational expenses leading to such Closing.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Note bears interest at 5% per annum, payable monthly in arrears on the first of the month, beginning on January 1, 2017 until the principal amount is paid in full. In addition, the Note is secured by a first priority security interest in all of the Company&amp;#8217;s intellectual property and certain other general assets pursuant to a Security Agreement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Securities Exchange Agreement with Alpha Capital:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;As of the effective time of the Merger, the Company entered into a Securities Exchange Agreement (the &amp;#8220;Exchange Agreement&amp;#8221;) with Alpha Capital, providing for the issuance to Alpha Capital of a convertible promissory note by the Company (the &amp;#8220;Convertible Note&amp;#8221;) in a principal amount of $2,028,767, which is equal to the principal and accrued interest under the Note, in exchange for (a) the full satisfaction, termination and cancellation of the Note and (b) the release and termination of the Security Agreement and the first priority security interest granted thereunder.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Convertible Note is convertible into the Company&amp;#8217;s Common Stock any time after November 28, 2017 and until the maturity date of November 28, 2019, based on a conversion price of $0.64, subject to adjustments as provided in the Exchange Agreement. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Pursuant to the terms of the Convertible Note, the Company is obligated to pay interest on the outstanding principal amount owed under the Convertible Note at a fixed rate per annum of 6.0%, payable at maturity or earlier upon conversion. The Exchange Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Convertible Note also contains certain customary events of default.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;As the Exchange Agreement represented the consummation of the original intent of the Company and Alpha Capital, as of the date of execution of the Merger Agreement (August 2016), to enter into a $2 million convertible note sale transaction, upon the consummation of the Merger, the Company accounted for the convertible note in accordance with such economic substance, as if it had been issued for a cash consideration equal to the principal and accrued interest on the Note, as of the effective date of the Merger, in the amount of $2,029,000 (the &amp;#8220;Assumed Consideration&amp;#8221;), which is equal to the principal amount of the Convertible Note as determined in the Exchange Agreement. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company concluded the conversion feature of the Convertible Note, based on the commitment date of November 28 2016 (the Exchange Agreement date), is a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &amp;#8220;Debt with Conversion and Other Options&amp;#8221;. Accordingly, $2,029,000 of the Assumed Consideration was recorded in equity with a corresponding discount on the Convertible Note, to be amortized over its term through maturity. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8 - DERIVATIVE WARRANT LIABILITIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As part of StemCell&amp;#8217;s obligations under the Merger Agreement, in August 2016, StemCells negotiated with certain institutional holders of its 2016 Series A and Series B Warrants, issued by prior to the Merger, to have such holders surrender their 2016 Series B Warrants in exchange for a reduced exercise price of $0.30 per share on their existing 2016 Series A Warrants and the elimination of the anti-dilution price protection in the 2016 Series A Warrants. As a result, the exercise price for all outstanding 2011 Series A Warrants and 2016 Series A and Series B Warrants was reset to $0.30 per share. Subsequent to the reset of the exercise price, an aggregate of 531,814 (from an outstanding aggregate of 578,081) 2011 Series A Warrants were exercised. For the exercise of these warrants, the Company issued 531,814 shares of its common stock prior to the Merger.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The remaining outstanding warrants and terms as of the closing date of the Merger (November 28, 2016) and as of Dec 31 2016 is as follows: &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Issuance Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding as of November 28, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable as of December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Through&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 30%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2011)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,230&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$151.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2013)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$194.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2013)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$183.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2023&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2015)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$91.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2016)(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series B (2016)(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2022&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;__________________&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As such anti-dilution price protection, does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at November 28, 2016 and December 31, 2016, was approximately $575,000 and $313,000, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As quoted prices in active markets for identical or similar warrants are not available, the Company uses directly observable inputs in the valuation of its derivative warrant liabilities (level 2 measurement). &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company uses the Black-Scholes valuation model to estimate fair value of these warrants. In using this model, the Company makes certain assumptions about risk-free interest rates, dividend yields, volatility, expected term of the warrants and other assumptions. Risk-free interest rates are derived from the yield on U.S. Treasury debt securities. Dividend yields are based on our historical dividend payments, which have been zero to date. Volatility is estimated from the historical volatility of our common stock as traded on NASDAQ. The expected term of the warrants is based on the time to expiration of the warrants from the date of measurement.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of November 28, 2016 and December 31, 2016 (in thousands):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Series A&lt;br /&gt;&#13;        (2011)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series A (2013)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series A (2013)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series A (2015)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series A&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(2016)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series B&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(2016)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 44%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balances at November 28, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;81&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Changes in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(161&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;227&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;313&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In accordance with ASC-820-10-50-2(g),&#13;the Company has performed a sensitivity analysis of the derivative warrant liabilities of the Company which are classified as&#13;level 3 financial instruments. The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables&#13;in the Black-Scholes model that vary overtime, namely, the volatility and the risk free rate. A 5.0% decrease in volatility would&#13;decrease the value of the warrants to $301,000; a 5.0% increase in volatility would increase the value of the warrants to $312,000.&#13;A 5.0% decrease or increase in the risk free rate would not have materially changed the value of the warrants; the value of the&#13;warrants is not strongly correlated with small changes in interest rates.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 - COMMITMENTS &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Microbot Israel obtained from the&#13;Israeli Innovation Authority grants for participation in research and development for the years 2013 through 2016 in the total&#13;amount of approximately $0.9 million, and, in return, Microbot Israel is obligated to pay royalties amounting to 3% of its future&#13;sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar to the New Israeli Shekel and bears&#13;interest of Libor per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The repayment of the grants is contingent&#13;upon the successful completion of the Company&amp;#8217;s research and development programs and generating sales. The Company has no&#13;obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial&#13;risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Microbot Israel signed an agreement&#13;with the Technion Research and Development Foundation (&amp;#8220;TRDF&amp;#8221;) in June 2012 by which TRDF transferred to Microbot Israel&#13;a global, exclusive, royalty-bearing license. As partial consideration for the license, Microbot Israel shall pay TRDF royalties&#13;on net sales (between 1.5%-3%) and on sublicense income as detailed in the agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Lease Agreements:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In June 2016, the Company entered&#13;into an office lease agreement, with a term ending on September 30, 2017. According to the lease agreement, the monthly office&#13;lease payment is approximately $3,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In December 2016, the Company entered&#13;into certain lease agreements for automobiles, which will end on December 31, 2019. According to the lease agreements, the monthly&#13;automobile lease payments are approximately $2,500.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Compensation liability&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company incurred compensation&#13;commitments of approximately $0.4 million to a former executive that management estimates as remote as therefore is not reflected&#13;in these consolidated financial statements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 SHARE CAPITAL&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Ordinary shares confer upon&#13;the holders voting rights and the right to receive cash and stock dividends.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Each share of the Series A&#13;Convertible Preferred Stock issued by the Company in December 2016, is convertible, at the option of the holder, into 1,000 shares&#13;of Common Stock, and confer upon the holder dividend rights on an as converted basis. The shares of Series A Preferred Stock do&#13;not confer upon the holder voting rights and do not confer upon the holder a preference upon a liquidation event.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Share Capital Developments:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -28.35pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The authorized capital stock&#13;consists of 221,000,000 shares of capital stock, which consists of 220,000,000 shares of common stock, par value $0.01 (the &amp;#8220;Common&#13;Stock&amp;#8221;), and 1,000,000 of undesignated preferred stock, par value $0.01 (the &amp;#8220;Preferred Stock&amp;#8221;). As of December&#13;31, 2016, the Company had 26,550,974 shares of Common Stock issued and outstanding, and 9,736 shares of Series A Convertible Preferred&#13;Stock issued and outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;On November 28, 2016, the&#13;Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State&#13;of the State of Delaware to (i) effect the Reverse Stock Split, (ii) change its name from &amp;#8220;StemCells , Inc.&amp;#8221; to &amp;#8220;Microbot&#13;Medical Inc.&amp;#8221; and (iii) increase the number of authorized shares of the Common Stock from 200,000,000 to 220,000,000 shares&#13;(the &amp;#8220;Certificate of Amendment&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;As a result of the Reverse&#13;Stock Split, the number of issued and outstanding shares of the Common Stock immediately prior to the Reverse Stock Split were&#13;reduced into a smaller number of shares, such that every nine shares of the Common Stock held by a stockholder immediately prior&#13;to the Reverse Stock Split were combined and reclassified into one share of the Common Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Immediately following the&#13;Reverse Stock Split and the Merger, there were 36,254,240 shares of the Common Stock issued and outstanding, which included certain&#13;rights to receive shares of Common Stock or equivalent securities but excludes shares underlying outstanding stock options and&#13;warrants and the Convertible Note.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;On December 27, 2016, the&#13;Company exchanged 9,735,925 shares or rights to acquire shares of its Common Stock, for 9,736 shares of a newly designated class&#13;of Series A Convertible Preferred Stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;b&gt;Employee Stock Option Grant:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In September 2014, Microbot&#13;Israel&amp;#8217;s board of directors approved a grant of 403,592 stock options (1,167,693 stock options as retroactively adjusted&#13;to reflect the Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise&#13;price of $0.8 ($0.28 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;On May 2, 2016, Microbot Israel&amp;#8217;s&#13;board of directors approved a grant of 500,000 stock options (1,447,223 as retroactively adjusted to reflect the Merger) to certain&#13;of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel,&#13;at an exercise price equal to the ordinary share&amp;#8217;s par value. The stock options were fully vested at the date of grant. As&#13;a result, the Company recognized compensation expenses in the amount of $675,389 included in general and administrative expenses.&#13;As the exercise price of the stock options is nominal, Microbot Israel estimated the fair value of the options as equal to the&#13;Company&amp;#8217;s share price of $1.35 ($0.47 as retroactively adjusted to reflect the Merger) at the date of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;A summary of the Company&amp;#8217;s&#13;option activity related to options to employees and directors, and related information is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the year ended December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of stock options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted average exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,611,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested and expected-to-vest at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;15,611,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less than $0.01.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For the year ended December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number of stock options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted average exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vested and expected-to-vest at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The aggregate intrinsic value&#13;in the table above represents the total intrinsic value (the difference between the fair market value of the Company&amp;#8217;s and&#13;Microbot Israel&amp;#8217;s common shares on December 31, 2016 and December 31, 2015 respectively and the exercise price, multiplied&#13;by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock&#13;option holders exercised their stock options on those dates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The stock options outstanding&#13;as of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock options outstanding as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted average remaining contractual life &amp;#8211; years as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock options exercisable as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less than $0.01.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;Compensation expense recorded&#13;by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December&#13;31, 2016 and 2015 was $675,389 and $186,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The fair value of the stock&#13;options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;77.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;70.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of up to (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Shares issued to service&#13;provider&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In connection with the Merger,&#13;the Company issued an aggregate of 7,802,639 restricted shares of its common stock to certain advisors. The fair value of the award&#13;of $9,987,000 was estimated based on the Company&amp;#8217;s common share price of $1.28 as of the date of grant. The portion of the&#13;expense in excess of the cash and other current assets acquired in the Merger, in the amount of $7,262,000, was included in general&#13;and administrative expenses in the Statement of Operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Securities Exchange Agreement&#13;with Alpha Capital &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;On December 16, 2016, the&#13;Company entered into a Securities Exchange Agreement with Alpha Capital, pursuant to which Alpha Capital exchanged 9,736,000 shares&#13;of common stock or rights to acquire shares of the common stock held by it, for 9,736 shares of a newly designated class of Series&#13;A Convertible Preferred Stock, par value $0.01 per share (the &amp;#8220;Preferred Stock&amp;#8221;). The common stock and common stock&#13;underlying the rights to acquire common stock include all of the shares of common stock issued or issuable to Alpha Capital pursuant&#13;to the Merger.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The 9,735,925 shares of common&#13;stock and the rights to acquire common stock were cancelled and the Company&amp;#8217;s issued and outstanding shares of Common Stock&#13;were reduced to 26,518,315.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Repurchase of Shares&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company intends to enter&#13;into a definitive agreement with up to three Israeli shareholders that were former shareholders of Microbot Medical Ltd., pursuant&#13;to which the Company would repurchase, at a discount on the fair value of the share at the date of repurchase, up to $500,000 of&#13;the Company&amp;#8217;s common stock held by them, in the aggregate, if and to the extent such shareholders are unable to sell enough&#13;of their shares to cover certain of their Israeli tax liabilities resulting from the Merger. Such repurchase(s), if any, would&#13;occur only after the two year anniversary of the Merger. The transaction is subject to negotiating final terms and entering into&#13;definitive agreements with such shareholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company evaluated whether&#13;an embedded derivative that requires bifurcation exists within such shares that may be subject to repurchase. The Company concluded&#13;the fair value of such derivative instrument would be nominal and in any case would represent an asset to the Company as (a) the&#13;settlement requires acquiring the shares at a discount on the fair market value of the share at the time of re purchase and in&#13;no circumstances the acquisition price will be higher than approximately one dollar per share (representing 25% discount on the&#13;fair market value of the share at the merger closing date) and (b)it is assumed that the selling shareholders would use such right&#13;as last resort as such repurchase at a discount on the fair market value of such shares results in a loss to be incurred by the&#13;selling shareholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;In accordance with ASC 480-10-S99-3A&#13;(formerly EITF D-98), the Company classified the maximum amount it may be required to pay in the event the repurchase right is&#13;exercised ($500,000) as temporary equity.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The basic and diluted net loss per&#13;share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows&#13;(in thousands, except share and per share data):&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss attributable to shareholders of the company&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,663&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss attributable to shareholders of preferred shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3,954&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss used in the calculation of basic net loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,293,296&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,182,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;As the inclusion of common share&#13;equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic&#13;net loss per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The weighted average number of common&#13;shares outstanding has been retroactively restated for the equivalent number of common shares received by the accounting acquirer&#13;as a result of the reverse recapitalization and reverse stock split as if these common shares had been outstanding as of the beginning&#13;of the earliest period presented.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 RESEARCH AND DEVELOPMENT&#13;EXPENSES, NET&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Office and maintenance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Professional services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;365&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less grants received from Israeli Innovation Authority&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(213&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(201&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;901&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <MBOT:GeneralAndAdministrativeExpensesTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 GENERAL AND ADMINISTRATIVE EXPENSES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Professional services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;528&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Common shares issued for services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,258&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Travel&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;180&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Share-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;676&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</MBOT:GeneralAndAdministrativeExpensesTextBlock>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 14 - FINANCE EXPENSES, NET&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Bank fees and interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Change in fair value of derivative warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Exchange rate differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Revaluation and interest on convertible loans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 15 - TRANSACTIONS AND BALANCES&#13;WITH INTERESTED AND RELATED PARTIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;A. Transactions:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Directors fees and insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Subcontracted work and consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;B. Balances:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 16 - TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company is subject to&#13;income taxes under the Israeli and U.S. tax laws:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;Corporate tax rates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company is subject to&#13;Israeli corporate tax rate of 26.5% in the years 2015 and 2014, 25% in the year 2016, 24% in 2017 and 23% from 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The Company is subject to&#13;a blended U.S. tax rate (Federal as well as state corporate tax) of 35%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2016, the Company generated net operating losses in Israel of approximately $5,556, which may be carried forward and offset against taxable income in the future for an indefinite period.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2016, the Company generated net operating losses in the U.S. of approximately $475,496. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the &amp;#8220;change in ownership&amp;#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify; text-indent: -30.45pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss carry-forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total deferred tax assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net deferred tax assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 17 - SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-decoration: underline"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;u&gt;Purchase Agreement&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the &amp;#8220;Purchaser&amp;#8221;) for the purchase and sale of an aggregate of 700,000 shares of the Company&amp;#8217;s common stock in a registered direct offering for $5.00 per share or gross proceeds of $3.5 million. The Company paid the placement agent a fee of $210,000 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-decoration: underline"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;&lt;u&gt;Contract Research Agreement&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;On January 27, 2017, the Company entered into a Contract Research Agreement (the &amp;#8220;Research Agreement&amp;#8221;) with The Washington University (&amp;#8220;Washington U.&amp;#8221;), pursuant to which the parties will collaborate to determine the effectiveness of the Company&amp;#8217;s self-cleaning shunt. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The initial research to be performed by Washington U. is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The cost of the initial study, to be paid by the Company, is expected to be approximately $130,000, with the cost of any further studies to be determined. Pursuant to the Research Agreement, all rights, title and interest in the data, information and results obtained or arrived at by Washington U. in the performance of its services under the Research Agreement, as well as any patentable inventions obtained or arrived at in the performance of such services, will be jointly owned by the Company and Washington U., and each will have full right to practice and grant licenses in joint inventions. Additionally, Washington U. granted to the Company: (a) a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable license to use and practice patentable inventions (other than joint inventions and improvements to Washington U.&amp;#8217;s animal models) obtained or arrived at by Washington U. in the provision of its services under the Research Agreement (&amp;#8220;University Inventions&amp;#8221;) with respect to the self-cleaning shunt; and (b) an exclusive option to obtain an exclusive worldwide license in University Inventions, on terms to be negotiated between the parties.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;A.Basis of presentation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;US GAAP&amp;#8221;).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;B. Financial statement in U.S. dollars:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The functional currency of the Company is the U.S. dollar (&amp;#8220;dollar&amp;#8221;) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, &amp;#8220;Foreign Currency Translation&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;C. Cash and cash equivalents:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;D. Fair value of financial instruments:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The carrying values of cash and cash equivalents, other receivable and other accounts payable approximate their fair value due to the short-term maturity of these instruments.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 8.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 72px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 1 &lt;/b&gt;- Quoted prices (unadjusted) in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt; - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt; - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;E. Fixed assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Fixed assets are presented at cost, net of investment grants received and less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25-33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 77%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;F. Liabilities due to termination of employment agreements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (&amp;#8220;Article 14&amp;#8221;) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company&amp;#8217;s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;G. Basic and diluted net loss per share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Basic net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights by the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 &amp;#8220;Earnings per Share&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;H. Research and development expenses, net:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;I. Convertible notes:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 &amp;#8220;Debt with Conversion and Other Options&amp;#8221;, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the Notes.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, &amp;#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&amp;#8221;.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;J. Share-based compensation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company applies ASC 718-10, &amp;#8220;Share-Based Payment,&amp;#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to service providers, employees and directors including stock options under the Company&amp;#8217;s stock plans based on estimated fair values. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&amp;#8217;s statement of operations.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company&amp;#8217;s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the &amp;#8220;simplified&amp;#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;K. Reclassification:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Certain prior year amounts have been reclassified to conform to the current year presentation.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <MBOT:TransactionCostsPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;L. Transaction Costs:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</MBOT:TransactionCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="text-align: justify; width: 48px"&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;M. Recent Accounting Standards:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In May 2014, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for us beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it is unable to determine the expected impact the new standard will have on its consolidated financial statements.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In January 2016, the FASB issued ASU 2016-01 &amp;#8220;Recognition and Measurement of Financial Assets and Financial Liabilities&amp;#8221;, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (&amp;#8220;ASU 2016-02&amp;#8221;), which amends, among other things, the existing guidance by requiring lessees to recognize lease assets (right-to-use) and liabilities (for reasonably certain lease payments) arising from operating leases on the balance sheet. For leases with a term of twelve months or less, ASU 2016-02 permits an entity to make an accounting policy election to recognize such leases as lease expense, generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (&amp;#8220;ASU 2016-09&amp;#8221;), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments &amp;#8211; Credit Losses &amp;#8211; Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The standard is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. The Company is evaluating the impact of the adoption on our consolidated balance sheet, results of operations, cash flows and disclosures.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <MBOT:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25-33&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 77%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</MBOT:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;437&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Deposit in escrow account (*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;505&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Government institutions&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Prepaid expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Shareholders&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;606&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(*) Purchase Agreement with BOCO. &lt;/b&gt;On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &amp;#8220;Sellers&amp;#8221;), entered into an Asset Purchase Agreement (the &amp;#8220;Asset Purchase Agreement&amp;#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&amp;#8220;BOCO US&amp;#8221;). &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Cost:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;117&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Accumulated Depreciation:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Research equipment and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Furniture and office equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;64&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;121&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Government institution&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;24&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Other current liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Israeli Innovation Authority&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;582&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;149&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The remaining outstanding warrants and terms as of the closing date of the Merger (November 28, 2016) and as of Dec 31 2016 is as follows: &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Issuance Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Outstanding as of November 28, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Per Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable as of December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercisable &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Through&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 30%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2011)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,230&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$151.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2013)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$194.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;October 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2013)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$183.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2023&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2015)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$91.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;April 2020&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series A (2016)(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Series B (2016)(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;41,116&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;March 2022&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;__________________&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(a)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of November 28, 2016 and December 31, 2016 (in thousands):&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid"&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;        &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Series A&lt;br /&gt;&#13;        (2011)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Series A (2013)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Series A (2013)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Series A (2015)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Series A&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(2016)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Series B&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(2016)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 44%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Balances at November 28, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;81&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;388&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 5%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Changes in fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(38&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(161&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Balances at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;227&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;313&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;A summary of the Company&amp;#8217;s&#13;option activity related to options to employees and directors, and related information is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the year ended December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of stock options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted average exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,611,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Vested and expected-to-vest at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.39&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,611,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Less than $0.01.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;For the year ended December 31, 2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of stock options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted average exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at beginning of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Vested and expected-to-vest at end of period&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The fair value of the stock options&#13;is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;77.3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;70.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Risk-free interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Expected life of up to (years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The basic and diluted net loss per&#13;share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows&#13;(in thousands, except share and per share data):&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss attributable to shareholders of the company&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,663&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;921&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss attributable to shareholders of preferred shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3,954&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss used in the calculation of basic net loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,709&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;561&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;14,293,296&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;13,182,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;155&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Patents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;37&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Office and maintenance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Professional services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;365&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;100&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less grants received from Israeli Innovation Authority&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(213&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(201&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;901&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;823&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <MBOT:ScheduleofGeneralandAdministrativeExpenseTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Professional services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;528&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;40&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Common shares issued for services&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,258&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Travel&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;180&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;47&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Share-based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;676&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;92&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</MBOT:ScheduleofGeneralandAdministrativeExpenseTableTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Years ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Bank fees and interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Change in fair value of derivative warrant liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Exchange rate differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(44&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Revaluation and interest on convertible loans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;A. Transactions:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Payroll and related expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Directors fees and insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Subcontracted work and consulting&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;253&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;122&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;b&gt;B. Balances:&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss carry-forward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Total deferred tax assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(481,052&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(471,980&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net deferred tax assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">54000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">606000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">149000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" decimals="-3">582000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AdditionalPaidInCapital contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" id="Foot-00-10" decimals="-3">3089000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2016-12-31" unitRef="USD" id="Foot-00-11" decimals="-3">14465000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">9635000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">915000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">28000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="-3">6000</us-gaap:InterestAndDebtExpense>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="-3">676000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="USD" decimals="-3">10000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2016-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2016-09-28to2016-09-30_custom_MicrobotIsraelMember" unitRef="USD" decimals="0">409750</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2016-01-01to2016-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;The stock options outstanding as&#13;of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock options outstanding as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted average remaining contractual life &amp;#8211; years as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Stock options exercisable as of December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 17%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,447,223&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,614,916&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,167,693&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 1pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;(*)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Less than $0.01.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2016-01-01to2016-12-31_custom_ExercisePriceOneMember" unitRef="USDPShares" decimals="INF">0.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_ExercisePriceOneMember" unitRef="USDPShares" decimals="INF">0.28</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2016-01-01to2016-12-31_custom_ExercisePriceTwoMember" unitRef="USDPShares" id="Foot-06-0" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2015-01-01to2015-12-31_custom_ExercisePriceTwoMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">2614916</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_ExercisePriceOneMember" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2016-12-31_custom_ExercisePriceOneMember" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2016-12-31_custom_ExercisePriceTwoMember" unitRef="Shares" decimals="INF">1447223</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2015-12-31_custom_ExercisePriceTwoMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="eol_PE9562----168-K-0007_STD_0_20151231_0" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">2614916</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_ExercisePriceOneMember" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2016-12-31_custom_ExercisePriceOneMember" unitRef="Shares" decimals="INF">1167693</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2016-12-31_custom_ExercisePriceTwoMember" unitRef="Shares" decimals="INF">1447223</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2015-12-31_custom_ExercisePriceTwoMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="From2016-01-01to2016-12-31_custom_DefinitiveAgreementMember_custom_ThreeIsraeliShareholdersMember" unitRef="USD" decimals="0">500000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <MBOT:PercentageOfDiscountOnFairMarketValueOfCommonStock contextRef="From2016-01-01to2016-12-31_custom_DefinitiveAgreementMember_custom_ThreeIsraeliShareholdersMember" unitRef="Pure" decimals="INF">0.25</MBOT:PercentageOfDiscountOnFairMarketValueOfCommonStock>
    <dei:DocumentFiscalYearFocus contextRef="From2016-01-01to2016-12-31">2016</dei:DocumentFiscalYearFocus>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-2" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-3" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-4" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-5" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-6" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-7" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-8" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-9" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-10" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-11" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-4" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-5" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-6" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-7" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-8" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-9" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-10" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-11" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-12" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-13" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-14" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-15" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-16" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-17" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-18" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-19" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-20" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-21" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-22" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-23" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-24" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-25" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-26" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-27" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-28" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-29" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-30" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-31" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-32" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-33" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-34" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-35" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-36" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-37" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-03" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-0" xlink:label="Foot-02_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-02_loc" xlink:to="Footnote-04" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-0" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-1" xlink:label="Foot-03_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-03_loc" xlink:to="Footnote-05" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-0" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-1" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-2" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-3" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-4" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-5" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-6" xlink:label="Foot-04_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-7" xlink:label="Foot-04_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-04_loc" xlink:to="Footnote-06" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-0" xlink:label="Foot-05_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-05_loc" xlink:to="Footnote-07" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-0" xlink:label="Foot-06_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-06_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Less than 1</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">December 31 2015 share data represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28 2016.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">Share data for periods prior to the reverse recapitalization represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28, 2016</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">Includes 10,702,838 shares of common stock classified as temporary equity.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">Purchase Agreement with BOCO. On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &#8220;Sellers&#8221;), entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&#8220;BOCO US&#8221;).</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-07" xml:lang="en-US">Less than $0.01.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>mbot-20161231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayEebP9z5Z8KekhvWB2bdmKfyUvRtKTIyxXJoumke4L -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:MBOT="http://microbotmedical.com/20161231" elementFormDefault="qualified" targetNamespace="http://microbotmedical.com/20161231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://microbotmedical.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" id="StatementsOfComprehensiveLoss">
	  <link:definition>00000004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" id="StatementsOfShareholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Consolidated Statements of Shareholder's Equity (Deficit)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" id="StatementsOfShareholdersEquityDeficitParenthetical">
	  <link:definition>00000006 - Statement - Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/General" id="General">
	  <link:definition>00000008 - Disclosure - General</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
	  <link:definition>00000010 - Disclosure - Cash and Cash Equivalents</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/OtherReceivables" id="OtherReceivables">
	  <link:definition>00000011 - Disclosure - Other Receivables</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000012 - Disclosure - Fixed Assets, Net</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/AccruedLiabilities" id="AccruedLiabilities">
	  <link:definition>00000013 - Disclosure - Accrued Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" id="ConvertibleLoanFromShareholders">
	  <link:definition>00000014 - Disclosure - Convertible Loan from Shareholders</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities" id="DerivativeWarrantLiabilities">
	  <link:definition>00000015 - Disclosure - Derivative Warrant Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/Commitments" id="Commitments">
	  <link:definition>00000016 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapital" id="ShareCapital">
	  <link:definition>00000017 - Disclosure - Share Capital</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" id="BasicAndDilutedNetLossPerShare">
	  <link:definition>00000018 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" id="ResearchAndDevelopmentExpensesNet">
	  <link:definition>00000019 - Disclosure - Research and Development Expenses, Net</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" id="GeneralAndAdministrativeExpenses">
	  <link:definition>00000020 - Disclosure - General and Administrative Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FinanceExpensesNet" id="FinanceExpensesNet">
	  <link:definition>00000021 - Disclosure - Finance Expenses, Net</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" id="TransactionsAndBalancesWithInterestedAndRelatedParties">
	  <link:definition>00000022 - Disclosure - Transactions and Balances with Interested and Related Parties</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TaxesOnIncome" id="TaxesOnIncome">
	  <link:definition>00000023 - Disclosure - Taxes on Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000024 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
	  <link:definition>00000027 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/OtherReceivablesTables" id="OtherReceivablesTables">
	  <link:definition>00000028 - Disclosure - Other Receivables (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000029 - Disclosure - Fixed Assets, Net (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
	  <link:definition>00000030 - Disclosure - Accrued Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" id="DerivativeWarrantLiabilitiesTables">
	  <link:definition>00000031 - Disclosure - Derivative Warrant Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapitalTables" id="ShareCapitalTables">
	  <link:definition>00000032 - Disclosure - Share Capital (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" id="BasicAndDilutedNetLossPerShareTables">
	  <link:definition>00000033 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" id="ResearchAndDevelopmentExpensesNetTables">
	  <link:definition>00000034 - Disclosure - Research and Development Expenses, Net (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" id="GeneralAndAdministrativeExpensesTables">
	  <link:definition>00000035 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FinanceExpensesNetTables" id="FinanceExpensesNetTables">
	  <link:definition>00000036 - Disclosure - Finance Expenses, Net (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" id="TransactionsAndBalancesWithInterestedAndRelatedPartiesTables">
	  <link:definition>00000037 - Disclosure - Transactions and Balances with Interested and Related Parties (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TaxesOnIncomeTables" id="TaxesOnIncomeTables">
	  <link:definition>00000038 - Disclosure - Taxes on Income (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/GeneralDetailsNarrative" id="GeneralDetailsNarrative">
	  <link:definition>00000039 - Disclosure - General (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" id="SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail">
	  <link:definition>00000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" id="CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails">
	  <link:definition>00000041 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" id="OtherReceivablesDetailsNarrative">
	  <link:definition>00000042 - Disclosure - Other Receivables (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" id="OtherReceivables-ScheduleOfOtherAssets-Details">
	  <link:definition>00000043 - Disclosure - Other Receivables - Schedule of Other Assets - (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" id="FixedAssetsNet-SummaryOfFixedAssetsNetDetails">
	  <link:definition>00000044 - Disclosure - Fixed Assets, Net - Summary of Fixed Assets, Net (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" id="AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" id="ConvertibleLoanFromShareholdersDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Convertible Loan from Shareholders (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" id="DerivativeWarrantLiabilitiesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Derivative Warrant Liabilities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" id="DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails">
	  <link:definition>00000048 - Disclosure - Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" id="DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails">
	  <link:definition>00000049 - Disclosure - Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" id="ShareCapitalDetailsNarrative">
	  <link:definition>00000051 - Disclosure - Share Capital (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" id="ShareCapital-SummaryOfStockOptionActivityDetails">
	  <link:definition>00000052 - Disclosure - Share Capital - Summary of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" id="ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical">
	  <link:definition>00000053 - Disclosure - Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" id="ShareCapital-ScheduleOfStockOptionsOutstandingDetails">
	  <link:definition>00000054 - Disclosure - Share Capital - Schedule of Stock Options Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" id="ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails">
	  <link:definition>00000055 - Disclosure - Share Capital - Schedule of Stock Options Valuation Assumptions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" id="BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails">
	  <link:definition>00000056 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" id="ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails">
	  <link:definition>00000057 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" id="GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails">
	  <link:definition>00000058 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" id="FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails">
	  <link:definition>00000059 - Disclosure - Finance Expenses, Net - Summary of Finance Expenses, Net (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" id="TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails">
	  <link:definition>00000060 - Disclosure - Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" id="TaxesOnIncomeDetailsNarrative">
	  <link:definition>00000061 - Disclosure - Taxes on Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" id="TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails">
	  <link:definition>00000062 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000063 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
    <element id="MBOT_EffectOfReverseRecapitalizationShares" name="EffectOfReverseRecapitalizationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_EffectOfReverseRecapitalization" name="EffectOfReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" name="TransactionCostsIncurredInReverseRecapitalizationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TransactionCostsIncurredInReverseRecapitalization" name="TransactionCostsIncurredInReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ReverseRecapitalizationEffectOnEquity" name="ReverseRecapitalizationEffectOnEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_CashAcquiredInConnectionWithReverseRecapitalization" name="CashAcquiredInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" name="AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" name="InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" name="ExerciseOfWarrantsIssuedUponConversionOfNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PercentageOfSeveranceAward" name="PercentageOfSeveranceAward" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_WarrantCalculationDescription" name="WarrantCalculationDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DerivativeWarrantLiabilitiesExercised" name="DerivativeWarrantLiabilitiesExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DerivativeWarrantLiabilitiesCancelled" name="DerivativeWarrantLiabilitiesCancelled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" name="DerivativeWarrantLiabilitiesBeginningBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_NetSalesRoyaltyPercentage" name="NetSalesRoyaltyPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_RightsToAcquireSharesOfCommonStock" name="RightsToAcquireSharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DesignatedPreferredStock" name="DesignatedPreferredStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_OperatingLossCarryforwardsExpiration" name="OperatingLossCarryforwardsExpiration" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" name="PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_CostOfInitialStudy" name="CostOfInitialStudy" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_GeneralAndAdministrativeExpensesTextBlock" name="GeneralAndAdministrativeExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TransactionCostsPolicyTextBlock" name="TransactionCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" name="ScheduleofGeneralandAdministrativeExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" name="PercentageOfDiscountOnFairMarketValueOfCommonStock" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" name="PreferredASharesMicrobotMedicalLtdPreMergerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" name="PreferredASharesMicrobotMedicalLtdPostMergerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TemporaryEquityMember" name="TemporaryEquityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_MicrobotIsraelMember" name="MicrobotIsraelMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_FormerMicrobotIsraelShareholdersMember" name="FormerMicrobotIsraelShareholdersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ResearchEquipmentAndSoftwareMember" name="ResearchEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DepositInEscrowAccountMember" name="DepositInEscrowAccountMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PriorToNovemberElevenTwoThousandSixteenMember" name="PriorToNovemberElevenTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_JuneTwoThousansdSixteenAgreementsMember" name="JuneTwoThousansdSixteenAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" name="PriorToDecemberThirtyFirstTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_AlphaCapitalMember" name="AlphaCapitalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_MergerAgreementMember" name="MergerAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" name="TwoThousandSixteenSeriesAandBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandSixteenSeriesAWarrantsMember" name="TwoThousandSixteenSeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DecreaseMember" name="DecreaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_IncreaseMember" name="IncreaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesATwoThousandAndElevenMember" name="SeriesATwoThousandAndElevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesATwoThousandAndThirteenMember" name="SeriesATwoThousandAndThirteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesATwoThousandAndThirteenOneMember" name="SeriesATwoThousandAndThirteenOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesATwoThousandAndFifteenMember" name="SeriesATwoThousandAndFifteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesATwoThousandAndSixteenMember" name="SeriesATwoThousandAndSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SeriesBTwoThousandAndSixteenMember" name="SeriesBTwoThousandAndSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_IsraeliInnovationAuthorityMember" name="IsraeliInnovationAuthorityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandThirteenToSixteenMember" name="TwoThousandThirteenToSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" name="TheTechnicianResearchAndDevelopmentFoundationLimitedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_OfficeLeaseAgreementMember" name="OfficeLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_CarLeaseAgreementMember" name="CarLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_FormerExecutiveMember" name="FormerExecutiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_BoardofDirectorsMember" name="BoardofDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_MEDXVentureGroupLLCMember" name="MEDXVentureGroupLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_EmployeesandDirectorsMember" name="EmployeesandDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_AdvisorsMember" name="AdvisorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_SecuritiesExchangeAgreementMember" name="SecuritiesExchangeAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_InterestedandRelatedPartiesMember" name="InterestedandRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandFourteenMember" name="TwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandFifteenMember" name="TwoThousandFifteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandSixteenMember" name="TwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandSeventeenMember" name="TwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_TwoThousandEighteenMember" name="TwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_USTaxAuthorityMember" name="USTaxAuthorityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DefinitiveSecuritiesPurchaseAgreementMember" name="DefinitiveSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ContractResearchAgreementMember" name="ContractResearchAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_LoanMember" name="LoanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ExercisePriceOneMember" name="ExercisePriceOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ExercisePriceTwoMember" name="ExercisePriceTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DefinitiveAgreementMember" name="DefinitiveAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_ThreeIsraeliShareholdersMember" name="ThreeIsraeliShareholdersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_EscrowAccountMember" name="EscrowAccountMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DerivativeWarrantLiabilitiesScheduleOfOutstandingWarrantsLiabilitiesDetailsAbstract" name="DerivativeWarrantLiabilitiesScheduleOfOutstandingWarrantsLiabilitiesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MBOT_DerivativeWarrantLiabilitiesScheduleOfValuationOfDerivativeWarrantLiabilitiesDetailsAbstract" name="DerivativeWarrantLiabilitiesScheduleOfValuationOfDerivativeWarrantLiabilitiesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>mbot-20161231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:href="mbot-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheets" xlink:href="mbot-20161231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:href="mbot-20161231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:href="mbot-20161231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:href="mbot-20161231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/General" xlink:href="mbot-20161231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables" xlink:href="mbot-20161231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet" xlink:href="mbot-20161231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities" xlink:href="mbot-20161231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholders" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/Commitments" xlink:href="mbot-20161231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital" xlink:href="mbot-20161231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet" xlink:href="mbot-20161231.xsd#FinanceExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome" xlink:href="mbot-20161231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEvents" xlink:href="mbot-20161231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:href="mbot-20161231.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesTables" xlink:href="mbot-20161231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:href="mbot-20161231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:href="mbot-20161231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalTables" xlink:href="mbot-20161231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:href="mbot-20161231.xsd#FinanceExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:href="mbot-20161231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:href="mbot-20161231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:href="mbot-20161231.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:href="mbot-20161231.xsd#OtherReceivables-ScheduleOfOtherAssets-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:href="mbot-20161231.xsd#FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:href="mbot-20161231.xsd#AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:href="mbot-20161231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:href="mbot-20161231.xsd#ShareCapitalDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:href="mbot-20161231.xsd#FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:href="mbot-20161231.xsd#TaxesOnIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:href="mbot-20161231.xsd#TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:href="mbot-20161231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Shareholder's Equity (Deficit)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="loc_us-gaapInterestOnConvertibleDebtNetOfTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestOnConvertibleDebtNetOfTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:label="loc_MBOTAcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MBOTAcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:label="loc_MBOTInflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MBOTInflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:label="loc_MBOTExerciseOfWarrantsIssuedUponConversionOfNotes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_MBOTExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/General" xlink:title="00000008 - Disclosure - General" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - Cash and Cash Equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables" xlink:title="00000011 - Disclosure - Other Receivables" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet" xlink:title="00000012 - Disclosure - Fixed Assets, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - Accrued Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:title="00000014 - Disclosure - Convertible Loan from Shareholders" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:title="00000015 - Disclosure - Derivative Warrant Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Commitments" xlink:title="00000016 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital" xlink:title="00000017 - Disclosure - Share Capital" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:title="00000018 - Disclosure - Basic and Diluted Net Loss Per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="00000019 - Disclosure - Research and Development Expenses, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000020 - Disclosure - General and Administrative Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet" xlink:title="00000021 - Disclosure - Finance Expenses, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:title="00000022 - Disclosure - Transactions and Balances with Interested and Related Parties" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome" xlink:title="00000023 - Disclosure - Taxes on Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:title="00000027 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesTables" xlink:title="00000028 - Disclosure - Other Receivables (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:title="00000029 - Disclosure - Fixed Assets, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:title="00000031 - Disclosure - Derivative Warrant Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalTables" xlink:title="00000032 - Disclosure - Share Capital (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:title="00000033 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="00000034 - Disclosure - Research and Development Expenses, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000035 - Disclosure - General and Administrative Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:title="00000036 - Disclosure - Finance Expenses, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:title="00000037 - Disclosure - Transactions and Balances with Interested and Related Parties (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:title="00000038 - Disclosure - Taxes on Income (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:title="00000039 - Disclosure - General (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000041 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaapTimeDepositsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapTimeDepositsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000042 - Disclosure - Other Receivables (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:title="00000043 - Disclosure - Other Receivables - Schedule of Other Assets - (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherReceivablesNetCurrent" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaapGovernmentContractReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherReceivablesNetCurrent" xlink:to="loc_us-gaapGovernmentContractReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherReceivablesNetCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherReceivablesNetCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:title="00000044 - Disclosure - Fixed Assets, Net - Summary of Fixed Assets, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="loc_us-gaapRefundsDueUnderGovernmentContracts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapRefundsDueUnderGovernmentContracts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Loan from Shareholders (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:title="00000047 - Disclosure - Derivative Warrant Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:title="00000048 - Disclosure - Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:title="00000049 - Disclosure - Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:title="00000050 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="00000051 - Disclosure - Share Capital (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:title="00000052 - Disclosure - Share Capital - Summary of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:title="00000053 - Disclosure - Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:title="00000054 - Disclosure - Share Capital - Schedule of Stock Options Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000055 - Disclosure - Share Capital - Schedule of Stock Options Valuation Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000056 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000057 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_us-gaapRevenueFromGrants" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000058 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:title="00000059 - Disclosure - Finance Expenses, Net - Summary of Finance Expenses, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestAndDebtExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestAndDebtExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestAndDebtExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInterestAndDebtExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:title="00000060 - Disclosure - Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpensesRelatedParty" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpensesRelatedParty" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpensesRelatedParty" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="00000061 - Disclosure - Taxes on Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000062 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>mbot-20161231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:href="mbot-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheets" xlink:href="mbot-20161231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:href="mbot-20161231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:href="mbot-20161231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:href="mbot-20161231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/General" xlink:href="mbot-20161231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables" xlink:href="mbot-20161231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet" xlink:href="mbot-20161231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities" xlink:href="mbot-20161231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholders" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/Commitments" xlink:href="mbot-20161231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital" xlink:href="mbot-20161231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet" xlink:href="mbot-20161231.xsd#FinanceExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome" xlink:href="mbot-20161231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEvents" xlink:href="mbot-20161231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:href="mbot-20161231.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesTables" xlink:href="mbot-20161231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:href="mbot-20161231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:href="mbot-20161231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalTables" xlink:href="mbot-20161231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:href="mbot-20161231.xsd#FinanceExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:href="mbot-20161231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:href="mbot-20161231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:href="mbot-20161231.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:href="mbot-20161231.xsd#OtherReceivables-ScheduleOfOtherAssets-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:href="mbot-20161231.xsd#FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:href="mbot-20161231.xsd#AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:href="mbot-20161231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:href="mbot-20161231.xsd#ShareCapitalDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:href="mbot-20161231.xsd#FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:href="mbot-20161231.xsd#TaxesOnIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:href="mbot-20161231.xsd#TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:href="mbot-20161231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Shareholder's Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TemporaryEquityMember" xlink:label="loc_MBOTTemporaryEquityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MBOTTemporaryEquityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:label="loc_MBOTPreferredASharesMicrobotMedicalLtdPreMergerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MBOTPreferredASharesMicrobotMedicalLtdPreMergerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:label="loc_MBOTPreferredASharesMicrobotMedicalLtdPostMergerMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_MBOTPreferredASharesMicrobotMedicalLtdPostMergerMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalization" xlink:label="loc_MBOTEffectOfReverseRecapitalization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTEffectOfReverseRecapitalization_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalizationShares" xlink:label="loc_MBOTEffectOfReverseRecapitalizationShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTEffectOfReverseRecapitalizationShares_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalization_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalization_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalizationShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalizationShares_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_80" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/General" xlink:title="00000008 - Disclosure - General" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - Cash and Cash Equivalents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables" xlink:title="00000011 - Disclosure - Other Receivables" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet" xlink:title="00000012 - Disclosure - Fixed Assets, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - Accrued Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:title="00000014 - Disclosure - Convertible Loan from Shareholders" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:title="00000015 - Disclosure - Derivative Warrant Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Commitments" xlink:title="00000016 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital" xlink:title="00000017 - Disclosure - Share Capital" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:title="00000018 - Disclosure - Basic and Diluted Net Loss Per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="00000019 - Disclosure - Research and Development Expenses, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000020 - Disclosure - General and Administrative Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet" xlink:title="00000021 - Disclosure - Finance Expenses, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:title="00000022 - Disclosure - Transactions and Balances with Interested and Related Parties" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome" xlink:title="00000023 - Disclosure - Taxes on Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:title="00000027 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesTables" xlink:title="00000028 - Disclosure - Other Receivables (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:title="00000029 - Disclosure - Fixed Assets, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:title="00000031 - Disclosure - Derivative Warrant Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalTables" xlink:title="00000032 - Disclosure - Share Capital (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:title="00000033 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="00000034 - Disclosure - Research and Development Expenses, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000035 - Disclosure - General and Administrative Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:title="00000036 - Disclosure - Finance Expenses, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:title="00000037 - Disclosure - Transactions and Balances with Interested and Related Parties (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:title="00000038 - Disclosure - Taxes on Income (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:title="00000039 - Disclosure - General (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerMicrobotIsraelShareholdersMember" xlink:label="loc_MBOTFormerMicrobotIsraelShareholdersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTFormerMicrobotIsraelShareholdersMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ResearchEquipmentAndSoftwareMember" xlink:label="loc_MBOTResearchEquipmentAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTResearchEquipmentAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FurnitureAndOfficeEquipmentMember" xlink:label="loc_MBOTFurnitureAndOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTFurnitureAndOfficeEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000041 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000042 - Disclosure - Other Receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToNovemberElevenTwoThousandSixteenMember" xlink:label="loc_MBOTPriorToNovemberElevenTwoThousandSixteenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_MBOTPriorToNovemberElevenTwoThousandSixteenMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:label="loc_MBOTPriorToDecemberThirtyFirstTwoThousandSixteenMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_MBOTPriorToDecemberThirtyFirstTwoThousandSixteenMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EscrowAccountMember" xlink:label="loc_MBOTEscrowAccountMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_MBOTEscrowAccountMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_JuneTwoThousansdSixteenAgreementsMember" xlink:label="loc_MBOTJuneTwoThousansdSixteenAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTJuneTwoThousansdSixteenAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfSeveranceAward" xlink:label="loc_MBOTPercentageOfSeveranceAward_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPercentageOfSeveranceAward_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:title="00000043 - Disclosure - Other Receivables - Schedule of Other Assets - (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:title="00000044 - Disclosure - Fixed Assets, Net - Summary of Fixed Assets, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ResearchEquipmentAndSoftwareMember" xlink:label="loc_MBOTResearchEquipmentAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTResearchEquipmentAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Loan from Shareholders (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AlphaCapitalMember" xlink:label="loc_MBOTAlphaCapitalMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTAlphaCapitalMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_LoanMember" xlink:label="loc_MBOTLoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MBOTLoanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapSecuredDebtMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ConvertibleNoteMember" xlink:label="loc_MBOTConvertibleNoteMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MBOTConvertibleNoteMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MergerAgreementMember" xlink:label="loc_MBOTMergerAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTMergerAgreementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaapFairValueInputsDiscountRate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueInputsDiscountRate_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_150" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:title="00000047 - Disclosure - Derivative Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" xlink:label="loc_MBOTTwoThousandSixteenSeriesAandBWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_MBOTTwoThousandSixteenSeriesAandBWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAWarrantsMember" xlink:label="loc_MBOTTwoThousandSixteenSeriesAWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_MBOTTwoThousandSixteenSeriesAWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DecreaseMember" xlink:label="loc_MBOTDecreaseMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTDecreaseMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IncreaseMember" xlink:label="loc_MBOTIncreaseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTIncreaseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_investInvestmentWarrantsExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentWarrantsExercisePrice_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_WarrantCalculationDescription" xlink:label="loc_MBOTWarrantCalculationDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTWarrantCalculationDescription_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:title="00000048 - Disclosure - Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndElevenMember" xlink:label="loc_MBOTSeriesATwoThousandAndElevenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndElevenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenOneMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndFifteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndFifteenMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndFifteenMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndSixteenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndSixteenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesBTwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesBTwoThousandAndSixteenMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesBTwoThousandAndSixteenMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:label="loc_MBOTShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_190" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:title="00000049 - Disclosure - Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndElevenMember" xlink:label="loc_MBOTSeriesATwoThousandAndElevenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndElevenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndFifteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndFifteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndFifteenMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndSixteenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndSixteenMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesBTwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesBTwoThousandAndSixteenMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesBTwoThousandAndSixteenMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesExercised" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesExercised_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesCancelled" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesCancelled_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesCancelled_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:title="00000050 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IsraeliInnovationAuthorityMember" xlink:label="loc_MBOTIsraeliInnovationAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_MBOTIsraeliInnovationAuthorityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandThirteenToSixteenMember" xlink:label="loc_MBOTTwoThousandThirteenToSixteenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MBOTTwoThousandThirteenToSixteenMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:label="loc_MBOTTheTechnicianResearchAndDevelopmentFoundationLimitedMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTTheTechnicianResearchAndDevelopmentFoundationLimitedMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OfficeLeaseAgreementMember" xlink:label="loc_MBOTOfficeLeaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTOfficeLeaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CarLeaseAgreementMember" xlink:label="loc_MBOTCarLeaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTCarLeaseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerExecutiveMember" xlink:label="loc_MBOTFormerExecutiveMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTFormerExecutiveMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromGrants_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_NetSalesRoyaltyPercentage" xlink:label="loc_MBOTNetSalesRoyaltyPercentage_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTNetSalesRoyaltyPercentage_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLeaseCommissions" xlink:label="loc_us-gaapPaymentsForLeaseCommissions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLeaseCommissions_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOfficersCompensation_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="00000051 - Disclosure - Share Capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_BoardofDirectorsMember" xlink:label="loc_MBOTBoardofDirectorsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTBoardofDirectorsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EmployeesandDirectorsMember" xlink:label="loc_MBOTEmployeesandDirectorsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTEmployeesandDirectorsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AdvisorsMember" xlink:label="loc_MBOTAdvisorsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTAdvisorsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MEDXVentureGroupLLCMember" xlink:label="loc_MBOTMEDXVentureGroupLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMEDXVentureGroupLLCMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AlphaCapitalMember" xlink:label="loc_MBOTAlphaCapitalMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTAlphaCapitalMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SecuritiesExchangeAgreementMember" xlink:label="loc_MBOTSecuritiesExchangeAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTSecuritiesExchangeAgreementMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveAgreementMember" xlink:label="loc_MBOTDefinitiveAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTDefinitiveAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ThreeIsraeliShareholdersMember" xlink:label="loc_MBOTThreeIsraeliShareholdersMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTThreeIsraeliShareholdersMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_RightsToAcquireSharesOfCommonStock" xlink:label="loc_MBOTRightsToAcquireSharesOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTRightsToAcquireSharesOfCommonStock_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DesignatedPreferredStock" xlink:label="loc_MBOTDesignatedPreferredStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDesignatedPreferredStock_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_200" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_200" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_200" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_200" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_200" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_200" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_200" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_200" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_200" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:label="loc_MBOTPercentageOfDiscountOnFairMarketValueOfCommonStock_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPercentageOfDiscountOnFairMarketValueOfCommonStock_200" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:title="00000052 - Disclosure - Share Capital - Summary of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:title="00000053 - Disclosure - Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:title="00000054 - Disclosure - Share Capital - Schedule of Stock Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceOneMember" xlink:label="loc_MBOTExercisePriceOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTExercisePriceOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceTwoMember" xlink:label="loc_MBOTExercisePriceTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTExercisePriceTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000055 - Disclosure - Share Capital - Schedule of Stock Options Valuation Assumptions (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000056 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000057 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServicesDirectMaterials" xlink:label="loc_us-gaapCostOfServicesDirectMaterials_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfServicesDirectMaterials_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRoyaltyExpense_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaapMaintenanceCosts_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMaintenanceCosts_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromGrants_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_30" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000058 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:title="00000059 - Disclosure - Finance Expenses, Net - Summary of Finance Expenses, Net (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:title="00000060 - Disclosure - Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InterestedandRelatedPartiesMember" xlink:label="loc_MBOTInterestedandRelatedPartiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTInterestedandRelatedPartiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent_50" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="00000061 - Disclosure - Taxes on Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_USTaxAuthorityMember" xlink:label="loc_MBOTUSTaxAuthorityMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MBOTUSTaxAuthorityMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFifteenMember" xlink:label="loc_MBOTTwoThousandFifteenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandFifteenMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFourteenMember" xlink:label="loc_MBOTTwoThousandFourteenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandFourteenMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenMember" xlink:label="loc_MBOTTwoThousandSixteenMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandSixteenMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSeventeenMember" xlink:label="loc_MBOTTwoThousandSeventeenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandSeventeenMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandEighteenMember" xlink:label="loc_MBOTTwoThousandEighteenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandEighteenMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OperatingLossCarryforwardsExpiration" xlink:label="loc_MBOTOperatingLossCarryforwardsExpiration_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTOperatingLossCarryforwardsExpiration_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000062 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="loc_MBOTDefinitiveSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTDefinitiveSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ContractResearchAgreementMember" xlink:label="loc_MBOTContractResearchAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTContractResearchAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:label="loc_MBOTPlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CostOfInitialStudy" xlink:label="loc_MBOTCostOfInitialStudy_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTCostOfInitialStudy_40" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>mbot-20161231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:to="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember_lbl" xml:lang="en-US">Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:to="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember_lbl" xml:lang="en-US">Preferred A Shares Microbot Medical Ltd. Post-Merger [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TemporaryEquityMember" xlink:label="MBOT_TemporaryEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TemporaryEquityMember" xlink:to="MBOT_TemporaryEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TemporaryEquityMember_lbl" xml:lang="en-US">Temporary Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="MBOT_MicrobotIsraelMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MicrobotIsraelMember" xlink:to="MBOT_MicrobotIsraelMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_MicrobotIsraelMember_lbl" xml:lang="en-US">Microbot Israel [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerMicrobotIsraelShareholdersMember" xlink:label="MBOT_FormerMicrobotIsraelShareholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FormerMicrobotIsraelShareholdersMember" xlink:to="MBOT_FormerMicrobotIsraelShareholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_FormerMicrobotIsraelShareholdersMember_lbl" xml:lang="en-US">Former Microbot Israel Shareholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FurnitureAndOfficeEquipmentMember" xlink:label="MBOT_FurnitureAndOfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FurnitureAndOfficeEquipmentMember" xlink:to="MBOT_FurnitureAndOfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_FurnitureAndOfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ResearchEquipmentAndSoftwareMember" xlink:label="MBOT_ResearchEquipmentAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ResearchEquipmentAndSoftwareMember" xlink:to="MBOT_ResearchEquipmentAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ResearchEquipmentAndSoftwareMember_lbl" xml:lang="en-US">Research Equipment and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToNovemberElevenTwoThousandSixteenMember" xlink:label="MBOT_PriorToNovemberElevenTwoThousandSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PriorToNovemberElevenTwoThousandSixteenMember" xlink:to="MBOT_PriorToNovemberElevenTwoThousandSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PriorToNovemberElevenTwoThousandSixteenMember_lbl" xml:lang="en-US">Prior to November 11, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_JuneTwoThousansdSixteenAgreementsMember" xlink:label="MBOT_JuneTwoThousansdSixteenAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_JuneTwoThousansdSixteenAgreementsMember" xlink:to="MBOT_JuneTwoThousansdSixteenAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_JuneTwoThousansdSixteenAgreementsMember_lbl" xml:lang="en-US">June 2016 Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:label="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:to="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember_lbl" xml:lang="en-US">Prior to Decmber 31, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Furniture and Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ResearchEquipmentAndSoftwareMember" xlink:to="MBOT_ResearchEquipmentAndSoftwareMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MBOT_ResearchEquipmentAndSoftwareMember_2_lbl" xml:lang="en-US">Research Equipment and Software [Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AlphaCapitalMember" xlink:label="MBOT_AlphaCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AlphaCapitalMember" xlink:to="MBOT_AlphaCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_AlphaCapitalMember_lbl" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ConvertibleNoteMember" xlink:label="MBOT_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ConvertibleNoteMember" xlink:to="MBOT_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MergerAgreementMember" xlink:label="MBOT_MergerAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MergerAgreementMember" xlink:to="MBOT_MergerAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" xlink:label="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" xlink:to="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember_lbl" xml:lang="en-US">2016 Series A and B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAWarrantsMember" xlink:label="MBOT_TwoThousandSixteenSeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenSeriesAWarrantsMember" xlink:to="MBOT_TwoThousandSixteenSeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandSixteenSeriesAWarrantsMember_lbl" xml:lang="en-US">2016 Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DecreaseMember" xlink:label="MBOT_DecreaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DecreaseMember" xlink:to="MBOT_DecreaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DecreaseMember_lbl" xml:lang="en-US">Decrease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IncreaseMember" xlink:label="MBOT_IncreaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_IncreaseMember" xlink:to="MBOT_IncreaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_IncreaseMember_lbl" xml:lang="en-US">Increase [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndElevenMember" xlink:label="MBOT_SeriesATwoThousandAndElevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndElevenMember" xlink:to="MBOT_SeriesATwoThousandAndElevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesATwoThousandAndElevenMember_lbl" xml:lang="en-US">Series A (2011) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenMember" xlink:label="MBOT_SeriesATwoThousandAndThirteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndThirteenMember" xlink:to="MBOT_SeriesATwoThousandAndThirteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesATwoThousandAndThirteenMember_lbl" xml:lang="en-US">Series A (2013) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:label="MBOT_SeriesATwoThousandAndThirteenOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:to="MBOT_SeriesATwoThousandAndThirteenOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MBOT_SeriesATwoThousandAndThirteenOneMember_lbl" xml:lang="en-US">Series A (2013) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndFifteenMember" xlink:label="MBOT_SeriesATwoThousandAndFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndFifteenMember" xlink:to="MBOT_SeriesATwoThousandAndFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesATwoThousandAndFifteenMember_lbl" xml:lang="en-US">Series A (2015) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndSixteenMember" xlink:label="MBOT_SeriesATwoThousandAndSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndSixteenMember" xlink:to="MBOT_SeriesATwoThousandAndSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesATwoThousandAndSixteenMember_lbl" xml:lang="en-US">Series A (2016) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesBTwoThousandAndSixteenMember" xlink:label="MBOT_SeriesBTwoThousandAndSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesBTwoThousandAndSixteenMember" xlink:to="MBOT_SeriesBTwoThousandAndSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesBTwoThousandAndSixteenMember_lbl" xml:lang="en-US">Series B (2016) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IsraeliInnovationAuthorityMember" xlink:label="MBOT_IsraeliInnovationAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_IsraeliInnovationAuthorityMember" xlink:to="MBOT_IsraeliInnovationAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_IsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandThirteenToSixteenMember" xlink:label="MBOT_TwoThousandThirteenToSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandThirteenToSixteenMember" xlink:to="MBOT_TwoThousandThirteenToSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandThirteenToSixteenMember_lbl" xml:lang="en-US">2013 Through 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:label="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:to="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_lbl" xml:lang="en-US">The Technician Research And Development Foundation Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OfficeLeaseAgreementMember" xlink:label="MBOT_OfficeLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_OfficeLeaseAgreementMember" xlink:to="MBOT_OfficeLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_OfficeLeaseAgreementMember_lbl" xml:lang="en-US">Office Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CarLeaseAgreementMember" xlink:label="MBOT_CarLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CarLeaseAgreementMember" xlink:to="MBOT_CarLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_CarLeaseAgreementMember_lbl" xml:lang="en-US">Car Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerExecutiveMember" xlink:label="MBOT_FormerExecutiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FormerExecutiveMember" xlink:to="MBOT_FormerExecutiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_FormerExecutiveMember_lbl" xml:lang="en-US">Former Executive [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_BoardofDirectorsMember" xlink:label="MBOT_BoardofDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_BoardofDirectorsMember" xlink:to="MBOT_BoardofDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_BoardofDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MEDXVentureGroupLLCMember" xlink:label="MBOT_MEDXVentureGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MEDXVentureGroupLLCMember" xlink:to="MBOT_MEDXVentureGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_MEDXVentureGroupLLCMember_lbl" xml:lang="en-US">MEDX Venture Group LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EmployeesandDirectorsMember" xlink:label="MBOT_EmployeesandDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EmployeesandDirectorsMember" xlink:to="MBOT_EmployeesandDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_EmployeesandDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AdvisorsMember" xlink:label="MBOT_AdvisorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AdvisorsMember" xlink:to="MBOT_AdvisorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_AdvisorsMember_lbl" xml:lang="en-US">Advisors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SecuritiesExchangeAgreementMember" xlink:label="MBOT_SecuritiesExchangeAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SecuritiesExchangeAgreementMember" xlink:to="MBOT_SecuritiesExchangeAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SecuritiesExchangeAgreementMember_lbl" xml:lang="en-US">Securities Exchange Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InterestedandRelatedPartiesMember" xlink:label="MBOT_InterestedandRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_InterestedandRelatedPartiesMember" xlink:to="MBOT_InterestedandRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_InterestedandRelatedPartiesMember_lbl" xml:lang="en-US">Interested and Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFourteenMember" xlink:label="MBOT_TwoThousandFourteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandFourteenMember" xlink:to="MBOT_TwoThousandFourteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandFourteenMember_lbl" xml:lang="en-US">2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFifteenMember" xlink:label="MBOT_TwoThousandFifteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandFifteenMember" xlink:to="MBOT_TwoThousandFifteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandFifteenMember_lbl" xml:lang="en-US">2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenMember" xlink:label="MBOT_TwoThousandSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenMember" xlink:to="MBOT_TwoThousandSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandSixteenMember_lbl" xml:lang="en-US">2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSeventeenMember" xlink:label="MBOT_TwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSeventeenMember" xlink:to="MBOT_TwoThousandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandSeventeenMember_lbl" xml:lang="en-US">2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandEighteenMember" xlink:label="MBOT_TwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandEighteenMember" xlink:to="MBOT_TwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TwoThousandEighteenMember_lbl" xml:lang="en-US">From 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_USTaxAuthorityMember" xlink:label="MBOT_USTaxAuthorityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_USTaxAuthorityMember" xlink:to="MBOT_USTaxAuthorityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_USTaxAuthorityMember_lbl" xml:lang="en-US">US Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="MBOT_DefinitiveSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:to="MBOT_DefinitiveSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DefinitiveSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Definitive Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ContractResearchAgreementMember" xlink:label="MBOT_ContractResearchAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ContractResearchAgreementMember" xlink:to="MBOT_ContractResearchAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ContractResearchAgreementMember_lbl" xml:lang="en-US">Contract Research Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_LoanMember" xlink:label="MBOT_LoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_LoanMember" xlink:to="MBOT_LoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_LoanMember_lbl" xml:lang="en-US">Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceOneMember" xlink:label="MBOT_ExercisePriceOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExercisePriceOneMember" xlink:to="MBOT_ExercisePriceOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceTwoMember" xlink:label="MBOT_ExercisePriceTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExercisePriceTwoMember" xlink:to="MBOT_ExercisePriceTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveAgreementMember" xlink:label="MBOT_DefinitiveAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DefinitiveAgreementMember" xlink:to="MBOT_DefinitiveAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DefinitiveAgreementMember_lbl" xml:lang="en-US">Definitive Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ThreeIsraeliShareholdersMember" xlink:label="MBOT_ThreeIsraeliShareholdersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ThreeIsraeliShareholdersMember" xlink:to="MBOT_ThreeIsraeliShareholdersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ThreeIsraeliShareholdersMember_lbl" xml:lang="en-US">Three Israeli Shareholders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EscrowAccountMember" xlink:label="MBOT_EscrowAccountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EscrowAccountMember" xlink:to="MBOT_EscrowAccountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_EscrowAccountMember_lbl" xml:lang="en-US">Escrow Account [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DocumentAndEntityInformationAbstract" xlink:label="MBOT_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DocumentAndEntityInformationAbstract" xlink:to="MBOT_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Long term liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Temporary equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Common stock of $0.01 par value; issued and outstanding: 10,702,838 shares as of December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' equity (deficit)*:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock of $0.01 par value; Authorized: 220,000,000 and 58,054,213 shares as of December 31, 2016, and December 31, 2015, respectively; issued and outstanding: 15,848,136 and 13,182,660 shares as of December 31, 2016, and December 31, 2015, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity (deficit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary equity, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Financing income (expenses), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xml:lang="en-US">Conversion of convertible notes and exercise of warrants issued upon conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of convertible notes and exercise of warrants issued upon conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalization" xlink:label="MBOT_EffectOfReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EffectOfReverseRecapitalization" xlink:to="MBOT_EffectOfReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_EffectOfReverseRecapitalization_lbl" xml:lang="en-US">Effect of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalizationShares" xlink:label="MBOT_EffectOfReverseRecapitalizationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EffectOfReverseRecapitalizationShares" xlink:to="MBOT_EffectOfReverseRecapitalizationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_EffectOfReverseRecapitalizationShares_lbl" xml:lang="en-US">Effect of reverse recapitalization, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common Stock classified as temporary equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial Conversion Feature recorded on convertible debt acquired in reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:to="MBOT_TransactionCostsIncurredInReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalization_lbl" xml:lang="en-US">Transaction costs incurred in reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" xlink:to="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares_lbl" xml:lang="en-US">Transaction costs incurred in reverse recapitalization, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Cancellation of ordinary shares and issuance of preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Cancellation of ordinary shares and issuance of preferred shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_2_lbl" xml:lang="en-US">Temporary equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US">Interest and revaluation of convertible notes, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="us-gaap_RecapitalizationCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RecapitalizationCosts" xlink:to="us-gaap_RecapitalizationCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RecapitalizationCosts_lbl" xml:lang="en-US">Share based transaction costs incurred in reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Changes in fair value of derivative warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Increase in other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in other payables and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTMENT ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:label="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:to="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization_lbl" xml:lang="en-US">Acquisition of a subsidiary in connection with reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:label="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:to="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet_lbl" xml:lang="en-US">Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:label="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:to="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes_lbl" xml:lang="en-US">Exercise of warrants issued upon conversion of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Issuance of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US">Supplemental information for Cash Flow:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US">Assets acquired (liabilities assumed):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Current assets excluding cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xml:lang="en-US">Derivative warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_lbl" xml:lang="en-US">Convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ReverseRecapitalizationEffectOnEquity" xlink:label="MBOT_ReverseRecapitalizationEffectOnEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ReverseRecapitalizationEffectOnEquity" xlink:to="MBOT_ReverseRecapitalizationEffectOnEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ReverseRecapitalizationEffectOnEquity_lbl" xml:lang="en-US">Reverse recapitalization effect on equity</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="MBOT_CashAcquiredInConnectionWithReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="MBOT_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_CashAcquiredInConnectionWithReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">General</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Loan from Shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Derivative Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Share Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and Development Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_GeneralAndAdministrativeExpensesTextBlock" xlink:label="MBOT_GeneralAndAdministrativeExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_GeneralAndAdministrativeExpensesTextBlock" xlink:to="MBOT_GeneralAndAdministrativeExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">Finance Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Transactions and Balances With Interested and Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Taxes on Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Financial Statement in U.S. Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Liabilities Due to Termination of Employment Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsPolicyTextBlock" xlink:label="MBOT_TransactionCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsPolicyTextBlock" xlink:to="MBOT_TransactionCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_TransactionCostsPolicyTextBlock_lbl" xml:lang="en-US">Transaction Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" xlink:label="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" xlink:to="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Estimated Useful Lives of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Fixed Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Summary of Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding Warrants Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Valuation of Derivative Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Valuation Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" xlink:label="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" xlink:to="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Summary of Finance Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transaction and Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of stock number of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion option to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Restricted shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_4_lbl" xml:lang="en-US">Cash and cash equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="us-gaap_TimeDepositsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimeDepositsAtCarryingValue" xlink:to="us-gaap_TimeDepositsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TimeDepositsAtCarryingValue_lbl" xml:lang="en-US">Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_5_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xml:lang="en-US">Asset consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfSeveranceAward" xlink:label="MBOT_PercentageOfSeveranceAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PercentageOfSeveranceAward" xlink:to="MBOT_PercentageOfSeveranceAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PercentageOfSeveranceAward_lbl" xml:lang="en-US">Percentage of severance award</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Sale of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Deposit in escrow account</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractReceivable_lbl" xml:lang="en-US">Government institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Shareholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_2_lbl" xml:lang="en-US">Total Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Fixed Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="us-gaap_RefundsDueUnderGovernmentContracts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RefundsDueUnderGovernmentContracts" xlink:to="us-gaap_RefundsDueUnderGovernmentContracts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RefundsDueUnderGovernmentContracts_lbl" xml:lang="en-US">Government institution</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Israeli Innovation Authority</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Loans Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">The loan bears interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt conversion, preferred shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Debt conversion, warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Number of preferred A shares, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">The loan bears interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US">Debt, discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Secured note principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible note principal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Convertible note, conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Principal and accrued interest of note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Discount on convertible note amortized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="invest_InvestmentWarrantsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentWarrantsExercisePrice" xlink:to="invest_InvestmentWarrantsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentWarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Warrants issued to purchase common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Estimated fair value warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_WarrantCalculationDescription" xlink:label="MBOT_WarrantCalculationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_WarrantCalculationDescription" xlink:to="MBOT_WarrantCalculationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_WarrantCalculationDescription_lbl" xml:lang="en-US">Warrant calculation description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Change in fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrant Outstanding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant Exercise Price, Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:label="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:to="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_lbl" xml:lang="en-US">Number of Warrant Exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant Exercisable Through, date</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:label="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:to="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_lbl" xml:lang="en-US">Balances at November 28, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesExercised" xlink:label="MBOT_DerivativeWarrantLiabilitiesExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesExercised" xlink:to="MBOT_DerivativeWarrantLiabilitiesExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DerivativeWarrantLiabilitiesExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesCancelled" xlink:label="MBOT_DerivativeWarrantLiabilitiesCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesCancelled" xlink:to="MBOT_DerivativeWarrantLiabilitiesCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DerivativeWarrantLiabilitiesCancelled_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Changes in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:to="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_2_lbl" xml:lang="en-US">Balances at December 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Total grants obtained</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_NetSalesRoyaltyPercentage" xlink:label="MBOT_NetSalesRoyaltyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_NetSalesRoyaltyPercentage" xlink:to="MBOT_NetSalesRoyaltyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_NetSalesRoyaltyPercentage_lbl" xml:lang="en-US">Royalties payable as percentage of future sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLeaseCommissions" xlink:label="us-gaap_PaymentsForLeaseCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeaseCommissions" xlink:to="us-gaap_PaymentsForLeaseCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLeaseCommissions_lbl" xml:lang="en-US">Monthly lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Compensation commitments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Conversion of stock, shares converted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Authorized capital stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Undesignated preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_2_lbl" xml:lang="en-US">Preferred stock, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Reverse stock splits</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_RightsToAcquireSharesOfCommonStock" xlink:label="MBOT_RightsToAcquireSharesOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_RightsToAcquireSharesOfCommonStock" xlink:to="MBOT_RightsToAcquireSharesOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_RightsToAcquireSharesOfCommonStock_lbl" xml:lang="en-US">Rights to acquire shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DesignatedPreferredStock" xlink:label="MBOT_DesignatedPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DesignatedPreferredStock" xlink:to="MBOT_DesignatedPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DesignatedPreferredStock_lbl" xml:lang="en-US">Designated preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price per share, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based employee compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, shares, restricted stock award, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, value, restricted stock award, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_2_lbl" xml:lang="en-US">Other current assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, forfeitures in period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Common stock repurchase</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:label="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:to="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock_lbl" xml:lang="en-US">Percentage of discount on the fair market value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Outstanding at Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Expired or Canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Outstanding at Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options Outstanding, Vested and expected-to-vest at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired or Canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected-to-vest at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Stock Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Stock options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of up to (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss attributable to shareholders of the company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Net loss attributable to shareholders of preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss used in the calculation of basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServicesDirectMaterials" xlink:label="us-gaap_CostOfServicesDirectMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServicesDirectMaterials" xlink:to="us-gaap_CostOfServicesDirectMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfServicesDirectMaterials_lbl" xml:lang="en-US">Materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="us-gaap_MaintenanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaintenanceCosts" xlink:to="us-gaap_MaintenanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaintenanceCosts_lbl" xml:lang="en-US">Office and maintenance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RevenueFromGrants_2_lbl" xml:lang="en-US">Less grants received from Israeli Innovation Authority</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="us-gaap_TravelAndEntertainmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Bank fees and interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Change in fair value of derivative warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Exchange rate differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Revaluation and interest on convertible loans</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestAndDebtExpense_2_lbl" xml:lang="en-US">Financial expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="us-gaap_NoninterestExpenseDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_lbl" xml:lang="en-US">Directors fees and insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Subcontracted work and consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Corporate income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating losses carried forward</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OperatingLossCarryforwardsExpiration" xlink:label="MBOT_OperatingLossCarryforwardsExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_OperatingLossCarryforwardsExpiration" xlink:to="MBOT_OperatingLossCarryforwardsExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_OperatingLossCarryforwardsExpiration_lbl" xml:lang="en-US">Operating loss carryforwards, expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred taxes due to carryforward losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock, gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:label="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:to="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_lbl" xml:lang="en-US">Placement agent fees plus reimbursement of out-of-pocket expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CostOfInitialStudy" xlink:label="MBOT_CostOfInitialStudy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CostOfInitialStudy" xlink:to="MBOT_CostOfInitialStudy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_CostOfInitialStudy_lbl" xml:lang="en-US">Cost of initial study</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:to="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember_doc" xml:lang="en-US">Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:to="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember_doc" xml:lang="en-US">Preferred A Shares Microbot Medical Ltd. Post-Merger [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TemporaryEquityMember" xlink:to="MBOT_TemporaryEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TemporaryEquityMember_doc" xml:lang="en-US">Temporary Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EffectOfReverseRecapitalization" xlink:to="MBOT_EffectOfReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_EffectOfReverseRecapitalization_doc" xml:lang="en-US">Effect of reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EffectOfReverseRecapitalizationShares" xlink:to="MBOT_EffectOfReverseRecapitalizationShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_EffectOfReverseRecapitalizationShares_doc" xml:lang="en-US">Effect of reverse recapitalization, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:to="MBOT_TransactionCostsIncurredInReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalization_doc" xml:lang="en-US">Transaction costs incurred in reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" xlink:to="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TransactionCostsIncurredInReverseRecapitalizationShares_doc" xml:lang="en-US">Transaction costs incurred in reverse recapitalization, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:to="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization_doc" xml:lang="en-US">Acquisition of a subsidiary in connection with reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:to="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet_doc" xml:lang="en-US">Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:to="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes_doc" xml:lang="en-US">Exercise of warrants issued upon conversion of notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ReverseRecapitalizationEffectOnEquity" xlink:to="MBOT_ReverseRecapitalizationEffectOnEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ReverseRecapitalizationEffectOnEquity_doc" xml:lang="en-US">Reverse recapitalization effect on equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CashAcquiredInConnectionWithReverseRecapitalization" xlink:to="MBOT_CashAcquiredInConnectionWithReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_CashAcquiredInConnectionWithReverseRecapitalization_doc" xml:lang="en-US">Cash acquired in connection with reverse recapitalization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_GeneralAndAdministrativeExpensesTextBlock" xlink:to="MBOT_GeneralAndAdministrativeExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_GeneralAndAdministrativeExpensesTextBlock_doc" xml:lang="en-US">General and administrative expenses [Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TransactionCostsPolicyTextBlock" xlink:to="MBOT_TransactionCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TransactionCostsPolicyTextBlock_doc" xml:lang="en-US">Transaction Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" xlink:to="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Property and Equipment Useful Lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" xlink:to="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock_doc" xml:lang="en-US">Schedule of General and Administrative Expense [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MicrobotIsraelMember" xlink:to="MBOT_MicrobotIsraelMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_MicrobotIsraelMember_doc" xml:lang="en-US">Microbot Israel [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FormerMicrobotIsraelShareholdersMember" xlink:to="MBOT_FormerMicrobotIsraelShareholdersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_FormerMicrobotIsraelShareholdersMember_doc" xml:lang="en-US">Former Microbot Israel Shareholders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FurnitureAndOfficeEquipmentMember" xlink:to="MBOT_FurnitureAndOfficeEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_FurnitureAndOfficeEquipmentMember_doc" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ResearchEquipmentAndSoftwareMember" xlink:to="MBOT_ResearchEquipmentAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ResearchEquipmentAndSoftwareMember_doc" xml:lang="en-US">Research Equipment and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DepositInEscrowAccountMember" xlink:label="MBOT_DepositInEscrowAccountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DepositInEscrowAccountMember" xlink:to="MBOT_DepositInEscrowAccountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DepositInEscrowAccountMember_doc" xml:lang="en-US">Deposit in Escrow Account [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PriorToNovemberElevenTwoThousandSixteenMember" xlink:to="MBOT_PriorToNovemberElevenTwoThousandSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PriorToNovemberElevenTwoThousandSixteenMember_doc" xml:lang="en-US">Prior to November 11, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_JuneTwoThousansdSixteenAgreementsMember" xlink:to="MBOT_JuneTwoThousansdSixteenAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_JuneTwoThousansdSixteenAgreementsMember_doc" xml:lang="en-US">June 2016 Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PercentageOfSeveranceAward" xlink:to="MBOT_PercentageOfSeveranceAward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PercentageOfSeveranceAward_doc" xml:lang="en-US">Percentage of severance award.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:to="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember_doc" xml:lang="en-US">Prior to Decmber 31, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AlphaCapitalMember" xlink:to="MBOT_AlphaCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_AlphaCapitalMember_doc" xml:lang="en-US">Alpha Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ConvertibleNoteMember" xlink:to="MBOT_ConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ConvertibleNoteMember_doc" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MergerAgreementMember" xlink:to="MBOT_MergerAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_MergerAgreementMember_doc" xml:lang="en-US">Merger Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_WarrantCalculationDescription" xlink:to="MBOT_WarrantCalculationDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_WarrantCalculationDescription_doc" xml:lang="en-US">Warrant calculation description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenSeriesAWarrantsMember" xlink:to="MBOT_TwoThousandSixteenSeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandSixteenSeriesAWarrantsMember_doc" xml:lang="en-US">2016 Series A Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DecreaseMember" xlink:to="MBOT_DecreaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DecreaseMember_doc" xml:lang="en-US">Decrease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_IncreaseMember" xlink:to="MBOT_IncreaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_IncreaseMember_doc" xml:lang="en-US">Increase [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:to="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndElevenMember" xlink:to="MBOT_SeriesATwoThousandAndElevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesATwoThousandAndElevenMember_doc" xml:lang="en-US">Series A (2011) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndThirteenMember" xlink:to="MBOT_SeriesATwoThousandAndThirteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesATwoThousandAndThirteenMember_doc" xml:lang="en-US">Series A (2013) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:to="MBOT_SeriesATwoThousandAndThirteenOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesATwoThousandAndThirteenOneMember_doc" xml:lang="en-US">Series A (2013) One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndFifteenMember" xlink:to="MBOT_SeriesATwoThousandAndFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesATwoThousandAndFifteenMember_doc" xml:lang="en-US">Series A (2015) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndSixteenMember" xlink:to="MBOT_SeriesATwoThousandAndSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesATwoThousandAndSixteenMember_doc" xml:lang="en-US">Series A (2016) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesBTwoThousandAndSixteenMember" xlink:to="MBOT_SeriesBTwoThousandAndSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SeriesBTwoThousandAndSixteenMember_doc" xml:lang="en-US">Series B (2016) [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:to="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_doc" xml:lang="en-US">Derivative warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesExercised" xlink:to="MBOT_DerivativeWarrantLiabilitiesExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DerivativeWarrantLiabilitiesExercised_doc" xml:lang="en-US">Exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesCancelled" xlink:to="MBOT_DerivativeWarrantLiabilitiesCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DerivativeWarrantLiabilitiesCancelled_doc" xml:lang="en-US">Cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_NetSalesRoyaltyPercentage" xlink:to="MBOT_NetSalesRoyaltyPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_NetSalesRoyaltyPercentage_doc" xml:lang="en-US">Net Sales Royalty Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_IsraeliInnovationAuthorityMember" xlink:to="MBOT_IsraeliInnovationAuthorityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_IsraeliInnovationAuthorityMember_doc" xml:lang="en-US">Israeli Innovation Authority [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandThirteenToSixteenMember" xlink:to="MBOT_TwoThousandThirteenToSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandThirteenToSixteenMember_doc" xml:lang="en-US">2013 Through 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:to="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember_doc" xml:lang="en-US">The Technician Research And Development Foundation Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_OfficeLeaseAgreementMember" xlink:to="MBOT_OfficeLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_OfficeLeaseAgreementMember_doc" xml:lang="en-US">Office Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CarLeaseAgreementMember" xlink:to="MBOT_CarLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_CarLeaseAgreementMember_doc" xml:lang="en-US">Car Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_FormerExecutiveMember" xlink:to="MBOT_FormerExecutiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_FormerExecutiveMember_doc" xml:lang="en-US">Former Executive [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_RightsToAcquireSharesOfCommonStock" xlink:to="MBOT_RightsToAcquireSharesOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_RightsToAcquireSharesOfCommonStock_doc" xml:lang="en-US">Rights to acquire shares of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DesignatedPreferredStock" xlink:to="MBOT_DesignatedPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DesignatedPreferredStock_doc" xml:lang="en-US">Designated preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_BoardofDirectorsMember" xlink:to="MBOT_BoardofDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_BoardofDirectorsMember_doc" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_MEDXVentureGroupLLCMember" xlink:to="MBOT_MEDXVentureGroupLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_MEDXVentureGroupLLCMember_doc" xml:lang="en-US">MEDX Venture Group LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EmployeesandDirectorsMember" xlink:to="MBOT_EmployeesandDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_EmployeesandDirectorsMember_doc" xml:lang="en-US">Employees and Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_AdvisorsMember" xlink:to="MBOT_AdvisorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_AdvisorsMember_doc" xml:lang="en-US">Advisors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SecuritiesExchangeAgreementMember" xlink:to="MBOT_SecuritiesExchangeAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_SecuritiesExchangeAgreementMember_doc" xml:lang="en-US">Securities Exchange Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_InterestedandRelatedPartiesMember" xlink:to="MBOT_InterestedandRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_InterestedandRelatedPartiesMember_doc" xml:lang="en-US">Interested and Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandFourteenMember" xlink:to="MBOT_TwoThousandFourteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandFourteenMember_doc" xml:lang="en-US">2014 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandFifteenMember" xlink:to="MBOT_TwoThousandFifteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandFifteenMember_doc" xml:lang="en-US">2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenMember" xlink:to="MBOT_TwoThousandSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandSixteenMember_doc" xml:lang="en-US">2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSeventeenMember" xlink:to="MBOT_TwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandSeventeenMember_doc" xml:lang="en-US">2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandEighteenMember" xlink:to="MBOT_TwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandEighteenMember_doc" xml:lang="en-US">From 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_USTaxAuthorityMember" xlink:to="MBOT_USTaxAuthorityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_USTaxAuthorityMember_doc" xml:lang="en-US">US Tax Authority [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_OperatingLossCarryforwardsExpiration" xlink:to="MBOT_OperatingLossCarryforwardsExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_OperatingLossCarryforwardsExpiration_doc" xml:lang="en-US">Operating Loss Carryforwards, Expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:to="MBOT_DefinitiveSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DefinitiveSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Definitive Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ContractResearchAgreementMember" xlink:to="MBOT_ContractResearchAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ContractResearchAgreementMember_doc" xml:lang="en-US">Contract Research Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:to="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses_doc" xml:lang="en-US">Placement agent fees plus reimbursement of out-of-pocket expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_CostOfInitialStudy" xlink:to="MBOT_CostOfInitialStudy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_CostOfInitialStudy_doc" xml:lang="en-US">Cost of initial study.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_LoanMember" xlink:to="MBOT_LoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_LoanMember_doc" xml:lang="en-US">Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" xlink:to="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_TwoThousandSixteenSeriesAandBWarrantsMember_doc" xml:lang="en-US">Two Thousand Sixteen Series A and B Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExercisePriceOneMember" xlink:to="MBOT_ExercisePriceOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ExercisePriceOneMember_doc" xml:lang="en-US">Exercise Price One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ExercisePriceTwoMember" xlink:to="MBOT_ExercisePriceTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ExercisePriceTwoMember_doc" xml:lang="en-US">Exercise Price Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DefinitiveAgreementMember" xlink:to="MBOT_DefinitiveAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_DefinitiveAgreementMember_doc" xml:lang="en-US">Definitive Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:to="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock_doc" xml:lang="en-US">Percentage of discount on the fair market value of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_ThreeIsraeliShareholdersMember" xlink:to="MBOT_ThreeIsraeliShareholdersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_ThreeIsraeliShareholdersMember_doc" xml:lang="en-US">Three Israeli Shareholders [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_EscrowAccountMember" xlink:to="MBOT_EscrowAccountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="MBOT_EscrowAccountMember_doc" xml:lang="en-US">Escrow Account [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_2_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:to="MBOT_SeriesATwoThousandAndThirteenOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_SeriesATwoThousandAndThirteenOneMember_3_lbl" xml:lang="en-US">SeriesATwoThousandAndThirteenOneMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_3_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_3_lbl" xml:lang="en-US">Interest and Debt Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_2_lbl" xml:lang="en-US">Interest on Convertible Debt, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_2_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2_lbl" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:to="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MBOT_DerivativeWarrantLiabilitiesBeginningBalance_4_lbl" xml:lang="en-US">DerivativeWarrantLiabilitiesBeginningBalance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_2_lbl" xml:lang="en-US">Costs and Expenses, Related Party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>mbot-20161231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: MBOT 20161231 10K DFN.xfr; Date: 2017%2D03%2D20T18:19:24Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:href="mbot-20161231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheets" xlink:href="mbot-20161231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:href="mbot-20161231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:href="mbot-20161231.xsd#StatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:href="mbot-20161231.xsd#StatementsOfShareholdersEquityDeficitParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:href="mbot-20161231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/General" xlink:href="mbot-20161231.xsd#General" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables" xlink:href="mbot-20161231.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet" xlink:href="mbot-20161231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities" xlink:href="mbot-20161231.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholders" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/Commitments" xlink:href="mbot-20161231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital" xlink:href="mbot-20161231.xsd#ShareCapital" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet" xlink:href="mbot-20161231.xsd#FinanceExpensesNet" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome" xlink:href="mbot-20161231.xsd#TaxesOnIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEvents" xlink:href="mbot-20161231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:href="mbot-20161231.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesTables" xlink:href="mbot-20161231.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:href="mbot-20161231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:href="mbot-20161231.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalTables" xlink:href="mbot-20161231.xsd#ShareCapitalTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:href="mbot-20161231.xsd#FinanceExpensesNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:href="mbot-20161231.xsd#TaxesOnIncomeTables" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:href="mbot-20161231.xsd#GeneralDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:href="mbot-20161231.xsd#SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:href="mbot-20161231.xsd#CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:href="mbot-20161231.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:href="mbot-20161231.xsd#OtherReceivables-ScheduleOfOtherAssets-Details" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:href="mbot-20161231.xsd#FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:href="mbot-20161231.xsd#AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:href="mbot-20161231.xsd#ConvertibleLoanFromShareholdersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:href="mbot-20161231.xsd#DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:href="mbot-20161231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:href="mbot-20161231.xsd#ShareCapitalDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:href="mbot-20161231.xsd#ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:href="mbot-20161231.xsd#ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="mbot-20161231.xsd#BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:href="mbot-20161231.xsd#ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:href="mbot-20161231.xsd#GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:href="mbot-20161231.xsd#FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:href="mbot-20161231.xsd#TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:href="mbot-20161231.xsd#TaxesOnIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:href="mbot-20161231.xsd#TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:href="mbot-20161231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DocumentAndEntityInformationAbstract" xlink:label="loc_MBOTDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaapConvertibleDebtNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapConvertibleDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit" xlink:title="00000005 - Statement - Consolidated Statements of Shareholder's Equity (Deficit)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="70" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TemporaryEquityMember" xlink:label="loc_MBOTTemporaryEquityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_MBOTTemporaryEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:label="loc_MBOTPreferredASharesMicrobotMedicalLtdPreMergerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_MBOTPreferredASharesMicrobotMedicalLtdPreMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:label="loc_MBOTPreferredASharesMicrobotMedicalLtdPostMergerMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_MBOTPreferredASharesMicrobotMedicalLtdPostMergerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalization" xlink:label="loc_MBOTEffectOfReverseRecapitalization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTEffectOfReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EffectOfReverseRecapitalizationShares" xlink:label="loc_MBOTEffectOfReverseRecapitalizationShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTEffectOfReverseRecapitalizationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleBeneficialConversionFeature" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalizationShares" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalizationShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalizationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="loc_us-gaapInterestOnConvertibleDebtNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestOnConvertibleDebtNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RecapitalizationCosts" xlink:label="loc_us-gaapRecapitalizationCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapRecapitalizationCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:label="loc_MBOTAcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_MBOTAcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsIncurredInReverseRecapitalization" xlink:label="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_MBOTTransactionCostsIncurredInReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:label="loc_MBOTInflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_MBOTInflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:label="loc_MBOTExerciseOfWarrantsIssuedUponConversionOfNotes" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_MBOTExerciseOfWarrantsIssuedUponConversionOfNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaapSupplementalCashFlowElementsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowElementsAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ReverseRecapitalizationEffectOnEquity" xlink:label="loc_MBOTReverseRecapitalizationEffectOnEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_MBOTReverseRecapitalizationEffectOnEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CashAcquiredInConnectionWithReverseRecapitalization" xlink:label="loc_MBOTCashAcquiredInConnectionWithReverseRecapitalization" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="loc_MBOTCashAcquiredInConnectionWithReverseRecapitalization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/General" xlink:title="00000008 - Disclosure - General">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents" xlink:title="00000010 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables" xlink:title="00000011 - Disclosure - Other Receivables">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet" xlink:title="00000012 - Disclosure - Fixed Assets, Net">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities" xlink:title="00000013 - Disclosure - Accrued Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholders" xlink:title="00000014 - Disclosure - Convertible Loan from Shareholders">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities" xlink:title="00000015 - Disclosure - Derivative Warrant Liabilities">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Commitments" xlink:title="00000016 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital" xlink:title="00000017 - Disclosure - Share Capital">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare" xlink:title="00000018 - Disclosure - Basic and Diluted Net Loss Per Share">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet" xlink:title="00000019 - Disclosure - Research and Development Expenses, Net">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses" xlink:title="00000020 - Disclosure - General and Administrative Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_GeneralAndAdministrativeExpensesTextBlock" xlink:label="loc_MBOTGeneralAndAdministrativeExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_MBOTGeneralAndAdministrativeExpensesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet" xlink:title="00000021 - Disclosure - Finance Expenses, Net">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties" xlink:title="00000022 - Disclosure - Transactions and Balances with Interested and Related Parties">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome" xlink:title="00000023 - Disclosure - Taxes on Income">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TransactionCostsPolicyTextBlock" xlink:label="loc_MBOTTransactionCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MBOTTransactionCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_MBOTScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MBOTScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalentsTables" xlink:title="00000027 - Disclosure - Cash and Cash Equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesTables" xlink:title="00000028 - Disclosure - Other Receivables (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNetTables" xlink:title="00000029 - Disclosure - Fixed Assets, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilitiesTables" xlink:title="00000030 - Disclosure - Accrued Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables" xlink:title="00000031 - Disclosure - Derivative Warrant Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalTables" xlink:title="00000032 - Disclosure - Share Capital (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables" xlink:title="00000033 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables" xlink:title="00000034 - Disclosure - Research and Development Expenses, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables" xlink:title="00000035 - Disclosure - General and Administrative Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock" xlink:label="loc_MBOTScheduleofGeneralandAdministrativeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_MBOTScheduleofGeneralandAdministrativeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNetTables" xlink:title="00000036 - Disclosure - Finance Expenses, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables" xlink:title="00000037 - Disclosure - Transactions and Balances with Interested and Related Parties (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeTables" xlink:title="00000038 - Disclosure - Taxes on Income (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralDetailsNarrative" xlink:title="00000039 - Disclosure - General (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerMicrobotIsraelShareholdersMember" xlink:label="loc_MBOTFormerMicrobotIsraelShareholdersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTFormerMicrobotIsraelShareholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail" xlink:title="00000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ResearchEquipmentAndSoftwareMember" xlink:label="loc_MBOTResearchEquipmentAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTResearchEquipmentAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FurnitureAndOfficeEquipmentMember" xlink:label="loc_MBOTFurnitureAndOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTFurnitureAndOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000041 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaapTimeDepositsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapTimeDepositsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000042 - Disclosure - Other Receivables (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToNovemberElevenTwoThousandSixteenMember" xlink:label="loc_MBOTPriorToNovemberElevenTwoThousandSixteenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_MBOTPriorToNovemberElevenTwoThousandSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:label="loc_MBOTPriorToDecemberThirtyFirstTwoThousandSixteenMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_MBOTPriorToDecemberThirtyFirstTwoThousandSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EscrowAccountMember" xlink:label="loc_MBOTEscrowAccountMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_MBOTEscrowAccountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_JuneTwoThousansdSixteenAgreementsMember" xlink:label="loc_MBOTJuneTwoThousansdSixteenAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTJuneTwoThousansdSixteenAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfSeveranceAward" xlink:label="loc_MBOTPercentageOfSeveranceAward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPercentageOfSeveranceAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details" xlink:title="00000043 - Disclosure - Other Receivables - Schedule of Other Assets - (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="loc_us-gaapGovernmentContractReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapGovernmentContractReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails" xlink:title="00000044 - Disclosure - Fixed Assets, Net - Summary of Fixed Assets, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ResearchEquipmentAndSoftwareMember" xlink:label="loc_MBOTResearchEquipmentAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MBOTResearchEquipmentAndSoftwareMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails" xlink:title="00000045 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RefundsDueUnderGovernmentContracts" xlink:label="loc_us-gaapRefundsDueUnderGovernmentContracts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapRefundsDueUnderGovernmentContracts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative" xlink:title="00000046 - Disclosure - Convertible Loan from Shareholders (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AlphaCapitalMember" xlink:label="loc_MBOTAlphaCapitalMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_LoanMember" xlink:label="loc_MBOTLoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MBOTLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ConvertibleNoteMember" xlink:label="loc_MBOTConvertibleNoteMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_MBOTConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MergerAgreementMember" xlink:label="loc_MBOTMergerAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTMergerAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaapFairValueInputsDiscountRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueInputsDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative" xlink:title="00000047 - Disclosure - Derivative Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAandBWarrantsMember" xlink:label="loc_MBOTTwoThousandSixteenSeriesAandBWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_MBOTTwoThousandSixteenSeriesAandBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenSeriesAWarrantsMember" xlink:label="loc_MBOTTwoThousandSixteenSeriesAWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_MBOTTwoThousandSixteenSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DecreaseMember" xlink:label="loc_MBOTDecreaseMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTDecreaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IncreaseMember" xlink:label="loc_MBOTIncreaseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTIncreaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_investInvestmentWarrantsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_investInvestmentWarrantsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_WarrantCalculationDescription" xlink:label="loc_MBOTWarrantCalculationDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTWarrantCalculationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails" xlink:title="00000048 - Disclosure - Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesScheduleOfOutstandingWarrantsLiabilitiesDetailsAbstract" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesScheduleOfOutstandingWarrantsLiabilitiesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDerivativeWarrantLiabilitiesScheduleOfOutstandingWarrantsLiabilitiesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndElevenMember" xlink:label="loc_MBOTSeriesATwoThousandAndElevenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndFifteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndFifteenMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndSixteenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesBTwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesBTwoThousandAndSixteenMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesBTwoThousandAndSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:label="loc_MBOTShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails" xlink:title="00000049 - Disclosure - Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesScheduleOfValuationOfDerivativeWarrantLiabilitiesDetailsAbstract" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesScheduleOfValuationOfDerivativeWarrantLiabilitiesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MBOTDerivativeWarrantLiabilitiesScheduleOfValuationOfDerivativeWarrantLiabilitiesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndElevenMember" xlink:label="loc_MBOTSeriesATwoThousandAndElevenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndElevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndThirteenOneMember" xlink:label="loc_MBOTSeriesATwoThousandAndThirteenOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndThirteenOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndFifteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndFifteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesATwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesATwoThousandAndSixteenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesATwoThousandAndSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SeriesBTwoThousandAndSixteenMember" xlink:label="loc_MBOTSeriesBTwoThousandAndSixteenMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_MBOTSeriesBTwoThousandAndSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesExercised" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesCancelled" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesCancelled" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DerivativeWarrantLiabilitiesBeginningBalance" xlink:label="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDerivativeWarrantLiabilitiesBeginningBalance_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/CommitmentsDetailsNarrative" xlink:title="00000050 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_IsraeliInnovationAuthorityMember" xlink:label="loc_MBOTIsraeliInnovationAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="loc_MBOTIsraeliInnovationAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandThirteenToSixteenMember" xlink:label="loc_MBOTTwoThousandThirteenToSixteenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_MBOTTwoThousandThirteenToSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:label="loc_MBOTTheTechnicianResearchAndDevelopmentFoundationLimitedMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTTheTechnicianResearchAndDevelopmentFoundationLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OfficeLeaseAgreementMember" xlink:label="loc_MBOTOfficeLeaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTOfficeLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CarLeaseAgreementMember" xlink:label="loc_MBOTCarLeaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTCarLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_FormerExecutiveMember" xlink:label="loc_MBOTFormerExecutiveMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTFormerExecutiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromGrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_NetSalesRoyaltyPercentage" xlink:label="loc_MBOTNetSalesRoyaltyPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTNetSalesRoyaltyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForLeaseCommissions" xlink:label="loc_us-gaapPaymentsForLeaseCommissions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForLeaseCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapitalDetailsNarrative" xlink:title="00000051 - Disclosure - Share Capital (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_BoardofDirectorsMember" xlink:label="loc_MBOTBoardofDirectorsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTBoardofDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_EmployeesandDirectorsMember" xlink:label="loc_MBOTEmployeesandDirectorsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTEmployeesandDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AdvisorsMember" xlink:label="loc_MBOTAdvisorsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MBOTAdvisorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MicrobotIsraelMember" xlink:label="loc_MBOTMicrobotIsraelMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMicrobotIsraelMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_MEDXVentureGroupLLCMember" xlink:label="loc_MBOTMEDXVentureGroupLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTMEDXVentureGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_AlphaCapitalMember" xlink:label="loc_MBOTAlphaCapitalMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MBOTAlphaCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_SecuritiesExchangeAgreementMember" xlink:label="loc_MBOTSecuritiesExchangeAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTSecuritiesExchangeAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveAgreementMember" xlink:label="loc_MBOTDefinitiveAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTDefinitiveAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ThreeIsraeliShareholdersMember" xlink:label="loc_MBOTThreeIsraeliShareholdersMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTThreeIsraeliShareholdersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_RightsToAcquireSharesOfCommonStock" xlink:label="loc_MBOTRightsToAcquireSharesOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTRightsToAcquireSharesOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DesignatedPreferredStock" xlink:label="loc_MBOTDesignatedPreferredStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTDesignatedPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:label="loc_MBOTPercentageOfDiscountOnFairMarketValueOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPercentageOfDiscountOnFairMarketValueOfCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails" xlink:title="00000052 - Disclosure - Share Capital - Summary of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical" xlink:title="00000053 - Disclosure - Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails" xlink:title="00000054 - Disclosure - Share Capital - Schedule of Stock Options Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceOneMember" xlink:label="loc_MBOTExercisePriceOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTExercisePriceOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ExercisePriceTwoMember" xlink:label="loc_MBOTExercisePriceTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_MBOTExercisePriceTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails" xlink:title="00000055 - Disclosure - Share Capital - Schedule of Stock Options Valuation Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000056 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails" xlink:title="00000057 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfServicesDirectMaterials" xlink:label="loc_us-gaapCostOfServicesDirectMaterials" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfServicesDirectMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="loc_us-gaapMaintenanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMaintenanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaapRevenueFromGrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails" xlink:title="00000058 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TravelAndEntertainmentExpense" xlink:label="loc_us-gaapTravelAndEntertainmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTravelAndEntertainmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails" xlink:title="00000059 - Disclosure - Finance Expenses, Net - Summary of Finance Expenses, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails" xlink:title="00000060 - Disclosure - Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_InterestedandRelatedPartiesMember" xlink:label="loc_MBOTInterestedandRelatedPartiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MBOTInterestedandRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableOtherCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative" xlink:title="00000061 - Disclosure - Taxes on Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="loc_us-gaapIsraelTaxAuthorityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_us-gaapIsraelTaxAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_USTaxAuthorityMember" xlink:label="loc_MBOTUSTaxAuthorityMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityNameDomain" xlink:to="loc_MBOTUSTaxAuthorityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFifteenMember" xlink:label="loc_MBOTTwoThousandFifteenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandFifteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandFourteenMember" xlink:label="loc_MBOTTwoThousandFourteenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandFourteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSixteenMember" xlink:label="loc_MBOTTwoThousandSixteenMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandSeventeenMember" xlink:label="loc_MBOTTwoThousandSeventeenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_TwoThousandEighteenMember" xlink:label="loc_MBOTTwoThousandEighteenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_MBOTTwoThousandEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_OperatingLossCarryforwardsExpiration" xlink:label="loc_MBOTOperatingLossCarryforwardsExpiration" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTOperatingLossCarryforwardsExpiration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails" xlink:title="00000062 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000063 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_DefinitiveSecuritiesPurchaseAgreementMember" xlink:label="loc_MBOTDefinitiveSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTDefinitiveSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_ContractResearchAgreementMember" xlink:label="loc_MBOTContractResearchAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MBOTContractResearchAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:label="loc_MBOTPlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTPlacementAgentFeesPlusReimbursementOfOutofpocketExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mbot-20161231.xsd#MBOT_CostOfInitialStudy" xlink:label="loc_MBOTCostOfInitialStudy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MBOTCostOfInitialStudy" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745720400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 16, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Microbot Medical Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,048,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,251,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745887520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">606<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,315<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,368<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">201<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">582<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">783<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">313<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">389<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Common stock of $0.01 par value; issued and outstanding: 10,702,838 shares as of December 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit)*:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.01 par value; Authorized: 220,000,000 and 58,054,213 shares as of December 31, 2016, and December 31, 2015, respectively; issued and outstanding: 15,848,136 and 13,182,660 shares as of December 31, 2016, and December 31, 2015, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">266<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,465<span></span>
</td>
<td class="nump">3,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(13,035)<span></span>
</td>
<td class="num">(3,372)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,696<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity (deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,368<span></span>
</td>
<td class="nump">$ 529<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">December 31 2015 share data represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28 2016.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745807232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">10,702,838<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">10,702,838<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">11,610,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">9,736<span></span>
</td>
<td class="nump">8,708,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">9,736<span></span>
</td>
<td class="nump">8,708,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">220,000,000<span></span>
</td>
<td class="nump">58,054,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">15,848,136<span></span>
</td>
<td class="nump">13,182,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">15,848,136<span></span>
</td>
<td class="nump">13,182,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905251488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">8,734<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,635)<span></span>
</td>
<td class="num">(915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Financing income (expenses), net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,663)<span></span>
</td>
<td class="num">$ (921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6751856816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholder's Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Temporary Equity [Member]</div></th>
<th class="th"><div>Preferred A Shares Microbot Medical Ltd. Pre-Merger [Member]</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Preferred A Shares Microbot Medical Ltd. Post-Merger [Member]</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">$ 87<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,089<span></span>
</td>
<td class="num">$ (2,451)<span></span>
</td>
<td class="nump">$ 857<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">8,708,132<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">13,182,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_TransactionCostsIncurredInReverseRecapitalization', window );">Transaction costs incurred in reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">$ 87<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,089<span></span>
</td>
<td class="num">(3,372)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">8,708,132<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">13,182,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Conversion of convertible notes and exercise of warrants issued upon conversion</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="nump">$ 48<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,803<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes and exercise of warrants issued upon conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">4,746,237<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_EffectOfReverseRecapitalization', window );">Effect of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="num">$ (135)<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">454<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_EffectOfReverseRecapitalizationShares', window );">Effect of reverse recapitalization, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(13,454,369)<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">15,301,675<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Common Stock classified as temporary equity</a></td>
<td class="nump">500<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial Conversion Feature recorded on convertible debt acquired in reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,029<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_TransactionCostsIncurredInReverseRecapitalization', window );">Transaction costs incurred in reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,817<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_TransactionCostsIncurredInReverseRecapitalizationShares', window );">Transaction costs incurred in reverse recapitalization, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">7,802,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Cancellation of ordinary shares and issuance of preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">97<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Cancellation of ordinary shares and issuance of preferred shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="nump">9,736<span></span>
</td>
<td class="num">(9,736,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">676<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,663)<span></span>
</td>
<td class="num">(9,663)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 500<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 14,465<span></span>
</td>
<td class="num">$ (13,035)<span></span>
</td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td colspan="2" class="nump">9,736<span></span>
</td>
<td class="nump">26,550,974<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Share data for periods prior to the reverse recapitalization represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28, 2016</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">December 31 2015 share data represents the legal equity structure of Microbot Medical Ltd. with the number of shares adjusted to retroactively reflect the one-to-nine Reverse Stock Split effected on November 28, 2016 as well as the reverse recapitalization consummated on November 28 2016.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes 10,702,838 shares of common stock classified as temporary equity.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_EffectOfReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_EffectOfReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_EffectOfReverseRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of reverse recapitalization, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_EffectOfReverseRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_TransactionCostsIncurredInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_TransactionCostsIncurredInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_TransactionCostsIncurredInReverseRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in reverse recapitalization, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_TransactionCostsIncurredInReverseRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MBOT_TemporaryEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MBOT_TemporaryEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MBOT_PreferredASharesMicrobotMedicalLtdPreMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=MBOT_PreferredASharesMicrobotMedicalLtdPostMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905196368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one-to-nine Reverse Stock Split<span></span>
</td>
<td class="text">10,702,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,702,838<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6752066240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,663,000)<span></span>
</td>
<td class="num">$ (921,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Interest and revaluation of convertible notes, net</a></td>
<td class="nump">333,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecapitalizationCosts', window );">Share based transaction costs incurred in reverse recapitalization</a></td>
<td class="nump">7,258,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of derivative warrant liability</a></td>
<td class="num">(262,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">676,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Increase in other receivables</a></td>
<td class="nump">538,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Increase in other payables and accrued liabilities</a></td>
<td class="nump">324,000<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(786,000)<span></span>
</td>
<td class="num">(765,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTMENT ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization', window );">Acquisition of a subsidiary in connection with reverse recapitalization</a></td>
<td class="nump">269,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_TransactionCostsIncurredInReverseRecapitalization', window );">Transaction costs incurred in reverse recapitalization</a></td>
<td class="num">(347,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet', window );">Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net</a></td>
<td class="nump">2,002,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes', window );">Exercise of warrants issued upon conversion of notes</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Issuance of convertible notes</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,083,000<span></span>
</td>
<td class="nump">413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">2,272,000<span></span>
</td>
<td class="num">(354,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">437,000<span></span>
</td>
<td class="nump">791,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">2,709,000<span></span>
</td>
<td class="nump">$ 437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Assets acquired (liabilities assumed):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Current assets excluding cash and cash equivalents</a></td>
<td class="nump">$ 7,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,618,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ReverseRecapitalizationEffectOnEquity', window );">Reverse recapitalization effect on equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_CashAcquiredInConnectionWithReverseRecapitalization', window );">Cash acquired in connection with reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of a subsidiary in connection with reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_AcquisitionOfSubsidiaryInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_CashAcquiredInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash acquired in connection with reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_CashAcquiredInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants issued upon conversion of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_ExerciseOfWarrantsIssuedUponConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflows in connection with current assets and liabilities acquired in reverse recapitalization, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_InflowsInConnectionWithCurrentAssetsAndLiabilitiesAcquiredInReverseRecapitalizationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_ReverseRecapitalizationEffectOnEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization effect on equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_ReverseRecapitalizationEffectOnEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_TransactionCostsIncurredInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_TransactionCostsIncurredInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financial Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6513127<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The after-tax amount of interest recognized in the period associated with any convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recapitalization costs for professional fees associated with restructuring debt and equity mixture that do not qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742048704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 GENERAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td><font style="font-size: 10pt"><b>A. Description of business:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Microbot Medical Inc. (the &#8220;Company&#8221;) is a pre-clinical medical device company specializing in the research, design and development of next generation micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of improving surgical outcomes for patients.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">It was incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to CytoTherapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (&#8220;Microbot Israel&#8221;), and C&#38;RD Israel Ltd. (&#8220;Merger Sub&#8221;), an Israeli corporation and wholly-owned subsidiary of the Company, whereby Merger Sub merged with and into Microbot Israel and Microbot Israel surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). Pursuant to the terms of the Merger, at the effective time of the Merger, each outstanding ordinary share of Microbot Israel capital stock was converted into the right to receive approximately 2.9 shares of the Company&#8217;s common stock, par value $0.01 per share, after giving effect to a one for nine reverse stock split (the &#8220;Reverse Stock Split&#8221;), for an aggregate of 26,550,974 shares of Company&#8217;s common Stock issued to the former Microbot Israel shareholders. In addition, all outstanding options to purchase the ordinary shares of Microbot Israel were assumed by the Company and converted into options to purchase an aggregate of 2,614,916 shares of the Company&#8217;s common Stock. Additionally, the Company issued an aggregate of 7,802,639 restricted shares of its common stock or rights to receive the Company&#8217;s common stock, to certain advisers. On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company&#8217;s common stock began trading on the Nasdaq Capital Market under the symbol &#8220;MBOT&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">As a result of the Merger Microbot Israel became a wholly owned subsidiary of the Company. The transaction between the Company and Microbot Israel was accounted for as a reverse recapitalization. As the shareholders of Microbot Israel received the largest ownership interest in the Company, Microbot Israel was determined to be the &#8220;accounting acquirer&#8221; in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Microbot Israel. Unless indicated otherwise, pre-acquisition share, options and warrants data included in these financial statements is retroactively adjusted to reflect the Reverse Stock Split and the Merger.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Prior to the Merger, the Company was a biopharmaceutical company that conducts research, development, and commercialization of stem cell therapeutics and related technologies. Substantially the sale of all material assets relating to the stem cell business were completed on November 29, 2016.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company and its subsidiaries are collectively referred to as the &#8220;Company&#8221;. &#8220;StemCells&#8221; or &#8220;StemCells, Inc.&#8221; refers to the Company prior to the Merger.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>B. Risk factors:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">To date the Company has not generated revenues from its operations. As of the date of issuance of these financial statements, the Company has a cash and cash equivalent balance of approximately $6.7 million, which the Company believes is sufficient to fund its operations for more than 12 months from the date of issuance of these financial statements and sufficient to fund its operations necessary to continue development activities of its current proposed products. The Company plans to continue to fund its current operations as well as other development activities relating to additional product candidates, through future issuances of either debt and/or equity securities and possibly additional grants from the Israeli Innovation Authority.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td><font style="font-size: 10pt"><b>C. Use of estimates:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management&#8217;s best judgment, actual results may differ from these estimates.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910190096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The significant accounting policies applied in the preparation of the financial statements are as follows:</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>A.Basis of presentation:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>B. Financial statement in U.S. dollars:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The functional currency of the Company is the U.S. dollar (&#8220;dollar&#8221;) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#8220;Foreign Currency Translation&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>C. Cash and cash equivalents:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>D. Fair value of financial instruments:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The carrying values of cash and cash equivalents, other receivable and other accounts payable approximate their fair value due to the short-term maturity of these instruments.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 8.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 1 </b>- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 2</b> - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 3</b> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td><font style="font-size: 10pt"><b>E. Fixed assets:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Fixed assets are presented at cost, net of investment grants received and less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">25-33</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>F. Liabilities due to termination of employment agreements</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (&#8220;Article 14&#8221;) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company&#8217;s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments. </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>G. Basic and diluted net loss per share</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Basic net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights by the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 &#8220;Earnings per Share&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>H. Research and development expenses, net:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>I. Convertible notes:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 &#8220;Debt with Conversion and Other Options&#8221;, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the Notes.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, &#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>J. Share-based compensation:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company applies ASC 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to service providers, employees and directors including stock options under the Company&#8217;s stock plans based on estimated fair values. </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s statement of operations.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company&#8217;s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>K. Reclassification:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Certain prior year amounts have been reclassified to conform to the current year presentation.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>L. Transaction Costs:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>M. Recent Accounting Standards:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In May 2014, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for us beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it is unable to determine the expected impact the new standard will have on its consolidated financial statements.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In January 2016, the FASB issued ASU 2016-01 &#8220;Recognition and Measurement of Financial Assets and Financial Liabilities&#8221;, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;), which amends, among other things, the existing guidance by requiring lessees to recognize lease assets (right-to-use) and liabilities (for reasonably certain lease payments) arising from operating leases on the balance sheet. For leases with a term of twelve months or less, ASU 2016-02 permits an entity to make an accounting policy election to recognize such leases as lease expense, generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (&#8220;ASU 2016-09&#8221;), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments &#8211; Credit Losses &#8211; Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The standard is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. The Company is evaluating the impact of the adoption on our consolidated balance sheet, results of operations, cash flows and disclosures.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742171536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 - CASH AND CASH EQUIVALENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,709</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">427</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Deposits</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,709</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">437</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910203296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other Receivables</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 - OTHER RECEIVABLES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Deposit in escrow account (*)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">505</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Government institutions</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">15</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">14</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Prepaid expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">86</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">25</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Shareholders</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">15</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">606</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><b>&#160;</b></p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>(*) Purchase Agreement with BOCO. </b>On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &#8220;Sellers&#8221;), entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&#8220;BOCO US&#8221;). </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Pursuant to the terms and subject to the conditions set forth in the Asset Purchase Agreement, the Sellers sold to BOCO US certain stem and progenitor cell lines that have been researched, studied or manufactured by the Company since 2007 (the &#8220;Cell Lines&#8221;) and certain other tangible and intangible assets, including intellectual property and books and records, related to the foregoing (together with the Cell Lines, the &#8220;Assets&#8221;) in exchange for $4 million in cash (the &#8220;Asset Consideration&#8221;).</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Of the Asset Consideration, $300,000 was provided to the Company prior to November 11, 2016 in exchange for the Sellers&#8217; agreement not to solicit or reach any agreement with any third party pertaining to the sale of the Assets, and $400,000 will remain in a twelve-month escrow for the benefit of BOCO US to satisfy certain indemnification obligations of the Sellers which may arise and which, subject to any valid indemnification claims of BOCO US, will be released to the Company at the end of such 12-month period. In addition, sixteen former employees of the Company received, in the aggregate, $495,000, in accordance with their June 2016 agreements with the Company under which each accepted a more than 50% reduction in his or her severance award otherwise payable.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Asset Purchase Agreement contains certain covenants prohibiting the Sellers from, during the four-year period immediately following the completion of the Asset Sale, (a) engaging in or having certain financial interests in a business that is engaged in the research, development or commercialization of the Cell Lines, or (b) soliciting for employment employees of BOCO US.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On November 29, 2016, the Sellers completed the sale of the Assets.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The opening balance sheet as of the Merger date included a receivable balance with respect to sale of the Assets of $3.5 million, from which $2.8 million were collected prior to December 31, 2016. </font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742103312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 - FIXED ASSETS, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Cost:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">29</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">63</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">63</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">117</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">92</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Accumulated Depreciation:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">42</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">36</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">64</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">38</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910150496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 - ACCRUED LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Employees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">102</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">121</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Government institution</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Other current liabilities</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">456</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Israeli Innovation Authority</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">582</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">149</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629603936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loan from Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Loan from Shareholders</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 - CONVERTIBLE LOAN FROM SHAREHOLDERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On October 8, 2015, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. According to the loan agreement, Microbot Israel received an amount of $419,000. The loan bore interest of 10%, and was converted to both equity shares and preferred shares warrants of Microbot Israel on the nine-month anniversary of the loan. The Company concluded the conversion feature is not a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &#8220;Debt with Conversion and Other Options&#8221;. Accordingly, the proceeds were recorded in liabilities in their entirety at the date of issuance.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On July 7, 2016, the outstanding principal and accrued interest were converted into 1,315,023 Series A preferred shares, of Microbot Israel (the &#8220;Series A Preferred Shares&#8221;) and 1,188,275 warrants to purchase the Series A Preferred Shares, at an exercise price of $1.00 per share. The preferred shares warrants were exercised in full in September 2016 for total gross proceeds to Microbot Israel of $409,750.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On May 11, 2016, Microbot Israel entered into a convertible loan agreement with several investors who were also existing shareholders. The loan bore interest at a fixed rate of 10% per annum beginning on the issuance date.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">At maturity, all of the outstanding principal and accrued interest was converted into Microbot Israel&#8217;s ordinary shares subject to the conversion or default events specified in the loan agreement, based on a conversion price that represents a 20% discount on Microbot Israel&#8217;s valuation upon such default events. Furthermore, in the event of a reverse merger transaction or a qualified financing, each as defined in the convertible loan agreement with respect to such loans, all of the outstanding principal and accrued interest would be converted into the securities issued in the reverse merger or the qualified financing, as the case may be.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On November 28, 2016, upon the consummation of the Merger, the loan was converted into an aggregate of 2,242,939 shares of Company&#8217;s common stock.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company concluded the value of the loan is predominantly based on a fixed monetary amount known at the date of issuance as represented by the 20% discount on the Company&#8217;s valuation. Accordingly, the loan was classified as debt and is measured at its fair value, pursuant to the provisions of ASC 480-10, &#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The fair value of the loan is measured based on observable inputs as the fixed monetary value of the variable amount of shares to be issued upon conversion (level 2 measurement). </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td><font style="font-size: 10pt"><b>Secured Note to Alpha Capital Anstalt:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On August 15, 2016, concurrent with the execution of the Agreement and Plan of Merger (see Note 1A), StemCells Inc issued a 5.0% secured note (the &#8220;Note&#8221;) to Alpha Capital Anstalt (&#8220;Alpha Capital&#8221;), in the principal amount of $2 million, for value received, payable upon the earlier of (i) 30 days following the consummation of the Merger and (ii) December 31, 2016. Proceeds from the Note were used for the payment of costs and expenses in connection with the Merger and operational expenses leading to such Closing.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Note bears interest at 5% per annum, payable monthly in arrears on the first of the month, beginning on January 1, 2017 until the principal amount is paid in full. In addition, the Note is secured by a first priority security interest in all of the Company&#8217;s intellectual property and certain other general assets pursuant to a Security Agreement.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>Securities Exchange Agreement with Alpha Capital:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">As of the effective time of the Merger, the Company entered into a Securities Exchange Agreement (the &#8220;Exchange Agreement&#8221;) with Alpha Capital, providing for the issuance to Alpha Capital of a convertible promissory note by the Company (the &#8220;Convertible Note&#8221;) in a principal amount of $2,028,767, which is equal to the principal and accrued interest under the Note, in exchange for (a) the full satisfaction, termination and cancellation of the Note and (b) the release and termination of the Security Agreement and the first priority security interest granted thereunder.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Convertible Note is convertible into the Company&#8217;s Common Stock any time after November 28, 2017 and until the maturity date of November 28, 2019, based on a conversion price of $0.64, subject to adjustments as provided in the Exchange Agreement. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Pursuant to the terms of the Convertible Note, the Company is obligated to pay interest on the outstanding principal amount owed under the Convertible Note at a fixed rate per annum of 6.0%, payable at maturity or earlier upon conversion. The Exchange Agreement contains customary representations and warranties and usual and customary affirmative and negative covenants. The Convertible Note also contains certain customary events of default.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">As the Exchange Agreement represented the consummation of the original intent of the Company and Alpha Capital, as of the date of execution of the Merger Agreement (August 2016), to enter into a $2 million convertible note sale transaction, upon the consummation of the Merger, the Company accounted for the convertible note in accordance with such economic substance, as if it had been issued for a cash consideration equal to the principal and accrued interest on the Note, as of the effective date of the Merger, in the amount of $2,029,000 (the &#8220;Assumed Consideration&#8221;), which is equal to the principal amount of the Convertible Note as determined in the Exchange Agreement. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company concluded the conversion feature of the Convertible Note, based on the commitment date of November 28 2016 (the Exchange Agreement date), is a Beneficial Conversion Feature pursuant to the provisions of ASC 470-20, &#8220;Debt with Conversion and Other Options&#8221;. Accordingly, $2,029,000 of the Assumed Consideration was recorded in equity with a corresponding discount on the Convertible Note, to be amortized over its term through maturity. </font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910198640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Warrant Liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 - DERIVATIVE WARRANT LIABILITIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">As part of StemCell&#8217;s obligations under the Merger Agreement, in August 2016, StemCells negotiated with certain institutional holders of its 2016 Series A and Series B Warrants, issued by prior to the Merger, to have such holders surrender their 2016 Series B Warrants in exchange for a reduced exercise price of $0.30 per share on their existing 2016 Series A Warrants and the elimination of the anti-dilution price protection in the 2016 Series A Warrants. As a result, the exercise price for all outstanding 2011 Series A Warrants and 2016 Series A and Series B Warrants was reset to $0.30 per share. Subsequent to the reset of the exercise price, an aggregate of 531,814 (from an outstanding aggregate of 578,081) 2011 Series A Warrants were exercised. For the exercise of these warrants, the Company issued 531,814 shares of its common stock prior to the Merger.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The remaining outstanding warrants and terms as of the closing date of the Merger (November 28, 2016) and as of Dec 31 2016 is as follows: </font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Issuance Date</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding as of November 28, 2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price </b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>Per Share</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable as of December 31, 2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable </b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>Through</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 30%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2011)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">64,230</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$151.20</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 2016</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2013)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,814</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$194.40</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,814</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">October 2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2013)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,718</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$183.60</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,718</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">April 2023</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2015)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,139</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$91.80</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,139</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">April 2020</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2016)(a)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,047</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,047</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series B (2016)(a)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">41,116</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">41,116</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 2022</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">__________________</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 48px; line-height: 115%">&#160;</td>
    <td style="width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">As such anti-dilution price protection, does not meet the specific conditions for equity classification, the Company is required to classify the fair value of these warrants as a liability, with changes in fair value to be recorded as income (loss) due to change in fair value of warrant liability. The estimated fair value of our warrant liability at November 28, 2016 and December 31, 2016, was approximately $575,000 and $313,000, respectively.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">As quoted prices in active markets for identical or similar warrants are not available, the Company uses directly observable inputs in the valuation of its derivative warrant liabilities (level 2 measurement). </font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The Company uses the Black-Scholes valuation model to estimate fair value of these warrants. In using this model, the Company makes certain assumptions about risk-free interest rates, dividend yields, volatility, expected term of the warrants and other assumptions. Risk-free interest rates are derived from the yield on U.S. Treasury debt securities. Dividend yields are based on our historical dividend payments, which have been zero to date. Volatility is estimated from the historical volatility of our common stock as traded on NASDAQ. The expected term of the warrants is based on the time to expiration of the warrants from the date of measurement.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of November 28, 2016 and December 31, 2016 (in thousands):</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Series A<br />
        (2011)</b></p></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Series A (2013)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Series A (2013)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Series A (2015)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Series A</b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>(2016)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Series B</b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>(2016)</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balances at November 28, 2016</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">43</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">45</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">81</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">388</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 5%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">575</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Changes in fair value</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(31</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(9</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(23</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(38</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(161</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(262</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balances at December 31, 2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">12</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">22</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">43</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">227</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">313</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In accordance with ASC-820-10-50-2(g),
the Company has performed a sensitivity analysis of the derivative warrant liabilities of the Company which are classified as
level 3 financial instruments. The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables
in the Black-Scholes model that vary overtime, namely, the volatility and the risk free rate. A 5.0% decrease in volatility would
decrease the value of the warrants to $301,000; a 5.0% increase in volatility would increase the value of the warrants to $312,000.
A 5.0% decrease or increase in the risk free rate would not have materially changed the value of the warrants; the value of the
warrants is not strongly correlated with small changes in interest rates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742723648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 - COMMITMENTS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Microbot Israel obtained from the
Israeli Innovation Authority grants for participation in research and development for the years 2013 through 2016 in the total
amount of approximately $0.9 million, and, in return, Microbot Israel is obligated to pay royalties amounting to 3% of its future
sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar to the New Israeli Shekel and bears
interest of Libor per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The repayment of the grants is contingent
upon the successful completion of the Company&#8217;s research and development programs and generating sales. The Company has no
obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial
risk is assumed completely by the Government of Israel. The grants are received from the Government on a project-by-project basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Microbot Israel signed an agreement
with the Technion Research and Development Foundation (&#8220;TRDF&#8221;) in June 2012 by which TRDF transferred to Microbot Israel
a global, exclusive, royalty-bearing license. As partial consideration for the license, Microbot Israel shall pay TRDF royalties
on net sales (between 1.5%-3%) and on sublicense income as detailed in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Lease Agreements:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In June 2016, the Company entered
into an office lease agreement, with a term ending on September 30, 2017. According to the lease agreement, the monthly office
lease payment is approximately $3,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In December 2016, the Company entered
into certain lease agreements for automobiles, which will end on December 31, 2019. According to the lease agreements, the monthly
automobile lease payments are approximately $2,500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Compensation liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company incurred compensation
commitments of approximately $0.4 million to a former executive that management estimates as remote as therefore is not reflected
in these consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908258736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Share Capital</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 SHARE CAPITAL</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Ordinary shares confer upon
the holders voting rights and the right to receive cash and stock dividends.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Each share of the Series A
Convertible Preferred Stock issued by the Company in December 2016, is convertible, at the option of the holder, into 1,000 shares
of Common Stock, and confer upon the holder dividend rights on an as converted basis. The shares of Series A Preferred Stock do
not confer upon the holder voting rights and do not confer upon the holder a preference upon a liquidation event.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Share Capital Developments:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -28.35pt"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The authorized capital stock
consists of 221,000,000 shares of capital stock, which consists of 220,000,000 shares of common stock, par value $0.01 (the &#8220;Common
Stock&#8221;), and 1,000,000 of undesignated preferred stock, par value $0.01 (the &#8220;Preferred Stock&#8221;). As of December
31, 2016, the Company had 26,550,974 shares of Common Stock issued and outstanding, and 9,736 shares of Series A Convertible Preferred
Stock issued and outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On November 28, 2016, the
Company filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended, with the Secretary of State
of the State of Delaware to (i) effect the Reverse Stock Split, (ii) change its name from &#8220;StemCells , Inc.&#8221; to &#8220;Microbot
Medical Inc.&#8221; and (iii) increase the number of authorized shares of the Common Stock from 200,000,000 to 220,000,000 shares
(the &#8220;Certificate of Amendment&#8221;).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As a result of the Reverse
Stock Split, the number of issued and outstanding shares of the Common Stock immediately prior to the Reverse Stock Split were
reduced into a smaller number of shares, such that every nine shares of the Common Stock held by a stockholder immediately prior
to the Reverse Stock Split were combined and reclassified into one share of the Common Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Immediately following the
Reverse Stock Split and the Merger, there were 36,254,240 shares of the Common Stock issued and outstanding, which included certain
rights to receive shares of Common Stock or equivalent securities but excludes shares underlying outstanding stock options and
warrants and the Convertible Note.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On December 27, 2016, the
Company exchanged 9,735,925 shares or rights to acquire shares of its Common Stock, for 9,736 shares of a newly designated class
of Series A Convertible Preferred Stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><b>Employee Stock Option Grant:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In September 2014, Microbot
Israel&#8217;s board of directors approved a grant of 403,592 stock options (1,167,693 stock options as retroactively adjusted
to reflect the Merger) to its CEO, through MEDX Venture Group LLC. Each option was exercisable into an ordinary share, at an exercise
price of $0.8 ($0.28 as retroactively adjusted to reflect the Merger). The stock options were fully vested at the date of grant.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On May 2, 2016, Microbot Israel&#8217;s
board of directors approved a grant of 500,000 stock options (1,447,223 as retroactively adjusted to reflect the Merger) to certain
of its employees and directors. Each stock option was exercisable into an ordinary share, NIS 0.001 par value, of Microbot Israel,
at an exercise price equal to the ordinary share&#8217;s par value. The stock options were fully vested at the date of grant. As
a result, the Company recognized compensation expenses in the amount of $675,389 included in general and administrative expenses.
As the exercise price of the stock options is nominal, Microbot Israel estimated the fair value of the options as equal to the
Company&#8217;s share price of $1.35 ($0.47 as retroactively adjusted to reflect the Merger) at the date of grant.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">A summary of the Company&#8217;s
option activity related to options to employees and directors, and related information is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the year ended December 31, 2016</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of stock options</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate intrinsic value</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at beginning of period</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,447,223</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at end of period</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,614,916</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.13</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,611,049</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Vested and expected-to-vest at end of period</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,614,916</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.39</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">15,611,049</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less than $0.01.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>For the year ended December 31, 2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of stock options</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate intrinsic value</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at beginning of period</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cancelled</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding at end of period</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Vested and expected-to-vest at end of period</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The aggregate intrinsic value
in the table above represents the total intrinsic value (the difference between the fair market value of the Company&#8217;s and
Microbot Israel&#8217;s common shares on December 31, 2016 and December 31, 2015 respectively and the exercise price, multiplied
by the number of in-the-money stock options on those dates) that would have been received by the stock option holders had all stock
option holders exercised their stock options on those dates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The stock options outstanding
as of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise price</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Stock options outstanding as of December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average remaining contractual life &#8211; years as of December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Stock options exercisable as of December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>$</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 17%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.28</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.0</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9.0</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,447,223</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9.5</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,447,223</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,614,916</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.4</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.2</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,614,916</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,167,693</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify">&#160;</p>

<p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(*)</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less than $0.01.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Compensation expense recorded
by the Company in respect of its stock-based employee compensation awards in accordance with ASC 718-10 for the year ended December
31, 2016 and 2015 was $675,389 and $186,000, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The fair value of the stock
options is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Years ended December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">77.3</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">70.0</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.6</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.0</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected life of up to (years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.0</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Shares issued to service
provider</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In connection with the Merger,
the Company issued an aggregate of 7,802,639 restricted shares of its common stock to certain advisors. The fair value of the award
of $9,987,000 was estimated based on the Company&#8217;s common share price of $1.28 as of the date of grant. The portion of the
expense in excess of the cash and other current assets acquired in the Merger, in the amount of $7,262,000, was included in general
and administrative expenses in the Statement of Operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Securities Exchange Agreement
with Alpha Capital </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">On December 16, 2016, the
Company entered into a Securities Exchange Agreement with Alpha Capital, pursuant to which Alpha Capital exchanged 9,736,000 shares
of common stock or rights to acquire shares of the common stock held by it, for 9,736 shares of a newly designated class of Series
A Convertible Preferred Stock, par value $0.01 per share (the &#8220;Preferred Stock&#8221;). The common stock and common stock
underlying the rights to acquire common stock include all of the shares of common stock issued or issuable to Alpha Capital pursuant
to the Merger.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The 9,735,925 shares of common
stock and the rights to acquire common stock were cancelled and the Company&#8217;s issued and outstanding shares of Common Stock
were reduced to 26,518,315.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Repurchase of Shares</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company intends to enter
into a definitive agreement with up to three Israeli shareholders that were former shareholders of Microbot Medical Ltd., pursuant
to which the Company would repurchase, at a discount on the fair value of the share at the date of repurchase, up to $500,000 of
the Company&#8217;s common stock held by them, in the aggregate, if and to the extent such shareholders are unable to sell enough
of their shares to cover certain of their Israeli tax liabilities resulting from the Merger. Such repurchase(s), if any, would
occur only after the two year anniversary of the Merger. The transaction is subject to negotiating final terms and entering into
definitive agreements with such shareholders.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company evaluated whether
an embedded derivative that requires bifurcation exists within such shares that may be subject to repurchase. The Company concluded
the fair value of such derivative instrument would be nominal and in any case would represent an asset to the Company as (a) the
settlement requires acquiring the shares at a discount on the fair market value of the share at the time of re purchase and in
no circumstances the acquisition price will be higher than approximately one dollar per share (representing 25% discount on the
fair market value of the share at the merger closing date) and (b)it is assumed that the selling shareholders would use such right
as last resort as such repurchase at a discount on the fair market value of such shares results in a loss to be incurred by the
selling shareholders.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">In accordance with ASC 480-10-S99-3A
(formerly EITF D-98), the Company classified the maximum amount it may be required to pay in the event the repurchase right is
exercised ($500,000) as temporary equity.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908258448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 - BASIC AND DILUTED NET LOSS PER SHARE </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The basic and diluted net loss per
share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows
(in thousands, except share and per share data):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Net loss attributable to shareholders of the company</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9,663</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">921</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Net loss attributable to shareholders of preferred shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,954</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(360</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Net loss used in the calculation of basic net loss per share</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,709</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">561</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Net loss per share</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.40</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.04</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Weighted average number of common shares</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,293,296</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">13,182,660</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">As the inclusion of common share
equivalents in the calculation would be anti-dilutive for all periods presented, diluted net loss per share is the same as basic
net loss per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The weighted average number of common
shares outstanding has been retroactively restated for the equivalent number of common shares received by the accounting acquirer
as a result of the reverse recapitalization and reverse stock split as if these common shares had been outstanding as of the beginning
of the earliest period presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742170848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and Development Expenses, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 RESEARCH AND DEVELOPMENT
EXPENSES, NET</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year ended December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Payroll and related expenses</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">491</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">464</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Materials</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">155</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Patents</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">75</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">37</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Office and maintenance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">36</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">29</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Professional services</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">365</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">76</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less grants received from Israeli Innovation Authority</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(213</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(201</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">901</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">823</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23218-108380<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741992400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_GeneralAndAdministrativeExpensesTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13 GENERAL AND ADMINISTRATIVE EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Years ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Payroll and related expenses</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">45</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Professional services</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">528</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">40</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Common shares issued for services</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,258</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Travel</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">180</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">15</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Depreciation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">47</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">26</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Share-based compensation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">676</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,734</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">92</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses [Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742171536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Finance Expenses, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 14 - FINANCE EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Years ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Bank fees and interest</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Change in fair value of derivative warrant liability</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(262</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Exchange rate differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(44</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Revaluation and interest on convertible loans</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">333</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">28</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741992400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Interested and Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Transactions and Balances With Interested and Related Parties</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 15 - TRANSACTIONS AND BALANCES
WITH INTERESTED AND RELATED PARTIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -28.35pt">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>A. Transactions:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Payroll and related expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Directors fees and insurance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Subcontracted work and consulting</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">122</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">122</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>B. Balances:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other accounts payable</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742079696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 16 - TAXES ON INCOME</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to
income taxes under the Israeli and U.S. tax laws:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>Corporate tax rates</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to
Israeli corporate tax rate of 26.5% in the years 2015 and 2014, 25% in the year 2016, 24% in 2017 and 23% from 2018.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The Company is subject to
a blended U.S. tax rate (Federal as well as state corporate tax) of 35%.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; line-height: 115%">&#160;</td>
    <td style="width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>A.</b></font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2016, the Company generated net operating losses in Israel of approximately $5,556, which may be carried forward and offset against taxable income in the future for an indefinite period.</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">As of December 31, 2016, the Company generated net operating losses in the U.S. of approximately $475,496. Net operating losses in the United States are available through 2035. Utilization of U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</font></td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>B.</b></font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The Company is still in its development stage and has not yet generated revenues, therefore, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the deferred tax assets to its recoverable amounts.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify; text-indent: -30.45pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss carry-forward</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,052</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">471,980</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total deferred tax assets</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,052</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">471,980</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(481,052</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(471,980</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net deferred tax assets</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742170848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 17 - SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-decoration: underline"><font style="font-size: 10pt"><b><u>Purchase Agreement</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On January 5, 2017, the Company entered into a definitive securities purchase agreement with an institutional investor (the &#8220;Purchaser&#8221;) for the purchase and sale of an aggregate of 700,000 shares of the Company&#8217;s common stock in a registered direct offering for $5.00 per share or gross proceeds of $3.5 million. The Company paid the placement agent a fee of $210,000 plus reimbursement of out-of-pocket expenses, as well as other offering-related expenses.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-decoration: underline"><font style="font-size: 10pt"><b><u>Contract Research Agreement</u></b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">On January 27, 2017, the Company entered into a Contract Research Agreement (the &#8220;Research Agreement&#8221;) with The Washington University (&#8220;Washington U.&#8221;), pursuant to which the parties will collaborate to determine the effectiveness of the Company&#8217;s self-cleaning shunt. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The initial research to be performed by Washington U. is expected to be completed within 6 months, with a comprehensive study to follow and be completed in 2018. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The cost of the initial study, to be paid by the Company, is expected to be approximately $130,000, with the cost of any further studies to be determined. Pursuant to the Research Agreement, all rights, title and interest in the data, information and results obtained or arrived at by Washington U. in the performance of its services under the Research Agreement, as well as any patentable inventions obtained or arrived at in the performance of such services, will be jointly owned by the Company and Washington U., and each will have full right to practice and grant licenses in joint inventions. Additionally, Washington U. granted to the Company: (a) a non-exclusive, worldwide, royalty-free, fully paid-up, perpetual and irrevocable license to use and practice patentable inventions (other than joint inventions and improvements to Washington U.&#8217;s animal models) obtained or arrived at by Washington U. in the provision of its services under the Research Agreement (&#8220;University Inventions&#8221;) with respect to the self-cleaning shunt; and (b) an exclusive option to obtain an exclusive worldwide license in University Inventions, on terms to be negotiated between the parties.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905419488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>A.Basis of presentation:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial Statement in U.S. Dollars</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>B. Financial statement in U.S. dollars:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The functional currency of the Company is the U.S. dollar (&#8220;dollar&#8221;) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.</font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in foreign currencies have been re-measured to dollars in accordance with the provisions of ASC 830-10, &#8220;Foreign Currency Translation&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>C. Cash and cash equivalents:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Cash and cash equivalents consist of cash and demand deposits in banks, and other short-term liquid investments (primarily interest-bearing time deposits) with original maturities of less than three months.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><font style="font-size: 10pt"><b>D. Fair value of financial instruments:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The carrying values of cash and cash equivalents, other receivable and other accounts payable approximate their fair value due to the short-term maturity of these instruments.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company measures the fair value of certain of its financial instruments (such as the derivative warrant liabilities) on a recurring basis. The method of determining the fair value of derivative warrant liabilities is discussed in Note 8.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 1 </b>- Quoted prices (unadjusted) in active markets for identical assets and liabilities.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 2</b> - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Level 3</b> - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td><font style="font-size: 10pt"><b>E. Fixed assets:</b></font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Fixed assets are presented at cost, net of investment grants received and less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives of the assets, as the following annual rates:</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">25-33</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7</font></td>
    <td>&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Liabilities Due to Termination of Employment Agreements</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>F. Liabilities due to termination of employment agreements</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Under Israeli employment laws, employees of Microbot Israel are included under Article 14 of the Severance Compensation Act, 1963 (&#8220;Article 14&#8221;) for a portion of their salaries. According to Article 14, these employees are entitled to monthly deposits made by Microbot Israel on their behalf with insurance companies. </font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Payments in accordance with Article 14 release Microbot Israel from any future severance payments (under the Israeli Severance Compensation Act, 1963) with respect of those employees. The aforementioned deposits are not recorded as an asset in the Company&#8217;s balance sheet, and there is no liability recorded as the Company does not have a future obligation to make any additional payments. </font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>G. Basic and diluted net loss per share</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Basic net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights by the weighted average number of common shares outstanding during the year. Common shares and preferred shares contingently issuable for little or no cash are included in basic net loss per share on an as issued basis.</font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Diluted net loss per share is computed by dividing net loss, as adjusted to include preferred shares dividend participation rights of preferred shares outstanding during the year as well as of preferred shares that would have been outstanding if all potentially dilutive preferred shares had been issued, by the weighted average number of common shares outstanding during the year, plus the number of common shares that would have been outstanding if all potentially dilutive common shares had been issued, using the treasury stock method, in accordance with ASC 260-10 &#8220;Earnings per Share&#8221;.</font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The weighted average number of shares outstanding has been retroactively restated for the equivalent number of shares received by the accounting acquirer as a result of the reverse recapitalization as if these shares had been outstanding as of the beginning of the earliest period presented.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>H. Research and development expenses, net:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Research and development expenses are charged to the statement of operations as incurred. Grants for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from the research and development expenses. </font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>I. Convertible notes:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Proceeds from the sale of debt securities with a conversion feature are allocated to equity based on the intrinsic value of such conversion feature in accordance with ASC 470-20 &#8220;Debt with Conversion and Other Options&#8221;, with a corresponding discount on the debt instrument recorded in liabilities which is amortized in finance expense over the term of the Notes.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">Convertible notes with characteristics of both liabilities and equity are classified as either debt or equity based on the characteristics of its monetary value, with convertible notes classified as debt being measured at fair value, in accordance with ASC 480-10, &#8220;Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity&#8221;.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>J. Share-based compensation:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The Company applies ASC 718-10, &#8220;Share-Based Payment,&#8221; which requires the measurement and recognition of compensation expenses for all share-based payment awards made to service providers, employees and directors including stock options under the Company&#8217;s stock plans based on estimated fair values. </font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s statement of operations.</font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are share price, expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on volatility of similar companies in the technology sector for equity awards granted prior to the Merger and on the Company&#8217;s trading share price for equity awards granted subsequent to the Merger. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. The expected stock option term is calculated for stock options granted to employees and directors using the &#8220;simplified&#8221; method. Grants to non-employees are based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>K. Reclassification:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Certain prior year amounts have been reclassified to conform to the current year presentation.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_TransactionCostsPolicyTextBlock', window );">Transaction Costs</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>L. Transaction Costs:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">Transaction costs incurred in the Merger were charged directly to equity to the extent of cash and net other current assets acquired. Transaction costs in excess of cash acquired were charged to general and administrative expenses.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top"><td style="text-align: justify; width: 48px"></td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>M. Recent Accounting Standards:</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In May 2014, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for us beginning in the first quarter of 2018; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. As the Company has not incurred revenues to date, it is unable to determine the expected impact the new standard will have on its consolidated financial statements.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In January 2016, the FASB issued ASU 2016-01 &#8220;Recognition and Measurement of Financial Assets and Financial Liabilities&#8221;, which provides targeted improvements to the recognition, measurement, presentation and disclosure of financial assets and financial liabilities. Specific accounting areas addressed include, equity investments, financial liabilities reported under the fair value option and valuation allowance assessment resulting from unrealized losses on available-for-sale securities. The standard also changes certain presentation and disclosure requirements for financial instruments. This ASU is effective for the Company in its first quarter of fiscal year 2019. Early adoption, with certain exceptions, is not permitted. The Company does not expect that the adoption of this standard will have a significant impact on the financial position or results of operations.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;), which amends, among other things, the existing guidance by requiring lessees to recognize lease assets (right-to-use) and liabilities (for reasonably certain lease payments) arising from operating leases on the balance sheet. For leases with a term of twelve months or less, ASU 2016-02 permits an entity to make an accounting policy election to recognize such leases as lease expense, generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 using a modified retrospective approach, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its consolidated financial statements. </font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (&#8220;ASU 2016-09&#8221;), which simplifies certain provisions associated with the accounting for stock compensation. Among other things, ASU 2016-09 requires companies to record excess tax benefits and tax deficiencies as income tax benefit or expense in the statement of income and eliminates the requirement to reclassify cash flows related to excess tax benefits from operating activities to financing activities in the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. The Company is currently reviewing and evaluating this guidance and its impact on its consolidated financial statements.</font></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt">In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments &#8211; Credit Losses &#8211; Measurement of Credit Losses on Financial Instruments, which introduces a model based on expected losses to estimate credit losses for most financial assets and certain other instruments. In addition, for available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. The standard is effective for annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. The Company is evaluating the impact of the adoption on our consolidated balance sheet, results of operations, cash flows and disclosures.</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_TransactionCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_TransactionCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6607381888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock', window );">Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>%</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">25-33</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7</font></td>
    <td>&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property and Equipment Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908264112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,709</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">427</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Deposits</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,709</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">437</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908265936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Deposit in escrow account (*)</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">505</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Government institutions</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">15</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">14</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Prepaid expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">86</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">25</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Shareholders</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">15</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">606</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><b>&#160;</b></p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="text-align: justify"><font style="font-size: 10pt"><b>(*) Purchase Agreement with BOCO. </b>On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &#8220;Sellers&#8221;), entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&#8220;BOCO US&#8221;). </font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908264112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Fixed Assets, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Cost:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">29</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">63</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">63</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">117</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">92</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt"><b>Accumulated Depreciation:</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Research equipment and software</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">22</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Furniture and office equipment</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">42</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">36</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">64</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">54</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">38</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741992400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>As of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Employees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">102</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">121</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Government institution</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">24</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Other current liabilities</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">456</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Israeli Innovation Authority</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">10</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">582</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">149</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6751682624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Warrant Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants Liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify">&#160;</td>
    <td style="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The remaining outstanding warrants and terms as of the closing date of the Merger (November 28, 2016) and as of Dec 31 2016 is as follows: </font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Issuance Date</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding as of November 28, 2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price </b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>Per Share</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable as of December 31, 2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercisable </b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>Through</b></font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 30%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2011)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">64,230</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 8%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$151.20</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#8211;</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 2016</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2013)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,814</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$194.40</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,814</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">October 2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2013)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,718</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$183.60</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,718</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">April 2023</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2015)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,139</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$91.80</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,139</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">April 2020</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series A (2016)(a)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,047</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,047</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Series B (2016)(a)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">41,116</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">41,116</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">March 2022</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.9pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">__________________</font></td></tr>
<tr style="vertical-align: top">
    <td style="width: 48px; line-height: 115%">&#160;</td>
    <td style="width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(a)</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Valuation of Derivative Warrant Liabilities</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt">The following table summarizes the observable inputs used in the valuation of the derivative warrant liabilities as of November 28, 2016 and December 31, 2016 (in thousands):</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Series A<br />
        (2011)</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Series A (2013)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Series A (2013)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Series A (2015)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Series A</b></font><br />
<font style="font-size: 10pt"><b>(2016)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Series B</b></font><br />
<font style="font-size: 10pt"><b>(2016)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%; text-align: justify"><font style="font-size: 10pt">Balances at November 28, 2016</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">43</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">18</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">45</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">81</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">388</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 5%; text-align: right"><font style="font-size: 10pt">575</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Cancelled</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Changes in fair value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(31</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(9</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(23</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(38</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(161</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(262</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Balances at December 31, 2016</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">43</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">227</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">313</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6631387344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">A summary of the Company&#8217;s
option activity related to options to employees and directors, and related information is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the year ended December 31, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of stock options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted average exercise price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Aggregate intrinsic value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Outstanding at beginning of period</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.28</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,447,223</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(*)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cancelled</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at end of period</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,614,916</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.13</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,611,049</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Vested and expected-to-vest at end of period</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,614,916</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.39</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,611,049</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(*)</font></td>
    <td><font style="font-size: 10pt">Less than $0.01.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>For the year ended December 31, 2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of stock options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted average exercise price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Aggregate intrinsic value</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%"><font style="font-size: 10pt">Outstanding at beginning of period</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">0.28</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Cancelled</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at end of period</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.28</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Vested and expected-to-vest at end of period</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.28</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Options Outstanding</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The stock options outstanding as
of December 31, 2016, and December 31, 2015, have been separated into exercise prices, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Exercise price</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Stock options outstanding as of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted average remaining contractual life &#8211; years as of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Stock options exercisable as of December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>$</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%">&#160;</td>
    <td style="width: 17%; text-align: right"><font style="font-size: 10pt">0.28</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">8.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">9.0</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">(*)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,447,223</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">9.5</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,447,223</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,614,916</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.4</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8.2</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,614,916</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,167,693</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67.5pt; text-align: justify">&#160;</p>

<p style="font: 1pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-size: 10pt">(*)</font></td>
    <td><font style="font-size: 10pt">Less than $0.01.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The fair value of the stock options
is estimated at the date of grant using Black-Scholes options pricing model with the following weighted-average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Years ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Expected volatility</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">77.3</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">70.0</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Risk-free interest</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.6</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected life of up to (years)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.0</font></td>
    <td>&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910232688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The basic and diluted net loss per
share and weighted average number of common shares used in the calculation of basic and diluted net loss per share are as follows
(in thousands, except share and per share data):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Year Ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Net loss attributable to shareholders of the company</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">9,663</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">921</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Net loss attributable to shareholders of preferred shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3,954</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(360</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Net loss used in the calculation of basic net loss per share</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,709</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">561</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Net loss per share</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.40</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.04</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt; text-align: justify"><font style="font-size: 10pt">Weighted average number of common shares</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">14,293,296</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">13,182,660</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908247744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year ended December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Payroll and related expenses</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">491</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">464</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Materials</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">155</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Patents</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">75</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">37</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Office and maintenance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">36</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">29</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Professional services</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">365</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">76</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">100</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less grants received from Israeli Innovation Authority</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(213</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(201</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">901</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">823</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910149632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Years ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Payroll and related expenses</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">45</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Professional services</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">528</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">40</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Common shares issued for services</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,258</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Travel</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">180</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">15</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Depreciation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">11</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">47</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">26</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Share-based compensation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">676</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">8,734</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">92</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of General and Administrative Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_ScheduleofGeneralandAdministrativeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742236096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Summary of Finance Expenses, Net</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Years ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2015</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 10pt"><b>(in thousands)</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify"><font style="font-size: 10pt">Bank fees and interest</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify"><font style="font-size: 10pt">Change in fair value of derivative warrant liability</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(262</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify"><font style="font-size: 10pt">Exchange rate differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(44</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt; text-align: justify"><font style="font-size: 10pt">Revaluation and interest on convertible loans</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">333</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">28</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742166720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Interested and Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transaction and Balances</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>A. Transactions:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year ended</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Payroll and related expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Directors fees and insurance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Subcontracted work and consulting</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">122</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">253</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">122</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 84.45pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><b>B. Balances:</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of</b></font><br />
<font style="font: 10pt Times New Roman, Times, Serif"><b>December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other accounts payable</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742236096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As of December 31,</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2015</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="6" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>(in thousands)</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss carry-forward</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,052</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">471,980</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Total deferred tax assets</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,052</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">471,980</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(481,052</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(471,980</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net deferred tax assets</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746024016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one-to-nine Reverse Stock Split<span></span>
</td>
<td class="text">10,702,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember', window );">Microbot Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock number of common stock issued</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">one for nine reverse stock split <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion option to purchase common stock</a></td>
<td class="nump">2,614,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Restricted shares issued</a></td>
<td class="nump">7,802,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember', window );">Microbot Israel [Member] | Former Microbot Israel Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock number of common stock issued</a></td>
<td class="nump">26,550,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of restricted shares issued as compensation, net of shares for the payment of withholding taxes. This element is to be used only if shares are used in lieu of cash to satisfy all or a portion of withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_MicrobotIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_FormerMicrobotIsraelShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_FormerMicrobotIsraelShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745965216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember', window );">Research Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember', window );">Research Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">33 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737476736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,709<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745947984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Asset consideration</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Sale of assets</a></td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MBOT_JuneTwoThousansdSixteenAgreementsMember', window );">June 2016 Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Asset consideration</a></td>
<td class="nump">$ 495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_PercentageOfSeveranceAward', window );">Percentage of severance award</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=MBOT_EscrowAccountMember', window );">Escrow Account [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Asset consideration</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=MBOT_PriorToNovemberElevenTwoThousandSixteenMember', window );">Prior to November 11, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Asset consideration</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember', window );">Prior to Decmber 31, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Sale of assets</a></td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_PercentageOfSeveranceAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of severance award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_PercentageOfSeveranceAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6411-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_JuneTwoThousansdSixteenAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_JuneTwoThousansdSixteenAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=MBOT_EscrowAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=MBOT_EscrowAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=MBOT_PriorToNovemberElevenTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=MBOT_PriorToNovemberElevenTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=MBOT_PriorToDecemberThirtyFirstTwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6908261472">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Receivables - Schedule of Other Assets - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Deposit in escrow account</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 505<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total Other Receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Purchase Agreement with BOCO. On November 11, 2016, the Company together with two of its wholly-owned subsidiaries, Stem Cell Sciences Holdings Limited and StemCells California, Inc. (collectively, with the Company, the &#8220;Sellers&#8221;), entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with BOCO Silicon Valley, Inc., a California corporation and wholly-owned subsidiary of Bright Oceans Corporation (&#8220;BOCO US&#8221;).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6745842032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets, Net - Summary of Fixed Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed Assets, net</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember', window );">Research Equipment and Software [Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Furniture and Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MBOT_ResearchEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6910172544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RefundsDueUnderGovernmentContracts', window );">Government institution</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">456<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Israeli Innovation Authority</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Liabilities</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RefundsDueUnderGovernmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of renegotiation refunds which have been determined to be probable and reasonably estimated at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 405<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68075306&amp;loc=d3e56153-109414<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RefundsDueUnderGovernmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753714272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Loan from Shareholders (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jul. 07, 2016</div></th>
<th class="th"><div>Oct. 08, 2015</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 15, 2016</div></th>
<th class="th"><div>May 11, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Loans Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Number of preferred A shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=MBOT_LoanMember', window );">Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, preferred shares issued</a></td>
<td class="nump">2,242,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember', window );">Microbot Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Loans Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">The loan bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">The loan bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Debt, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember', window );">Microbot Israel [Member] | Series A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, preferred shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt conversion, warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,188,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Number of preferred A shares, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember', window );">Alpha Capital [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal and accrued interest of note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount on convertible note amortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember', window );">Alpha Capital [Member] | Secured Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">The loan bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember', window );">Alpha Capital [Member] | Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">The loan bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">The loan bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible note principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,028,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 28,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible note, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=MBOT_LoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=MBOT_LoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_MicrobotIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=MBOT_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=MBOT_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753760960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Warrant Liabilities (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Warrants issued to purchase common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Estimated fair value warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_WarrantCalculationDescription', window );">Warrant calculation description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company recalculated the value of warrants by applying a +/- 5% changes to the input variables in the Black-Scholes model that vary overtime, namely, the volatility and the risk free rate. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=MBOT_DecreaseMember', window );">Decrease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=MBOT_IncreaseMember', window );">Increase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAandBWarrantsMember', window );">2016 Series A and B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAWarrantsMember', window );">2016 Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_WarrantCalculationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant calculation description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_WarrantCalculationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=MBOT_DecreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=MBOT_DecreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=MBOT_IncreaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=MBOT_IncreaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAandBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAandBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=MBOT_TwoThousandSixteenSeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753225520">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember', window );">Series A (2011) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 151.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember', window );">Series A (2013) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 194.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Oct. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember', window );">Series A (2013) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 183.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember', window );">Series A (2015) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 91.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Apr. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember', window );">Series A (2016) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember', window );">Series B (2016) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrant Outstanding, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant Exercise Price, Per Share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber', window );">Number of Warrant Exercisable, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant Exercisable Through, date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These warrants contain a full ratchet anti-dilution price protection so that, in most situations upon the issuance of any common stock or securities convertible into common stock at a price below the then-existing exercise price of the outstanding warrants, the warrant exercise price will be reset to the lower common stock sales price.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753596032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember', window );">Series A (2011) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember', window );">Series A (2013) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember', window );">Series A (2013) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember', window );">Series A (2015) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember', window );">Series A (2016) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember', window );">Series B (2016) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at November 28, 2016</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesExercised', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesCancelled', window );">Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value</a></td>
<td class="num">(161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance', window );">Balances at December 31, 2016</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_DerivativeWarrantLiabilitiesBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_DerivativeWarrantLiabilitiesBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_DerivativeWarrantLiabilitiesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_DerivativeWarrantLiabilitiesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_DerivativeWarrantLiabilitiesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_DerivativeWarrantLiabilitiesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndThirteenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesATwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=MBOT_SeriesBTwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753436832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=MBOT_FormerExecutiveMember', window );">Former Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Compensation commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MBOT_OfficeLeaseAgreementMember', window );">Office Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeaseCommissions', window );">Monthly lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MBOT_CarLeaseAgreementMember', window );">Car Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeaseCommissions', window );">Monthly lease payment</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember', window );">The Technician Research And Development Foundation Limited [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_NetSalesRoyaltyPercentage', window );">Royalties payable as percentage of future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember', window );">The Technician Research And Development Foundation Limited [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_NetSalesRoyaltyPercentage', window );">Royalties payable as percentage of future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=MBOT_IsraeliInnovationAuthorityMember', window );">Israeli Innovation Authority [Member] | 2013 Through 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Total grants obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_NetSalesRoyaltyPercentage', window );">Royalties payable as percentage of future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_NetSalesRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_NetSalesRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeaseCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for lease commissions incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeaseCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=MBOT_FormerExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=MBOT_FormerExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_OfficeLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_OfficeLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_CarLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_CarLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_TheTechnicianResearchAndDevelopmentFoundationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=MBOT_IsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=MBOT_IsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=MBOT_TwoThousandThirteenToSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=MBOT_TwoThousandThirteenToSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6755207632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2016</div></th>
<th class="th"><div>Dec. 16, 2016</div></th>
<th class="th"><div>Nov. 28, 2016</div></th>
<th class="th"><div>May 02, 2016</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 07, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Authorized capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,054,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,610,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,848,136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,182,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,848,136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,182,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,708,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,708,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock splits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,254,240<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based employee compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,618,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,262,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MBOT_DefinitiveAgreementMember', window );">Definitive Agreement [Member] | Three Israeli Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock', window );">Percentage of discount on the fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember', window );">Microbot Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember', window );">Alpha Capital [Member] | Securities Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Reverse stock splits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,518,315<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based compensation arrangement by share-based payment award, options, forfeitures in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,735,925<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=MBOT_BoardofDirectorsMember', window );">Board of Directors [Member] | Microbot Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">403,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">CEO [Member] | MEDX Venture Group LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=MBOT_EmployeesandDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,447,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=MBOT_AdvisorsMember', window );">Advisors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,802,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock award, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,987,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_RightsToAcquireSharesOfCommonStock', window );">Rights to acquire shares of common stock</a></td>
<td class="nump">9,735,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DesignatedPreferredStock', window );">Designated preferred stock</a></td>
<td class="nump">9,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares [Member] | Microbot Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Shares [Member] | Alpha Capital [Member] | Securities Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_RightsToAcquireSharesOfCommonStock', window );">Rights to acquire shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_DesignatedPreferredStock', window );">Designated preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $0.01.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_DesignatedPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Designated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_DesignatedPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount on the fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_PercentageOfDiscountOnFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_RightsToAcquireSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rights to acquire shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_RightsToAcquireSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_DefinitiveAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_DefinitiveAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_ThreeIsraeliShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_ThreeIsraeliShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_MicrobotIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_MicrobotIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_AlphaCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_AlphaCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_SecuritiesExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_SecuritiesExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=MBOT_BoardofDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=MBOT_BoardofDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MBOT_MEDXVentureGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MBOT_MEDXVentureGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=MBOT_EmployeesandDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=MBOT_EmployeesandDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=MBOT_AdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=MBOT_AdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6751817264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding, Outstanding at Beginning Balance</a></td>
<td class="nump">1,167,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Options Outstanding, Granted</a></td>
<td class="nump">1,447,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Stock Options Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Stock Options Outstanding, Expired or Canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding, Outstanding at Ending Balance</a></td>
<td class="nump">2,614,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Stock Options Outstanding, Vested and expected-to-vest at end of period</a></td>
<td class="nump">2,614,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Beginning Balance</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ .28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or Canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending Balance</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected-to-vest at end of period</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Stock Options Outstanding</a></td>
<td class="nump">$ 15,611,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">$ 15,611,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than $0.01.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6742033536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Summary of Stock Option Activity (Details) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753440656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Stock Options Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding</a></td>
<td class="nump">2,614,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options exercisable</a></td>
<td class="nump">2,614,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=MBOT_ExercisePriceOneMember', window );">Exercise Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding</a></td>
<td class="nump">1,167,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options exercisable</a></td>
<td class="nump">1,167,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,167,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=MBOT_ExercisePriceTwoMember', window );">Exercise Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding</a></td>
<td class="nump">1,447,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options exercisable</a></td>
<td class="nump">1,447,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less than 1</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=MBOT_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=MBOT_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=MBOT_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=MBOT_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6740052096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Stock Options Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.30%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of up to (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6905322192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to shareholders of the company</a></td>
<td class="nump">$ 9,663<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Net loss attributable to shareholders of preferred shares</a></td>
<td class="num">(3,954)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss used in the calculation of basic net loss per share</a></td>
<td class="nump">$ 5,709<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares</a></td>
<td class="nump">14,293,296<span></span>
</td>
<td class="nump">13,182,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6753439888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="num">(901)<span></span>
</td>
<td class="num">(823)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesDirectMaterials', window );">Materials</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Patents</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaintenanceCosts', window );">Office and maintenance</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Less grants received from Israeli Innovation Authority</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServicesDirectMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of materials used in services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServicesDirectMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaintenanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating maintenance revenues. Also includes cost of maintenance on client contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaintenanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741157088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">675,389<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="num">(8,734,000)<span></span>
</td>
<td class="num">(92,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">528,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for services</a></td>
<td class="nump">7,258,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">676,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 8,734,000<span></span>
</td>
<td class="nump">$ 92,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6739832928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Expenses, Net - Summary of Finance Expenses, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Bank fees and interest</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative warrant liability</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange rate differences</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Revaluation and interest on convertible loans</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Financial expenses, net</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749993712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent', window );">Other accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_InterestedandRelatedPartiesMember', window );">Interested and Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Directors fees and insurance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Subcontracted work and consulting</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Total</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred and payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_InterestedandRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MBOT_InterestedandRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6740366160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carried forward</a></td>
<td class="nump">$ 5,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel Tax Authority [Member] | From 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=MBOT_USTaxAuthorityMember', window );">US Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carried forward</a></td>
<td class="nump">$ 475,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_OperatingLossCarryforwardsExpiration', window );">Operating loss carryforwards, expiration</a></td>
<td class="text">2035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_OperatingLossCarryforwardsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_OperatingLossCarryforwardsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=MBOT_TwoThousandFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=MBOT_TwoThousandFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=MBOT_TwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=MBOT_TwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=MBOT_TwoThousandSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=MBOT_TwoThousandSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=MBOT_TwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=MBOT_TwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=MBOT_TwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=MBOT_TwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=MBOT_USTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=MBOT_USTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6607381888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred taxes due to carryforward losses</a></td>
<td class="nump">$ 481,052<span></span>
</td>
<td class="nump">$ 471,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">481,052<span></span>
</td>
<td class="nump">471,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(481,052)<span></span>
</td>
<td class="num">(471,980)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6741218160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 05, 2017</div></th>
<th class="th"><div>Jan. 27, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Definitive Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of aggregate shares</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, gross proceeds</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses', window );">Placement agent fees plus reimbursement of out-of-pocket expenses</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Contract Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_MBOT_CostOfInitialStudy', window );">Cost of initial study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_CostOfInitialStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of initial study.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_CostOfInitialStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees plus reimbursement of out-of-pocket expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MBOT_PlacementAgentFeesPlusReimbursementOfOutofpocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MBOT_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_DefinitiveSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_DefinitiveSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MBOT_ContractResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MBOT_ContractResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #B<75*XWC'I^X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>*$Y&!R;UI:.G#@8K;.QF;+4UBQUC:R1]^SE9
MFS*V!QCX8NGWIT_@5@>A^XC/L0\8R6*Z&UWGD]!AS4Y$00 D?4*G4ID3/C</
M?72*\C4>(2C]H8X(=56MP"$IHTC!!"S"0F2R-5KHB(KZ>,$;O>##9^QFF-&
M'3KTE("7')B<)H;SV+5P TPPPNC2=P'-0IRK?V+G#K!+<DQV20W#4 [-G,L[
M<'A[VKW,ZQ;6)U)>8WZ5K*!SP#6[3GYM-H_[+9-UQ1^*JBEJON?W8CJK]\GU
MA]]-V/7&'NP_-KX*RA9^_0OY!5!+ P04    " #B<75*F5R<(Q &  "<)P
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MK[51%C]\M#4\JGQW>RC5WG2WB;UOAI/R\&#T:?P7(+C]%;'Z"U!+ P04
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M;;@1UG_.-.!L!79_7'?\<X'-)K8V!!.2: 0F)2:#.S/]>1-A?QU':DYZ1<#
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MQAXN?P1J*0U8N>C.EFSL+3(%'&KCMH]VK\9_:0R,[,,U0::[JO@+4$L#!!0
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M\(,MAH(FQ.,=GMTT9I,1;#__(+9\X_(G4$L#!!0    ( .)Q=4K'K%'YM0$
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MX[T_FVG,)L-A/_\@MGSC\A=02P,$%     @ XG%U2O+1N+BU 0  T@,  !D
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M?SBF(3X&_)(PVM69A$K.B,_!^%;E=!<$@8+2!0;AMPO<@U*!R,OX/7/2)64
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M:<:")O35\23:S@<'*_.>M_ -_/?^8M%BBTHM%&@GC"86FH(^)*=S%O 1\$/
MZ%9G$BJY&O,<C,]U07<A(9!0^:# <;O!(T@9A#"-7[,F74(&XOK\JOXQUHZU
M7+F#1R-_BMIW!3U24D/#!^F?S/@)YGKN*9F+_P(WD @/F6",RD@75U(-SALU
MJV JBK],N]!Q'Z>;^W2F;1/2F9 NA&.,PZ9 ,?,/W/,RMV8D=NI]S\,3)Z<4
M>U,%9VQ%O,/D'7IO97;(V2WHS)#S!$E7D&1!,!1?(J1;$<[I&WJZ3=]O)KB/
M]/TZ^N&X+9!M"F11(/M?A6\AR>']/S'8JJ,*;!MGR9'*##K.\<J[C.M#?$+V
M%S[-^E=N6Z$=N1J/[QJ[WQCC 5/9W>$ =?B]%D-"X\/Q'9[M-&23X4T__Q^V
M?.+R#U!+ P04    " #B<75*ATH0<[(!  #2 P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q]4]MNW" 0_17$!P0ONTU6*]M2-E642JVT2M7FF;7'
M-@H7!_ Z_?L")H[;NGD!9IASYLPPY*,VS[8#<.A5"F4+W#G7'PBQ50>2V2O=
M@_(WC3:2.6^:EMC> *LC2 I"L^R:2,85+O/H.YDRUX,37,')(#M(R<RO(P@]
M%GB#WQR/O.U<<) R[UD+W\']Z$_&6V1FJ;D$9;E6R$!3X-O-X;@+\3'@)X?1
M+LXH5'+6^CD87^H"9T$0"*A<8&!^N\ ="!&(O(R7Q(GGE &X/+^QW\?:?2UG
M9N%.BR=>NZ[ >XQJ:-@@W*,>'R#5\PFC5/Q7N(#PX4&)SU%I8>.*JL$Z+1.+
MER+9Z[1S%?<QW>P3;!U $X#.@'W,0Z9$4?EGYEB9&STB,_6^9^&)-P?J>U,%
M9VQ%O//BK?=>RLU-EI-+($HQQRF&+F/F".+9YQ1T+<61_@.GZ_#MJL)MA&__
M4/B?_+M5@ETDV'U8XEK,WRK)HJ<23!NGR:)*#RI.\L([#^PMC6_R'CY-^S=F
M6JXL.FOG7S;VO]':@9>27?D1ZOP'FPT!C0O'&W\VTYA-AM-]^D%D_L;E;U!+
M P04    " #B<75*1YAWBK0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6Q]4V%OW" ,_2N('U#N2+JK3DFD7JMIDS;IU&GK9RYQ$E2(,R"7
M[M\/2)IF6[0O@(W?\[,QV8CFQ;8 CKQJU=F<ML[U1\9LV8(6]@9[Z/Q-C48+
MYTW3,-L;$%4$:<7X;O>!:2$[6F31=S9%AH-3LH.S(7;06IA?)U XYG1/WQQ/
MLFE=<+ BZT4#W\!][\_&6VQAJ:2&SDKLB($ZI_?[XRD-\3'@AX31KLXD5')!
M? G&YRJGNR (%)0N, B_7>$!E I$7L;/F9,N*0-P?7YC_QAK][5<A(4'5,^R
M<FU.[RBIH!:#<D\X?H*YGEM*YN*_P!64#P]*?(X2E8TK*0?K4,\L7HH6K],N
MN[B/TTURF&'; #X#^ *XBWG8E"@J?Q1.%)G!D9BI][T(3[P_<M^;,CAC*^*=
M%V^]]UKL#TG&KH%HCCE-,7P=LT0PS[ZDX%LI3OP?.-^&)YL*DPA/_E"8;A.D
MFP1I)$C_6^)6S.U?2=BJIQI,$Z?)DA*'+D[RRKL,[#V/;_(>/DW[5V$:V5ER
M0>=?-O:_1G3@I>QN_ BU_H,MAH+:A>/!G\TT9I/AL)]_$%N^<?$;4$L#!!0
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MJ?\UHH<@97,71J@-'VPV%-0^'@_A;,<Q&PV/W?2#V/R-BU]02P,$%     @
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MM=1@O+2&.&@*>I\=3X<8GP*^2AC]ZDQB)1=KGZ+QH2[H+@H"!56(# *W*SR
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MPOXY@3)#1K?TP_$DZ\8'!\O33M3P#/YG=[9HL5FEE!I:)TU++%09O=\>3TG
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MUF\?W5[/;WDVK!J6,27KOZ+\ U!+ P04    " #B<75*KES*M]0!  "<!
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M<6E:Z9VYTO??WM**<P5:+WC2@K5^Z*: 0J7,=*OG8OC=AT#Q;GS)T/2<YO\
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MFP8$CD)U4]EG0TD?!H)VXW.%IC>S^ =02P,$%     @ XG%U2@^ BLP& @
M[P4  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL?93M;ILP&(5O!7$!
M-=^D$2 UJ:9-VJ2HT[K?#KP$5(.9[83N[F<;@JAQ]P=_<,[Q\QKL;*3LC3<
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M<H("F"<$>4* 9YS6%A,->'SDCQ([Q81Q" N)0"$1(&0Y$@)@0A<FB4&2&'"
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M"/B VPX #+N V"L(>047 OL #6D)R'_1TY1Y:@H;@1K2%  0)P*%?4 -:0H
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M=5\3:E2^&N'IPQ+!2 %GGF!TV%[J>M-_[VDFJ^I]WW:'M:.GPS>EC,T>^R]
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M:W-H965T<R]S:&5E=#4S+GAM;(53VX[3,!3\%<L?4.?2I:A*(K%!""20JD7
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M17<?Z2:*M_U=*Q@N?*N_4$L#!!0    ( .)Q=4K0\ RD+P(  'P&   9
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M<R[[F=DOM&B'[X%H_"@I_@)02P,$%     @ XG%U2F)GG&GN 0  ?04  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULA91?;YLP%,6_"N)]-?]#(D!J
M4TV;M$E1IV[/#EP"JHV9[83NV\\V!%'B92^QKWWN\>\0<#8P_B8: .F\4]*)
MW&VD['<(B;(!BL4#ZZ%3.S7C%$M5\A,2/0=<F29*4.!Y":*X[=PB,VL'7F3L
M+$G;P8$[XDPIYG^>@+ A=WWWNO#2GAJI%U"1]?@$/T"^]@>N*C2[5"V%3K2L
M<SC4N?OH[_:)UAO!SQ8&L9@[.LF1L3==?*URU]- 0*"4V@&KX0)[($0;*8S?
MDZ<['ZD;E_.K^V>3764Y8@%[1GZUE6QR-W6="FI\)O*%#5]@RA.[SA3^&UR
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MJ,QS9"!*0H-O\=]DF=M43-P*+3824(>M3N>(64"-0]3A<EUG<'?L< "P!7U
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M_'Z9SG_NW,U!74<Q0[FK_!,,G:VYN-02,2R_5T*Y MJ4O@)6Y?I.2A$7:$;
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MM,S0WPX\AQ6BK&\B0PO-^\?=$8PZB ._!:FC:WY6Y:-56%ODVRJMQM4HS!'
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M_GQ[<7UW(:7B_Q+V;[17)[]-7TN@1([_2EL$WL6C$TRL&AV-HH^2-H)M<L9
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MINX4#YUG&#6K6^7(,Z'3EKMZYSF<2:EHU2:GJC<+BWU_7U7U[_\/4$L#!!0
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M=V]R:V)O;VLN>&UL+G)E;'/%V<UNVD 4AN%;0;Z #'-^)DD5LNHFV[8W8,&
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MZJ?[9TJ/TY8<+I]7__->IOZ)"/.*\OP;4$L#!!0    ( .)Q=4IU'BN_[P$
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M<F]P<R]A<' N>&UL4$L! A0#%     @ XG%U2N-XQZ?N    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ XG%U
M2IE<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #B<75* &\T2YL"  "@"0  &
M@ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ XG%U
M2BOE@="? P  EA   !@              ( !R L  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( .)Q=4J1VB=7B@(  &P)   8
M      "  9T/  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #B<75*'@'K'TP"   -!P  &               @ %=$@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ XG%U2IZ]_&@&!@  ;B   !@
M             ( !WQ0  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( .)Q=4K8!&5RUP$  +<$   8              "  1L;  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #B<75*=_4[Q@4$  !X
M$P  &               @ $H'0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ XG%U2B0%<KBP 0  T@,  !@              ( !8R$
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .)Q=4I>7'(
MM0$  -(#   8              "  4DC  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #B<75*5W+]=;,!  #2 P  &0
M@ $T)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .)Q
M=4K'K%'YM0$  -(#   9              "  1XG  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ XG%U2ATDJ$"T 0  T@,  !D
M         ( !"BD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #B<75*\M&XN+4!  #2 P  &0              @ 'U*@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .)Q=4I249_KM $  -(#
M   9              "  >$L  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ XG%U2DIG1E>T 0  T@,  !D              ( !S"X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #B<75*&43"
M9[8!  #0 P  &0              @ &W,   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( .)Q=4J'2A!SL@$  -(#   9
M  "  :0R  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MXG%U2D>8=XJT 0  T@,  !D              ( !C30  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #B<75*%%Y15;0!  #2 P  &0
M            @ %X-@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( .)Q=4I"//F0M0$  -(#   9              "  6,X  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ XG%U2G(@W\2T 0
MT@,  !D              ( !3SH  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #B<75*OSO![K<!  #2 P  &0              @ $Z
M/   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( .)Q=4I7
MFT)FM@$  -(#   9              "  2@^  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ XG%U2@K8=J6T 0  T@,  !D
M     ( !%4   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .)Q=4HC7G^GMP$  -(#   9              "
M 61*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ XG%U
M2AL_6B&V 0  T@,  !D              ( !4DP  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #B<75*"A3LH,4!   W!   &0
M        @ $_3@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( .)Q=4JN7,JWU $  )P$   9              "  3M0  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ XG%U2A[\R-*X 0  T@,
M !D              ( !1E(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #B<75*V1!+6K@!  #2 P  &0              @ $U5
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( .)Q=4KJ,KB!
MM@$  -(#   9              "  216  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ XG%U2F"M[PZW 0  T@,  !D
M ( !$5@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #B
M<75*/L>,W[@!  #2 P  &0              @ '_60  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .)Q=4I]65 YMP$  -(#   9
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M970T,BYX;6Q02P$"% ,4    " #B<75*B@-7E4D"   L!P  &0
M    @ %Z9P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M .)Q=4I567EP+@(  #\'   9              "  ?II  !X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ XG%U2@^ BLP& @  [P4  !D
M             ( !7VP  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #B<75*1JK1IH0#  !M$   &0              @ &<;@  >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( .)Q=4J3ZD9P@ (
M ,@(   9              "  5=R  !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ XG%U2@ 68K)O P  Y!   !D              ( !
M#G4  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #B<75*
M6H2K.]@#  !6%   &0              @ &T>   >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .)Q=4H>IDZM>@(  ,4(   9
M      "  <-\  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ XG%U2IU:1LY5!0  J1L  !D              ( !='\  'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #B<75*L8:81 T#  "]#
M&0              @ $ A0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( .)Q=4JH?>93L $  -(#   9              "  42(  !X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ XG%U2JE+I^+&
M @  7PL  !D              ( !*XH  'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #B<75*5S\>MPT"  #]!0  &0
M@ $HC0  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( .)Q
M=4JZF0S100(  )8&   9              "  6R/  !X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ XG%U2I(A@S.] @  5 H  !D
M         ( !Y)$  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " #B<75*$ $ !K,"  #\"0  &0              @ '8E   >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .)Q=4K0\ RD+P(  'P&
M   9              "  <*7  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ XG%U2L4Y5UXQ @   P<  !D              ( !*)H
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #B<75*!2.$
M>%\"  "@"   &0              @ &0G   >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( .)Q=4IB9YQI[@$  'T%   9
M  "  2:?  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
MXG%U2J:JR03O 0  A@4  !D              ( !2Z$  'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " #B<75*], C9!I<  "+;P$ %
M            @ %QHP  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M" #B<75*0A?+44@"  !^"P  #0              @ &]_P  >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( .)Q=4H72[(8H00  # I   /              "
M 3 " 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #B<75*N/4##B,"   2
M)@  &@              @ '^!@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #B<75*=1XKO^\!  !])0  $P              @ %9
L"0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2 !( *H3  !Y"P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/StatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Shareholder's Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Shareholder's Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/StatementsOfShareholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholder's Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/OtherReceivables</Role>
      <ShortName>Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Fixed Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FixedAssetsNet</Role>
      <ShortName>Fixed Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Convertible Loan from Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ConvertibleLoanFromShareholders</Role>
      <ShortName>Convertible Loan from Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Derivative Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DerivativeWarrantLiabilities</Role>
      <ShortName>Derivative Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Research and Development Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet</Role>
      <ShortName>Research and Development Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/GeneralAndAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Finance Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FinanceExpensesNet</Role>
      <ShortName>Finance Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Transactions and Balances with Interested and Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties</Role>
      <ShortName>Transactions and Balances with Interested and Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TaxesOnIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/CashAndCashEquivalents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/OtherReceivables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Fixed Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FixedAssetsNetTables</Role>
      <ShortName>Fixed Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/FixedAssetsNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/AccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Derivative Warrant Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables</Role>
      <ShortName>Derivative Warrant Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/DerivativeWarrantLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/ShareCapital</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/BasicAndDilutedNetLossPerShareTables</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Research and Development Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNetTables</Role>
      <ShortName>Research and Development Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/GeneralAndAdministrativeExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Finance Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FinanceExpensesNetTables</Role>
      <ShortName>Finance Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/FinanceExpensesNet</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Transactions and Balances with Interested and Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedPartiesTables</Role>
      <ShortName>Transactions and Balances with Interested and Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TaxesOnIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/TaxesOnIncome</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - General (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/GeneralDetailsNarrative</Role>
      <ShortName>General (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/GeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SummaryOfSignificantAccountingPolicies-EstimatedUsefulLivesOfPropertyAndEquipmentDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/CashAndCashEquivalents-ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Other Receivables (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/OtherReceivablesDetailsNarrative</Role>
      <ShortName>Other Receivables (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/OtherReceivablesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Other Receivables - Schedule of Other Assets - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/OtherReceivables-ScheduleOfOtherAssets-Details</Role>
      <ShortName>Other Receivables - Schedule of Other Assets - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Fixed Assets, Net - Summary of Fixed Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FixedAssetsNet-SummaryOfFixedAssetsNetDetails</Role>
      <ShortName>Fixed Assets, Net - Summary of Fixed Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/AccruedLiabilities-SummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Convertible Loan from Shareholders (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ConvertibleLoanFromShareholdersDetailsNarrative</Role>
      <ShortName>Convertible Loan from Shareholders (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/ConvertibleLoanFromShareholders</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Derivative Warrant Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DerivativeWarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>Derivative Warrant Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/DerivativeWarrantLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfOutstandingWarrantsLiabilitiesDetails</Role>
      <ShortName>Derivative Warrant Liabilities - Schedule of Outstanding Warrants Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/DerivativeWarrantLiabilities-ScheduleOfValuationOfDerivativeWarrantLiabilitiesDetails</Role>
      <ShortName>Derivative Warrant Liabilities - Schedule of Valuation of Derivative Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/Commitments</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Share Capital (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapitalDetailsNarrative</Role>
      <ShortName>Share Capital (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/ShareCapitalTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Share Capital - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share Capital - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapital-SummaryOfStockOptionActivityDetailsParenthetical</Role>
      <ShortName>Share Capital - Summary of Stock Option Activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Share Capital - Schedule of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsOutstandingDetails</Role>
      <ShortName>Share Capital - Schedule of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Share Capital - Schedule of Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ShareCapital-ScheduleOfStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Share Capital - Schedule of Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/ResearchAndDevelopmentExpensesNet-ScheduleOfResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Research and Development Expenses, Net - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/GeneralAndAdministrativeExpenses-ScheduleOfGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Finance Expenses, Net - Summary of Finance Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/FinanceExpensesNet-SummaryOfFinanceExpensesNetDetails</Role>
      <ShortName>Finance Expenses, Net - Summary of Finance Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TransactionsAndBalancesWithInterestedAndRelatedParties-ScheduleOfRelatedPartyTransactionAndBalancesDetails</Role>
      <ShortName>Transactions and Balances with Interested and Related Parties - Schedule of Related Party Transaction and Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Taxes on Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TaxesOnIncomeDetailsNarrative</Role>
      <ShortName>Taxes on Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/TaxesOnIncomeTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/TaxesOnIncome-ScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Taxes on Income - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mbot-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://microbotmedical.com/role/SubsequentEvents</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mbot-20161231.xml</File>
    <File>mbot-20161231.xsd</File>
    <File>mbot-20161231_cal.xml</File>
    <File>mbot-20161231_def.xml</File>
    <File>mbot-20161231_lab.xml</File>
    <File>mbot-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001493152-17-002678-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-17-002678-xbrl.zip
M4$L#!!0    ( .)Q=4KF'M['';T  #D&"@ 1    ;6)O="TR,#$V,3(S,2YX
M;6SLO7UWVTBN)_S_GK/?@9OMWI/<E1R]2T[/]![%+SV>26+?V-USY_FG#R66
M;-ZF2 U?[+@__0.@JL@B14FD1$J4PKF[,[%$L0 4"D"A4#_\Y?]]FUO:,W,]
MT['_^J9]UGJC,7OJ&*;]^-<WO]XWQ_<7-S=OM/_W\__\'QK\YR__J]G4KDUF
M&1^T2V?:O+%GSD_:%WW./FB_,)NYNN^X/VF_Z5: GSC7IL5<[<*9+RSF,_B"
MC_1!ZYVU1[K6;&9X[V_,-ASWUZ\WX7N??'_QX?W[EY>7,]MYUE\<]P_O;.ID
M>]V]$[A3%K[K\\?;!ZW3:@_:G6Y;:[?^H5U>?SG[-@,N+G4?'H#OAC]V+EM=
M^*].ZZ$]^M ^_]#I_7\91_-U/_#"T5K?6N(__.=_^39Q+?,#_K<&,V%['[YY
MYE_?* R^=,\<]_%]I]5JO_^OSY_NIT]LKC=-V_-U>\K>R%]9IOU'VN_:Y^?G
M[^E;^>C2DSBX'*/['K^>Z%[T9B1PS?-+E,"WAA_^0'VX_YY_&7O43'UTP!\U
MY:,&2SSGL>G9H_/\'KZ Y]N]9JO=[+;EXRZ;K21Y\!Z^E0^:GM/KM(?K^.-/
MR!\$7O-1UQ?A#V:Z-Z&'Q1=(S"!.#'SC.A;S4G]#WZ3\R'9L.YBGTV7X[GO_
M=<'>PT-->(JYYC3\W>8?Q7]@VL_,\].%R[]#ZKIQZG#1A#^9FU/7F3C^G!GF
M5+=@(<[?RP7U1BX15*L/'BGO5S;32",_/-$\S>&W3?F#LV^>\49\C>3^]8UG
MHO%XH[V7K^)+9NK8/OOF:Z;QUS?7KC.7(FRU?8?^W>XTH_'#GS';-_W7\-/P
M<]/ ;V8F6"NBDL6D* 5R<?./-S_CZAV-NN?#_E_>)W\<#?<^=3PQV@)FP#&6
MJ8"EY/IH=GZ.V)%OBKY;^AD8R.A'Q'<TO!'[B?P\1H#\4(ATM9S'WNV,$S9H
M=EM')EMNJ/R?(P;"(<0WA0IIV&QUF^W!\0I),%".D)AC_7YW==X?=)KPG_9@
MU/Q'$[@:_G[_</E[ZW<8OH_6X/<C5K)^?"7N6WZ]8Y=?KTSYA9;L&+U$S)*5
M*"3A5ON*6^T?I<!B;K6_C5OME^E65X<OOT\#SW?FO]]!H,1<EQGC^R?=9=YG
M$7)]YB'7)]^ )SXS]Y&YG]E\PMR#35 D<_8X9XHJAE\90,RWA65.39_3JADF
M/,DWH"**_H#;)H:_O_IW '3C!M*QX4]O_,WTWOR,\>>'W$+YR_O4\57:WZ<3
M?Y+1W.KE7:O=R:A=]:R=<+VUJIV JNTKW(V':[7.G(C.E!J]"IWIU3IS4CI3
MZK:PD$C<\?Q:@39)I8[%BX_%:\6KNN*=4#1>*UL%E:WR\7BM-=76FFI&Y+76
M5%MK#A63"X'^#A*<._:][TS_^"XT1#ZVQ'<=56>-JFO5J9+J5#XNKM7EP.IR
MH,BVGO?JS/L^8]-ZWJLS[X>.+L>&8?H@1-VZTTWCQK[0%Z:O6]^5/JR501UU
MYHTZ:Y6JLDH=331:JU'%U.C 46JM#]75AT-$K[4^5%<?#AW5?F6^;MK,N-)=
MV[0?O>]**=*9K^/8O'%LK4354J*CB5QKQ3FXXAPX5JTUH$H:<(CHM-: *FG
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MSX>K<SY<-9VH#VJJ<E!3%<VH,ZA5R:!612.^PPBSHJF-@VE$O>>HZ)YC'_#
MZZY?$827>6/;#EXG=>QQX#\Y;MC7.N5:K?2Y#\Y):9$$D0;=N(3=A^5P).D(
M". "!.OJ4__!N6/NS''GUXY[ZS\QUUL"I-XDU<WZEH?R\8ON&@D*-L]7G<)+
M6RJ=9FL@EPK]N]L*E\ 3>V#3)QMDI=OIVG+M!+9!$_[)G)L^,\0B.LE6?+E;
MZ6XOP&+72Z4[]0D%S+<RA*8>\\HXI3ZL)[4R*M.FM;(K8Z"LC$%\9? F-M3
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MEP:]SJ?5J9!WY;"R@UNN,%?%Y!1*60.%.%^EVN7!63&%M,0FNL<,;%K)(*+
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M81]5<S@0NM[JGI:NK_<0J@2&I .=<B1 3B5*'(M?*/EC>21EY#]9V(Q]7.3
M6Y:+5H7"]3V!JD7CRFX_U2!S;2.?:I"X%GCE0"3F:;ZS-8D7B-6##=KW;4[R
M#KQ_<U(HA269DU)H+-Z<%$IF.>:D4!*KL58/8$X^LD?3QD[<'W4+J2T%AD&T
M>,U-3#%<Y+E!V17([Y4@=?\6M"CB\O1G;'>.1.(Y6S6>'PE;.;HV=HYEJG+
M\O4JN^"W[^78$>"ZAV6J7V4KEH6X/%:L$FJ4AZF,5DR /U2?KQQFK%>%<"0+
M3SF6_*A=59ZV-V/=41'*]X7YB*[J?75>=<M_70&1D*'4E.X^F3>V[3SS,Z/
M?W+PAD>\9E]A5ZZU!V<5UZMJA[N"ZY7$;\]BI]D:2!;IW]U62/H3>V#3)]N<
MFKHM089@SB[!2%L.8?Q<.X%M$/N?S+GI,V,M8/YF1MO]H^4TUN>@P"F-P&S
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MY^DP,LM(2!'T[R:QJ]D,?(;YS'A !J$ WAG^RF"$J6GQ:N:Q?\T,++/",[0
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M"U7O&U][T3V8]:GC+AP73Q-Q)L?!([Q(ZS2T]OEH))62+L;A;%TR2W_!W5.
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M&@3:H !6?&'410],#*%/@T&CYC!4QR/0^01VH0+N: 2N++-Y9;I[AH9)>92
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MT//&57/*X22?=$+F#X% 5][6@W@%K_H99]HO AD,C!:"G0F#0-<@G@G0;L7
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M3Y\9$CJ%"7+FF/J8^ 0]3ELXQXJ:&CAS2C8\.IBJPPTGS][Q2U:VB.1XFE#
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MTK"N\X59S[*!!R&5,KR'J,A*+$9^O,Y#Z.@*_E*K38BO,1@7P7<D":J;%22
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M30.+ !4EHIR*7>QIDU>$%+9>$:).U_[O^Z;6_S&$2Q;(XP1-![]U35053H6
MJ(NC; ILS2>=GG[5'$I2S%E#L_4YLUXY<*:"XHC(=/@18F1JA%OI$BCD6.N?
MM7X$H4T1E)*PEY5?O3B!91 5X0,QYF)0C<###]U6&X&1?P(.Z;VFO?J]T9<;
MWMGNX#O/B(XDO8BCJXRQS*(8"Z%T"1@3,2]!O);U*H1OK![^IZ6OB 85SQ+?
M"SKAV(_X0L=U&=<!4FT/EH^E0F+'L4+/HL7XE_>!UWS4]<6'RU!];R)E&]O&
MWY@!R^QQ/"6U!TV^-+VIY2 6Y@,LMH^6,_WCY__Y/]!J_46^"[1S;OKR#1>P
MLN$-#%0Y]=?4&@#^^,IF?WUS[3IS3!4U6VWX?[Y#_VYWFMWVFY]C]B)<_@L_
MM,D9#4QFRQ*^>(+_^'+[<*6=:TWMXO;SYYN'SU=?'N[)4J="TY5 0 9 O$)&
MS6)0/YM3UP%OJMUXK@XFP9D@.*Z"ZDJ4\"]-[<:V'50NQ];&@?_DN+@8'P72
M*BREA8ZI3G/!'P&%Q;X(U$X&[8>!]M!9H#[1TX1L"U][F%3LPI^N$SP^<<Q+
ML19] H]!$O2Y$\#OL#5$'%B]=7:NS4W+(F!Z&*;!Q_4#%_Y.LH=F?@)2X';6
M0>Q;S75>=8O#<M(8A 'J:-T?)>;U+("7<4'P/@[!0AK<B"K\BR3!#3O]$X<#
MI_\''\LG?%N!4>\*.%KR.(A8Z<I'<%ZEO.^?V!] -0IO@H(2!ET8 ?CY)W."
M8D=T8=L.YF<EJM%PK1YM%2$4JLDH=9<),./8C)"AG4KKY1-%8=,1+YA.F>?-
M @LABA<64V%<A7OFS(TZ[>%/WFJ5!JV$X>8<\AD&8@A)#+I$.A-W]QB/V X1
M(M01!P4%( 8$LO6C:#]B<EK@]?_-ICY68%GX*:BAK1 /:J"#+J!>HT^;P?M%
MUQ$,3@0YS.!TA!$)D4 .S_0X0#4SI!QP=4UX'X=?,#ZPI6"Y=BIZSL> &(;%
M8:O5G]G4DH58:$Y>FY*;B0ZAU_>LMDD+Y<$3&$*"O!XA!IE+A:6  (7ZP*9/
M-JK+5U41+Q5%O,8S):Y2;Z7J=EH_/7R]O [_;/_T#NWDWP.;H<'MX$SS6!8?
M0W1NVYLQ5S3U2!#)#;+V:#D3W4( ]*D5>##U#6%+7YMHK5#W+7,*H3;&B1YW
M#CHN,PB^#28 NZ4C$$\NFVSO"8,@7!9$66BM^>JQ-9OY0M'?3IC_@KCE[;/^
MC\WNC^\X^+H-:WPB7B_[ANC8R0 \G15A.(?B_IZU,8Q1/E%$/)8R\3[L)539
M()XJ!E WT2(:Q-L-$+8>,Z3/=G!-.[,9-N.Q2+JAQHG>-SI'O6>\_Q3H[3U;
M^.+DM44GKT-82+3]%3$*+9SDN_##.3#[A(T]:#RQ&\7GI'\TEQK4=/DFZ?O5
M?9C)\*0[PVS*/A()^?- 6 ]\9^Y,P+Z$;16H51CC!BEYHGZ^>5Z]V,1R"QP.
MHL4FE[OCQ/1V&OWO>WI#ZX$S"KZ NY^POU-MWU:'U6&K+WL:4$@P541(E$RC
M3$'J%JTGMVBHW;I&B3@7F^E- \JT428*2-4?2=G#[B+4*L%E<\<GGXU]5!C\
MF,G4"?QE4<,0)=4%"P%##*Q/XOU)PO2;Y\,'//N6ECK)E^Y()DONL;/)DV-!
M9.-=4=NT+T!U%?(DN\'GIVHHY5#:+>W^;^.O5]K%^.[F8?QI*V4M@;@=ET\9
M>>M;-.V8:(5HUF6T&X7HFEI?ALEJH3O:LT/;1CJY\)3$*_S)MXBTS=*FNL=#
M?]Y21[;SR;69*H/5RIP57.G@=4G><CL? H<C)1=*"]$[L"-\LT.KF#J1PA]B
M]QN9OV2 8,8ZD3:P6(Z:Q2S4) *?UP;O4TKI;:$%? <SP_=C:R0:FE)8JGHH
MKXA:-@G=P$TU-K*21"#)M)^FK;E0-1@@A*9/\FGP' 1:TA5#+BNCX6AKGL=-
M/H[!\'R&OL0>CV .Q884MJGY=E@GK:*AR;HG-;W0%Z8/0RB;^2TW7CL3&W;4
M[HS.NGW%YU35PJ+&ZSPG_2=&*$*49!Q%B&+#TN#Q2:=#ZU!9B_AI[#<R;(__
MK)7V,Z6S60.S'.+$!\*>5EM[BXM#R<+PQ4X4T1I4,S)\\4>DP<L#F =,">F\
M':1<OAD'2ZQW=2Q*R<  TJ(115$'T_CIJ:%U!HU^O]4X'_84SE7#)6TFI5RB
M-LJ<I?/&L#M(,TBI1C@2SHJ7UO9#AA7V,A1\(SRUD?,WHS27KEV@I*F)+WG$
M,=@7@Z)M\$MXSO&548!L)!^\L6%KNG!XPJY!?7OQI\P0>0ON6J<N\^DH&:87
M7R.]&WWKBU==,DM_05,'0[XUWVEL-L,L,#[S%8R>ZS&A3?<+V)0UX!EX2+;U
M!1+Q=)KGEQ4MOX>@_@*[C&D-I/5,47,<1WE2YA:)ML_,H%Z%R9^@LL&XYKOX
M ;,=D)AQ=Q.9F4BEQ8*)U@-1V6E%%@-(638@1,F2C5@Q4;'U6Z\!3L@8VTB#
M) ,K//41JJ38$:%.\7E,-R[KYM2<ST%I^*YVX9I.>&B7HKS:"Q.'AF#2@BDE
MFFGS2Z?Z0$%$"!^QP9MWTU887_>JV:;-UI'SA%U!L2Z$^P,1@BT1R7<8ZPE%
M+S8Q;2$.V&-$U2Q$MB,I22.DUD690E1$KS24%/8X3?9R>_>9N8^X2: ,!Y^1
M[J#1Z?<:G5YKK4JN<+L\>@$+9@789U5D*\5Y'P7SREYRA4L7#> APD O$36:
MU2:!ST]](#B1/\9(Q>7E2;'5Q-\D&^W:1KP$1O*O!@*8-ZE5*G+QT:9SN,K%
MR[H"'FKU&^>=?CBIKA9-N#Z%^735"4>O&M^ 8OXZ&;#IFLU>+.PX' :C9"&D
MDU\?T'V75B*^8[J:+RSGE<G%?\LS!+_@(MCW#J_R6[D;]>0+]+T7'0HKU4BQ
MHHR)H[L&*BIO:>^XXGCKF0)?7HP#W_9:W4;_O),P2F_;C?9@V!B<=Y/6"G//
MONOH6#2'-ETWD$ZQ0R'[2>EGQ8*_D\'TQ=5M(RQI^GQU^5_:;V!$ UA[O\!G
M"^W3IXLSC5)4(EOT J,Q#BLNV@R+(\-8ZI!R3/"I>)); ?#R4W+,L L<:6_A
MOSNCU<1KZ82+I%%, .2'9@$6.SXS^JW(<,ENVKSBZ?M:V&MM]6?]5>M(*YTL
MFU TEDC+J+5]N6-(:FVO-VQT.MW<4ZU%QY?2@*/*,F&C1)Y/TB345!T]L[)^
MN;D'H;5:[2A5T4"6$I+A%=MQS=:X5D,  K,DHM?XZV,6('S_#GJLC3U1VL+W
M$_$T"(C#>;1Y=DD]0L2>];;'"W3C-8$_#(;]1G=T'H5A\ @OQ>)%?;HQ-VW3
M\UU>;R[?)$J5/5$R&).'B 'C_-%I&+P*JW&2]3/R*(W'61%^EWR38NQ46:OA
M14S0?!<0F9SV6;=/-J<WS*^(M3E9M[,53>A?UY0C\O7+%Z4^%5<:9!$Y[MO$
M[,(_5RSOAMCQ\9^8-I[-BOI=4@J^CQ%YZ%*%L6L%P2GVF]^$\;#G1J/M5H4[
MC5XK->4:)2A70%=$0>[>+F^=J#Y4N?'LERB_ICK+O6C ]RGQ?])K,;H")=<?
MD[%++?G2)#]^?'09WFK!2-PU;<^<*BBM%;1WNS5>[H_*:=AVJR0N(32=,(A/
M;,IHSO"2C>GD[;M0_<YW[?UU9959EI.38:6Z!^YQ1C'/]!U-9NFKJWQJ"[+4
M&Y')2U VRI77C6_6F%>1#CQ""1V+C-_^Q_YQ/JOPAE),6#4CS!*TIFX6NTE"
MQPA76<NVRF\X%8MUB$CK<$T&OR=,ZV-<E_7\5'M^:KMYV$@OD3^DV]Y;9@X/
MBNA8\"A[PMUL#-J]QOD!X.EK],V]3W;KK%3XS7J>*S+/[3ZLZG:CU2L3!OV(
M8_7?1#D;>!JL'D,HA*;O-+'*[?]O[UN;VT:2!+]?Q/V'"I_[0MX@:;XI=<],
M!"7+,]JS+9TE]]Q^ZBB"11';(,!! 9(YO_XRJP 0($$*(!X$R-K9[I8HHI"5
MK\K*ISJ!U FD-%.!)U!/C68X SH?ZP0JL-UW9T>>Y6;M?QOP[=>+I$Z*30_;
M@2^J%!;JD8/J6,L$63;=_O)GM<-H68#XPC@FV%-3]DYH[82H--D\*1:K=5IK
MW=.<!V*3%4S[2\H/;^!197X&W*"RG%66\[E@7F4YJRSGPQ936<XJRUEE.5=#
MNE26L\IR5ED9"K<564%EO&3A&97;K*1*X;:JN*VVQE*YS2IWMCI2I>A3;?HH
MO:ERF\\VL^Q0KV(5Q$YE'!7O<%1TKB&=BSR%:VRBJY3F"O&H.GC.2"&I@^<\
MZ%SRP5-@)O/EH-4&_-6@F:^83[8S?P6!\=I'R_1..K%>&+'9TF9<3%45?[)P
M/-G&LW+HUU2?^5/W_"GH0;MG@/-/YD2[/L=U=O:'<^QI6QX,._,F0VR/,AYZ
MX^@W$A*QHS:>Y5Y;:&_J1S1SJD$6KN'H2T/W.NQ[\Q=#$WO,)GS0! C8*IKO
M1L080HO+7M+\@QRC\VJYQI3,Z0MB!5#BS3L))CM&>IK[\S=QW!F.G%^/CMOX
M@@^UV(-N[P5$-;,.\?\&HM8.!0$,C<RC(^M9=+$,U0B1E;,EM;WVU=CH.L)5
MO*&Z6)>:WEV+5,+;4\K9'%88T8^[9)YLR[LB0WE)RS9;4%UD?>(X<IMJ#LY^
M,/39>A)AI_.;*#+@BE3'DYCPE)4CD>$ 7U)]#X;W->?L*N.VM $,9XO><@J_
MSA:]BGL5]]87O8I[3X!["S3&*E> 6PCOJ%VJ7:I=JEV>ZRX/.$"RE3'G6VLX
M4G6?E5E,5557;#%%D(HM5AY!+EMM18I]B[5+(\65(D552*'4U'D3)"=C]] T
MZ,H5S-9S@-DYE>;5>8S?.=&ICB64YT2?J]9 4:C2%%(25&WZJ).H'G2J01GA
MX17K=2KO+Y693[CF\$S'J-225F=:'UI+6HU:?46ERE/ILM555*H\E=0951]:
ME7%&Q1C*!98]#T>MG*N>SWQ:C1J(5,6!2'L8W/#R;C<8<!( >+Q*9RRM9R:G
MHF8<.]B8',OM-.312%V[5X-/=-.OCA<U[@XGHE"Z.:%88\X62\-:,8:E]^MU
MZ2NUIQP?I1JNC&TM02:<.1D_WI!1Y[+9:9/9[DE! HY(R;ZHTG^EG+P?C@:-
MWN65^/1]YW+8:+?;C4@!OZIJ#U6UBQX+D>8*FYT#@$Z<,'AJ(8K4J2.^A?T!
M\(EG;/E.7(ZUF-=X2C8?M;EE8'L%[VFL4<:_+JPI,R2517,'4=..?WCUJCN;
M?G4GY=Q=R*=5R;N::%;M@M?_$C7&VY/,-C1Z93R<-66!BI?/J.HD59U42VDZ
M?DK_>>SR -[*5K@PZOX2:]44(JNW7JM+\F(98.(;NK-**:?53S,L+QMZ-&KE
MGV&8!:!?%#$/)V:[@(3J8HB9DXYZ,]^T+*WT7>=_-F<V$QT+F0UWV#K99J6F
MUK9;.<4"RE0SYT.>3FH=4D?%D<"X*4MU?-)?]"DVZU[IS%#CP7:JC2ISI2).
MA8ES:K9&< ,230BM&7&7Q+'(A6A!6,>RE7)X=)#7P587Y\0)83=&A%6S].>0
MX_)1]AG7.7>QW;9%.+-?L&$O K2T+30Q; %L%2*_ =@5C$K?F=CHU<0(KF6N
M8XA?F?W,[(: )A*3EABG9JAI/:CD4>.RW6T,>U<8#G9L7>AKOQF\C%W['>)%
M%U.@F 8G$<4X]?1%YY;-6R0^:"HBVC)H.B/OKQI7ER,,/(N0]#IV*F/BEKFS
MB7VX0;UL[HPO>-]I=2^]_JE;L5<)T=*R!6KD-P0@?O!>QSB^AND1WN,:Y7,1
M'K?@-YMHKFTS4#"4<P88H-J_7-T6W<C#./9_I0LX?D6H__VHT1UV97@=MZF;
MFN%.Y8//S&0V-00<^"8Z7>BF#CBG&(+W\PJXO^BC SM:,+GN_9+9(DU M9_?
MUB@,J*4[.JQ\^U.;4_.9D3%PN$">@$IF41C+.24W=*GCR(7*2'&5-<Q]:!@$
MMNV7S?M]6?(5BP@=^)WZ*=E+#K)-B@99NC9W,6,"G@?;5=ND%?.6F9*KQJ@G
MDE<\#>4KEXB&LFQI/7!<SY/<D$83TA[^_APNLS@^0G<:(K]&O"3T "4F>S56
M9,HX8$CH+,V@4G4@5CTPQJ"\3&&D8^K#@\UFS$:TB.;/L$GJ:T>1BX73KCR5
M)J9]^!JOV_YMX]'@+YW?/DB]%H$>-4GX P$+7 :8;:PPD007WT9'9 E/28D1
M&7Z^2[#[Z#?E&0)(PI]$C@<L&J663TUY %DA?:E45RC'"+ELT+CJ#K9P+:!9
M$S<! 5\9?N+/00Z>BCM, RM@&NG<OX;A1B[\&/"26!RXT=6DO=8=-@:=RT:O
M,U#TW-3AWQEP/R@K+DP1:>I61IM7^:1YBB1/.LR<"FX71XN Q3M<IFP&-I.P
MEVCT3)&N!6>.D0TYY4B77.W/^)'C@Y"90<DO?.WK_Q7(%0Q)^LJFZ&@A7YQI
MJ[&ES^0)%;:LY4PB.Z!] _,! 5:=:](N#$UNBF85"OV_D3P87D=NZOT S$D\
M]*S9IE4?:RA'3C7X\F)MJ/J6/WPRDWK"\L8V.8A)[L+6(GA! %W3U_0<% P0
MQ7*?Y_[1ZPU,DOH#+P?6"]K/WA4A^()/$H?^A$L]G6 X'$T$> HG1($*FMG6
M(GQ8D$<$9HV-"_[!@WK5D"B7(&A@;@"*<0;5#+A%CM5ZM62*+#5-X!6;4WOE
M(]U?'ED.;&^34WF!TCEL?_+?F+,+VS#9L^7H5$*FF\ -L/:"RQF6R)7X!V1*
M 40<6W+)EULH55HS1N89RH4PK5[G#&]@WBV)H/$YQ0L4H$Y_D3<E(<DV$P<A
M)Q-]!ASBYV;#?4HB'IAOC7I/^A=T128L3.8U>TF&\.&!B[6\N 4"%Y5>L70(
M)-V$>YPKM9'0!O :TUH(QD&6P=LR+HLG0Z NY" X<2/':Z8OBSX,<'V\H!\"
M<QN^X1A2X05[E]: ;^9Y6]VM?.+&QD5T$-S)/1U$@H-,@B] ,$&\=5MS%V@W
M:$R.L!,P<%W@7][.7W70$H" .5@M0B!QA\NE;?T45WZ05,L$?8?)NG;8#@Y0
M@AOJ#G[9W(2 (=E&%D+(P4ZW1!(VZM8/8B<7DP^Z@[(N\JG%P#?O$=1M@2GD
MJS])*Y<S27%AATG6Y 3N $@*;MGH)_"^L#8 DI,AS*=2'\HR  +0"YTZ0083
M+@E?I7L<L0VQTBYK[UA<'47_LMWLM)N/5U?-WEC ="'- >#*V[NGS^13\^KR
M0R,BB.*VI\]T.1X0P  ^=A>^UT</](HGEN)07=*5?^BR%Y198<:ON4-P$O"A
MYY7RQP]>^&?]!V0IARV6EHUG%Z[LA(LT_O+1Y<UG2I>_"DO=H_ZM^-HWRV&?
M@/& ?5R;/0&"K@WXSM_^Y_] W_9?_ =OJ8W3HO@#LX6E&GQ1S(^"7[ZSV5_?
M?89C&>_]S78'_M^QQ,^=;K/7>?>W"#D#ZBR==RDMRI05:KX=^^W^Z99T.J1)
MKL>/=S=D_.T3^73WY<?3[2?R[?:)?+E_?"0/M]_)XS_&WV\/<_D<"%I&$SOW
M<W9"<;HH*L"I;KAXSIJ@@81^67J'K:<_X2M^[4DP66P]KC,Z+-3E:Y<H&,R:
M:U#?X;K_A;ZRMEEHDJ.41K&<Y7)X%/:+3EI,L@Y@6S\,.IU^2%,*4X4ZR.[;
M8%2@Q"5UY,[;<) @+U+C2Z]IV1D;;'+]WTPRP7:="KG-KTPE+1X."/C7A939
MBB?2DS)3O4G&3=<?=8?7DAR)Y9-B-0OV=^$VQ]?F!5Y::<^5/L749"3FXV^^
M84$=Q]8GKA-XJS8<?%[D1_C-TC%YD'Q^>*)^XNV\/Q"VV.S]Q&^]:@R'!]=7
M9,7**>*SVRD FSD)YYL)@K%*O20I70;A3[Z.GY1]E+]U\.:^8!9>N^@UK@9I
M&X'MP5."5Z9-WCQ+J@S3)AH619/RSO3-'71S5!QO>ANV/0P9\=_-CTLC;;(*
M.[L.ZM"5&)I!8]2^.@I*%6'V$V:8UMA(B]!C&1YYZ@^E%0IAOG:KG_6<4TJA
M$+JTL]J$)6F%X]@5_TP8Y:BTMBBZ>V=B;';ZC>Y5#_Y)6S)=1UU0':SW&IW+
M;F.8^:9Q@*0G*VNJ0CU3KM'4L<QZ$3G3W+M^A/6%#.C_R]5?J"&RP&)N+$&*
M$#4=O2D"I)A$A,GGF(,-AHIN3;%)H,B&8=/&OB"J+@'B="&"J>(J)+-UMKZ;
M)CFD[(Z!943!WPQLKP/A/)(>/4?$,H9=/1W;HE[/3%$Q)9+6_+:<:[KOC)G;
M3&/PM)_((Y)47)GRY.5VVWZ"$?6R@7S?M<TPE5%T'I6Y]OJ_O=:AYC3XH\S^
MY$M#%UE)NGB4LPTHYG0J-Q3>Y;J8:L( L9@<$LKR)(S:A@X[]OASS9ZQ:2D[
MLTLVTU"^PRK4UN:?8 .&M<0$M[$YQ=P;X'C[T9HYK_!X3#Y+Z6DJ!32[E2DL
M7?+]]O%V_/WF'S*'Y?;WVR_W#U]OOST)<&[_W\/MM\?;QP9FM0AXBT[9SCF)
M7'4#/?MNH*H9Z)EWJU3-0%4ST!I)T_"0-IFY$#.2 ?E!D;6$[J>G,5NNBILL
MST-XC ZO#W1E@Y'IW;\,<17TVSBD%->2NX-FV76N"36%0-B_.CCYIK+-6<^6
MEL.T48P#T9^3JJI,\[6O%*M4J9%6$U7A%"RI@>B@C@/%:X/=M#JXFG9%>;8$
M5N K8=W9,ES):G'([8VJ+ZN5.5CO9S.L<D>C?T%%LQ(L,:XA=Y8T5[7(<Z"Z
M*ZA#MH*'['?L"%@_;BSI$*CCY..Z(+>;-G'ZG$_8!]N:,8[9-=3P^P,KRW@G
M:PV*'(-=W17*THI%7CQ.[XC]A$V<-%TD)M60+4NZS-80,PJWIW?0WHM6>_7C
MQ9(X21G$!=Y<VR6/X:CYN?H%AQ6(X0:A'&+1,]5OK7IGFM:+3 @>N\[<LM,/
M'#T?]KOH=G*RFK- H68@[:9/.R?75C'TJ:(E4"H;)"ELJD#"PD'U5X5 ?I47
M0RLR5YG,E]TBO3$Q:F>S#F_]+R-1V<NZ9.?@2AR_I.?K]?W3KW^78X[@R7%D
MP-&MEQA7@S:SB0MW>N3OM]]NOX^_B+J=\:>O=]_N'I^^CY_N?K\E?MF.@'!2
M%*SB?X-A:_16/?0DAJOV0J7ZF^XLEZU3?U.>9^F-:G"J&IS6$G6U:W":!\MG
M45!YX#UC*<N)XGA/>4;N;ZT:=#E=FTOL+EM$C4=JQ5N7KJ?]M+%2U4)V]UN;
M!> R)_D[Q&V57.(R9'_DKA?WZ\($NQET+X\$>WE[3-P K@H'0Q;6O(DT4?%F
M:6+SE]JSZ:C1'9P^HR95J?56H$\V?6%&;5FQ<YE=G51^CTD-I;IKS /2P:I'
MK>QJH^H[3%Q'4&_-F";?J7I$ZB=-;:LO'W:3IEQ502\6,"5#M,IK3BBVNL=1
M-<SDAV32GN&XA6'J;+U*^,3KB.JTCHD2/.BE-)O/P!6J-WD$FLO&J%=T<W)%
MF(/&5A5,E1C9SI[ DB[O9+,!K3 *OUFFM63XA/E\9\+1RV A[]%3RECIDR;Y
M?/=M_.UFG:!R>%_9G+-4HARC4E+*B,6KE)33H:5*2:D3ZE1*2DH%I5)2BL*Q
M2DG)?-LL,27EFII_DAD#BP:34K #$0ZB2*E#3C]_HH@!O J7^>$R)\$K-&!P
M,Z?F,T[[(3.JV^2%&B[#(2E@(>@OXGI)7JF-59G$T.E$-Y+77.:N+S,[WR^Z
MPZ37_Z1+)BUPK!XR*I,J4'" ]O:G)GG<I@XC4WTV@]/$K',JRT4_J6OQ]+GX
M(E5<-Q,JRE+G!43=OC-4[.M96KY)1>!WS3(%\.AX,BQJJGGT;Z*SUTM; ED)
M7T =45UTS+,"9UCU\AB. %$5(#^6@E=AV;*B?XE3U55,MD2J%#U1.4:N\^LI
MD#RXNCT75!1;/5#;63W!#9OCV%7+Y"<]"71 FN3I^_C;X_CFZ>[^VZ/H*W ]
M_H+QVD<!T3_OGOY![KX]W7Z_?7RZ_22^\/WVRQA_?AA_?[H[L.% VBV].:_9
M^U WIPS?T>Q>MGH[&+% "-^8"AR@?]PB82;[M40<]EO]-V\PDQBL[87N5$:N
M5F.BVO&F :YGIV[0//EYH"8![B=I]>9YJBFYA9&]XF-<U91<-26W1M*DIN2>
M)%DK-$#V+#9Y &=5O%MQCEU3"B-%EOVE]1"5TWLR;6%.A459$>><YQ)\TFVF
M.9;-PVENW+75H+WSD/ZSPFUYI_\;":B%8.[1G:!WWJ8:V@"OEOVG$&?XC+L&
M!@128K:HX>IOWU?S>UVR]U5U>EC)X^T5.=.0L]--6\%Y( 6J:'*4>O"HSOAG
M,:=0D;EP#93S  2CZK'9LF/;URUR30V\.Y44UU:Q[)H<9;6(AHXYL68;7!)6
M+A.;?(S02 5@*\QI%8\0J@"L"L#64IJ.'L0ZBTV>MJ].).L2JFD J\/)DJZ$
M95T-]]#!'ITRKV%5= D=/$?@)/U[Y\X-5^5P0TZ*\BS=@SF_I9I:1M'H""-H
MC^N8BW<S)9M,FK@6:+.,2-8;/=&?)UTW-,2ZH?'_NWTD]]_(W;>;^Z^W=?3T
ME>09?9HS@F-MJ;DB.B?<G?PWTQSB6 (077 ,<>A/>"&<16 2@UU,[KA-F:&+
MZ/6/UF,+OT ,^NKY5(_HYZU<,=6-92\MT4\$<80_\,K0OKY\Z3.@MH5=[$C4
M';8&OQ"1%<W(2C391'^+8%?XH=\@W>C?\=,A?-H7G\(O(_G=WB]D!JH0/[EL
M'9M856'M_92A<*C+CJ:!8A!DN?C,IMB3F%!.7IDA_LL=_$N$AA^0?KW!+T5B
MN^RNN^7'7QQKF<"?TK]<_LSQ*MKM[UDN%Z?IN'6PR[0LMY$(T$2:^7JZQ0E)
MS;-HSXTY8"9S2% .3L DXSA+S?0.6%R*+I>V]5-?P->-%7D_: P&L!K<!;4Y
M</2*3( ;J6WK<OC:*[6G0G59LQF'M>DSU4WNH&0)QO7.<T_US5P'3$ QM(V:
M!*N39[H)ETP"$.G6M+43QZENM&\P8Q4N/YEOSN>,D J("WY;'#?; M,?#1K]
MJV$+P-CS+'+]E#SB><0)!9F@+U0WA,@X<]MRG^< 5V_0(C\<W=#_+=MCP<O$
M2V.A\F1S?3KBCW#@F8Z.AZ!INO ?0U_HCEQLZC+\$D(C"779[;9_TX*>B]8K
M(('/]67PU\YO!';ZHN-T4(%&89ECZ J'A7YG+\QT$8E381-UKBZ'0C-P>*=!
M;>_P7:_0(GBP;P.&&[$9)JCZV&(_E[H=H"!V]Q,&2H41=XTMI4Q.2YGD<J!?
M5_] W[1V@:,-% 3=X60*,F98RP43:]-G)@1L#I:M:3EPL7!"JLN6\LB%:K.%
M>#1@$5QS@:)BZ'^BOG) X,73\ ,LZLYFNJ;C^ALG^"N"@=^;A'45GN0HH>(Z
M+B41=,K$%T0VC9[\0N1]6"@)-?XS#.L5DZ3(*VS&9AH:I%-<RV935V-B#; 6
MF&WCQ_ V"B]SQ-L0,?@$,*J B2Y$!"V5_!\IC6VS34NO+;Y[4E>#6H?X*Y^:
ME<\8#Y7?4<-T'I4MI;*E:B1-JEW%R:0JX<T6K3WA"%HU/3=02G2JY)2*):?T
M+SN-]J"D"C;%$_7@B5&G<779+H<G<E*:]4U;*K,@OV8;.P'4E&<3E&4'!!;6
MD^50(\X_4\\K2FJ.*?_8K0)^:H/A@PZQNI]<63#V^[9CMG3^+*.)1%7,K(M<
ME4 62)).6U)T/HS.>:JB8NA<33/E9 ^VFFWL!%!S:H=U8(6C6ZY:-KCJWZ(*
M>121C]S/,+]*H'WE/)NE/X_NA+-_N<QT;E_@7_QX=3^)TS4VM*FH[1F1)GG\
M<?UX^W]_W'Y[(K>_P[\/F_%S(!A%]^KIO@W9L5+%#S,MII@\)"ZOO\H"(A2?
MG4*[.>]KC7?XP<4?'EQ;FU/.R/C99@Q3KP0@;D"(_4=K*FMC!VZ2XB$GFR<C
M%'OLG\1DN#?)?U+3I?:*#$2&[BB:H2NBQB*[S+$()5X>.4X$YTQS;?@1&'KI
M4X[ZE -6=N8R]1S@<5SD$HK9=2^,.Y9-+C:R87W:VZ$<V ]!TMMZ?<QRI89(
M>X7%Z3.\[]DK#1JUVXUVNTWXG-HLR)KU]N$OVQG]QD&0%@O+!*R@DM1A&0*K
MZ%QN="J:,F.6/<BD^2Q@>#]HP<)+9LO%"7P$)BKGF&.K,385;WO?:PW(0C<,
M3(DEX>3")=6G<A]P%$KTT&?Q;VS\+)[M=B3P2\/%'#M],7%M+K\*?[9<IVG-
MFDN %RQ/O\-\(UQP8XFF%C[4S<UN],7FZ-98;/)68C>6[ ),OC/.*+"MTF;'
MT6;=40)UMH=:6RHJAJ!A7244'DK]/RF?@P@ZH&%^F* H;:X[*W(16BG\C59X
MD09J.NY24U05R$H@H3>H+?2L2 T69L#$*ZNS0"/#CA; M#*!'Q2 ANK99'RO
M#N3,F#4U@U$3E1R?NZ;3(HH;<^5&Y 9Q6L+)9_O<([.VX2R!@V4!G#A913BF
MA6GCJ+5%(W'Y93BOE@83C<6!R># &A(XOYPYG #RF!7?L-D<5+TXF1UWNL)G
M9Q8&%<2I&5E&5L)>*H(70'#-XHXO>#[Q!4$:/NG1&IBLPI+9B"'Z1K%3IR<,
M!(_B3NA%J-9FKBW.?WR1'I0&!*IAVB(/(<6"3V]KLP:&H.1E'$L9=,=@WD@*
M5)D\J!&:4H<"P";RKQ>Z$N-OL(X(5,[$H?A&M)&P>/$%?J1.#)?+Q3PY$ 4)
ML!>L,  C\$77(DT)8H%=VS[2QG+@8Z^. N_!LG0J'IKXEW,7WN"_O2&5+6#Q
MORW  )  R[0V"2>V'ME80WS$*"PE%IC3%ZS)\#&+Z%_BB0/O$-]\MI$H!OQJ
M>E5KXGVA3;3(&*Z4TH V@%6B>!3/2Z8)P?4KN: ?0"^8EMED/S4P*F'K#9Q+
M8$SAW@<_VM:*&LZJ.0.$-@2 TDYMNLL&(F;)')?*R4:Z;;,72Q.X]0#%U[F>
M/1YL)YX$%](R%=4OFUN3RR^P4DU053!N[.DHSBPXJ[ H9&%-F<$_I&8UOQXN
M%:-%#N[0>7X7;&+;"@!96'J5@;AHS%'[F]CYQ>0#WF(" A%K*>0)GI-[B_XU
MH%Y !3UB8JQ!:A!<!63?UP0F>[9 $R&C3)CSRI@9MBLR%? <[N3:Z;C:]'!=
M4Z[S^]E8=NP#)#Y8@(&5_'=)[JY4'I]2_3A)W4OI+S7CEL \RLL2[1=3UHUN
M=M<NNO(SW08+K[M,[L[+:DK,=!/.)FE @.Q*#2D.E E*,- $!%B:<\#[>)2A
M&I F82 K\#4=%@'+CWLUBZCJX>]LZ:RK!J-ETD#P\0+VH-&H^GLD?Q^/'\(*
M[TBJ(YE&V-0CGRV; 3%N7#C03"W28FML3L6OAN!PKE1+P:KEND4^;W.W.-"P
M[GZ*^["W^O@K35.4IG%-S7/1:IYT;#@/\(82]&*0Y(GH!OE1Q!;BNNG7$\OO
M>TMLO@$4U (]-@RDS%KH&F'FBVY;IL\1:S^(#PO68<O&!$SV1)%W)V'MH*CJ
MIFRYX'TG*(VV\!1CLIY:EDDKMBJ,K4+:57H@O.$<<"U%,IO4.WX\61>].3PS
M0QKR0#+=!N->!RV*5Q&OVIPD7GDF];W/<'@Q7I^>-FLN&,7(JK@\^5"@T:UA
M4;RLD?<OV]%V'./'&W+9:S<[<!\/R8!WOA#_@"&A(R4D&8KI"F.Z,=RSG35[
M$-$C2?"(US-!]'Q;D]X/L"PLDSFH@SQ6@EL:8Z!\X%C:XBJ\4WL*+<18R+TV
MFQG2A>,IG/7!AD$<V4E%,"T/V79>VP>XQ$8".\+_ ZH15CB2D76PN;1I=]W
M=1R>P/_<_LO57ZB!EJRRL0JVL6Y:!%$N!U'B#VR-?&59E:"-=F)?S 75I?M6
M\[\T90OYGZ7%T3T%.F1"S3^Y]"A*+QJ?6[;31,\.,718;^I%U.75\$):4CK<
M[WRG;7/"J AC.["K8&W/3Q4<K0OJ^*%\@,C T)'PUSESFS$OUG D)91(=VQ=
M]*AN8V4%NY\%MXP[DSNVNU@_72&%4[$,H52!FS0:Z1/<^H THAV1<+F'3\&
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MVO"<L RE%.>-D77\-+QP."%^:C$YF4SD-U,?*=8$:$/]FL(%_9,)E-&@GC1
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M8Y:WQ2B+S=)?K&*4=80H*1+WW%T L>![7(K2A#/[A4H!78)<$9>+8>GBKR_
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MV29K?S@X!+#[:#?@+R+TERRS:2]QKX:]*#PQ+SH0ED$(ED$B6#JI0;GS)E"
M[OO$)H[7)#D7S'0O(\#$O^EP>%)C9W@ .&(Z_#4.A[\)S8;/!3W#412@^%<=
M#E "_/SD^J^F;H"9#_KH'?FX^;)/+GNR0LF&!6OL=@0?NU]^()C[U<Y;N'BP
M+8VQ*4?LWG'NHC_Q?O9@>T;$HP-& O"2_ #G&HE/=G#*5;-[Z7$*_-QK_Z'!
MW<I:_/%5UVP+K+L[;E-F?!5)<;N1UG[WMW[[:C0((>TP*'=GBL:SF_B4CUUG
M;MGZO]GTAPE6J5CI?HE_?S"HR:]7MS^9K>F</=BZQK[C[*?C]4W/M:C\:<[@
M#;@-2^R7$\MUN$--3%B%&ZL 9".OD>"N&J+MS^;'@P:9TQ=&)HR9A+,EM46K
M0-UT+,(\')(E(A'@I9S,+'1H>V7LQ6Q_M+^H/FJVG^#\[*.-Z[V-T/M@MT<E
MYAP=;?3WXQ[9S"W?^+Q1_$]QE0<M!8K+ICC5CRVH;B*._4YG+IC]ACYC1.[D
MLMOI_$968BJ[(D,AG.X=%D+W'A'%!SBGJZ6$WY\(-QYAUOSA"?UGC[K#D_7/
M'G6*ZQ37*:ZK$>K*X[H"C9%=N$B _+R_I\!3X"GPC@O> 9HF6[U<Y_!ZHM$O
M,8D"B35YNY5Z@&MVD(_Q9"<3FCJ-SG#4&%X=W%M<X:K2.SX6KBY;!Q>SU0I+
M[4Q8NE)84G)7&USE9#RDGGF?X\TS"VHO_B-MT48EKM )K\VY+YB-B_O]4:/;
M3<O%"N$'(CQMJJQ"],$G_D"A6O'T22%::>L3X^R<#+T$7J)-R+JYL$!WKZF7
M=>$CK?)V74T!2V;ATFYCV.DWKKP0U.'<JI!>POU/(3T#TD>MOD)W>>B^;*5M
MX*#0K?1XO9!>EAZ/,?62C>E+EZT_'&V;9.FR]3=!2 %!PC?4HA[ L98)HJ[=
M_O)G 7[-I"M^89P39TY-\K[=:G=:.Y=/P'WQ3)"NBKJH"J%DA6^)WK/]EA_+
M);/%3U_TA>XDK$;RJ[0BZ]V;+*Y.ZT%"%B[7NOOV^=W?,'3^5LU?/ILZ-@)C
MZ@\5 HO@P*=7:R\"UP75L.+;A8Y5Y9.WMEGJOKZY",G]['Y=6W3O%6%DK8S=
MP?<=L%G 9"F(]7?OIPIHW%FYNP-773"JP:8^9UREU;B*Z][@.H7)0C$9I]UW
M8;+?'W6[9XW)M.?D4<_(VW55XDF<D=O[J0(:JWE&5AI7M3HC*XW)6IV1M<5D
MY<[(2F.RJ#/R@:X6S'3X9\O^SI:NK<UA>_<SV-\"=K:GZ<^NR_PG-M,!"/V%
MC9]MQG!Q"9S_A:<Y?"Q; ND"RKEE ,)X@OY V \LW%3I;>#][7Z]OG_Z]0%P
M!E^GS]@N4>=B)/:]^9GJ]E=J_\D<[+%>D;T_N#:+<Q8-_O+QP*WXF)@R_==/
MEN8B<)_A26K\%Z/V9_@D<0>YO^'/?_FX9R7_989N_OGKS+(<TW+8%_B%_!0?
M.:LE UOII\- 5J;OO$]M"QVV<\=9_OKQX^OK:^OGQ#9:EOW\L=MN]S[BGS_B
M%]]YR_LO,"PMLB[\3AW+]I<%G,-^_I??A:_M?V[0"3."[GQ_P%-K^3ALZ4YQ
M2W>+6[I7W-+]XI8>%+?TL+BE1\4M?5G<TE<%BDR1XIA*'GTU-;:C[Z"VYB\#
M/[ZAH[QO?)Q1S6GZ*_J/ST"E;@#AO<B2'^.7FVT0=1'[^^N[3C8,=';HNDYV
MY'9VZ+I<EH[7=;DL':_K<EDZ7M?ELG2\KLMEZ7A=E\O2\;HNEZ7C=5TN2\?K
MNGQ$IDAQ+% >.P4*9*= B>P4*)*= F6R4Z!0=@J4RDZ!8MDI4"Z[!<IEM\AS
MLD"Y[!8HE]T"Y;);H%QV"Y3+;H%RV2U0+KL%RF6O0+GL%2B7O2(-V +ELE>@
M7/8*E,M>@7+92R67Y=XA.[OOD+V\[I#='7?(;A40T-V-@'Y>".CM0$ O.W?U
M=ERB=RQ=+FY[NW$[R NW_1VX[6?';7\';G-9.EZ_Y[)TO'K/9>EX[9[+TO'*
M/9>EXW5[+DO'J_8=2Y<K??W=TC?,2_H&.Z1O4 4$#'8C8)07 H8[$#"L @*&
MNQ'0V8< ?\T(B#;CEFMKP8N21-HV@0NA* #CY\* S['>A9G-'X_O_K:NY^C\
MY6,$GJ.!V8T!,]1(7HPL(1R#L61*'4ILM@0X,*P,&V'$8,_4(.Q?KNZL"'=L
M5W-<^*HU(_YX&_*53;'PAGQQIBWRJCMS\: IXOOX1;$X)W2*=4PX"-2"ESBV
M!2R@OS!C!;_-#*8YXC'+9$W':IJZR<AW]L)LSHB,13\N#=TA;#:#K\(JEDF^
M62]R&]U+.9$%^^2_,L/ _^)BMK> S30Y1TS_=S!AB;N+!=U>2*S3J@KQ>C'$
M>US3:F;99,ELW9IR'#$"OP%N]V[\S*DK%ZH*=?LQU+TS-<.= D([[<:HW6U<
M]BY]% .R-9'00.2X(LV@G.LS'>=V $;88FG9U%YYY*P,#P]B=OG@):N0(%%$
MLM;U_<U]B]R':-8)ABTAR3'OB)HK8+)GAI,J/89\M1 Y.C#UZ]PRC%73>C4!
M*]R=<'VJ4UL758: (7*#_/.HZ3@MBY-_6 ;FYG(BZED0C^94? ^_QLD-L!2(
MF*G3!@&ZM,@%%B$RC[$;:VGPP)(P_N__==GMMG][A"6 /<5OG=\^-(CH3.M/
M@H(38HQC2DD,)BY"J^SZDK_L&FWD43=TX'SR.X47KR3$#4)#NP#VL9%'A)#@
M5N.QM4)D7HLJ7'*O,6H")D(/7GB@B9?^>/0AJ0R_#6/X[6D.2H^\4MNFJ/HP
MT8?J@ ,R<X$?8&/:'- ,?].;4]UPQ3[%S";X-RRJB0\XZE;J-(""9&%QAW#=
M<:E,67.7\ 6DF^[-:4,<(J=&)!84-&>::XLQH0B%*%K%8EK!%)'O4H#'@P$V
M:+V*U>$?L\E^ZASG0&Z,$\,W"AT;FI#D[UARIO?;YG.O.N!@@GH4><T[0>"-
M(%X1B#@U&)?/5(;8H[U&F"RJC8=UX],O\ O\Y2\?$0K]5_PW_/K_ 5!+ P04
M    " #B<75*.O,U#[D0   PN0  $0   &UB;W0M,C Q-C$R,S$N>'-D[5UM
M<]LV$OY\-W/_@>>9F\O-G"S+3IS8C7MC6W9'C=_&5II<OW1H$I(PH0 %(&6I
MO_X6X#M!0J!LE^J)_9#*Q.YB=Q^\[0(D/OYG,?6L.6(<4W*RT]O=V[$0<:B+
MR?ADY_-#Y_3A?##8L?[SX]_^:L%_'__>Z5B7&'GNL=6G3F= 1O0'Z\:>HF/K
M)T00LWW*?K!^L;U /*&7V$/,.J?3F8=\! 5A3<?6V]W>!]OJ= SD_H*(2]GG
M^T$B=^+[L^-N]^GI:9?0N?U$V3>^ZU S<0\T8 Y*9%V?W0ZM_;W>86__H&?U
M]CY9_<N;W<4(K.C;/A! V?M_[/?W#N"?_;UA[\-Q[^AX_^VOAK7YMA_PI+:]
MQ5[TGQG[->9.PGQT>#WC[Q?W^.L8D0]!WR9/_(N]O$"/=T>_O_OUPR?T;3+_
M<K;_Z$X_C9:?Y_?^I^%@N?CZ,PVFW]#;J[#*C]R9H*EM ?"$G^QD?/ETL$O9
MN+N_M]?K?KV^>I!T.R'A\<+#Y%L9>>_HZ*@K2V-2A7+QR+Q8]$%7%#_:'"62
MH11KZ#'AODV<'+WK)PQ9XG?=L#!'BDM)#T-2').ZJ$#'D;,[IO,N% !][VUG
MK]<YZ,7D >^,;7N6L(QL_BA%1P6"Y3#/0B@AP;3<4-=G77\Y0UT@Z@ 58MA)
M^%8SY1E$DTXXIMAA])'Z4^1BQ_:@FTR[<7.'ONZA*2+^)673/AK9@0=^_1[8
M'AYAY.Y8OLW&R!=-D<]L!YD)C9NU30B%U@_=/7HBGLUF&)HW//C+1]$.CAGU
MT!!LL,0/Z./:*@1-%[I(('0^)>X%\;&_%/V%365%.Q9V3W:T%*)J4$16[J(1
M)EAJ&/7*GM6Q8O;L3YNX5BC+R@C[V"V*R0@/.')OR8_R]XPA#F(DTQ4\B!@C
MD@HFL-H)O'H\J2JE+-&#V.G/@>',]D2G?)@@Y//0[_E'>D?O@W?%V(@B3Y]3
MPJF'77CB6I$@*Y34>CERZ9W-P+P)\@5-B<OSY7K_'YC[WWJ3$_RO;<8C<1F_
M'8E5#4,31#B>HRO*HUZ@)]&C\E:'2BK8HB,K)]H2LEM<0J<_3*"Y3JCGPEKS
MXGL 8S9,;=C!OHI/-:D>IW?F.&6J^">WPDJL-U$U;5]:!43)F+<&GQ[-PY="
MLQTI*T9*FT\N/?I4-D(F17J,WM<8&4&D)65NL__#:#SJ,O$?>A]_$"M>"#@]
MR@.&X(^(;9O=^!!,IS9;PDB#QP2B(L>&N,)Q: #! !G?01-T,(K;M1FM'H2C
M(@B15#GZI'*M5+ 52]YFG$2GAWA/_$^,RG/;$\-!B$M%F1:'WEX1!SFLB#A0
M_L@(VF:WW\)<Q^Z1@\ 9CU[<$92G>E?WBJZ6_%9&P#:[^!(OD'O*.41B-RA:
MPQ:>Z=V[7W2OY+9"]G];(&";W0OC* N0>X7M1^Q!C7$;+GFN=_-!T<V1!"LC
M8IL=#2NV.6(^AOY\16URR>@TNWJ/ANH51'H(WBIC=BK.$O*L$0C,+N*W&I$^
M8C"^^GB.OMB,P:)"Z01:"CT6[XI8I+*L2%C;,^*>,9UB?YI9L&0>Z+U\J+;X
MA'6;72J[^+D]PWZ2-<@^T3OUO;($%[Q6Q+S-;CVS.79@*=W'7@"!-RP=1.+Q
M#C'IH3@EK:71NUX)0:4TN>R.Y(GUBDQW6B R1&:;$;D'BVSFB/BFC^;(HS/1
M]R\6,T0X2A>,J\GTN"A1:2PPA"85:<4RMWYA&25/P..G[A3JY#Z3LU_LH%QF
MIII*B\N^$J5&\B0L>8D),ML,RB4F8F=+Z1\ES_6.5V+62$+;_F-7#V&)QVU'
M5,6A>4=[BOP+]B<#XB,P&$9S*+A'GDCBWMDL77>NR:N'3(F#L[7(#A/78SU!
M159:DRR,ZK*BRK8:6GN!^"T9$'@2S?KY1WH@E$A9,EN46"'[-KOV(7CDZ'L@
M)N=Y&A H3_4.5N+@E-\*!6RWBTW2].ND]LU2_/M*:&R>XK?>Q+^V>W/1"(YA
M)B5=BT,/GQ)SUX$OK&&KP2O?CLF"I:70@Z/$[I7;-BT6)?LW0\TNCI'_E0!>
MV<MI_:YLZF2]7EJB][D2G"L;/*W/2W=ZLGZO+-7Z_D )P$MV?5KOK]ALR.)@
M0*='1(G,]1L/+3B%='ENU:0^USM?B;%SJ?/6URMSZ%GO&U'J\5!";9-\>@N3
M26(]BY0IL1XL)6PW2[*W<!EDV[-H&=+JP5*">(/,>XM4:0H^O_RM*-6CH<3D
MI>GXUO]KY^6S&#U+@AY')7Q_5HZ^Q;N8K,_!6%*@1T<)[@N)^];?Z4S41[Z-
M/7XC(@XQ">2F'J50[W<EP(_GFC>1("N1M-6N-TOR=BZXCZ=BG/C,T2CPKL!M
M_'9TQ^@,,7\IWAK^'F"YT K=6R>#7%^X%OJW2GZA1K*Y8R7*6*$VEE1'\,8*
MA6\VQRK%#6JK6U%Y]KDC/H?@!AX*WUE2":*NJ,M@&\O0MPDEPU&=XX;V$E69
MO!E5G@N/:MYJX(L)[_(A?"65'CPE0U*2(&]'=1TLF5XDB\(\=R?7_VKRZ"%3
MDB@J9/E^%I:'=4!1V[F4'8].,IOFG^= K,>BQU#)K:A[)+FYM60+I46Q; \E
MA44MRZ&Y'JL>524)4[;[DL.U='NF17;EZSGE<V%=)CV:)2\SK'I]IYTKS7?9
MRB&LQ:''3TG>K-IY:[$SQ2Z[?@E\\3TT\86^B(Y7#;DO*E&/O9(:6H%]8<&4
M:A!3\W:(7K.!B*\%2A-N1P:=NU9+J2E:WV24K%:M)I.H(OXP'&BVNO5DW@RL
MFLRK";1(OE._E9"*:D?YZJ,6Y3AH*?1 *)FAPO&+%HHJ*-)8Y,&GSK?;F5#@
MU $?R6]*98;*VEQZR%:<F,DG?$4E5EB+%5?3CF[K8%GV7;%GB="CK*20UD>Y
M_<A8%>K),B6#&<\L+37=V)15C[+ZWDT1Y<P")@LSSZV VPYM!FVR!#SE/)B&
MS^IBK).A!UM]B\<8['3MFJFUA7WUZ<@,B'K"7#-X89GZ9J$DL8Q.7.9;B]DA
MS;:Y&)S2S*"KI\VUF)<7JV\T2N;,\.1GOMFL9&K;C,E1T0RVJTASC>85Y.I;
M3=7W.K5'4/--QNC0:MMHRDZM9O<CBV6%;<QU6/70E[SR57;>M;"E67HDMD5W
MW3.QN4D@*5AFA&5DY9K$'UB?MAT=*IF[YYVW+<Y':>DR*SDON&V!Q5.ZY7E!
M/8D>9R4QJ)S<;5.#E7!D^ET?C1!CR(7R\&Q(OEO7Y=*#IGZPI@!:OKO%M0BR
M^/!1V[=*OJE2D79?1:4'2\WP%;^Y\O_=Q\0_XE:O>S2RY&U@Q^)JJI,=CL7=
M;SO1LPE#HY.=*:#4B>^+^@U,VUU,O9A$B-;<!B81+7HCJC@6 4&0(D6YK0R$
MR"/0,&]U8^5C 3[V!?M=IAI+U /]O/L2)GOV8UV3@05YKVCKE9#_HD:*/EC3
MR$*#?253S]-:7M1@Z#IU#<[WME>RMY]4DC4WNI&MFU[)%OU=O+;M(QA.F6\1
MY1HXW5U]X2V#5]21HC0LXJ].S-<1CSJ]_<Y!;W?!W533.DJD;JBG1,RWAA+:
M&P,KM"CE$3\Z*;-I_=KK!W7UES)VD>?S^$DG%;6.-J+S\!=21\I:0Q^#JQ9-
M6DJ6\R9D%$WE2#25WN$SE5E/D;6UR#4^3.80TPE?']1ILQFVZ'<G%5%0)+IH
M4JZTQ/V4OUV,1LCQ120K;I^%8<\)-T[P[[)&F>.&D4IH?K)C2HP]3YS'/]GQ
M62!&07&SZ#&,CIBZ0SF(NP&3'#M6.*B'%%SR#WPT%51@/"S=8.P,!.5/C :S
MF! #R3.,,C2GGB%AV6,839_L.! !B*O.LO9-*8&5)UN^@(69*/Z<<I]#)!*(
MH&- C(!<G[UI:&MKOK;)SX+?18^OB'Z%QE%[)N%]:+'AIL0KC0T7!_X?W=3E
M*WH.:"G!.J>$((FBR-*MP'P]UDUUA+2$RP7D[4B$M=C%0G(]GSQ;RJ9VB@$9
MB<OFBH:<BUY._# 1<TJR+[>D3:/"6OE=ZM!MKR9]4]UYL4#,P1S=CN*3X /.
M ^1^GHD!E$1WU=^.;JB?62#49-I4X^_ #)%Q&(MC*@(]4>GID\W<V%(MA?D(
M$NH/ZT=1+ 2^@/*1ZS/A=1]QA^%9=AA81;3N/.\S3,8O8(1<<)Q!%.B*&W81
M3-UR8T4H/9:D9\N4Y,Y>RHO&A?O#^6P #F9!>+FE> MT.+%)=.PG:J/"NALJ
ME\O(A3#B$;'8-PW57;?5O/#*2O<F0=ROD^9O2KRI'5RG_[E0P//,C,T2_QF-
M/4-C3 CTV6@?T,3F$IZUUTRO:SE,L0^VA_@]7=J>OTP'[=A,'4'M(?!EA_%[
M/)[X?$BC=408@<F[S,%!\B!CLL(WH6PZ<(/I!8^)W"UGT0Y9S@A-><,#XRU4
M98M/NHB3?^?0&Y8CRL1P#R/=#+/<ZMJ0=DTPQO]%-GN)Y8UG._+1Z1C^N42(
MWWD!OT=X^AC 0E64R-<1Z6@&"*#D%%VR^%F??U/'2)$3N!T-1'[>]A[\P$WB
MY]*2#1WO5GY2$2W\,R_3Z^HPU!\/(52"(=&/9;Q"^D=^9&FIF+6:;!.,24\F
ME'V7ZG/ZX2KY.3?%R/79-\EX&I_"M"O:H-[X^NR;8'PV>A2G%<0WPV[)I8W9
MM<U@P!1O)J#2N7XMSH97,LF$?AHN3:ZC$R+7X0F1*U],^=>(C1&[1ME ;!W&
M=>%UZ=3&Y(^Q%H:D-<U5.1NW=XC$YA;,7V'TFS>IJK!QK6/?#CBSD9=7NJ*L
M<9TO*9L"\CGMLE]AR5MA3-V\70&#U57 $,Q?MZ,1=E RBQ5,,B!LW)KX]8]$
M-5#V@8Y\B )0WAPCRL;MZ:,9Y=@?D L.3>DI^L)EWI(5-(W;< =5L2&]H7.I
MTH6'YH@,G^AP0@,.*X<'O/ 1(L7AN!Y3XU;^'!"4ZL=C!4_'#$G*P@!A3MZX
M91$4?>1(E883#*O=2\RX;PAB/<[&[3WU9A,[>H4U;T]I2>/Z9KX0)K9V\BI7
M%3:N=;B22MI[81%04=BXUFJ[?8#:$3^%!V?QMEMA%5:+97,MK&G=YED&PQ!#
M-D?%V;/PM'$]!Z1,3^5IXWI&0&=:@$B!R(DZK[H)X69:(V<L95HS(]ULBVX)
MJF%4EGHS[;K$(T.@BI2;:4_I>LJ(<D/L.3.V9P5EX_:$T3L>$$+GX6&$P)]0
MIJ1;#.@:MR7CZKAO#VDI-D:4S=LS04/D3 AVL$W*OT)Q"=&P&[U.,P5Y;L'.
MYTAHW/XP$7,E%@852VDM1>/ZG]M,IWQU<>.:AQF^BP5R K'A49;^4PL;U_J,
MVLREHSYFR/%I,6M96=JXWM<7_:^_P). (<EW=75>B!@U!(UK?S&=>72)D!A,
M*URO)VG<@E-WCKFBM/*T<3T?H,>QZ""<,Q%'!BM&%A/"QJU)OS1A%[^#40P.
M5Q,V;DUF10$S:DE<I2/8*.W+8@U-^2;IOFJMMWDKO(QN(F.@UUZAV"3]+\11
M09WZ"D'CVG]^$-_K*(]W*LH:USE^U7N.TD'^+H!5??4ZLQY+XQ:>4^(SV_&3
M<*5B];R2K'%+Q(TF>:5S3QK7+SY.?\<@B%)R9I6EFZ4WC# :O;.EC>N==L25
M/74#6_-P BI%::#JLR$KJ1JW0W/88$//&/2I$T2'."Z(+]\#&D$,'J;A'KD<
M!I,F9$1K1[]BFQI_*4OW4DC->VP4C[R&Z#^I ^M=[[*>)]>MHT&7?NR&7\.
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M!=A<.T2_]D5B%G.G(5/%!?'BLX0LJ@Y-:V@P\%Y)GN&$V4[*)KQ?O"1A0]%
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M[79)_'+'%$.9Z<.OPA^_%+_1^2',:< V&YIK UHR0)%/_4&NVM;66;^QWN7
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M&%16B@M*DT;K8MH!/D9*QF'>"*BP/$UB&KN1'T3S!@@5>NTA3!7N809EZI8
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M'_WQOW]__$7$IB_:B,I_B:M:Z:%7=H+MLS>0%]H97<*RKFJ8IIL=3[^)^HT
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M2SJ[9TM$M?M2R/IT7UJX??<E%0S.+QMTPD$^W10LEJ@GS1;C5T5^'/5^US^
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MC'07B912WF;,:HC=B">*!.>"'I=P@8,* KT#=(;OZWE>U>7&L%,D$_3I2=1
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MAF&1,=[31BLLB_3QG&85P"RRB=<<L.A/GEAT,HE%>BW/++(IPHA%.A5(+++
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M]5"KB+AF.$)]+K)-7D?ERT6:X7(<>::1\TL@!<PA<49"@ @C1Z8D2B>.F'S
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M%8'L)S37 :N;Z(4N 0RS;H6PUW%1"W@P3DHEP9!("T\80LLHP6C-18$,HJ0
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M<,E6ZW:[6FKM@'N5IB)I-B!5JF!&6C>\IDWYH^T*"20Y>7HAED0SL:N0H49
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MG5QL&9&=C8'C^-026-/__'F-\PI#"C]BT:3S/"Y6-"R@!6BZYFY0\AX<;"R
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MN*SZ>["*<LM%O>9'UH =)$>6R(&ACP:<>']O*\+B8E,VZPWV9G9W>?!ZR:*
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M#L_4M)N1A_C2:^JGFJHZ7%0&L&W.@Y5M4A?]&=(AK?8PA/UQF)11><5PBB$
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MQRT4,26@+/K<'N;1F+8O=,/>MA9DFD'YI2Z*EFRB&K1S?7O(8S9^WA[5MI)
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MBG\7J/K;NP.LY]_K?)E<$E#7, !4W9IHO-=]:+?57(#>U%5-$!%^2"=D8R%
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MB@,'=AW%B)6+(AP3:WZ.X9; U[+7U<H'<!=W(JHAD=A7@JHD@H)LS:NR)\@
MB>#0OT>R7"74HVNHYT1* (7,FJ=D3\@TDD )5Q4\.EWR(^AU[$=Y( J142'U
M+*/A4Y[Q8^ECPG< -@^9/-FHYM7=4X6"VO@6=))8\\;H4%;.B0'%C6,Z]7&=
M#N L?7<([TV?-6 L/M*[RDH0 ]8$TSL;@T/G]OS:AM@H>,8!2BT/4Y?>T&H)
MA<.:YZ:7A=/%+0XL3H- 1$B\Z,X+@^NX\:Y'A[M31@!%QIK'Q1@9#>\X +KG
M-0AB$EQZ-&;[8WKJ^_DR%Y4N&N^BM;&"T$)AL^9O,88-+A$<"+89-+$9X @=
MPK<RC*WP6H[S.L'T#ZO#4;?FO;$83[>"/X8D].[Z?#L9Z1_@&>F3O^ST]Z_'
M#/4#>0N8V*=4##H0)EOS\3"M"T#>P7ASV@UEA&/O;0RZN/8E+G '8#!WB5PG
MO@^'8)<P$*.FOKVH8K'/_46+IY1A\;-\AW$HUXOYD@JE=YTLOP>@9B+""&LQ
M!T_S;)'0\)^J155'YSK3?C 892+!"Y]N/U31N,ZE'Q@VC+MAUSA!FZ&6T'5&
M_L#@H=T*:RY@\WT01#SBY'L#X:!#$[[]*8E<9]X/@Q[NC:\U4-VN)R5PG7@_
M)%H8]SO#NC4RUGI5K;$8Q1T.--@^Y\@?NF$TG<[8R-D7%B1.>8YEDDJ*='Q4
MN42W_4V2V62GQXGHTMU$+8J=;P:H]X-*"9S&%Q5/3JA"BTHRQVY.#3*M@")
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M*J*F\GDB:>XZ!?& <T,I,!SKP)474A'3V(IE.OO-H]13IBQKR%QG,AX08Y
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M)MG>,:5".H%XT.6.4,$W"&<YL>O,SCYXZT2!0S=W\]OAZJFC<YT8"K_9"A+
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M4%".23_(DDL0)_W(YM39NOX7S8-4!GV,"#43MG!D"-7'I4L+ZFJ+ QSS*:D
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M89<#950X -)/.Q!8J&X&7J?4(U%]B+K+@'(*U\XHR,QK(J1A?U^[6^*N_?P
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M%/T@R[IILJFW@.04&!(]1IEOHP/AF&R#+#B'.-FF,9<>V??4(5(IP9CPD/&
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G+3(P,38Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  0YL!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
